

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2010262774 B2**

(54) Title  
**Fuel compositions comprising isoprene derivatives**

(51) International Patent Classification(s)  
**C07C 5/02 (2006.01)**

(21) Application No: **2010262774** (22) Date of Filing: **2010.06.17**

(87) WIPO No: **WO10/148256**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>61/187,959</b>	<b>2009.06.17</b>	<b>US</b>

(43) Publication Date: **2010.12.23**

(44) Accepted Journal Date: **2015.12.03**

(71) Applicant(s)  
**DANISCO US INC.**

(72) Inventor(s)  
**McAuliffe, Joseph C.;Paramonov, Sergey E.;Sanford, Karl J.**

(74) Agent / Attorney  
**Houlihan<sup>2</sup>, Level 1 70 Doncaster Road, BALWYN NORTH, VIC, 3104**

(56) Related Art  
**US 3,185,739**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
23 December 2010 (23.12.2010)

(10) International Publication Number  
**WO 2010/148256 A1**

- (51) **International Patent Classification:**  
C07C 5/02 (2006.01)
- (21) **International Application Number:**  
PCT/US2010/039088
- (22) **International Filing Date:**  
17 June 2010 (17.06.2010)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/187,959 17 June 2009 (17.06.2009) US
- (71) **Applicant (for all designated States except US):** **DANISCO US INC.** [US/US]; 925 Page Mill Road, Palo Alto, CA 94304-1013 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **MCAULIFFE, Joseph, C.** [AU/US]; 663 Princeton Drive, Sunnyvale, CA 94087 (US). **PARAMONOV, Sergey, E.** [RU/US]; 2415 Van Ness Avenue, Apt. #602, San Francisco, CA 94109 (US). **SANFORD, Karl, J.** [US/US]; 10434 Alicia Court, Cupertino, CA 95014 (US).
- (74) **Agents:** **SHIEH-NEWTON, Terri** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report (Art. 21(3))

(54) **Title:** FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES

Figure 173



(57) **Abstract:** The invention provides for methods, compositions and systems using bioisoprene derived from renewable carbon for production of a variety of hydrocarbon fuels and fuel additives.

WO 2010/148256 A1

**FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES**

## CROSS-REFERENCE TO RELATED APPLICATIONS

**[0001]** This application claims priority to U.S. Provisional Patent Application No. 61/187,959, filed June 17, 2009, the disclosure of which is incorporated herein by reference in its entirety.

## BACKGROUND OF THE INVENTION

**[0002]** The development of renewable transportation fuels is one of the key challenges of the twenty-first century. The current market is dominated by ethanol derived from yeast fermentation of sucrose and starch, and to a lesser extent by biodiesel (fatty acid esters) derived from triglycerides. Ethanol has limitations as a liquid fuel with a lower energy density relative to hydrocarbons. In addition, ethanol cannot be transported in conventional infrastructure due to its affinity for water and corrosive nature. Processes for the conversion of renewable carbon sources (biomass, sugars, oils) to hydrocarbon fuels offer an attractive alternative to bioethanol.

**[0003]** Isoprene (2-methyl-1,3-butadiene) is a key industrial chemical used primarily for the production of synthetic rubber. Currently isoprene is derived from petrochemical sources either directly by cracking of naphtha and other light petroleum fractions, or indirectly through chemical synthesis (See, for examples, H. Pommer and A. Nurrenbach, *Industrial Synthesis of Terpene Compounds*, *Pure Appl. Chem.*, **1975**, 43, 527-551; H. M. Weitz and E. Loser, Isoprene, in *Ullmann's Encyclopedia of Industrial Chemistry*, Seventh Edition, Electronic Release, Wiley-VCH Verlag GMBH, Weinheim, **2005**; and H.M. Lybarger, Isoprene in *Kirk-Othmer Encyclopedia of Chemical Technology*, 4th ed., Wiley, New York (1995), 14, 934-952.) The resulting crude isoprene streams are typically subjected to extensive purification processes in order to remove numerous chemically similar impurities, many of which can interfere with subsequent transformation of isoprene to polymers and other chemicals.

**[0004]** In contrast, isoprene derived from biological sources contains very few hydrocarbon impurities and instead contains a number of oxygenated compounds such as ethanol, acetaldehyde and acetone. Many of these compounds can be easily removed by contact with water or passage through alumina or other adsorbents.

**[0005]** Industry relies on petrochemical feedstocks for isoprene production and extensive purification trains are needed before isoprene can be converted to polymers and other chemicals. Cost effective methods are desirable for converting biologically produced isoprene to valuable

chemical products taking advantage of the high purity and/or the unique impurity profiles of bioisoprene.

**[0006]** All patents, patent applications, documents, and articles cited herein are herein incorporated by reference in their entirety.

#### BRIEF SUMMARY OF THE INVENTION

**[0007]** Disclosed are methods and systems for producing fuel constituents from highly pure isoprene and fuel compositions produced from highly pure isoprene.

**[0008]** In one aspect, the invention provides a method for producing a fuel constituent from a bioisoprene composition comprising chemically transforming a substantial portion of the isoprene in the bioisoprene composition to non-isoprene compounds. In one embodiment, the bioisoprene composition is chemically transformed by subjecting the bioisoprene composition to heat or catalytic conditions suitable for isoprene dimerization to produce an isoprene dimer and then catalytically hydrogenating the isoprene dimer to form a saturated C<sub>10</sub> fuel constituent. In another embodiment, the bioisoprene composition is chemically transformed by (i) partially hydrogenating the bioisoprene composition to produce an isoamylene, (ii) dimerizing the isoamylene with a mono-olefin selected from the group consisting of isoamylene, propylene and isobutene to form a dimate and (iii) completely hydrogenating the dimate to produce a fuel constituent. In some embodiments, at least about 95% of isoprene in the bioisoprene composition is converted to non-isoprene compounds during the chemical transformation. In some embodiments, the bioisoprene composition is heated to about 150 °C to about 250 °C to produce an unsaturated cyclic isoprene dimer and the unsaturated cyclic isoprene dimer is hydrogenated catalytically to produce a saturated cyclic isoprene dimer fuel constituent. In some embodiments, the method comprises: (i) contacting the bioisoprene composition with a catalyst for catalyzing cyclo-dimerization of isoprene to produce an unsaturated cyclic isoprene dimer and the unsaturated cyclic isoprene dimer is hydrogenated catalytically to produce a saturated cyclic isoprene dimer fuel constituent. In some embodiments, the catalyst for catalyzing cyclo-dimerization of isoprene comprising a catalyst selected from the group consisting of a nickel catalyst, iron catalysts and chromium catalysts. In some embodiments, the step of partially hydrogenating the bioisoprene composition comprises contacting the bioisoprene composition with hydrogen gas and a catalyst for catalyzing partial hydrogenation of isoprene. In some embodiments, the catalyst for catalyzing partial hydrogenation of isoprene comprises a palladium catalyst. In some embodiments, the step of dimerizing the isoamylene with a mono-

olefin comprises contacting the isoamylene with the mono-olefin in the presence of a catalyst for catalyzing dimerization of mono-olefin. In some embodiments, the catalyst for catalyzing dimerization of mono-olefin comprises an acid catalyst. In some embodiments, the method further comprises purifying the isoprene from the bioisoprene composition prior to chemically transforming the bioisoprene composition to a fuel constituent.

**[0009]** In one aspect, the invention provides a system for producing a fuel constituent from a bioisoprene composition, wherein a substantial portion of the isoprene in the bioisoprene composition is chemically converted to non-isoprene compounds, the system comprising a bioisoprene composition and (a) (i) one or more chemicals capable of dimerizing isoprene in the bioisoprene composition or a source of heat capable of dimerizing isoprene in the bioisoprene composition; and (ii) a catalyst capable of hydrogenating the isoprene dimer to form a saturated C10 fuel constituent; or (b) (i) a chemical capable of partially hydrogenating isoprene in the bioisoprene composition to produce an isoamylene, (ii) a chemical capable of dimerizing the isoamylene with mono-olefins selected from the group consisting of isoamylene, propylene and isobutene to form a dimate and (iii) a chemical capable of completely hydrogenating the dimate to produce a fuel constituent.

**[0010]** In some embodiments of the system, the bioisoprene composition comprising greater than about 2 mg of isoprene and comprising greater than or about 99.94% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition. In some embodiments of the system, the one or more chemicals capable of dimerizing isoprene comprises catalyst for catalyzing cyclo-dimerization of isoprene comprising a catalyst selected from the group consisting of ruthenium catalysts, nickel catalysts, iron catalysts and chromium catalysts. In some embodiments of the system, the catalyst for hydrogenating the unsaturated isoprene dimers comprises a catalyst selected from the group consisting of palladium catalysts, nickel catalysts, ruthenium catalysts and rhodium catalysts. In some embodiments of the system, the chemical capable of partially hydrogenating isoprene comprises a palladium catalyst. In some embodiments of the system, the chemical capable of dimerizing the isoamylene with mono-olefins comprises an acid catalyst.

**[0011]** In one aspect, the invention provides a fuel composition comprising a fuel constituent produced by the methods described herein. In some embodiments, the fuel composition is substantially free of isoprene. In some embodiments, the fuel composition has  $\delta^{13}\text{C}$  value which is greater than -22‰ or within the range of -32‰ to -24‰.

**[0012]** In some aspects, the invention provides a system for producing a fuel constituent from isoprene comprising: (a) a commercially beneficial amount of highly pure isoprene; and (b) a fuel constituent produced from at least a portion of the highly pure isoprene; wherein at least a portion of the commercially beneficial amount of highly pure isoprene undergoes a chemical transformation.

**[0013]** In some embodiments of the system, the commercially beneficial amount of highly pure isoprene comprises greater than about 2 mg of isoprene and comprising greater than or about 99.94% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition. In some embodiments, the commercially beneficial amount of highly pure isoprene comprises greater than about 2 mg of isoprene and comprising one or more compounds selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms. In some embodiments, the commercially beneficial amount of highly pure isoprene comprises greater than about 2 mg of isoprene and comprising one or more second compounds selected from the group consisting of ethanol, acetone, methanol, acetaldehyde, methacrolein, methyl vinyl ketone, 2-methyl-2-vinyloxirane, *cis*- and *trans*-3-methyl-1,3-pentadiene, a C5 prenyl alcohol, 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (*trans*-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene, and 2,3-cycloheptenolpyridine; wherein the amount of the second compound relative to the amount of the isoprene is greater than or about 0.01 % (w/w). In some embodiments, the commercially beneficial amount of highly pure isoprene comprises greater than about 2 mg of isoprene and comprising less than or about 0.5 µg/L per compound for any compound in the composition that inhibits the polymerization of isoprene. In some preferred embodiments, the commercially beneficial amount of highly pure isoprene is produced by a biological process.

**[0014]** In some embodiments of the system, the fuel constituent comprises one or more compounds selected from the group consisting of cyclic isoprene dimers and trimers, linear isoprene oligomers, aromatic and alicyclic isoprene derivatives, and oxygenated isoprene

derivatives. In some embodiments, the oxygenated isoprene derivatives are compounds selected from the group consisting of alcohols, ketones, esters and ethers derived from isoprene.

**[0015]** In some embodiments, the fuel constituent comprises cyclic isoprene dimers and the chemical transformation comprises a dimerization reaction of isoprene. In some embodiments, the dimerization reaction is carried out by heating the commercially beneficial amount of highly pure isoprene. In some embodiments, the dimerization reaction of isoprene produces a product comprising unsaturated isoprene dimers and the chemical transformation further comprises a hydrogenation reaction of the unsaturated isoprene dimers. In some embodiments, the system further comprises a catalyst for catalyzing the hydrogenation reaction of the unsaturated isoprene dimers. In some embodiments, the catalyst for catalyzing the hydrogenation reaction of the unsaturated isoprene dimers comprising a catalyst selected from the group consisting of palladium catalysts, nickel catalysts, ruthenium catalysts and rhodium catalysts.

**[0016]** In some embodiments, the dimerization reaction is carried out by contacting the commercially beneficial amount of highly pure isoprene with a catalyst for catalyzing cyclo-dimerization of isoprene. In some embodiments, the catalyst for catalyzing cyclo-dimerization of isoprene comprising a catalyst selected from the group consisting of ruthenium catalysts, nickel catalysts, iron catalysts and chromium catalysts. In some embodiments, the catalyst for catalyzing cyclo-dimerization of isoprene is a nickel catalyst and the fuel constituent comprising one or more eight-membered ring dimers of isoprene.

**[0017]** In some embodiments, the fuel constituent comprises linear and/or cyclic trimers of isoprene and the chemical transformation comprises catalytic trimerization of isoprene.

**[0018]** In one aspect, the invention provides a method for producing a fuel constituent from isoprene comprising: (a) obtaining a commercially beneficial amount of highly pure isoprene; and (b) chemically transforming at least a portion of the commercially beneficial amount of highly pure isoprene to a fuel constituent. In some embodiments, the commercially beneficial amount of highly pure isoprene comprises bioisoprene.

**[0019]** In some embodiments, the commercially beneficial amount of highly pure isoprene is obtained by the steps comprising: (i) culturing cells comprising a heterologous nucleic acid encoding an isoprene synthase polypeptide under suitable culture conditions for the production of isoprene, wherein the cells (1) produce greater than about 400 nmole/g<sub>wcm</sub>/hr of isoprene, (2) convert more than about 0.002 molar percent of the carbon that the cells consume from a cell culture medium into isoprene, or (3) have an average volumetric productivity of isoprene greater than about 0.1 mg/L<sub>broth</sub>/hr of isoprene, and (ii) producing isoprene. In some embodiments, the

cells further comprise a heterologous nucleic acid encoding an isoprene synthase polypeptide or an MVA pathway polypeptide.

**[0020]** In some embodiments of the methods described herein, chemically transforming at least a portion of the commercially beneficial amount of highly pure isoprene to a fuel constituent comprises: (i) heating the commercially beneficial amount of highly pure isoprene to about 150 °C to about 250 °C; (ii) converting at least a portion of the commercially beneficial amount of highly pure isoprene to unsaturated cyclic isoprene dimers; (iii) hydrogenating the unsaturated cyclic isoprene dimers to produce saturated cyclic isoprene dimers; and (iv) producing the fuel constituent. In some embodiments, at least about 20% to about 100% of isoprene in the commercially beneficial amount of highly pure isoprene is converted to unsaturated cyclic isoprene dimers.

**[0021]** In some embodiments of the method, chemically transforming at least a portion of the commercially beneficial amount of highly pure isoprene to a fuel constituent comprises: (i) contacting the commercially beneficial amount of highly pure isoprene with a catalyst for catalyzing cyclo-dimerization of isoprene, (ii) converting at least a portion of the commercially beneficial amount of highly pure isoprene to cyclic isoprene dimers; and (iii) producing the fuel constituent.

**[0022]** In some embodiments of the method, chemically transforming at least a portion of the commercially beneficial amount of highly pure isoprene to a fuel constituent comprises: (i) contacting the commercially beneficial amount of highly pure isoprene with a catalyst for catalyzing cyclo-dimerization of isoprene, (ii) converting at least a portion of the commercially beneficial amount of highly pure isoprene to unsaturated cyclic isoprene dimers; (iii) hydrogenating the unsaturated cyclic isoprene dimers to produce saturated cyclic isoprene dimers; and (iv) producing the fuel constituent. In some embodiments of the method, the catalyst for catalyzing cyclo-dimerization of isoprene comprising a catalyst selected from the group consisting of a nickel catalyst, iron catalysts and chromium catalysts.

**[0023]** In some embodiments of the method, chemically transforming at least a portion of the commercially beneficial amount of highly pure isoprene to a fuel constituent comprises: (i) contacting the highly pure isoprene composition with a catalyst system; (ii) converting at least a portion of the starting isoprene composition to unsaturated isoprene dimers and/or trimers; and (iii) hydrogenating the unsaturated dimers and/or trimers to produce saturated C10 and/or C15 hydrocarbons.

**[0024]** In some embodiments, the method for producing a fuel constituent from isoprene comprises: (a) obtaining a commercially beneficial amount of any of the highly pure isoprene starting composition described herein; (b) converting at least a portion of the starting isoprene composition to oxygenated isoprene derivatives; and optionally (c) hydrogenating any unsaturated oxygenated isoprene derivatives to produce saturated oxygenates. In some embodiments, the oxygenated isoprene derivatives are compounds selected from the group consisting of alcohols, ketones, esters and ethers derived from isoprene.

**[0025]** In some embodiments, any of the methods described herein further comprises purifying the commercially beneficial amount of highly pure isoprene prior to chemically transforming at least a portion of the commercially beneficial amount of highly pure isoprene to a fuel constituent.

**[0026]** In one aspect, provided is a continuous process for producing a fuel constituent from isoprene comprising: (a) continuously producing a commercially beneficial amount of highly pure isoprene; and (b) continuously transforming chemically at least a portion of the commercially beneficial amount of highly pure isoprene to a fuel constituent. In some embodiments, the commercially beneficial amount of highly pure isoprene comprising a gas phase comprising isoprene. In some embodiments, the method further comprises passing the gas phase comprising isoprene to a reactor for chemically transforming at least a portion of the commercially beneficial amount of highly pure isoprene to a fuel constituent. In a preferred embodiment, the commercially beneficial amount of highly pure isoprene comprises bioisoprene.

**[0027]** Also provided is a fuel composition comprising a fuel constituent produced by any of the methods described herein. In some embodiments, the fuel constituent comprises less than or about 0.5 µg/L a product from a C5 hydrocarbon other than isoprene after undergoing the steps according to the methods described herein. In some embodiments, the fuel constituent comprises one or more product from one or more compound selected from the group consisting of ethanol, acetone, methanol, acetaldehyde, methacrolein, methyl vinyl ketone, 2-methyl-2-vinyloxirane, *cis*- and *trans*-3-methyl-1,3-pentadiene, a C5 prenyl alcohol, 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl

acetate, limonene, geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene and 2,3-cycloheptenolpyridine after undergoing the steps according to the methods described herein.

**[0028]** In some embodiments, the fuel composition comprises a fuel composition having  $\delta^{13}\text{C}$  value which is greater than -22‰. In some embodiments, the fuel composition has  $\delta^{13}\text{C}$  value which is within the range of -22‰ to -10‰ or -34‰ to -24‰. In some embodiments, the fuel composition has  $f_M$  value which is greater than 0.9. Also provided is a blend of any of the fuel compositions described herein with a petroleum based fuel in the amount of from about 1% to about 95% by weight or volume, based on the total weight or volume of the total fuel composition.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0029]** Figure 1 is the nucleotide sequence of a kudzu isoprene synthase gene codon-optimized for expression in *E. coli* (SEQ ID NO:1). The atg start codon is in italics, the stop codon is in bold and the added *PstI* site is underlined.

**[0030]** Figure 2 is a map of pTrcKudzu.

**[0031]** Figures 3A-C are the nucleotide sequence of pTrcKudzu (SEQ ID NO:2). The RBS is underlined, the kudzu isoprene synthase start codon is in bold capital letters and the stop codon is in bold, capital letters. The vector backbone is pTrcHis2B.

**[0032]** Figure 4 is a map of pETNHisKudzu.

**[0033]** Figures 5A-C are the nucleotide sequence of pETNHisKudzu (SEQ ID NO:3).

**[0034]** Figure 6 is a map of pCL-lac-Kudzu.

**[0035]** Figures 7A-C are the nucleotide sequence of pCL-lac-Kudzu (SEQ ID NO:4).

**[0036]** Figure 8A is a graph showing the production of isoprene in *E. coli* BL21 cells with no vector.

**[0037]** Figure 8B is a graph showing the production of isoprene in *E. coli* BL21 cells with pCL-lac-Kudzu

**[0038]** Figure 8C is a graph showing the production of isoprene in *E. coli* BL21 cells with pTrcKudzu.

**[0039]** Figure 8D is a graph showing the production of isoprene in *E. coli* BL21 cells with pETN-HisKudzu.

**[0040]** Figure 9A is a graph showing OD over time of fermentation of *E. coli* BL21/pTrcKudzu in a 14 liter fed batch fermentation.

[0041] Figure 9B is a graph showing isoprene production over time of fermentation of *E. coli* BL21/pTrcKudzu in a 14 liter fed batch fermentation.

[0042] Figure 10A is a graph showing the production of isoprene in *Pantaea citrea*. Control cells without recombinant kudzu isoprene synthase. Grey diamonds represent isoprene synthesis, black squares represent OD<sub>600</sub>.

[0043] Figure 10B is a graph showing the production of isoprene in *Pantaea citrea* expressing pCL-lac Kudzu. Grey diamonds represent isoprene synthesis, black squares represent OD<sub>600</sub>.

[0044] Figure 10C is a graph showing the production of isoprene in *Pantaea citrea* expressing pTrcKudzu. Grey diamonds represent isoprene synthesis, black squares represent OD<sub>600</sub>.

[0045] Figure 11 is a graph showing the production of isoprene in *Bacillus subtilis* expressing recombinant isoprene synthase. BG3594comK is a *B. subtilis* strain without plasmid (native isoprene production). CF443 is *B. subtilis* strain BG3594comK with pBSKudzu (recombinant isoprene production). IS on the y-axis indicates isoprene.

[0046] Figures 12A-C are the nucleotide sequence of pBS Kudzu #2 (SEQ ID NO:5).

[0047] Figure 13 is the nucleotide sequence of kudzu isoprene synthase codon-optimized for expression in *Yarrowia* (SEQ ID NO:6).

[0048] Figure 14 is a map of pTrex3g comprising a kudzu isoprene synthase gene codon-optimized for expression in *Yarrowia*.

[0049] Figures 15A-C are the nucleotide sequence of vector pSPZ1(MAP29Sph) (SEQ ID NO:7).

[0050] Figure 16 is the nucleotide sequence of the synthetic kudzu (*Pueraria montana*) isoprene gene codon-optimized for expression in *Yarrowia* (SEQ ID NO:8).

[0051] Figure 17 is the nucleotide sequence of the synthetic hybrid poplar (*Populus alba x Populus tremula*) isoprene synthase gene (SEQ ID NO:9). The ATG start codon is in bold and the stop codon is underlined.

[0052] Figure 18A (Figures 18A1 and 18A2) shows a schematic outlining construction of vectors pYLA 1, pYL1 and pYL2 (SEQ ID NO:75, 73, 72, 71, 70, 69).

[0053] Figure 18B shows a schematic outlining construction of the vector pYLA(POP1) (SEQ ID NO:68, 69).

[0054] Figure 18C shows a schematic outlining construction of the vector pYLA(KZ1)

[0055] Figure 18D shows a schematic outlining construction of the vector pYLI(KZ1) (SEQ ID NO:66, 67)

[0056] Figure 18E shows a schematic outlining construction of the vector pYLI(MAP29)

[0057] Figure 18F shows a schematic outlining construction of the vector pYLA(MAP29)

[0058] Figure 19A shows the MVA and DXP metabolic pathways for isoprene (based on F. Bouvier *et al.*, *Progress in Lipid Res.* 44: 357-429, 2005). The following description includes alternative names for each polypeptide in the pathways and a reference that discloses an assay for measuring the activity of the indicated polypeptide (each of these references are each hereby incorporated by reference in their entirety, particularly with respect to assays for polypeptide activity for polypeptides in the MVA and DXP pathways). **Mevalonate Pathway: AACT**; Acetyl-CoA acetyltransferase, MvaE, EC 2.3.1.9. Assay: *J. Bacteriol.*, 184: 2116–2122, 2002; **HMGS**; Hydroxymethylglutaryl-CoA synthase, MvaS, EC 2.3.3.10. Assay: *J. Bacteriol.*, 184: 4065–4070, 2002; **HMGR**; 3-Hydroxy-3-methylglutaryl-CoA reductase, MvaE, EC 1.1.1.34. Assay: *J. Bacteriol.*, 184: 2116–2122, 2002; **MVK**; Mevalonate kinase, ERG12, EC 2.7.1.36. Assay: *Curr Genet* 19:9-14, 1991. **PMK**; Phosphomevalonate kinase, ERG8, EC 2.7.4.2, Assay: *Mol Cell Biol.*, 11:620–631, 1991; **DPMDC**; Diphosphomevalonate decarboxylase, MVD1, EC 4.1.1.33. Assay: *Biochemistry*, 33:13355-13362, 1994; **IDI**; Isopentenyl-diphosphate delta-isomerase, IDI1, EC 5.3.3.2. Assay: *J. Biol. Chem.* 264:19169-19175, 1989. **DXP Pathway: DXS**; 1-Deoxyxylulose-5-phosphate synthase, dxs, EC 2.2.1.7. Assay: *PNAS*, 94:12857-62, 1997; **DXR**; 1-Deoxy-D-xylulose 5-phosphate reductoisomerase, dxr, EC 2.2.1.7. Assay: *Eur. J. Biochem.* 269:4446–4457, 2002; **MCT**; 4-Diphosphocytidyl-2C-methyl-D-erythritol synthase, IspD, EC 2.7.7.60. Assay: *PNAS*, 97: 6451–6456, 2000; **CMK**; 4-Diphosphocytidyl-2-C-methyl-D-erythritol kinase, IspE, EC 2.7.1.148. Assay: *PNAS*, 97:1062-1067, 2000; **MCS**; 2C-Methyl-D-erythritol 2,4-cyclodiphosphate synthase, IspF, EC 4.6.1.12. Assay: *PNAS*, 96:11758-11763, 1999; **HDS**; 1-Hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase, ispG, EC 1.17.4.3. Assay: *J. Org. Chem.*, 70:9168 -9174, 2005; **HDR**; 1-Hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase, IspH, EC 1.17.1.2. Assay: *JACS*, 126:12847-12855, 2004.

[0059] Figure 19B illustrates the classical and modified MVA pathways. 1, acetyl-CoA acetyltransferase (**AACT**); 2, HMG-CoA synthase (**HMGS**); 3, HMG-CoA reductase (**HMGR**); 4, mevalonate kinase (**MVK**); 5, phosphomevalonate kinase (**PMK**); 6, diphosphomevalonate decarboxylase (**MVD or DPMDC**); 7, isopentenyl diphosphate isomerase (**IDI**); 8, phosphomevalonate decarboxylase (**PMDC**); 9, isopentenyl phosphate kinase (**IPK**). The classical MVA pathway proceeds from reaction 1 through reaction 7 via reactions 5 and 6, while a modified MVA pathway goes through reactions 8 and 9. P and PP in the structural formula are phosphate and pyrophosphate, respectively. This figure was taken from Koga and Morii, *Microbiology and Mol. Biology Reviews*, 71:97-120, 2007, which is incorporated by reference in

its entirety, particular with respect to nucleic acids and polypeptides of the modified MVA pathway. The modified MVA pathway is present, for example, in some archaeal organisms, such as *Methanosarcina mazei*.

**[0060]** Figure 20 (Figures 20A and 20B) shows graphs representing results of the GC-MS analysis of isoprene production by recombinant *Y. lipolytica* strains without (left) or with (right) a kudzu isoprene synthase gene. The arrows indicate the elution time of the authentic isoprene standard.

**[0061]** Figure 21 is a map of pTrcKudzu yIDI DXS Kan.

**[0062]** Figures 22A-D are the nucleotide sequence of pTrcKudzu yIDI DXS Kan (SEQ ID NO:10).

**[0063]** Figure 23A is a graph showing production of isoprene from glucose in BL21/pTrcKudzukan. Time 0 is the time of induction with IPTG (400  $\mu\text{mol}$ ). The x-axis is time after induction; the y-axis is  $\text{OD}_{600}$  and the y2-axis is total productivity of isoprene ( $\mu\text{g/L}$  headspace or specific productivity ( $\mu\text{g/L headspace/OD}$ )). Diamonds represent  $\text{OD}_{600}$ , circles represent total isoprene productivity ( $\mu\text{g/L}$ ) and squares represent specific productivity of isoprene ( $\mu\text{g/L/OD}$ ).

**[0064]** Figure 23B is a graph showing production of isoprene from glucose in BL21/pTrcKudzu yIDI kan. Time 0 is the time of induction with IPTG (400  $\mu\text{mol}$ ). The x-axis is time after induction; the y-axis is  $\text{OD}_{600}$  and the y2-axis is total productivity of isoprene ( $\mu\text{g/L headspace or specific productivity ( $\mu\text{g/L headspace/OD}$ )). Diamonds represent  $\text{OD}_{600}$ , circles represent total isoprene productivity ( $\mu\text{g/L}$ ) and squares represent specific productivity of isoprene ( $\mu\text{g/L/OD}$ ).$

**[0065]** Figure 23C is a graph showing production of isoprene from glucose in BL21/pTrcKudzu DXS kan. Time 0 is the time of induction with IPTG (400  $\mu\text{mol}$ ). The x-axis is time after induction; the y-axis is  $\text{OD}_{600}$  and the y2-axis is total productivity of isoprene ( $\mu\text{g/L headspace or specific productivity ( $\mu\text{g/L headspace/OD}$ )). Diamonds represent  $\text{OD}_{600}$ , circles represent total isoprene productivity ( $\mu\text{g/L}$ ) and squares represent specific productivity of isoprene ( $\mu\text{g/L/OD}$ ).$

**[0066]** Figure 23D is a graph showing production of isoprene from glucose in BL21/pTrcKudzu yIDI DXS kan. Time 0 is the time of induction with IPTG (400  $\mu\text{mol}$ ). The x-axis is time after induction; the y-axis is  $\text{OD}_{600}$  and the y2-axis is total productivity of isoprene ( $\mu\text{g/L headspace or specific productivity ( $\mu\text{g/L headspace/OD}$ )). Diamonds represent  $\text{OD}_{600}$ ,$

circles represent total isoprene productivity ( $\mu\text{g/L}$ ) and squares represent specific productivity of isoprene ( $\mu\text{g/L/OD}$ ).

**[0067]** Figure 23E is a graph showing production of isoprene from glucose in BL21/pCL PtrcKudzu. Time 0 is the time of induction with IPTG (400  $\mu\text{mol}$ ). The x-axis is time after induction; the y-axis is  $\text{OD}_{600}$  and the y2-axis is total productivity of isoprene ( $\mu\text{g/L}$  headspace or specific productivity ( $\mu\text{g/L}$  headspace/OD)). Diamonds represent  $\text{OD}_{600}$ , circles represent total isoprene productivity ( $\mu\text{g/L}$ ) and squares represent specific productivity of isoprene ( $\mu\text{g/L/OD}$ ).

**[0068]** Figure 23F is a graph showing production of isoprene from glucose in BL21/pCL PtrcKudzu yIDI. Time 0 is the time of induction with IPTG (400  $\mu\text{mol}$ ). The x-axis is time after induction; the y-axis is  $\text{OD}_{600}$  and the y2-axis is total productivity of isoprene ( $\mu\text{g/L}$  headspace or specific productivity ( $\mu\text{g/L}$  headspace/OD)). Diamonds represent  $\text{OD}_{600}$ , circles represent total isoprene productivity ( $\mu\text{g/L}$ ) and squares represent specific productivity of isoprene ( $\mu\text{g/L/OD}$ ).

**[0069]** Figure 23G is a graph showing production of isoprene from glucose in BL21/pCL PtrcKudzu DXS. Time 0 is the time of induction with IPTG (400  $\mu\text{mol}$ ). The x-axis is time after induction; the y-axis is  $\text{OD}_{600}$  and the y2-axis is total productivity of isoprene ( $\mu\text{g/L}$  headspace or specific productivity ( $\mu\text{g/L}$  headspace/OD)). Diamonds represent  $\text{OD}_{600}$ , circles represent total isoprene productivity ( $\mu\text{g/L}$ ) and squares represent specific productivity of isoprene ( $\mu\text{g/L/OD}$ ).

**[0070]** Figure 23H is a graph showing production of isoprene from glucose in BL21/pTrcKudzuIDIDXkan. The arrow indicates the time of induction with IPTG (400  $\mu\text{mol}$ ). The x-axis is time after induction; the y-axis is  $\text{OD}_{600}$  and the y2-axis is total productivity of isoprene ( $\mu\text{g/L}$  headspace or specific productivity ( $\mu\text{g/L}$  headspace/OD)). Black diamonds represent  $\text{OD}_{600}$ , black triangles represent isoprene productivity ( $\mu\text{g/L}$ ) and white squares represent specific productivity of isoprene ( $\mu\text{g/L/OD}$ ).

**[0071]** Figure 24 is a map of pTrcKKDyIkIS kan.

**[0072]** Figures 25A-D are a nucleotide sequence of pTrcKKDyIkIS kan (SEQ ID NO:11).

**[0073]** Figure 26 is a map of pCL PtrcUpperPathway.

**[0074]** Figures 27A-27D is a nucleotide sequence of pCL PtrcUpperPathway (SEQ ID NO:12).

**[0075]** Figure 28 shows a map of the cassette containing the lower MVA pathway and yeast *idi* for integration into the *B. subtilis* chromosome at the *nprE* locus. *nprE* upstream/downstream indicates 1 kb each of sequence from the *nprE* locus for integration. *aprE* promoter (alkaline serine protease promoter) indicates the promoter (-35, -10, +1 transcription start site, RBS) of the *aprE* gene. MVK1 indicates the yeast mevalonate kinase gene. RBS-PMK indicates the yeast

phosphomevalonate kinase gene with a *Bacillus* RBS upstream of the start site. RBS-MPD indicates the yeast diphosphomevalonate decarboxylase gene with a *Bacillus* RBS upstream of the start site. RBS-IDI indicates the yeast idi gene with a *Bacillus* RBS upstream of the start site. Terminator indicates the terminator alkaline serine protease transcription terminator from *B. amyliquefaciens*. SpecR indicates the spectinomycin resistance marker. “nprE upstream repeat for amp.” indicates a direct repeat of the upstream region used for amplification.

[0076] Figures 29A-D are a nucleotide sequence of cassette containing the lower MVA pathway and yeast idi for integration into the *B. subtilis* chromosome at the *nprE* locus (SEQ ID NO:13).

[0077] Figure 30 is a map of p9796-poplar.

[0078] Figures 31A-B are a nucleotide sequence of p9796-poplar (SEQ ID NO:14).

[0079] Figure 32 is a map of pTrcPoplar.

[0080] Figures 33A-C are a nucleotide sequence of pTrcPoplar (SEQ ID NO:15).

[0081] Figure 34 is a map of pTrcKudzu yIDI Kan.

[0082] Figures 35A-C are a nucleotide sequence of pTrcKudzu yIDI Kan (SEQ ID NO:16).

[0083] Figure 36 is a map of pTrcKudzuDXS Kan.

[0084] Figures 37A-C are a nucleotide sequence of pTrcKudzuDXS Kan (SEQ ID NO:17).

[0085] Figure 38 is a map of pCL PtrcKudzu.

[0086] Figures 39A-C are a nucleotide sequence of pCL PtrcKudzu (SEQ ID NO:18).

[0087] Figure 40 is a map of pCL PtrcKudzu A3.

[0088] Figures 41A-C are a nucleotide sequence of pCL PtrcKudzu A3 (SEQ ID NO:19).

[0089] Figure 42 is a map of pCL PtrcKudzu yIDI.

[0090] Figures 43A-C are a nucleotide sequence of pCL PtrcKudzu yIDI (SEQ ID NO:20).

[0091] Figure 44 is a map of pCL PtrcKudzu DXS.

[0092] Figures 45A-D are a nucleotide sequence of pCL PtrcKudzu DXS (SEQ ID NO:21).

[0093] Figures 46A-E show graphs representing isoprene production from biomass feedstocks. Panel A shows isoprene production from corn stover, Panel B shows isoprene production from bagasse, Panel C shows isoprene production from softwood pulp, Panel D shows isoprene production from glucose, and Panel E shows isoprene production from cells with no additional feedstock. Grey squares represent OD<sub>600</sub> measurements of the cultures at the indicated times post-inoculation and black triangles represent isoprene production at the indicated times post-inoculation.

[0094] Figure 47A shows a graph representing isoprene production by BL21 ( $\lambda$ DE3) pTrcKudzu yIDI DXS (kan) in a culture with no glucose added. Squares represent OD<sub>600</sub>, and triangles represent isoprene produced ( $\mu$ g/ml).

[0095] Figure 47B shows a graph representing isoprene production from 1% glucose feedstock invert sugar by BL21 ( $\lambda$ DE3) pTrcKudzu yIDI DXS (kan). Squares represent OD<sub>600</sub>, and triangles represent isoprene produced ( $\mu$ g/ml).

[0096] Figure 47C shows a graph representing isoprene production from 1% invert sugar feedstock by BL21 ( $\lambda$ DE3) pTrcKudzu yIDI DXS (kan). Squares represent OD<sub>600</sub>, and triangles represent isoprene produced ( $\mu$ g/ml).

[0097] Figure 47D shows a graph representing isoprene production from 1% AFEX corn stover feedstock by BL21 ( $\lambda$ DE3) pTrcKudzu yIDI DXS (kan). Squares represent OD<sub>600</sub>, and triangles represent isoprene produced ( $\mu$ g/ml).

[0098] Figures 48A-C show graphs demonstrating the effect of yeast extract on isoprene production. Panel A shows the time course of optical density within fermentors fed with varying amounts of yeast extract. Panel B shows the time course of isoprene titer within fermentors fed with varying amounts of yeast extract. The titer is defined as the amount of isoprene produced per liter of fermentation broth. Panel C shows the effect of yeast extract on isoprene production in *E. coli* grown in fed-batch culture.

[0099] Figures 49A-C show graphs demonstrating isoprene production from a 500 L bioreactor with *E. coli* cells containing the pTrcKudzu + yIDI + DXS plasmid. Panel A shows the time course of optical density within the 500-L bioreactor fed with glucose and yeast extract. Panel B shows the time course of isoprene titer within the 500-L bioreactor fed with glucose and yeast extract. The titer is defined as the amount of isoprene produced per liter of fermentation broth. Panel C shows the time course of total isoprene produced from the 500-L bioreactor fed with glucose and yeast extract.

[0100] Figure 50 is a map of pJMupperpathway2.

[0101] Figures 51A-C are the nucleotide sequence of pJMupperpathway2 (SEQ ID NO:22).

[0102] Figure 52 is a map of pBS Kudzu #2.

[0103] Figure 53A is a graph showing growth during fermentation time of *Bacillus* expressing recombinant kudzu isoprene synthase in 14 liter fed batch fermentation. Black diamonds represent a control strain (BG3594comK) without recombinant isoprene synthase (native isoprene production) and grey triangles represent CF443, *Bacillus* strain BG3594comK with pBSKudzu (recombinant isoprene production).

- [0104] Figure 53B is a graph showing isoprene production during fermentation time of *Bacillus* expressing recombinant kudzu isoprene synthase in 14 liter fed batch fermentation. Black diamonds represent a control strain (BG3594comK) without recombinant isoprene synthase (native isoprene production) and grey triangles represent CF443, *Bacillus* strain BG3594comK with pBSKudzu (recombinant isoprene production).
- [0105] Figure 54 is a time course of optical density within the 15-L bioreactor fed with glucose.
- [0106] Figure 55 is a time course of isoprene titer within the 15-L bioreactor fed with glucose. The titer is defined as the amount of isoprene produced per liter of fermentation broth.
- [0107] Figure 56 is a time course of total isoprene produced from the 15-L bioreactor fed with glucose.
- [0108] Figure 57 is a time course of optical density within the 15-L bioreactor fed with glycerol.
- [0109] Figure 58 is a time course of isoprene titer within the 15-L bioreactor fed with glycerol. The titer is defined as the amount of isoprene produced per liter of fermentation broth.
- [0110] Figure 59 is a time course of total isoprene produced from the 15-L bioreactor fed with glycerol.
- [0111] Figures 60A-60C are the time courses of optical density, mevalonic acid titer, and specific productivity within the 150-L bioreactor fed with glucose.
- [0112] Figures 61A-61C are the time courses of optical density, mevalonic acid titer, and specific productivity within the 15-L bioreactor fed with glucose.
- [0113] Figures 62A-62C are the time courses of optical density, mevalonic acid titer, and specific productivity within the 15-L bioreactor fed with glucose.
- [0114] Figure 63A-63C are the time courses of optical density, isoprene titer, and specific productivity within the 15-L bioreactor fed with glucose.
- [0115] Figures 64A-64C are the time courses of optical density, isoprene titer, and specific productivity within the 15-L bioreactor fed with glucose.
- [0116] Figures 65A-65C are the time courses of optical density, isoprene titer, and specific productivity within the 15-L bioreactor fed with glucose.
- [0117] Figures 66A-66C are the time courses of optical density, isoprene titer, and specific productivity within the 15-L bioreactor fed with glucose.
- [0118] Figure 67A-67C are the time courses of optical density, isoprene titer, and specific productivity within the 15-L bioreactor fed with glucose.

[0119] Figure 68 is a graph of the calculated adiabatic flame temperatures for Series A as a function of fuel concentration for various oxygen levels. The figure legend lists the curves in the order in which they appear in the graph. For example, the first entry in the figure legend (isoprene in air at 40 °C) corresponds to the highest curve in the graph.

[0120] Figure 69 is a graph of the calculated adiabatic flame temperatures for Series B as a function of fuel concentration for various oxygen levels with 4% water. The figure legend lists the curves in the order in which they appear in the graph.

[0121] Figure 70 is a graph of the calculated adiabatic flame temperatures for Series C as a function of fuel concentration for various oxygen levels with 5% CO<sub>2</sub>. The figure legend lists the curves in the order in which they appear in the graph.

[0122] Figure 71 is a graph of the calculated adiabatic flame temperatures for Series D as a function of fuel concentration for various oxygen levels with 10% CO<sub>2</sub>. The figure legend lists the curves in the order in which they appear in the graph.

[0123] Figure 72 is a graph of the calculated adiabatic flame temperatures for Series E as a function of fuel concentration for various oxygen levels with 15% CO<sub>2</sub>. The figure legend lists the curves in the order in which they appear in the graph.

[0124] Figure 73 is a graph of the calculated adiabatic flame temperatures for Series F as a function of fuel concentration for various oxygen levels with 20% CO<sub>2</sub>. The figure legend lists the curves in the order in which they appear in the graph.

[0125] Figure 74 is a graph of the calculated adiabatic flame temperatures for Series G as a function of fuel concentration for various oxygen levels with 30% CO<sub>2</sub>. The figure legend lists the curves in the order in which they appear in the graph.

[0126] Figure 75A is a table of the conversion of the CAFT Model results from weight percent to volume percent for series A.

[0127] Figure 75B is a graph of the flammability results from the CAFT model for Series A in Figure 68 plotted as volume percent.

[0128] Figure 76A is a table of the conversion of the CAFT Model results from weight percent to volume percent for series B.

[0129] Figure 76B is a graph of the flammability results from the CAFT model for Series B in Figure 69 plotted as volume percent.

[0130] Figure 77 is a figure depicting the flammability test vessel.

[0131] Figure 78A is a graph of the flammability Curve for Test Series 1: 0% Steam, 0 psig, and 40°C.

[0132] Figure 78B is a table summarizing the explosion and non-explosion data points for Test Series 1.

[0133] Figure 78C is a graph of the flammability curve for Test Series 1 compared with the CAFT Model.

[0134] Figure 79A is a graph of the flammability curve for Test Series 2: 4% Steam, 0 psig, and 40°C.

[0135] Figure 79B is a table summarizing the explosion and non-explosion data points for Test Series 2.

[0136] Figure 79C is a graph of the flammability curve for Test Series 2 compared with the CAFT Model.

[0137] Figures 80A-B are a table of the detailed experimental conditions and results for Test Series 1.

[0138] Figure 81 is a table of the detailed experimental conditions and results for Test Series 2.

[0139] Figure 82 is a graph of the calculated adiabatic flame temperature plotted as a function of fuel concentration for various nitrogen/oxygen ratios at 3 atmospheres of pressure.

[0140] Figure 83 is a graph of the calculated adiabatic flame temperature plotted as a function of fuel concentration for various nitrogen/oxygen ratios at 1 atmosphere of pressure.

[0141] Figure 84 is a graph of the flammability envelope constructed using data from Figure 82 and following the methodology described in Example 13. The experimental data points (circles) are from tests described herein that were conducted at 1 atmosphere initial system pressure.

[0142] Figure 85 is a graph of the flammability envelope constructed using data from Figure 83 and following the methodology described in Example 13. The experimental data points (circles) are from tests described herein that were conducted at 1 atmosphere initial system pressure.

[0143] Figure 86A is a GC/MS chromatogram of fermentation off-gas.

[0144] Figure 86B is an expansion of Fig 86A to show minor volatiles present in fermentation off-gas.

[0145] Figure 87A is a GC/MS chromatogram of trace volatiles present in off-gas following cryo-trapping at -78°C.

[0146] Figure 87B is a GC/MS chromatogram of trace volatiles present in off-gas following cryo-trapping at -196°C.

- [0147] Figure 87C is an expansion of Figure 87B.
- [0148] Figure 87D is an expansion of Figure 87C.
- [0149] Figures 88A-B are GC/MS chromatogram comparing C5 hydrocarbons from petroleum-derived isoprene (Figure 88A) and biologically produced isoprene (Figure 88B). The standard contains three C5 hydrocarbon impurities eluting around the main isoprene peak (Figure 88A). In contrast, biologically produced isoprene contains amounts of ethanol and acetone (run time of 3.41 minutes) (Figure 88A).
- [0150] Figure 89 is a graph of the analysis of fermentation off-gas of an *E. coli* BL21 (DE3) pTrcIS strain expressing a Kudzu isoprene synthase and fed glucose with 3 g/L yeast extract.
- [0151] Figure 90 shows the structures of several impurities that are structurally similar to isoprene and may also act as polymerization catalyst poisons.
- [0152] Figure 91 is a map of pTrcHis2AUpperPathway (also called pTrcUpperMVA).
- [0153] Figures 92A-92C are the nucleotide sequence of pTrcHis2AUpperPathway (also called pTrcUpperMVA) (SEQ ID NO:23).
- [0154] Figure 93 is a time course of optical density within the 15-L bioreactor fed with glucose.
- [0155] Figure 94 is a time course of isoprene titer within the 15-L bioreactor fed with glucose. The titer is defined as the amount of isoprene produced per liter of fermentation broth.
- [0156] Figure 95 is a time course of total isoprene produced from the 15-L bioreactor fed with glucose.
- [0157] Figure 96 is a time course of optical density within the 15-L bioreactor fed with invert sugar.
- [0158] Figure 97 is a time course of isoprene titer within the 15-L bioreactor fed with invert sugar. The titer is defined as the amount of isoprene produced per liter of fermentation broth.
- [0159] Figure 98 is a time course of total isoprene produced from the 15-L bioreactor fed with invert sugar.
- [0160] Figure 99 is a time course of optical density within the 15-L bioreactor fed with glucose.
- [0161] Figure 100 is a time course of isoprene titer within the 15-L bioreactor fed with glucose. The titer is defined as the amount of isoprene produced per liter of fermentation broth.
- [0162] Figure 101 is a time course of isoprene specific activity from the 15-L bioreactor fed with glucose.
- [0163] Figure 102 is a map of pCLPtrcUpperPathwayHGS2.

- [0164] Figures 103A-103C are the nucleotide sequence of pCLPtrcUpperPathwayHGS2 (SEQ ID NO:24).
- [0165] Figure 104 is a time course of optical density within the 15-L bioreactor fed with glucose.
- [0166] Figure 105 is a time course of isoprene titer within the 15-L bioreactor fed with glucose. The titer is defined as the amount of isoprene produced per liter of fermentation broth.
- [0167] Figure 106 is a time course of total isoprene produced from the 15-L bioreactor fed with glucose.
- [0168] Figure 107 is a map of plasmid MCM330 (FRT-cm-FRT-gi1.2-KKDy at attTn7).
- [0169] Figures 108A-108C are the nucleotide sequence of plasmid MCM330 (SEQ ID NO:25).
- [0170] Figure 109 is a map of pET24D-Kudzu.
- [0171] Figures 110A-B are the nucleotide sequence of pET24D-Kudzu (SEQ ID NO:26).
- [0172] Figure 111A is a time course of optical density within the 15-L bioreactor fed with glucose.
- [0173] Figure 111B is a time course of isoprene titer within the 15-L bioreactor fed with glucose. The titer is defined as the amount of isoprene produced per liter of fermentation broth.
- [0174] Figure 111C is a time course of specific productivity of isoprene in the 15-L bioreactor fed with glucose.
- [0175] Figure 112A is a map of the *M. mazei* archaeal Lower Pathway operon.
- [0176] Figures 112B-C are the nucleotide sequence of the *M. mazei* archaeal lower Pathway operon (SEQ ID NO:27).
- [0177] Figure 113A is a map of MCM382 – pTrcKudzuMVK(mazei).
- [0178] Figures 113B-C are the nucleotide sequence of MCM382 – pTrcKudzuMVK(mazei) (SEQ ID NO:28).
- [0179] Figure 114A is a map of MCM376 - MVK from *M. mazei* archaeal Lower in pET200D.
- [0180] Figures 114B-C are the nucleotide sequence of MCM376 - MVK from *M. mazei* archaeal Lower in pET200D (SEQ ID NO:29).
- [0181] Figures 115A-115D demonstrate that over-expression of MVK and isoprene synthase results in increased isoprene production. Accumulated isoprene and CO<sub>2</sub> from MCM401 and MCM343 during growth on glucose in 100 mL bioreactors with 100 and 200 μM IPTG induction of isoprene production was measured over a 22 hour time course. Figure 115A is a

graph of the accumulated isoprene (%) from MCM343. Figure 115B is a graph of the accumulated isoprene (%) from MCM401. Figure 115C is a graph of the accumulated CO<sub>2</sub> (%) from MCM343. Figure 115D is a graph of the accumulated CO<sub>2</sub> (%) from MCM401.

**[0182]** Figure 116 is a time course of optical density within the 15-L bioreactor fed with glucose.

**[0183]** Figure 117 is a time course of isoprene titer within the 15-L bioreactor fed with glucose. The titer is defined as the amount of isoprene produced per liter of fermentation broth.

**[0184]** Figure 118 is a time course of total isoprene produced from the 15-L bioreactor fed with glucose.

**[0185]** Figure 119 is a graph of the total carbon dioxide evolution rate (TCER), or metabolic activity profile, within the 15-L bioreactor fed with glucose.

**[0186]** Figure 120 is a graph of the cell viability during isoprene production within the 15-L bioreactor fed with glucose. TVC/OD is the total viable counts (colony forming units) in 1 mL of broth per optical density unit (OD<sub>550</sub>).

**[0187]** Figure 121 is a time course of optical density within the 15-L bioreactor fed with glucose.

**[0188]** Figure 122 is a time course of isoprene titer within the 15-L bioreactor fed with glucose. The titer is defined as the amount of isoprene produced per liter of fermentation broth.

**[0189]** Figure 123 is a time course of total isoprene produced from the 15-L bioreactor fed with glucose.

**[0190]** Figure 124 is a time course of volumetric productivity within the 15-L bioreactor fed with glucose. The volumetric productivity is defined as the amount of isoprene produced per liter of broth per hour.

**[0191]** Figure 125 is a time course of instantaneous yield within the 15-L bioreactor fed with glucose. The instantaneous yield is defined as the amount of isoprene (gram) produced per amount of glucose (gram) fed to the bioreactor (w/w) during the time interval between the data points.

**[0192]** Figure 126 is a graph of the total carbon dioxide evolution rate (TCER), or metabolic activity profile, within the 15-L bioreactor fed with glucose.

**[0193]** Figure 127 is cell viability during isoprene production within the 15-L bioreactor fed with glucose. TVC/OD is the total viable counts (colony forming units) in 1 mL of broth per optical density unit (OD<sub>550</sub>).

- [0194] Figure 128 is a time course of optical density within the 15-L bioreactor fed with glucose.
- [0195] Figure 129 is a time course of isoprene titer within the 15-L bioreactor fed with glucose. The titer is defined as the amount of isoprene produced per liter of fermentation broth.
- [0196] Figure 130 is a time course of total isoprene produced from the 15-L bioreactor fed with glucose.
- [0197] Figure 131 is a graph of total carbon dioxide evolution rate (TCER), or metabolic activity profile, within the 15-L bioreactor fed with glucose.
- [0198] Figure 132 is a graph showing that a transient decrease in the airflow to the bioreactor caused a spike in the concentration of isoprene in the off-gas that did not cause a dramatic decrease in metabolic activity (TCER). TCER, or metabolic activity, is the total carbon dioxide evolution rate.
- [0199] Figure 133 is a graph of the cell viability during isoprene production within the 15-L bioreactor fed with glucose. TVC/OD is the total viable counts (colony forming units) in 1 mL of broth per optical density unit (OD<sub>550</sub>).
- [0200] Figure 134 is a time course of optical density within the 15-L bioreactor fed with glucose. Dotted vertical lines denote the time interval when isoprene was introduced into the bioreactor at a rate of 1 g/L/hr.
- [0201] Figure 135 is total carbon dioxide evolution rate (TCER), or metabolic activity profile, within the 15-L bioreactor fed with glucose. Dotted vertical lines denote the time interval when isoprene was introduced into the bioreactor at a rate of 1 g/L/hr.
- [0202] Figure 136 is cell viability during isoprene production within the 15-L bioreactor fed with glucose. TVC/OD is the total viable counts (colony forming units) in 1 mL of broth per optical density unit (OD<sub>550</sub>). Dotted vertical lines denote the time interval when isoprene was introduced into the bioreactor at a rate of 1 g/L/hr.
- [0203] Figures 137A-B are the sequence of *Populus alba* pET24a: isoprene synthase gene highlighted in bold letters (SEQ ID NO:30).
- [0204] Figures 137C-D are the sequence of *Populus nigra* pET24a: isoprene synthase gene highlighted in bold letters (SEQ ID NO:31).
- [0205] Figures 137E-F are the sequence of *Populus tremuloides* pET24a (SEQ ID NO:32).
- [0206] Figure 137G is the amino acid sequence of *Populus tremuloides* isoprene synthase gene (SEQ ID NO:33).

- [0207] Figures 137H-I are the sequence of *Populus trichocarpa* pET24a: isoprene synthase gene highlighted in bold letters (SEQ ID NO:34).
- [0208] Figures 137J-K are the sequence of *Populus tremula* × *Populus alba* pET24a: isoprene synthase gene highlighted in bold letters (SEQ ID NO:35).
- [0209] Figure 137L is a map of MCM93 which contains the kudzu IspS coding sequence in a pCR2.1 backbone.
- [0210] Figures 137M-N are the sequence of MCM93 (SEQ ID NO:36).
- [0211] Figure 137O is a map of pET24D-Kudzu.
- [0212] Figures 137P-Q are the sequence of pET24D-Kudzu (SEQ ID NO:37).
- [0213] Figure 138 is isoprene synthase expression data for various poplar species as measured in the whole cell head space assay. Y-axis is  $\mu\text{g/L/OD}$  of isoprene produced by 0.2 mL of a culture induced with IPTG.
- [0214] Figure 139 is relative activity of Poplar isoprene synthase enzymes as measured by DMAPP assay. Poplar enzymes have significantly higher activity than the isoprene synthase from Kudzu. Poplar [*alba* × *tremula*] only had traces (< 1%) of activity and is not shown in the plot.
- [0215] Figure 140 is a map of pDONR221:19430 - hybrid\_HGS.
- [0216] Figure 141 is the nucleotide sequence of pDONR221:19430 - hybrid\_HGS, the sequence of Kudzu isoprene synthase codon-optimized for yeast (SEQ ID NO:38).
- [0217] Figure 142A is a map of pDW14.
- [0218] Figures 142B-C are the complete nucleotide sequence of pDW14 (SEQ ID NO:39).
- [0219] Figure 143 shows induced INVSc-1 strains harboring pDW14 or pYES-DEST52. Figure 143A. A 4-12% bis tris gel (Novex, Invitrogen) of lysates generated from INVSc-1 strains induced with galactose and stained with SimplyBlue SafeStain (Invitrogen). Figure 143B. Western blot analysis of the same strains using the WesternBreeze kit (Invitrogen). Lanes are as follows: 1, INVSc-1 + pYES-DEST52; 2, INVSc-1 + pDW14 (isolate 1); 3, INVSc-1 + pDW14 (isolate 2). MW (in kDa) is indicated (using the SeeBlue Plus2 molecular weight standard).
- [0220] Figure 144 (Figures 144A and 144B) shows induced INVSc-1 strains harboring pDW14 or pYES-DEST52. Figure 144A.  $\text{OD}_{600}$  of galactose-induced strains prior to lysis. The y-axis is  $\text{OD}_{600}$ . Figure 144B. DMAPP assay of isoprene synthase headspace in control and isoprene synthase-harboring strains. Specific activity was calculated as  $\mu\text{g HG/L/OD}$ . Samples are as follows: Control, INVSc-1 + pYES-DEST52; HGS-1, INVSc-1 + pDW14 (isolate 1); HGS-2, INVSc-1 + pDW14 (isolate 2).

- [0221] Figure 145A is a map of codon optimized isoprene synthase fluo-opt2v2.
- [0222] Figure 145B is the nucleotide sequence of codon optimized isoprene synthase fluo-opt2v2 (SEQ ID NO:40).
- [0223] Figure 146A is a map of pBBR1MCS5.
- [0224] Figures 146B-C are the nucleotide sequence of pBBR1MCS5 (SEQ ID NO:41).
- [0225] Figure 147A is a map of pBBR5HGSOpt2\_2.
- [0226] Figures 147B-C are the nucleotide sequence of pBBR5HGSOpt2\_2 (SEQ ID NO:42).
- [0227] Figure 148 is a graph of CER versus fermentation time for strain MCM401, uninduced, induced with IPTG (4 x 50  $\mu$ mol) or IPTG (2 x 100  $\mu$ mol).
- [0228] Figure 149 shows concentration of glucose in sugar cane solutions, pH adjusted or not, as a function of the number of autoclaving cycles (one cycle = 30 min).
- [0229] Figure 150 shows growth curves ( $OD_{600}$  as a function of time) of *Pseudomonas putida* F1 and *Pseudomonas fluorescens* ATCC13525 on glucose, sugar cane, and inverted sugar cane.
- [0230] Figure 151 shows growth curves ( $OD_{600}$  as a function of time) of *E. coli* BL21(DE3), MG1655, ATCC11303 and B REL 606 on glucose, sugar cane, and inverted sugar cane.
- [0231] Figure 152 is a map of plasmid pET24 P. alba HGS.
- [0232] Figure 153A-B are the nucleotide sequence of plasmid pET24 P. alba HGS (SEQ ID NO:43).
- [0233] Figure 154 is a schematic diagram showing restriction sites used for endonuclease digestion to construct plasmid EWL230 and compatible cohesive ends between BspHI and NcoI sites.
- [0234] Figure 155 is a map of plasmid EWL230.
- [0235] Figures 156A-B are the nucleotide sequence of plasmid EWL230 (SEQ ID NO:44).
- [0236] Figure 157 is a schematic diagram showing restriction sites used for endonuclease digestion to construct plasmid EWL244 and compatible cohesive ends between NsiI and PstI sites.
- [0237] Figure 158 is a map of plasmid EWL244.
- [0238] Figures 159A-B are the nucleotide sequence of plasmid EWL244 (SEQ ID NO:45).
- [0239] Figure 160A is a map of the *M. mazei* archaeal Lower Pathway operon.
- [0240] Figures 160B-C are the nucleotide sequence of the *M. mazei* archaeal Lower Pathway operon (SEQ ID NO:46).
- [0241] Figure 161A is a map of MCM376-MVK from *M. mazei* archaeal Lower in pET200D.

- [0242] Figures 161B-C are the nucleotide sequence of MCM376-MVK from *M. mazei* archaeal Lower in pET200D (SEQ ID NO:47).
- [0243] Figure 162 is a map of plasmid pBBRCMPG11.5-pgl.
- [0244] Figures 163A-B are the nucleotide sequence of plasmid pBBRCMPG11.5-pgl (SEQ ID NO:48).
- [0245] Figures 164A-F are graphs of isoprene production by *E. coli* strain expressing *M. mazei* mevalonate kinase, *P. alba* isoprene synthase, and *pgl* (RHM111608-2), and grown in fed-batch culture at the 15-L scale. Figure 164A shows the time course of optical density within the 15-L bioreactor fed with glucose. Figure 164B shows the time course of isoprene titer within the 15-L bioreactor fed with glucose. The titer is defined as the amount of isoprene produced per liter of fermentation broth. Method for calculating isoprene: cumulative isoprene produced in 59 hrs, g/Fermentor volume at 59 hrs, L [=] g/L broth. Figure 164C also shows the time course of isoprene titer within the 15-L bioreactor fed with glucose. Method for calculating isoprene:  $\int$ (Instantaneous isoprene production rate, g/L/hr)dt from t = 0 to 59 hours [=] g/L broth. Figure 164D shows the time course of total isoprene produced from the 15-L bioreactor fed with glucose. Figure 164E shows volumetric productivity within the 15-L bioreactor fed with glucose. Figure 164F shows carbon dioxide evolution rate (CER), or metabolic activity profile, within the 15-L bioreactor fed with glucose.
- [0246] Figures 165A-B are graphs showing analysis of off-gas from fermentation in 15L bioreactors. Sample A is strain RM111608-2 sampled at 64.8 hours. Sample B is strain EWL256 was *E. coli* BL21 (DE3), pCL upper, cmR-gi1.2-yKKDyI, pTrcAlba-mMVK sampled at 34.5 hours. Hydrogen is detected above the baseline ( $0.95 \times 10^{-8}$  torr) for both samples.
- [0247] Figure 166A shows an exemplary Bioisoprene™ recovery unit.
- [0248] Figure 166B shows an exemplary Bioisoprene™ desorption/condensation setup.
- [0249] Figure 167 shows a GC/FID chromatogram of a Bioisoprene™ product. The material was determined to be 99.7% pure.
- [0250] Figure 168A-C show the GC/FID chromatograms of a Bioisoprene™ sample before (A) and after treatment with alumina (B) or silica (C). The isoprene peak is not shown in these chromatograms.
- [0251] Figure 169 shows a diagram of a process and associated apparatus for purifying isoprene from a fermentation off-gas.
- [0252] Figure 170 shows GC/FID chromatogram of partially hydrogenated BioIsoprene™ monomer. Compound 1 (RT = 12.30 min) = 3-methyl-1-butene, compound 2 (RT = 12.70 min)

= 2-methylbutane, compound 3 (RT = 13.23 min) = 2-methyl-1-butene, compound 4 (RT = 13.53 min) = isoprene, compound 5 (RT = 14.01 min) = 2-methyl-2-butene).

**[0253]** Figure 171 shows the GC/MS Total Ion Chromatogram for products derived from the Amberlyst-15 acid resin-catalyzed dimerization of 2-methyl-2-butene.

**[0254]** Figure 172 shows the GC/MS Total Ion Chromatogram for products derived from Amberlyst 15 acid resin-catalyzed oligomerization of BioIsoprene™ monomer.

**[0255]** Figure 173 shows a process flow diagram for the conversion of a C5 stream into a C10/C15 product stream using a dimerization reactor. The C5 stream comprises BioIsoprene™ monomer and/or C5 derivatives of BioIsoprene™ monomer.

#### DETAILED DESCRIPTION OF THE INVENTION

**[0256]** The invention provides, *inter alia*, compositions and methods for producing a fuel constituent from isoprene. Provided herein are fuel constituents or additives, for example, cyclic isoprene dimers and trimers, linear isoprene oligomers, aromatic and alicyclic isoprene derivatives, and oxygenated isoprene derivatives. The fuel constituent can be produced by chemical transformations of a starting material comprising a commercially beneficial amount of highly pure isoprene. In one aspect, the commercially beneficial amount of highly pure isoprene comprises bioisoprene. In another aspect, a commercially beneficial amount of highly pure isoprene can be bioisoprene. In another aspect, a commercially beneficial amount of highly pure isoprene can be highly pure isoprene compositions produced by culturing cells expressing a heterologous isoprene synthase enzyme. In other aspects, highly pure isoprene undergoes oligomerization to form unsaturated isoprene oligomers such as cyclic dimers or trimers and linear oligomers. The unsaturated oligomers may be hydrogenated to produce saturated hydrocarbon fuel constituent. In some embodiment, reaction of highly pure isoprene with alcohols in the presence of an acid catalyst produces fuel oxygenates. In another aspect, the highly pure isoprene is partially hydrogenated to produce isoamylenes. In some embodiments, an isoamylene product derived from the highly pure isoprene undergoes dimerization to form isodecenes. In some embodiments, isoamylene products derived from the highly pure isoprene react with alcohols in the presence of an acid catalyst to produce fuel oxygenates.

**[0257]** Bioisoprene derived from renewable carbon can be converted to a variety of hydrocarbon fuels by chemical catalysis. Provided herein are methods for recovering isoprene from fermentation and subsequent conversion to hydrocarbon fuels by chemical catalysis to compounds of higher molecular weight. These methods include, but are not limited to,

recovering and purifying isoprene from fermentation off-gas and subsequent gas or liquid phase catalysis to provide compounds with fuel value. Both continuous and batch mode processes are contemplated within the scope of the invention.

**[0258]** As further detailed herein, a bioisoprene composition is distinguished from a petro-isoprene composition in that a bioisoprene composition is substantially free of any contaminating unsaturated C5 hydrocarbons that are usually present in petro-isoprene compositions, such as, but not limited to, 1,3-cyclopentadiene, *trans*-1,3-pentadiene, *cis*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, and *cis*-pent-3-ene-1-yne. If any contaminating unsaturated C5 hydrocarbons are present in the bioisoprene starting material described herein, they are present in lower levels than that in petro-isoprene compositions. Accordingly, any fuel products derived from bioisoprene compositions described herein is essentially free of, or contains at lower levels than that in fuel products derived from petro-isoprene, any contaminating unsaturated C5 hydrocarbons or products derived from such contaminating unsaturated C5 hydrocarbons. In addition, the sulfur levels in a bioisoprene composition are lower than the sulfur levels in petro-isoprene compositions. Fuel products derived from bioisoprene compositions contain lower levels of sulfur than that in fuel products derived from petro-isoprene.

**[0259]** Bioisoprene is distinguished from petro-isoprene in that bioisoprene is produced with other bio-byproducts (compounds derived from the biological sources and/or associated the biological processes that are obtained together with bioisoprene) that are not present or present in much lower levels in petro-isoprene compositions, such as alcohols, aldehydes, ketone and the like. The bio-byproducts may include, but are not limited to, ethanol, acetone, methanol, acetaldehyde, methacrolein, methyl vinyl ketone, 2-methyl-2-vinylloxirane, *cis*- and *trans*-3-methyl-1,3-pentadiene, a C5 prenyl alcohol (such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-1-ol), 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (*trans*-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (*E*)-3,7-dimethyl-1,3,6-octatriene, (*Z*)-3,7-dimethyl-1,3,6-octatriene, 2,3-cycloheptenolpyridine, or a linear isoprene polymer (such as a linear isoprene dimer or a linear isoprene trimer derived from the polymerization of multiple isoprene units). Fuel products

derived from bioisoprene contain one or more of the bio-byproducts or compounds derived from any of the bio-byproducts. In addition, fuel products derived from bioisoprene may contain compounds formed from these bio-byproducts during subsequent chemical conversion.

Examples of such compounds include those derived from Diels-Alder cycloaddition of dienophiles to isoprene or fuel derivatives thereof, the oxidation of isoprene or fuel derivatives.

**[0260]** Further, bioisoprene is distinguished from petro-isoprene by carbon finger-printing. In one aspect, bioisoprene has a higher radioactive carbon-14 ( $^{14}\text{C}$ ) content or higher  $^{14}\text{C}/^{12}\text{C}$  ratio than petro-isoprene. Bioisoprene is produced from renewable carbon sources, thus the  $^{14}\text{C}$  content or the  $^{14}\text{C}/^{12}\text{C}$  ratio in bioisoprene is the same as that in the present atmosphere. Petro-isoprene, on the other hand, is derived from fossil fuels deposited thousands to millions of years ago, thus the  $^{14}\text{C}$  content or the  $^{14}\text{C}/^{12}\text{C}$  ratio is diminished due to radioactive decay. As discussed in greater detail herein, the fuel products derived from bioisoprene has higher  $^{14}\text{C}$  content or  $^{14}\text{C}/^{12}\text{C}$  ratio than fuel products derived from petro-isoprene. In one embodiment, a fuel product derived from bioisoprene described herein has a  $^{14}\text{C}$  content or  $^{14}\text{C}/^{12}\text{C}$  ratio similar to that in the atmosphere. In another aspect, bioisoprene can be analytically distinguished from petro-isoprene by the stable carbon isotope ratio ( $^{13}\text{C}/^{12}\text{C}$ ), which can be reported as “delta values” represented by the symbol  $\delta^{13}\text{C}$ . For examples, for isoprene derived from extractive distillation of  $\text{C}_5$  streams from petroleum refineries,  $\delta^{13}\text{C}$  is about -22‰ to about -24‰. This range is typical for light, unsaturated hydrocarbons derived from petroleum, and products derived from petroleum-based isoprene typically contain isoprenic units with the same  $\delta^{13}\text{C}$ . Bioisoprene produced by fermentation of corn-derived glucose ( $\delta^{13}\text{C}$  -10.73‰) with minimal amounts of other carbon-containing nutrients (e.g., yeast extract) produces isoprene which can be polymerized into polyisoprene with  $\delta^{13}\text{C}$  -14.66‰ to -14.85‰. Products produced from such bioisoprene are expected to have  $\delta^{13}\text{C}$  values that are less negative than those derived from petroleum-based isoprene.

**[0261]** Compounds made by these methods include cyclic isoprene dimers and trimers, linear oligomers, aromatic and alicyclic derivatives. Diisoamylenes are made by methods comprising partial hydrogenation of bioisoprene compositions. These chemical derivatives of isoprene are useful as liquid transportation fuels (IsoFuels™) and as fuel additives.

**[0262]** Also provided herein are methods for the production of oxygenated derivatives of isoprene including alcohols, ketones, esters and ethers. Methods for the synthesis of oxygenated derivatives of isoprene can also be performed in liquid or gas phase, using homogeneous and heterogeneous catalysts. Compounds of this chemical class are also useful as liquid

transportation fuels, and can be used in fuel blends as fuel oxygenates for emissions reduction and as fuel modifiers, for example as cetane boosters for diesel.

**[0263]** While isoprene can be obtained by fractionating petroleum, the purification of this material is expensive and time-consuming. Petroleum cracking of the C5 stream of hydrocarbons produces only about 15% isoprene. Isoprene is also naturally produced by a variety of microbial, plant, and animal species. In particular, two pathways have been identified for the biosynthesis of isoprene: the mevalonate (MVA) pathway and the non-mevalonate (DXP) pathway. Genetically engineered cell cultures in bioreactors have produced isoprene more efficiently, in larger quantities, in higher purities and/or with unique impurity profiles, e.g. as described in U.S. provisional patent application Nos. 61/013,386 and 61/013,574, filed on December 13, 2007, WO 2009/076676, U.S. provisional patent application Nos. 61/134,094, 61/134,947, 61/134,011 and 61/134,103, filed on July 2, 2008, WO 2010/003007, U.S. provisional patent application No. 61/097,163, filed on September 15, 2008, WO 2010/031079, U.S. provisional patent application No. 61/097,186, filed on September 15, 2008, WO 2010/031062, U.S. provisional patent application No. 61/097,189, filed on September 15, 2008, WO 2010/031077, U.S. provisional patent application No. 61/097,200, filed on September 15, 2008, WO 2010/031068, U.S. provisional patent application No. 61/097,204, filed on September 15, 2008, WO 2010/031076, U.S. provisional patent application No. 61/141,652, filed on December 30, 2008, PCT/US09/069862, U.S. patent application No. 12/335,071, filed December 15, 2008 (US 2009/0203102 A1) and U.S. patent application No. 12/429,143, filed April 23, 2009 (US 2010/0003716 A1), which are incorporated by reference in their entireties.

### *Definitions*

**[0264]** Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although any methods and materials similar or equivalent to those described herein find use in the practice of the present invention, the preferred methods and materials are described herein. Accordingly, the terms defined immediately below are more fully described by reference to the Specification as a whole. All documents cited are, in relevant part, incorporated herein by reference. However, the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.

**[0265]** As used herein, the singular terms “a,” “an,” and “the” include the plural reference unless the context clearly indicates otherwise.

**[0266]** It is intended that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification will include every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification will include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.

**[0267]** The term “isoprene” refers to 2-methyl-1,3-butadiene (CAS# 78-79-5), which is the direct and final volatile C5 hydrocarbon product from the elimination of pyrophosphate from 3,3-dimethylallyl pyrophosphate (DMAPP), and does not involve the linking or polymerization of [an] IPP molecule(s) to [a] DMAPP molecule(s). The term “isoprene” is not generally intended to be limited to its method of production unless indicated otherwise herein.

**[0268]** As used herein, “biologically produced isoprene” or “bioisoprene” is isoprene produced by any biological means, such as produced by genetically engineered cell cultures, natural microbes, plants or animals.

**[0269]** A “bioisoprene composition” refers to a composition that can be produced by any biological means, such as systems (e.g., cells) that are engineered to produce isoprene. It contains isoprene and other compounds that are co-produced (including impurities) and/or isolated together with isoprene. A bioisoprene composition usually contains fewer hydrocarbon impurities than isoprene produced from petrochemical sources and often requires minimal treatment in order to be of polymerization grade. As detailed herein, bioisoprene composition also has a different impurity profile from a petrochemically produced isoprene composition.

**[0270]** As used herein, “at least a portion of the isoprene starting composition” can refer to at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% of the isoprene starting composition undergoing chemical transformation.

**[0271]** As used herein, IsoFuels™ refers to fuels including liquid transportation fuels that are derived from isoprene. BioIsoFuels™ refers to fuels including liquid transportation fuels that are derived from bioisoprene.

**[0272]** The term “oligomerization” as used herein refers to a chemical process for combining two or more monomer units. “Oligomerization” of isoprene produces a derivative of isoprene

derived from two or more molecules of isoprene, such as linear dimers of isoprene, cyclic dimers of isoprene, linear trimers of isoprene, cyclic trimers of isoprene and the like.

**[0273]** “Complete hydrogenation”, “Completely hydrogenate” or “Fully hydrogenate” is defined as the addition of hydrogen ( $H_2$ ), typically in the presence of a hydrogenation catalyst, to all unsaturated functional groups, such as carbon-carbon double bonds, within a precursor compound to give fully saturated product compounds. For example, complete hydrogenation of isoprene forms isopentane whereby 2 moles of  $H_2$  is consumed per mole of isoprene.

**[0274]** “Partial hydrogenation” or “Partially hydrogenate” is defined as the addition of hydrogen ( $H_2$ ), typically in the presence of a hydrogenation catalyst, to at least one, but not all unsaturated functional groups, such as carbon-carbon double bonds, within a precursor compound. The product(s) of partial hydrogenation can be further completely hydrogenated to give fully saturated product compounds. Partial hydrogenation of a diene forms one or more mono-olefins. For example, partial hydrogenation of isoprene can give 3 isomeric isopentenes (2-methylbut-1-ene, 2-methylbut-2-ene and 3-methylbut-1-ene) whereby 1 mole of  $H_2$  is consumed per mole of isoprene.

**[0275]** “Selective hydrogenation” or “Selectively hydrogenate” is defined as the addition of hydrogen ( $H_2$ ), typically in the presence of a hydrogenation catalyst, to at least one, but not all unsaturated functional groups, such as carbon-carbon double bonds, within a precursor compound whereby certain unsaturated functional groups are preferentially hydrogenated over other unsaturated groups under the chosen conditions. For example, selective hydrogenation of isoprene may form preferentially 2-methyl-2-butene, 2-methyl-1-butene, 3-methyl-1-butene or a mixture thereof.

**[0276]** As used herein, the term “polypeptides” includes polypeptides, proteins, peptides, fragments of polypeptides, and fusion polypeptides.

**[0277]** As used herein, an “isolated polypeptide” is not part of a library of polypeptides, such as a library of 2, 5, 10, 20, 50 or more different polypeptides and is separated from at least one component with which it occurs in nature. An isolated polypeptide can be obtained, for example, by expression of a recombinant nucleic acid encoding the polypeptide.

**[0278]** By “heterologous polypeptide” is meant a polypeptide whose amino acid sequence is not identical to that of another polypeptide naturally expressed in the same host cell. In particular, a heterologous polypeptide is not identical to a wild-type polypeptide that is found in the same host cell in nature.

**[0279]** “Codon degeneracy” refers to divergence in the genetic code permitting variation of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid for improved expression in a host cell, it is desirable in some embodiments to design the nucleic acid such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

**[0280]** As used herein, a “nucleic acid” refers to two or more deoxyribonucleotides and/or ribonucleotides covalently joined together in either single or double-stranded form.

**[0281]** By “recombinant nucleic acid” is meant a nucleic acid of interest that is free of one or more nucleic acids (*e.g.*, genes) which, in the genome occurring in nature of the organism from which the nucleic acid of interest is derived, flank the nucleic acid of interest. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (*e.g.*, a cDNA, a genomic DNA fragment, or a cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences.

**[0282]** By “heterologous nucleic acid” is meant a nucleic acid whose nucleic acid sequence is not identical to that of another nucleic acid naturally found in the same host cell. In particular, a heterologous nucleic acid is not identical to a wild-type nucleic acid that is found in the same host cell in nature.

**[0283]** As used herein, a “vector” means a construct that is capable of delivering, and desirably expressing one or more nucleic acids of interest in a host cell. Examples of vectors include, but are not limited to, plasmids, viral vectors, DNA or RNA expression vectors, cosmids, and phage vectors.

**[0284]** As used herein, an “expression control sequence” means a nucleic acid sequence that directs transcription of a nucleic acid of interest. An expression control sequence can be a promoter, such as a constitutive or an inducible promoter, or an enhancer. An “inducible promoter” is a promoter that is active under environmental or developmental regulation. The expression control sequence is operably linked to the nucleic acid segment to be transcribed.

**[0285]** The term “selective marker” or “selectable marker” refers to a nucleic acid capable of expression in a host cell that allows for ease of selection of those host cells containing an introduced nucleic acid or vector. Examples of selectable markers include, but are not limited to,

antibiotic resistance nucleic acids (*e.g.*, kanamycin, ampicillin, carbenicillin, gentamicin, hygromycin, phleomycin, bleomycin, neomycin, or chloramphenicol) and/or nucleic acids that confer a metabolic advantage, such as a nutritional advantage on the host cell. Exemplary nutritional selective markers include those markers known in the art as *amdS*, *argB*, and *pyr4*.

### *Compositions and Systems*

[0286] Isoprene derived from petrochemical sources usually is an impure C5 hydrocarbon fraction which requires extensive purification before the material is suitable for polymerization or other chemical transformations. Several impurities are particularly problematic given their structural similarity to isoprene and the fact that they can act as polymerization catalyst poisons. Such compounds include, but are not limited to, 1,3-cyclopentadiene, *cis*- and *trans*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, and *cis*-pent-3-ene-1-yne. As detailed below, biologically produced isoprene can be substantially free of any contaminating unsaturated C5 hydrocarbons without undergoing extensive purification. Some biologically produced isoprene compositions contain ethanol, acetone, and C5 prenyl alcohols. These components are more readily removed from the isoprene stream than the isomeric C5 hydrocarbon fractions that are present in isoprene compositions derived from petrochemical sources. Further, these impurities can be managed in the bioprocess, for example by genetic modification of the producing strain, carbon feedstock, alternative fermentation conditions, recovery process modifications and additional or alternative purification methods.

[0287] In one aspect, the invention features compositions and systems for producing a fuel constituent from isoprene comprising: (a) a commercially beneficial amount of highly pure isoprene starting composition; and (b) a fuel constituent produced from at least a portion of the highly pure isoprene starting material; where at least a portion of the commercially beneficial amount of highly pure isoprene starting composition undergoes a chemical transformation. A highly pure isoprene starting material is subjected to chemical reactions to produce a commercially beneficial amount of product that is useful for making fuels. In one aspect, a commercially beneficial amount of highly pure isoprene comprises bioisoprene. In one aspect, a commercially beneficial amount of highly pure isoprene can be bioisoprene.

*Exemplary starting isoprene compositions*

**[0288]** In some embodiments, the commercially beneficial amount of highly pure isoprene starting composition comprises greater than or about 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mg of isoprene. In some embodiments, the starting isoprene composition comprises greater than or about 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 g of isoprene. In some embodiments, the starting isoprene composition comprises greater than or about 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000 kg of isoprene. In some embodiments, the amount of isoprene in the starting composition is between about 2 to about 5,000 mg, such as between about 2 to about 100 mg, about 100 to about 500 mg, about 500 to about 1,000 mg, about 1,000 to about 2,000 mg, or about 2,000 to about 5,000 mg. In some embodiments, the amount of isoprene in the starting composition is between about 20 to about 5,000 mg, about 100 to about 5,000 mg, about 200 to about 2,000 mg, about 200 to about 1,000 mg, about 300 to about 1,000 mg, or about 400 to about 1,000 mg. In some embodiments, the amount of isoprene in the starting composition is between about 2 to about 5,000 g, such as between about 2 to about 100 g, about 100 to about 500 g, about 500 to about 1,000 g, about 1,000 to about 2,000 g, or about 2,000 to about 5,000 g. In some embodiments, the amount of isoprene in the starting composition is between about 2 to about 5,000 kg, about 10 to about 2,000 kg, about 20 to about 1,000 kg, about 20 to about 500 kg, about 30 to about 200 kg, or about 40 to about 100 kg. In some embodiments, greater than or about 20, 25, 30, 40, 50, 60, 70, 80, 90, or 95% (w/w) of the volatile organic fraction of the starting composition is isoprene.

**[0289]** In some embodiments, the highly pure isoprene starting composition comprises greater than or about 98.0, 98.5, 99.0, 99.5, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the starting composition. In some embodiments, the highly pure isoprene starting composition comprises greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the starting composition. In some embodiments, the starting composition has a relative detector response of greater than or about 98.0, 98.5, 99.0, 99.5, or 100% for isoprene compared to the detector response for all C5 hydrocarbons in the starting composition. In some embodiments, the starting composition has a relative detector response of greater than or about 99.90, 99.91, 99.92, 99.93, 99.94, 99.95, 99.96, 99.97, 99.98, 99.99, or 100% for isoprene compared to the detector response for all C5 hydrocarbons in the starting composition. In some embodiments, the starting isoprene composition comprises between about 98.0 to about 98.5, about 98.5 to about 99.0,

about 99.0 to about 99.5, about 99.5 to about 99.8, about 99.8 to 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the starting composition. In some embodiments, the starting isoprene composition comprises between about 99.90 to about 99.92, about 99.92 to about 99.94, about 99.94 to about 99.96, about 99.96 to about 99.98, about 99.98 to 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the starting composition.

**[0290]** In some embodiments, the highly pure isoprene starting composition comprises less than or about 2.0, 1.5, 1.0, 0.5, 0.2, 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% C5 hydrocarbons other than isoprene (such 1,3-cyclopentadiene, *cis*-1,3-pentadiene, *trans*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the starting composition. In some embodiments, the starting composition has a relative detector response of less than or about 2.0, 1.5, 1.0, 0.5, 0.2, 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% for C5 hydrocarbons other than isoprene compared to the detector response for all C5 hydrocarbons in the starting composition. In some embodiments, the starting composition has a relative detector response of less than or about 2.0, 1.5, 1.0, 0.5, 0.2, 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% for 1,3-cyclopentadiene, *cis*-1,3-pentadiene, *trans*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne compared to the detector response for all C5 hydrocarbons in the starting composition. In some embodiments, the highly pure isoprene starting composition comprises between about 0.02 to about 0.04%, about 0.04 to about 0.06%, about 0.06 to 0.08%, about 0.08 to 0.10%, or about 0.10 to about 0.12% C5 hydrocarbons other than isoprene (such 1,3-cyclopentadiene, *cis*-1,3-pentadiene, *trans*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the starting composition.

**[0291]** In some embodiments, the highly pure isoprene starting composition comprises less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005  $\mu\text{g/L}$  of a compound that inhibits the polymerization of isoprene for any compound in the starting composition that inhibits the polymerization of isoprene. In some embodiments, the starting isoprene composition comprises between about 0.005 to about 50, such as about 0.01 to about 10, about

0.01 to about 5, about 0.01 to about 1, about 0.01 to about 0.5, or about 0.01 to about 0.005  $\mu\text{g/L}$  of a compound that inhibits the polymerization of isoprene for any compound in the starting composition that inhibits the polymerization of isoprene. In some embodiments, the starting isoprene composition comprises less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005  $\mu\text{g/L}$  of a hydrocarbon other than isoprene (such as 1,3-cyclopentadiene, *cis*-1,3-pentadiene, *trans*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne). In some embodiments, the starting isoprene composition comprises between about 0.005 to about 50, such as about 0.01 to about 10, about 0.01 to about 5, about 0.01 to about 1, about 0.01 to about 0.5, or about 0.01 to about 0.005  $\mu\text{g/L}$  of a hydrocarbon other than isoprene. In some embodiments, the starting isoprene composition comprises less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005  $\mu\text{g/L}$  of a protein or fatty acid (such as a protein or fatty acid that is naturally associated with natural rubber).

**[0292]** In some embodiments, the highly pure isoprene starting composition comprises less than or about 10, 5, 1, 0.8, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of alpha acetylenes, piperylenes, acetonitrile, or 1,3-cyclopentadiene. In some embodiments, the starting isoprene composition comprises less than or about 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of sulfur or allenes. In some embodiments, the starting isoprene composition comprises less than or about 30, 20, 15, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of all acetylenes (such as 1-pentyne, 2-pentyne, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, and *cis*-pent-3-ene-1-yne). In some embodiments, the starting isoprene composition comprises less than or about 2000, 1000, 500, 200, 100, 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of isoprene dimers, such as cyclic isoprene dimers (*e.g.*, cyclic C<sub>10</sub> compounds derived from the dimerization of two isoprene units).

**[0293]** In some embodiments, the highly pure isoprene starting composition includes ethanol, acetone, methanol, acetaldehyde, methacrolein, methyl vinyl ketone, 2-methyl-2-vinyloxirane, *cis*- and *trans*-3-methyl-1,3-pentadiene, a C<sub>5</sub> prenyl alcohol (such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-1-ol), or any two or more of the foregoing. In particular embodiments, the starting isoprene composition comprises greater than or about 0.005, 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 60, 80, 100, or 120  $\mu\text{g/L}$  of ethanol, acetone, methanol, acetaldehyde, methacrolein, methyl vinyl ketone, 2-methyl-2-vinyloxirane, *cis*- and *trans*-3-methyl-1,3-pentadiene, a C<sub>5</sub> prenyl alcohol (such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-1-ol), or any two or more of the foregoing. In some embodiments, the isoprene composition comprises

between about 0.005 to about 120, such as about 0.01 to about 80, about 0.01 to about 60, about 0.01 to about 40, about 0.01 to about 30, about 0.01 to about 20, about 0.01 to about 10, about 0.1 to about 80, about 0.1 to about 60, about 0.1 to about 40, about 5 to about 80, about 5 to about 60, or about 5 to about 40  $\mu\text{g/L}$  of ethanol, acetone, methanol, acetaldehyde, methacrolein, methyl vinyl ketone, 2-methyl-2-vinylloxirane, *cis*- and *trans*-3-methyl-1,3-pentadiene, a C5 prenyl alcohol, or any two or more of the foregoing.

**[0294]** In some embodiments, the highly pure isoprene starting composition includes one or more of the following components: 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, acetaldehyde, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (*trans*-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (*E*)-3,7-dimethyl-1,3,6-octatriene, (*Z*)-3,7-dimethyl-1,3,6-octatriene, 2,3-cycloheptenolpyridine, or a linear isoprene polymer (such as a linear isoprene dimer or a linear isoprene trimer derived from the polymerization of multiple isoprene units). In various embodiments, the amount of one of these components relative to amount of isoprene in units of percentage by weight (*i.e.*, weight of the component divided by the weight of isoprene times 100) is greater than or about 0.01, 0.02, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 110% (w/w). In some embodiments, the relative detector response for the second compound compared to the detector response for isoprene is greater than or about 0.01, 0.02, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 110%. In various embodiments, the amount of one of these components relative to amount of isoprene in units of percentage by weight (*i.e.*, weight of the component divided by the weight of isoprene times 100) is between about 0.01 to about 105 % (w/w), such as about 0.01 to about 90, about 0.01 to about 80, about 0.01 to about 50, about 0.01 to about 20, about 0.01 to about 10, about 0.02 to about 50, about 0.05 to about 50, about 0.1 to about 50, or 0.1 to about 20% (w/w).

**[0295]** In some embodiments, at least a portion of the highly pure isoprene starting composition is in a gas phase. In some embodiments, at least a portion of the highly pure isoprene starting composition is in a liquid phase (such as a condensate). In some embodiments, at least a portion of the highly pure isoprene starting composition is in a solid phase. In some embodiments, at least a portion of the highly pure isoprene starting composition is absorbed to a

solid support, such as a support that includes silica and/or activated carbon. In some embodiments, the starting isoprene composition is mixed with one or more solvents. In some embodiments, the starting isoprene composition is mixed with one or more gases.

**[0296]** In other embodiments, the commercially beneficial amount of highly pure isoprene starting composition is produced by a biological process. In some preferred embodiments, the highly pure isoprene starting composition is a bioisoprene composition produced by culturing cells that produce greater than about 400 nmole of isoprene/gram of cells for the wet weight of the cells/hour (nmole/g<sub>wcm</sub>/hr) of isoprene. In one embodiment, the bioisoprene composition is produced by culturing cells that convert more than about 0.002% of the carbon in a cell culture medium into isoprene. In other embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide, e.g. a naturally-occurring polypeptide from a plant such as *Pueraria*, and (ii) is operably linked to a promoter, e.g. a T7 promoter. Other isoprene synthase polypeptides, for example, from poplar and variants of naturally-occurring as well as parent isoprene synthase, can be used to produce bioisoprene. Examples of isoprene synthase and its variants that can be used are described in U.S. Appl. No. 12/429,143, which is incorporated herein in its entirety.

**[0297]** In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, polypeptide (e.g., a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing. In some embodiments, the cells are cultured under limited glucose conditions. In some embodiment, the cells further comprise a heterologous nucleic acid encoding an IDI polypeptide. In some embodiments, the cells further comprise a heterologous nucleic acid encoding an MDV pathway polypeptide. In some embodiment, the starting isoprene composition is an isoprene composition as described or is produced by culturing any of the cells described in U.S. provisional patent application Nos. 61/134,094, filed on July 2, 2008, WO 2010/003007, and U.S. patent application No. 12/335,071, filed December 15, 2008 (US 2009/0203102 A1), which are incorporated by reference in their entireties.

**[0298]** In some embodiments, the highly pure isoprene starting composition comprises a gas phase (off-gas) produced by cells in culture that produces isoprene. In some embodiments, the gas phase has a nonflammable concentration of isoprene. In some embodiments, the gas phase comprises less than about 9.5 % (volume) oxygen. In some embodiments, the gas phase

comprises greater than or about 9.5 % (volume) oxygen, and the concentration of isoprene in the gas phase is less than the lower flammability limit or greater than the upper flammability limit. In some embodiments, the portion of the gas phase other than isoprene comprises between about 0% to about 100% (volume) oxygen, such as between about 10% to about 100% (volume) oxygen. In some embodiments, the portion of the gas phase other than isoprene comprises between about 0% to about 99% (volume) nitrogen. In some embodiments, the portion of the gas phase other than isoprene comprises between about 1% to about 50% (volume) CO<sub>2</sub>.

**[0299]** In some embodiments, the highly pure isoprene starting composition includes one or more of the following: an alcohol, an aldehyde, a ketone, or an ester (such as any of the alcohols, aldehydes, ketones or esters described herein). In some embodiments, the isoprene composition includes (i) an alcohol and an aldehyde, (ii) an alcohol and a ketone, (iii) an aldehyde and a ketone, or (iv) an alcohol, an aldehyde, and a ketone. In some embodiments, any of the isoprene compositions further includes an ester.

**[0300]** In some embodiments, the highly pure isoprene starting composition derived from a biological source (such as a cell culture) contains one or more of the following: methanol, acetaldehyde, ethanol, methanethiol, 1-butanol, 3-methyl-1-propanol, acetone, acetic acid, 2-butanone, 2-methyl-1-butanol, or indole. In some embodiments, the starting isoprene composition contains 1 ppm or more of one or more of the following: methanol, acetaldehyde, ethanol, methanethiol, 1-butanol, 3-methyl-1-propanol, acetone, acetic acid, 2-butanone, 2-methyl-1-butanol, or indole. In some embodiments, the concentration of more of one or more of the following: methanol, acetaldehyde, ethanol, methanethiol, 1-butanol, 3-methyl-1-propanol, acetone, acetic acid, 2-butanone, 2-methyl-1-butanol, or indole, is between about 1 to about 10,000 ppm in a starting isoprene composition (such as off-gas before it is purified). In some embodiments, the starting isoprene composition (such as off-gas after it has undergone one or more purification steps) includes one or more of the following: methanol, acetaldehyde, ethanol, methanethiol, 1-butanol, 3-methyl-1-propanol, acetone, acetic acid, 2-butanone, 2-methyl-1-butanol, or indole, at a concentration between about 1 to about 100 ppm, such as about 1 to about 10 ppm, about 10 to about 20 ppm, about 20 to about 30 ppm, about 30 to about 40 ppm, about 40 to about 50 ppm, about 50 to about 60 ppm, about 60 to about 70 ppm, about 70 to about 80 ppm, about 80 to about 90 ppm, or about 90 to about 100 ppm. In some embodiments, the starting isoprene composition contains less than 1 ppm of methanethiol (a potent catalyst poison and a source of sulfur in the final fuel product). Volatile organic compounds from cell cultures (such as volatile organic compounds in the headspace of cell cultures) can be analyzed

using standard methods such as those described herein or other standard methods such as proton transfer reaction-mass spectrometry (*see, for example, Bunge et al., Applied and Environmental Microbiology, 74(7):2179-2186, 2008* which is hereby incorporated by reference in its entirety, particular with respect to the analysis of volatile organic compounds).

**[0301]** The invention also contemplates the use of highly pure isoprene starting composition that is derived from a biological source (such as a cell culture) the co-produces isoprene and hydrogen. In some embodiments, the starting bioisoprene compositions comprise isoprene and hydrogen in ratios ranging from at least one molar percent of isoprene for every three molar percent of hydrogen to at least one molar percent of isoprene for every four molar percent of hydrogen. In some embodiments, the starting bioisoprene compositions comprise isoprene and hydrogen in molar ratios of about 1 to 9, 2 to 8, 3 to 7, 4 to 6, 5 to 5, 6 to 4, 7 to 3, 8 to 2, or 9 to 1. In some embodiments, the composition further comprises from 1 to 11 molar percent isoprene and from 4 to 44 molar percent hydrogen. In some embodiments, the composition further comprises oxygen, carbon dioxide, or nitrogen. In some embodiments, the composition further comprises from 0 to 21 molar percent oxygen, from 18 to 44 molar percent carbon dioxide, and from 0 to 78 molar percent nitrogen. In some embodiments, the composition further comprises  $1.0 \times 10^{-4}$  molar percent or less of non-methane volatile impurities. In some embodiments, the non-methane volatile impurities comprise one or more of the following: 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, acetaldehyde, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene, 2,3-cycloheptenolpyridine, or a linear isoprene polymer (such as a linear isoprene dimer or a linear isoprene trimer derived from the polymerization of multiple isoprene units). In some embodiments, the non-methane volatile impurities comprise one or more of the following: the isoprene composition includes one or more of the following: an alcohol, an aldehyde, or a ketone (such as any of the alcohols, aldehydes, or ketones described herein). In some embodiments, the isoprene composition includes (i) an alcohol and an aldehyde, (ii) an alcohol and a ketone, (iii) an aldehyde and a ketone, or (iv) an alcohol, an aldehyde, and a ketone. In some embodiments, the non-methane volatile impurities comprise one or more of the

following: methanol, acetaldehyde, ethanol, methanethiol, 1-butanol, 3-methyl-1-propanol, acetone, acetic acid, 2-butanone, 2-methyl-1-butanol, or indole.

**[0302]** Techniques for producing isoprene in cultures of cells that produce isoprene are described in U.S. provisional patent application Nos. 61/013,386 and 61/013,574, filed on December 13, 2007, WO 2009/076676, U.S. provisional patent application Nos. 61/134,094, 61/134,947, 61/134,011 and 61/134,103, filed on July 2, 2008, WO 2010/003007, U.S. provisional patent application No. 61/097,163, filed on September 15, 2008, WO 2010/031079, U.S. provisional patent application No. 61/097,186, filed on September 15, 2008, WO 2010/031062, U.S. provisional patent application No. 61/097,189, filed on September 15, 2008, WO 2010/031077, U.S. provisional patent application No. 61/097,200, filed on September 15, 2008, WO 2010/031068, U.S. provisional patent application No. 61/097,204, filed on September 15, 2008, WO 2010/031076, U.S. provisional patent application No. 61/141,652, filed on December 30, 2008, PCT/US09/069862, U.S. patent application No. 12/335,071, filed December 15, 2008 (US 2009/0203102 A1) and U.S. patent application No. 12/429,143, filed April 23, 2009 (US 2010/0003716 A1), the teachings of which are incorporated herein by reference for the purpose of teaching techniques for producing and recovering isoprene by such a process. In any case, U.S. provisional patent application Nos. 61/013,386 and 61/013,574, filed on December 13, 2007, WO 2009/076676, U.S. provisional patent application Nos. 61/134,094, 61/134,947, 61/134,011 and 61/134,103, filed on July 2, 2008, WO 2010/003007, U.S. provisional patent application No. 61/097,163, filed on September 15, 2008, WO 2010/031079, U.S. provisional patent application No. 61/097,186, filed on September 15, 2008, WO 2010/031062, U.S. provisional patent application No. 61/097,189, filed on September 15, 2008, WO 2010/031077, U.S. provisional patent application No. 61/097,200, filed on September 15, 2008, WO 2010/031068, U.S. provisional patent application No. 61/097,204, filed on September 15, 2008, WO 2010/031076, U.S. provisional patent application No. 61/141,652, filed on December 30, 2008, PCT/US09/069862, U.S. patent application No. 12/335,071, filed December 15, 2008 (US 2009/0203102 A1) and U.S. patent application No. 12/429,143, filed April 23, 2009 (US 2010/0003716 A1) teach compositions and methods for the production of increased amounts of isoprene in cell cultures. U.S. patent application No. 12/335,071, filed December 15, 2008 and US 2009/0203102 A1 further teaches compositions and methods for co-production of isoprene and hydrogen from cultured cells. In particular, these compositions and methods increase the rate of isoprene production and increase the total amount of isoprene that is produced. For example, cell culture systems that generate 4.8 x

$10^4$  nmole/ $g_{\text{wcm}}$ /hr of isoprene have been produced (Table 1). The efficiency of these systems is demonstrated by the conversion of about 2.2% of the carbon that the cells consume from a cell culture medium into isoprene. As shown in the Examples and Table 2, approximately 3 g of isoprene per liter of broth was generated. If desired, even greater amounts of isoprene can be obtained using other conditions, such as those described herein. In some embodiments, a renewable carbon source is used for the production of isoprene. In some embodiments, the production of isoprene is decoupled from the growth of the cells. In some embodiments, the concentrations of isoprene and any oxidants are within the nonflammable ranges to reduce or eliminate the risk that a fire may occur during production or recovery of isoprene. The compositions and methods are desirable because they allow high isoprene yield per cell, high carbon yield, high isoprene purity, high productivity, low energy usage, low production cost and investment, and minimal side reactions. This efficient, large scale, biosynthetic process for isoprene production provides an isoprene source for synthetic isoprene-based products such as rubber and provides a desirable, low-cost alternative to using natural rubber.

**[0303]** As discussed further below, the amount of isoprene produced by cells can be greatly increased by introducing a heterologous nucleic acid encoding an isoprene synthase polypeptide (e.g., a plant isoprene synthase polypeptide) into the cells. Isoprene synthase polypeptides convert dimethyl allyl diphosphate (DMAPP) into isoprene. As shown in the Examples, a heterologous *Pueraria Montana* (kudzu) isoprene synthase polypeptide was expressed in a variety of host cells, such as *Escherichia coli*, *Pantoea citrea*, *Bacillus subtilis*, *Yarrowia lipolytica*, and *Trichoderma reesei*. All of these cells produced more isoprene than the corresponding cells without the heterologous isoprene synthase polypeptide. As illustrated in Tables 1 and 2, large amounts of isoprene are produced using the methods described herein. For example, *B. subtilis* cells with a heterologous isoprene synthase nucleic acid produced approximately 10-fold more isoprene in a 14 liter fermentor than the corresponding control *B. subtilis* cells without the heterologous nucleic acid (Table 2). The production of 300 mg of isoprene per liter of broth (mg/L, wherein the volume of broth includes both the volume of the cell medium and the volume of the cells) by *E. coli* and 30 mg/L by *B. subtilis* in fermentors indicates that significant amounts of isoprene can be generated (Table 2). If desired, isoprene can be produced on an even larger scale or other conditions described herein can be used to further increase the amount of isoprene. The vectors listed in Tables 1 and 2 and the experimental conditions are described in further detail below and in the Examples section.

**Table 1: Exemplary yields of isoprene from a shake flask using the cell cultures and methods described herein.** The assay for measuring isoprene production is described in Example I, part II. For this assay, a sample was removed at one or more time points from the shake flask and cultured for 30 minutes. The amount of isoprene produced in this sample was then measured. The headspace concentration and specific rate of isoprene production are listed in Table 1 and described further herein.

Strain	Isoprene Production in a Headspace vial*	
	Headspace concentration $\mu\text{g/L}_{\text{gas}}$	Specific Rate $\mu\text{g/L}_{\text{broth}}/\text{hr}/\text{OD}$ ( $\text{nmol/g}_{\text{wcm}}/\text{hr}$ )
<i>E. coli</i> BL21/ pTrcKudzu IS	1.40	53.2 (781.2)
<i>E. coli</i> BL21/ pCL DXS yidi Kudzu IS	7.61	289.1 ( $4.25 \times 10^3$ )
<i>E. coli</i> BL21/MCM127 with kudzu IS and entire MVA pathway	23.0	874.1 ( $1.28 \times 10^4$ )
<i>E. coli</i> BL21/ pET N-HisKudzu IS	1.49	56.6 (831.1)
<i>Pantoea citrea</i> /pTrcKudzu IS	0.66	25.1 (368.6)
<i>E. coli</i> w/ <i>Poplar IS</i> [Miller (2001)]	-	5.6 (82.2)
<i>Bacillus licheniformis</i> Fall US 5849970	-	4.2 (61.4)
<i>Yarrowia lipolytica</i> with kudzu isoprene synthase	$\sim 0.05 \mu\text{g/L}$	$\sim 2$ ( $\sim 30$ )
<i>Trichoderma reesei</i> with kudzu isoprene synthase	$\sim 0.05 \mu\text{g/L}$	$\sim 2$ ( $\sim 30$ )
<i>E. coli</i> BL21/ pTrcKKD <sub>y</sub> I <sub>k</sub> IS with	85.9	$3.2 \times 10^3$

Strain	Isoprene Production in a Headspace vial*	
kudzu IS and lower MVA pathway		(4.8 x 10 <sup>4</sup> )

\*Normalized to 1 mL of 1 OD<sub>600</sub>, cultured for 1 hour in a sealed headspace vial with a liquid to headspace volume ratio of 1:19.

**Table 2: Exemplary yields of isoprene in a fermentor using the cell cultures and methods described herein.** The assay for measuring isoprene production is described in Example I, part II. For this assay, a sample of the off-gas of the fermentor was taken and analyzed for the amount of isoprene. The peak headspace concentration (which is the highest headspace concentration during the fermentation), titer (which is the cumulative, total amount of isoprene produced per liter of broth), and peak specific rate of isoprene production (which is the highest specific rate during the fermentation) are listed in Table 2 and described further herein.

Strain	Isoprene Production in Fermentors		
	Peak Headspace concentration** ( $\mu\text{g}/\text{L}_{\text{gas}}$ )	Titer ( $\text{mg}/\text{L}_{\text{broth}}$ )	Peak Specific rate $\mu\text{g}/\text{L}_{\text{broth}}/\text{hr}/\text{OD}$ ( $\text{nmol}/\text{g}_{\text{wcm}}/\text{hr}$ )
<i>E. coli</i> BL21 /pTrcKudzu with Kudzu IS	52	41.2	37 (543.3)
<i>E. coli</i> FM5/pTrcKudzu IS	3	3.5	21.4 (308.1)
<i>E. coli</i> BL21/ triple strain (DXS, yidi, IS)	285	300	240 (3.52 x 10 <sup>3</sup> )
<i>E. coli</i> FM5/ triple strain (DXS, yidi, IS)	50.8	29	180.8 (2.65 x 10 <sup>3</sup> )
<i>E. coli</i> /MCM127 with Kudzu IS and entire MVA pathway	3815	3044	992.5 (1.46 x 10 <sup>4</sup> )
<i>E. coli</i> BL21/pCLP <sub>trc</sub> Upper Pathway gi1.2 integrated lower pathway pTrcKudzu	2418	1640	1248 (1.83 x 10 <sup>4</sup> )
<i>E. coli</i> BL21/MCM401 with 4 x 50 $\mu\text{M}$ IPTG	13991	23805	3733 (5.49 x 10 <sup>4</sup> )
<i>E. coli</i> BL21/MCM401 with 2 x 1000 $\mu\text{M}$ IPTG	22375	19541	5839.5 (8.59 x 10 <sup>4</sup> )

Strain	Isoprene Production in Fermentors		
<i>E. coli</i> BL21/pCLPtrc UpperPathwayHGS2 - pTrcKKDyIkIS	3500	3300	1088 ( $1.60 \times 10^4$ )
<i>Bacillus subtilis</i> wild-type	1.5	2.5	0.8 (11.7)
<i>Bacillus pBS Kudzu IS</i>	16.6	~30 (over 100 hrs)	5 (73.4)
<i>Bacillus Marburg 6051</i> [Wagner and Fall (1999)]	2.04	0.61	24.5 (359.8)
<i>Bacillus Marburg 6051</i> Fall US 5849970	0.7	0.15	6.8 (100)
<i>E. coli</i> BL21/pCLPtrcUpperPathway and gil.2KKDyI and pTrcAlba-mMVK	$2.03 \times 10^4$	$3.22 \times 10^4$	$5.9 \times 10^3$ ( $8.66 \times 10^4$ )
<i>E. coli</i> BL21/pCLPtrcUpper Pathway and gi1.2KKDyI and pTrcAlba-mMVK plus pBBRCMPGI1.5pgl	$3.22 \times 10^4$	$6.05 \times 10^4$	$1.28 \times 10^4$ ( $1.88 \times 10^5$ )

\*\*Normalized to an off-gas flow rate of 1 vvm (1 volume off-gas per 1  $L_{broth}$  per minute).

[0304] Additionally, isoprene production by cells that contain a heterologous isoprene synthase nucleic acid can be enhanced by increasing the amount of a 1-deoxy-D-xylulose-5-phosphate synthase (DXS) polypeptide and/or an isopentenyl diphosphate isomerase (IDI) polypeptide expressed by the cells. For example, a DXS nucleic acid and/or an IDI nucleic acid can be introduced into the cells. The DXS nucleic acid may be a heterologous nucleic acid or a duplicate copy of an endogenous nucleic acid. Similarly, the IDI nucleic acid may be a heterologous nucleic acid or a duplicate copy of an endogenous nucleic acid. In some embodiments, the amount of DXS and/or IDI polypeptide is increased by replacing the endogenous DXS and/or IDI promoters or regulatory regions with other promoters and/or regulatory regions that result in greater transcription of the DXS and/or IDI nucleic acids. In

some embodiments, the cells contain both a heterologous nucleic acid encoding an isoprene synthase polypeptide (*e.g.*, a plant isoprene synthase nucleic acid) and a duplicate copy of an endogenous nucleic acid encoding an isoprene synthase polypeptide.

**[0305]** The encoded DXS and IDI polypeptides are part of the DXP pathway for the biosynthesis of isoprene (Figure 19A). DXS polypeptides convert pyruvate and D-glyceraldehyde-3-phosphate into 1-deoxy-D-xylulose-5-phosphate. While not intending to be bound by any particular theory, it is believed that increasing the amount of DXS polypeptide increases the flow of carbon through the DXP pathway, leading to greater isoprene production. IDI polypeptides catalyze the interconversion of isopentenyl diphosphate (IPP) and dimethyl allyl diphosphate (DMAPP). While not intending to be bound by any particular theory, it is believed that increasing the amount of IDI polypeptide in cells increases the amount (and conversion rate) of IPP that is converted into DMAPP, which in turn is converted into isoprene.

**[0306]** For example, fermentation of *E. coli* cells with a kudzu isoprene synthase, *S. cerevisia* IDI, and *E. coli* DXS nucleic acids was used to produce isoprene. The levels of isoprene varied from 50 to 300 µg/L over a time period of 15 hours (Example 7, part VII).

**[0307]** In some embodiments, the presence of heterologous or extra endogenous isoprene synthase, IDI, and DXS nucleic acids causes cells to grow more reproducibly or remain viable for longer compared to the corresponding cell with only one or two of these heterologous or extra endogenous nucleic acids. For example, cells containing heterologous isoprene synthase, IDI, and DXS nucleic acids grew better than cells with only heterologous isoprene synthase and DXS nucleic acids or with only a heterologous isoprene synthase nucleic acid. Also, heterologous isoprene synthase, IDI, and DXS nucleic acids were successfully operably linked to a strong promoter on a high copy plasmid that was maintained by *E. coli* cells, suggesting that large amounts of these polypeptides could be expressed in the cells without causing an excessive amount of toxicity to the cells. While not intending to be bound to a particular theory, it is believed that the presence of heterologous or extra endogenous isoprene synthase and IDI nucleic acids may reduce the amount of one or more potentially toxic intermediates that would otherwise accumulate if only a heterologous or extra endogenous DXS nucleic acid was present in the cells.

**[0308]** In some embodiments, the production of isoprene by cells that contain a heterologous isoprene synthase nucleic acid is augmented by increasing the amount of a MVA polypeptide expressed by the cells (Figures 19A and 19B). Exemplary MVA pathway polypeptides include any of the following polypeptides: acetyl-CoA acetyltransferase (AA-CoA thiolase)

polypeptides, 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoA synthase) polypeptides, 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) polypeptides, mevalonate kinase (MVK) polypeptides, phosphomevalonate kinase (PMK) polypeptides, diphosphomevalonate decarboxylase (MVD) polypeptides, phosphomevalonate decarboxylase (PMDC) polypeptides, isopentenyl phosphate kinase (IPK) polypeptides, IDI polypeptides, and polypeptides (*e.g.*, fusion polypeptides) having an activity of two or more MVA pathway polypeptides. For example, one or more MVA pathway nucleic acids can be introduced into the cells. In some embodiments, the cells contain the upper MVA pathway, which includes AA-CoA thiolase, HMG-CoA synthase, and HMG-CoA reductase nucleic acids. In some embodiments, the cells contain the lower MVA pathway, which includes MVK, PMK, MVD, and IDI nucleic acids. In some embodiments, the cells contain an entire MVA pathway that includes AA-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, MVK, PMK, MVD, and IDI nucleic acids. In some embodiments, the cells contain an entire MVA pathway that includes AA-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, MVK, PMDC, IPK, and IDI nucleic acids. The MVA pathway nucleic acids may be heterologous nucleic acids or duplicate copies of endogenous nucleic acids. In some embodiments, the amount of one or more MVA pathway polypeptides is increased by replacing the endogenous promoters or regulatory regions for the MVA pathway nucleic acids with other promoters and/or regulatory regions that result in greater transcription of the MVA pathway nucleic acids. In some embodiments, the cells contain both a heterologous nucleic acid encoding an isoprene synthase polypeptide (*e.g.*, a plant isoprene synthase nucleic acid) and a duplicate copy of an endogenous nucleic acid encoding an isoprene synthase polypeptide.

**[0309]** For example, *E. coli* cells containing a nucleic acid encoding a kudzu isoprene synthase polypeptide and nucleic acids encoding *Saccharomyces cerevisiae* MVK, PMK, MVD, and IDI polypeptides generated isoprene at a rate of  $6.67 \times 10^{-4}$  mol/L<sub>broth</sub>/OD<sub>600</sub>/hr (*see* Example 8). Additionally, a 14 liter fermentation of *E. coli* cells with nucleic acids encoding *Enterococcus faecalis* AA-CoA thiolase, HMG-CoA synthase, and HMG-CoA reductase polypeptides produced 22 grams of mevalonic acid (an intermediate of the MVA pathway). A shake flask of these cells produced 2-4 grams of mevalonic acid per liter. These results indicate that heterologous MVA pathway nucleic acids are active in *E. coli*. *E. coli* cells that contain nucleic acids for both the upper MVA pathway and the lower MVA pathway as well as a kudzu isoprene synthase (strain MCM 127) produced significantly more isoprene (874 µg/L) compared to *E.*

*coli* cells with nucleic acids for only the lower MVA pathway and the kudzu isoprene synthase (strain MCM 131) (*see* Table 3 and Example 8, part VIII).

**[0310]** In some embodiments, at least a portion of the cells maintain the heterologous isoprene synthase, DXS, IDI, and/or MVA pathway nucleic acid for at least about 5, 10, 20, 50, 75, 100, 200, 300, or more cell divisions in a continuous culture (such as a continuous culture without dilution). In some embodiments of any of the aspects described herein, the nucleic acid comprising the heterologous or duplicate copy of an endogenous isoprene synthase, DXS, IDI, and/or MVA pathway nucleic acid also comprises a selective marker, such as a kanamycin, ampicillin, carbenicillin, gentamicin, hygromycin, phlecomycin, bleomycin, neomycin, or chloramphenicol antibiotic resistance nucleic acid.

**[0311]** As indicated in Example 7, part VI, the amount of isoprene produced can be further increased by adding yeast extract to the cell culture medium. In this example, the amount of isoprene produced was linearly proportional to the amount of yeast extract in the cell medium for the concentrations tested (Figure 48C). Additionally, approximately 0.11 grams of isoprene per liter of broth was produced from a cell medium with yeast extract and glucose (Example 7, part VIII). Both of these experiments used *E. coli* cells with kudzu isoprene synthase, *S. cerevisia* IDI, and *E. coli* DXS nucleic acids to produce isoprene. Increasing the amount of yeast extract in the presence of glucose resulted in more isoprene being produced than increasing the amount of glucose in the presence of yeast extract. Also, increasing the amount of yeast extract allowed the cells to produce a high level of isoprene for a longer length of time and improved the health of the cells.

**[0312]** Isoprene production was also demonstrated using three types of hydrolyzed biomass (bagasse, corn stover, and soft wood pulp) as the carbon source (Figures 46A-C). *E. coli* cells with kudzu isoprene synthase, *S. cerevisia* IDI, and *E. coli* DXS nucleic acids produced as much isoprene from these hydrolyzed biomass carbon sources as from the equivalent amount of glucose (*e.g.*, 1% glucose, w/v). If desired, any other biomass carbon source can be used in the compositions and methods described herein. Biomass carbon sources are desirable because they are cheaper than many conventional cell mediums, thereby facilitating the economical production of isoprene.

**[0313]** Additionally, invert sugar was shown to function as a carbon source for the generation of isoprene (Figures 47C and 96-98). For example, 2.4 g/L of isoprene was produced from cells expressing MVA pathway polypeptides and a Kudzu isoprene synthase (Example 8, part XV). Glycerol was also used as a carbon source for the generation of 2.2 mg/L of isoprene from

cells expressing a Kudzu isoprene synthase (Example 8, part XIV). Expressing a DXS nucleic acid, an IDI nucleic acid, and/or one or more MVA pathway nucleic acids (such as nucleic acids encoding the entire MVA pathway) in addition to an isoprene synthase nucleic acid may increase the production of isoprene from glycerol.

**[0314]** In some embodiments, an oil is included in the cell medium. For example, *B. subtilis* cells containing a kudzu isoprene synthase nucleic acid produced isoprene when cultured in a cell medium containing an oil and a source of glucose (Example 4, part III). As another example, *E. coli* fadR atoC mutant cells containing the upper and lower MVA pathway plus kudzu isoprene synthase produced isoprene when cultured in a cell medium containing palm oil and a source of glucose (Example 27, part II). In some embodiments, more than one oil (such as 2, 3, 4, 5, or more oils) is included in the cell medium. While not intending to be bound to any particular theory, it is believed that (i) the oil may increase the amount of carbon in the cells that is available for conversion to isoprene, (ii) the oil may increase the amount of acetyl-CoA in the cells, thereby increasing the carbon flow through the MVA pathway, and/or (iii) the oil may provide extra nutrients to the cells, which is desirable since much of the carbon in the cells is converted to isoprene rather than other products. In some embodiments, cells that are cultured in a cell medium containing oil naturally use the MVA pathway to produce isoprene or are genetically modified to contain nucleic acids for the entire MVA pathway. In some embodiments, the oil is partially or completely hydrolyzed before being added to the cell culture medium to facilitate the use of the oil by the host cells.

**[0315]** One of the major hurdles to commercial production of small molecules such as isoprene in cells (*e.g.*, bacteria) is the decoupling of production of the molecule from growth of the cells. In some embodiments for the commercially viable production of isoprene, a significant amount of the carbon from the feedstock is converted to isoprene, rather than to the growth and maintenance of the cells ("carbon efficiency"). In various embodiments, the cells convert greater than or about 0.0015, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.12, 0.14, 0.16, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, or 8.0% of the carbon in the cell culture medium into isoprene. In particular embodiments, a significant portion of the carbon from the feedstock that is converted to downstream products is converted to isoprene. As described further in Example 11, *E. coli* cells expressing MVA pathway and kudzu isoprene synthase nucleic acids exhibited decoupling of the production of isoprene or the intermediate mevalonic acid from growth, resulting in high carbon efficiency. In particular, mevalonic acid was formed from cells expressing the upper MVA pathway from *Enterococcus faecalis*.

Isoprene was formed from cells expressing the upper MVA pathway from *Enterococcus faecalis*, the lower MVA pathway from *Saccharomyces cerevisiae*, and the isoprene synthase from *Pueraria montana* (Kudzu). This decoupling of isoprene or mevalonic acid production from growth was demonstrated in four different strains of *E. coli*: BL21(LDE3), BL21(LDE3) Tuner, FM5, and MG1655. The first two *E. coli* strains are B strains, and the latter two are K12 strains. Decoupling of production from growth was also demonstrated in a variant of MG1655 with *ack* and *pta* genes deleted. This variant also demonstrated less production of acetate.

#### *Exemplary Polypeptides and Nucleic Acids*

**[0316]** Various isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor polypeptides and nucleic acids can be used in the compositions and methods described herein.

**[0317]** In some embodiments, the fusion polypeptide includes part or all of a first polypeptide (*e.g.*, an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor polypeptide or catalytically active fragment thereof) and may optionally include part or all of a second polypeptide (*e.g.*, a peptide that facilitates purification or detection of the fusion polypeptide, such as a His-tag). In some embodiments, the fusion polypeptide has an activity of two or more MVA pathway polypeptides (such as AA-CoA thiolase and HMG-CoA reductase polypeptides). In some embodiments, the polypeptide is a naturally-occurring polypeptide (such as the polypeptide encoded by an *Enterococcus faecalis mvaE* nucleic acid) that has an activity of two or more MVA pathway polypeptides.

**[0318]** In various embodiments, a polypeptide has at least or about 50, 100, 150, 175, 200, 250, 300, 350, 400, or more amino acids. In some embodiments, the polypeptide fragment contains at least or about 25, 50, 75, 100, 150, 200, 300, or more contiguous amino acids from a full-length polypeptide and has at least or about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% of an activity of a corresponding full-length polypeptide. In particular embodiments, the polypeptide includes a segment of or the entire amino acid sequence of any naturally-occurring isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor polypeptide. In some embodiments, the polypeptide has one or more mutations compared to the sequence of a wild-type (*i.e.*, a sequence occurring in nature) isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor polypeptide.

**[0319]** In some embodiments, the polypeptide is an isolated polypeptide. In some embodiments, the polypeptide is a heterologous polypeptide.

**[0320]** In some embodiments, the nucleic acid is a recombinant nucleic acid. In some embodiments, an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor nucleic acid is operably linked to another nucleic acid encoding all or a portion of another polypeptide such that the recombinant nucleic acid encodes a fusion polypeptide that includes an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor polypeptide and all or part of another polypeptide (*e.g.*, a peptide that facilitates purification or detection of the fusion polypeptide, such as a His-tag). In some embodiments, part or all of a recombinant nucleic acid is chemically synthesized. It is to be understood that mutations, including single nucleotide mutations, can occur within a nucleic acid as defined herein.

**[0321]** In some embodiments, the nucleic acid is a heterologous nucleic acid. In particular embodiments, the nucleic acid includes a segment of or the entire nucleic acid sequence of any naturally-occurring isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor nucleic acid. In some embodiments, the nucleic acid includes at least or about 50, 100, 150, 200, 300, 400, 500, 600, 700, 800, or more contiguous nucleotides from a naturally-occurring isoprene synthase nucleic acid DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor nucleic acid. In some embodiments, the nucleic acid has one or more mutations compared to the sequence of a wild-type (*i.e.*, a sequence occurring in nature) isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor nucleic acid. In some embodiments, the nucleic acid has one or more mutations (*e.g.*, a silent mutation) that increase the transcription or translation of isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, or transcription factor nucleic acid. In some embodiments, the nucleic acid is a degenerate variant of any nucleic acid encoding an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor polypeptide.

**[0322]** The accession numbers of exemplary isoprene synthase, DXS, IDI, and/or MVA pathway polypeptides and nucleic acids are listed in Appendix 1 (the accession numbers of Appendix 1 and their corresponding sequences are herein incorporated by reference in their entireties, particularly with respect to the amino acid and nucleic acid sequences of isoprene synthase, DXS, IDI, and/or MVA pathway polypeptides and nucleic acids). The Kegg database also contains the amino acid and nucleic acid sequences of numerous exemplary isoprene

synthase, DXS, IDI, and/or MVA pathway polypeptides and nucleic acids (*see*, for example, the world-wide web at “genome.jp/kegg/pathway/map/map00100.html” and the sequences therein, which are each hereby incorporated by reference in their entireties, particularly with respect to the amino acid and nucleic acid sequences of isoprene synthase, DXS, IDI, and/or MVA pathway polypeptides and nucleic acids). In some embodiments, one or more of the isoprene synthase, DXS, IDI, and/or MVA pathway polypeptides and/or nucleic acids have a sequence identical to a sequence publicly available on December 12, 2007 or September 14, 2008 such as any of the sequences that correspond to any of the accession numbers in Appendix 1 or any of the sequences present in the Kegg database. Additional exemplary isoprene synthase, DXS, IDI, and/or MVA pathway polypeptides and nucleic acids are described further below.

#### *Exemplary Isoprene Synthase Polypeptides and Nucleic Acids*

**[0323]** As noted above, isoprene synthase polypeptides convert dimethyl allyl diphosphate (DMAPP) into isoprene. Exemplary isoprene synthase polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions polypeptides that have at least one activity of an isoprene synthase polypeptide. Standard methods can be used to determine whether a polypeptide has isoprene synthase polypeptide activity by measuring the ability of the polypeptide to convert DMAPP into isoprene *in vitro*, in a cell extract, or *in vivo*. In an exemplary assay, cell extracts are prepared by growing a strain (*e.g.*, the *E. coli*/pTrcKudzu strain described herein) in the shake flask method as described in Example 1. After induction is complete, approximately 10 mL of cells are pelleted by centrifugation at 7000 x g for 10 minutes and re-suspended in 5 ml of PEB without glycerol. The cells are lysed using a French Pressure cell using standard procedures. Alternatively the cells are treated with lysozyme (Ready-Lyse lysozyme solution; EpiCentre) after a freeze/thaw at -80 °C.

**[0324]** Isoprene synthase polypeptide activity in the cell extract can be measured, for example, as described in Silver *et al.*, J. Biol. Chem. 270:13010-13016, 1995 and references therein, which are each hereby incorporated by reference in their entireties, particularly with respect to assays for isoprene synthase polypeptide activity. DMAPP (Sigma) is evaporated to dryness under a stream of nitrogen and re-hydrated to a concentration of 100 mM in 100 mM potassium phosphate buffer pH 8.2 and stored at -20 °C. To perform the assay, a solution of 5 µL of 1M MgCl<sub>2</sub>, 1 mM (250 µg/ml) DMAPP, 65 µL of Plant Extract Buffer (PEB) (50 mM Tris-HCl, pH 8.0, 20 mM MgCl<sub>2</sub>, 5% glycerol, and 2 mM DTT) is added to 25 µL of cell extract in a 20 ml Headspace vial with a metal screw cap and teflon coated silicon septum (Agilent Technologies)

and cultured at 37 °C for 15 minutes with shaking. The reaction is quenched by adding 200 µL of 250 mM EDTA and quantified by GC/MS as described in Example 1, part II.

**[0325]** Exemplary isoprene synthase nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of an isoprene synthase polypeptide. Exemplary isoprene synthase polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein.

**[0326]** In some embodiments, the isoprene synthase polypeptide or nucleic acid is from the family Fabaceae, such as the Faboideae subfamily. In some embodiments, the isoprene synthase polypeptide or nucleic acid is a polypeptide or nucleic acid from *Pueraria montana* (kudzu) (Sharkey *et al.*, Plant Physiology 137: 700-712, 2005), *Pueraria lobata*, poplar (such as *Populus alba*, *Populus nigra*, *Populus trichocarpa*, or *Populus alba x tremula* (CAC35696) Miller *et al.*, Planta 213: 483-487, 2001) aspen (such as *Populus tremuloides*) Silver *et al.*, JBC 270(22): 13010-1316, 1995), or English Oak (*Quercus robur*) (Zimmer *et al.*, WO 98/02550), which are each hereby incorporated by reference in their entireties, particularly with respect to isoprene synthase nucleic acids and the expression of isoprene synthase polypeptides. Suitable isoprene synthases include, but are not limited to, those identified by Genbank Accession Nos. AY341431, AY316691, AY279379, AJ457070, and AY182241, which are each hereby incorporated by reference in their entireties, particularly with respect to sequences of isoprene synthase nucleic acids and polypeptides. In some embodiments, the isoprene synthase polypeptide or nucleic acid is not a naturally-occurring polypeptide or nucleic acid from *Quercus robur* (*i.e.*, the isoprene synthase polypeptide or nucleic acid is an isoprene synthase polypeptide or nucleic acid other than a naturally-occurring polypeptide or nucleic acid from *Quercus robur*). In some embodiments, the isoprene synthase nucleic acid or polypeptide is a naturally-occurring polypeptide or nucleic acid from poplar. In some embodiments, the isoprene synthase nucleic acid or polypeptide is not a naturally-occurring polypeptide or nucleic acid from poplar.

#### *Exemplary DXS Polypeptides and Nucleic Acids*

**[0327]** As noted above, 1-deoxy-D-xylulose-5-phosphate synthase (DXS) polypeptides convert pyruvate and D-glyceraldehyde-3-phosphate into 1-deoxy-D-xylulose-5-phosphate. Exemplary DXS polypeptides include polypeptides, fragments of polypeptides, peptides, and

fusions polypeptides that have at least one activity of a DXS polypeptide. Standard methods (such as those described herein) can be used to determine whether a polypeptide has DXS polypeptide activity by measuring the ability of the polypeptide to convert pyruvate and D-glyceraldehyde-3-phosphate into 1-deoxy-D-xylulose-5-phosphate *in vitro*, in a cell extract, or *in vivo*. Exemplary DXS nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of a DXS polypeptide. Exemplary DXS polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein.

#### *Exemplary IDI Polypeptides and Nucleic Acids*

**[0328]** Isopentenyl diphosphate isomerase polypeptides (isopentenyl-diphosphate delta-isomerase or IDI) catalyses the interconversion of isopentenyl diphosphate (IPP) and dimethyl allyl diphosphate (DMAPP) (*e.g.*, converting IPP into DMAPP and/or converting DMAPP into IPP). Exemplary IDI polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions polypeptides that have at least one activity of an IDI polypeptide. Standard methods (such as those described herein) can be used to determine whether a polypeptide has IDI polypeptide activity by measuring the ability of the polypeptide to interconvert IPP and DMAPP *in vitro*, in a cell extract, or *in vivo*. Exemplary IDI nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of an IDI polypeptide. Exemplary IDI polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein.

#### *Exemplary MVA Pathway Polypeptides and Nucleic Acids*

**[0329]** Exemplary MVA pathway polypeptides include acetyl-CoA acetyltransferase (AA-CoA thiolase) polypeptides, 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoA synthase) polypeptides, 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) polypeptides, mevalonate kinase (MVK) polypeptides, phosphomevalonate kinase (PMK) polypeptides, diphosphomevalonate decarboxylase (MVD) polypeptides, phosphomevalonate decarboxylase (PMDC) polypeptides, isopentenyl phosphate kinase (IPK) polypeptides, IDI polypeptides, and polypeptides (*e.g.*, fusion polypeptides) having an activity of two or more MVA pathway polypeptides. In particular, MVA pathway polypeptides include polypeptides, fragments of

polypeptides, peptides, and fusions polypeptides that have at least one activity of an MVA pathway polypeptide. Exemplary MVA pathway nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of an MVA pathway polypeptide. Exemplary MVA pathway polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein.

**[0330]** In particular, acetyl-CoA acetyltransferase polypeptides (AA-CoA thiolase or AACT) convert two molecules of acetyl-CoA into acetoacetyl-CoA. Standard methods (such as those described herein) can be used to determine whether a polypeptide has AA-CoA thiolase polypeptide activity by measuring the ability of the polypeptide to convert two molecules of acetyl-CoA into acetoacetyl-CoA *in vitro*, in a cell extract, or *in vivo*.

**[0331]** 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoA synthase or HMGS) polypeptides convert acetoacetyl-CoA into 3-hydroxy-3-methylglutaryl-CoA. Standard methods (such as those described herein) can be used to determine whether a polypeptide has HMG-CoA synthase polypeptide activity by measuring the ability of the polypeptide to convert acetoacetyl-CoA into 3-hydroxy-3-methylglutaryl-CoA *in vitro*, in a cell extract, or *in vivo*.

**[0332]** 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase or HMGR) polypeptides convert 3-hydroxy-3-methylglutaryl-CoA into mevalonate. Standard methods (such as those described herein) can be used to determine whether a polypeptide has HMG-CoA reductase polypeptide activity by measuring the ability of the polypeptide to convert 3-hydroxy-3-methylglutaryl-CoA into mevalonate *in vitro*, in a cell extract, or *in vivo*.

**[0333]** Mevalonate kinase (MVK) polypeptides phosphorylates mevalonate to form mevalonate-5-phosphate. Standard methods (such as those described herein) can be used to determine whether a polypeptide has MVK polypeptide activity by measuring the ability of the polypeptide to convert mevalonate into mevalonate-5-phosphate *in vitro*, in a cell extract, or *in vivo*.

**[0334]** Phosphomevalonate kinase (PMK) polypeptides phosphorylates mevalonate-5-phosphate to form mevalonate-5-diphosphate. Standard methods (such as those described herein) can be used to determine whether a polypeptide has PMK polypeptide activity by measuring the ability of the polypeptide to convert mevalonate-5-phosphate into mevalonate-5-diphosphate *in vitro*, in a cell extract, or *in vivo*.

**[0335]** Diphosphomevalonate decarboxylase (MVD or DPMDC) polypeptides convert mevalonate-5-diphosphate into isopentenyl diphosphate (IPP). Standard methods (such as those described herein) can be used to determine whether a polypeptide has MVD polypeptide activity by measuring the ability of the polypeptide to convert mevalonate-5-diphosphate into IPP *in vitro*, in a cell extract, or *in vivo*.

**[0336]** Phosphomevalonate decarboxylase (PMDC) polypeptides convert mevalonate-5-phosphate into isopentenyl phosphate (IP). Standard methods (such as those described herein) can be used to determine whether a polypeptide has PMDC polypeptide activity by measuring the ability of the polypeptide to convert mevalonate-5-phosphate into IP *in vitro*, in a cell extract, or *in vivo*.

**[0337]** Isopentenyl phosphate kinase (IPK) polypeptides phosphorylate isopentyl phosphate (IP) to form isopentenyl diphosphate (IPP). Standard methods (such as those described herein) can be used to determine whether a polypeptide has IPK polypeptide activity by measuring the ability of the polypeptide to convert IP into IPP *in vitro*, in a cell extract, or *in vivo*.

**[0338]** Exemplary IDI polypeptides and nucleic acids are described above.

#### *Exemplary Hydrogenase Polypeptides and Nucleic Acids*

**[0339]** Hydrogenase polypeptides catalyze the reaction:  $2\text{H}^+ + 2\text{e}^- \leftrightarrow \text{H}_2$ . *In vitro* that reaction is reversible, but certain hydrogenases may work in only one direction *in vivo*, either oxidizing  $\text{H}_2$  or reducing  $\text{H}^+$ . Hydrogenase polypeptides can be oxygen-sensitive, contain complex metal cofactors as part of their catalytic center and sometimes consist of multiple subunits, with hydrogenase gene expression sometimes involving additional accessory polypeptides, such as ‘maturation’ factors or transcription regulatory factors (*i.e.*, activators or repressors). Hydrogenases are classified into at least three broad groups based upon the type of metal cofactor in their catalytic center: (1) nickel-iron (“NiFe”) hydrogenases have a nickel/iron cofactor; (2) iron-iron hydrogenases (“FeFe”) have an iron/iron cofactor; and (3) iron/sulfur-free (“Fe”) hydrogenases, which lack the 4Fe4S clusters found in groups (1) and (2), have an iron cofactor and a methenyl-tetrahydromethanopterin electron carrier. *See, e.g.*, Chung-Jung Chou et al., “Hydrogenesis in hyperthermophilic microorganisms: implications for biofuels,” *Metabol. Eng.* 10:394-404 (2008), and Gönül Vardar-Schara et al., “Metabolically engineered bacteria for producing hydrogen via fermentation,” *Microbial Biotechnol.* 1(2):107-125 (2008), both of which are incorporated herein by reference in their entireties, particularly with respect to

the various types and classes of hydrogenases. Although many organisms contain multiple hydrogenases, few contain genes for both NiFe and FeFe hydrogenases.

**[0340]** The catalytic center of NiFe hydrogenases consists of a nickel atom and an iron atom, each with two carbon monoxide (CO) and two cyanide (CN<sup>-</sup>) ligands. The NiFe hydrogenases all comprise at least a second subunit containing multiple iron-sulfur (Fe-S) centers for the transfer of electrons to and from the catalytic center. The NiFe hydrogenases can be subdivided into four main classes: (1) respiratory enzymes, which are part of multi-enzyme systems that couple the oxidation of H<sub>2</sub> to reduction of terminal electron acceptors such as SO<sub>4</sub><sup>2-</sup> or NO<sub>3</sub><sup>-</sup> under anaerobic conditions, or to O<sub>2</sub> in aerobic microorganisms; (2) H<sub>2</sub> sensors, which activate expression of the metabolically active NiFe hydrogenases; (3) cytoplasmic hydrogenases, containing multiple subunits able to utilize NADP<sup>+</sup>, which are readily reversible *in vitro*, but *in vivo* may only oxidize H<sub>2</sub>; and (4) membrane-bound, energy-conserving multi-enzyme complexes also found in bacteria and Archaea. Chung-Jung Chou et al., "Hydrogenesis in hyperthermophilic microorganisms: implications for biofuels," *Metabol. Eng.* 10:394-404 (2008).

**[0341]** The catalytic center of FeFe hydrogenases contains a catalytic "H cluster" which coordinates a binuclear (FeFe) site bridged to a [4Fe-4S] center by a single protein (cysteine) ligand. The two iron atoms of the binuclear center each have two carbon monoxide (CO) and two cyanide (CN<sup>-</sup>) ligands, and are also bridged by two sulfur atoms which are part of a small organic molecule. Most FeFe hydrogenases are monomeric enzymes of about 50 kilodaltons (kDa), and appear to function *in vivo* primarily to dispose of excess reducing equivalents by reducing protons to hydrogen gas. Chung-Jung Chou et al., "Hydrogenesis in hyperthermophilic microorganisms: implications for biofuels," *Metabol. Eng.* 10:394-404 (2008).

**[0342]** The catalytic center of Fe hydrogenases was originally thought to have an active site based on an organic cofactor with no metals involved, but was later shown to contain a mononuclear Fe atom. Despite the phylogenetic differences between the three types of hydrogenase, in addition to at least one iron atom, all three groups of hydrogenases also contain at least one carbon monoxide (CO) ligand to the iron atom in their active sites, which facilitates the catalytic oxidation of H<sub>2</sub> and the reduction of protons. Chung-Jung Chou et al., "Hydrogenesis in hyperthermophilic microorganisms: implications for biofuels," *Metabol. Eng.* 10:394-404 (2008).

**[0343]** Exemplary hydrogenase polypeptides include, but are not limited to, the *E. coli* hydrogenase-1 (Hyd-1) polypeptides, *E. coli* hydrogenase-2 (Hyd-2) polypeptides, *E. coli*

hydrogenase-3 (Hyd-3) polypeptides, *E. coli* hydrogenase-4 (Hyd-4) polypeptides, *E. coli* formate hydrogen lyase (FHL) complex, which produces hydrogen gas from formate and CO<sub>2</sub> under anaerobic conditions at acidic pH (see, e.g., Akihito Yoshida et al., "Efficient induction of formate hydrogen lyase of aerobically grown *Escherichia coli* in a three-step biohydrogen production process," *Appl. Microbiol. Biotechnol.* 74:754-760 (2007), which is incorporated herein by reference in its entirety, particularly with respect to the induction of expression of formate hydrogen lyase in *E. coli*), *Ralstonia eutropha* H16 hydrogenase (*R. eutropha* HoxH) *Rhodococcus opacus* MR11 hydrogenase (*R. opacus* HoxH) polypeptides, *Synechosystis* sp. PCC 6803 hydrogenase (*Syn.* PCC 6803 HoxH) polypeptides, *Desulfovibrio gigas* hydrogenase (*D. gigas*) polypeptides, and *Desulfovibrio desulfuricans* ATCC 7757 hydrogenase (*D. desulfuricans*) polypeptides (see, e.g., Gönül Vardar-Schaha et al., "Metabolically engineered bacteria for producing hydrogen via fermentation," *Microbial Biotechnol.* 1(2):107-125 (2008), which is incorporated herein by reference in its entirety, particularly with respect to the various types and classes of hydrogenases) and polypeptides (e.g., fusion polypeptides) having an activity of two or more hydrogenase polypeptides. In particular, hydrogenase polypeptides include polypeptides, fragments of polypeptides, peptides, and fusion polypeptides that have at least one activity of a hydrogenase polypeptide. Exemplary hydrogenase nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of a hydrogenase polypeptide, or at least one activity necessary for expression, processing, or maturation of a hydrogenase polypeptide. Exemplary hydrogenase polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein.

**[0344]** *E. coli* Hyd-3, which is part of the anaerobic formate hydrogen lyase (FHL) complex, is encoded by the *hyc* operon (comprising the *hycA*, *hycB*, *hycC*, *hycD*, *hycE*, *hycF*, *hycG*, *hycH*, and *hycI* genes). *E. coli* Hyd-4 is encoded by the *hyf* operon (comprising the *hyfA*, *hyfB*, *hyfC*, *hyfD*, *hyfE*, *hyfF*, *hyfG*, *hyfH*, *hyfI*, *hyfJ*, and *hyfR* genes). *E. coli* FHL is encoded by six genes from the *hyc* operon (*hycB*, *hycC*, *hycD*, *hycE*, *hycF* and *hycG*) and the *fdhF* gene (encoding formate dehydrogenase H (Fdh-H)). Expression of the FHL complex can further involve expression of pyruvate formate lyase (*pfl*), FhlA, a transcription factor that activates transcription of *fdhF* and the *hyc* operon, or deletion/inactivation of HycA, a transcription factor encoded by the *hycA* gene that negatively regulates transcription of FHL. Co-production of isoprene and hydrogen can be improved by expression or inactivation/deletion of additional

proteins involved in the regulation of gene expression for hydrogenases and other enzymes, such as, for example, iron-sulfur complex transcriptional regulator (*iscR*) (Kalim-Akhtar et al., “Deletion of *iscR* stimulates recombinant Clostridial Fe/Fe hydrogenase activity and H<sub>2</sub>-accumulation in *Escherichia coli* BL21(DE3),” *Appl. Microbiol. Biotechnol.* 78:853–862 (2008), which is incorporated herein by reference in its entirety, particularly with reference to stimulation of Clostridial Fe/Fe hydrogenase activity and hydrogen accumulation in *E. coli* by deleting the *iscR* gene).

**[0345]** Exemplary ferredoxin-dependent hydrogenase polypeptides include, but are not limited to, *Clostridium acetobutylicum* hydrogenase A (HydA) (*see, e.g.*, P.W. King et al., “Functional studies of [FeFe] hydrogenase maturation in an *Escherichia coli* biosynthetic system,” *J. Bacteriol.* 188(6):163-172 (2006), which is incorporated herein by reference in its entirety, particularly with respect to production of hydrogen by HydA and three HydA-associated maturation enzymes (HydE, HydG, and HydF), which may be expressed alone or in conjunction with one or more of: (1) *Bacillus subtilis* NADPH ferredoxin oxidoreductase (NFOR) (*see, e.g.*, Viet et al., (2008)), which is incorporated herein by reference in its entirety, particularly with respect to production of hydrogen by NFOR; *see also* PCT Publication No. WO/2007/089901, which is incorporated herein by reference in its entirety, particularly with respect to optimization of *E. coli* strains for production of hydrogen), *Clostridium kluyveri* NADH ferredoxin oxidoreductase (RnfCDGEAB) (Henning Seedorf et al., “The genome of *Clostridium kluyveri*, a strict anaerobe with unique metabolic features,” *Proc. Nat'l Acad. Sci. U.S.A.* 105(6):2128-2133 (2008), which is incorporated herein by reference in its entirety, particular with reference to NADH ferredoxin oxidoreductase, and with reference to components of the anaerobic ethanol-acetate fermentation pathway), or *Clostridium pasteurianum* ferredoxin oxidoreductase (Fdx); (2) glyceraldehyde-6-phosphate ferredoxin oxidoreductase (“GAPOR”); or (3) pyruvate ferredoxin oxidoreductase (“POR”), and polypeptides (*e.g.*, fusion polypeptides) having an activity of two or more hydrogenase polypeptides or of one or more hydrogenase polypeptides and an activity of one or more ferredoxin-dependent oxidoreductases. In particular, ferredoxin-dependent hydrogenase polypeptides include polypeptides, fragments of polypeptides, peptides, and fusion polypeptides that have at least one activity of a ferredoxin-dependent hydrogenase polypeptide.

**[0346]** Exemplary NADPH-dependent hydrogenase polypeptides include, but are not limited to thermophilic hydrogenase polypeptides such as *Pyrococcus furiosus* hydrogenase (*see, e.g.*, J. Woodward et al., “Enzymatic production of biohydrogen,” *Nature* 405(6790):1014-1015

(2000)), and polypeptides (*e.g.*, fusion polypeptides) having an activity of two or more NADPH-dependent hydrogenase polypeptides. In particular, NADPH-dependent hydrogenase polypeptides include polypeptides, fragments of polypeptides, peptides, and fusion polypeptides that have at least one activity of a NADPH-dependent hydrogenase polypeptide.

**[0347]** Exemplary oxygen-tolerant or oxygen-insensitive hydrogenases include, but are not limited to, *Rubrivivax gelatinosus* hydrogenase (*see, e.g.*, P.C. Maness et al., "Characterization of the oxygen tolerance of a hydrogenase linked to a carbon monoxide oxidation pathway in *Rubrivivax gelatinosus*," *Appl. Environ. Microbiol.* 68(6):2633-2636 (2002), which is incorporated herein by reference in its entirety, particularly with respect to *R. gelatinosus* hydrogenase), and *Ralstonia eutropha* hydrogenase polypeptides (*see, e.g.*, T. Burgdorf et al., "[NiFe]-hydrogenases of *Ralstonia eutropha* H16: modular enzymes for oxygen-tolerant biological hydrogen oxidation," *J. Mol. Microbiol. Biotechnol.* 10(2-4):181-196 (2005), which is incorporated herein by reference in its entirety, particularly with respect to *R. eutropha* hydrogenase polypeptides). Alternatively, heterologous nucleic acids encoding hydrogenase polypeptides can be mutagenized and screened for O<sub>2</sub>-tolerance or O<sub>2</sub>-insensitivity using standard methods and assays (*see, e.g.*, L.E. Nagy et al., "Application of gene-shuffling for the rapid generation of novel [FeFe]-hydrogenase libraries," *Biotechnol. Letts.* 29(3)421-430 (2007), which is incorporated herein by reference, particularly with respect to mutagenesis and screening for oxygen tolerant hydrogenase polypeptides).

**[0348]** Standard methods (such as those described herein) can be used to determine whether a polypeptide has hydrogenase activity by measuring the ability of the polypeptide to produce hydrogen gas *in vitro*, in a cell extract, or *in vivo*.

#### *Exemplary Polypeptides and Nucleic Acids for Genes Related to Production of Fermentation Side Products*

**[0349]** In addition to expressing or over-expressing heterologous or native hydrogenases in *E. coli*, co-production of isoprene and hydrogen can be improved by inactivation of anaerobic biosynthetic pathways, thereby blocking the carbon flow to a variety of metabolites (*i.e.*, fermentation side products) produced under oxygen-limited or anaerobic conditions, including, but not limited to, lactate, acetate, pyruvate, ethanol, succinate, and glycerol. Exemplary polypeptides involved in the production of fermentation side products include formate dehydrogenase N, alpha subunit (*fdnG*), formate dehydrogenase O, large subunit (*fdoG*), nitrate reductase (*narG*), formate transporter A (*focA*), formate transporter B (*focB*), pyruvate oxidase

(*poxB*), pyruvate dehydrogenase E1 component *ackA/pta* (*aceE*), alcohol dehydrogenase (*adhE*), fumarate reductase membrane protein (*frdC*), and lactate dehydrogenase (*ldhA*). See, e.g., Toshinori Maeda et al., "Enhanced hydrogen production from glucose by metabolically engineered *Escherichia coli*," *Appl. Microbiol. Biotechnol.* 77(4):879-890 (2007), which is incorporated by reference in its entirety, particularly with respect to production of *E. coli* strains with modified glucose metabolism. Exemplary polypeptides involved in the regulation or expression of genes involved in the production of fermentation side products that may also be inactivated to improve co-production of isoprene and hydrogen include, but are not limited to, repressor of formate hydrogen lyase (*hycA*), fumarate reductase regulator (*fnr*), acetyl-coenzyme A synthetase (*acs*), and formate dehydrogenase regulatory protein (*hycA*), which regulates expression of the transcriptional regulator *fhfA* (formate hydrogen lyase transcriptional activator).

#### *Exemplary Polypeptides and Nucleic Acids for Genes Related to Hydrogen Re-uptake*

**[0350]** Exemplary polypeptides involved in hydrogen re-uptake that may also be inactivated to improve co-production of isoprene and hydrogen include, but are not limited to, *E. coli* hydrogenase-1 (Hyd-1) (*hya* operon) and *E. coli* hydrogenase-2 (Hyd-2) (*hyb* operon). *E. coli* Hyd-1 is encoded by the *hya* operon (comprising the *hyaA*, *hyaB*, *hyaC*, *hyaD*, *hyaE*, and *hyaF* genes). *E. coli* Hyd-2 is encoded by the *hyb* operon (comprising the *hybA*, *hybB*, *hybC*, *hybD*, *hybE*, *hybF*, *hybG*, and *hybO* genes).

#### *Exemplary Methods for Isolating Nucleic Acids*

**[0351]** Isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids can be isolated using standard methods. Methods of obtaining desired nucleic acids from a source organism of interest (such as a bacterial genome) are common and well known in the art of molecular biology (see, for example, WO 2004/033646 and references cited therein, which are each hereby incorporated by reference in their entireties, particularly with respect to the isolation of nucleic acids of interest). For example, if the sequence of the nucleic acid is known (such as any of the known nucleic acids described herein), suitable genomic libraries may be created by restriction endonuclease digestion and may be screened with probes complementary to the desired nucleic acid sequence. Once the sequence is isolated, the DNA may be amplified using standard primer directed amplification methods such as polymerase chain reaction (PCR) (U.S. Patent No. 4,683,202,

which is incorporated by reference in its entirety, particularly with respect to PCR methods) to obtain amounts of DNA suitable for transformation using appropriate vectors.

**[0352]** Alternatively, isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids (such as any isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids with a known nucleic acid sequence) can be chemically synthesized using standard methods.

**[0353]** Additional isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor polypeptides and nucleic acids which may be suitable for use in the compositions and methods described herein can be identified using standard methods. For example, cosmid libraries of the chromosomal DNA of organisms known to produce isoprene naturally can be constructed in organisms such as *E. coli*, and then screened for isoprene production. In particular, cosmid libraries may be created where large segments of genomic DNA (35-45 kb) are packaged into vectors and used to transform appropriate hosts. Cosmid vectors are unique in being able to accommodate large quantities of DNA. Generally cosmid vectors have at least one copy of the cos DNA sequence which is needed for packaging and subsequent circularization of the heterologous DNA. In addition to the cos sequence, these vectors also contain an origin of replication such as ColEI and drug resistance markers such as a nucleic acid resistant to ampicillin or neomycin. Methods of using cosmid vectors for the transformation of suitable bacterial hosts are well described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., Cold Spring Harbor, 1989, which is hereby incorporated by reference in its entirety, particularly with respect to transformation methods.

**[0354]** Typically to clone cosmids, heterologous DNA is isolated using the appropriate restriction endonucleases and ligated adjacent to the cos region of the cosmid vector using the appropriate ligases. Cosmid vectors containing the linearized heterologous DNA are then reacted with a DNA packaging vehicle such as bacteriophage. During the packaging process, the cos sites are cleaved and the heterologous DNA is packaged into the head portion of the bacterial viral particle. These particles are then used to transfect suitable host cells such as *E. coli*. Once injected into the cell, the heterologous DNA circularizes under the influence of the cos sticky ends. In this manner, large segments of heterologous DNA can be introduced and expressed in host cells.

**[0355]** Additional methods for obtaining isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids include screening a metagenomic library by assay (such as the headspace assay described herein) or by PCR using

primers directed against nucleotides encoding for a length of conserved amino acids (for example, at least 3 conserved amino acids). Conserved amino acids can be identified by aligning amino acid sequences of known isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor polypeptides. Conserved amino acids for isoprene synthase polypeptides can be identified based on aligned sequences of known isoprene synthase polypeptides. An organism found to produce isoprene naturally can be subjected to standard protein purification methods (which are well known in the art) and the resulting purified polypeptide can be sequenced using standard methods. Other methods are found in the literature (see, for example, Julsing *et al.*, *Applied. Microbiol. Biotechnol.* 75: 1377-84, 2007; Withers *et al.*, *Appl Environ Microbiol.* 73(19):6277-83, 2007, which are each hereby incorporated by reference in their entirety, particularly with respect to identification of nucleic acids involved in the synthesis of isoprene).

**[0356]** Additionally, standard sequence alignment and/or structure prediction programs can be used to identify additional DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor polypeptides and nucleic acids based on the similarity of their primary and/or predicted polypeptide secondary structure with that of known DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor polypeptides and nucleic acids. Standard databases such as the swissprot-trembl database (world-wide web at “expasy.org”, Swiss Institute of Bioinformatics Swiss-Prot group CMU - 1 rue Michel Servet CH-1211 Geneva 4, Switzerland) can also be used to identify isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription regulatory polypeptides and nucleic acids. The secondary and/or tertiary structure of an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor polypeptide can be predicted using the default settings of standard structure prediction programs, such as PredictProtein (630 West, 168 Street, BB217, New York, N.Y. 10032, USA). Alternatively, the actual secondary and/or tertiary structure of an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor polypeptide can be determined using standard methods. Additional isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids can also be identified by hybridization to probes generated from known isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids.

*Exemplary Promoters and Vectors*

**[0357]** Any of the isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids described herein can be included in one or more vectors. Accordingly, also described herein are vectors with one more nucleic acids encoding any of the isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor polypeptides that are described herein. In some embodiments, the vector contains a nucleic acid under the control of an expression control sequence.

**[0358]** In some embodiments, the vector contains a selective marker or selectable marker. Markers useful in vector systems for transformation of *Trichoderma* are known in the art (*see, e.g.*, Finkelstein, Chapter 6 in *Biotechnology of Filamentous Fungi*, Finkelstein *et al.*, Eds. Butterworth-Heinemann, Boston, MA, Chap. 6., 1992; and Kinghorn *et al.*, *Applied Molecular Genetics of Filamentous Fungi*, Blackie Academic and Professional, Chapman and Hall, London, 1992, which are each hereby incorporated by reference in their entireties, particularly with respect to selective markers). In some embodiments, the selective marker is the *amdS* nucleic acid, which encodes the enzyme acetamidase, allowing transformed cells to grow on acetamide as a nitrogen source. The use of an *A. nidulans amdS* nucleic acid as a selective marker is described in Kelley *et al.*, *EMBO J.* 4:475 – 479, 1985 and Penttila *et al.*, *Gene* 61:155-164, 1987 (which are each hereby incorporated by reference in their entireties, particularly with respect to selective markers). In some embodiments, an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation, or transcription regulatory nucleic acid integrates into a chromosome of the cells without a selective marker.

**[0359]** Suitable vectors are those which are compatible with the host cell employed. Suitable vectors can be derived, for example, from a bacterium, a virus (such as bacteriophage T7 or a M-13 derived phage), a cosmid, a yeast, or a plant. Protocols for obtaining and using such vectors are known to those in the art (*see, for example*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., Cold Spring Harbor, 1989, which is hereby incorporated by reference in its entirety, particularly with respect to the use of vectors).

**[0360]** Promoters are well known in the art. Any promoter that functions in the host cell can be used for expression of an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid in the host cell. Initiation control regions or promoters, which are useful to drive expression of isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids in various host cells are numerous and familiar to those skilled in the art (*see, for example*, WO

2004/033646 and references cited therein, which are each hereby incorporated by reference in their entireties, particularly with respect to vectors for the expression of nucleic acids of interest). Virtually any promoter capable of driving these nucleic acids can be used including, but not limited to, CYC1, HIS3, GAL1, GAL10, ADH1, PGK, PHO5, GAPDH, ADCI, TRP1, URA3, LEU2, ENO, and TPI (useful for expression in *Saccharomyces*); AOX1 (useful for expression in *Pichia*); and lac, trp,  $\lambda P_L$ ,  $\lambda P_R$ , T7, tac, and tre (useful for expression in *E. coli*).

**[0361]** In some embodiments, a glucose isomerase promoter is used (*see*, for example, U.S. Patent No. 7,132,527 and references cited therein, which are each hereby incorporated by reference in their entireties, particularly with respect promoters and plasmid systems for expressing polypeptides of interest). Reported glucose isomerase promoter mutants can be used to vary the level of expression of the polypeptide encoded by a nucleic acid operably linked to the glucose isomerase promoter (U.S. Patent No. 7,132,527). In various embodiments, the glucose isomerase promoter is contained in a low, medium, or high copy plasmid (U.S. Patent No. 7,132,527).

**[0362]** In various embodiments, an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid is contained in a low copy plasmid (*e.g.*, a plasmid that is maintained at about 1 to about 4 copies per cell), medium copy plasmid (*e.g.*, a plasmid that is maintained at about 10 to about 15 copies per cell), or high copy plasmid (*e.g.*, a plasmid that is maintained at about 50 or more copies per cell). In some embodiments, the heterologous or extra endogenous isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid is operably linked to a T7 promoter. In some embodiments, the heterologous or extra endogenous isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid operably linked to a T7 promoter is contained in a medium or high copy plasmid. In some embodiments, the heterologous or extra endogenous isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid is operably linked to a Trc promoter. In some embodiments, the heterologous or extra endogenous isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid operably linked to a Trc promoter is contained in a medium or high copy plasmid. In some embodiments, the heterologous or extra endogenous isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid operably linked to a Trc promoter is contained in a medium or high copy plasmid. In some embodiments, the heterologous or extra endogenous isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid operably linked to a Lac promoter. In some embodiments, the heterologous or extra endogenous isoprene synthase, DXS, IDI, MVA

pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid operably linked to a Lac promoter is contained in a low copy plasmid. In some embodiments, the heterologous or extra endogenous isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid is operably linked to an endogenous promoter, such as an endogenous *Escherichia*, *Pantoea*, *Bacillus*, *Yarrowia*, *Streptomyces*, or *Trichoderma* promoter or an endogenous alkaline serine protease, isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor promoter. In some embodiments, the heterologous or extra endogenous isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid operably linked to an endogenous promoter is contained in a high copy plasmid. In some embodiments, the vector is a replicating plasmid that does not integrate into a chromosome in the cells. In some embodiments, part or all of the vector integrates into a chromosome in the cells.

**[0363]** In some embodiments, the vector is any vector which when introduced into a fungal host cell is integrated into the host cell genome and is replicated. Reference is made to the Fungal Genetics Stock Center Catalogue of Strains (FGSC, the world-wide web at “fgsc.net” and the references cited therein, which are each hereby incorporated by reference in their entireties, particularly with respect to vectors) for a list of vectors. Additional examples of suitable expression and/or integration vectors are provided in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., Cold Spring Harbor, 1989, Current Protocols in Molecular Biology (F. M. Ausubel *et al.* (eds) 1987, Supplement 30, section 7.7.18); van den Hondel *et al.* in Bennett and Lasure (Eds.) More Gene Manipulations in Fungi, Academic Press pp. 396-428, 1991; and U.S. Patent No. 5,874,276, which are each hereby incorporated by reference in their entireties, particularly with respect to vectors. Particularly useful vectors include pFB6, pBR322, PUC18, pUC100, and pENTR/D.

**[0364]** In some embodiments, an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid is operably linked to a suitable promoter that shows transcriptional activity in a fungal host cell. The promoter may be derived from one or more nucleic acids encoding a polypeptide that is either endogenous or heterologous to the host cell. In some embodiments, the promoter is useful in a *Trichoderma* host. Suitable non-limiting examples of promoters include *cbh1*, *cbh2*, *egl1*, *egl2*, *pepA*, *hfb1*, *hfb2*, *xyn1*, and *amy*. In some embodiments, the promoter is one that is native to the host cell. For example, in some embodiments when *T. reesei* is the host, the promoter is a native *T. reesei* promoter. In

some embodiments, the promoter is *T. reesei cbh1*, which is an inducible promoter and has been deposited in GenBank under Accession No. D86235, which is incorporated by reference in its entirety, particularly with respect to promoters. In some embodiments, the promoter is one that is heterologous to the fungal host cell. Other examples of useful promoters include promoters from the genes of *A. awamori* and *A. niger* glucoamylase (*glaA*) (Nunberg *et al.*, *Mol. Cell Biol.* 4:2306-2315, 1984 and Boel *et al.*, *EMBO J.* 3:1581-1585, 1984, which are each hereby incorporated by reference in their entireties, particularly with respect to promoters); *Aspergillus niger* alpha amylases, *Aspergillus oryzae* TAKA amylase, *T. reesei xln1*, and the *T. reesei cellobiohydrolase 1* (EP 137280, which is incorporated by reference in its entirety, particularly with respect to promoters).

**[0365]** In some embodiments, the expression vector also includes a termination sequence. Termination control regions may also be derived from various genes native to the host cell. In some embodiments, the termination sequence and the promoter sequence are derived from the same source. In another embodiment, the termination sequence is endogenous to the host cell. A particularly suitable terminator sequence is *cbh1* derived from a *Trichoderma* strain (such as *T. reesei*). Other useful fungal terminators include the terminator from an *A. niger* or *A. awamori* glucoamylase nucleic acid (Nunberg *et al.*, *Mol. Cell Biol.* 4:2306-2315, 1984 and Boel *et al.*, *EMBO J.* 3:1581-1585, 1984; which are each hereby incorporated by reference in their entireties, particularly with respect to fungal terminators). Optionally, a termination site may be included. For effective expression of the polypeptides, DNA encoding the polypeptide are linked operably through initiation codons to selected expression control regions such that expression results in the formation of the appropriate messenger RNA.

**[0366]** In some embodiments, the promoter, coding, region, and terminator all originate from the isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid to be expressed. In some embodiments, the coding region for an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid is inserted into a general-purpose expression vector such that it is under the transcriptional control of the expression construct promoter and terminator sequences. In some embodiments, genes or part thereof are inserted downstream of the strong *cbh1* promoter.

**[0367]** An isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid can be incorporated into a vector, such as an expression vector, using standard techniques (Sambrook *et al.*, *Molecular Cloning: A Laboratory*

Manual, Cold Spring Harbor, 1982, which is hereby incorporated by reference in its entirety, particularly with respect to the screening of appropriate DNA sequences and the construction of vectors). Methods used to ligate the DNA construct comprising a nucleic acid of interest (such as an isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid), a promoter, a terminator, and other sequences and to insert them into a suitable vector are well known in the art. For example, restriction enzymes can be used to cleave the isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid and the vector. Then, the compatible ends of the cleaved isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid and the cleaved vector can be ligated. Linking is generally accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide linkers are used in accordance with conventional practice (*see*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., Cold Spring Harbor, 1989, and Bennett and Lasure, *More Gene Manipulations in Fungi*, Academic Press, San Diego, pp 70–76, 1991, which are each hereby incorporated by reference in their entireties, particularly with respect to oligonucleotide linkers). Additionally, vectors can be constructed using known recombination techniques (*e.g.*, Invitrogen Life Technologies, Gateway Technology).

**[0368]** In some embodiments, it may be desirable to over-express isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids at levels far higher than currently found in naturally-occurring cells. This result may be accomplished by the selective cloning of the nucleic acids encoding those polypeptides into multicopy plasmids or placing those nucleic acids under a strong inducible or constitutive promoter. Methods for over-expressing desired polypeptides are common and well known in the art of molecular biology and examples may be found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., Cold Spring Harbor, 1989, which is hereby incorporated by reference in its entirety, particularly with respect to cloning techniques.

**[0369]** In some embodiments, it may be desirable to under-express (*e.g.*, mutate, inactivate, or delete) isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation, or transcription factor polypeptide-encoding nucleic acids at levels far below that those currently found in naturally-occurring cells. This result may be accomplished by the mutation or inactivation of transcriptional regulatory proteins required for expression of isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids, by deletion of the isoprene synthase, DXS, IDI, MVA pathway, hydrogenase,

hydrogenase maturation and/or transcription factor nucleic acids, or by placing those nucleic acids under the control of a strong repressible promoter. Methods for mutating, inactivating, or deleting desired polypeptides are common and well known in the art of molecular biology and examples may be found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., Cold Spring Harbor, 1989, which is hereby incorporated by reference in its entirety, particularly with respect to cloning and mutagenesis techniques.

**[0370]** The following resources include descriptions of additional general methodology useful in accordance with the compositions and methods described herein: Kreigler, *Gene Transfer and Expression; A Laboratory Manual*, 1990 and Ausubel *et al.*, Eds. *Current Protocols in Molecular Biology*, 1994, which are each hereby incorporated by reference in their entireties, particularly with respect to molecular biology and cloning techniques.

#### *Exemplary Source Organisms*

**[0371]** Isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids (and their encoded polypeptides) can be obtained from any organism that naturally contains isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids. As noted above, isoprene is formed naturally by a variety of organisms, such as bacteria, yeast, plants, and animals. Organisms contain the MVA pathway, DXP pathway, or both the MVA and DXP pathways for producing isoprene (Figures 19A and 19B). Thus, DXS nucleic acids can be obtained, *e.g.*, from any organism that contains the DXP pathway or contains both the MVA and DXP pathways. IDI and isoprene synthase nucleic acids can be obtained, *e.g.*, from any organism that contains the MVA pathway, DXP pathway, or both the MVA and DXP pathways. MVA pathway nucleic acids can be obtained, *e.g.*, from any organism that contains the MVA pathway or contains both the MVA and DXP pathways. Hydrogenase nucleic acids can be obtained, *e.g.*, from any organism that oxidizes hydrogen or reduces hydrogen ions. Fermentation side product genes can be obtained or identified, *e.g.*, from any organism that undergoes oxygen-limited or anaerobic respiration, such as glycolysis.

**[0372]** In some embodiments, the nucleic acid sequence of the isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid is identical to the sequence of a nucleic acid that is produced by any of the following organisms in nature. In some embodiments, the amino acid sequence of the isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor polypeptide is

identical to the sequence of a polypeptide that is produced by any of the following organisms in nature. In some embodiments, the isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acid or polypeptide is a mutant nucleic acid or polypeptide derived from any of the organisms described herein. As used herein, "derived from" refers to the source of the nucleic acid or polypeptide into which one or more mutations is introduced. For example, a polypeptide that is "derived from a plant polypeptide" refers to polypeptide of interest that results from introducing one or more mutations into the sequence of a wild-type (*i.e.*, a sequence occurring in nature) plant polypeptide.

**[0373]** In some embodiments, the source organism is a fungus, examples of which are species of *Aspergillus* such as *A. oryzae* and *A. niger*, species of *Saccharomyces* such as *S. cerevisiae*, species of *Schizosaccharomyces* such as *S. pombe*, and species of *Trichoderma* such as *T. reesei*. In some embodiments, the source organism is a filamentous fungal cell. The term "filamentous fungi" refers to all filamentous forms of the subdivision Eumycotina (*see*, Alexopoulos, C. J. (1962), *Introductory Mycology*, Wiley, New York). These fungi are characterized by a vegetative mycelium with a cell wall composed of chitin, cellulose, and other complex polysaccharides. The filamentous fungi are morphologically, physiologically, and genetically distinct from yeasts. Vegetative growth by filamentous fungi is by hyphal elongation and carbon catabolism is obligatory aerobic. The filamentous fungal parent cell may be a cell of a species of, but not limited to, *Trichoderma*, (*e.g.*, *Trichoderma reesei*, the asexual morph of *Hypocrea jecorina*, previously classified as *T. longibrachiatum*, *Trichoderma viride*, *Trichoderma koningii*, *Trichoderma harzianum*) (Sheir-Neirs *et al.*, *Appl. Microbiol. Biotechnol* 20: 46-53, 1984; ATCC No. 56765 and ATCC No. 26921); *Penicillium sp.*, *Humicola sp.* (*e.g.*, *H. insolens*, *H. lanuginosa*, or *H. grisea*); *Chrysosporium sp.* (*e.g.*, *C. lucknowense*), *Gliocladium sp.*, *Aspergillus sp.* (*e.g.*, *A. oryzae*, *A. niger*, *A. sojae*, *A. japonicus*, *A. nidulans*, or *A. awamori*) (Ward *et al.*, *Appl. Microbiol. Biotechnol.* 39: 7380743, 1993 and Goedegebuur *et al.*, *Genet* 41: 89-98, 2002), *Fusarium sp.*, (*e.g.*, *F. roseum*, *F. gramineum*, *F. cerealis*, *F. oxysporum*, or *F. venenatum*), *Neurospora sp.*, (*e.g.*, *N. crassa*), *Hypocrea sp.*, *Mucor sp.*, (*e.g.*, *M. miehei*), *Rhizopus sp.* and *Emericella sp.* (*see also*, Innis *et al.*, *Sci.* 228: 21-26, 1985). The term "Trichoderma" or "Trichoderma sp." or "Trichoderma spp." refer to any fungal genus previously or currently classified as *Trichoderma*.

**[0374]** In some embodiments, the fungus is *A. nidulans*, *A. awamori*, *A. oryzae*, *A. aculeatus*, *A. niger*, *A. japonicus*, *T. reesei*, *T. viride*, *F. oxysporum*, or *F. solani*. *Aspergillus* strains are disclosed in Ward *et al.*, *Appl. Microbiol. Biotechnol.* 39:738-743, 1993 and Goedegebuur *et al.*,

Curr Gene 41:89-98, 2002, which are each hereby incorporated by reference in their entireties, particularly with respect to fungi. In particular embodiments, the fungus is a strain of *Trichoderma*, such as a strain of *T. reesei*. Strains of *T. reesei* are known and non-limiting examples include ATCC No. 13631, ATCC No. 26921, ATCC No. 56764, ATCC No. 56765, ATCC No. 56767, and NRRL 15709, which are each hereby incorporated by reference in their entireties, particularly with respect to strains of *T. reesei*. In some embodiments, the host strain is a derivative of RL-P37. RL-P37 is disclosed in Sheir-Neiss *et al.*, Appl. Microbiol. Biotechnology 20:46–53, 1984, which is hereby incorporated by reference in its entirety, particularly with respect to strains of *T. reesei*.

**[0375]** In some embodiments, the source organism is a yeast, such as *Saccharomyces sp.*, *Schizosaccharomyces sp.*, *Pichia sp.*, or *Candida sp.* In some embodiments, the *Saccharomyces sp.* is *Saccharomyces cerevisiae*.

**[0376]** In some embodiments, the source organism is a bacterium, such as strains of *Bacillus* such as *B. licheniformis* or *B. subtilis*, strains of *Pantoea* such as *P. citrea*, strains of *Pseudomonas* such as *P. alcaligenes*, *P. putida*, or *P. fluorescens*, strains of *Streptomyces* such as *S. lividans* or *S. rubiginosus*, strains of *Corynebacterium sp.* such as *Corynebacterium glutamicum*, strains of *Rhodopseudomonas sp.* such as *Rhodopseudomonas palustris*, or strains of *Escherichia* such as *E. coli*.

**[0377]** As used herein, “the genus *Bacillus*” includes all species within the genus “*Bacillus*,” as known to those of skill in the art, including but not limited to *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, and *B. thuringiensis*. It is recognized that the genus *Bacillus* continues to undergo taxonomical reorganization. Thus, it is intended that the genus include species that have been reclassified, including but not limited to such organisms as *B. stearothermophilus*, which is now named “*Geobacillus stearothermophilus*.” The production of resistant endospores in the presence of oxygen is considered the defining feature of the genus *Bacillus*, although this characteristic also applies to the recently named *Alicyclobacillus*, *Amphibacillus*, *Aneurinibacillus*, *Anoxybacillus*, *Brevibacillus*, *Filobacillus*, *Gracilibacillus*, *Halobacillus*, *Paenibacillus*, *Salibacillus*, *Thermobacillus*, *Ureibacillus*, and *Virgibacillus*.

**[0378]** In some embodiments, the source organism is a gram-positive bacterium. Non-limiting examples include strains of *Streptomyces* (e.g., *S. lividans*, *S. coelicolor*, or *S. griseus*) and *Bacillus*. In some embodiments, the source organism is a gram-negative bacterium, such as *E.*

*coli.*, *Rhodopseudomonas sp.* such as *Rhodopseudomonas palustris*, or *Pseudomonas sp.*, such as *P. alcaligenes*, *P. putida*, or *P. fluorescens*.

**[0379]** In some embodiments, the source organism is a plant, such as a plant from the family Fabaceae, such as the Faboideae subfamily. In some embodiments, the source organism is kudzu, poplar (such as *Populus alba x tremula* CAC35696), aspen (such as *Populus tremuloides*), or *Quercus robur*.

**[0380]** In some embodiments, the source organism is an alga, such as a green alga, red alga, glaucophytes, chlorarachniophytes, euglenids, chromista, or dinoflagellates.

**[0381]** In some embodiments, the source organism is a cyanobacteria, such as cyanobacteria classified into any of the following groups based on morphology: *Chroococcales*, *Pleurocapsales*, *Oscillatoriales*, *Nostocales*, or *Stigonematales*.

**[0382]** In some embodiments, the source organism is an anaerobic organism. Anaerobic organisms can include, but are not limited to, obligate anaerobes, facultative anaerobes, and aerotolerant anaerobes. Such organisms can be any of the organisms listed above, bacteria, yeast, etc. In one embodiment, the obligate anaerobes can be any one or combination selected from the group consisting of *Clostridium ljungdahlii*, *Clostridium autoethanogenum*, *Eurobacterium limosum*, *Clostridium carboxydvorans*, *Peptostreptococcus productus*, and *Butyribacterium methylotrophicum*. It is to be understood that any combination of any of the source organisms described herein can be used for other embodiments of the invention.

#### *Exemplary Host Cells*

**[0383]** A variety of host cells can be used to express isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor polypeptides and to co-produce isoprene and hydrogen in the methods described herein. Exemplary host cells include cells from any of the organisms listed in the prior section under the heading “*Exemplary Source Organisms*.” The host cell may be a cell that naturally produces isoprene or a cell that does not naturally produce isoprene. In some embodiments, the host cell naturally produces isoprene using the DXP pathway, and an isoprene synthase, DXS, and/or IDI nucleic acid is added to enhance production of isoprene using this pathway. In some embodiments, the host cell naturally produces isoprene using the MVA pathway, and an isoprene synthase and/or one or more MVA pathway nucleic acids are added to enhance production of isoprene using this pathway. In some embodiments, the host cell naturally produces isoprene using the DXP pathway and one or more MVA pathway nucleic acids are added to produce isoprene using part

or all of the MVA pathway as well as the DXP pathway. In some embodiments, the host cell naturally produces isoprene using both the DXP and MVA pathways and one or more isoprene synthase, DXS, IDI, or MVA pathway nucleic acids are added to enhance production of isoprene by one or both of these pathways.

**[0384]** In some embodiments, the host cell naturally produces isoprene using both the DXP and MVA pathways, and one or more isoprene synthase, DXS, IDI, or MVA pathway nucleic acids are added to enhance production of isoprene by one or both of these pathways, one or more hydrogenase nucleic acids are added to enhance hydrogen production and one or more fermentation side product-producing genes are inactivated or deleted to limit production of fermentation side products. In some embodiments, the host cell naturally co-produces isoprene and hydrogen using both the DXP and MVA pathways and one or more isoprene synthase, DXS, IDI, or MVA pathway nucleic acids are added to enhance production of isoprene by one or both of these pathways, one or more hydrogenase nucleic acids are added to enhance hydrogen production, one or more fermentation side product-producing genes are inactivated or deleted to limit production of fermentation side products, and one or more hydrogen reuptake genes are inactivated or deleted to increase hydrogen production. In some embodiments, the host cell naturally co-produces isoprene and hydrogen using both the DXP and MVA pathways and a hydrogenase, and one or more isoprene synthase, DXS, IDI, or MVA pathway nucleic acids are added to enhance production of isoprene by one or both of these pathways, one or more hydrogenase nucleic acids are added to enhance hydrogen production, one or more hydrogenase maturation nucleic acids are added to enhance hydrogen production, one or more fermentation side product-producing genes are inactivated or deleted to limit production of fermentation side products, and one or more hydrogen reuptake genes are inactivated or deleted to increase hydrogen production. In some embodiments, the host cell naturally co-produces isoprene and hydrogen using both the DXP and MVA pathways and one or more isoprene synthase, DXS, IDI, or MVA pathway nucleic acids are added to enhance production of isoprene by one or both of these pathways, one or more hydrogenase nucleic acids are added to enhance hydrogen production, one or more hydrogenase maturation nucleic acids are added to enhance hydrogen production, one or more transcription factor nucleic acids are added or inactivated or deleted to enhance hydrogenase production, one or more fermentation side product-producing genes are inactivated or deleted to limit production of fermentation side products, and one or more hydrogen reuptake genes are inactivated or deleted to increase hydrogen production.

*Exemplary Transformation Methods*

**[0385]** Isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor nucleic acids or vectors containing them can be inserted into a host cell (e.g., a plant cell, a fungal cell, a yeast cell, or a bacterial cell described herein) using standard techniques for expression of the encoded isoprene synthase, DXS, IDI, MVA pathway, hydrogenase, hydrogenase maturation and/or transcription factor polypeptide. Introduction of a DNA construct or vector into a host cell can be performed using techniques such as transformation, electroporation, nuclear microinjection, transduction, transfection (e.g., lipofection mediated or DEAE-Dextrin mediated transfection or transfection using a recombinant phage virus), incubation with calcium phosphate DNA precipitate, high velocity bombardment with DNA-coated microprojectiles, and protoplast fusion. General transformation techniques are known in the art (see, e.g., Current Protocols in Molecular Biology (F. M. Ausubel *et al.* (eds) Chapter 9, 1987; Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., Cold Spring Harbor, 1989; and Campbell *et al.*, *Curr. Genet.* 16:53-56, 1989, which are each hereby incorporated by reference in their entireties, particularly with respect to transformation methods). The expression of heterologous polypeptide in *Trichoderma* is described in U.S. Patent No. 6,022,725; U.S. Patent No. 6,268,328; U.S. Patent No. 7,262,041; WO 2005/001036; Harkki *et al.*, *Enzyme Microb. Technol.* 13:227-233, 1991; Harkki *et al.*, *Bio Technol.* 7:596-603, 1989; EP 244,234; EP 215,594; and Nevalainen *et al.*, "The Molecular Biology of *Trichoderma* and its Application to the Expression of Both Homologous and Heterologous Genes," in *Molecular Industrial Mycology*, Eds. Leong and Berka, Marcel Dekker Inc., NY pp. 129 – 148, 1992, which are each hereby incorporated by reference in their entireties, particularly with respect to transformation and expression methods). Reference is also made to Cao *et al.*, (*Sci.* 9:991–1001, 2000; EP 238023; and Yelton *et al.*, *Proceedings. Natl. Acad. Sci. USA* 81:1470-1474, 1984 (which are each hereby incorporated by reference in their entireties, particularly with respect to transformation methods) for transformation of *Aspergillus* strains. The introduced nucleic acids may be integrated into chromosomal DNA or maintained as extrachromosomal replicating sequences.

**[0386]** Any method known in the art may be used to select transformants. In one non-limiting example, stable transformants including an *amdS* marker are distinguished from unstable transformants by their faster growth rate and the formation of circular colonies with a smooth, rather than ragged outline on solid culture medium containing acetamide. Additionally, in some cases a further test of stability is conducted by growing the transformants on a solid non-

selective medium (*e.g.*, a medium that lacks acetamide), harvesting spores from this culture medium, and determining the percentage of these spores which subsequently germinate and grow on selective medium containing acetamide.

**[0387]** In some embodiments, fungal cells are transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a known manner. In one specific embodiment, the preparation of *Trichoderma sp.* for transformation involves the preparation of protoplasts from fungal mycelia (*see*, Campbell *et al.*, *Curr. Genet.* 16:53-56, 1989, which is incorporated by reference in its entirety, particularly with respect to transformation methods). In some embodiments, the mycelia are obtained from germinated vegetative spores. The mycelia are treated with an enzyme that digests the cell wall resulting in protoplasts. The protoplasts are then protected by the presence of an osmotic stabilizer in the suspending medium. These stabilizers include sorbitol, mannitol, potassium chloride, magnesium sulfate, and the like. Usually the concentration of these stabilizers varies between 0.8 M and 1.2 M. It is desirable to use about a 1.2 M solution of sorbitol in the suspension medium.

**[0388]** Uptake of DNA into the host *Trichoderma sp.* strain is dependent upon the calcium ion concentration. Generally, between about 10 mM CaCl<sub>2</sub> and 50 mM CaCl<sub>2</sub> is used in an uptake solution. In addition to the calcium ion in the uptake solution, other compounds generally included are a buffering system such as TE buffer (10 mM Tris, pH 7.4; 1 mM EDTA) or 10 mM MOPS, pH 6.0 buffer (morpholinepropanesulfonic acid) and polyethylene glycol (PEG). While not intending to be bound to any particular theory, it is believed that the polyethylene glycol acts to fuse the cell membranes, thus permitting the contents of the medium to be delivered into the cytoplasm of the *Trichoderma sp.* strain and the plasmid DNA to be transferred to the nucleus. This fusion frequently leaves multiple copies of the plasmid DNA integrated into the host chromosome.

**[0389]** Usually a suspension containing the *Trichoderma sp.* protoplasts or cells that have been subjected to a permeability treatment at a density of 10<sup>5</sup> to 10<sup>7</sup>/mL (such as 2 x 10<sup>6</sup>/mL) are used in the transformation. A volume of 100 μL of these protoplasts or cells in an appropriate solution (*e.g.*, 1.2 M sorbitol and 50 mM CaCl<sub>2</sub>) are mixed with the desired DNA. Generally, a high concentration of PEG is added to the uptake solution. From 0.1 to 1 volume of 25% PEG 4000 can be added to the protoplast suspension. In some embodiments, about 0.25 volumes are added to the protoplast suspension. Additives such as dimethyl sulfoxide, heparin, spermidine, potassium chloride, and the like may also be added to the uptake solution and aid in

transformation. Similar procedures are available for other fungal host cells (*see, e.g.*, U.S. Patent Nos. 6,022,725 and 6,268,328, which are each hereby incorporated by reference in their entireties, particularly with respect to transformation methods).

**[0390]** Generally, the mixture is then cultured at approximately 0°C for a period of between 10 to 30 minutes. Additional PEG is then added to the mixture to further enhance the uptake of the desired nucleic acid sequence. The 25% PEG 4000 is generally added in volumes of 5 to 15 times the volume of the transformation mixture; however, greater and lesser volumes may be suitable. The 25% PEG 4000 is desirably about 10 times the volume of the transformation mixture. After the PEG is added, the transformation mixture is then cultured either at room temperature or on ice before the addition of a sorbitol and CaCl<sub>2</sub> solution. The protoplast suspension is then further added to molten aliquots of a growth medium. When the growth medium includes a growth selection (*e.g.*, acetamide or an antibiotic) it permits the growth of transformants only.

**[0391]** The transformation of bacterial cells may be performed according to conventional methods, *e.g.*, as described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, 1982, which is hereby incorporated by reference in its entirety, particularly with respect to transformation methods.

#### *Exemplary Cell Culture Media*

**[0392]** Also described herein is a cell or a population of cells in culture that co-produce isoprene and hydrogen. By “cells in culture” is meant two or more cells in a solution (*e.g.*, a cell growth medium) that allows the cells to undergo one or more cell divisions. “Cells in culture” do not include plant cells that are part of a living, multicellular plant containing cells that have differentiated into plant tissues. In various embodiments, the cell culture includes at least or about 10, 20, 50, 100, 200, 500, 1,000, 5,000, 10,000 or more cells.

**[0393]** By “cells in oxygen-limited culture” is meant two or more cells in a solution (*e.g.*, a cell growth medium) that allows the cell to undergo one or more cell divisions, wherein the solution contains a limiting amount of oxygen. The term “oxygen-limited culture” means that the culture is either anoxic or contains less than the required amount of oxygen to support respiration via the biological transfer of reducing equivalents to oxygen, and also encompasses anaerobic cultures. Under oxygen-limited culture conditions, some electrons derived from carbon metabolism cannot be accepted because oxygen concentrations are too low, causing cells to switch to hydrogen production if they comprise the appropriate metabolic pathways for doing

so. Oxygen-limited culture conditions occur when the oxygen transfer rate (“OTR”) is less than the oxygen uptake rate (“OUR”) indicated by dissolved oxygen concentrations of close to zero in culture medium.

**[0394]** Any carbon source can be used to cultivate the host cells. The term “carbon source” refers to one or more carbon-containing compounds capable of being metabolized by a host cell or organism. For example, the cell medium used to cultivate the host cells may include any carbon source suitable for maintaining the viability or growing the host cells.

**[0395]** In some embodiments, the carbon source is a carbohydrate (such as monosaccharide, disaccharide, oligosaccharide, or polysaccharides), invert sugar (*e.g.*, enzymatically treated sucrose syrup), glycerol, glycerine (*e.g.*, a glycerine byproduct of a biodiesel or soap-making process), dihydroxyacetone, one-carbon source, oil (*e.g.*, a plant or vegetable oil such as corn, palm, or soybean oil), animal fat, animal oil, fatty acid (*e.g.*, a saturated fatty acid, unsaturated fatty acid, or polyunsaturated fatty acid), lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, polypeptide (*e.g.*, a microbial or plant protein or peptide), renewable carbon source (*e.g.*, a biomass carbon source such as a hydrolyzed biomass carbon source), yeast extract, component from a yeast extract, polymer, acid, alcohol, aldehyde, ketone, amino acid, succinate, lactate, acetate, ethanol, or any combination of two or more of the foregoing. In some embodiments, the carbon source is a product of photosynthesis, including, but not limited to, glucose.

**[0396]** Exemplary monosaccharides include glucose and fructose; exemplary oligosaccharides include lactose and sucrose, and exemplary polysaccharides include starch and cellulose. Exemplary carbohydrates include C6 sugars (*e.g.*, fructose, mannose, galactose, or glucose) and C5 sugars (*e.g.*, xylose or arabinose). In some embodiments, the cell medium includes a carbohydrate as well as a carbon source other than a carbohydrate (*e.g.*, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, or a component from a yeast extract). In some embodiments, the cell medium includes a carbohydrate as well as a polypeptide (*e.g.*, a microbial or plant protein or peptide). In some embodiments, the microbial polypeptide is a polypeptide from yeast or bacteria. In some embodiments, the plant polypeptide is a polypeptide from soy, corn, canola, jatropha, palm, peanut, sunflower, coconut, mustard, rapeseed, cottonseed, palm kernel, olive, safflower, sesame, or linseed.

**[0397]** In some embodiments, the concentration of the carbohydrate is at least or about 5 grams per liter of broth (g/L, wherein the volume of broth includes both the volume of the cell

medium and the volume of the cells), such as at least or about 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, or more g/L. In some embodiments, the concentration of the carbohydrate is between about 50 and about 400 g/L, such as between about 100 and about 360 g/L, between about 120 and about 360 g/L, or between about 200 and about 300 g/L. In some embodiments, this concentration of carbohydrate includes the total amount of carbohydrate that is added before and/or during the culturing of the host cells.

**[0398]** In some embodiments, the cells are cultured under limited glucose conditions. By “limited glucose conditions” is meant that the amount of glucose that is added is less than or about 105% (such as about 100%) of the amount of glucose that is consumed by the cells. In particular embodiments, the amount of glucose that is added to the culture medium is approximately the same as the amount of glucose that is consumed by the cells during a specific period of time. In some embodiments, the rate of cell growth is controlled by limiting the amount of added glucose such that the cells grow at the rate that can be supported by the amount of glucose in the cell medium. In some embodiments, glucose does not accumulate during the time the cells are cultured. In various embodiments, the cells are cultured under limited glucose conditions for greater than or about 1, 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, or 70 hours. In various embodiments, the cells are cultured under limited glucose conditions for greater than or about 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 95, or 100% of the total length of time the cells are cultured. While not intending to be bound by any particular theory, it is believed that limited glucose conditions may allow more favorable regulation of the cells.

**[0399]** In some embodiments, the cells are cultured in the presence of an excess of glucose. In particular embodiments, the amount of glucose that is added is greater than about 105% (such as about or greater than 110, 120, 150, 175, 200, 250, 300, 400, or 500%) or more of the amount of glucose that is consumed by the cells during a specific period of time. In some embodiments, glucose accumulates during the time the cells are cultured.

**[0400]** Exemplary lipids are any substance containing one or more fatty acids that are C4 and above fatty acids that are saturated, unsaturated, or branched.

**[0401]** Exemplary oils are lipids that are liquid at room temperature. In some embodiments, the lipid contains one or more C4 or above fatty acids (*e.g.*, contains one or more saturated, unsaturated, or branched fatty acid with four or more carbons). In some embodiments, the oil is obtained from soy, corn, canola, jatropha, palm, peanut, sunflower, coconut, mustard, rapeseed, cottonseed, palm kernel, olive, safflower, sesame, linseed, oleagineous microbial cells, Chinese tallow, or any combination of two or more of the foregoing.

**[0402]** Exemplary fatty acids include compounds of the formula RCOOH, where “R” is a hydrocarbon. Exemplary unsaturated fatty acids include compounds where “R” includes at least one carbon-carbon double bond. Exemplary unsaturated fatty acids include, but are not limited to, oleic acid, vaccenic acid, linoleic acid, palmitoleic acid, and arachidonic acid. Exemplary polyunsaturated fatty acids include compounds where “R” includes a plurality of carbon-carbon double bonds. Exemplary saturated fatty acids include compounds where “R” is a saturated aliphatic group. In some embodiments, the carbon source includes one or more C<sub>12</sub>-C<sub>22</sub> fatty acids, such as a C<sub>12</sub> saturated fatty acid, a C<sub>14</sub> saturated fatty acid, a C<sub>16</sub> saturated fatty acid, a C<sub>18</sub> saturated fatty acid, a C<sub>20</sub> saturated fatty acid, or a C<sub>22</sub> saturated fatty acid. In an exemplary embodiment, the fatty acid is palmitic acid. In some embodiments, the carbon source is a salt of a fatty acid (*e.g.*, an unsaturated fatty acid), a derivative of a fatty acid (*e.g.*, an unsaturated fatty acid), or a salt of a derivative of fatty acid (*e.g.*, an unsaturated fatty acid). Suitable salts include, but are not limited to, lithium salts, potassium salts, sodium salts, and the like. Di- and triglycerols are fatty acid esters of glycerol.

**[0403]** In some embodiments, the concentration of the lipid, oil, fat, fatty acid, monoglyceride, diglyceride, or triglyceride is at least or about 1 gram per liter of broth (g/L, wherein the volume of broth includes both the volume of the cell medium and the volume of the cells), such as at least or about 5, 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, or more g/L. In some embodiments, the concentration of the lipid, oil, fat, fatty acid, monoglyceride, diglyceride, or triglyceride is between about 10 and about 400 g/L, such as between about 25 and about 300 g/L, between about 60 and about 180 g/L, or between about 75 and about 150 g/L. In some embodiments, the concentration includes the total amount of the lipid, oil, fat, fatty acid, monoglyceride, diglyceride, or triglyceride that is added before and/or during the culturing of the host cells. In some embodiments, the carbon source includes both (i) a lipid, oil, fat, fatty acid, monoglyceride, diglyceride, or triglyceride and (ii) a carbohydrate, such as glucose. In some embodiments, the ratio of the lipid, oil, fat, fatty acid, monoglyceride, diglyceride, or triglyceride to the carbohydrate is about 1:1 on a carbon basis (*i.e.*, one carbon in the lipid, oil, fat, fatty acid, monoglyceride, diglyceride, or triglyceride per carbohydrate carbon). In particular embodiments, the amount of the lipid, oil, fat, fatty acid, monoglyceride, diglyceride, or triglyceride is between about 60 and 180 g/L, and the amount of the carbohydrate is between about 120 and 360 g/L.

**[0404]** Exemplary microbial polypeptide carbon sources include one or more polypeptides from yeast or bacteria. Exemplary plant polypeptide carbon sources include one or more

polypeptides from soy, corn, canola, jatropha, palm, peanut, sunflower, coconut, mustard, rapeseed, cottonseed, palm kernel, olive, safflower, sesame, or linseed.

**[0405]** Exemplary renewable carbon sources include cheese whey permeate, cornsteep liquor, sugar beet molasses, barley malt, and components from any of the foregoing. Exemplary renewable carbon sources also include glucose, hexose, pentose and xylose present in biomass, such as corn, switchgrass, sugar cane, cell waste of fermentation processes, and protein by-product from the milling of soy, corn, or wheat. In some embodiments, the biomass carbon source is a lignocellulosic, hemicellulosic, or cellulosic material such as, but are not limited to, a grass, wheat, wheat straw, bagasse, sugar cane bagasse, soft wood pulp, corn, corn cob or husk, corn kernel, fiber from corn kernels, corn stover, switch grass, rice hull product, or a by-product from wet or dry milling of grains (*e.g.*, corn, sorghum, rye, triticale, barley, wheat, and/or distillers grains). Exemplary cellulosic materials include wood, paper and pulp waste, herbaceous plants, and fruit pulp. In some embodiments, the carbon source includes any plant part, such as stems, grains, roots, or tubers. In some embodiments, all or part of any of the following plants are used as a carbon source: corn, wheat, rye, sorghum, triticale, rice, millet, barley, cassava, legumes, such as beans and peas, potatoes, sweet potatoes, bananas, sugarcane, and/or tapioca. In some embodiments, the carbon source is a biomass hydrolysate, such as a biomass hydrolysate that includes both xylose and glucose or that includes both sucrose and glucose.

**[0406]** In some embodiments, the renewable carbon source (such as biomass) is pretreated before it is added to the cell culture medium. In some embodiments, the pretreatment includes enzymatic pretreatment, chemical pretreatment, or a combination of both enzymatic and chemical pretreatment (*see*, for example, Farzaneh *et al.*, *Bioresource Technology* 96 (18): 2014-2018, 2005; U.S. Patent No. 6,176,176; U.S. Patent No. 6,106,888; which are each hereby incorporated by reference in their entireties, particularly with respect to the pretreatment of renewable carbon sources). In some embodiments, the renewable carbon source is partially or completely hydrolyzed before it is added to the cell culture medium.

**[0407]** In some embodiments, the renewable carbon source (such as corn stover) undergoes ammonia fiber expansion (AFEX) pretreatment before it is added to the cell culture medium (*see*, for example, Farzaneh *et al.*, *Bioresource Technology* 96 (18): 2014-2018, 2005). During AFEX pretreatment, a renewable carbon source is treated with liquid anhydrous ammonia at moderate temperatures (such as about 60 to about 100 °C) and high pressure (such as about 250 to about 300 psi) for about 5 minutes. Then, the pressure is rapidly released. In this process, the combined

chemical and physical effects of lignin solubilization, hemicellulose hydrolysis, cellulose decrystallization, and increased surface area enables near complete enzymatic conversion of cellulose and hemicellulose to fermentable sugars. AFEX pretreatment has the advantage that nearly all of the ammonia can be recovered and reused, while the remaining serves as nitrogen source for microbes in downstream processes. Also, a wash stream is not required for AFEX pretreatment. Thus, dry matter recovery following the AFEX treatment is essentially 100%. AFEX is basically a dry to dry process. The treated renewable carbon source is stable for long periods and can be fed at very high solid loadings in enzymatic hydrolysis or fermentation processes. Cellulose and hemicellulose are well preserved in the AFEX process, with little or no degradation. There is no need for neutralization prior to the enzymatic hydrolysis of a renewable carbon source that has undergone AFEX pretreatment. Enzymatic hydrolysis of AFEX-treated carbon sources produces clean sugar streams for subsequent fermentation use.

**[0408]** In some embodiments, the concentration of the carbon source (*e.g.*, a renewable carbon source) is equivalent to at least or about 0.1, 0.5, 1, 1.5, 2, 3, 4, 5, 10, 15, 20, 30, 40, or 50% glucose (w/v). The equivalent amount of glucose can be determined by using standard HPLC methods with glucose as a reference to measure the amount of glucose generated from the carbon source. In some embodiments, the concentration of the carbon source (*e.g.*, a renewable carbon source) is equivalent to between about 0.1 and about 20% glucose, such as between about 0.1 and about 10% glucose, between about 0.5 and about 10% glucose, between about 1 and about 10% glucose, between about 1 and about 5% glucose, or between about 1 and about 2% glucose.

**[0409]** In some embodiments, the carbon source includes yeast extract or one or more components of yeast extract. In some embodiments, the concentration of yeast extract is at least 1 gram of yeast extract per liter of broth (g/L, wherein the volume of broth includes both the volume of the cell medium and the volume of the cells), such as at least or about 5, 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, or more g/L. In some embodiments, the concentration of yeast extract is between about 1 and about 300 g/L, such as between about 1 and about 200 g/L, between about 5 and about 200 g/L, between about 5 and about 100 g/L, or between about 5 and about 60 g/L. In some embodiments, the concentration includes the total amount of yeast extract that is added before and/or during the culturing of the host cells. In some embodiments, the carbon source includes both yeast extract (or one or more components thereof) and another carbon source, such as glucose. In some embodiments, the ratio of yeast extract to the other carbon source is about 1:5, about 1:10, or about 1:20 (w/w).

**[0410]** Additionally the carbon source may also be one-carbon substrates such as carbon dioxide, or methanol. Glycerol production from single carbon sources (*e.g.*, methanol, formaldehyde, or formate) has been reported in methylotrophic yeasts (Yamada *et al.*, *Agric. Biol. Chem.*, 53(2) 541-543, 1989, which is hereby incorporated by reference in its entirety, particularly with respect to carbon sources) and in bacteria (Hunter *et al.*, *Biochemistry*, 24, 4148-4155, 1985, which is hereby incorporated by reference in its entirety, particularly with respect to carbon sources). These organisms can assimilate single carbon compounds, ranging in oxidation state from methane to formate, and produce glycerol. The pathway of carbon assimilation can be through ribulose monophosphate, through serine, or through xylulose-5-phosphate (Gottschalk, Bacterial Metabolism, Second Edition, Springer-Verlag: New York, 1986, which is hereby incorporated by reference in its entirety, particularly with respect to carbon sources). The ribulose monophosphate pathway involves the condensation of formate with ribulose-5-phosphate to form a six carbon sugar that becomes fructose and eventually the three carbon product glyceraldehyde-3-phosphate. Likewise, the serine pathway assimilates the one-carbon compound into the glycolytic pathway via methylenetetrahydrofolate.

**[0411]** In addition to one and two carbon substrates, methylotrophic organisms are also known to utilize a number of other carbon containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity. For example, methylotrophic yeast are known to utilize the carbon from methylamine to form trehalose or glycerol (Bellion *et al.*, *Microb. Growth Cl Compd.*, [Int. Symp.], 7<sup>th</sup> ed., 415-32. Editors: Murrell *et al.*, Publisher: Intercept, Andover, UK, 1993, which is hereby incorporated by reference in its entirety, particularly with respect to carbon sources). Similarly, various species of *Candida* metabolize alanine or oleic acid (Sulter *et al.*, *Arch. Microbiol.* 153(5), 485-9, 1990, which is hereby incorporated by reference in its entirety, particularly with respect to carbon sources).

**[0412]** In some embodiments, cells are cultured in a standard medium containing physiological salts and nutrients (*see, e.g.*, Pourquie, J. *et al.*, *Biochemistry and Genetics of Cellulose Degradation*, eds. Aubert *et al.*, Academic Press, pp. 71-86, 1988 and Ilmen *et al.*, *Appl. Environ. Microbiol.* 63:1298-1306, 1997, which are each hereby incorporated by reference in their entireties, particularly with respect to cell medias). Exemplary growth media are common commercially prepared media such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth, or Yeast medium (YM) broth. Other defined or synthetic growth media may also be used, and the appropriate medium for growth of particular host cells are known by someone skilled in the art of microbiology or fermentation science.

**[0413]** In addition to an appropriate carbon source, the cell medium desirably contains suitable minerals, salts, cofactors, buffers, and other components known to those skilled in the art suitable for the growth of the cultures or the enhancement of isoprene production (*see*, for example, WO 2004/033646 and references cited therein and WO 96/35796 and references cited therein, which are each hereby incorporated by reference in their entireties, particularly with respect cell medias and cell culture conditions). In some embodiments where an isoprene synthase, DXS, IDI, and/or MVA pathway nucleic acid is under the control of an inducible promoter, the inducing agent (*e.g.*, a sugar, metal salt or antimicrobial), is desirably added to the medium at a concentration effective to induce expression of an isoprene synthase, DXS, IDI, and/or MVA pathway polypeptide. In some embodiments, cell medium has an antibiotic (such as kanamycin) that corresponds to the antibiotic resistance nucleic acid (such as a kanamycin resistance nucleic acid) on a vector that has one or more DXS, IDI, or MVA pathway nucleic acids.

#### *Exemplary Cell Culture Conditions*

**[0414]** Materials and methods suitable for the maintenance and growth of bacterial cultures are well known in the art. Exemplary techniques may be found in *Manual of Methods for General Bacteriology* Gerhardt *et al.*, eds), American Society for Microbiology, Washington, D.C. (1994) or Brock in *Biotechnology: A Textbook of Industrial Microbiology*, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA, which are each hereby incorporated by reference in their entireties, particularly with respect to cell culture techniques. In some embodiments, the cells are cultured in a culture medium under conditions permitting the expression of one or more isoprene synthase, DXS, IDI, or MVA pathway polypeptides encoded by a nucleic acid inserted into the host cells.

**[0415]** Standard cell culture conditions can be used to culture the cells (*see*, for example, WO 2004/033646 and references cited therein, which are each hereby incorporated by reference in their entireties, particularly with respect to cell culture and fermentation conditions). Cells are grown and maintained at an appropriate temperature, gas mixture, and pH (such as at about 20°C to about 37°C, at about 6% to about 84% CO<sub>2</sub>, and at a pH between about 5 to about 9). In some embodiments, cells are grown at 35°C in an appropriate cell medium. In some embodiments, *e.g.*, cultures are cultured at approximately 28°C in appropriate medium in shake cultures or fermentors until the desired amount of isoprene and hydrogen co-production is achieved. In some embodiments, the pH ranges for fermentation are between about pH 5.0 to about pH 9.0

(such as about pH 6.0 to about pH 8.0 or about 6.5 to about 7.0). Reactions may be performed under aerobic, anoxic, or anaerobic conditions based on the requirements of the host cells. In some embodiments, the cells are cultured under oxygen-limited conditions. In some embodiments, the cells are cultured in the presence of oxygen under conditions where 0.5 moles of oxygen are taken up per mole of isoprene produced. In some embodiments, the cells are cultured under anaerobic conditions. Exemplary culture conditions for a given filamentous fungus are known in the art and may be found in the scientific literature and/or from the source of the fungi such as the American Type Culture Collection and Fungal Genetics Stock Center.

**[0416]** In various embodiments, the cells are grown using any known mode of fermentation, such as batch, fed-batch, or continuous processes. In some embodiments, a batch method of fermentation is used. Classical batch fermentation is a closed system where the composition of the media is set at the beginning of the fermentation and is not subject to artificial alterations during the fermentation. Thus, at the beginning of the fermentation the cell medium is inoculated with the desired host cells and fermentation is permitted to occur adding nothing to the system. Typically, however, “batch” fermentation is batch with respect to the addition of carbon source and attempts are often made at controlling factors such as pH and oxygen concentration. In batch systems, the metabolite and biomass compositions of the system change constantly until the time the fermentation is stopped. Within batch cultures, cells moderate through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or halted. In some embodiments, cells in log phase are responsible for the bulk of the isoprene production. In some embodiments, cells in stationary phase produce isoprene.

**[0417]** In some embodiments, a variation on the standard batch system is used, such as the Fed-Batch system. Fed-Batch fermentation processes comprise a typical batch system with the exception that the carbon source is added in increments as the fermentation progresses. Fed-Batch systems are useful when catabolite repression is apt to inhibit the metabolism of the cells and where it is desirable to have limited amounts of carbon source in the cell medium. Fed-batch fermentations may be performed with the carbon source (*e.g.*, glucose) in a limited or excess amount. Measurement of the actual carbon source concentration in Fed-Batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen, and the partial pressure of waste gases such as CO<sub>2</sub>. Batch and Fed-Batch fermentations are common and well known in the art and examples may be found in Brock, *Biotechnology: A Textbook of Industrial Microbiology*, Second Edition (1989) Sinauer

Associates, Inc., which is hereby incorporated by reference in its entirety, particularly with respect to cell culture and fermentation conditions.

**[0418]** In some embodiments, continuous fermentation methods are used. Continuous fermentation is an open system where a defined fermentation medium is added continuously to a bioreactor and an equal amount of conditioned medium is removed simultaneously for processing. Continuous fermentation generally maintains the cultures at a constant high density where cells are primarily in log phase growth.

**[0419]** Continuous fermentation allows for the modulation of one factor or any number of factors that affect cell growth or isoprene production. For example, one method maintains a limiting nutrient such as the carbon source or nitrogen level at a fixed rate and allows all other parameters to moderate. In other systems, a number of factors affecting growth can be altered continuously while the cell concentration (*e.g.*, the concentration measured by media turbidity) is kept constant. Continuous systems strive to maintain steady state growth conditions. Thus, the cell loss due to media being drawn off is balanced against the cell growth rate in the fermentation. Methods of modulating nutrients and growth factors for continuous fermentation processes as well as techniques for maximizing the rate of product formation are well known in the art of industrial microbiology and a variety of methods are detailed by Brock, *Biotechnology: A Textbook of Industrial Microbiology*, Second Edition (1989) Sinauer Associates, Inc., which is hereby incorporated by reference in its entirety, particularly with respect to cell culture and fermentation conditions.

**[0420]** In some embodiments, cells are immobilized on a substrate as whole cell catalysts and subjected to fermentation conditions for isoprene production.

**[0421]** In some embodiments, bottles of liquid culture are placed in shakers in order to introduce oxygen to the liquid and maintain the uniformity of the culture. In some embodiments, an incubator is used to control the temperature, humidity, shake speed, and/or other conditions in which a culture is grown. The simplest incubators are insulated boxes with an adjustable heater, typically going up to ~65 °C. More elaborate incubators can also include the ability to lower the temperature (via refrigeration), or the ability to control humidity or CO<sub>2</sub> levels. Most incubators include a timer; some can also be programmed to cycle through different temperatures, humidity levels, *etc.* Incubators can vary in size from tabletop to units the size of small rooms.

**[0422]** If desired, a portion or all of the cell medium can be changed to replenish nutrients and/or avoid the build up of potentially harmful metabolic byproducts and dead cells. In the case of suspension cultures, cells can be separated from the media by centrifuging or filtering the

suspension culture and then resuspending the cells in fresh media. In the case of adherent cultures, the media can be removed directly by aspiration and replaced. In some embodiments, the cell medium allows at least a portion of the cells to divide for at least or about 5, 10, 20, 40, 50, 60, 65, or more cell divisions in a continuous culture (such as a continuous culture without dilution).

**[0423]** In some embodiments, a constitutive or leaky promoter (such as a Trc promoter) is used and a compound (such as IPTG) is not added to induce expression of the isoprene synthase, DXS, IDI, or MVA pathway nucleic acid(s) operably linked to the promoter. In some embodiments, a compound (such as IPTG) is added to induce expression of the isoprene synthase, DXS, IDI, or MVA pathway nucleic acid(s) operably linked to the promoter.

*Exemplary Methods for Decoupling Isoprene Production from Cell Growth*

**[0424]** Desirably, carbon from the feedstock is converted to isoprene rather than to the growth and maintenance of the cells. In some embodiments, the cells are grown to a low to medium OD<sub>600</sub>, then production of isoprene is started or increased. This strategy permits a large portion of the carbon to be converted to isoprene.

**[0425]** In some embodiments, cells reach an optical density such that they no longer divide or divide extremely slowly, but continue to make isoprene for several hours (such as about 2, 4, 6, 8, 10, 15, 20, 25, 30, or more hours). For example, Figs. 60A-67C illustrate that cells may continue to produce a substantial amount of mevalonic acid or isoprene after the cells reach an optical density such that they no longer divide or divide extremely slowly. In some cases, the optical density at 550 nm decreases over time (such as a decrease in the optical density after the cells are no longer in an exponential growth phase due to cell lysis), and the cells continue to produce a substantial amount of mevalonic acid or isoprene. In some embodiments, the optical density at 550 nm of the cells increases by less than or about 50% (such as by less than or about 40, 30, 20, 10, 5, or 0%) over a certain time period (such as greater than or about 5, 10, 15, 20, 25, 30, 40, 50 or 60 hours), and the cells produce isoprene at greater than or about 1, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, or more nmole of isoprene/gram of cells for the wet weight of the cells/hour (nmole/g<sub>wcm</sub>/hr) during this time period. In some embodiments, the amount of isoprene is between about 2 to about 5,000 nmole/g<sub>wcm</sub>/hr, such as between about 2 to about 100 nmole/g<sub>wcm</sub>/hr, about 100 to about 500 nmole/g<sub>wcm</sub>/hr, about 150 to about 500 nmole/g<sub>wcm</sub>/hr, about 500 to about 1,000 nmole/g<sub>wcm</sub>/hr, about 1,000 to about 2,000 nmole/g<sub>wcm</sub>/hr, or about

2,000 to about 5,000 nmole/g<sub>wcm</sub>/hr. In some embodiments, the amount of isoprene is between about 20 to about 5,000 nmole/g<sub>wcm</sub>/hr, about 100 to about 5,000 nmole/g<sub>wcm</sub>/hr, about 200 to about 2,000 nmole/g<sub>wcm</sub>/hr, about 200 to about 1,000 nmole/g<sub>wcm</sub>/hr, about 300 to about 1,000 nmole/g<sub>wcm</sub>/hr, or about 400 to about 1,000 nmole/g<sub>wcm</sub>/hr.

**[0426]** In some embodiments, the optical density at 550 nm of the cells increases by less than or about 50% (such as by less than or about 40, 30, 20, 10, 5, or 0%) over a certain time period (such as greater than or about 5, 10, 15, 20, 25, 30, 40, 50 or 60 hours), and the cells produce a cumulative titer (total amount) of isoprene at greater than or about 1, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 10,000, 50,000, 100,000, or more mg of isoprene/L of broth (mg/L<sub>broth</sub>, wherein the volume of broth includes the volume of the cells and the cell medium) during this time period. In some embodiments, the amount of isoprene is between about 2 to about 5,000 mg/L<sub>broth</sub>, such as between about 2 to about 100 mg/L<sub>broth</sub>, about 100 to about 500 mg/L<sub>broth</sub>, about 500 to about 1,000 mg/L<sub>broth</sub>, about 1,000 to about 2,000 mg/L<sub>broth</sub>, or about 2,000 to about 5,000 mg/L<sub>broth</sub>. In some embodiments, the amount of isoprene is between about 20 to about 5,000 mg/L<sub>broth</sub>, about 100 to about 5,000 mg/L<sub>broth</sub>, about 200 to about 2,000 mg/L<sub>broth</sub>, about 200 to about 1,000 mg/L<sub>broth</sub>, about 300 to about 1,000 mg/L<sub>broth</sub>, or about 400 to about 1,000 mg/L<sub>broth</sub>.

**[0427]** In some embodiments, the optical density at 550 nm of the cells increases by less than or about 50% (such as by less than or about 40, 30, 20, 10, 5, or 0%) over a certain time period (such as greater than or about 5, 10, 15, 20, 25, 30, 40, 50 or 60 hours), and the cells convert greater than or about 0.0015, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.12, 0.14, 0.16, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, or 8.0% of the carbon in the cell culture medium into isoprene during this time period. In some embodiments, the percent conversion of carbon into isoprene is between such as about 0.002 to about 4.0%, about 0.002 to about 3.0%, about 0.002 to about 2.0%, about 0.002 to about 1.6%, about 0.002 to about 0.005%, about 0.005 to about 0.01%, about 0.01 to about 0.05%, about 0.05 to about 0.15%, 0.15 to about 0.2%, about 0.2 to about 0.3%, about 0.3 to about 0.5%, about 0.5 to about 0.8%, about 0.8 to about 1.0%, or about 1.0 to about 1.6%. In some embodiments, the percent conversion of carbon into isoprene is between about 0.002 to about 0.4%, 0.002 to about 0.16%, 0.04 to about 0.16%, about 0.005 to about 0.3%, about 0.01 to about 0.3%, or about 0.05 to about 0.3%.

**[0428]** In some embodiments, isoprene is only produced in stationary phase. In some embodiments, isoprene is produced in both the growth phase and stationary phase. In various

embodiments, the amount of isoprene produced (such as the total amount of isoprene produced or the amount of isoprene produced per liter of broth per hour per OD<sub>600</sub>) during stationary phase is greater than or about 2, 3, 4, 5, 10, 20, 30, 40, 50, or more times the amount of isoprene produced during the growth phase for the same length of time. In various embodiments, greater than or about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 99% or more of the total amount of isoprene that is produced (such as the production of isoprene during a fermentation for a certain amount of time, such as 20 hours) is produced while the cells are in stationary phase. In various embodiments, greater than or about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 99% or more of the total amount of isoprene that is produced (such as the production of isoprene during a fermentation for a certain amount of time, such as 20 hours) is produced while the cells divide slowly or not at all such that the optical density at 550 nm of the cells increases by less than or about 50% (such as by less than or about 40, 30, 20, 10, 5, or 0%). In some embodiments, isoprene is only produced in the growth phase.

**[0429]** In some embodiments, one or more MVA pathway, IDI, DXP, or isoprene synthase nucleic acids are placed under the control of a promoter or factor that is more active in stationary phase than in the growth phase. For example, one or more MVA pathway, IDI, DXP, or isoprene synthase nucleic acids may be placed under control of a stationary phase sigma factor, such as RpoS. In some embodiments, one or more MVA pathway, IDI, DXP, or isoprene synthase nucleic acids are placed under control of a promoter inducible in stationary phase, such as a promoter inducible by a response regulator active in stationary phase.

#### *Production of Isoprene within Safe Operating Ranges*

**[0430]** The production of isoprene within safe operating levels according to its flammability characteristics simplifies the design and construction of commercial facilities, vastly improves the ability to operate safely, and limits the potential for fires to occur. In particular, the optimal ranges for the production of isoprene are within the safe zone, i.e., the nonflammable range of isoprene concentrations. In one such aspect, described herein is a method for the production of isoprene within the nonflammable range of isoprene concentrations (outside the flammability envelope of isoprene).

**[0431]** Thus, computer modeling and experimental testing were used to determine the flammability limits of isoprene (such as isoprene in the presence of O<sub>2</sub>, N<sub>2</sub>, CO<sub>2</sub>, or any combination of two or more of the foregoing gases) in order to ensure process safety. The flammability envelope is characterized by the lower flammability limit (LFL), the

upper flammability limit (UFL), the limiting oxygen concentration (LOC), and the limiting temperature. For a system to be flammable, a minimum amount of fuel (such as isoprene) must be in the presence of a minimum amount of oxidant, typically oxygen. The LFL is the minimum amount of isoprene that must be present to sustain burning, while the UFL is the maximum amount of isoprene that can be present. Above this limit, the mixture is fuel rich and the fraction of oxygen is too low to have a flammable mixture. The LOC indicates the minimum fraction of oxygen that must also be present to have a flammable mixture. The limiting temperature is based on the flash point of isoprene and is that lowest temperature at which combustion of isoprene can propagate. These limits are specific to the concentration of isoprene, type and concentration of oxidant, inerts present in the system, temperature, and pressure of the system. Compositions that fall within the limits of the flammability envelope propagate combustion and require additional safety precautions in both the design and operation of process equipment.

**[0432]** The following conditions were tested using computer simulation and mathematical analysis and experimental testing. If desired, other conditions (such as other temperature, pressure, and permanent gas compositions) may be tested using the methods described herein to determine the LFL, UFL, and LOC concentrations.

#### **(1) Computer simulation and mathematical analysis**

##### ***Test Suite 1:***

isoprene: 0 wt% - 14 wt%

O<sub>2</sub>: 6 wt% - 21 wt%

N<sub>2</sub>: 79 wt% - 94 wt%

##### ***Test Suite 2:***

isoprene: 0 wt% - 14 wt%

O<sub>2</sub>: 6 wt% - 21 wt%

N<sub>2</sub>: 79 wt% - 94 wt%

Saturated with H<sub>2</sub>O

##### ***Test Suite 3:***

isoprene: 0 wt% - 14 wt%

O<sub>2</sub>: 6 wt% - 21 wt%

N<sub>2</sub>: 79 wt% - 94 wt%

CO<sub>2</sub>: 5 wt% - 30 wt%

## (2) Experimental testing for final determination of flammability limits

### *Test Suite 1:*

isoprene: 0 wt% - 14 wt%

O<sub>2</sub>: 6 wt% - 21 wt%

N<sub>2</sub>: 79 wt% - 94 wt%

### *Test Suite 2:*

isoprene: 0 wt% - 14 wt%

O<sub>2</sub>: 6 wt% - 21 wt%

N<sub>2</sub>: 79 wt% - 94 wt%

Saturated with H<sub>2</sub>O

**[0433]** Simulation software was used to give an estimate of the flammability characteristics of the system for several different testing conditions. CO<sub>2</sub> showed no significant affect on the system's flammability limits. Test suites 1 and 2 were confirmed by experimental testing. The modeling results were in-line with the experimental test results. Only slight variations were found with the addition of water.

**[0434]** The LOC was determined to be 9.5 vol% for an isoprene, O<sub>2</sub>, N<sub>2</sub>, and CO<sub>2</sub> mixture at 40°C and 1 atmosphere. The addition of up to 30% CO<sub>2</sub> did not significantly affect the flammability characteristics of an isoprene, O<sub>2</sub>, and N<sub>2</sub> mixture. Only slight variations in flammability characteristics were shown between a dry and water saturated isoprene, O<sub>2</sub>, and N<sub>2</sub> system. The limiting temperature is about -54 °C. Temperatures below about -54 °C are too low to propagate combustion of isoprene.

**[0435]** In some embodiments, the LFL of isoprene ranges from about 1.5 vol.% to about 2.0 vol%, and the UFL of isoprene ranges from about 2.0 vol.% to about 12.0 vol.%, depending on the amount of oxygen in the system. In some embodiments, the LOC is about 9.5 vol% oxygen. In some embodiments, the LFL of isoprene is between about 1.5 vol.% to about 2.0 vol%, the UFL of isoprene is between about 2.0 vol.% to about 12.0 vol.%, and the LOC is about 9.5 vol%

oxygen when the temperature is between about 25 °C to about 55 °C (such as about 40 °C) and the pressure is between about 1 atmosphere and 3 atmospheres.

**[0436]** In some embodiments, isoprene is produced in the presence of less than about 9.5 vol% oxygen (that is, below the LOC required to have a flammable mixture of isoprene). In some embodiments in which isoprene is produced in the presence of greater than or about 9.5 vol% oxygen, the isoprene concentration is below the LFL (such as below about 1.5 vol.%). For example, the amount of isoprene can be kept below the LFL by diluting the isoprene composition with an inert gas (c.g., by continuously or periodically adding an inert gas such as nitrogen to keep the isoprene composition below the LFL). In some embodiments in which isoprene is produced in the presence of greater than or about 9.5 vol% oxygen, the isoprene concentration is above the UFL (such as above about 12 vol.%). For example, the amount of isoprene can be kept above the UFL by using a system (such as any of the cell culture systems described herein) that produces isoprene at a concentration above the UFL. If desired, a relatively low level of oxygen can be used so that the UFL is also relatively low. In this case, a lower isoprene concentration is needed to remain above the UFL.

**[0437]** In some embodiments in which isoprene is produced in the presence of greater than or about 9.5 vol% oxygen, the isoprene concentration is within the flammability envelope (such as between the LFL and the UFL). In some embodiments when the isoprene concentration may fall within the flammability envelope, one or more steps are performed to reduce the probability of a fire or explosion. For example, one or more sources of ignition (such as any materials that may generate a spark) can be avoided. In some embodiments, one or more steps are performed to reduce the amount of time that the concentration of isoprene remains within the flammability envelope. In some embodiments, a sensor is used to detect when the concentration of isoprene is close to or within the flammability envelope. If desired, the concentration of isoprene can be measured at one or more time points during the culturing of cells, and the cell culture conditions and/or the amount of inert gas can be adjusted using standard methods if the concentration of isoprene is close to or within the flammability envelope. In particular embodiments, the cell culture conditions (such as fermentation conditions) are adjusted to either decrease the concentration of isoprene below the LFL or increase the concentration of isoprene above the UFL. In some embodiments, the amount of isoprene is kept below the LFL by diluting the isoprene composition with an inert gas (such as by continuously or periodically adding an inert gas to keep the isoprene composition below the LFL).

**[0438]** In some embodiments, the amount of flammable volatiles other than isoprene (such as one or more sugars) is at least about 2, 5, 10, 50, 75, or 100-fold less than the amount of isoprene produced. In some embodiments, the portion of the gas phase other than isoprene gas comprises between about 0% to about 100% (volume) oxygen, such as between about 0% to about 10%, about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 90% to about 90%, or about 90% to about 100% (volume) oxygen. In some embodiments, the portion of the gas phase other than isoprene gas comprises between about 0% to about 99% (volume) nitrogen, such as between about 0% to about 10%, about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 90% to about 90%, or about 90% to about 99% (volume) nitrogen.

**[0439]** In some embodiments, the portion of the gas phase other than isoprene gas comprises between about 1% to about 50% (volume) CO<sub>2</sub>, such as between about 1% to about 10%, about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, or about 40% to about 50% (volume) CO<sub>2</sub>.

**[0440]** In some embodiments, an isoprene composition also contains ethanol. For example, ethanol may be used for extractive distillation of isoprene, resulting in compositions (such as intermediate product streams) that include both ethanol and isoprene. Desirably, the amount of ethanol is outside the flammability envelope for ethanol. The LOC of ethanol is about 8.7 vol%, and the LFL for ethanol is about 3.3 vol% at standard conditions, such as about 1 atmosphere and about 60 F (NFPA 69 Standard on Explosion Prevention Systems, 2008 edition, which is hereby incorporated by reference in its entirety, particularly with respect to LOC, LFL, and UFL values). In some embodiments, compositions that include isoprene and ethanol are produced in the presence of less than the LOC required to have a flammable mixture of ethanol (such as less than about 8.7% vol%). In some embodiments in which compositions that include isoprene and ethanol are produced in the presence of greater than or about the LOC required to have a flammable mixture of ethanol, the ethanol concentration is below the LFL (such as less than about 3.3 vol%).

**[0441]** In various embodiments, the amount of oxidant (such as oxygen) is below the LOC of any fuel in the system (such as isoprene or ethanol). In various embodiments, the amount of oxidant (such as oxygen) is less than about 60, 40, 30, 20, 10, or 5% of the LOC of isoprene or ethanol. In various embodiments, the amount of oxidant (such as oxygen) is less than the LOC

of isoprene or ethanol by at least 2, 4, 5, or more absolute percentage points (vol %). In particular embodiments, the amount of oxygen is at least 2 absolute percentage points (vol %) less than the LOC of isoprene or ethanol (such as an oxygen concentration of less than 7.5 vol% when the LOC of isoprene is 9.5 vol%). In various embodiments, the amount of fuel (such as isoprene or ethanol) is less than or about 25, 20, 15, 10, or 5% of the LFL for that fuel.

*High Efficiency Production and Recovery of Isoprene, a Volatile Hydrocarbon, by Fermentation*

**[0442]** Methods are provided herein of producing isoprene comprising a) culturing cells under suitable conditions for production of isoprene; and b) producing isoprene, wherein the liquid phase concentration of isoprene is less than about 200 mg/L. In some embodiments, the liquid phase concentration of isoprene in the culture is less than about any of 175 mg/L, 150 mg/L, 125 mg/L, 100 mg/L, 75 mg/L, 50 mg/L, 25 mg/L, 20 mg/L, 15 mg/L, 10 mg/L, 5 mg/L, or 2.5 mg/L. In some embodiments, the liquid phase concentration of isoprene in culture is between about any of 0.1 mg/L to 200 mg/L, 1 mg/L to 200 mg/L, 1 mg/L to 150 mg/L, 1 mg/L to 100 mg/L, 1 mg/L to 50 mg/L, 1 mg/L to 25 mg/L, 1 mg/L to 20 mg/L, or 10 mg/L to 20 mg/L. In some embodiments, the isoprene produced is any concentration or amount disclosed in the section entitled "Exemplary Production of Isoprene." In some embodiments, the liquid phase concentration is below the solubility limit of isoprene.

**[0443]** In some embodiments of the methods, the cells produce greater than about 400 nmole/g<sub>wcm</sub>/hour of isoprene. In some embodiments, the amount of isoprene is between about any of 400 nmole/g<sub>wcm</sub>/hour to 1 mole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 1 mmole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 40 mmole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 4 mmole/g<sub>wcm</sub>/hour, 1 mmole/g<sub>wcm</sub>/hour to 1.5 mmole/g<sub>wcm</sub>/hour, 1.5 mmole/g<sub>wcm</sub>/hour to 3 mmole/g<sub>wcm</sub>/hour, 3 mmole/g<sub>wcm</sub>/hour to 5 mmole/g<sub>wcm</sub>/hour, 5 mmole/g<sub>wcm</sub>/hour to 25 mmole/g<sub>wcm</sub>/hour, 25 mmole/g<sub>wcm</sub>/hour to 100 mmole/g<sub>wcm</sub>/hour, 100 mmole/g<sub>wcm</sub>/hour to 500 mmole/g<sub>wcm</sub>/hour, or 500 mmole/g<sub>wcm</sub>/hour to 1000 mmole/g<sub>wcm</sub>/hour. In some embodiments, the amount of isoprene is about any of 1 mmole/g<sub>wcm</sub>/hour, 1.5 mmole/g<sub>wcm</sub>/hour, 2 mmole/g<sub>wcm</sub>/hour, 3 mmole/g<sub>wcm</sub>/hour, 4 mmole/g<sub>wcm</sub>/hour, or 5 mmole/g<sub>wcm</sub>/hour.

**[0444]** The low value for Henry's coefficient (in M atm<sup>-1</sup> units) means that isoprene can be recovered from fermentation broth by gas stripping at low sparging rates, for example 0.01 vvm to 2 vvm. In some embodiments, the gas sparging rate is between about any of 0.1 vvm to 1 vvm, 0.01 vvm to 0.5 vvm, 0.2 vvm to 1 vvm, or 0.5 vvm to 1 vvm. In some embodiments, the gas sparging rate is about any of 0.1 vvm, 0.25 vvm, 0.5 vvm, 0.75 vvm, 1 vvm, 1.25 vvm, 1.5

vvm, 1.75 vvm, or 2 vvm. In some embodiments, the low sparging rates are maintained for the entire course of the fermentation run, during growth phase, or during stationary phase. In some embodiments, the low sparging rates are maintained for between about any of 1 hour to 5 hours, 5 hours to 10 hours, 10 hours to 20 hours, 20 hours to 30 hours, 30 hours to 40 hours, 40 hours to 50 hours, or 50 hours to 60 hours. The lower desirable gas sparge limit is defined by the point at which the aqueous phase becomes saturated with isoprene and a liquid organic phase forms. This can only occur below the boiling point of isoprene (34.1 °C at 1 atm), above which a liquid isoprene phase will never form. At temperatures below the boiling point of isoprene, the formation of a liquid phase is determined by the aqueous solubility of isoprene, which is approximately 650 mg/L at 25 °C. While it is highly desirable to avoid the formation of a liquid isoprene phase, it is not absolutely required provided that the cells can tolerate the presence of liquid isoprene without toxic effects.

**[0445]** In some embodiments, the oxygen, CO<sub>2</sub>, and isoprene are any of the amounts or concentrations discussed in the section entitled “Production of Isoprene with Safe Operating Ranges.” In some embodiments, all the oxygen is consumed by the cells while maintaining fully aerobic metabolism. In some embodiments, an excess of oxygen is used in order to satisfy the oxygen demands of the cells. Desirable ranges of oxygen in the off-gas are less than 20%, or less than 15% or less than 10% (v/v). Levels of oxygen below the limiting oxygen concentration required for combustion of isoprene (9.5% v/v at 1 atm) are particularly desirable. In some embodiments, oxygen-enriched air is utilized with the purpose of allowing minimal gas sweep rates while satisfying the cellular oxygen demand. In some embodiments, the portion of the gas phase of the gas sweep comprises between about 0.1% to about 10%, about 10% to about 20%, or about 20% to about 30% (volume) oxygen. In some embodiments, isoprene fermentations are performed under high pressure in order minimize the amount of excess oxygen required to maintain the required dissolved oxygen levels in the liquid phase.

**[0446]** In some embodiments, the reduction of the gas sweep rate through the fermentor is advantageous for an integrated isoprene production process in that such conditions enrich the off-gas isoprene levels up to about 30,000 µg/L (about 1% v/v) without adversely affecting the physiology of the cells.

**[0447]** In some embodiments, reduced gas-sparge rates do not significantly adversely affect the physiology of the cells. In some embodiments, the carbon dioxide evolution rate of cells in culture with reduced gas-sparge rates is between about any of 1 x 10<sup>-18</sup> mmol/L/hour to about 1 mol/L/hour, 1 mmol/L/hour to 1 mol/L/hour, 25 mmol/L/hour to 750 mmol/L/hour, 25

mmol/L/hour to 75 mmol/L/hour, 250 mmol/L/hour to 750 mmol/L/hour, or 450 mmol/L/hour to 550 mmol/L/hour. In some embodiments, the carbon dioxide evolution rate is about any of 50 mmol/L/hour, 100 mmol/L/hour, 150 mmol/L/hour, 200 mmol/L/hour, 250 mmol/L/hour, 300 mmol/L/hour, 350 mmol/L/hour, 400 mmol/L/hour, 450 mmol/L/hour, or 500 mmol/L/hour. In some embodiments, cell viability with reduced gas-sparg rates is reduced by less than about any of 1.75-fold, 1.5-fold, 1.25-fold, 1-fold, 0.75-fold, 0.5-fold, or 0.25-fold. In some embodiments, cell viability with reduced gas-sparg rates is reduced by about 2-fold. In some embodiments, cell viability with reduced gas-sparg rates of a cell expressing a MVA pathway and/or DXP pathway RNA and/or protein from one or more of a heterologous and/or duplicate copy of a MVA pathway and/or DXP pathway nucleic acid is compared to a control cell lacking one or more of a heterologous and/or duplicate copy of a MVA pathway and/or DXP pathway nucleic acid with reduced gas-sparg rates. In some embodiments, cell viability with reduced gas-sparg rates of a cell expressing a MVA pathway and/or DXP pathway RNA and/or protein from one or more of a heterologous and/or duplicate copy of a MVA pathway and/or DXP pathway nucleic acid under the control of an inducible promoter, wherein the promoter is induced, is compared to a control cell containing one or more of a heterologous and/or duplicate copy of a MVA pathway and/or DXP pathway nucleic acid under the control of an inducible promoter, wherein the promoter is not induced (uninduced) with reduced gas-sparg rates. In some embodiments, the inducible promoter is a beta-galactosidase promoter.

**[0448]** In some embodiments, the fermentation of a genetically modified host organism that converts at least 5% of the total carbon consumed by the organism into a volatile, unsaturated hydrocarbon. In some embodiments, the production of an unsaturated hydrocarbon at such a rate as to be present in the fermentation off-gas at a level of at least about any of 100 µg/L, 500 µg/L, 1000 µg/L, 2,500 µg/L, 5,000 µg/L, 7,500 µg/L, or 10,000 µg/L.

**[0449]** In some embodiments, the unsaturated hydrocarbon is recovered from the off-gas stream in a manner that is suited to high-rates of production, which correspond to concentrations in the off-gas of at least about any of 100 µg/L, 500 µg/L, 1000 µg/L, 2,500 µg/L, 5,000 µg/L, 7,500 µg/L, or 10,000 µg/L. In some embodiments, the continuous extraction and recovery of an unsaturated hydrocarbon from the fermentation off-gas in particular at low gas sweep rates such that the resulting off-gas is enriched in the volatile component of interest. In some embodiments, recovery of the volatile hydrocarbon by methods that depend on elevated concentrations of the volatile. For example, efficient capture of isoprene in fermentation off-gas through the use of compression/condensation or extractive distillation technologies. Also contemplated is the use of

activated carbon cartridges in addition to silica gel adsorbants, desorption and concentration of isoprene from carbon cartridges, and/or construction and fermentation of host organisms such as *E. coli* strains that can convert about 5% or more of the glucose substrate to isoprene and result in off-gas concentrations of greater than about 15,000  $\mu\text{g/L}$  isoprene. Recovery methods include any of the methods described herein.

**[0450]** Also provided herein are methods of producing a compound, wherein the compound has one or more characteristics selected from the group consisting of (a) a Henry's law coefficient of less than about 250 M/atm and (b) a solubility in water of less than about 100 g/L. In some embodiments, the method comprises: a) culturing cells under suitable conditions for production of the compound, wherein gas is added (such as the addition of gas to a system such as a fermentation system) at a gas sparging rate between about 0.01 vvm to about 2 vvm; and b) producing the compound.

**[0451]** In some embodiments, the amount of the compound that partitions into the cell mass is not included in the liquid phase solubility values. In some embodiments, the liquid phase concentration is below the solubility limit of compound.

**[0452]** In some embodiments, the compounds can be continuously recovered from fermentation broth by gas stripping at moderate to low gas sparging rates, in particular those compounds with Henry's law coefficients of about any of less than 250 M/atm, 200 M/atm, 150 M/atm, 100 M/atm, 75 M/atm, 50 M/atm, 25 M/atm, 10 M/atm, 5 M/atm, or 1 M/atm. Examples include aldehydes such as acetaldehyde (15 M/atm), ketones such as acetone (30 M/atm) or 2-butanone (20 M/atm), or alcohols including methanol (220 M/atm), ethanol (200 M/atm), 1-butanol (120 M/atm) or C5 alcohols including 3-methyl-3-buten-1-ol, and 3-methyl-2-buten-1-ol (50- 100 M/atm). Esters of alcohols generally have lower Henry's constants than the respective alcohols, for example ethyl acetate (6-9 M/atm) or the acetyl esters of C5 alcohols (<5 M/atm). Compounds with Henry's law coefficients of less than 1 M/atm are particularly desirable. Examples include hemiterpenes, monoterpenes, or sesquiterpenes, in addition to other hydrocarbons such as C1 to C5 hydrocarbons (*e.g.*, methane, ethane, ethylene, or propylene). In some embodiments, the hydrocarbons such as C1 to C5 hydrocarbons are saturated, unsaturated, or branched.

**[0453]** In general, there is a correlation between Henry's law coefficient and water solubility in that compounds with very low coefficients are sparingly soluble in water (substantially water insoluble). Although volatiles with infinite solubilities in water (*e.g.* acetone or ethanol) can be

removed by gas stripping, desirable solubility limits are less than about any of 100 g/L, 75 g/L, 50 g/L, 25 g/L, 10 g/L, 5 g/L, or 1g/L.

**[0454]** In some embodiments of any of the methods of producing any of the compounds described above, the gas sparging rate is between about any of 0.1 vvm to 1 vvm, 0.2 vvm to 1 vvm, or 0.5 vvm to 1 vvm. In some embodiments, the gas sparging rate is about any of 0.1 vvm, 0.25 vvm, 0.5 vvm, 0.75 vvm, 1 vvm, 1.25 vvm, 1.5 vvm, 1.75 vvm, or 2 vvm. In some embodiments, the low sparging rates are maintained for the entire course of the fermentation run, during growth phase, or during stationary phase. In some embodiments, the low sparging rates are maintained for between about any of 1 hour to 5 hours, 5 hours to 10 hours, 10 hours to 20 hours, 20 hours to 30 hours, 30 hours to 40 hours, 40 hours to 50 hours, or 50 hours to 60 hours.

**[0455]** Any of the systems described herein can be used in the methods of producing a compound described above. Standard methods would be used to purify such as those described in the section entitled "Exemplary Purification Methods." Separation can be performed post-recovery for example, by distillation or selective adsorption techniques.

#### *Exemplary Production of Biolsoprene*

**[0456]** In some embodiments, the cells are cultured in a culture medium under conditions permitting the production of isoprene by the cells.

**[0457]** By "peak absolute productivity" is meant the maximum absolute amount of isoprene in the off-gas during the culturing of cells for a particular period of time (*e.g.*, the culturing of cells during a particular fermentation run). By "peak absolute productivity time point" is meant the time point during a fermentation run when the absolute amount of isoprene in the off-gas is at a maximum during the culturing of cells for a particular period of time (*e.g.*, the culturing of cells during a particular fermentation run). In some embodiments, the isoprene amount is measured at the peak absolute productivity time point. In some embodiments, the peak absolute productivity for the cells is about any of the isoprene amounts disclosed herein.

**[0458]** By "peak specific productivity" is meant the maximum amount of isoprene produced per cell during the culturing of cells for a particular period of time (*e.g.*, the culturing of cells during a particular fermentation run). By "peak specific productivity time point" is meant the time point during the culturing of cells for a particular period of time (*e.g.*, the culturing of cells during a particular fermentation run) when the amount of isoprene produced per cell is at a maximum. The peak specific productivity is determined by dividing the total productivity by the amount of cells, as determined by optical density at 600nm (OD<sub>600</sub>). In some embodiments, the

isoprene amount is measured at the peak specific productivity time point. In some embodiments, the peak specific productivity for the cells is about any of the isoprene amounts per cell disclosed herein.

**[0459]** By “peak volumetric productivity” is meant the maximum amount of isoprene produced per volume of broth (including the volume of the cells and the cell medium) during the culturing of cells for a particular period of time (*e.g.*, the culturing of cells during a particular fermentation run). By “peak specific volumetric productivity time point” is meant the time point during the culturing of cells for a particular period of time (*e.g.*, the culturing of cells during a particular fermentation run) when the amount of isoprene produced per volume of broth is at a maximum. The peak specific volumetric productivity is determined by dividing the total productivity by the volume of broth and amount of time. In some embodiments, the isoprene amount is measured at the peak specific volumetric productivity time point. In some embodiments, the peak specific volumetric productivity for the cells is about any of the isoprene amounts per volume per time disclosed herein.

**[0460]** By “peak concentration” is meant the maximum amount of isoprene produced during the culturing of cells for a particular period of time (*e.g.*, the culturing of cells during a particular fermentation run). By “peak concentration time point” is meant the time point during the culturing of cells for a particular period of time (*e.g.*, the culturing of cells during a particular fermentation run) when the amount of isoprene produced per cell is at a maximum. In some embodiments, the isoprene amount is measured at the peak concentration time point. In some embodiments, the peak concentration for the cells is about any of the isoprene amounts disclosed herein.

**[0461]** By “average volumetric productivity” is meant the average amount of isoprene produced per volume of broth (including the volume of the cells and the cell medium) during the culturing of cells for a particular period of time (*e.g.*, the culturing of cells during a particular fermentation run). The average volumetric productivity is determined by dividing the total productivity by the volume of broth and amount of time. In some embodiments, the average specific volumetric productivity for the cells is about any of the isoprene amounts per volume per time disclosed herein.

**[0462]** By “cumulative total productivity” is meant the cumulative, total amount of isoprene produced during the culturing of cells for a particular period of time (*e.g.*, the culturing of cells during a particular fermentation run). In some embodiments, the cumulative, total amount of

isoprene is measured. In some embodiments, the cumulative total productivity for the cells is about any of the isoprene amounts disclosed herein.

**[0463]** As used herein, “relative detector response” refers to the ratio between the detector response (such as the GC/MS area) for one compound (such as isoprene) to the detector response (such as the GC/MS area) of one or more compounds (such as all C5 hydrocarbons). The detector response may be measured as described herein, such as the GC/MS analysis performed with an Agilent 6890 GC/MS system fitted with an Agilent HP-5MS GC/MS column (30 m x 250  $\mu$ m; 0.25  $\mu$ m film thickness). If desired, the relative detector response can be converted to a weight percentage using the response factors for each of the compounds. This response factor is a measure of how much signal is generated for a given amount of a particular compound (that is, how sensitive the detector is to a particular compound). This response factor can be used as a correction factor to convert the relative detector response to a weight percentage when the detector has different sensitivities to the compounds being compared. Alternatively, the weight percentage can be approximated by assuming that the response factors are the same for the compounds being compared. Thus, the weight percentage can be assumed to be approximately the same as the relative detector response.

**[0464]** In some embodiments, the cells in culture produce isoprene at greater than or about 1, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 10,000, 12,500, 20,000, 30,000, 40,000, 50,000, 75,000, 100,000, 125,000, 150,000, 188,000, or more nmole of isoprene/gram of cells for the wet weight of the cells/hour (nmole/g<sub>wcm</sub>/hr). In some embodiments, the amount of isoprene is between about 2 to about 200,000 nmole/g<sub>wcm</sub>/hr, such as between about 2 to about 100 nmole/g<sub>wcm</sub>/hr, about 100 to about 500 nmole/g<sub>wcm</sub>/hr, about 150 to about 500 nmole/g<sub>wcm</sub>/hr, about 500 to about 1,000 nmole/g<sub>wcm</sub>/hr, about 1,000 to about 2,000 nmole/g<sub>wcm</sub>/hr, or about 2,000 to about 5,000 nmole/g<sub>wcm</sub>/hr, about 5,000 to about 10,000 nmole/g<sub>wcm</sub>/hr, about 10,000 to about 50,000 nmole/g<sub>wcm</sub>/hr, about 50,000 to about 100,000 nmole/g<sub>wcm</sub>/hr, about 100,000 to about 150,000 nmole/g<sub>wcm</sub>/hr, or about 150,000 to about 200,000 nmole/g<sub>wcm</sub>/hr. In some embodiments, the amount of isoprene is between about 20 to about 5,000 nmole/g<sub>wcm</sub>/hr, about 100 to about 5,000 nmole/g<sub>wcm</sub>/hr, about 200 to about 2,000 nmole/g<sub>wcm</sub>/hr, about 200 to about 1,000 nmole/g<sub>wcm</sub>/hr, about 300 to about 1,000 nmole/g<sub>wcm</sub>/hr, or about 400 to about 1,000 nmole/g<sub>wcm</sub>/hr, about 1,000 to about 5,000 nmole/g<sub>wcm</sub>/hr, about 2,000 to about 20,000 nmole/g<sub>wcm</sub>/hr, about 5,000 to about 50,000 nmole/g<sub>wcm</sub>/hr, about 10,000 to about 100,000 nmole/g<sub>wcm</sub>/hr, about 20,000 to about 150,000 nmole/g<sub>wcm</sub>/hr, or about 20,000 to about 200,000 nmole/g<sub>wcm</sub>/hr.

**[0465]** The amount of isoprene in units of nmole/g<sub>wcm</sub>/hr can be measured as disclosed in U.S. Patent No. 5,849,970, which is hereby incorporated by reference in its entirety, particularly with respect to the measurement of isoprene production. For example, two mL of headspace (*e.g.*, headspace from a culture such as 2 mL of culture cultured in sealed vials at 32 °C with shaking at 200 rpm for approximately 3 hours) are analyzed for isoprene using a standard gas chromatography system, such as a system operated isothermally (85 °C) with an n-octane/porasil C column (Alltech Associates, Inc., Deerfield, Ill.) and coupled to a RGD2 mercuric oxide reduction gas detector (Trace Analytical, Menlo Park, CA) (*see*, for example, Greenberg et al, *Atmos. Environ.* 27A: 2689-2692, 1993; Silver *et al.*, *Plant Physiol.* 97:1588-1591, 1991, which are each hereby incorporated by reference in their entireties, particularly with respect to the measurement of isoprene production). The gas chromatography area units are converted to nmol isoprene via a standard isoprene concentration calibration curve. In some embodiments, the value for the grams of cells for the wet weight of the cells is calculated by obtaining the A<sub>600</sub> value for a sample of the cell culture, and then converting the A<sub>600</sub> value to grams of cells based on a calibration curve of wet weights for cell cultures with a known A<sub>600</sub> value. In some embodiments, the grams of the cells is estimated by assuming that one liter of broth (including cell medium and cells) with an A<sub>600</sub> value of 1 has a wet cell weight of 1 gram. The value is also divided by the number of hours the culture has been incubating for, such as three hours.

**[0466]** In some embodiments, the cells in culture produce isoprene at greater than or about 1, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 10,000, 100,000, or more ng of isoprene/gram of cells for the wet weight of the cells/hr (ng/g<sub>wcm</sub>/h). In some embodiments, the amount of isoprene is between about 2 to about 5,000 ng/g<sub>wcm</sub>/h, such as between about 2 to about 100 ng/g<sub>wcm</sub>/h, about 100 to about 500 ng/g<sub>wcm</sub>/h, about 500 to about 1,000 ng/g<sub>wcm</sub>/h, about 1,000 to about 2,000 ng/g<sub>wcm</sub>/h, or about 2,000 to about 5,000 ng/g<sub>wcm</sub>/h. In some embodiments, the amount of isoprene is between about 20 to about 5,000 ng/g<sub>wcm</sub>/h, about 100 to about 5,000 ng/g<sub>wcm</sub>/h, about 200 to about 2,000 ng/g<sub>wcm</sub>/h, about 200 to about 1,000 ng/g<sub>wcm</sub>/h, about 300 to about 1,000 ng/g<sub>wcm</sub>/h, or about 400 to about 1,000 ng/g<sub>wcm</sub>/h. The amount of isoprene in ng/g<sub>wcm</sub>/h can be calculated by multiplying the value for isoprene production in the units of nmole/g<sub>wcm</sub>/hr discussed above by 68.1 (as described in Equation 5 below).

**[0467]** In some embodiments, the cells in culture produce a cumulative titer (total amount) of isoprene at greater than or about 1, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 10,000, 50,000, 100,000, or

more mg of isoprene/L of broth ( $\text{mg/L}_{\text{broth}}$ , wherein the volume of broth includes the volume of the cells and the cell medium). In some embodiments, the amount of isoprene is between about 2 to about 5,000  $\text{mg/L}_{\text{broth}}$ , such as between about 2 to about 100  $\text{mg/L}_{\text{broth}}$ , about 100 to about 500  $\text{mg/L}_{\text{broth}}$ , about 500 to about 1,000  $\text{mg/L}_{\text{broth}}$ , about 1,000 to about 2,000  $\text{mg/L}_{\text{broth}}$ , or about 2,000 to about 5,000  $\text{mg/L}_{\text{broth}}$ . In some embodiments, the amount of isoprene is between about 20 to about 5,000  $\text{mg/L}_{\text{broth}}$ , about 100 to about 5,000  $\text{mg/L}_{\text{broth}}$ , about 200 to about 2,000  $\text{mg/L}_{\text{broth}}$ , about 200 to about 1,000  $\text{mg/L}_{\text{broth}}$ , about 300 to about 1,000  $\text{mg/L}_{\text{broth}}$ , or about 400 to about 1,000  $\text{mg/L}_{\text{broth}}$ .

**[0468]** The specific productivity of isoprene in mg of isoprene/L of headspace from shake flask or similar cultures can be measured by taking a 1 ml sample from the cell culture at an  $\text{OD}_{600}$  value of approximately 1.0, putting it in a 20 mL vial, incubating for 30 minutes, and then measuring the amount of isoprene in the headspace (as described, for example, in Example I, part II). If the  $\text{OD}_{600}$  value is not 1.0, then the measurement can be normalized to an  $\text{OD}_{600}$  value of 1.0 by dividing by the  $\text{OD}_{600}$  value. The value of mg isoprene/L headspace can be converted to  $\text{mg/L}_{\text{broth}}/\text{hr}/\text{OD}_{600}$  of culture broth by multiplying by a factor of 38. The value in units of  $\text{mg/L}_{\text{broth}}/\text{hr}/\text{OD}_{600}$  can be multiplied by the number of hours and the  $\text{OD}_{600}$  value to obtain the cumulative titer in units of mg of isoprene/L of broth.

**[0469]** In some embodiments, the cells in culture have an average volumetric productivity of isoprene at greater than or about 0.1, 1.0, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, or more mg of isoprene/L of broth/hr ( $\text{mg/L}_{\text{broth}}/\text{hr}$ , wherein the volume of broth includes the volume of the cells and the cell medium). In some embodiments, the average volumetric productivity of isoprene is between about 0.1 to about 3,500  $\text{mg/L}_{\text{broth}}/\text{hr}$ , such as between about 0.1 to about 100  $\text{mg/L}_{\text{broth}}/\text{hr}$ , about 100 to about 500  $\text{mg/L}_{\text{broth}}/\text{hr}$ , about 500 to about 1,000  $\text{mg/L}_{\text{broth}}/\text{hr}$ , about 1,000 to about 1,500  $\text{mg/L}_{\text{broth}}/\text{hr}$ , about 1,500 to about 2,000  $\text{mg/L}_{\text{broth}}/\text{hr}$ , about 2,000 to about 2,500  $\text{mg/L}_{\text{broth}}/\text{hr}$ , about 2,500 to about 3,000  $\text{mg/L}_{\text{broth}}/\text{hr}$ , or about 3,000 to about 3,500  $\text{mg/L}_{\text{broth}}/\text{hr}$ . In some embodiments, the average volumetric productivity of isoprene is between about 10 to about 3,500  $\text{mg/L}_{\text{broth}}/\text{hr}$ , about 100 to about 3,500  $\text{mg/L}_{\text{broth}}/\text{hr}$ , about 200 to about 1,000  $\text{mg/L}_{\text{broth}}/\text{hr}$ , about 200 to about 1,500  $\text{mg/L}_{\text{broth}}/\text{hr}$ , about 1,000 to about 3,000  $\text{mg/L}_{\text{broth}}/\text{hr}$ , or about 1,500 to about 3,000  $\text{mg/L}_{\text{broth}}/\text{hr}$ .

**[0470]** In some embodiments, the cells in culture have a peak volumetric productivity of isoprene at greater than or about 0.5, 1.0, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600,

700, 800, 900, 1,000, 1100, 1200, 1300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,750, 4,000, 4,250, 4,500, 4,750, 5,000, 5,250, 5,500, 5,750, 6,000, 6,250, 6,500, 6,750, 7,000, 7,250, 7,500, 7,750, 8,000, 8,250, 8,500, 8,750, 9,000, 9,250, 9,500, 9,750, 10,000, 12,500, 15,000, or more mg of isoprene/L of broth/hr (mg/L<sub>broth</sub>/hr, wherein the volume of broth includes the volume of the cells and the cell medium). In some embodiments, the peak volumetric productivity of isoprene is between about 0.5 to about 15,000 mg/L<sub>broth</sub>/hr, such as between about 0.5 to about 10 mg/L<sub>broth</sub>/hr, about 1.0 to about 100 mg/L<sub>broth</sub>/hr, about 100 to about 500 mg/L<sub>broth</sub>/hr, about 500 to about 1,000 mg/L<sub>broth</sub>/hr, about 1,000 to about 1,500 mg/L<sub>broth</sub>/hr, about 1,500 to about 2,000 mg/L<sub>broth</sub>/hr, about 2,000 to about 2,500 mg/L<sub>broth</sub>/hr, about 2,500 to about 3,000 mg/L<sub>broth</sub>/hr, about 3,000 to about 3,500 mg/L<sub>broth</sub>/hr, about 3,500 to about 5,000 mg/L<sub>broth</sub>/hr, about 5,000 to about 7,500 mg/L<sub>broth</sub>/hr, about 7,500 to about 10,000 mg/L<sub>broth</sub>/hr, about 10,000 to about 12,500 mg/L<sub>broth</sub>/h, or about 12,500 to about 15,000 mg/L<sub>broth</sub>/hr. In some embodiments, the peak volumetric productivity of isoprene is between about 10 to about 15,000 mg/L<sub>broth</sub>/hr, about 100 to about 2,500 mg/L<sub>broth</sub>/hr, about 1,000 to about 5,000 mg/L<sub>broth</sub>/hr, about 2,500 to about 7,500 mg/L<sub>broth</sub>/hr, about 5,000 to about 10,000 mg/L<sub>broth</sub>/hr, about 7,500 to about 12,500 mg/L<sub>broth</sub>/hr, or about 10,000 to about 15,000 mg/L<sub>broth</sub>/hr.

**[0471]** The instantaneous isoprene production rate in mg/L<sub>broth</sub>/hr in a fermentor can be measured by taking a sample of the fermentor off-gas, analyzing it for the amount of isoprene (in units such as mg of isoprene per L<sub>gas</sub>) as described, for example, in Example I, part II and multiplying this value by the rate at which off-gas is passed through each liter of broth (*e.g.*, at 1 vvm (volume of air/volume of broth/minute) this is 60 L<sub>gas</sub> per hour). Thus, an off-gas level of 1 mg/L<sub>gas</sub> corresponds to an instantaneous production rate of 60 mg/L<sub>broth</sub>/hr at air flow of 1 vvm. If desired, the value in the units mg/L<sub>broth</sub>/hr can be divided by the OD<sub>600</sub> value to obtain the specific rate in units of mg/L<sub>broth</sub>/hr/OD. The average value of mg isoprene/L<sub>gas</sub> can be converted to the total product productivity (grams of isoprene per liter of fermentation broth, mg/L<sub>broth</sub>) by multiplying this average off-gas isoprene concentration by the total amount of off-gas sparged per liter of fermentation broth during the fermentation. Thus, an average off-gas isoprene concentration of 0.5 mg/L<sub>broth</sub>/hr over 10 hours at 1 vvm corresponds to a total product concentration of 300 mg isoprene/L<sub>broth</sub>.

**[0472]** In some embodiments, the cells in culture convert greater than or about 0.0015, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.12, 0.14, 0.16, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0,

18.0, 19.0, 20.0, 21.0, 22.0, 23.0, 23.2, 23.4, 23.6, 23.8, 24.0, 25.0, 30.0, 31.0, 32.0, 33.0, 35.0, 37.5, 40.0, 45.0, 47.5, 50.0, 55.0, 60.0, 65.0, 70.0, 75.0, 80.0, 85.0, or 90.0 molar % of the carbon in the cell culture medium into isoprene. In some embodiments, the percent conversion of carbon into isoprene is between about 0.002 to about 90.0 molar %, such as about 0.002 to about 0.005%, about 0.005 to about 0.01%, about 0.01 to about 0.05%, about 0.05 to about 0.15%, 0.15 to about 0.2%, about 0.2 to about 0.3%, about 0.3 to about 0.5%, about 0.5 to about 0.8%, about 0.8 to about 1.0%, about 1.0 to about 1.6%, about 1.6 to about 3.0%, about 3.0 to about 5.0%, about 5.0 to about 8.0%, about 8.0 to about 10.0%, about 10.0 to about 15.0%, about 15.0 to about 20.0%, about 20.0 to about 25.0%, about 25.0% to 30.0%, about 30.0% to 35.0%, about 35.0% to 40.0%, about 45.0% to 50.0%, about 50.0% to 55.0%, about 55.0% to 60.0%, about 60.0% to 65.0%, about 65.0% to 70.0%, about 75.0% to 80.0%, about 80.0% to 85.0%, or about 85.0% to 90.0%. In some embodiments, the percent conversion of carbon into isoprene is between about 0.002 to about 0.4 molar %, 0.002 to about 0.16 molar %, 0.04 to about 0.16 molar %, about 0.005 to about 0.3 molar %, about 0.01 to about 0.3 molar %, about 0.05 to about 0.3 molar %, about 0.1 to 0.3 molar %, about 0.3 to about 1.0 molar %, about 1.0 to about 5.0 molar %, about 2 to about 5.0 molar %, about 5.0 to about 10.0 molar %, about 7 to about 10.0 molar %, about 10.0 to about 20.0 molar %, about 12 to about 20.0 molar %, about 16 to about 20.0 molar %, about 18 to about 20.0 molar %, about 18 to 23.2 molar %, about 18 to 23.6 molar %, about 18 to about 23.8 molar %, about 18 to about 24.0 molar %, about 18 to about 25.0 molar %, about 20 to about 30.0 molar %, about 30 to about 40.0 molar %, about 30 to about 50.0 molar %, about 30 to about 60.0 molar %, about 30 to about 70.0 molar %, about 30 to about 80.0 molar %, or about 30 to about 90.0 molar %.

**[0473]** The percent conversion of carbon into isoprene (also referred to as “% carbon yield”) can be measured by dividing the moles carbon in the isoprene produced by the moles carbon in the carbon source (such as the moles of carbon in batched and fed glucose and yeast extract). This number is multiplied by 100% to give a percentage value (as indicated in Equation 1).

#### **Equation 1**

% Carbon Yield = (moles carbon in isoprene produced)/(moles carbon in carbon source) \* 100

**[0474]** For this calculation, yeast extract can be assumed to contain 50% w/w carbon. As an example, for the 500 liter described in Example 7, part VIII, the percent conversion of carbon into isoprene can be calculated as shown in Equation 2.

**Equation 2**

$$\% \text{ Carbon Yield} = (39.1 \text{ g isoprene} * 1/68.1 \text{ mol/g} * 5 \text{ C/mol}) / [(181221 \text{ g glucose} * 1/180 \text{ mol/g} * 6 \text{ C/mol}) + (17780 \text{ g yeast extract} * 0.5 * 1/12 \text{ mol/g})] * 100 = 0.042\%$$

**[0475]** For the two 500 liter fermentations described herein (Example 7, parts VII and VIII), the percent conversion of carbon into isoprene was between 0.04-0.06%. A 0.11-0.16% carbon yield has been achieved using 14 liter systems as described herein. Example 11, part V describes the 1.53% conversion of carbon to isoprene using the methods described herein.

**[0476]** One skilled in the art can readily convert the rates of isoprene production or amount of isoprene produced into any other units. Exemplary equations are listed below for interconverting between units.

Units for Rate of Isoprene production (total and specific)**Equation 3**

$$1 \text{ g isoprene/L}_{\text{broth}}/\text{hr} = 14.7 \text{ mmol isoprene/L}_{\text{broth}}/\text{hr} \text{ (total volumetric rate)}$$

**Equation 4**

$$1 \text{ nmol isoprene/g}_{\text{wcm}}/\text{hr} = 1 \text{ nmol isoprene/L}_{\text{broth}}/\text{hr}/\text{OD}_{600} \text{ (This conversion assumes that one liter of broth with an OD}_{600} \text{ value of 1 has a wet cell weight of 1 gram.)}$$

**Equation 5**

$$1 \text{ nmol isoprene/g}_{\text{wcm}}/\text{hr} = 68.1 \text{ ng isoprene/g}_{\text{wcm}}/\text{hr} \text{ (given the molecular weight of isoprene)}$$

**Equation 6**

$$1 \text{ nmol isoprene/L}_{\text{gas}} \text{ O}_2/\text{hr} = 90 \text{ nmol isoprene/L}_{\text{broth}}/\text{hr} \text{ (at an O}_2 \text{ flow rate of 90 L/hr per L of culture broth)}$$

**Equation 7**

$$1 \text{ }\mu\text{g isoprene/L}_{\text{gas}} \text{ isoprene in off-gas} = 60 \text{ }\mu\text{g isoprene/L}_{\text{broth}}/\text{hr} \text{ at a flow rate of 60 L}_{\text{gas}} \text{ per L}_{\text{broth}} \text{ (1 vvm)}$$

Units for Titer (total and specific)

**Equation 8**

1 nmol isoprene/mg cell protein = 150 nmol isoprene/L<sub>broth</sub>/OD<sub>600</sub> (This conversion assumes that one liter of broth with an OD<sub>600</sub> value of 1 has a total cell protein of approximately 150 mg) (specific productivity)

**Equation 9**

1 g isoprene/L<sub>broth</sub> = 14.7 mmol isoprene/L<sub>broth</sub> (total titer)

[0477] If desired, Equation 10 can be used to convert any of the units that include the wet weight of the cells into the corresponding units that include the dry weight of the cells.

**Equation 10**

Dry weight of cells = (wet weight of cells)/3.3

[0478] If desired, Equation 11 can be used to convert between units of ppm and µg/L. In particular, “ppm” means parts per million defined in terms of µg/g (w/w). Concentrations of gases can also be expressed on a volumetric basis using “ppmv” (parts per million by volume), defined in terms of µL/L (vol/vol). Conversion of µg/L to ppm (*e.g.*, µg of analyte per g of gas) can be performed by determining the mass per L of off-gas (*i.e.*, the density of the gas). For example, a liter of air at standard temperature and pressure (STP; 101.3 kPa (1 bar) and 273.15K). has a density of approximately 1.29 g/L. Thus, a concentration of 1 ppm (µg/g) equals 1.29 µg/L at STP (equation 11). The conversion of ppm (µg/g) to µg/L is a function of both pressure, temperature, and overall composition of the off-gas.

**Equation 11**

1 ppm (µg/g) equals 1.29 µg/L at standard temperature and pressure (STP; 101.3 kPa (1 bar) and 273.15K).

[0479] Conversion of µg/L to ppmv (*e.g.*, µL of analyte per L of gas) can be performed using the Universal Gas Law (equation 12). For example, an off-gas concentration of 1000 µg/L<sub>gas</sub> corresponds to 14.7 µmol/L<sub>gas</sub>. The universal gas constant is 0.082057 L.atm K<sup>-1</sup>mol<sup>-1</sup>, so using equation 12, the volume occupied by 14.7 µmol of HG at STP is equal to 0.329 mL. Therefore, the concentration of 1000 µg/L HG is equal to 329 ppmv or 0.0329% (v/v) at STP.

**Equation 12**

**[0480]**  $PV = nRT$ , where “P” is pressure, “V” is volume, “n” is moles of gas, “R” is the Universal gas constant, and “T” is temperature in Kelvin.

**[0481]** The amount of impurities in isoprene compositions are typically measured herein on a weight per volume (w/v) basis in units such as  $\mu\text{g/L}$ . If desired, measurements in units of  $\mu\text{g/L}$  can be converted to units of  $\text{mg/m}^3$  using equation 13.

**Equation 13**

$$1 \mu\text{g/L} = 1 \text{mg/m}^3$$

**[0482]** In some embodiments described herein, a cell comprising a heterologous nucleic acid encoding an isoprene synthase polypeptide produces an amount of isoprene that is at least or about 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 150-fold, 200-fold, 400-fold, or greater than the amount of isoprene produced from a corresponding cell grown under essentially the same conditions without the heterologous nucleic acid encoding the isoprene synthase polypeptide.

**[0483]** In some embodiments described herein, a cell comprising a heterologous nucleic acid encoding an isoprene synthase polypeptide and one or more heterologous nucleic acids encoding a DXS, IDI, and/or MVA pathway polypeptide produces an amount of isoprene that is at least or about 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 150-fold, 200-fold, 400-fold, or greater than the amount of isoprene produced from a corresponding cell grown under essentially the same conditions without the heterologous nucleic acids.

**[0484]** In some embodiments, the isoprene composition comprises greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition. In some embodiments, the composition has a relative detector response of greater than or about 99.90, 99.91, 99.92, 99.93, 99.94, 99.95, 99.96, 99.97, 99.98, 99.99, or 100% for isoprene compared to the detector response for all C5 hydrocarbons in the composition. In some embodiments, the isoprene composition comprises between about 99.90 to about 99.92, about 99.92 to about 99.94, about 99.94 to about 99.96, about 99.96 to about 99.98, about 99.98 to 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition.

**[0485]** In some embodiments, the isoprene composition comprises less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% C5

hydrocarbons other than isoprene (such as 1,3-cyclopentadiene, cis-1,3-pentadiene, trans-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, trans-pent-3-ene-1-yne, or cis-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the composition. In some embodiments, the composition has a relative detector response of less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% for C5 hydrocarbons other than isoprene compared to the detector response for all C5 hydrocarbons in the composition. In some embodiments, the composition has a relative detector response of less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% for 1,3-cyclopentadiene, cis-1,3-pentadiene, trans-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, trans-pent-3-ene-1-yne, or cis-pent-3-ene-1-yne compared to the detector response for all C5 hydrocarbons in the composition. In some embodiments, the isoprene composition comprises between about 0.02 to about 0.04%, about 0.04 to about 0.06%, about 0.06 to 0.08%, about 0.08 to 0.10%, or about 0.10 to about 0.12% C5 hydrocarbons other than isoprene (such as 1,3-cyclopentadiene, cis-1,3-pentadiene, trans-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, trans-pent-3-ene-1-yne, or cis-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the composition.

**[0486]** In some embodiments, the isoprene composition comprises less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005  $\mu\text{g/L}$  of a compound that inhibits the polymerization of isoprene for any compound in the composition that inhibits the polymerization of isoprene. In some embodiments, the isoprene composition comprises between about 0.005 to about 50, such as about 0.01 to about 10, about 0.01 to about 5, about 0.01 to about 1, about 0.01 to about 0.5, or about 0.01 to about 0.005  $\mu\text{g/L}$  of a compound that inhibits the polymerization of isoprene for any compound in the composition that inhibits the polymerization of isoprene. In some embodiments, the isoprene composition comprises less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005  $\mu\text{g/L}$  of a hydrocarbon other than isoprene (such as 1,3-cyclopentadiene, cis-1,3-pentadiene, trans-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, trans-pent-3-ene-1-yne, or cis-pent-3-ene-1-yne). In some embodiments, the isoprene composition comprises between about 0.005 to about 50, such as about 0.01 to about 10, about 0.01 to about 5, about 0.01 to about 1, about 0.01 to about 0.5, or about 0.01 to about 0.005  $\mu\text{g/L}$  of a hydrocarbon other than isoprene. In some embodiments, the isoprene composition comprises less than or about 50, 40,

30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 µg/L of a protein or fatty acid (such as a protein or fatty acid that is naturally associated with natural rubber).

**[0487]** In some embodiments, the isoprene composition comprises less than or about 10, 5, 1, 0.8, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of alpha acetylenes, piperylenes, acetonitrile, or 1,3-cyclopentadiene. In some embodiments, the isoprene composition comprises less than or about 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of sulfur or allenes. In some embodiments, the isoprene composition comprises less than or about 30, 20, 15, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of all acetylenes (such as 1-pentyne, 2-pentyne, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, and *cis*-pent-3-ene-1-yne). In some embodiments, the isoprene composition comprises less than or about 2000, 1000, 500, 200, 100, 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 ppm of isoprene dimers, such as cyclic isoprene dimers (*e.g.*, cyclic C10 compounds derived from the dimerization of two isoprene units).

**[0488]** In some embodiments, the isoprene composition includes ethanol, acetone, a C5 prenyl alcohol (such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-1-ol), or any two or more of the foregoing. In particular embodiments, the isoprene composition comprises greater than or about 0.005, 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 60, 80, 100, or 120 µg/L of ethanol, acetone, a C5 prenyl alcohol (such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-1-ol), or any two or more of the foregoing. In some embodiments, the isoprene composition comprises between about 0.005 to about 120, such as about 0.01 to about 80, about 0.01 to about 60, about 0.01 to about 40, about 0.01 to about 30, about 0.01 to about 20, about 0.01 to about 10, about 0.1 to about 80, about 0.1 to about 60, about 0.1 to about 40, about 5 to about 80, about 5 to about 60, or about 5 to about 40 µg/L of ethanol, acetone, a C5 prenyl alcohol, or any two or more of the foregoing.

**[0489]** In some embodiments, the isoprene composition includes one or more of the following components: 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, acetaldehyde, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butanal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (*trans*-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (*E*)-3,7-dimethyl-1,3,6-octatriene, (*Z*)-3,7-dimethyl-1,3,6-octatriene, 2,3-cycloheptenolpyridine, or a linear isoprene polymer (such as a linear isoprene dimer or a linear isoprene trimer derived from the polymerization of multiple isoprene units). In various embodiments, the amount of one of these components relative to

amount of isoprene in units of percentage by weight (*i.e.*, weight of the component divided by the weight of isoprene times 100) is greater than or about 0.01, 0.02, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 110% (w/w). In some embodiments, the relative detector response for the second compound compared to the detector response for isoprene is greater than or about 0.01, 0.02, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 110%. In various embodiments, the amount of one of these components relative to amount of isoprene in units of percentage by weight (*i.e.*, weight of the component divided by the weight of isoprene times 100) is between about 0.01 to about 105 % (w/w), such as about 0.01 to about 90, about 0.01 to about 80, about 0.01 to about 50, about 0.01 to about 20, about 0.01 to about 10, about 0.02 to about 50, about 0.05 to about 50, about 0.1 to about 50, or 0.1 to about 20% (w/w).

**[0490]** In some embodiments, the isoprene composition includes one or more of the following: an alcohol, an aldehyde, or a ketone (such as any of the alcohols, aldehydes, or ketones described herein). In some embodiments, the isoprene composition includes (i) an alcohol and an aldehyde, (ii) an alcohol and a ketone, (iii) an aldehyde and a ketone, or (iv) an alcohol, an aldehyde, and a ketone.

**[0491]** In some embodiments, the isoprene composition contains one or more of the following: methanol, acetaldehyde, ethanol, methanethiol, 1-butanol, 3-methyl-1-propanol, acetone, acetic acid, 2-butanone, 2-methyl-1-butanol, or indole. In some embodiments, the isoprene composition contains 1 ppm or more of one or more of the following: methanol, acetaldehyde, ethanol, methanethiol, 1-butanol, 3-methyl-1-propanol, acetone, acetic acid, 2-butanone, 2-methyl-1-butanol, or indole. In some embodiments, the concentration of more of one or more of the following: methanol, acetaldehyde, ethanol, methanethiol, 1-butanol, 3-methyl-1-propanol, acetone, acetic acid, 2-butanone, 2-methyl-1-butanol, or indole, is between about 1 to about 10,000 ppm in an isoprene composition (such as off-gas before it is purified). In some embodiments, the isoprene composition (such as off-gas after it has undergone one or more purification steps) includes one or more of the following: methanol, acetaldehyde, ethanol, methanethiol, 1-butanol, 3-methyl-1-propanol, acetone, acetic acid, 2-butanone, 2-methyl-1-butanol, or indole, at a concentration between about 1 to about 100 ppm, such as about 1 to about 10 ppm, about 10 to about 20 ppm, about 20 to about 30 ppm, about 30 to about 40 ppm, about 40 to about 50 ppm, about 50 to about 60 ppm, about 60 to about 70 ppm, about 70 to about 80 ppm, about 80 to about 90 ppm, or about 90 to about 100 ppm. Volatile organic compounds from cell cultures (such as volatile organic compounds in the headspace of cell cultures) can be analyzed using standard methods such as those described herein or other

standard methods such as proton transfer reaction-mass spectrometry (*see, for example, Bunge et al., Applied and Environmental Microbiology, 74(7):2179-2186, 2008* which is hereby incorporated by reference in its entirety, particular with respect to the analysis of volatile organic compounds).

**[0492]** In some embodiments, the composition comprises greater than about 2 mg of isoprene, such as greater than or about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mg of isoprene. In some embodiments, the composition comprises greater than or about 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 g of isoprene. In some embodiments, the amount of isoprene in the composition is between about 2 to about 5,000 mg, such as between about 2 to about 100 mg, about 100 to about 500 mg, about 500 to about 1,000 mg, about 1,000 to about 2,000 mg, or about 2,000 to about 5,000 mg. In some embodiments, the amount of isoprene in the composition is between about 20 to about 5,000 mg, about 100 to about 5,000 mg, about 200 to about 2,000 mg, about 200 to about 1,000 mg, about 300 to about 1,000 mg, or about 400 to about 1,000 mg. In some embodiments, greater than or about 20, 25, 30, 40, 50, 60, 70, 80, 90, or 95% by weight of the volatile organic fraction of the composition is isoprene.

**[0493]** In some embodiments, the composition includes ethanol. In some embodiments, the composition includes between about 75 to about 90% by weight of ethanol, such as between about 75 to about 80%, about 80 to about 85%, or about 85 to about 90% by weight of ethanol. In some embodiments in which the composition includes ethanol, the composition also includes between about 4 to about 15% by weight of isoprene, such as between about 4 to about 8%, about 8 to about 12%, or about 12 to about 15% by weight of isoprene.

**[0494]** In some embodiments described herein, a cell comprising one or more heterologous nucleic acids encoding an isoprene synthase polypeptide, DXS polypeptide, IDI polypeptide, and/or MVA pathway polypeptide produces an amount of an isoprenoid compound (such as a compound with 10 or more carbon atoms that is formed from the reaction of one or more IPP molecules with one or more DMAPP molecules) that is greater than or about 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 150-fold, 200-fold, 400-fold, or greater than the amount of the isoprenoid compound produced from a corresponding cell grown under essentially the same conditions without the one or more heterologous nucleic acids. In some embodiments described herein, a cell comprising one or more heterologous nucleic acids encoding an isoprene synthase polypeptide, DXS polypeptide, IDI polypeptide, and/or MVA pathway polypeptide produces an amount of a C5 prenyl alcohol (such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-

1-ol) that is greater than or about 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 150-fold, 200-fold, 400-fold, or greater than the amount of the C5 prenyl alcohol produced from a corresponding cell grown under essentially the same conditions without the one or more heterologous nucleic acids.

*Exemplary Co-Production of BioIsoprene and Hydrogen*

**[0495]** In some embodiments, any of the isoprene-producing cells described herein that comprise one or more heterologous nucleic acids encoding an isoprene synthase polypeptide, a DXS polypeptide, an IDI polypeptide, and/or an MVA pathway polypeptide operably linked to a promoter further comprise a heterologous nucleic acid also operably linked to a promoter encoding one or more hydrogenase polypeptides or one or more polypeptides involved in the regulation or expression of hydrogenase polypeptides (*e.g.*, hydrogenase maturation proteins or transcription factors). In some embodiments, any of the isoprene-producing cells described herein that comprise one or more heterologous nucleic acids encoding an isoprene synthase polypeptide, a DXS polypeptide, an IDI polypeptide, an MVA pathway polypeptide, one or more hydrogenase polypeptides or one or more polypeptides involved in the regulation or expression of hydrogenase polypeptides operably linked to a promoter further comprise a mutation or deletion inactivating one or more polypeptides involved in the production of fermentation side products, one or more polypeptides involved in the regulation or expression of genes for the production of fermentation side products, or one or more polypeptides involved in hydrogen reuptake. Such cells can co-produce isoprene and hydrogen.

**[0496]** In some embodiments of any of the aspects described herein, the cells are bacterial cells, such as gram-positive bacterial cells (*e.g.*, *Bacillus* cells such as *Bacillus subtilis* cells or *Streptomyces* cells such as *Streptomyces lividans*, *Streptomyces coelicolor*, or *Streptomyces griseus* cells). In some embodiments of any of the aspects described herein, the cells are gram-negative bacterial cells (*e.g.*, *Escherichia* cells such as *Escherichia coli* cells, *Rhodopseudomonas sp.* such as *Rhodopseudomonas palustris* cells, *Pseudomonas sp.* such as *Pseudomonas fluorescens* cells or *Pseudomonas putida* cells, or *Pantoea* cells such as *Pantoea citrea* cells). In some embodiments of any of the aspects described herein, the cells are fungal cells such as filamentous fungal cells (*e.g.*, *Trichoderma* cells such as *Trichoderma reesei* cells or *Aspergillus* cells such as *Aspergillus oryzae* and *Aspergillus niger*) or yeast cells (*e.g.*, *Yarrowia* cells such as *Yarrowia lipolytica* cells or *Saccharomyces* cells such as *Saccharomyces cerevisiae*).

**[0497]** In some embodiments of any of the aspects described herein, the isoprene synthase polypeptide is a polypeptide from a plant such as *Pueraria* (e.g., *Pueraria montana* or *Pueraria lobata*) or *Populus* (e.g., *Populus tremuloides*, *Populus alba*, *Populus nigra*, *Populus trichocarpa*, or the hybrid, *Populus alba* x *Populus tremula*).

**[0498]** In some embodiments of any of the aspects described herein, the cells further comprise a heterologous nucleic acid encoding an IDI polypeptide. In some embodiments of any of the aspects described herein, the cells further comprise an insertion of a copy of an endogenous nucleic acid encoding an IDI polypeptide. In some embodiments of any of the aspects described herein, the cells further comprise a heterologous nucleic acid encoding a DXS polypeptide. In some embodiments of any of the aspects described herein, the cells further comprise an insertion of a copy of an endogenous nucleic acid encoding a DXS polypeptide. In some embodiments of any of the aspects described herein, the cells further comprise one or more nucleic acids encoding an IDI polypeptide and a DXS polypeptide. In some embodiments of any of the aspects described herein, one nucleic acid encodes the isoprene synthase polypeptide, IDI polypeptide, and DXS polypeptide. In some embodiments of any of the aspects described herein, one vector encodes the isoprene synthase polypeptide, IDI polypeptide, and DXS polypeptide. In some embodiments, the vector comprises a selective marker or a selectable marker, such as an antibiotic resistance nucleic acid.

**[0499]** In some embodiments of any of the aspects described herein, the cells further comprise a heterologous nucleic acid encoding an MVA pathway polypeptide (such as an MVA pathway polypeptide from *Saccharomyces cerevisia* or *Enterococcus faecalis*). In some embodiments of any of the aspects described herein, the cells further comprise an insertion of a copy of an endogenous nucleic acid encoding an MVA pathway polypeptide (such as an MVA pathway polypeptide from *Saccharomyces cerevisia* or *Enterococcus faecalis*). In some embodiments of any of the aspects described herein, the cells comprise an isoprene synthase, DXS, and MVA pathway nucleic acid. In some embodiments of any of the aspects described herein, the cells comprise an isoprene synthase nucleic acid, a DXS nucleic acid, an IDI nucleic acid, and a MVA pathway nucleic acid.

**[0500]** In some embodiments, the isoprene-producing cells described herein further comprise a heterologous nucleic acid encoding a hydrogenase polypeptide operably linked to a promoter. In some embodiments, the hydrogenase polypeptide comprises *E. coli* hydrogenase-1 (Hyd-1), *E. coli* hydrogenase-2 (Hyd-2), *E. coli* hydrogenase-3 (Hyd-3), *E. coli* hydrogenase-4 (Hyd-4), *E. coli* formate hydrogen lyase (FHL) complex, which produces hydrogen gas from formate and

CO<sub>2</sub> under anaerobic conditions at acidic pH, *Rhodococcus opacus* MR11 hydrogenase (*R. opacus* HoxH), *Synechosystis* sp. PCC 6803 hydrogenase (*Syn.* PCC 6803 HoxH), *Desulfovibrio gigas* hydrogenase (*D. gigas*), and *Desulfovibrio desulfuricans* ATCC 7757 hydrogenase (*D. desulfuricans*). In some embodiments, the isoprene-producing cells further comprising a heterologous nucleic acid encoding a hydrogenase polypeptide operably linked to a promoter further comprise *E. coli* hydrogenase-3 (Hyd-3), *E. coli* pyruvate formate lyase (*pfl*), and *E. coli* formate hydrogen lyase (FHL) complex.

**[0501]** In some embodiments, the hydrogenase polypeptide encodes a ferredoxin-dependent hydrogenase polypeptide. In some embodiments, the ferredoxin-dependent hydrogenase polypeptide comprises *Clostridium acetobutolicum* hydrogenase A (HydA), which can be expressed in conjunction with one or more of: (1) *Bacillus subtilis* NADPH ferredoxin oxidoreductase (NFOR) or *Clostridium kluyveri* NADH ferredoxin oxidoreductase (RnfCDGEAB), *Clostridium pasteurianum* ferredoxin oxidoreductase (Fdx); (2) glyceraldehyde-6-phosphate ferredoxin oxidoreductase (GAPOR); or (3) pyruvate ferredoxin oxidoreductase (POR). In some embodiments, the ferredoxin-dependent hydrogenase polypeptide *Clostridium acetobutolicum* hydrogenase A (HydA) is expressed with three HydA-associated maturation enzymes (HydE, HydG, and HydF), and further in conjunction with one or more of: (1) *Bacillus subtilis* NADPH ferredoxin oxidoreductase (NFOR) or *Clostridium kluyveri* NADH ferredoxin oxidoreductase (RnfCDGEAB), *Clostridium pasteurianum* ferredoxin oxidoreductase (Fdx); (2) glyceraldehyde-6-phosphate ferredoxin oxidoreductase (GAPOR); or (3) pyruvate ferredoxin oxidoreductase (POR).

**[0502]** In some embodiments, the hydrogenase polypeptide encodes an NADPH-dependent hydrogenase polypeptide. In some embodiments, the NADPH-dependent hydrogenase polypeptide comprises *Pyrococcus furiosus* hydrogenase. In some embodiments, the hydrogenase polypeptide encodes an oxygen-tolerant hydrogenase. In some embodiments, the oxygen-tolerant hydrogenase comprises *Rubrivivax gelatinosus* hydrogenase, and *Ralstonia eutropha* hydrogenase.

**[0503]** In some embodiments, the isoprene-producing cells described herein further comprise a mutation or deletion inactivating a gene involved in regulation of hydrogenase activity, such as iron-sulfur complex transcriptional regulator (*iscR*) (Kalim-Akhtar et al., "Deletion of *iscR* stimulates recombinant Clostridial Fe/Fe hydrogenase activity and H<sub>2</sub>-accumulation in *Escherichia coli* BL21(DE3)," *Appl. Microbiol. Biotechnol.* 78:853–862 (2008), which is incorporated herein by reference in its entirety, particularly with reference to stimulation of

Clostridial Fe/Fe hydrogenase activity and hydrogen accumulation in *E. coli* by deleting the *iscR* gene).

**[0504]** In some embodiments, the isoprene-producing cells described herein further comprise a mutation or deletion inactivating a gene encoding one or more cellular polypeptides involved in production of fermentation side products, such as lactate, acetate, pyruvate, ethanol, succinate, and glycerol. In some embodiments, the inactivated polypeptides involved in production of fermentation side products comprise one or more polypeptides encoding formate dehydrogenase N, alpha subunit (*fdnG*), formate dehydrogenase O, large subunit (*fdoG*), nitrate reductase (*narG*), formate transporter A (*focA*), formate transporter B (*focB*), pyruvate oxidase (*poxB*), pyruvate dehydrogenase E1 component *ackA/pta* (*aceE*), alcohol dehydrogenase (*adhE*), fumarate reductase membrane protein (*frdC*), or lactate dehydrogenase (*ldhA*).

**[0505]** In some embodiments, the isoprene-producing cells described herein further comprise a mutation or deletion inactivating a gene encoding one or more cellular polypeptides involved in the regulation or expression of genes involved in production of fermentation side products. In some embodiments, the inactivated polypeptides involved in the regulation or expression of genes involved in production of fermentation side products comprise repressor of formate hydrogen lyase (*hycA*), fumarate reductase regulator (*fnr*), acetyl-coenzyme A synthetase (*acs*), and formate dehydrogenase regulatory protein (*hycA*).

**[0506]** In some embodiments, the isoprene-producing cells described herein further comprise a mutation or deletion inactivating a gene encoding one or more cellular polypeptides involved in hydrogen re-uptake. In some embodiments, the inactivated polypeptides involved in hydrogen re-uptake comprise *E. coli* hydrogenase-1 (Hyd-1) (*hya* operon) and *E. coli* hydrogenase-2 (Hyd-2) (*hyb* operon).

**[0507]** In some embodiments of any of the aspects described herein, the heterologous isoprene synthase, DXS polypeptide, IDI polypeptide, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor polypeptide or nucleic acid is operably linked to a T7 promoter, such as a T7 promoter contained in a medium or high copy plasmid. In some embodiments of any of the aspects described herein, the heterologous isoprene synthase, DXS polypeptide, IDI polypeptide, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor nucleic acid is operably linked to a Trc promoter, such as a Trc promoter contained in a medium or high copy plasmid. In some embodiments of any of the aspects described herein, the heterologous isoprene synthase, DXS polypeptide, IDI polypeptide, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor nucleic acid is operably

linked to a Lac promoter, such as a Lac promoter contained in a low copy plasmid. In some embodiments of any of the aspects described herein, the heterologous isoprene synthase, DXS polypeptide, IDI polypeptide, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor nucleic acid is operably linked to an endogenous promoter, such as an endogenous alkaline serine protease promoter. In some embodiments, the heterologous isoprene synthase, DXS polypeptide, IDI polypeptide, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor nucleic acid integrates into a chromosome of the cells without a selective marker or without a selectable marker.

**[0508]** In some embodiments, one or more MVA pathway, IDI, DXS, isoprene synthase, hydrogenase, hydrogenase maturation or transcription factor nucleic acids are placed under the control of a promoter or factor that is more active in stationary phase than in the growth phase. For example, one or more MVA pathway, IDI, DXS, isoprene synthase, hydrogenase, hydrogenase maturation or transcription factor nucleic acids may be placed under control of a stationary phase sigma factor, such as RpoS. In some embodiments, one or more MVA pathway, IDI, DXS, isoprene synthase, hydrogenase, hydrogenase maturation or transcription factor nucleic acids are placed under control of a promoter inducible in stationary phase, such as a promoter inducible by a response regulator active in stationary phase.

**[0509]** In some embodiments of any of the aspects described herein, at least a portion of the cells maintain the heterologous isoprene synthase, DXS polypeptide, IDI polypeptide, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor nucleic acid for at least or about 5, 10, 20, 40, 50, 60, 65, or more cell divisions in a continuous culture (such as a continuous culture without dilution). In some embodiments of any of the aspects described herein, the nucleic acid comprising the isoprene synthase, DXS polypeptide, IDI polypeptide, MVA pathway, hydrogenase, hydrogenase maturation or transcription factor nucleic acid also comprises a selective marker or a selectable marker, such as an antibiotic resistance nucleic acid.

**[0510]** In some embodiments of any of the aspects described herein, cells that co-produce isoprene and hydrogen are cultured in any of the culture media described herein, under oxygen-limited conditions to facilitate the co-production of isoprene and hydrogen by the cells. In some embodiments, the cells are grown in oxygen-limited culture. In some embodiments, the cells are grown in the presence of 0.5 moles of oxygen per mole of isoprene. In some embodiments, the cells are grown anaerobically, in the absence of oxygen.

**[0511]** In some embodiments, any of the cells described herein are grown in oxygen-limited culture and co-produce isoprene and hydrogen. In some embodiments, the cells in oxygen-

limited culture produce isoprene at a rate greater than about 400 nmole/g<sub>wcm</sub>/hr, and produce hydrogen at a rate greater than about 125 nmole/g<sub>wcm</sub>/hr. In some embodiments, the cells in oxygen-limited culture produce isoprene at a rate between about 400 nmole/g<sub>wcm</sub>/hr to about  $2.0 \times 10^5$  nmole/g<sub>wcm</sub>/hr and hydrogen at a rate between about 125 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr. In some embodiments, the cells in oxygen-limited culture produce isoprene at a rate between about 400 nmole/g<sub>wcm</sub>/hr and about  $2.0 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 500 nmole/g<sub>wcm</sub>/hr and about  $1.5 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 750 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 1000 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 2500 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 5000 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 7500 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, and between about  $1 \times 10^4$  nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr. In some embodiments, the cells in oxygen-limited culture produce greater than about 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, or more nmole/g<sub>wcm</sub>/hr isoprene. In some embodiments, the cells in oxygen-limited culture produce hydrogen at a rate between about 125 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 250 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 500 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 750 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 1000 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 1250 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 2500 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 5000 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 7500 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, and between about  $1.00 \times 10^4$  nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr. In some embodiments, the cells in oxygen-limited culture produce greater than about 125, 250, 500, 750, 1000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 7,500, 10,000, or more nmole/g<sub>wcm</sub>/hr hydrogen.

**[0512]** In some embodiments, any of the cells described herein are grown in oxygen-limited culture and co-produce isoprene and hydrogen. In some embodiments, the cells in oxygen-limited culture have an average volumetric productivity of isoprene greater than about 0.1 mg/L<sub>broth</sub>/hr and an average volumetric productivity of hydrogen greater than about 0.005 mg/L<sub>broth</sub>/hr. In some embodiments, the cells in oxygen-limited culture have a peak volumetric productivity of isoprene greater than about 1000 mg/L<sub>broth</sub>/hr and a peak volumetric productivity of hydrogen greater than about 5 mg/L<sub>broth</sub>/hr. In some embodiments, the cells in oxygen-limited culture have a peak volumetric productivity of isoprene greater than about 3000 mg/L<sub>broth</sub>/hr and

a peak volumetric productivity of hydrogen greater than about 5 mg/L<sub>broth</sub>/hr. In some embodiments, the cells in oxygen-limited culture have a peak volumetric productivity of isoprene greater than about 5000 mg/L<sub>broth</sub>/hr and a peak volumetric productivity of hydrogen greater than about 5 mg/L<sub>broth</sub>/hr. In some embodiments, the cells in oxygen-limited culture have an average volumetric productivity of isoprene between about 0.1 mg/L<sub>broth</sub>/hr and about 5000 mg/L<sub>broth</sub>/hr, and an average volumetric productivity of hydrogen between about 0.005 mg/L<sub>broth</sub>/hr and about 5 mg/L<sub>broth</sub>/hr. In some embodiments, the cells in oxygen-limited culture have an average volumetric productivity of isoprene between about 1 mg/L<sub>broth</sub>/hr and about 5000 mg/L<sub>broth</sub>/hr, between about 5 mg/L<sub>broth</sub>/hr and about 5000 mg/L<sub>broth</sub>/hr, between about 10 mg/L<sub>broth</sub>/hr and about 5000 mg/L<sub>broth</sub>/hr, between about 25 mg/L<sub>broth</sub>/hr and about 5000 mg/L<sub>broth</sub>/hr, between about 50 mg/L<sub>broth</sub>/hr and about 5000 mg/L<sub>broth</sub>/hr, between about 100 mg/L<sub>broth</sub>/hr and about 5000 mg/L<sub>broth</sub>/hr, between about 250 mg/L<sub>broth</sub>/hr and about 5000 mg/L<sub>broth</sub>/hr, between about 500 mg/L<sub>broth</sub>/hr and about 5000 mg/L<sub>broth</sub>/hr, between about 1000 mg/L<sub>broth</sub>/hr and about 5000 mg/L<sub>broth</sub>/hr, and between about 2500 mg/L<sub>broth</sub>/hr and about 5000 mg/L<sub>broth</sub>/hr, and an average volumetric productivity of hydrogen between about 0.01 mg/L<sub>broth</sub>/hr and about 5 mg/L<sub>broth</sub>/hr, between about 0.025 mg/L<sub>broth</sub>/hr and about 5 mg/L<sub>broth</sub>/hr, between about 0.05 mg/L<sub>broth</sub>/hr and about 5 mg/L<sub>broth</sub>/hr, between about 0.1 mg/L<sub>broth</sub>/hr and about 5 mg/L<sub>broth</sub>/hr, between about 0.25 mg/L<sub>broth</sub>/hr and about 5 mg/L<sub>broth</sub>/hr, between about 0.5 mg/L<sub>broth</sub>/hr and about 5 mg/L<sub>broth</sub>/hr, between about 1 mg/L<sub>broth</sub>/hr and about 5 mg/L<sub>broth</sub>/hr, and between about 2.5 mg/L<sub>broth</sub>/hr and about 5 mg/L<sub>broth</sub>/hr.

**[0513]** In some embodiments, any of the cells described herein are grown in oxygen-limited culture and co-produce isoprene and hydrogen. In some embodiments, the cells in oxygen-limited culture convert more than about 0.002 molar percent of the carbon that the cells consume from a cell culture medium into isoprene, and produce hydrogen equivalent to more than about 0.024 molar percent of the carbon that the cells consume from a cell culture medium. In some embodiments, the cells in oxygen-limited culture convert more than about 0.002 molar percent of the carbon that the cells consume from a cell culture medium into isoprene, and produce hydrogen equivalent to more than about 400 molar percent of the carbon that the cells consumer from a cell culture medium.

**[0514]** In some embodiments, any of the cells described herein that co-produce isoprene and hydrogen are grown in oxygen-limited culture. In some embodiments, the cells in oxygen-limited culture co-produce isoprene and hydrogen in a ratio ranging from at least one molar percent of isoprene for every three molar percent of hydrogen to at least one molar percent of

isoprene for every four molar percent of hydrogen. In some embodiments, the cells in oxygen-limited culture produce an off-gas containing from 1 to 11 molar percent isoprene and from 3 to 33 molar percent hydrogen. In some embodiments, the cells produce from 1 to 11 molar percent isoprene and from 4 to 44 molar percent hydrogen. In some embodiments, the cells in oxygen-limited culture also produce an off-gas containing oxygen, carbon dioxide, or nitrogen. In some embodiments, the cells in oxygen limited culture produce an off-gas containing from 0 to 21 molar percent oxygen, from 18 to 44 molar percent carbon dioxide, and from 0 to 78 molar percent nitrogen.

**[0515]** In another aspect, provided herein are cells in oxygen-limited culture that co-produce isoprene and hydrogen, comprising a heterologous nucleic acid encoding an isoprene synthase polypeptide, wherein the cells: (i) produce isoprene at a rate greater than about 400 nmole/g<sub>wcm</sub>/hr and produce hydrogen at a rate greater than about 125 nmole/g<sub>wcm</sub>/hr; (ii) have an average volumetric productivity of isoprene greater than about 0.1 mg/L<sub>broth</sub>/hr and an average volumetric productivity of hydrogen greater than about 0.005 mg/L<sub>broth</sub>/hr; or (iii) convert more than about 0.002 molar percent of the carbon that the cells consume from a cell culture medium into isoprene, and produce hydrogen equivalent to more than about 0.024 molar percent of the carbon that the cells consume from a cell culture medium.

**[0516]** In some embodiments, the cells in oxygen-limited culture comprise a heterologous nucleic acid encoding an isoprene synthase polypeptide, wherein the heterologous nucleic acid is operably linked to a promoter, and wherein the cells produce greater than about 400 nmole/g<sub>wcm</sub>/hr of isoprene and greater than about 125 nmole/g<sub>wcm</sub>/hr of hydrogen. In some embodiments, the cells in oxygen-limited culture comprise a heterologous nucleic acid encoding an isoprene synthase polypeptide, wherein the heterologous nucleic acid is operably linked to a promoter, and wherein the cells have an average volumetric productivity of isoprene greater than about 0.1 mg/L<sub>broth</sub>/hr and an average volumetric productivity of hydrogen greater than about 0.005 mg/L<sub>broth</sub>/hr. In some embodiments, the cells in oxygen-limited culture comprise a heterologous nucleic acid encoding an isoprene synthase polypeptide, wherein the heterologous nucleic acid is operably linked to a promoter, and wherein the cells convert more than about 0.002 molar percent of the carbon that the cells consume from a cell culture medium into isoprene, and more than about 0.024 molar percent of the carbon that the cells consume from a cell culture medium into hydrogen. In some embodiments, the isoprene synthase polypeptide is a plant isoprene synthase polypeptide.

**[0517]** In some embodiments, the cells in oxygen-limited culture comprising a heterologous nucleic acid encoding an isoprene synthase polypeptide produce isoprene at a rate between about 400 nmole/g<sub>wcm</sub>/hr and about  $2.0 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 500 nmole/g<sub>wcm</sub>/hr and about  $1.5 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 750 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 1000 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 2500 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 5000 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 7500 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, and between about  $1 \times 10^4$  nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, and produce hydrogen at a rate between about 125 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 250 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 500 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 750 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 1000 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 1250 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 2500 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 5000 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 7500 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, and between about  $1.00 \times 10^4$  nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr.

**[0518]** In some embodiments, provided herein are methods of co-producing isoprene and hydrogen, the methods comprising: (a) culturing cells under conditions suitable for the co-production of isoprene and hydrogen; and (b) co-producing isoprene and hydrogen, wherein the cells produce greater than about 400 nmole/g<sub>wcm</sub>/hour of isoprene, and wherein the cells produce greater than about 125 nmole/g<sub>wcm</sub>/hr of hydrogen.

**[0519]** In some embodiments, the cells in oxygen-limited culture comprising a heterologous nucleic acid encoding an isoprene synthase polypeptide produce isoprene at a rate between about 400 nmole/g<sub>wcm</sub>/hr and about  $2.0 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 500 nmole/g<sub>wcm</sub>/hr and about  $1.5 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 750 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 1000 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 2500 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 5000 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, between about 7500 nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, and between about  $1 \times 10^4$  nmole/g<sub>wcm</sub>/hr and about  $1 \times 10^5$  nmole/g<sub>wcm</sub>/hr, and produce hydrogen at a rate between about 125 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 250 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 500 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 750 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 1000 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr,

between about 1250 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 2500 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 5000 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, between about 7500 nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr, and between about  $1.00 \times 10^4$  nmole/g<sub>wcm</sub>/hr to about  $1.25 \times 10^4$  nmole/g<sub>wcm</sub>/hr.

**[0520]** In some embodiments, provided herein are methods of co-producing isoprene and hydrogen, the methods comprising: (a) culturing cells under conditions suitable for the co-production of isoprene and hydrogen; and (b) co-producing isoprene and hydrogen, wherein the cells have an average volumetric productivity of isoprene greater than about 0.1 mg/L<sub>broth</sub>/hr and an average volumetric productivity of hydrogen greater than about 0.005 mg/L<sub>broth</sub>/hr.

**[0521]** In some embodiments, provided herein are methods of co-producing isoprene and hydrogen, the methods comprising: (a) culturing cells under conditions suitable for the co-production of isoprene and hydrogen; and (b) co-producing isoprene and hydrogen, wherein the cells convert more than about 0.002 molar percent of the carbon that the cells consume from a cell culture medium into isoprene, and produce hydrogen equivalent to more than about 0.024 molar percent of the carbon that the cells consume from a cell culture medium.

**[0522]** In some embodiments, provided herein are compositions comprising isoprene and hydrogen in a ratio ranging from at least one molar percent of isoprene for every three molar percent of hydrogen to at least one molar percent of isoprene for every four molar percent of hydrogen, and 0.1 molar percent or less of volatile impurities. In some embodiments, the compositions further comprise from 1 to 11 molar percent isoprene and from 4 to 44 molar percent hydrogen. In some embodiments, the compositions further comprise oxygen, carbon dioxide, or nitrogen. In some embodiments, the compositions further comprise from 0 to 21 molar percent oxygen, from 18 to 44 molar percent carbon dioxide, and from 0 to 78 molar percent nitrogen. In some embodiments, the composition further comprises  $1.0 \times 10^{-4}$  molar percent or less of non-methane volatile impurities. In some embodiments, the non-methane volatile impurities comprise one or more of the following: 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, acetaldehyde, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene, 2,3-cycloheptenolpyridine, or a

linear isoprene polymer (such as a linear isoprene dimer or a linear isoprene trimer derived from the polymerization of multiple isoprene units). In some embodiments, the non-methane volatile impurities comprise one or more of the following: the isoprene composition includes one or more of the following: an alcohol, an aldehyde, or a ketone (such as any of the alcohols, aldehydes, or ketones described herein). In some embodiments, the isoprene composition includes (i) an alcohol and an aldehyde, (ii) an alcohol and a ketone, (iii) an aldehyde and a ketone, or (iv) an alcohol, an aldehyde, and a ketone. In some embodiments, the non-methane volatile impurities comprise one or more of the following: methanol, acetaldehyde, ethanol, methanethiol, 1-butanol, 3-methyl-1-propanol, acetone, acetic acid, 2-butanone, 2-methyl-1-butanol, or indole.

**[0523]** Also provided herein are methods of co-producing isoprene and hydrogen, the methods comprising: a) culturing cells under conditions suitable for the co-production of isoprene and hydrogen; and b) co-producing isoprene and hydrogen, wherein the peak concentration of the isoprene produced by the cells in oxygen-limited culture is greater than about 10 ng/L<sub>broth</sub> and the hydrogen evolution rate of the cells is greater than about 0.0025 mmol/L<sub>broth</sub>/hour. In some embodiments of any of these methods, the hydrogen evolution rate is between about any of 0.0025 mmol/L<sub>broth</sub>/hr and about 10 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 5 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 2.5 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 1 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 0.5 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 0.25 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 0.025 mmol/L<sub>broth</sub>/hr, between about 0.025 mmol/L<sub>broth</sub>/hr and about 0.5 mmol/L<sub>broth</sub>/hr, between about 0.025 mmol/L<sub>broth</sub>/hr and about 1 mmol/L<sub>broth</sub>/hr, between about 0.025 mmol/L<sub>broth</sub>/hr and about 2.5 mmol/L<sub>broth</sub>/hr, between about 0.025 mmol/L<sub>broth</sub>/hr and about 5 mmol/L<sub>broth</sub>/hr, between about 0.025 mmol/L<sub>broth</sub>/hr and about 10 mmol/L<sub>broth</sub>/hr, between about 0.25 mmol/L<sub>broth</sub>/hr and 1 mmol/L<sub>broth</sub>/hr, between about 0.25 mmol/L<sub>broth</sub>/hr and 2.5 mmol/L<sub>broth</sub>/hr, between about 0.25 mmol/L<sub>broth</sub>/hr and 2.5 mmol/L<sub>broth</sub>/hr, and between about 0.25 mmol/L<sub>broth</sub>/hr and 10 mmol/L<sub>broth</sub>/hr.

**[0524]** Provided herein are also methods of co-producing isoprene and hydrogen comprising a) culturing cells under conditions suitable for the co-production of isoprene and hydrogen; and b) co-producing isoprene and hydrogen, wherein the liquid phase concentration of isoprene is less than about 200 mg/L, the cells produce greater than about 400 nmole/g<sub>wcm</sub>/hour of isoprene, and the hydrogen evolution rate of the cells is greater than about 0.0025 mmol/L/hour. In some

embodiments, the liquid phase concentration of isoprene in the culture is less than about any of 175 mg/L, 150 mg/L, 125 mg/L, 100 mg/L, 75 mg/L, 50 mg/L, 25 mg/L, 20 mg/L, 15 mg/L, 10 mg/L, 5 mg/L, or 2.5 mg/L. In some embodiments, the liquid phase concentration of isoprene in culture is between about any of 0.1 mg/L to 200 mg/L, 1 mg/L to 200 mg/L, 1 mg/L to 150 mg/L, 1 mg/L to 100 mg/L, 1 mg/L to 50 mg/L, 1 mg/L to 25 mg/L, 1 mg/L to 20 mg/L, or 10 mg/L to 20 mg/L. In some embodiments of any of these methods, the hydrogen evolution rate is between about any of 0.0025 mmol/L<sub>broth</sub>/hr and about 10 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 5 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 2.5 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 1 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 0.5 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 0.25 mmol/L<sub>broth</sub>/hr, between about 0.0025 mmol/L<sub>broth</sub>/hr and about 0.025 mmol/L<sub>broth</sub>/hr, between about 0.025 mmol/L<sub>broth</sub>/hr and about 0.5 mmol/L<sub>broth</sub>/hr, between about 0.025 mmol/L<sub>broth</sub>/hr and about 1 mmol/L<sub>broth</sub>/hr, between about 0.025 mmol/L<sub>broth</sub>/hr and about 2.5 mmol/L<sub>broth</sub>/hr, between about 0.025 mmol/L<sub>broth</sub>/hr and about 5 mmol/L<sub>broth</sub>/hr, between about 0.025 mmol/L<sub>broth</sub>/hr and about 10 mmol/L<sub>broth</sub>/hr, between about 0.25 mmol/L<sub>broth</sub>/hr and 1 mmol/L<sub>broth</sub>/hr, between about 0.25 mmol/L<sub>broth</sub>/hr and 2.5 mmol/L<sub>broth</sub>/hr, between about 0.25 mmol/L<sub>broth</sub>/hr and 2.5 mmol/L<sub>broth</sub>/hr, and between about 0.25 mmol/L<sub>broth</sub>/hr and 10 mmol/L<sub>broth</sub>/hr.

**[0525]** In one aspect, provided herein are cells in oxygen-limited culture that co-produce isoprene and hydrogen. In some embodiments, the oxygen-limited culture is anaerobic. In some embodiments, the cells in oxygen-limited culture produce greater than about 400 nmole/g<sub>wcm</sub>/hr of isoprene and greater than about 125 nmole/g<sub>wcm</sub>/hr of hydrogen. In some embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter. In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, polypeptide (*e.g.*, a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing. In some embodiments, the cells are cultured under limited glucose conditions.

**[0526]** In some embodiments, provided herein are cells in oxygen-limited culture that convert more than about 0.002% of the carbon in a cell culture medium into isoprene and produce hydrogen equivalent to more than about 0.024 molar percent of the carbon in a cell culture

medium. In some embodiments, the oxygen-limited culture is anaerobic. In some embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter. In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, polypeptide (*e.g.*, a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing. In some embodiments, the cells are cultured under limited glucose conditions.

**[0527]** In some embodiments, provided herein are cells in oxygen-limited culture that comprise a heterologous nucleic acid encoding an isoprene synthase polypeptide. In some embodiments, the oxygen-limited culture is anaerobic. In some embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter. In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, polypeptide (*e.g.*, a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing. In some embodiments, the cells are cultured under limited glucose conditions.

**[0528]** In one aspect, provided herein are methods of co-producing isoprene with another compound, such as methods of using any of the cells described herein to co-produce isoprene and hydrogen. In some embodiments, the method involves culturing cells under oxygen-limited conditions sufficient to produce greater than about 400 nmole/g<sub>wcm</sub>/hr of isoprene and greater than about 125 nmole/g<sub>wcm</sub>/hr of hydrogen. In some embodiments, the oxygen-limited culture is anaerobic. In some embodiments, the method also includes recovering the isoprene and hydrogen produced by the cells. In some embodiments, the method further includes purifying the isoprene and the hydrogen produced by the cells. In some embodiments, the method includes polymerizing the isoprene. In some embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter. In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride,

triglyceride, renewable carbon source, polypeptide (*e.g.*, a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing. In some embodiments, the cells are cultured under limited glucose conditions. In various embodiments, the amount of isoprene produced (such as the total amount of isoprene produced or the amount of isoprene produced per liter of broth per hour per OD<sub>600</sub>) during stationary phase is greater than or about 2 or more times the amount of isoprene produced during the growth phase for the same length of time.

**[0529]** In some embodiments, the method includes culturing cells under oxygen-limited conditions sufficient to convert more than about 0.002% of the carbon (mol/mol) in a cell culture medium into isoprene and to produce hydrogen equivalent to more than about 0.024 molar percent of the carbon in a cell culture medium. In some embodiments, the oxygen-limited culture is anaerobic. In some embodiments, the method also includes recovering isoprene and hydrogen produced by the cells. In some embodiments, the method further includes purifying isoprene and hydrogen produced by the cells. In some embodiments, the method includes polymerizing the isoprene. In some embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter. In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, polypeptide (*e.g.*, a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing.

**[0530]** In some embodiments of any of the aspects described herein, the microbial polypeptide carbon source includes one or more polypeptides from yeast or bacteria. In some embodiments of any of the aspects described herein, the plant polypeptide carbon source includes one or more polypeptides from soy, corn, canola, jatropha, palm, peanut, sunflower, coconut, mustard, rapeseed, cottonseed, palm kernel, olive, safflower, sesame, or linseed.

**[0531]** In some embodiments, isoprene and hydrogen are only co-produced in stationary phase. In some embodiments, isoprene and hydrogen are co-produced in both the growth phase and stationary phase. In various embodiments, the amount of isoprene produced (such as the total amount of isoprene produced or the amount of isoprene produced per liter of broth per hour per OD<sub>600</sub>) during stationary phase is greater than or about 2, 3, 4, 5, 10, 20, 30, 40, 50, or more times the amount of isoprene produced during the growth phase for the same length of time. In

various embodiments, the amount of hydrogen produced (such as the total amount of hydrogen produced or the amount of hydrogen produced per liter of broth per hour per OD<sub>600</sub>) during stationary phase is greater than or about 2, 3, 4, 5, 10, 20, 30, 40, 50, or more times the amount of hydrogen produced during the growth phase for the same length of time.

**[0532]** In some embodiments, the compositions provided herein comprise hydrogen and greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition. In some embodiments, the composition comprises less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% C5 hydrocarbons other than isoprene (such as 1,3-cyclopentadiene, cis-1,3-pentadiene, trans-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, trans-pent-3-ene-1-yne, or cis-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the composition. In some embodiments, the composition has less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% for 1,3-cyclopentadiene, cis-1,3-pentadiene, trans-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, trans-pent-3-ene-1-yne, or cis-pent-3-ene-1-yne by weight compared to the total weight of all C5 hydrocarbons in the composition. In particular embodiments, the composition has greater than about 2 mg of isoprene and has greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition. In some embodiments, the composition has less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 µg/L of a compound that inhibits the polymerization of isoprene for any compound in the composition that inhibits the polymerization of isoprene. In particular embodiments, the composition also comprises greater than about 2 mg of isoprene and greater than about 0.48 mg of hydrogen.

**[0533]** In some embodiments, the volatile organic fraction of the gas phase has less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 µg/L of a compound that inhibits the polymerization of isoprene for any compound in the volatile organic fraction of the gas phase that inhibits the polymerization of isoprene. In particular embodiments, the volatile organic fraction of the gas phase also has greater than about 2 mg of isoprene and greater than about 0.48 mg of hydrogen.

**[0534]** In some embodiments, the systems include any of the cells and/or compositions described herein. In some embodiments, the system includes a reactor that chamber comprises

cells in oxygen-limited culture that produce greater than about 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, or more nmole/g<sub>wcm</sub>/hr isoprene and greater than about 125, 250, 500, 750, 1000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 7,500, 10,000, or more nmole/g<sub>wcm</sub>/hr hydrogen. In some embodiments, the system is not a closed system. In some embodiments, at least a portion of the isoprene is removed from the system. In some embodiments, the system includes a gas phase comprising isoprene and hydrogen. In various embodiments, the gas phase comprises any of the compositions described herein.

**[0535]** In one aspect, featured herein is a product produced by any of the compositions or methods described herein.

#### *Cell Viability at High Isoprene Titer*

**[0536]** Isoprene is a hydrophobic molecule secreted by many plants, animals, and microbes. Bacteria, such as Bacillus, produce isoprene at fairly low levels. While there is some evidence that plants secrete isoprene to help with thermoprotection, it has been hypothesized that isoprene may act antagonistically to cyanobacteria or fungi, or as an antimicrobial agent. *See, e.g.,* Ladygina et al., *Process Biochemistry* 41:1001-1014 (2006), which is incorporated by reference in its entirety, particularly with respect to isoprene acting antagonistically. Since the very low production levels happening in nature are sufficient to be anti-microbial, it was of great concern that the titers and productivity levels of isoprene necessary for commercialization of isoprene would kill the host microbe.

**[0537]** We have found methods for producing titers and productivity levels of isoprene for commercialization of isoprene while maintaining cell viability and/or metabolic activity as indicated by carbon dioxide evolution rate or total carbon dioxide evolution rate.

**[0538]** Provided herein are methods of producing isoprene comprising: a) culturing cells under suitable conditions for production of isoprene; and b) producing isoprene, wherein cells produce greater than about 400 nmole/g<sub>wcm</sub>/hour of isoprene, and the carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. In some embodiments, the isoprene produced is any concentration or amount disclosed in the section entitled "Exemplary Production of Isoprene." In some embodiments, the amount of isoprene is between about any of 400 nmole/g<sub>wcm</sub>/hour to 1 mole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 1 mmole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 40 mmole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 4 mmole/g<sub>wcm</sub>/hour, 1 mmole/g<sub>wcm</sub>/hour to 1.5 mmole/g<sub>wcm</sub>/hour, 1.5 mmole/g<sub>wcm</sub>/hour to 3 mmole/g<sub>wcm</sub>/hour, 3

mmole/g<sub>wcm</sub>/hour to 5 mmole/g<sub>wcm</sub>/hour, 5 mmole/g<sub>wcm</sub>/hour to 25 mmole/g<sub>wcm</sub>/hour, 25 mmole/g<sub>wcm</sub>/hour to 100 mmole/g<sub>wcm</sub>/hour, 100 mmole/g<sub>wcm</sub>/hour to 500 mmole/g<sub>wcm</sub>/hour, or 500 mmole/g<sub>wcm</sub>/hour to 1000 mmole/g<sub>wcm</sub>/hour. In some embodiments, the amount of isoprene is about any of 1 mmole/g<sub>wcm</sub>/hour, 1.5 mmole/g<sub>wcm</sub>/hour, 2 mmole/g<sub>wcm</sub>/hour, 3 mmole/g<sub>wcm</sub>/hour, 4 mmole/g<sub>wcm</sub>/hour, or 5 mmole/g<sub>wcm</sub>/hour. In some embodiments, the carbon dioxide evolution rate is between about any of  $1 \times 10^{-18}$  mmol/L/hour to about 1 mol/L/hour, 1 mmol/L/hour to 1 mol/L/hour, 25 mmol/L/hour to 750 mmol/L/hour, 25 mmol/L/hour to 75 mmol/L/hour, 250 mmol/L/hour to 750 mmol/L/hour, or 450 mmol/L/hour to 550 mmol/L/hour. In some embodiments, the carbon dioxide evolution rate is about any of 50 mmol/L/hour, 100 mmol/L/hour, 150 mmol/L/hour, 200 mmol/L/hour, 250 mmol/L/hour, 300 mmol/L/hour, 350 mmol/L/hour, 400 mmol/L/hour, 450 mmol/L/hour, or 500 mmol/L/hour.

**[0539]** Provided herein are also methods of producing isoprene comprising: a) culturing cells under suitable conditions for production of isoprene; and b) producing isoprene, wherein cells produce greater than about 400 nmole/g<sub>wcm</sub>/hour of isoprene, and cell viability is reduced by less than about two-fold. In some embodiments, the isoprene produced is any concentration or amount disclosed in the section entitled "Exemplary Production of Isoprene." In some embodiments, the amount of isoprene is between about any of 400 nmole/g<sub>wcm</sub>/hour to 1 mole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 1 mmole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 40 mmole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 4 mmole/g<sub>wcm</sub>/hour, 1 mmole/g<sub>wcm</sub>/hour to 1.5 mmole/g<sub>wcm</sub>/hour, 1.5 mmole/g<sub>wcm</sub>/hour to 3 mmole/g<sub>wcm</sub>/hour, 3 mmole/g<sub>wcm</sub>/hour to 5 mmole/g<sub>wcm</sub>/hour, 5 mmole/g<sub>wcm</sub>/hour to 25 mmole/g<sub>wcm</sub>/hour, 25 mmole/g<sub>wcm</sub>/hour to 100 mmole/g<sub>wcm</sub>/hour, 100 mmole/g<sub>wcm</sub>/hour to 500 mmole/g<sub>wcm</sub>/hour, or 500 mmole/g<sub>wcm</sub>/hour to 1000 mmole/g<sub>wcm</sub>/hour. In some embodiments, the amount of isoprene is about any of 1 mmole/g<sub>wcm</sub>/hour, 1.5 mmole/g<sub>wcm</sub>/hour, 2 mmole/g<sub>wcm</sub>/hour, 3 mmole/g<sub>wcm</sub>/hour, 4 mmole/g<sub>wcm</sub>/hour, or 5 mmole/g<sub>wcm</sub>/hour. In some embodiments, cell viability is reduced by less than about any of 1.75-fold, 1.5-fold, 1.25-fold, 1-fold, 0.75-fold, 0.5-fold, or 0.25-fold. In some embodiments, cell viability is reduced by about 2-fold.

**[0540]** Further provided herein are methods of producing isoprene comprising: a) culturing cells under suitable conditions for production of isoprene; and b) producing isoprene, wherein the cumulative total productivity of the isoprene produced by the cells in culture is greater than about 0.2 mg/L<sub>broth</sub>/hour and the carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. In some embodiments, the cumulative total productivity of isoprene is any concentration or amount disclosed in the section entitled "Exemplary Production of Isoprene." In

some embodiments, the cumulative total productivity of the isoprene is between about any of 0.2 mg/L<sub>broth</sub>/hour to 5 g/L<sub>broth</sub>/hour, 0.2 mg/L<sub>broth</sub>/hour to 1 g/L<sub>broth</sub>/hour, 1 g/L<sub>broth</sub>/hour to 2.5 g/L<sub>broth</sub>/hour, 2.5 g/L<sub>broth</sub>/hour to 5 g/L<sub>broth</sub>/hour. In some embodiments, the carbon dioxide evolution rate is between about any of  $1 \times 10^{-18}$  mmol/L/hour to about 1 mol/L/hour, 1 mmol/L/hour to 1 mol/L/hour, 25 mmol/L/hour to 750 mmol/L/hour, 25 mmol/L/hour to 75 mmol/L/hour, 250 mmol/L/hour to 750 mmol/L/hour, or 450 mmol/L/hour to 550 mmol/L/hour. In some embodiments, the carbon dioxide evolution rate is about any of 50 mmol/L/hour, 100 mmol/L/hour, 150 mmol/L/hour, 200 mmol/L/hour, 250 mmol/L/hour, 300 mmol/L/hour, 350 mmol/L/hour, 400 mmol/L/hour, 450 mmol/L/hour, or 500 mmol/L/hour.

**[0541]** Provided herein are methods of producing isoprene comprising: a) culturing cells under suitable conditions for production of isoprene; and b) producing isoprene, wherein the cumulative total productivity of the isoprene produced by the cells in culture is greater than about 0.2 mg/L<sub>broth</sub>/hour and cell viability is reduced by less than about two-fold. In some embodiments, the cumulative total productivity of isoprene is any concentration or amount disclosed in the section entitled "Exemplary Production of Isoprene." In some embodiments, the cumulative total productivity of the isoprene is between about any of 0.2 mg/L<sub>broth</sub>/hour to 5 g/L<sub>broth</sub>/hour, 0.2 mg/L<sub>broth</sub>/hour to 1 g/L<sub>broth</sub>/hour, 1 g/L<sub>broth</sub>/hour to 2.5 g/L<sub>broth</sub>/hour, 2.5 g/L<sub>broth</sub>/hour to 5 g/L<sub>broth</sub>/hour. In some embodiments, cell viability is reduced by less than about any of 1.75-fold, 1.5-fold, 1.25-fold, 1-fold, 0.75-fold, 0.5-fold, or 0.25-fold.

**[0542]** Methods of producing isoprene are also provided herein comprising: a) culturing cells under suitable conditions for production of isoprene; and b) producing isoprene, wherein the peak concentration of the isoprene produced by the cells in culture is greater than about 10 ng/L<sub>broth</sub> and the carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. In some embodiments, the peak concentration of isoprene is any concentration or amount disclosed in the section entitled "Exemplary Production of Isoprene." In some embodiments, the peak concentration of isoprene is between about any of 10 ng/L<sub>broth</sub> to 500 ng/L<sub>broth</sub>, 500 ng/L<sub>broth</sub> to 1 µg/L<sub>broth</sub>, 1 µg/L<sub>broth</sub> to 5 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 50 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 100 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 250 µg/L<sub>broth</sub>, 250 µg/L<sub>broth</sub> to 500 µg/L<sub>broth</sub>, 500 µg/L<sub>broth</sub> to 1 mg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub> to 50 mg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub> to 100 mg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub> to 200 mg/L<sub>broth</sub>, 10 ng/L<sub>broth</sub> to 200 mg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 100 mg/L<sub>broth</sub>, or 5 µg/L<sub>broth</sub> to 200 mg/L<sub>broth</sub>. In some embodiments, the peak concentration is any of about 10 ng/L<sub>broth</sub>, 100 ng/L<sub>broth</sub>, 1 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub>, 30 mg/L<sub>broth</sub>, 100 mg/L<sub>broth</sub>, or 200 mg/L<sub>broth</sub>. In some embodiments, the carbon dioxide evolution rate is between about any of  $1 \times 10^{-18}$  mmol/L/hour

to about 1 mol/L/hour, 1 mmol/L/hour to 1 mol/L/hour, 25 mmol/L/hour to 750 mmol/L/hour, 25 mmol/L/hour to 75 mmol/L/hour, 250 mmol/L/hour to 750 mmol/L/hour, or 450 mmol/L/hour to 550 mmol/L/hour. In some embodiments, the carbon dioxide evolution rate is about any of 50 mmol/L/hour, 100 mmol/L/hour, 150 mmol/L/hour, 200 mmol/L/hour, 250 mmol/L/hour, 300 mmol/L/hour, 350 mmol/L/hour, 400 mmol/L/hour, 450 mmol/L/hour, or 500 mmol/L/hour.

**[0543]** In addition, methods of producing isoprene are also provided herein comprising: a) culturing cells under suitable conditions for production of isoprene; and b) producing isoprene, wherein the peak concentration of the isoprene produced by the cells in culture is greater than about 10 ng/L<sub>broth</sub> and cell viability is reduced by less than about two-fold. In some embodiments, the peak concentration of isoprene is any concentration or amount disclosed in the section entitled "Exemplary Production of Isoprene." In some embodiments, the peak concentration of isoprene is between about any of 10 ng/L<sub>broth</sub> to 500 ng/L<sub>broth</sub>, 500 ng/L<sub>broth</sub> to 1 µg/L<sub>broth</sub>, 1 µg/L<sub>broth</sub> to 5 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 50 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 100 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 250 µg/L<sub>broth</sub>, 250 µg/L<sub>broth</sub> to 500 µg/L<sub>broth</sub>, 500 µg/L<sub>broth</sub> to 1 mg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub> to 50 mg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub> to 100 mg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub> to 200 mg/L<sub>broth</sub>, 10 ng/L<sub>broth</sub> to 200 mg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 100 mg/L<sub>broth</sub>, or 5 µg/L<sub>broth</sub> to 200 mg/L<sub>broth</sub>. In some embodiments, the peak concentration is any of about 10 ng/L<sub>broth</sub>, 100 ng/L<sub>broth</sub>, 1 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub>, 30 mg/L<sub>broth</sub>, 100 mg/L<sub>broth</sub>, or 200 mg/L<sub>broth</sub>. In some embodiments, cell viability is reduced by less than about any of 1.75-fold, 1.5-fold, 1.25-fold, 1-fold, 0.75-fold, 0.5-fold, or 0.25-fold. In some embodiments, cell viability is reduced by about 2-fold.

**[0544]** Cells in culture are also provided herein comprising a nucleic acid encoding an isoprene synthase polypeptide, wherein the cells produce greater than about 400 nmole/g<sub>wcm</sub>/hour of isoprene and carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. In some embodiments, the isoprene produced is any concentration or amount disclosed in the section entitled "Exemplary Production of Isoprene." In some embodiments, the amount of isoprene is between about any of 400 nmole/g<sub>wcm</sub>/hour to 1 mole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 1 mmole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 40 mmole/g<sub>wcm</sub>/hour, 400 nmole/g<sub>wcm</sub>/hour to 4 mmole/g<sub>wcm</sub>/hour, 1 mmole/g<sub>wcm</sub>/hour to 1.5 mmole/g<sub>wcm</sub>/hour, 1.5 mmole/g<sub>wcm</sub>/hour to 3 mmole/g<sub>wcm</sub>/hour, 3 mmole/g<sub>wcm</sub>/hour to 5 mmole/g<sub>wcm</sub>/hour, 5 mmole/g<sub>wcm</sub>/hour to 25 mmole/g<sub>wcm</sub>/hour, 25 mmole/g<sub>wcm</sub>/hour to 100 mmole/g<sub>wcm</sub>/hour, 100 mmole/g<sub>wcm</sub>/hour to 500 mmole/g<sub>wcm</sub>/hour, or 500 mmole/g<sub>wcm</sub>/hour to 1000 mmole/g<sub>wcm</sub>/hour. In some embodiments, the amount of isoprene is about any of 1

mmole/g<sub>wcm</sub>/hour, 1.5 mmole/g<sub>wcm</sub>/hour, 2 mmole/g<sub>wcm</sub>/hour, 3 mmole/g<sub>wcm</sub>/hour, 4 mmole/g<sub>wcm</sub>/hour, or 5 mmole/g<sub>wcm</sub>/hour. In some embodiments, the carbon dioxide evolution rate is between about any of  $1 \times 10^{-18}$  mmol/L/hour to about 1 mol/L/hour, 1 mmol/L/hour to 1 mol/L/hour, 25 mmol/L/hour to 750 mmol/L/hour, 25 mmol/L/hour to 75 mmol/L/hour, 250 mmol/L/hour to 750 mmol/L/hour, or 450 mmol/L/hour to 550 mmol/L/hour. In some embodiments, the carbon dioxide evolution rate is about any of 50 mmol/L/hour, 100 mmol/L/hour, 150 mmol/L/hour, 200 mmol/L/hour, 250 mmol/L/hour, 300 mmol/L/hour, 350 mmol/L/hour, 400 mmol/L/hour, 450 mmol/L/hour, or 500 mmol/L/hour.

**[0545]** Provided herein are also cells in culture comprising a nucleic acid encoding an isoprene synthase polypeptide, wherein cumulative total productivity of the isoprene produced by the cells in culture is greater than about 0.2 mg/L<sub>broth</sub>/hour and carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. In some embodiments, the cumulative total productivity of isoprene is any concentration or amount disclosed in the section entitled "Exemplary Production of Isoprene." In some embodiments, the cumulative total productivity of the isoprene is between about any of 0.2 mg/L<sub>broth</sub>/hour to 5 g/L<sub>broth</sub>/hour, 0.2 mg/L<sub>broth</sub>/hour to 1 g/L<sub>broth</sub>/hour, 1 g/L<sub>broth</sub>/hour to 2.5 g/L<sub>broth</sub>/hour, 2.5 g/L<sub>broth</sub>/hour to 5 g/L<sub>broth</sub>/hour. In some embodiments, the carbon dioxide evolution rate is between about any of  $1 \times 10^{-18}$  mmol/L/hour to about 1 mol/L/hour, 1 mmol/L/hour to 1 mol/L/hour, 25 mmol/L/hour to 750 mmol/L/hour, 25 mmol/L/hour to 75 mmol/L/hour, 250 mmol/L/hour to 750 mmol/L/hour, or 450 mmol/L/hour to 550 mmol/L/hour. In some embodiments, the carbon dioxide evolution rate is about any of 50 mmol/L/hour, 100 mmol/L/hour, 150 mmol/L/hour, 200 mmol/L/hour, 250 mmol/L/hour, 300 mmol/L/hour, 350 mmol/L/hour, 400 mmol/L/hour, 450 mmol/L/hour, or 500 mmol/L/hour.

**[0546]** In addition, provided herein are cells in culture comprising a nucleic acid encoding an isoprene synthase polypeptide, wherein peak concentration of the isoprene produced by the cells in culture is greater than about 10 ng/L<sub>broth</sub> and carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. In some embodiments, the peak concentration of isoprene is any concentration or amount disclosed in the section entitled "Exemplary Production of Isoprene." In some embodiments, the peak concentration of isoprene is between about any of 10 ng/L<sub>broth</sub> to 500 ng/L<sub>broth</sub>, 500 ng/L<sub>broth</sub> to 1 µg/L<sub>broth</sub>, 1 µg/L<sub>broth</sub> to 5 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 50 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 100 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 250 µg/L<sub>broth</sub>, 250 µg/L<sub>broth</sub> to 500 µg/L<sub>broth</sub>, 500 µg/L<sub>broth</sub> to 1 mg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub> to 50 mg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub> to 100 mg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub> to 200 mg/L<sub>broth</sub>, 10 ng/L<sub>broth</sub> to 200 mg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub> to 100 mg/L<sub>broth</sub>, or 5 µg/L<sub>broth</sub> to 200

mg/L<sub>broth</sub>. In some embodiments, the peak concentration is any of about 10 ng/L<sub>broth</sub>, 100 ng/L<sub>broth</sub>, 1 µg/L<sub>broth</sub>, 5 µg/L<sub>broth</sub>, 1 mg/L<sub>broth</sub>, 30 mg/L<sub>broth</sub>, 100 mg/L<sub>broth</sub>, or 200 mg/L<sub>broth</sub>. In some embodiments, the carbon dioxide evolution rate is between about any of  $1 \times 10^{-18}$  mmol/L/hour to about 1 mol/L/hour, 1 mmol/L/hour to 1 mol/L/hour, 25 mmol/L/hour to 750 mmol/L/hour, 25 mmol/L/hour to 75 mmol/L/hour, 250 mmol/L/hour to 750 mmol/L/hour, or 450 mmol/L/hour to 550 mmol/L/hour. In some embodiments, the carbon dioxide evolution rate is about any of 50 mmol/L/hour, 100 mmol/L/hour, 150 mmol/L/hour, 200 mmol/L/hour, 250 mmol/L/hour, 300 mmol/L/hour, 350 mmol/L/hour, 400 mmol/L/hour, 450 mmol/L/hour, or 500 mmol/L/hour.

**[0547]** In some embodiments of any of the methods and cells described herein, carbon dioxide evolution rate and/or cell viability of a cell expressing a MVA pathway and/or DXP pathway RNA and/or protein from one or more of a heterologous and/or duplicate copy of a MVA pathway and/or DXP pathway nucleic acid is compared to a control cell lacking one or more of a heterologous and/or duplicate copy of a MVA pathway and/or DXP pathway nucleic acid. In some embodiments, carbon dioxide evolution rate and/or cell viability of a cell expressing a MVA pathway and/or DXP pathway RNA and/or protein from one or more of a heterologous and/or duplicate copy of a MVA pathway and/or DXP pathway nucleic acid under the control of an inducible promoter, wherein the promoter is induced, is compared to a control cell containing one or more of a heterologous and/or duplicate copy of a MVA pathway and/or DXP pathway nucleic acid under the control of an inducible promoter, wherein the promoter is not induced (uninduced). In some embodiments, the inducible promoter is a beta-galactosidase promoter.

**[0548]** In some embodiments, the methods of producing isoprene comprise: a) culturing cells under suitable conditions for production of isoprene; and b) producing isoprene, wherein cells produce greater than about 400 nmole/g<sub>wcm</sub>/hour of isoprene, and the carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. Further provided herein are methods of producing isoprene comprising: a) culturing cells under suitable conditions for production of isoprene; and b) producing isoprene, wherein the cumulative total productivity of the isoprene produced by the cells in culture is greater than about 0.2 mg/L<sub>broth</sub>/hour and the carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. Methods of producing isoprene are also provided herein comprising: a) culturing cells under suitable conditions for production of isoprene; and b) producing isoprene, wherein the peak concentration of the isoprene produced by the cells in culture is greater than about 10 ng/L<sub>broth</sub> and the carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. In some embodiments of

any of these methods, the carbon dioxide evolution rate is between about any of  $1 \times 10^{-18}$  mmol/L/hour to about 1 mol/L/hour, 1 mmol/L/hour to 1 mol/L/hour, 25 mmol/L/hour to 750 mmol/L/hour, 25 mmol/L/hour to 75 mmol/L/hour, 250 mmol/L/hour to 750 mmol/L/hour, or 450 mmol/L/hour to 550 mmol/L/hour. In some embodiments, the carbon dioxide evolution rate is about 50 mmol/L/hour or about 500 mmol/L/hour.

**[0549]** Further provided herein are cells in culture comprising a nucleic acid encoding an isoprene synthase polypeptide, wherein the cells produce greater than about 400 nmole/g<sub>wcm</sub>/hour of isoprene and carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. Provided herein are also cells in culture comprising a nucleic acid encoding an isoprene synthase polypeptide, wherein cumulative total productivity of the isoprene produced by the cells in culture is greater than about 0.2 mg/L<sub>broth</sub>/hour and carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. In addition, provided herein are cells in culture comprising a nucleic acid encoding an isoprene synthase polypeptide, wherein peak concentration of the isoprene produced by the cells in culture is greater than about 10 ng/L<sub>broth</sub> and carbon dioxide evolution rate of the cells is greater than about  $1 \times 10^{-18}$  mmol/L/hour. In some embodiments of any of these cells in culture, the carbon dioxide evolution rate is between about any of  $1 \times 10^{-18}$  mmol/L/hour to about 1 mol/L/hour, 1 mmol/L/hour to 1 mol/L/hour, 25 mmol/L/hour to 750 mmol/L/hour, 25 mmol/L/hour to 75 mmol/L/hour, 250 mmol/L/hour to 750 mmol/L/hour, or 450 mmol/L/hour to 550 mmol/L/hour. In some embodiments, the carbon dioxide evolution rate is about 50 mmol/L/hour or about 500 mmol/L/hour.

**[0550]** Provided herein are also methods of producing isoprene comprising a) culturing cells under suitable conditions for production of isoprene; and b) producing isoprene, wherein the liquid phase concentration of isoprene is less than about 200 mg/L and the cells produce greater than about 400 nmole/g<sub>wcm</sub>/hour of isoprene. In some embodiments, the liquid phase concentration of isoprene in the culture is less than about any of 175 mg/L, 150 mg/L, 125 mg/L, 100 mg/L, 75 mg/L, 50 mg/L, 25 mg/L, 20 mg/L, 15 mg/L, 10 mg/L, 5 mg/L, or 2.5 mg/L. In some embodiments, the liquid phase concentration of isoprene in culture is between about any of 0.1 mg/L to 200 mg/L, 1 mg/L to 200 mg/L, 1 mg/L to 150 mg/L, 1 mg/L to 100 mg/L, 1 mg/L to 50 mg/L, 1 mg/L to 25 mg/L, 1 mg/L to 20 mg/L, or 10 mg/L to 20 mg/L.

**[0551]** Also provided herein are methods of producing a compound, wherein the compound has one or more characteristics selected from the group consisting of (a) a Henry's law coefficient of less than about 250 M/atm and (b) a solubility in water of less than about 100 g/L.

In some embodiments, the method comprises: a) culturing cells under suitable conditions for production of the compound, wherein gas is added (such as the addition of gas to a system such as a fermentation system) at a gas sparging rate between about 0.01 vvm to about 2 vvm; and b) producing the compound. In some embodiments, the Henry's law coefficient of the compound is less than about any of 200 M/atm, 150 M/atm, 100 M/atm, 75 M/atm, 50 M/atm, 25 M/atm, 10 M/atm, 5 M/atm, or 1 M/atm. In some embodiments, the solubility in water of the compound is less than about any of 75 g/L, 50 g/L, 25 g/L, 10 g/L, 5 g/L, or 1 g/L. In some embodiments, the compound is selected from a group consisting of isoprene, an aldehyde (*e.g.*, acetaldehyde), a ketone (*e.g.*, acetone or 2-butanone), an alcohol (*e.g.*, methanol, ethanol, 1-butanol, or C5 alcohols such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-1-ol), an ester of an alcohol (*e.g.*, ethyl acetate or acetyl esters of C5 alcohols), a hemiterpene, a monoterpene, a sesquiterpene, and C1 to C5 hydrocarbons (*e.g.*, methane, ethane, ethylene, or propylene). In some embodiments, the C1 to C5 hydrocarbons are saturated, unsaturated, or branched. In particular embodiments, the compound is isoprene. In some embodiments of the methods of producing any of the compounds described above, the gas sparging rate is between about any of 0.1 vvm to 1 vvm, 0.2 vvm to 1 vvm, or 0.5 vvm to 1 vvm.

**[0552]** In one aspect, cells in culture are used to produce isoprene. In some embodiments, the cells in culture produce greater than about 400 nmole of isoprene/gram of cells for the wet weight of the cells/hour (nmole/g<sub>wcm</sub>/hr) of isoprene. In some embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter. In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, polypeptide (*e.g.*, a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing. In some embodiments, the cells are cultured under limited glucose conditions.

**[0553]** In some embodiments, the cells in culture convert more than about 0.002% of the carbon in a cell culture medium into isoprene. In some embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter. In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid,

glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, polypeptide (e.g., a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing. In some embodiments, the cells are cultured under limited glucose conditions.

**[0554]** In some embodiments, the cells in culture comprise a heterologous nucleic acid encoding an isoprene synthase polypeptide. In some embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter. In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, polypeptide (e.g., a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing. In some embodiments, the cells are cultured under limited glucose conditions.

**[0555]** In one aspect, described herein are methods of producing isoprene, such as methods of using any of the cells described herein to produce isoprene. In some embodiments, the method involves culturing cells under conditions sufficient to produce greater than about 400 nmole/g<sub>wcm</sub>/hr of isoprene. In some embodiments, the method also includes recovering isoprene produced by the cells. In some embodiments, the method includes purifying isoprene produced by the cells. In some embodiments, the method includes polymerizing the isoprene. In some embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter. In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, polypeptide (e.g., a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing. In some embodiments, the cells are cultured under limited glucose conditions. In various embodiments, the amount of isoprene produced (such as the total amount of isoprene produced or the amount of isoprene produced per liter of broth per hour per OD<sub>600</sub>) during stationary phase is greater than or about 2 or more times the amount of isoprene produced during the growth phase for the same length of time. In some embodiments, the gas phase comprises greater than or about 9.5 % (volume) oxygen, and the concentration of isoprene in the gas phase is less than the

lower flammability limit or greater than the upper flammability limit. In particular embodiments, (i) the concentration of isoprene in the gas phase is less than the lower flammability limit or greater than the upper flammability limit, and (ii) the cells produce greater than about 400 nmole/g<sub>wcm</sub>/hr of isoprene.

**[0556]** In some embodiments, the method includes culturing cells under conditions sufficient to convert more than about 0.002% of the carbon (mol/mol) in a cell culture medium into isoprene. In some embodiments, the method also includes recovering isoprene produced by the cells. In some embodiments, the method includes purifying isoprene produced by the cells. In some embodiments, the method includes polymerizing the isoprene. In some embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter. In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, polypeptide (*e.g.*, a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing. In some embodiments, the cells are cultured under limited glucose conditions.

**[0557]** In some embodiments, isoprene is only produced in stationary phase. In some embodiments, isoprene is produced in both the growth phase and stationary phase. In various embodiments, the amount of isoprene produced (such as the total amount of isoprene produced or the amount of isoprene produced per liter of broth per hour per OD<sub>600</sub>) during stationary phase is greater than or about 2, 3, 4, 5, 10, 20, 30, 40, 50, or more times the amount of isoprene produced during the growth phase for the same length of time.

**[0558]** In one aspect, described herein are compositions and systems that comprise isoprene. In some embodiments, the composition comprises greater than or about 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mg of isoprene. In some embodiments, the composition comprises greater than or about 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 g of isoprene(w/w) of the volatile organic fraction of the composition is isoprene.

**[0559]** In some embodiments, the composition comprises greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition. In some embodiments, the composition comprises less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% C5 hydrocarbons other than isoprene (such as 1,3-cyclopentadiene, cis-1,3-

pentadiene, trans-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, trans-pent-3-ene-1-yne, or cis-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the composition. In some embodiments, the composition has less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% for 1,3-cyclopentadiene, cis-1,3-pentadiene, trans-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, trans-pent-3-ene-1-yne, or cis-pent-3-ene-1-yne by weight compared to the total weight of all C5 hydrocarbons in the composition. In particular embodiments, the composition has greater than about 2 mg of isoprene and has greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition.

**[0560]** In some embodiments, the composition has less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005  $\mu\text{g/L}$  of a compound that inhibits the polymerization of isoprene for any compound in the composition that inhibits the polymerization of isoprene. In particular embodiments, the composition also has greater than about 2 mg of isoprene.

**[0561]** In some embodiments, the composition has one or more compounds selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms. In some embodiments, the composition has greater than or about 0.005, 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 60, 80, 100, or 120  $\mu\text{g/L}$  of ethanol, acetone, a C5 prenyl alcohol (such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-1-ol), or any two or more of the foregoing. In particular embodiments, the composition has greater than about 2 mg of isoprene and has one or more compounds selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms.

**[0562]** In some embodiments, the composition includes isoprene and one or more second compounds selected from the group consisting of 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, acetaldehyde, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene, and 2,3-cycloheptenolpyridine. In various embodiments, the amount of one of these second components relative to the amount of

isoprene in units of percentage by weight (*i.e.*, weight of the component divided by the weight of isoprene times 100) is at greater than or about 0.01, 0.02, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 110% (w/w).

**[0563]** In some embodiments, the composition comprises (i) a gas phase that comprises isoprene and (ii) cells in culture that produce greater than about 400 nmolc/g<sub>wcm</sub>/hr of isoprene. In some embodiments, the composition comprises a closed system, and the gas phase comprises greater than or about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 µg/L of isoprene when normalized to 1 mL of 1 OD<sub>600</sub> cultured for 1 hour. In some embodiments, the composition comprises an open system, and the gas phase comprises greater than or about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 µg/L of isoprene when sparged at a rate of 1 vvm. In some embodiments, the volatile organic fraction of the gas phase comprises greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the volatile organic fraction. In some embodiments, the volatile organic fraction of the gas phase comprises less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% C5 hydrocarbons other than isoprene (such as 1,3-cyclopentadiene, cis-1,3-pentadiene, trans-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, trans-pent-3-ene-1-yne, or cis-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the volatile organic fraction. In some embodiments, the volatile organic fraction of the gas phase has less than or about 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% for 1,3-cyclopentadiene, cis-1,3-pentadiene, trans-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, trans-pent-3-ene-1-yne, or cis-pent-3-ene-1-yne by weight compared to the total weight of all C5 hydrocarbons in the volatile organic fraction. In particular embodiments, the volatile organic fraction of the gas phase has greater than about 2 mg of isoprene and has greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the volatile organic fraction.

**[0564]** In some embodiments, the volatile organic fraction of the gas phase has less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005 µg/L of a compound that inhibits the polymerization of isoprene for any compound in the volatile organic fraction of the gas phase that inhibits the polymerization of isoprene. In particular embodiments, the volatile organic fraction of the gas phase also has greater than about 2 mg of isoprene.

**[0565]** In some embodiments, the volatile organic fraction of the gas phase has one or more compounds selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms. In some embodiments, the volatile organic fraction of the gas phase has greater than or about 0.005, 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 60, 80, 100, or 120 µg/L of ethanol, acetone, a C5 prenyl alcohol (such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-1-ol), or any two or more of the foregoing. In particular embodiments, the volatile organic fraction of the gas phase has greater than about 2 mg of isoprene and has one or more compounds selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms.

**[0566]** In some embodiments, the volatile organic fraction of the gas phase includes isoprene and one or more second compounds selected from the group consisting of 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, acetaldehyde, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene, and 2,3-cycloheptenolpyridine. In various embodiments, the amount of one of these second components relative to amount of isoprene in units of percentage by weight (*i.e.*, weight of the component divided by the weight of isoprene times 100) is at greater than or about 0.01, 0.02, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 110% (w/w) in the volatile organic fraction of the gas phase.

**[0567]** In some embodiments of any of the compositions described herein, at least a portion of the isoprene is in a gas phase. In some embodiments, at least a portion of the isoprene is in a liquid phase (such as a condensate). In some embodiments, at least a portion of the isoprene is in a solid phase. In some embodiments, at least a portion of the isoprene is adsorbed to a solid support, such as a support that includes silica and/or activated carbon. In some embodiments, the composition includes ethanol. In some embodiments, the composition includes between about 75 to about 90% by weight of ethanol, such as between about 75 to about 80%, about 80 to about 85%, or about 85 to about 90% by weight of ethanol. In some embodiments, the composition includes between about 4 to about 15% by weight of isoprene, such as between about 4 to about 8%, about 8 to about 12%, or about 12 to about 15% by weight of isoprene.

**[0568]** In some embodiments, the systems include any of the cells and/or compositions described herein. In some embodiments, the system includes a reactor that chamber comprises cells in culture that produce greater than about 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, or more nmole/g<sub>wcm</sub>/hr isoprene. In some embodiments, the system is not a closed system. In some embodiments, at least a portion of the isoprene is removed from the system. In some embodiments, the system includes a gas phase comprising isoprene. In various embodiments, the gas phase comprises any of the compositions described herein.

**[0569]** In some embodiments of any of the compositions, systems, and methods described herein, a nonflammable concentration of isoprene in the gas phase is produced. In some embodiments, the gas phase comprises less than about 9.5 % (volume) oxygen. In some embodiments, the gas phase comprises greater than or about 9.5 % (volume) oxygen, and the concentration of isoprene in the gas phase is less than the lower flammability limit or greater than the upper flammability limit. In some embodiments, the portion of the gas phase other than isoprene comprises between about 0% to about 100% (volume) oxygen, such as between about 10% to about 100% (volume) oxygen. In some embodiments, the portion of the gas phase other than isoprene comprises between about 0% to about 99% (volume) nitrogen. In some embodiments, the portion of the gas phase other than isoprene comprises between about 1% to about 50% (volume) CO<sub>2</sub>.

**[0570]** In some embodiments of any of the aspects described herein, the cells in culture produce isoprene at greater than or about 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, or more nmole/g<sub>wcm</sub>/hr isoprene. In some embodiments of any of the aspects described herein, the cells in culture convert greater than or about 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.12, 0.14, 0.16, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6%, or more of the carbon in the cell culture medium into isoprene. In some embodiments of any of the aspects described herein, the cells in culture produce isoprene at greater than or about 1, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 10,000, 100,000, or more ng of isoprene/gram of cells for the wet weight of the cells/hr (ng/g<sub>wcm</sub>/h). In some embodiments of any of the aspects described herein, the cells in culture produce a cumulative titer (total amount) of isoprene at greater than or about 1, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 10,000, 50,000, 100,000, or more mg of isoprene/L of broth (mg/L<sub>broth</sub>, wherein the volume of broth includes the volume of the cells and the cell

medium). Other exemplary rates of isoprene production and total amounts of isoprene production are disclosed herein.

**[0571]** In some embodiments of any of the aspects described herein, the cells further comprise a heterologous nucleic acid encoding an IDI polypeptide. In some embodiments of any of the aspects described herein, the cells further comprise an insertion of a copy of an endogenous nucleic acid encoding an IDI polypeptide. In some embodiments of any of the aspects described herein, the cells further comprise a heterologous nucleic acid encoding a DXS polypeptide. In some embodiments of any of the aspects described herein, the cells further comprise an insertion of a copy of an endogenous nucleic acid encoding a DXS polypeptide. In some embodiments of any of the aspects described herein, the cells further comprise one or more nucleic acids encoding an IDI polypeptide and a DXS polypeptide. In some embodiments of any of the aspects described herein, one nucleic acid encodes the isoprene synthase polypeptide, IDI polypeptide, and DXS polypeptide. In some embodiments of any of the aspects described herein, one vector encodes the isoprene synthase polypeptide, IDI polypeptide, and DXS polypeptide. In some embodiments, the vector comprises a selective marker, such as an antibiotic resistance nucleic acid.

**[0572]** In some embodiments of any of the aspects described herein, the heterologous isoprene synthase nucleic acid is operably linked to a T7 promoter, such as a T7 promoter contained in a medium or high copy plasmid. In some embodiments of any of the aspects described herein, the heterologous isoprene synthase nucleic acid is operably linked to a Trc promoter, such as a Trc promoter contained in a medium or high copy plasmid. In some embodiments of any of the aspects described herein, the heterologous isoprene synthase nucleic acid is operably linked to a Lac promoter, such as a Lac promoter contained in a low copy plasmid. In some embodiments of any of the aspects described herein, the heterologous isoprene synthase nucleic acid is operably linked to an endogenous promoter, such as an endogenous alkaline serine protease promoter. In some embodiments, the heterologous isoprene synthase nucleic acid integrates into a chromosome of the cells without a selective marker.

**[0573]** In some embodiments, one or more MVA pathway, IDI, DXP, or isoprene synthase nucleic acids are placed under the control of a promoter or factor that is more active in stationary phase than in the growth phase. For example, one or more MVA pathway, IDI, DXP, or isoprene synthase nucleic acids may be placed under control of a stationary phase sigma factor, such as RpoS. In some embodiments, one or more MVA pathway, IDI, DXP, or isoprene synthase

nucleic acids are placed under control of a promoter inducible in stationary phase, such as a promoter inducible by a response regulator active in stationary phase.

**[0574]** In some embodiments of any of the aspects described herein, at least a portion of the cells maintain the heterologous isoprene synthase nucleic acid for at least or about 5, 10, 20, 40, 50, 60, 65, or more cell divisions in a continuous culture (such as a continuous culture without dilution). In some embodiments of any of the aspects described herein, the nucleic acid comprising the isoprene synthase, IDI, or DXS nucleic acid also comprises a selective marker, such as an antibiotic resistance nucleic acid.

**[0575]** In some embodiments of any of the aspects described herein, the cells further comprise a heterologous nucleic acid encoding an MVA pathway polypeptide (such as an MVA pathway polypeptide from *Saccharomyces cerevisia* or *Enterococcus faecalis*). In some embodiments of any of the aspects described herein, the cells further comprise an insertion of a copy of an endogenous nucleic acid encoding an MVA pathway polypeptide (such as an MVA pathway polypeptide from *Saccharomyces cerevisia* or *Enterococcus faecalis*). In some embodiments of any of the aspects described herein, the cells comprise an isoprene synthase, DXS, and MVA pathway nucleic acid. In some embodiments of any of the aspects described herein, the cells comprise an isoprene synthase nucleic acid, a DXS nucleic acid, an IDI nucleic acid, and a MVA pathway nucleic (in addition to the IDI nucleic acid).

**[0576]** In some embodiments of any of the aspects described herein, the isoprene synthase polypeptide is a polypeptide from a plant such as *Pueraria* (e.g., *Pueraria montana* or *Pueraria lobata*) or *Populus* (e.g., *Populus tremuloides*, *Populus alba*, *Populus nigra*, *Populus trichocarpa*, or the hybrid, *Populus alba* x *Populus tremula*).

**[0577]** In some embodiments of any of the aspects described herein, the cells are bacterial cells, such as gram-positive bacterial cells (e.g., *Bacillus* cells such as *Bacillus subtilis* cells or *Streptomyces* cells such as *Streptomyces lividans*, *Streptomyces coelicolor*, or *Streptomyces griseus* cells). In some embodiments of any of the aspects described herein, the cells are gram-negative bacterial cells (e.g., *Escherichia* cells such as *Escherichia coli* cells, *Rhodopseudomonas* sp. such as *Rhodopseudomonas palustris* cells, *Pseudomonas* sp. such as *Pseudomonas fluorescens* cells or *Pseudomonas putida* cells, or *Pantoea* cells such as *Pantoea citrea* cells). In some embodiments of any of the aspects described herein, the cells are fungal cells such as filamentous fungal cells (e.g., *Trichoderma* cells such as *Trichoderma reesei* cells or *Aspergillus* cells such as *Aspergillus oryzae* and *Aspergillus niger*) or yeast cells (e.g.,

*Yarrowia* cells such as *Yarrowia lipolytica* cells or *Saccharomyces* cells such as *Saccharomyces cerevisiae*).

**[0578]** In some embodiments of any of the aspects described herein, the microbial polypeptide carbon source includes one or more polypeptides from yeast or bacteria. In some embodiments of any of the aspects described herein, the plant polypeptide carbon source includes one or more polypeptides from soy, corn, canola, jatropha, palm, peanut, sunflower, coconut, mustard, rapeseed, cottonseed, palm kernel, olive, safflower, sesame, or linseed.

*Production of isoprene in anaerobic microorganisms using synthesis gas as an energy source*

**[0579]** In some embodiments, the bioisoprene composition is produced in anaerobic microorganisms using synthesis gas as an energy source as described in US Provisional Patent Application Nos. 61/289,347 and 61/289,355, filed on December 22, 2009, the disclosures of which are incorporated herein by reference in their entireties.

**[0580]** Production of isoprene from syngas by anaerobic organisms may provide a number of advantages over production of isoprene from sugars by aerobic organisms. First, the maximum theoretical mass yield of isoprene can be greater for the anaerobic organisms, as discussed further below. Second, the anaerobic organisms do not have excess reducing power in the form of NAD(P)H that must be turned over via cell growth, formation of byproducts (such as glycerol, lactic acid, or ethanol) or oxidation using molecular oxygen. Without this NAD(P)H turnover requirement, anaerobic organisms can have higher energy yield, lower oxygen demand, lower heat of fermentation, and lower utility costs to run the process. Third, due to the lack of oxygen in the system, anaerobic organisms can have greater isoprene concentration in the offgas, lower probability of creating a flammable isoprene-oxygen mixture, easier recovery, and higher isoprene quality. Fourth, the anaerobic organisms can be more easily grown by using existing infrastructure, such as existing plants designed for production of bioethanol.

**[0581]** Anaerobic organisms useful for isoprene production can include obligate anaerobes, facultative anaerobes, and aerotolerant anaerobes. The obligate anaerobes can be any one or combination selected from the group consisting of *Clostridium ljungdahlii*, *Clostridium autoethanogenum*, *Eurobacterium limosum*, *Clostridium carboxydovorans*, *Peptostreptococcus productus*, and *Butyrivacterium methylotrophicum*. Syngas useful as energy source for production of isoprene can be derived from a feedstock by a variety of processes, including

methane reforming, coal liquefaction, co-firing, fermentative reactions, enzymatic reactions, and biomass gasification.

*Exemplary Purification Methods*

**[0582]** In some embodiments, any of the methods described herein further include recovering the co-produced compounds. In some embodiments, any of the methods described herein further include recovering the isoprene. In some embodiments, any of the methods described herein further include recovering the hydrogen by cryogenic membrane, adsorption matrix-based separation methods.

**[0583]** The isoprene and hydrogen produced using the compositions and methods described herein can be recovered using standard techniques, such as gas stripping, membrane enhanced separation, fractionation, adsorption/desorption, pervaporation, thermal or vacuum desorption of isoprene from a solid phase, or extraction of isoprene immobilized or absorbed to a solid phase with a solvent (see, for example, U.S. Patent Nos. 4,703,007, 4,570,029, and 4,740,222 (“Recovery and Purification of Hydrogen from Refinery and Petrochemical Off-gas Streams”) which are each hereby incorporated by reference in their entireties, particularly with respect to isoprene recovery and purification methods (’007 and ’029 patents) and with respect to hydrogen recovery and purification methods (’222 patent)). In particular embodiments, extractive distillation with an alcohol (such as ethanol, methanol, propanol, or a combination thereof) is used to recover the isoprene. In some embodiments, the recovery of isoprene involves the isolation of isoprene in a liquid form (such as a neat solution of isoprene or a solution of isoprene in a solvent). Gas stripping involves the removal of isoprene vapor from the fermentation off-gas stream in a continuous manner. Such removal can be achieved in several different ways including, but not limited to, adsorption to a solid phase, partition into a liquid phase, or direct condensation (such as condensation due to exposure to a condensation coil or do to an increase in pressure). In some embodiments, membrane enrichment of a dilute isoprene vapor stream above the dew point of the vapor resulting in the condensation of liquid isoprene. In some embodiments, the isoprene is compressed and condensed.

**[0584]** The recovery of isoprene may involve one step or multiple steps. In some embodiments, the removal of isoprene vapor from the fermentation off-gas and the conversion of isoprene to a liquid phase are performed simultaneously. For example, isoprene can be directly condensed from the off-gas stream to form a liquid. In some embodiments, the removal of isoprene vapor from the fermentation off-gas and the conversion of isoprene to a liquid phase are

performed sequentially. For example, isoprene may be adsorbed to a solid phase and then extracted from the solid phase with a solvent.

**[0585]** The recovery of hydrogen may involve one step or multiple steps. In some embodiments, the removal of hydrogen gas from the fermentation off-gas and the conversion of hydrogen to a liquid phase are performed simultaneously. In some embodiments, the removal of hydrogen gas from the fermentation off-gas and the conversion of hydrogen to a liquid phase are performed sequentially. For example, hydrogen may be adsorbed to a solid phase and then desorbed from the solid phase by a pressure swing. In some embodiments, recovered hydrogen gas is concentrated and compressed.

**[0586]** In some embodiments, any of the methods described herein further include purifying the isoprene. For example, the isoprene produced using the compositions and methods described herein can be purified using standard techniques. Purification refers to a process through which isoprene is separated from one or more components that are present when the isoprene is produced. In some embodiments, the isoprene is obtained as a substantially pure liquid. Examples of purification methods include (i) distillation from a solution in a liquid extractant and (ii) chromatography. As used herein, "purified isoprene" means isoprene that has been separated from one or more components that are present when the isoprene is produced. In some embodiments, the isoprene is at least about 20%, by weight, free from other components that are present when the isoprene is produced. In various embodiments, the isoprene is at least or about 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 95%, or 99%, by weight, pure. Purity can be assayed by any appropriate method, *e.g.*, by column chromatography, HPLC analysis, or GC-MS analysis.

**[0587]** In some embodiments, any of the methods described herein further include purifying the hydrogen. For example, the hydrogen produced using the compositions and methods described herein can be purified using standard techniques. Purification refers to a process through which hydrogen is separated from one or more components that are present when the hydrogen is produced. In some embodiments, the hydrogen is obtained as a substantially pure gas. In some embodiments, the hydrogen is obtained as a substantially pure liquid. Examples of purification methods include (i) cryogenic condensation and (ii) solid matrix adsorption. As used herein, "purified hydrogen" means hydrogen that has been separated from one or more components that are present when the hydrogen is produced. In some embodiments, the hydrogen is at least about 20%, by weight, free from other components that are present when the hydrogen is produced. In various embodiments, the hydrogen is at least or about 25%, 30%,

40%, 50%, 60%, 70%, 75%, 80%, 90%, 95%, or 99%, by weight, pure. Purity can be assayed by any appropriate method, *e.g.*, by column chromatography or GC-MS analysis.

**[0588]** In some embodiments, at least a portion of the gas phase remaining after one or more recovery steps for the removal of isoprene is recycled by introducing the gas phase into a cell culture system (such as a fermentor) for the production of isoprene.

**[0589]** Methods and apparatus for the purification of a bioisoprene composition from fermentor off-gas is described in US Provisional Patent Application No. 61/88,142, filed December 18, 2009, which is incorporated herein by reference in its entirety.

**[0590]** A bioisoprene composition from a fermentor off-gas may contain bioisoprene with volatile impurities and bio-byproduct impurities. In some embodiments, a bioisoprene composition from a fermentor off-gas is purified using a method comprising: (a) contacting the fermentor off-gas with a solvent in a first column to form: an isoprene-rich solution comprising the solvent, a major portion of the isoprene and a major portion of the bio-byproduct impurity; and a vapor comprising a major portion of the volatile impurity; (b) transferring the isoprene-rich solution from the first column to a second column; and (c) stripping isoprene from the isoprene-rich solution in the second column to form: an isoprene-lean solution comprising a major portion of the bio-byproduct impurity; and a purified isoprene composition.

**[0591]** Figure 169 illustrates an exemplary method of purifying isoprene and an exemplary apparatus. Fermentor off-gas comprising isoprene may be generated from renewable resources (*e.g.*, carbon sources) by any method in the art for example, as described in U.S. provisional patent application Nos. 61/187,944, the content of which is hereby incorporated by reference, particularly with respect to the methods of generating fermentor off-gas comprising isoprene. The fermentor off-gas generated from one or more individual fermentors **12** (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, or more fermentors connected in series and/or in parallel) may be directed to a first column **14**. As described below, the fermentor off-gas may be directed through an isolation unit **16** and/or compressed by a compression means, such as compression system **18**. Additionally, the temperature of the fermentor off-gas may optionally be reduced at any point, for example, to form a condensate or partial condensate prior to contact with the solvent (which may aid in solubilization of one or more off-gas components, such as isoprene). The fermentor off-gas may be contacted (*e.g.*, absorbed) at column **14** with a solvent (*e.g.*, any solvent described herein, such as a non-polar high boiling-point solvent). The volatile impurities having less propensity

for absorption in the solvent (particularly with non-polar high boiling-point solvents) are separated from the remaining solvent/fermentor off-gas mixture, resulting in a vapor comprising a major portion of the volatile impurity (*e.g.*, exiting at port **20**), and an isoprene-rich solution having a major portion of the isoprene and a major portion of the bio-byproduct impurity (*e.g.*, at port **22**). The solvent may optionally be heated by any suitable means (*e.g.*, by steam) prior to, simultaneously, and/or after contact with the fermentor off-gas, which may aid in separation of the volatile impurity from the remaining solution. Steam may be directed through the column (at any suitable location, such as near entry of the off-gas and/or the opposite end of the volatile impurity exit as shown in Figure 169) to provide a sweeping vapor phase which may aid in the removal of the volatile impurity.

**[0592]** The isoprene-rich solution having a major portion of the isoprene and a major portion of the bio-byproduct impurity (*e.g.*, at port **22**) may be directed to a second column **24**. The second column may be isolated from the first column **14** (as shown in Figure 169) or may be part of a single column comprising both the first and second columns (*e.g.*, a tandem column wherein the solvent enters the first column at or near one end, and exits the second column at or near an opposite end). The isoprene may be stripped from the isoprene-rich solution in the second column to generate a purified isoprene composition (*e.g.*, at port **26**) and an isoprene-lean solution comprising a major portion of the bio-byproduct impurity (*e.g.*, at port **28**). The isoprene-rich solution may be heated by any suitable means (*e.g.*, by steam), which may aid in stripping of the isoprene from the remaining solution. Steam may be directed through the column (at any suitable location, such as the opposite end of the entry point of the isoprene-rich solution and/or the near the end of the isoprene-lean solution exit as shown in Figure 169).

**[0593]** As described herein, the columns may be conventional and of any suitable size. Exemplary types of columns are commercially available from manufacturers including Koch Modular Process Systems (Paramus, NJ), Fluor Corporation (Irving, TX), Kuhni USA (Mount Holly, NC). In general, columns are designed to maximize vapor/liquid contact in order to achieve the desired efficiency. This is achieved by filling the column with either a packing material, or trays spaced at regular intervals along the column. Suitable packing materials include both random and structured types based on metal, glass, polymer and ceramic materials. Exemplary random packing types include Raschig rings, Pall rings, A-PAK rings, Saddle rings, Pro-Pak, Heli-Pak, Ceramic saddles and FLEXIRINGS<sup>®</sup>. Structured packings include wire mesh and perforated metal plate type materials. Manufacturers specializing in column packings include ACS Separations & Mass-Transfer Products (Houston, TX), Johnson Bros. Metal Forming Co.

(Berkeley, IL) and Koch Glitsch, Inc. Knight Div. (East Canton, OH). The efficiency of a gas stripping column is expressed in terms of the theoretical plate height and the total number of plates in the column. In general, the greater the number of theoretical plates present, the greater the efficiency of the column. Laboratory scale columns can be purchased from Ace Glass (Vineland, NJ), Sigma-Aldrich (St. Louis, MO) and Chemglass (Vineland, NJ). Suitable types of glass column include Vigreux, Snyder, Hemple and Perforated-plate type columns. Columns can include packing materials, or contain features designed to maximize vapor/liquid contact. A laboratory scale gas scrubber unit (part # CG-1830-10) is available from Chemglass and consists of a packed glass column, solvent reservoir and solvent recirculation pump.

**[0594]** The purified isoprene composition from the second column **24** (*e.g.*, exiting at port **26**) may be further purified by any suitable means (*e.g.*, by using a reflux condenser **34** and/or an adsorption system **36**, such as a silica adsorption system). The reflux reduces the solvent composition in the isoprene product. The isoprene-lean solution may be recycled back to the first column for reuse (*e.g.*, as shown in Figure 169 at port **30**). The isoprene-lean solution may be purified by any suitable means (*e.g.*, by liquid-liquid extraction and/or an adsorption system **32**, such as a silica adsorption system) prior to recycling to the first column **14** to reduce to amount of bio-byproduct. Additionally, the temperature of the isoprene-lean solution may be reduced by any suitable means prior to recycling to the first column **14** (*e.g.*, prior to, simultaneously, and/or after optionally purifying the isoprene solution). Figure 169 shows an example of reducing the temperature of the isoprene-lean solution at port **40** prior to purification of the isoprene-lean solution (in this case, using coolant for temperature reduction).

**[0595]** The vapor comprising a major portion of the volatile impurity (*e.g.*, the vapor exiting at port **20** in Figure 169) may comprise a minor portion of isoprene (*e.g.*, residual isoprene not remaining in the isoprene-rich solution). The residual isoprene may be recollected for use from the vapor comprising a major portion of the volatile impurity by any suitable means (*e.g.*, an adsorption system **38**, such as an activated carbon adsorption system) and in some cases, as shown in Figure 169, may be combined with the purified isoprene composition (*e.g.*, prior to, during, or after additional purification, such as an adsorption system similar to system **36**). Figure 169 also shows an optional capture device **42** (*e.g.*, a thermal oxidizer and/or CO<sub>2</sub> capture system) capable of reducing the amount of undesirable components released into the atmosphere (*e.g.*, CO<sub>2</sub>) from the vapor.

*Exemplary chemical transformations of isoprene*

**[0596]** Although current industrial use of isoprene is predominantly in the production of synthetic rubber, isoprene is a reactive conjugated diene and undergoes a varieties of chemical transformations to form oxygenates and higher molecular weight hydrocarbons. For example, Palladium(0) complexes (Pd(acac)<sub>2</sub>-Ph<sub>3</sub>P and Pd(OAc)<sub>2</sub>-Ph<sub>3</sub>P) catalyze dimerization and telomerization of isoprene in alcohol solvents to give linear isoprene dimers (e.g. 2,7-dimethyl-1,3,7-octatriene) and methoxydimethyloctadienes (Zakharkin, L. I. and Babich, S. A. *Russ. Chem. Bull.* (1976), pp 1967-1968.) Adams, J. M. and Clapp, T. V. (*Clay and Clay Minerals* (1986), 34(3), 287-294) reported reactions of isoprene over divalent and trivalent transition metal-exchanged montmorillonites (e.g. Cr<sup>3+</sup>-montmorillonite) to give isoprene dimers and adducts with methanol. The linear dimerization of isoprene catalyzed by Ni(0)-aminophosphinite systems resulted in regioselective tail-to-tail linear dimers, accompanied by a competitive cyclodimerization reaction (Denis, Philippe; Croizy, Jean Francois; Mortreux, Andre; Petit, Francis, *Journal of Molecular Catalysis* (1991), 68(2), 159-75. Denis, Philippe; Jean, Andre; Croizy, Jean Francois; Mortreux, Andre; Petit, Francis, *Journal of the American Chemical Society* (1990), 112(3), 1292-4.) New chiral aminophosphinite ligands, e.g., (+)-MeCH<sub>2</sub>CHMeCH(NH<sub>2</sub>)CH<sub>2</sub>OPPh<sub>2</sub> was investigated as homogeneous catalysts in the linear dimerization of isoprene, leading to a conversion rate above 50% (Masotti, Henriette; Peiffer, Gilbert; Siv, Chhan; Courbis, Pierre; Sergent, Michelle; Phan Tan Luu, Roger, *Bulletin des Societes Chimiques Belges* (1991), 100(1), 63-77.)

**[0597]** Thermal dimerization of isoprene at 110-250° in presence of dinitrocresol as polymerization inhibitor gives high yields of dimers and little polymer (U.S. Patent No. 4,973,787.) Ni-catalyzed dimerization of isoprene yields a dimethyl-1,5-cyclooctadiene mixture consisting of 80% 1,5-dimethyl-1,5-cyclooctadiene and 20% 1,6-dimethyl-1,5-cyclooctadiene (Doppelt, Pascal; Baum, Thomas H.; Ricard, Louis, *Inorganic Chemistry* (1996), 35(5), 1286-91.) Isoprene is converted to dimethylcyclooctadienes with a catalytic amt. of Cp\*Ru(η<sup>4</sup>-isoprene)Cl and AgOTf (Itoh, Kenji; Masuda, Katsuyuki; Fukahori, Takahiko; Nakano, Katsumasa; Aoki, Katsuyuki; Nagashima, Hideo, *Organometallics* (1994), 13(3), 1020-9.) JP59065026A (1984) reported preparation of 1,6-dimethyl-1,5-cyclooctadiene by cyclic dimerization of isoprene in the presence of catalysts comprising Fe carboxylates or β-diketone compounds, organo-Al or Mg compounds, and 2,2'-dipyridyl derivatives having electron-donating groups. Dimethylcyclooctadiene was prepared by cyclodimerization of isoprene over 3-component catalysts containing Ni carboxylates or β-ketones, organoaluminum or

organomagnesium compounds and substituted triphenylphosphite (JP58055434A, 1983.) 1,5-Dimethyl-1,5-cyclooctadiene was prepared by cyclodimerization of isoprene at 100-300° in an inert organic solvent in the presence of a homogeneous catalyst containing Fe(3) salt, organoaluminum compound and an activator (SU615056A1, 1978), in the presence of a homogeneous catalyst containing Ni acetylacetonate, a triarylphosphite and perhydroalumophenolene (SU493455A1, 1975), in the presence of a catalyst containing a mixture of a Ni carboxylate or carboxylate or chelate compounds of Ni and 1-hydroxy-3-carbonyl compounds, trialkylaluminum, dialkylmagnesium or active organo-Mg compounds obtained from conjugated dienes and Mg, triaryl phosphites and tertiary amines (JP48064049A, 1973), or in the presence of a catalyst composed of Ni naphthenate, Et<sub>3</sub>Al, and tri-*o*-cresyl phosphate (Suga, K.; Watanabe, S.; Fujita, T.; Shimada, T., *Israel Journal of Chemistry* (1972), 10(1), 15-18.) U.S. Patent No. 3,954,665 disclosed dimerization of isoprene in the presence of reaction products of  $[(\eta^3\text{-C}_6\text{H}_5)\text{NiBr}]_2$  or  $[\text{M}(\text{NO})_2\text{X}]_2$  (M = Fe, Co; X = Cl, I, Br) with Fe, Co, or Ni carbonyls. European Patent No. 2411(1981) disclosed cyclodimerization of isoprene over a  $\text{Fe}(\text{NO})_2\text{Cl}$ -bis(1,5-cyclooctadiene)nickel catalyst at from -5° to +20° to give 1-methyl- and 2-methyl-4-isopropenyl-1-cyclohexene and 1,4- and 2,4-dimethyl-4-vinyl-1-cyclohexene. U.S. Patent No. 4,189,403 disclosed preparation of 1,5-dimethyl-1,5-cyclooctadiene and 1,4-dimethyl-4-vinyl-1-cyclohexene by contacting isoprene with a mixed catalyst of a tris(substituted hydrocarbyl) phosphite, arsenite, or antimonite and a Group VIII metal(0) compound (e.g. Ni acetylacetonate). Jackstell, R.; Grotevendt, A.; Michalik, D.; El Firdoussi, L.; Beller, M. *J. Organometallic Chem.* (2007) 692(21), 4737-4744 cites the use of palladium/carbene catalysts for isoprene dimerization. Bowen, L.; Charernsuk, M.; Wass, D.F. *Chem. Commun.* (2007) 2835-2837 describes the use of a chromium *N,N*-bis(diarylphosphino)amine catalyst for the production of linear and cyclic trimers of isoprene. [0598] Isoprene was reportedly dimerized in the presence of a Ni catalyst to yield cis-2-isopropenyl-1-methylvinylcyclobutane (Billups, W. E.; Cross, J. H.; Smith, C. V., *Journal of the American Chemical Society* (1973), 95(10), 3438-9.) The oligomerization of isoprene [78-79-5] catalyzed by nickel naphthenate and isoprenemagnesium in the presence of various phosphites as electron donors gave cyclic dimers containing dimethylcyclooctadiene [39881-79-3]; in particular 1,1,1-tris(hydroxymethyl)propane phosphite [39865-19-5] gave trimethylcyclododecatriene [39881-80-6] selectively (Suga, Kyoichi; Watanabe, Shoji; Fujita, Tsutomu; Shimada, Takashi, *Journal of Applied Chemistry & Biotechnology* (1973), 23(2), 131-8.) WO2006/051011 discloses preparation of trimethylcyclododecatriene, useful in perfumes

and fragrances, by the trimerization of isoprene in the presence of a catalyst system comprising Ni and/or Ti, one or more organometallic compound, and a Group VA compound, and that the reaction is conducted in a hydroxyl group-containing solvent. Ligabue, R. A.; Dupont, J.; de Souza, R. F., Alegre, R.S. *J. Mol. Cat. A: Chem.* (2001), 169(1-2), 11-17, describes the selective dimerization of isoprene to six-membered dimers using an iron nitrosyl catalyst in an ionic liquid. Huchette, D.; Nicole, J.; Petit, F., *Tetrahedron Letters* (1979), (12), 1035-8, describes the electrochemical generation of an iron nitrosyl catalyst and subsequent use for the dimerization of isoprene to cyclohexene dimers. Zakharkin, L. I.; Zhigareva, G. G.; Pryanishnikov, A. P. *Zhurnal Obshchei Khimii* (1987), 57(11), 2551-6, describes the cyclooligomerization of isoprene on complex nickel and iron catalysts.

**[0599]** The highly pure isoprene starting compositions described herein are chemically transformed using each catalyst systems and reaction conditions disclosed in the references cited. Other catalysts and reaction conditions known in the art such as catalysts and reaction conditions applied to chemical transformations of 1,3-butadiene can be adapted to the isoprene starting compositions by one skilled in the art.

#### ***Dimerization and Trimerization***

**[0600]** In some embodiments, a commercially beneficial amount of highly pure isoprene starting material undergoes catalytic chemical transformation to give dimers and trimers. Catalyst systems are identified using methods known in the art. Preferred catalysts include those known to convert isoprene to dimers and trimers with high efficiency. Examples include those based upon Palladium, Nickel, Cobalt, Iron and Chromium.

**[0601]** In some embodiments, a commercially beneficial amount of highly pure isoprene starting material undergoes thermal or catalytic dimerization. The isoprene starting composition is converted to a mixture of dimers that includes unsaturated 6 and 8-membered rings by heating the starting composition under pressure. In some embodiments, the starting isoprene composition is heated to over or about 100, 125, 150, 175, 200, 225 or 250 °C under pressure. In some embodiments, the starting isoprene composition is heated in the presence of an antioxidant (e.g. 2,6-di-tert-butyl-4-methylphenol) to prevent radical-mediated polymerization. In some embodiments, the reaction is accelerated by one or more catalysts selected from catalysts known in the art for catalyzing cyclic dimerization of isoprene, e.g., iron nitrosyl halide catalysts described in US patents 4,144,278, 4,181,707, 5,545,789 and European patent EP0397266A2. The use of iron nitrosyl catalysts in ionic liquids is described by Ligabue *et al.*

(2001) *J. Mol. Catalysis A: Chemical*, 169 (2), 11-17. Examples of catalysts include but are not limited to  $\text{Fe}(\text{NO})_2\text{Cl}_2$  and  $\text{Cr}^{3+}$ -montmorillonite. In another example, an isoprene starting composition is converted to C10 cyclic dimers (e.g. a mixture of dimethyl-cyclooctadienes) using a ruthenium catalyst (Itoh, Kenji; Masuda, Katsuyuki; Fukahori, Takahiko; Nakano, Katsumasa; Aoki, Katsuyuki; Nagashima, Hidco, *Organometallics* (1994), 13(3), 1020-9.)

**[0602]** In a specific embodiment, an isoprene starting composition in a liquid state is heated to over 100 °C under pressure and in the presence of an antioxidant to produce a mixture of dimers that includes 6 and 8-membered rings, for examples, limonene (1-methyl-4-(prop-1-en-2-yl)cyclohex-1-ene), 1-methyl-5-(prop-1-en-2-yl)cyclohex-1-ene, 1,4-dimethyl-4-vinylcyclohexene, 2,4-dimethyl-4-vinylcyclohexene, 1,5-dimethylcycloocta-1,5-diene, 1,6-dimethylcycloocta-1,5-diene, 2,6-dimethyl-1,3-cyclooctadiene, 2,6-dimethyl-1,4-cyclooctadiene, 3,7-dimethyl-1,5-cyclooctadiene, 3,7-dimethyl-1,3-cyclooctadiene, 3,6-dimethyl-1,3-cyclooctadiene and other 8-membered ring isoprene dimers as described in *Organometallics* (1994), 13(3), 1020-9. All stereoisomers of these compounds are contemplated. Conversion of isoprene to dimers is best performed in the absence of oxygen so as to avoid the production of undesirable reaction products.

**[0603]** In some embodiments, a commercially beneficial amount of highly pure isoprene starting material undergoes photo-dimerization to give 4-membered ring dimers. The isoprene starting composition is converted by light irradiation to a mixture comprising one or more of 1,2-di(prop-1-en-2-yl)cyclobutane, 1,3-di(prop-1-en-2-yl)cyclobutane, 1-methyl-1-vinyl-3-(prop-1-en-2-yl)cyclobutane, 1-methyl-1-vinyl-2-(prop-1-en-2-yl)cyclobutane, 1,3-dimethyl-1,3-divinylcyclobutane, 1,2-dimethyl-1,2-divinylcyclobutane and stereoisomers thereof. In some embodiments, the highly pure isoprene starting material is dimerized in the presence of a catalyst (e.g. a nickel catalyst) or a photosensitizer (e.g. benzophenone) to yield 4-membered ring dimers, e.g. cis-2-isopropenyl-1-methylvinylcyclobutane, in addition to 6- and 8-membered rings [See: Hammond, J.S.; Turro, N.J.; Liu, R.S.H. (1963) "Mechanisms of Photochemical Reactions in Solution. XVI. Photosensitized Dimerization of Conjugated Dienes. *J. Org. Chem.*, 28, 3297-3303.]

**[0604]** In some embodiments, a commercially beneficial amount of highly pure isoprene starting material is converted to a cyclic trimer in the presence of a catalyst system. In some embodiments, the cyclic trimer is trimethylcyclododecatriene. In some embodiments, the catalyst system comprises a nickel catalyst. In some embodiments, the catalyst system comprises a titanium compound. In some embodiments, the catalyst system comprises a nickel

catalyst and a titanium compound. In some embodiments, the catalyst system comprises one or more organometallic compound and a Group VA compound. In some embodiments, the catalytic transformation is conducted in a hydroxyl group-containing solvent. In a particular embodiment, a starting isoprene composition is converted to trimethylcyclododecatriene in the presence of a catalyst system comprising Ni and/or Ti, one or more organometallic compound, and a Group VA compound, and that the reaction is conducted in a hydroxyl group-containing solvent.

**[0605]** In some embodiments, a commercially beneficial amount of highly pure isoprene starting material undergoes thermal or catalytic conversion to hydrocarbons in the C7 to C14 range by treatment with a C2 to C5 unsaturated hydrocarbon. The C2 to C5 hydrocarbon can be an alkene, a diene or an alkyne. For example, in some embodiments, isoprene is contacted with ethylene and an appropriate catalyst to produce C7 compounds. In another embodiment, isoprene is contacted with 1,3-butadiene to form cyclic C9 hydrocarbons. Hydrogenation of these C7 to C14 hydrocarbons results in compositions suitable for use as jet fuels and other aviation fuels. In yet another embodiment, unsaturated C7 to C14 hydrocarbons derived from isoprene and one or more unsaturated hydrocarbons undergo dehydrogenation to form aromatic derivatives suitable for use as jet fuels and other aviation fuels, or as blendstocks for such fuels.

**[0606]** In some embodiments, a commercially beneficial amount of highly pure isoprene starting material is converted to a mixture of linear dimers and trimers using a catalyst system in alcohol solvents. This reaction also produces alkoxy derivatives when performed in methanol or ethanol. In some embodiments, the catalyst system is a palladium-based catalyst system, e.g., a palladium acetylacetonate – triphenylphosphine system or a palladium acetate – triphenylphosphine system. In some embodiments, the alcohol solvent is methanol, ethanol or isopropyl alcohol. The nature of the products depends on the catalyst and the solvent used. For example, when a palladium-based catalyst system, e.g., Pd(acac)<sub>2</sub>-Ph<sub>3</sub>P or Pd(OAc)<sub>2</sub>-Ph<sub>3</sub>P, is used in isopropyl alcohol solvent, linear dimers of isoprene is formed, e.g. 2,7-dimethyl-1,3,7-octatriene and 2,7-dimethyl-2,4,6-octatriene. When this reaction is performed in methanol, methoxydimethyloctadienes (e.g., 1-methoxy-2,7-dimethyl-2,7-octadiene and 3-methoxy-2,7-dimethyl-1,7-octadiene) are formed in addition to linear isoprene dimers such as dimethyloctatrienes. Some reactions produce linear trimers of isoprene, such as α-farnesene (3,7,11-trimethyl-1,3,6,10-dodecatetraene), β-farnesene (7,11-dimethyl-3-methylene-1,6,10-dodecatriene) and other positional isomers (e.g. from tail to tail and head to head addition of isoprene units). In another example, isoprene is converted to linear and cyclic C15 trimers using

a chromium *N,N*-bis(diarylphosphino)amine catalyst (Bowen, L.; Charernsuk, M.; Wass, D.F. *Chem. Commun.* (2007) 2835-2837.)

### ***Conversion to Oxygenates***

[0607] In some embodiments, a commercially beneficial amount of highly pure isoprene starting material is converted to fuel oxygenates by reaction with ethanol and other alcohols in the presence of an acid catalyst. In one embodiment, the acid catalyst is sulfuric acid. In another embodiment, the acid catalyst is a solid phase sulfuric acid (e.g., Dowex Marathon®). Other catalysts include both liquid and solid-phase fluorosulfonic acids, for example, trifluoromethanesulfonic acid and Nafion-H (DuPont). Zeolite catalysts can also be used, for example beta-zeolite, under conditions similar to those described by Hensel *et al.* [Hensen, K.; Mahaim, C.; Holderich, W.F., *Applied Catalysis A: General* (1997) 140(2), 311-329.] for the methoxylation of limonene and related monoterpenes. In some embodiments, a highly pure isoprene starting material is converted to alcohols and esters by a hydroxylation/esterification process or other known reaction of alkenes in the art, for example peroxidation to epoxides with peracids such as peracetic acid and 3-chloroperbenzoic acid; and hydration to give alcohols and diols with i) water and acid catalysts and ii) hydroboration methods. Such reactions are described in, for example, Michael B. Smith and Jerry March, *Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, Sixth Edition, John Wiley & Sons, 2007. Figures 3 and 4 show examples of alcohols and oxygenates that can be produced from the starting isoprene compositions.

### ***Partial Hydrogenation***

[0608] In some embodiments, a commercially beneficial amount of highly pure isoprene starting material is partially hydrogenated to a mono-olefin (e.g. 2-methylbut-1-ene, 3-methylbut-1-ene and 2-methylbut-2-ene). In some embodiments, the mono-olefin undergoes dimerization or reaction with other olefins using traditional hydrocarbon cationic catalysis, such as that used to convert isobutylene to isooctane. See, for example, H.M. Lybarger. Isoprene in *Kirk-Othmer Encyclopedia of Chemical Technology*, 4th ed., Wiley, New York (1995), 14, 934-952. In some preferred embodiments, the highly pure isoprene starting material is a bioisoprene composition.

[0609] In some embodiments, a commercially beneficial amount of highly pure isoprene starting material undergoes partial hydrogenation to form mono-olefins (e.g. 2-methylbut-1-ene, 3-methylbut-1-ene and 2-methylbut-2-ene). In some preferred embodiments, the highly pure

isoprene starting material is a bioisoprene composition. In some embodiments, partial hydrogenation of the isoprene starting material produces high yields of mono-olefins with minimal conversion to isopentane and low residual isoprene levels. In some embodiments, a mixture of mono-olefin and isopentane is produced, with low levels of residual isoprene. In some embodiments, the partial hydrogenation is selective hydrogenation where a particular mono-olefin such as 2-methylbut-2-ene, 2-methylbut-1-ene, or 3-methylbut-1-ene is preferentially produced. Preferred hydrogenation catalysts give high catalytic activity, maintain catalytic activity over time, and are highly selective for the conversion of isoprene to mono-olefins.

**[0610]** Suitable catalysts for partial hydrogenation of the isoprene starting composition may contain a platinum-group metal such as platinum, palladium, rhodium, or ruthenium, or a transition metal such as nickel, cobalt, copper, iron, molybdenum, or a noble metal such as silver or gold in elemental form, or a salt or complex with organic and inorganic ligands. Alloys of these metals can also be used in some circumstances. These metals and their derivatives can be pure or mixed with other active and inert materials. Catalysts may be adsorbed to a support material (such as activated carbon, alumina, or silica) in order to maximize the effective surface area. The physical morphology of hydrogenation catalysts is known to have a considerable influence on their performance. Preferred hydrogenation catalysts include heterogeneous palladium catalysts such as palladium on carbon (Pd/C), palladium on alumina (Pd/Al<sub>2</sub>O<sub>3</sub>), or palladium on silica (Pd/SiO<sub>2</sub>) in grades ranging from 0.1% Pd to 20% Pd (w/w) relative to the support material. An example of a suitable selective hydrogenation catalyst is LD 2773, a sulfur tolerant promoted Pd on alumina (Axens, Rueil-Malmaison Cedex, France). Partial hydrogenation catalysts that allow the conversion of isoprene into isoamylenes with minimal conversion to isopentane include the Lindlar catalyst (Pd/BaSO<sub>4</sub> treated with quinoline), Pd/C treated with the triphenyl derivative of a group 15 element (N, P, As), Pd/C treated with a sulfur-containing compound, molybdenum sulfide, and Pd/Fe alloys. One preferred catalyst comprises palladium adsorbed to egg-shell alumina (d-Al<sub>2</sub>O<sub>3</sub>). Catalysts used in the refining industry for the removal of diolefins and alkynes from pyrolysis gasoline are particularly preferred, for example Ni/Al<sub>2</sub>O<sub>3</sub> and Pd/Al<sub>2</sub>O<sub>3</sub> based catalysts. Another suitable class of catalyst for the conversion of isoprene to isoamylenes are those used in industry for the hydrotreating of pyrolysis gasoline. See for example US Patent Nos. 7,014,750 and 6,994,686, and references cited therein. In general, the catalysts used in pyrolysis gas hydrotreatment allow for selective conversion of acetylenes and diolefins (e.g. isoprene and piperylenes) into monoolefins.

**[0611]** The hydrogen source can be hydrogen gas or a hydrogen source including, but not limited to, hydrogen gas (H<sub>2</sub>), formic acid, hydrazine, or isopropanol. The hydrogen source can be either chemically or biologically derived. In some embodiments the hydrogen used for hydrogenation is co-produced with isoprene during fermentation. The hydrogenation can be performed at hydrogen pressures ranging from 0.5 atm to 200 atm, or higher. The temperature can range from 0 °C to 200 °C.

**[0612]** Products from partial hydrogenation of a bioisoprene composition are expected to contain certain impurities originally present in the starting isoprene composition and/or hydrogenated derivatives of the impurities such as acetone, ethanol, amyl alcohol, ethyl acetate, isoamyl acetate, methyl ethyl ketone and other saturated polar impurities.

**[0613]** In some embodiments, the isoprene starting composition undergoes partial hydrogenation or selective hydrogenation in the presence of a palladium catalyst. For example, palladium catalysts, such as Pd/CaCO<sub>3</sub>, Pd/BaSO<sub>4</sub>, Pd/C, Pd black, Pd/SiO<sub>3</sub>, Pd/Al<sub>2</sub>O<sub>3</sub>, or Pd/SiO<sub>2</sub>, were shown to convert isoprene to mono-olefins with a selectivity of greater than 95% over fully reduced C<sub>5</sub> alkanes. Use of these palladium catalysts gave a mixture of mono-olefin products, with 5%Pd/CaCO<sub>3</sub> having the greatest selectivity for 3-methylbut-1-ene and 5% Pd/SiO<sub>2</sub> having the greatest selectivity for 2-methylbut-2-ene. (See G.C. Bond and A.F. Rawle. *J. Mol. Catalysis A: Chemical* 109 (1996) 261-271.) Bond and Rawle have also shown that palladium-gold and palladium-silver catalysts (e.g., Pd-Au/SiO<sub>2</sub> and Pd-Ag/SiO<sub>2</sub>) have high selectivity for reducing isoprene to mono-olefins over fully reduced C<sub>5</sub> alkanes. In some embodiments, silica-supported polyamidoamine (PAMAM) dendrimer-palladium complexes have been used to selectively catalyze the reduction of cyclic and acyclic dienes to a mixture of mono-olefin isomers. Selectivity for the various mono-olefin isomers was dependent on the precise PAMAM ligand used in the catalyst. (See P.P. Zweni and H. Alper. *Adv. Synth. Catal.* 348 (2006) 725-731.) In some embodiments, reduction of isoprene to mono-olefins can be carried out using a Group VIB metal on an inorganic support (e.g., a metal zeolite) as a catalyst. For example, a Mo/Al<sub>2</sub>O<sub>3</sub> catalyst was used to selectively reduce 1,3-butadiene to the respective mono-olefins. (See US 6,235,954 B1.) In some embodiment, isoprene can be reduced to mono-olefins using a Group VIII metal catalyst promoted by a metal from Group IB, VIB, VIIB, or zinc to reduce poisoning of the catalyst. (See US 6,949,686 B2). In some embodiments, isoprene can be reduced to mono-olefins using a monolithic catalyst bed, which may be in a honeycomb configuration. Catalyst support materials for the monolithic catalyst bed may include metals such as nickel, platinum, palladium, rhodium, ruthenium, silver, iron, copper,

cobalt, chromium, iridium, tin, and alloys or mixtures thereof. (See US 7,014,750 B2). In some embodiments, isoprene can be reduced to mono-olefins using an eggshell Pd/d-Al<sub>2</sub>O<sub>3</sub> catalyst, particularly if the reaction is free of water. The eggshell Pd/d-Al<sub>2</sub>O<sub>3</sub> catalyst is selective for mono-olefins over fully reduced alkanes and 2-methylbut-2-ene is the thermodynamically favorable isomer. (See J.-R. Chang and C.-H. Cheng. *Ind. Eng. Chem. Res.* 36 (1997) 4094-4099.)

**[0614]** Light olefins (C3-C6) can be readily dimerized using acid catalysts to give higher olefins (C6-C12) also known as dimates. For example, the conversion of isobutylene (2-methylpropene) to isooctene is well described in the art using a variety of acid catalysts including sulfuric, phosphoric and other mineral acids, sulfonic acids, fluorosulfonic acids, zeolites and acidic clays.

**[0615]** In some embodiments, the isoprene starting composition undergoes partial hydrogenation or selective hydrogenation to form a mono-olefin, and the mono-olefin undergoes dimerization or reaction with other olefins using traditional hydrocarbon cationic catalysis, such as that used to convert isobutylene to isooctane, e.g. sulfuric, phosphoric and other mineral acids, sulfonic acids, fluorosulfonic acids, zeolites and acidic clays. See, for example, H.M. Lybarger. *Isoprene in Kirk-Othmer Encyclopedia of Chemical Technology*, 4th ed., Wiley, New York (1995), 14, 934-952. In some preferred embodiments, the highly pure isoprene starting material is a bioisoprene composition. Acid catalyst in both liquid and solid forms can be used. Acid resins are preferred and include Amberlyst 15, 35, XE586, XN1010 (Rohm and Haas) and similar acidic ion-exchange resins. Acidic molecular sieves are also preferred catalysts including a medium-pore acid molecular sieve such as ZSM-5, ferrierite, ZSM-22 and ZSM-23.

**[0616]** In some embodiments, the isoprene starting composition undergoes partial hydrogenation or selective hydrogenation to form isoamylenes. In some embodiments, the isoamylenes are dimerized to give C10 dimates such as isodecenes. In some embodiments, the isoamylenes are dimerized with an olefin such as propylene, butane or isobutene to give C8-C10 dimates. In some embodiments, the mono-olefin undergoes dimerization using a resin catalyst (e.g., Amberlyst, Amberlyst 35, Amberlyst 15, Amberlyst XN1010, Amberlyst XE586) to produce diisoamylenes. Use of such resin catalysts has been shown to minimize cracking and further oligomerization reactions, and under optimal conditions the resin catalysts provide selectivity for dimers of greater than 92%, with trimer formation of less than 8%. See, for example, M. Marchionna et al. *Catalysis Today* 65 (2001) 397-403. In some embodiments, the mono-olefin undergoes dimerization using a catalytic material containing an acidic mesoporous

molecular sieve, such as a mesoporous sieve embedded in a zeolite structure, ZSM-5, ferrierite, ZSM-22, or ZSM-23. In a particular embodiment, the catalytic material is thermally stable at high temperatures (e.g., at least 900 °C). In another particular embodiment, the mono-olefin is substantially free of multi-unsaturated hydrocarbons, such as isoprene. Use of a catalytic material containing an acidic mesoporous molecular sieve for dimerization can lead to selectivity for dimers in excess of 80%. See, for example, US 2007/0191662 A1. In some embodiments, the mono-olefin undergoes dimerization using a solid acidic catalyst (e.g., a solid phosphoric acid catalyst, acidic ion exchange resins). Selectivity for dimers using a solid phosphoric acid catalyst can be at least 75%, at least 85% or at least 90%. See, for example, US 2009/0099400 A1 and US 6,660,898 B1.

**[0617]** Efficient dimerization can sometimes require the presence of a polar component(s) such as water and oxygenated compound in the feed stream. Examples include alcohols such as methanol, ethanol and t-butanol, ethers such as methyl t-butyl ether (MTBE) and methyl t-amyl ether (TAME) or an ester such as C1 to C5 acetates. In some embodiments, isoamylenes can be converted to ethers such as TAME by treatment with alcohols in the presence of an acid catalyst.


**[0618]** In some embodiments, the C10 dimers of mono-olefins produced by any of the methods described herein can be reduced to fully saturated C10 alkylates (e.g., by hydrogenation). In a particular embodiment, isoprene or a mono-olefin can be reduced to an alkylate using a catalyst containing an acid component, such as sulfuric acid, a fluorosulfonic acid, a perhaloalkylsulfonic acid, an ionic liquid, or a mixture of Bronsted acids and Lewis acids, mixed with a polymer component, such as a polyacrylate. (See US 2010/0094072 A1).

**[0619]** In some embodiments, a commercially beneficial amount of highly pure isoprene starting material undergoes oligomerization in the presence of an acid catalysts to produce dimers, trimers, higher oligomers, aromatic products, and/or polymeric products. Kinetic control of the reaction can favor certain products, for example lower oligomers, although gum formation and coking are known issues leading to catalyst deactivation.


#### *Exemplary unsaturated isoprene derivatives*

**[0620]** In some embodiments, the compositions and systems for producing a fuel constituent from isoprene further comprise an unsaturated hydrocarbon or oxygenate intermediate for chemical transformation of an isoprene starting composition to a fuel constituent. In some embodiment, the unsaturated hydrocarbon intermediate comprise one or more unsaturated dimers of isoprene selected from the group consisting of 1,2-di(prop-1-en-2-yl)cyclobutane, 1,3-


di(prop-1-en-2-yl)cyclobutane, 1-methyl-1-vinyl-3-(prop-1-en-2-yl)cyclobutane, 1-methyl-1-vinyl-2-(prop-1-en-2-yl)cyclobutane, 1,3-dimethyl-1,3-divinylcyclobutane, 1,2-dimethyl-1,2-divinylcyclobutane, 1-methyl-4-(prop-1-en-2-yl)cyclohex-1-ene, 1-methyl-5-(prop-1-en-2-yl)cyclohex-1-ene, 1,4-dimethyl-4-vinylcyclohexene, 2,4-dimethyl-4-vinylcyclohexene, 1,5-dimethylcycloocta-1,5-diene, 1,6-dimethylcycloocta-1,5-diene, 1,4-dimethyl-4-vinyl-1-cyclohexene, 2,4-dimethyl-4-vinyl-1-cyclohexene, 2,7-dimethyl-1,3,7-octatriene, 2,7-dimethyl-2,4,6-octatriene, 2,6-dimethyl-1,3-cyclooctadiene, 2,6-dimethyl-1,4-cyclooctadiene, 3,7-dimethyl-1,5-cyclooctadiene, 3,7-dimethyl-1,3-cyclooctadiene and 3,6-dimethyl-1,3-cyclooctadiene. In some embodiments, the unsaturated hydrocarbon intermediate comprises one or more unsaturated trimers such as  $\alpha$ -farnesene,  $\beta$ -farnesene, trimethylcyclododecatrienes (e.g. 1,5,9-trimethyl-(1*E*,5*E*,9*E*)-cyclododecatriene and positional and geometric isomers thereof) and trimethyldodecatetraenes and the like. In some embodiments, the unsaturated oxygenate intermediate comprise one or more unsaturated methyl ethers such as 1-methoxy-2,7-dimethyl-2,7-octadiene and 3-methoxy-2,7-dimethyl-1,7-octadiene and the like. In some embodiments, the unsaturated oxygenate intermediate comprise one or more unsaturated ethyl ethers such as ethyl 3-methyl-3-butenyl ether, ethyl 1,1-dimethyl-2-propenyl ether, ethyl 1,2-dimethyl-2-propenyl ether, ethyl 2-methyl-3-butenyl ether and the like. In some embodiments, the unsaturated oxygenate intermediate comprise one or more unsaturated alcohols such as 3-methyl-3-buten-1-ol, 2-methyl-3-buten-2-ol, 3-methyl-3-buten-2-ol, 2-methyl-3-buten-1-ol and the like. In some embodiments, the unsaturated oxygenate intermediate comprise one or more unsaturated esters such as 3-methyl-3-buten-1-yl acetate, 2-methyl-3-buten-2-yl acetate, 3-methyl-3-buten-2-yl acetate, 2-methyl-3-buten-1-yl acetate and esters of other C<sub>3</sub>-C<sub>18</sub> aliphatic carboxylic acids. In some embodiment, the unsaturated hydrocarbon intermediate comprise one or more isoamylenes, e.g. 2-methylbut-1-ene, 3-methyl-but-1-ene and 2-methylbut-2-ene. In some embodiments, the unsaturated hydrocarbon intermediate comprise one or more diisoamylenes derived from dimerization of isoamylenes.

**Scheme I.** Exemplary unsaturated 6- and 8-membered ring intermediates


1-methyl-4-(prop-1-en-2-yl)cyclohex-1-ene




1-methyl-5-(prop-1-en-2-yl)cyclohex-1-ene




1,4-dimethyl-4-vinylcyclohexene




2,4-dimethyl-4-vinylcyclohexene




2,6-dimethyl-1,3-cyclooctadiene




2,6-dimethyl-1,4-cyclooctadiene




3,7-dimethyl-1,3-cyclooctadiene




3,7-dimethyl-1,5-cyclooctadiene




1,5-dimethylcycloocta-1,5-diene




1,6-dimethylcycloocta-1,5-diene




3,6-dimethyl-1,3-cyclooctadiene

**Scheme II.** Exemplary unsaturated 4-membered ring intermediates


1-methyl-3-(prop-1-en-2-yl)-1-vinylcyclobutane




1,3-dimethyl-1,3-divinylcyclobutane




1,2-di(prop-1-en-2-yl)cyclobutane






1-methyl-2-(prop-1-en-2-yl)-1-vinylcyclobutane




1,2-dimethyl-1,2-divinylcyclobutane





1,3-di(prop-1-en-2-yl)cyclobutane

**Scheme III.** Exemplary unsaturated isoprene telomer and oxygenate intermediates**Scheme IV.** Exemplary unsaturated ethyl ether intermediates**Scheme V.** Exemplary unsaturated alcohol intermediates


**Scheme VI.** Exemplary unsaturated ester intermediates*Exemplary hydrogenation of unsaturated intermediates*

**[0621]** The unsaturated isoprene derivatives are subject hydrogenation in the presence of a hydrogenation catalyst to produce saturated compounds. The saturated compounds are characterized and their values as fuels are assessed. In some embodiments, the hydrogen source for hydrogenation is hydrogen gas. In some embodiments, the hydrogen gas is co-produced with the bioisoprene as described in U.S. provisional patent application No.61/141,652, filed on December 30, 2008 and US 2009/0203102 A1. In some embodiments, the hydrogenation catalyst is a palladium based catalyst such as Pd/C (e.g. 5% (wt.) Pd/C). In some embodiments, the hydrogenation catalyst is a Raney Nickel catalyst. In some embodiments, the hydrogenation catalyst is a homogenous catalyst such as ruthenium or rhodium based homogenous hydrogenation catalysts. In some embodiments, unsaturated isoprene dimers and trimers are hydrogenated to produce saturated C10 and C15 hydrocarbons suitable for making fuels. In some embodiments, unsaturated cyclic dimers are hydrogenated to produce saturated cyclic C10 hydrocarbons such as 1,2-bis(isopropyl)cyclobutane, 1,2-bis(isopropyl)cyclobutane, 1-methyl-4-isopropylcyclohexane, 1-methyl-3-isopropylcyclohexane, 1-ethyl-1,4-dimethylcyclohexane, 1-ethyl-1,3-dimethylcyclohexane, 1,5-dimethylcyclooctane and 1,4-dimethylcyclooctane. In some embodiments, unsaturated cyclic trimers are hydrogenated to produce saturated cyclic C15 hydrocarbons such as 1,5,9-trimethylcyclododecane and 1,5,10-trimethylcyclododecane (see Scheme VII). In some embodiments, unsaturated linear dimers are hydrogenated to produce saturated aliphatic C10 hydrocarbons such as 2,6-dimethyloctane, 2,7-dimethyloctane and 3,6-dimethyloctane. In some embodiments, unsaturated linear trimers are hydrogenated to produce saturated aliphatic C15 hydrocarbons such as 2,6,10-trimethyldodecane, 2,7,10-trimethyldodecane and 3,7,10-trimethyldodecane (see Scheme VIII). In some embodiments, the product of the dimerization of isoamylenes (diamylenes or C10 dimates) are fully hydrogenated


to isoparaffins (e.g. 2,3,4,4-tetramethylhexane, 2,2,3,4-tetramethylhexane, 2,3,3,4-tetramethylhexane and 3,3,5-trimethylheptane) (see Scheme VIIIa). In some embodiments, a commercially beneficial amount of highly pure isoprene starting composition is hydrogenated to produce a product comprising 2-methylbutane. In some embodiments, the unsaturated isoprene hydroxylates are hydrogenated to produce saturated hydroxylates such as C5 alcohols and diols (e.g. 3-methyl-butan-1-ol, 2-methyl-butan-1-ol and 2-methyl-butan-2-ol, 3-methyl-butan-1,3-diol and 2-methyl-butan-2,3-diol), C-10 alcohols and diols (e.g. 3,7-dimethyloctan-1-ol, 2,7-dimethyloctan-1-ol, 2,7-dimethyloctan-2-ol and 2,7-dimethyloctan-2,7-diol) and cyclic C-10 alcohols (e.g. 2-(4-methylcyclohexyl)propan-2-ol, 2-(4-methylcyclohexyl)propan-1-ol, 2-(1,4-dimethylcyclohexyl)ethanol and 4-ethyl-1,4-dimethylcyclohexanol) (see Scheme IX). In some embodiments, the unsaturated isoprene oxygenates are hydrogenated to produce saturated others such as 1,3-diethoxy-3-methylbutane, 1-ethoxy-3-methylbutane, 1-methoxy-2,7-dimethyloctane and 3-methoxy-2,7-dimethyloctane (see Scheme X). It is understood that when an alkene moiety is hydrogenated, one or more stereo isomers are produced. The relative ratios between the stereo isomers depend on the reaction conditions and the catalysts used. When applicable, each and every stereo isomer is intended for the saturated hydrocarbons and oxygenates described herein.

**Scheme VII.** Examples of cyclic hydrocarbons derived from isoprene



Cyclohexanes from thermal or catalytic cyclodimerization




1,5-dimethyl- and 1,6-dimethylcyclooctane from thermal or catalytic cyclodimerization




1,5,9- and 1,5,10-trimethylcyclododecane from cyclic trimerization of isoprene

**Scheme VIII.** Examples of aliphatic hydrocarbons derived from isoprene**Scheme VIIIa.** Examples of isodecanes derived from isoamylenes


**Scheme IX.** Examples of IsoFuel™ alcohols derived from isoprene



C5 alcohols and diols




C10 alcohols and diols




Cyclic C10 alcohols


**Scheme X.** Examples of IsoFuel™ oxygenates derived from isoprene





3-methyltetrahydrofuran





3-methyl-2-butanone



Isopentyl acetate



Reaction products of isoprene and ethanol  
(see attached presentation from S. Reyer)



Alkoxy-derivatives produced by Pd-catalyzed  
telomerization of isoprene in methanol solvent.  
(see Zakharkin (1976))

**[0622]** In some embodiment, the fuel constituent produced by chemical transformation of a commercially beneficial amount of highly pure isoprene starting composition comprises saturated isoprene derivatives. In some embodiments, the fuel constituent comprises saturated C10 and C15 hydrocarbons derived from isoprene. In some embodiments, the fuel constituent comprises one or more saturated cyclic C10 hydrocarbons selected from the group consisting of 1,2-bis(isopropyl)cyclobutane, 1,2-bis(isopropyl)cyclobutane, 1-methyl-4-isopropylcyclohexane, 1-methyl-3-isopropylcyclohexane, 1-ethyl-1,4-dimethylcyclohexane, 1-ethyl-1,3-dimethylcyclohexane, 1,5-dimethylcyclooctane and 1,4-dimethylcyclooctane. In some embodiments, the fuel constituent comprises one or more saturated cyclic C15 hydrocarbons selected from the group consisting of 1,5,9-trimethylcyclododecane and 1,5,10-trimethylcyclododecane. In some embodiments, the fuel constituent comprises one or more saturated aliphatic C10 hydrocarbons selected from the group consisting of 2,6-dimethyloctane, 2,7-dimethyloctane and 3,6-dimethyloctane. In some embodiments, the fuel constituent comprises one or more saturated aliphatic C15 hydrocarbons selected from the group consisting

of 2,6,10-trimethyldodecane, 2,7,10-trimethyldodecane and 3,7,10-trimethyldodecane. In some embodiments, the fuel constituent comprises 2-methylbutane. In some embodiments, the fuel constituent comprises one or more isoparaffins selected from the group consisting of 2,3,4,4-tetramethylhexane, 2,2,3,4-tetramethylhexane, 2,3,3,4-tetramethylhexane and 3,3,5-trimethylheptane. In some embodiments, the fuel constituent comprises one or more saturated hydroxylates selected from the group consisting of 3-methyl-butan-1-ol, 2-methyl-butan-1-ol and 2-methyl-butan-2-ol, 3-methyl-butan-1,3-diol, 2-methyl-butan-2,3-diol, 3,7-dimethyloctan-1-ol, 2,7-dimethyloctan-1-ol, 2,7-dimethyloctan-2-ol, 2,7-dimethyloctan-2,7-diol, 2-(4-methylcyclohexyl)propan-2-ol, 2-(4-methylcyclohexyl)propan-1-ol, 2-(1,4-dimethylcyclohexyl)ethanol and 4-ethyl-1,4-dimethylcyclohexanol. In some embodiments, the fuel constituent comprises one or more saturated ethers selected from the group consisting of 1,3-dicthoxy-3-methylbutane, 1-ethoxy-3-methylbutane, 1-methoxy-2,7-dimethyloctane and 3-methoxy-2,7-dimethyloctane. In some embodiments, the fuel constituent comprises one or more oxygenates of isoprene selected from the group consisting of 3-methyltetrahydrofuran, 3-methyl-2-butanone and isopentyl acetate.

**[0623]** In some embodiments, the compositions and systems for producing a fuel constituent from isoprene further comprise catalysts for catalyzing the chemical transformation of an isoprene starting composition to a fuel constituent or an intermediate for making a fuel constituent. In some embodiments, the compositions and systems for producing a fuel constituent from isoprene further comprise catalysts for catalyzing hydrogenation of an unsaturated intermediate to produce a saturated fuel constituent. In some embodiments, the catalyst is any catalyst described or a combination of one or more of the catalyst described herein.

#### ***Method and/or Processes for Producing Fuels***

**[0624]** The invention provides methods and/or processes for producing a fuel constituent from isoprene comprising: (a) obtaining a commercially beneficial amount of highly pure isoprene; and (b) chemically transforming at least a portion of the commercially beneficial amount of highly pure isoprene to a fuel constituent. In one embodiment, a highly pure isoprene composition is transformed to a fuel component in a continuous chemical process. In another embodiment, a highly pure isoprene is further purified before chemical transformation to a fuel composition. In yet another embodiment, a highly pure isoprene is chemically transformed to an intermediate composition; the intermediate composition undergoes further chemical

transformations to produce a fuel or a fuel component. In a further embodiment, the fuel component produced is mixed with a petroleum distillate and other optional additives to make a fuel. In some preferred embodiments, the highly pure isoprene is a bioisoprene composition.

**[0625]** In some embodiments, the method for producing a fuel constituent from isoprene comprises obtaining a commercially beneficial amount of highly pure isoprene composition. In some embodiments, the highly pure isoprene composition useful in the invention comprises greater than or about 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mg of isoprene. In some embodiments, the highly pure isoprene composition comprises greater than or about 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 g of isoprene. In some embodiments, the starting isoprene composition comprises greater than or about 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000 kg of isoprene.

**[0626]** In some embodiments, the method for producing a fuel constituent from isoprene comprises obtaining a commercially beneficial amount of highly pure isoprene composition. In some embodiments, the highly pure isoprene starting composition comprises greater than or about 98.0, 98.5, 99.0, 99.5, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the starting composition. In some embodiments, the highly pure isoprene composition useful in the invention comprises greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition. In some embodiments, the highly pure isoprene composition comprises less than or about 2.0, 1.5, 1.0, 0.5, 0.2, 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% C5 hydrocarbons other than isoprene (such 1,3-cyclopentadiene, *cis*-1,3-pentadiene, *trans*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the composition. In some embodiments, the highly pure isoprene composition has less than or about 2.0, 1.5, 1.0, 0.5, 0.2, 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% for 1,3-cyclopentadiene, *cis*-1,3-pentadiene, *trans*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne by weight compared to the total weight of all C5 hydrocarbons in the composition. In particular embodiments, the highly pure isoprene composition has greater than about 2 mg of isoprene and has greater than or about 98.0, 98.5, 99.0, 99.5, 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition.

**[0627]** In some embodiments, the method for producing a fuel constituent from isoprene comprises obtaining a commercially beneficial amount of highly pure isoprene composition. In some embodiments, the highly pure isoprene composition useful in the invention has less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005  $\mu\text{g/L}$  of a compound that inhibits the polymerization of isoprene for any compound in the composition that inhibits the polymerization of isoprene. In particular embodiments, the composition also has greater than about 2 mg of isoprene.

**[0628]** In some embodiments, the method for producing a fuel constituent from isoprene comprises obtaining a commercially beneficial amount of highly pure isoprene composition. In some embodiments, the highly pure isoprene composition useful in the invention has one or more compounds selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms. In some embodiments, the highly pure isoprene composition has greater than or about 0.005, 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 60, 80, 100, or 120  $\mu\text{g/L}$  of ethanol, acetone, a C5 prenyl alcohol (such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-1-ol), or any two or more of the foregoing. In particular embodiments, the highly pure isoprene composition has greater than about 2 mg of isoprene and has one or more compounds selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms.

**[0629]** In some embodiments, the method for producing a fuel constituent from isoprene comprises obtaining a commercially beneficial amount of highly pure isoprene composition. In some embodiments, the highly pure isoprene composition useful in the invention includes isoprene and one or more second compounds selected from the group consisting of 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, acetaldehyde, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene, and 2,3-cycloheptenolpyridine. In various embodiments, the amount of one of these second components relative to the amount of isoprene in units of percentage by weight (*i.e.*, weight of the component divided by the weight of isoprene times 100) is at greater than or about 0.01, 0.02, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 110% (w/w). In some

embodiments, the amount of methanethiol relative to the amount of isoprene in units of percentage by weight is at less than 0.01% (w/w).

**[0630]** In some embodiments, the method for producing a fuel constituent from isoprene comprises obtaining a commercially beneficial amount of highly pure isoprene composition. In some embodiments, the method comprises obtaining a commercially beneficial amount of highly pure isoprene composition from a biological process comprising: (a) culturing cells comprising a heterologous nucleic acid encoding an isoprene synthase polypeptide under suitable culture conditions for the production of isoprene, wherein the cells (i) produce greater than about 400 nmole/g<sub>wcm</sub>/hr of isoprene, (ii) convert more than about 0.002 molar percent of the carbon that the cells consume from a cell culture medium into isoprene, or (iii) have an average volumetric productivity of isoprene greater than about 0.1 mg/L<sub>broth</sub>/hr of isoprene, and (b) producing isoprene. In some embodiments, the cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide, e.g. a naturally-occurring polypeptide from a plant such as *Pueraria*, and (ii) is operably linked to a promoter, e.g. a T7 promoter. In some embodiments, the cells are cultured in a culture medium that includes a carbon source, such as, but not limited to, a carbohydrate, glycerol, glycerine, dihydroxyacetone, one-carbon source, oil, animal fat, animal oil, fatty acid, lipid, phospholipid, glycerolipid, monoglyceride, diglyceride, triglyceride, renewable carbon source, polypeptide (e.g., a microbial or plant protein or peptide), yeast extract, component from a yeast extract, or any combination of two or more of the foregoing. In some embodiments, the cells are cultured under limited glucose conditions. In some embodiment, the cells further comprise a heterologous nucleic acid encoding an IDI polypeptide. In some embodiments, the cells further comprise a heterologous nucleic acid encoding an MDV pathway polypeptide. In some embodiment, the method comprises producing isoprene using the methods described in U.S. provisional patent application Nos. 61/134,094, filed on July 2, 2008, WO 2010/003007, and U.S. patent application No. 12/335,071, filed December 15, 2008 (US 2009/0203102 A1), which are incorporated by reference in their entireties.

**[0631]** In some embodiment, the method comprises obtaining a gas phase (off-gas) produced by cells in culture that produces isoprene. In some embodiments, the cells in culturing produce greater than about 400 nmole/g<sub>wcm</sub>/hr of isoprene. In some embodiments, the gas phase comprises greater than or about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 µg/L of isoprene when sparged at a rate of 1 vvm. In some embodiments, the volatile organic fraction of the gas phase comprises greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the volatile organic fraction. In some

embodiments, the volatile organic fraction of the gas phase comprises less than or about 2.0, 1.5, 1.0, 0.5, 0.2, 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% C5 hydrocarbons other than isoprene (such 1,3-cyclopentadiene, *cis*-1,3-pentadiene, *trans*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the volatile organic fraction. In some embodiments, the volatile organic fraction of the gas phase has less than or about 2.0, 1.5, 1.0, 0.5, 0.2, 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% for 1,3-cyclopentadiene, *cis*-1,3-pentadiene, *trans*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne by weight compared to the total weight of all C5 hydrocarbons in the volatile organic fraction. In particular embodiments, the volatile organic fraction of the gas phase has greater than about 2 mg of isoprene and has greater than or about 99.90, 99.92, 99.94, 99.96, 99.98, or 100% isoprene by weight compared to the total weight of all C5 hydrocarbons in the volatile organic fraction.

**[0632]** In some embodiment, the method comprises obtaining a gas phase (off-gas) produced by cells in culture that produces isoprene. In some embodiments, the volatile organic fraction of the gas phase has less than or about 50, 40, 30, 20, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, or 0.005  $\mu\text{g/L}$  of a compound that inhibits the polymerization of isoprene for any compound in the volatile organic fraction of the gas phase that inhibits the polymerization of isoprene. In particular embodiments, the volatile organic fraction of the gas phase also has greater than about 2 mg of isoprene. In some embodiments, the volatile organic fraction of the gas phase has one or more compounds selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms. In some embodiments, the volatile organic fraction of the gas phase has greater than or about 0.005, 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 60, 80, 100, or 120  $\mu\text{g/L}$  of ethanol, acetone, a C5 prenyl alcohol (such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-1-ol), or any two or more of the foregoing. In particular embodiments, the volatile organic fraction of the gas phase has greater than about 2 mg of isoprene and has one or more compounds selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms. In some embodiments, the volatile organic fraction of the gas phase has includes isoprene and one or more second compounds selected from the group consisting of 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, acetaldehyde, methanethiol, methyl acetate, 1-propanol,

diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene, and 2,3-cycloheptenolpyridine. In various embodiments, the amount of one of these second components relative to amount of isoprene in units of percentage by weight (*i.e.*, weight of the component divided by the weight of isoprene times 100) is at greater than or about 0.01, 0.02, 0.05, 0.1, 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 110% (w/w) in the volatile organic fraction of the gas phase. In some embodiments, the method further includes recovering the isoprene from the gas phase. For example, the isoprene in the gas phase comprising isoprene can be recovered using standard techniques, such as gas stripping, membrane enhanced separation, fractionation, adsorption/desorption, pervaporation, thermal or vacuum desorption of isoprene from a solid phase, or extraction of isoprene immobilized or absorbed to a solid phase with a solvent (see, for example, U.S. Patent Nos. 4,703,007 and 4,570,029, which are each hereby incorporated by reference in their entireties, particularly with respect to isoprene recovery and purification methods). In some particular embodiments, extractive distillation with an alcohol (such as ethanol, methanol, propanol, or a combination thereof) is used to recover the isoprene. In some embodiments, the recovery of isoprene involves the isolation of isoprene in a liquid form (such as a neat solution of isoprene or a solution of isoprene in a solvent). Gas stripping involves the removal of isoprene vapor from the fermentation off-gas stream in a continuous manner. Such removal can be achieved in several different ways including, but not limited to, adsorption to a solid phase, partition into a liquid phase, or direct condensation (such as condensation due to exposure to a condensation coil or do to an increase in pressure). In some embodiments, membrane enrichment of a dilute isoprene vapor stream above the dew point of the vapor resulting in the condensation of liquid isoprene. In some embodiments, the recovered isoprene is compressed and condensed.

**[0633]** The recovery of isoprene may involve one step or multiple steps. In some embodiments, the removal of isoprene vapor from a fermentation off-gas and the conversion of isoprene to a liquid phase are performed simultaneously. For example, isoprene can be directly condensed from the off-gas stream to form a liquid. In some embodiments, the removal of isoprene vapor from the fermentation off-gas and the conversion of isoprene to a liquid phase are

performed sequentially. For example, isoprene may be adsorbed to a solid phase and then extracted from the solid phase with a solvent.

**[0634]** In some embodiments, a method is provided for producing a cyclic dimer of isoprene comprising heating neat bioisoprene. The cyclic dimers of isoprene produced may be 6-membered ring dimers (e.g. a [2+4] electrocyclization product such as limonene) or 8-membered ring dimers or a mixture thereof. Examples of 6-membered ring dimers include but not limited to 1-methyl-4-(prop-1-en-2-yl)cyclohex-1-ene, 1-methyl-5-(prop-1-en-2-yl)cyclohex-1-ene, 1,4-dimethyl-4-vinylcyclohexene, 2,4-dimethyl-4-vinylcyclohexene and the like. Examples of 8-membered ring dimers include but not limited to 1,5-dimethylcycloocta-1,5-diene, 1,6-dimethylcycloocta-1,5-diene and the like. In one embodiment, neat biologically produced isoprene is dimerized by heating to a temperature of about 100 °C to about 300 °C, preferably about 150 °C to about 250 °C. The pressure is maintained at about 2 to 3 atm. In another embodiment, a catalyst suitable for catalyzing dimerization of conjugated dienes may be used. The proportions of various dimers in the product mixture may be controlled by the catalyst and other reaction conditions. For example, a nickel catalyst can promote formation of 8-membered ring dimers.

**[0635]** In some embodiments, a method is provided for producing a cyclic dimer of isoprene comprising photo-dimerization of bioisoprene. The cyclic dimer of isoprene produced may be one or more 4-membered ring dimer or a mixture thereof. Examples of 4-membered ring dimers include but not limited to 1,2-di(prop-1-en-2-yl)cyclobutane, 1,3-di(prop-1-en-2-yl)cyclobutane, 1-methyl-1-vinyl-3-(prop-1-en-2-yl)cyclobutane, 1-methyl-1-vinyl-2-(prop-1-en-2-yl)cyclobutane, 1,3-dimethyl-1,3-divinylcyclobutane, 1,2-dimethyl-1,2-divinylcyclobutane and the like. In one embodiment, neat biologically produced isoprene is dimerized by irradiating with UV light, preferably in presence of a photosensitizer such as benzophenone.

**[0636]** Isoprene dimers can be hydrogenated to form saturated C<sub>10</sub> hydrocarbons that can serve as fuels or blended into fuels. In one embodiment, the unsaturated isoprene dimers are subjected to catalytic hydrogenation to produce partially hydrogenated and/or fully hydrogenated products. Examples of fully hydrogenated products include but not limited to 1-methyl-4-isopropylcyclohexane and 1-methyl-5-isopropylcyclohexane, 1,4-dimethyl-4-ethylcyclohexane, 2,4-dimethyl-4-ethylcyclohexane, 1,2-diisopropylcyclobutane and 1,3-diisopropylcyclobutane, 1-methyl-1-vinyl-3-(prop-1-en-2-yl)cyclobutane, 1-methyl-1-ethyl-2-(prop-2-yl)cyclobutane,

1,3-dimethyl-1,3-ethylcyclobutane, 1,2-dimethyl-1,2-diethylcyclobutane, 1,5-dimethylcyclooctane, 1,6-dimethylcyclooctane and the like.

**[0637]** In some embodiments, the method for producing a fuel constituent from isoprene comprises: (a) obtaining a commercially beneficial amount of any of the highly pure isoprene starting composition described herein; (b) chemically transforming at least a portion of the highly pure isoprene starting composition to a fuel constituent comprising: (i) heating the highly pure isoprene composition to over or about 100 °C under pressure; (ii) converting at least a portion of the starting isoprene composition to unsaturated cyclic isoprene dimers; and (iii) hydrogenating the unsaturated cyclic isoprene dimers to produce saturated cyclic isoprene dimers. In some embodiments, the starting isoprene composition is heated to over or about 100, 125, 150, 175, 200, 225 or 250 °C under pressure. In some embodiments, the starting isoprene composition is heated in the presence of an antioxidant (e.g. 2,6-di-tert-butyl-4-methylphenol) to prevent radical-mediated polymerization. In one embodiment, the thermal dimerization of isoprene is performed in presence of dinitroresol as polymerization inhibitor. Suitable antioxidants may be used as polymerization inhibitors. In some embodiments, at least a portion of the starting isoprene composition to a mixture of unsaturated dimers that includes 6 and 8-membered rings, for examples, limonene (1-methyl-4-(prop-1-en-2-yl)cyclohex-1-ene), 1-methyl-5-(prop-1-en-2-yl)cyclohex-1-ene, 1,4-dimethyl-4-vinylcyclohexene, 2,4-dimethyl-4-vinylcyclohexene, 1,5-dimethylcycloocta-1,5-diene, 1,6-dimethylcycloocta-1,5-diene, 2,6-dimethyl-1,3-cyclooctadiene, 2,6-dimethyl-1,4-cyclooctadiene, 3,7-dimethyl-1,5-cyclooctadiene, 3,7-dimethyl-1,3-cyclooctadiene and 3,6-dimethyl-1,3-cyclooctadiene. In some embodiments, greater than or about 20, 30, 40, 50, 60, 70, 75, 80, 85, 90, 95, 98, 99 or 100% of isoprene in starting isoprene composition is converted to unsaturated cyclic isoprene dimers. In some embodiments, hydrogenation of the unsaturated cyclic isoprene dimers is catalyzed by a hydrogenation catalyst such as a palladium based catalyst (e.g. Pd/C, e.g. 5% (wt.) Pd/C.) In some embodiments, the saturated cyclic isoprene dimers comprise one or more C<sub>10</sub> hydrocarbons selected from the group consisting of 1-methyl-4-isopropylcyclohexane, 1-methyl-3-isopropylcyclohexane, 1,5-dimethylcyclooctane and 1,4-dimethylcyclooctane. In some preferred embodiments, the starting isoprene composition is a bioisoprene composition.

**[0638]** In some embodiments, the method for producing a fuel constituent from isoprene comprises: (a) obtaining a commercially beneficial amount of any of the highly pure isoprene starting composition described herein; (b) chemically transforming at least a portion of the highly pure isoprene starting composition to a fuel constituent comprising: (i) contacting the

highly pure isoprene composition with a catalyst system; (ii) converting at least a portion of the starting isoprene composition to unsaturated isoprene dimers and/or trimers; and (iii) hydrogenating the unsaturated dimers and/or trimers to produce saturated C<sub>10</sub> and/or C<sub>15</sub> hydrocarbons. In some embodiments, greater than or about 20, 30, 40, 50, 60, 70, 75, 80, 85, 90, 95, 98, 99 or 100% of isoprene in starting isoprene composition is converted to unsaturated dimers and/or trimers of isoprene. In some embodiments, the starting isoprene composition is contacted with appropriate catalyst systems known in the art to yield one or more of unsaturated cyclic isoprene dimers selected from the group consisting of 1,2-di(prop-1-en-2-yl)cyclobutane, 1,3-di(prop-1-en-2-yl)cyclobutane, 1-methyl-1-vinyl-3-(prop-1-en-2-yl)cyclobutane, 1-methyl-1-vinyl-2-(prop-1-en-2-yl)cyclobutane, 1,3-dimethyl-1,3-divinylcyclobutane, 1,2-dimethyl-1,2-divinylcyclobutane, 1-methyl-4-(prop-1-en-2-yl)cyclohex-1-ene, 1-methyl-5-(prop-1-en-2-yl)cyclohex-1-ene, 1,4-dimethyl-4-vinylcyclohexene, 2,4-dimethyl-4-vinylcyclohexene, 1,5-dimethylcycloocta-1,5-diene, 1,6-dimethylcycloocta-1,5-diene, 1,4-dimethyl-4-vinyl-1-cyclohexene, 2,4-dimethyl-4-vinyl-1-cyclohexene, 2,7-dimethyl-1,3,7-octatriene, 2,7-dimethyl-2,4,6-octatriene, 2,6-dimethyl-1,3-cyclooctadiene, 2,6-dimethyl-1,4-cyclooctadiene, 3,7-dimethyl-1,5-cyclooctadiene, 3,7-dimethyl-1,3-cyclooctadiene and 3,6-dimethyl-1,3-cyclooctadiene. In some embodiments, the starting isoprene composition is contacted with appropriate catalyst systems known in the art to yield one or more of unsaturated cyclic isoprene trimers such as trimethylcyclododecatrienes and trimethyldodecatetraenes and the like. In some embodiments, the starting isoprene composition is contacted with appropriate catalyst systems known in the art to yield one or more of unsaturated linear dimers and/or trimers of isoprene such as dimethyloctatrienes (e.g. 2,7-dimethyl-1,3,7-octatriene and 2,7-dimethyl-2,4,6-octatriene) and trimethyldodecatetraenes (e.g. 2,6,10-trimethyl-1,5,9,11-dodecatetraene,  $\alpha$ -farnesene and  $\beta$ -farnesene) and the like. In some preferred embodiments, the starting isoprene composition is a bioisoprene composition.

**[0639]** In some embodiments, the method for producing a fuel constituent from isoprene comprises contacting the highly pure isoprene composition with a catalyst system to convert at least a portion of the starting isoprene composition to unsaturated isoprene dimers and/or trimers. In some embodiments, the catalyst system comprise a Ni, Fe or Co catalyst and the isoprene in the starting composition is converted an 8-membered ring isoprene dimer comprising dimethylcyclooctadienes such as 1,5-dimethylcycloocta-1,5-diene and 1,6-dimethylcycloocta-1,5-diene. In some embodiments, the catalyst system comprises a nickel compound. Ni-catalyzed dimerization of isoprene yields a dimethyl-1,5-cyclooctadiene mixture consisting of


about 90 to 10, 80 to 20, 70 to 30, 60 to 40, 50 to 50, 40 to 60, 30 to 70, 20 to 80 and 10 to 90 ratio of 1,5-dimethyl-1,5-cyclooctadiene to 1,6-dimethyl-1,5-cyclooctadiene. In one embodiment, the catalyst system comprises a 3-component catalyst containing Ni carboxylates or  $\beta$ -ketoones, organoaluminum or organomagnesium compounds and substituted triphenylphosphite. For example, a degassed solution of a highly pure isoprene starting composition in anhydrous toluene is mixed with Ni(acac)<sub>2</sub>, Et<sub>3</sub>Al, and tris(3,4-bis(dimethylamino)phenyl)phosphite under nitrogen atmosphere and the mixture is heated at 95 °C to give dimethylcyclooctadiene. In another embodiment, the catalyst system comprises Fe carboxylates or  $\beta$ -diketone compounds, organo-Al or Mg compounds, and 2,2'-dipyridyl derivatives having electron-donating groups. For example, a starting isoprene composition is heated with a mixture of Fe acetylacetonate, 4,4'-dimethyl-2,2'-dipyridyl, and Et<sub>3</sub>Al in toluene to give 1,6-dimethyl-1,5-cyclooctadiene in good yields. In some preferred embodiments, the starting isoprene composition is a bioisoprene composition.

**[0640]** In some embodiments, the method for producing a fuel constituent from isoprene comprises contacting the highly pure isoprene composition with a catalyst system to convert at least a portion of the starting isoprene composition to unsaturated isoprene dimers and/or trimers. In some embodiments, the catalyst system comprises a Ru, Fe, Ni or Pd catalyst or a combination thereof and the isoprene in the starting composition is converted to a mixture comprising 6-membered ring isoprene dimers. In one embodiment, the catalyst system is a Fe(NO)<sub>2</sub>Cl-bis(1,5-cyclooctadiene)nickel catalyst system and the isoprene in the starting composition is cyclodimerized at low temperatures (e.g. from -5 to +20 °C) to give 1-methyl- and 2-methyl-4-isopropenyl-1-cyclohexene and 1,4- and 2,4-dimethyl-4-vinyl-1-cyclohexene. In another embodiment, contacting with a mixed catalyst of a tris(substituted hydrocarbyl) phosphite, arsenite, or antimonite and a Group VIII metal(0) compound (e.g. Ni acetylacetonate) converts the isoprene in the starting composition to 1,4-dimethyl-4-vinyl-1-cyclohexene and 1,5-dimethyl-1,5-cyclooctadiene. In another embodiment, contacting an isoprene starting composition with a ruthenium catalyst (e.g. see Itoh, Kenji; Masuda, Katsuyuki; Fukahori, Takahiko; Nakano, Katsumasa; Aoki, Katsuyuki; Nagashima, Hideo, *Organometallics* (1994), 13(3), 1020-9) converts isoprene to C<sub>10</sub> cyclic dimers (e.g. a mixture of dimethyl-cyclooctadienes). The ruthenium catalyst can be synthesized in two steps from RuCl<sub>3</sub> and pentamethylcyclopentadiene (C<sub>5</sub>Me<sub>5</sub>H). The process may be performed in batch mode and the catalyst recovered and recycled. In some preferred embodiments, the starting

isoprene composition is a bioisoprene composition. One embodiment of the method is illustrated in Scheme XI.

**[0641]** In some embodiments, the method for producing a fuel constituent from isoprene comprises contacting the highly pure isoprene composition with a catalyst system to convert at least a portion of the starting isoprene composition to unsaturated isoprene dimers and/or trimers. In some embodiments, the catalyst system comprises a Ni, Ti, Al, or Mg catalyst or a mixture thereof and the isoprene in the starting composition is converted to a mixture comprising cyclic isoprene trimers such as trimethylcyclododecatrienes. In one embodiment, the catalyst system for the trimerization of isoprene comprising Ni and/or Ti, one or more organometallic compound, and a Group VA compound. The reaction may be conducted in a hydroxyl group-containing solvent. In another embodiment, oligomerization of isoprene catalyzed by nickel naphthenate and isoprenemagnesium in the presence of various phosphites as electron donors give cyclic dimers containing dimethylcyclooctadiene, in particular 1,1,1-tris(hydroxymethyl)propane phosphite gives trimethylcyclododecatriene selectively.

**Scheme XI**




**[0642]** In some embodiments, the method for producing a fuel constituent from isoprene comprises contacting the highly pure isoprene composition with a catalyst system to convert at least a portion of the starting isoprene composition to unsaturated isoprene dimers and/or trimers. In some embodiments, the catalyst system comprises a Ni, Pd or Cr catalyst or a mixture thereof and the isoprene in the starting composition is converted to telomers or linear dimers and/or trimers. In one embodiment, a catalyst system comprising Pd(0) complexes (e.g. Pd(acac)<sub>2</sub>-Ph<sub>3</sub>P and Pd(OAc)<sub>2</sub>-Ph<sub>3</sub>P) catalyzes dimerization and telomerization of isoprene to

give linear isoprene dimers (e.g. 2,7-dimethyl-1,3,7-octatriene). In one variation, the reaction is performed in methanol as a solvent and methyl ethers such as methoxydimethyloctadienes (e.g. 1-methoxy-2,7-dimethyl-2,7-octadiene and 3-methoxy-2,7-dimethyl-1,7-octadiene) are produced. In another embodiment, the catalyst system comprises divalent and trivalent transition metal-exchanged montmorillonites (e.g. Cr<sup>3+</sup>-montmorillonite). In another embodiment, the catalyst system comprises a Ni(0)-aminophosphinite catalyst and the isoprene in the starting composition is converted to regioselective tail-to-tail linear dimers. In some variations, the linear dimer formation is accompanied by a competitive cyclodimerization reaction. In another embodiment, the catalyst system comprises a chromium *N,N*-bis(diarylphosphino)amine catalyst (e.g. see Bowen, L.; Charernsuk, M.; Wass, D.F. *Chem. Commun.* (2007) 2835-2837) and the isoprene is converted to linear and cyclic C15 trimers. In one variation, the chromium catalyst is made *in situ* from CrCl<sub>3</sub>(THF)<sub>3</sub> and a PNP phosphine ligand.

**[0643]** In some embodiments, the method for producing a fuel constituent from a bioisoprene composition comprises chemically transforming a substantial portion of the isoprene in the bioisoprene composition by (i) contacting the bioisoprene composition with a catalyst for catalyzing trimerization of isoprene to produce an unsaturated isoprene trimer and (ii) hydrogenating the isoprene trimer to produce a fuel constituent. In some embodiments, at least about 95% of isoprene in the bioisoprene composition is converted to non-isoprene compounds during the chemical transformation.

**[0644]** In some embodiments, the method for producing a fuel constituent from isoprene comprises: (a) obtaining a commercially beneficial amount of any of the highly pure isoprene starting composition described herein; (b) converting at least a portion of the starting isoprene composition to unsaturated isoprene derivatives; and (c) hydrogenating the unsaturated isoprene derivatives to produce saturated compounds. In some embodiments, hydrogenation of unsaturated isoprene derivatives to saturated compounds is performed in batch mode. In some embodiments, hydrogenation of unsaturated isoprene derivatives to saturated compounds is performed in continuous mode. One embodiment of the method is illustrated in Scheme XII.

## Scheme XII




[0645] In some embodiments, the method for producing a fuel constituent from isoprene comprises: (a) obtaining a commercially beneficial amount of any of the highly pure isoprene starting composition described herein; (b) converting at least a portion of the starting isoprene composition to oxygenated isoprene derivatives; and optionally (c) hydrogenating any unsaturated oxygenated isoprene derivatives to produce saturated oxygenates. In some embodiments, the isoprene starting composition is contacted with a catalyst in the presence of alcohols (e.g. methanol or ethanol or mixtures thereof) to form oxygenated isoprene derivatives comprise one or more unsaturated or saturated ethers (e.g. methyl ethers or ethyl ethers or mixtures thereof). In some embodiments, the catalyst is an acid catalyst such as sulfuric acid, solid phase sulfuric acid (e.g., Dowex Marathon®), liquid and solid-phase fluorosulfonic acids (e.g. trifluoromethanesulfonic acid and Nafion-H (DuPont)). Zeolite catalysts can also be used, for example beta-zeolite, under conditions similar to those described by Hensel *et al.* [Hensen, K.; Mahaim, C.; Holderich, W.F., *Applied Catalysis A: General* (1997) 140(2), 311-329.] for the methoxylation of limonene and related monoterpenes. In some embodiments, the isoprene starting compositions or the unsaturated isoprene dimers or trimers undergo oxidation/hydrogenation to form the hydroxylated isoprene derivatives comprise one or more alcohols such as C5, C10 and C15 alcohols and diols. In some embodiments, the isoprene starting composition undergoes hydroxylation/esterification to form alcohols and esters. For example, bioisoprene or an unsaturated intermediate undergoes peroxidation to epoxides with peracids such as peracetic and 3-chloroperbenzoic acid; and hydration to give alcohols and diols with i) water and acid catalysts and ii) hydroboration methods. Such reactions are described in, for example, Michael B. Smith and Jerry March, *Advanced Organic Chemistry: Reactions*,

*Mechanisms, and Structure*, Sixth Edition, John Wiley & Sons, 2007. In some preferred embodiments, the starting isoprene composition is a bioisoprene composition.

**[0646]** In some embodiments, the method for producing a fuel constituent from isoprene comprises: (a) obtaining a commercially beneficial amount of any of the highly pure isoprene starting composition described herein; (b) partially hydrogenating the starting isoprene composition to mono-olefins (e.g. 2-methylbut-1-ene, 3-methyl-but-1-ene and 2-methylbut-2-ene); and (c) producing the fuel constituent from the mono-olefins. In one embodiment, the mono-olefin undergoes dimerization. In another embodiment, the mono-olefin is reacted with other olefins using traditional hydrocarbon cationic catalysis, such as that used to convert isobutylene to isooctane. The product of dimerization or reaction with other olefins are then undergoes hydrogenation to give saturated fuel constituents. In some preferred embodiments, the highly pure isoprene is a bioisoprene composition. In some embodiment, the starting isoprene composition partially hydrogenated using a palladium catalyst, such as Pd/CaCO<sub>3</sub>, Pd/BaSO<sub>4</sub>, Pd/C, Pd black, Pd/SiO<sub>3</sub>, Pd/Al<sub>2</sub>O<sub>3</sub>, or Pd/SiO<sub>2</sub>. In some embodiment, the starting isoprene composition partially hydrogenated using a silica-supported polyamidoamine (PAMAM) dendrimer-palladium complex. In some embodiment, the starting isoprene composition partially hydrogenated using a palladium-gold and palladium-silver catalysts (e.g., Pd-Au/SiO<sub>2</sub> and Pd-Ag/SiO<sub>2</sub>) have high selectivity for reducing isoprene to mono-olefins over fully reduced C5 alkanes. In some embodiment, the starting isoprene composition partially hydrogenated using a Group VIB metal on an inorganic support (e.g., a metal zeolite) as a catalyst, e.g. a Mo/Al<sub>2</sub>O<sub>3</sub> catalyst. In some embodiment, the starting isoprene composition partially hydrogenated using a monolithic catalyst bed, which may be in a honeycomb configuration. Catalyst support materials for the monolithic catalyst bed may include metals such as nickel, platinum, palladium, rhodium, ruthenium, silver, iron, copper, cobalt, chromium, iridium, tin, and alloys or mixtures thereof. In some embodiment, the starting isoprene composition partially hydrogenated using an eggshell Pd/d-Al<sub>2</sub>O<sub>3</sub> catalyst, particularly if the reaction is free of water. In some embodiment, the starting isoprene composition partially hydrogenated using a Group VIII metal catalyst promoted by a metal from Group IB, VIB, VIIB, or zinc to reduce poisoning of the catalyst. Methods for converting isoprene into isoamylenes (mono-olefins) can be performed in continuous or batch mode using both homogeneous or heterogeneous catalysts. One embodiment of the method is illustrated in Scheme XIII.

[0647] In some embodiments, isoamylenes produce from partial hydrogenation of isoprene undergoes trimerization in liquid phase over ion exchange resins and zeolites. See, GranGranollers, *Ind. Eng. Chem. Res.*, 49 (8), pp 3561–3570 (2001).


**Scheme XIII**



[0648] In some embodiments, the method for producing a fuel constituent from isoprene comprises: (a) obtaining a commercially beneficial amount of any of the highly pure isoprene starting composition described herein; (b) partially hydrogenating the starting isoprene composition to a mono-olefin (e.g. 2-methylbut-1-ene, 3-methyl-but-1-ene and 2-methylbut-2-ene); (c) contacting the mono-olefin with a catalyst for dimerization of mono-olefins to form a dimate with another mono-olefin; and (d) hydrogenating the product of dimerization (dimate) to produce saturated hydrocarbon fuel constituents. In some preferred embodiments, the highly pure isoprene is a bioisoprene composition. In some embodiments, the other mono-olefin is an isoamylenes derived from the highly pure isoprene starting composition. In some embodiments, the other mono-olefin is an olefin from another source such as propylene, butane or isobutene. In some embodiments, the catalyst for dimerization is a resin catalyst (e.g., Amberlyst, Amberlyst 35, Amberlyst 15, Amberlyst XN1010, Amberlyst XE586). In some embodiments, the catalyst for dimerization is a catalytic material containing an acidic mesoporous molecular sieve, such as a mesoporous sieve embedded in a zeolite structure, ZSM-5, ferrierite, ZSM-22, or ZSM-23. In some embodiments, the catalyst for dimerization is the catalytic material is thermally stable at high temperatures (e.g., at least 900 °C). In some embodiments, the catalyst for dimerization is a catalytic material containing an acidic mesoporous molecular sieve. In some embodiments, the catalyst for dimerization is a solid acidic catalyst (e.g., a solid phosphoric

acid catalyst, acidic ion exchange resins). One embodiment of the method is illustrated in Scheme XIV.

**Scheme XIV**



**[0649]** In some embodiments, the method for producing a fuel constituent from isoprene comprises: (a) obtaining a commercially beneficial amount of any of the highly pure isoprene starting composition described herein; (b) partially hydrogenating the starting isoprene composition to an isoamylenes (e.g. 2-methylbut-1-ene, 3-methyl-but-1-ene and 2-methylbut-2-ene); (c) contacting the isoamylenes with an alcohol and a catalyst to form an oxygenate; and (d) producing the fuel constituent from the isoamylenes oxygenate. In some preferred embodiments, the highly pure isoprene is a bioisoprene composition. In some embodiments, the isoamylenes is contacted with ethanol and the fuel oxygenate formed is an ether such as TAME.

**[0650]** In some embodiments, any of the methods described herein further include purifying the starting isoprene composition before the chemical transformation. For example, the isoprene produced using the compositions and methods of the invention can be purified using standard techniques. Purification refers to a process through which isoprene is separated from one or more components that are present when the isoprene is produced. In some embodiments, the isoprene is obtained as a substantially pure liquid. Examples of purification methods include (i) distillation from a solution in a liquid extractant and (ii) chromatography. As used herein, “purified isoprene” means isoprene that has been separated from one or more components that are present when the isoprene is produced. In some embodiments, the isoprene is at least about 20%, by weight, free from other components that are present when the isoprene is produced. In various embodiments, the isoprene is at least or about 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 95%, or 99%, by weight, pure. Purity can be assayed by any appropriate method,

e.g., by column chromatography, HPLC analysis, or GC-MS analysis. In some embodiments, bioisoprene is recovered from fermentation off-gas by initial adsorption to activated carbon, followed by desorption and condensation to give a liquid isoprene composition for chemical transformation to a fuel constituent.

### ***Continuous Process for Producing Fuels***

**[0651]** The invention also provides a continuous process for producing a fuel constituent from isoprene comprising: (a) continuously producing a commercially beneficial amount of highly pure isoprene; and (b) continuously transforming chemically at least a portion of the commercially beneficial amount of highly pure isoprene to a fuel constituent. In a continuous process according to the invention, a stream of highly pure isoprene is produced continuously, for example, by a biological process (e.g. culturing cells producing isoprene) and is passed to a reactor for chemical transformation. In some embodiments, the isoprene from a fermentation off-gas is separated from water and other permanent gases (e.g., O<sub>2</sub>, N<sub>2</sub> and CO<sub>2</sub>) using extractive distillation, condensation, adsorption or membranes in a continuous purification unit, where the oxygen level is lowered to ppm range and other impurities of concern are removed; the isoprene vapor is catalytically converted to dimers (C<sub>10</sub>) and trimers (C<sub>15</sub>) using a heterogeneous catalyst; the desired product is separated and the unreacted isoprene is returned to the reactor for further conversion. In some embodiments, the catalytic dimerization is monitored by measuring the levels of desirable C<sub>10</sub> hydrocarbons in the gas phase.

**[0652]** In some embodiments, a stream of biologically produced isoprene is passed through a chemical reactor (e.g., a reaction tube) maintained at a temperature of about 100 °C to about 300 °C, where the biologically produced isoprene undergoes dimerization reactions. In one variation, the isoprene dimers are separated from the product stream and at least a portion of the unreacted isoprene is recycled back into the chemical reactor. In one embodiment, the unsaturated isoprene dimers produced is contacted with a hydrogenation catalyst and a hydrogen source in a second chemical reactor producing partially hydrogenated and/or fully hydrogenated products. The process can further comprise a step of recovering isoprene from the off-gas of a bio-reactor producing isoprene.

**[0653]** In some embodiments, a stream of bioisoprene containing co-produced hydrogen is first separated from the hydrogen gas, the bioisoprene stream is passed through a chemical reactor (e.g., a reaction tube) maintained at a temperature of about 100 °C to about 300 °C, where the biologically produced isoprene undergoes dimerization reactions. In one variation, the

isoprene dimers are separated from the product stream and at least a portion of the unreacted isoprene is recycled back into the chemical reactor. In one embodiment, the unsaturated isoprene dimers produced is contacted with a hydrogenation catalyst and a hydrogen source in a second chemical reactor producing partially hydrogenated and/or fully hydrogenated products. In one variation, the hydrogen stream isolated from the isoprene-hydrogen co-production is used in the hydrogenation step. The process can further comprise a step of recovering isoprene from the off-gas of a bio-reactor producing isoprene. The process can further comprise a step of purifying the hydrogen stream isolated from the isoprene-hydrogen co-production using purification methods known in the art such as cryogenic condensation and solid matrix adsorption.

#### ***Removal of Dienes and Polymers from Fuel Products***

**[0654]** Fuel compositions often contain unsaturated compounds (olefins, diolefins and polyolefins) that can form gums, resins, polymers and other undesirable byproducts over time (for example, see Pereira and Pasa (2006) *Fuel*, **85**, 1860–1865 and references therein). In general, as the degree of unsaturation increases of a given compound, the more likely that compound is to form such byproducts. Isoprene is a 1,3-diene that readily forms undesirable polymeric byproducts when present in fuel compositions. While there exist fuel additives (anti-oxidants, radical quenchers etc.) that can reduce the extent of byproduct formation, such byproducts can still form over time. Olefins can also contribute to the formation of ground-level ozone when released into the atmosphere upon evaporation from fuels, or as the result of incomplete combustion of olefin-containing fuels.

**[0655]** Accordingly, fuel compositions derived wholly or in part from isoprene should contain little to no free isoprene. A range of methods can be used to either remove isoprene from fuel compositions such as purification by distillation, reaction with alcohols to form ethers, or hydrogenation to convert isoprene to saturated derivatives. Alternately, isoprene can be treated with a dienophile such as malic anhydride producing inert adducts that do not contribute to the formation of undesirable byproducts.

**[0656]** Provided are fuel compositions comprising isoprene derivatives that are substantially free of isoprene. In some embodiments, the fuel composition contains less than 0.01%, 0.1%, 1%, 2%, 3%, 4%, 5%, 10% or 15% isoprene. Also provided are methods for chemically transforming a bioisoprene composition to fuel compositions comprising isoprene derivatives that are substantially free of isoprene. In some embodiments, a substantial portion of the

isoprene from the bioisoprene composition is converted to fuel constituents. In some embodiments, a substantial portion of the isoprene from the bioisoprene composition is converted to intermediates that can be further converted to produce fuel constituents. In some embodiments, a substantial portion of the isoprene from the bioisoprene composition is converted to compounds other than isoprene. A “substantial portion” is 99.99%, 99.9%, 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80%.

**[0657]** In some instances, isoprene and other conjugated dienes can form polymeric products with gum-like consistencies that can reduce the yields of desired products and/or deactivate catalysts. (See, e.g., R.C.C. Pereira and V.M.D. Pasa. *Fuel* 85 (2006) 1860-1865.) In some embodiments, methods are provided for determining the amount of conjugated diene present in a product mixture. D.F. Andrade et al. describe various methods for determining the amount of conjugated diene present (*Fuel* (2010), doi:10.106/j.fuel/2010.01.003), including the following: 1) UOP-326 method (maleic anhydride method), a semi-quantitative method in which the amount of maleic anhydride consumed via Diels-Alder reaction with the diene is measured; 2) polarography; 3) gas chromatography, in which the diene may be reacted with a derivatization agent, such as 4-methyl-1,2,4-triazoline-3,5-dione (MTAD) or 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD); 4) HPLC; 5) supercritical fluid chromatography; 6) NMR; 7) UV and near IR spectroscopy; and 8) other spectroscopic methods, which may include first derivatizing the diene with p-nitrobenzenediazonium fluoroborate.

**[0658]** Methods are provided herein for minimizing gum-formation and/or reducing the amount of gum that has been produced. In some embodiments, an anti-oxidant is used to minimize gum-formation. In other embodiments, polymeric by-products are recycled back to the process stream. In some embodiments, depolymerization of polymeric by-products is carried out via olefin metathesis. Olefin metathesis can be carried out using a molybdenum or tungsten catalyst, such as 2,6-diisopropylphenylimido neophylidene molybdenum bis(2-tertbutylphenoxide). (See US 5,446,102.)

**[0659]** In some embodiments, any of the methods described herein further include characterizing the products of these reactions and assessing the potential fuel value. For example, the products are characterized by standard methods known in the art, e.g. GC/MS, NMR, UV-Vis and IR spectroscopies, boiling temperature, density and other physical properties. The products can be further characterized by dual carbon-isotopic fingerprinting (see, US Patent Number 7,169,588). The potential fuel value of the products are assessed by parameters measuring fuel properties such as the energy density, heating value, water solubility,

octane/cetane number, density, viscosity, surface tension, enthalpy of vaporization, vapor diffusivity, flash point, autoignition point, flammability limits, cloud point and chemical stability.

**[0660]** As with commercial petroleum fuels, BioIsoFuel™ products can be tested for their acidity, density, trace mineral content, benzene, total aromatics content, water content, and corrosivity. To assure that minor impurities in BioIsoFuel™ products are not adversely affecting their material properties, samples can also be tested for their corrosivity and compatibility with fuel systems by standard ASTM tests such as Karl Fischer for water and copper strip for corrosivity.

### *Fuel Compositions*

**[0661]** The invention provides a fuel composition comprising a fuel constituent produced by any of the methods and processes described herein. In some embodiments, the fuel constituent comprises one or more of the hydrocarbons selected from the group consisting of saturated C10 and C15 hydrocarbons derived from isoprene and oxygenated derivatives of isoprene. The hydrocarbon BioIsoFuel™ products are expected to be completely compatible with petroleum gasoline and diesel. Blends of BioIsoFuel™ with commercial petroleum fuels are expected to have more desirable properties, as they do not contain acids, sulfur, aromatics, or other undesirable impurities.

**[0662]** In some preferred embodiments, the fuel constituent comprises derivatives of bioisoprene. It is anticipated that there will be a significant demand for fuels derived from bioisoprene which is made from renewable, non-petrochemical based resources. It is believed that industrial customers and consumers would prefer to purchase fuel components derived from such environmentally friendly sources to those that are made with isoprene derived from a petrochemical process. It is further believed that customers would be willing to pay premium prices for such environmentally friendly products that are made with renewable resources. Fuel components derived from bioisoprene compositions described herein offer the benefit of being verifiable as to be derived from non-petrochemical based resources.

**[0663]** In some embodiments, the fuel constituent comprises one or more of the saturated cyclic C10 hydrocarbons such as 1,2-bis(isopropyl)cyclobutane, 1,2-bis(isopropyl)cyclobutane, 1-methyl-4-isopropylcyclohexane, 1-methyl-3-isopropylcyclohexane, 1-ethyl-1,4-dimethylcyclohexane, 1-ethyl-1,3-dimethylcyclohexane, 1,5-dimethylcyclooctane and 1,4-dimethylcyclooctane. In some embodiments, the fuel constituent comprises one or more of the

saturated cyclic C15 hydrocarbons such as 1,5,9-trimethylcyclododecane and 1,5,10-trimethylcyclododecane. In some embodiments, the fuel constituent comprises one or more of the saturated aliphatic C10 hydrocarbons such as 2,6-dimethyloctane, 2,7-dimethyloctane and 3,6-dimethyloctane. In some embodiments, the fuel constituent comprises one or more of the saturated aliphatic C15 hydrocarbons such as 2,6,10-trimethyldodecane, 2,7,10-trimethyldodecane and 3,7,10-trimethyldodecane. In some embodiments, the fuel constituent comprises 2-methylbutane. In some embodiments, the fuel constituent comprises one or more of the hydrocarbons selected from the group consisting of 1,2-bis(isopropyl)cyclobutane, 1,2-bis(isopropyl)cyclobutane, 1-methyl-4-isopropylcyclohexane, 1-methyl-3-isopropylcyclohexane, 1-ethyl-1,4-dimethylcyclohexane, 1-ethyl-1,3-dimethylcyclohexane, 1,5-dimethylcyclooctane, 1,4-dimethylcyclooctane, 1,5,9-trimethylcyclododecane, 1,5,10-trimethylcyclododecane, 2,6-dimethyloctane, 2,7-dimethyloctane, 3,6-dimethyloctane, 2,6,10-trimethyldodecane, 2,7,10-trimethyldodecane, 3,7,10-trimethyldodecane and 2-methylbutane.

**[0664]** In some embodiments, the fuel constituent comprises one or more of the saturated hydroxylates such as C5 alcohols and diols (e.g. 3-methyl-butan-1-ol, 2-methyl-butan-1-ol and 2-methyl-butan-2-ol, 3-methyl-butan-1,3-diol and 2-methyl-butan-2,3-diol), C-10 alcohols and diols (e.g. 3,7-dimethyloctan-1-ol, 2,7-dimethyloctan-1-ol, 2,7-dimethyloctan-2-ol and 2,7-dimethyloctan-2,7-diol) and cyclic C-10 alcohols (e.g. 2-(4-methylcyclohexyl)propan-2-ol, 2-(4-methylcyclohexyl)propan-1-ol, 2-(1,4-dimethylcyclohexyl)ethanol and 4-ethyl-1,4-dimethylcyclohexanol). In some embodiments, the fuel constituent comprises one or more of the saturated ethers such as 1,3-diethoxy-3-methylbutane, 1-ethoxy-3-methylbutane, 1-methoxy-2,7-dimethyloctane and 3-methoxy-2,7-dimethyloctane. In some embodiments, the fuel constituent comprises one or more of the isoprene derived oxygenates selected from the group consisting of 3-methyl-butan-1-ol, 2-methyl-butan-1-ol, 2-methyl-butan-2-ol, 3-methyl-butan-1,3-diol, 2-methyl-butan-2,3-diol, 3,7-dimethyloctan-1-ol, 2,7-dimethyloctan-1-ol, 2,7-dimethyloctan-2-ol, 2,7-dimethyloctan-2,7-diol, 2-(4-methylcyclohexyl)propan-2-ol, 2-(4-methylcyclohexyl)propan-1-ol, 2-(1,4-dimethylcyclohexyl)ethanol, 4-ethyl-1,4-dimethylcyclohexanol, 1,3-diethoxy-3-methylbutane, 1-ethoxy-3-methylbutane, 1-methoxy-2,7-dimethyloctane and 3-methoxy-2,7-dimethyloctane.


**[0665]** In some embodiments, the fuel constituent comprises less than or about 0.5 µg/L a product from a C5 hydrocarbon other than isoprene after undergoing the steps according to any of the methods and processes described herein. In one embodiment, the fuel constituent is substantially free of a product from a C5 hydrocarbon other than isoprene after undergoing the

steps according to any of the methods and processes described herein. In some embodiments, the fuel constituent comprises less than or about 0.2, 0.12, 0.10, 0.08, 0.06, 0.04, 0.02, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001% C5 hydrocarbons other than isoprene (such 1,3-cyclopentadiene, *cis*-1,3-pentadiene, *trans*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne) by weight compared to the total weight of all C5 hydrocarbons in the starting composition. In some embodiments, the fuel constituent comprises C5 hydrocarbons other than isoprene (such 1,3-cyclopentadiene, *trans*-1,3-pentadiene, *cis*-1,3-pentadiene, 1,4-pentadiene, 1-pentyne, 2-pentyne, 1-pentene, 2-methyl-1-butene, 3-methyl-1-butyne, pent-4-ene-1-yne, *trans*-pent-3-ene-1-yne, or *cis*-pent-3-ene-1-yne) at a concentration of less than 100, 10, 1, 0.1 or 0.01 ppm.

**[0666]** It is understood that components other than isoprene in the bioisoprene compositions described herein will be converted to different products after undergoing various processes described herein. The sensitivities of metal-based catalysts used in the methods/processes to the components other than isoprene are different depending on the nature and levels of these components. For the thermal dimerization process, a far wider range of compounds will be tolerated. In some cases, a component other than isoprene will react with isoprene to produce adducts, for example the Diels-Alder reactions of methacrolein and methyl vinyl ketone with isoprene to give 6-membered products. The unsaturated adducts can be further hydrogenated to saturated derivatives which are present in the fuel constituents and compositions, e.g. 1,4-dimethyl-1-(hydroxymethyl)cyclohexane and 1-(1-hydroxyethyl)-4-methylcyclohexane (see Scheme XV).

**Scheme XV.** Examples of trace impurities derived from Bioisoprene™

## i) Hydrogenated Diels-Alder adducts



1,4-dimethyl-1-(hydroxymethyl)cyclohexane    1-(1-hydroxyethyl)-4-methylcyclohexane


## ii) Alkanes



2-methylbutane

3-methylpentane

## iii) Alcohols




2-propanol

2-methyl-1-propanol

2-butanol

3-methyl-1-butanol

## iv) Esters



ethyl acetate

3-methyl-1-butyl acetate

**[0667]** In some embodiments, the fuel constituent comprises a product from a compound selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms after undergoing the steps according to any of the methods and processes described herein. In some embodiments, the fuel constituent comprises one or more products from one or more compounds selected from the group consisting of ethanol, acetone, methanol, acetaldehyde, methacrolein, methyl vinyl ketone, 2-methyl-2-vinylloxirane, *cis*- and *trans*-3-methyl-1,3-pentadiene, a C5 prenyl alcohol (such as 3-methyl-3-

buten-1-ol or 3-methyl-2-buten-1-ol), 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene, and 2,3-cycloheptenolpyridine after undergoing the steps according to any of the methods and processes described herein. In some embodiments, the fuel constituent comprises one or more compounds selected from the group consisting of 1,4-dimethyl-1-(hydroxymethyl)cyclohexane, 1-(1-hydroxyethyl)-4-methylcyclohexane, 2-methylbutane, 3-methylpentane, 2-propanol, 2-methyl-1-propanol, 2-butanol, 3-methyl-1-butanol, ethyl acetate and 3-methyl-1-butyl acetate. In some embodiments, the fuel constituent comprises one or more compounds selected from the group consisting of 1,4-dimethyl-1-(hydroxymethyl)cyclohexane, 1-(1-hydroxyethyl)-4-methylcyclohexane, 2-methylbutane, 3-methylpentane, 2-propanol, 2-methyl-1-propanol, 2-butanol, 3-methyl-1-butanol, ethyl acetate and 3-methyl-1-butyl acetate at levels greater than or about 10 ppm, 1 ppm, 100 ppb, 10 ppb or 1 ppb.

**[0668]** In some embodiments, the fuel constituent comprises one or more compounds selected from the group consisting of ethanol, acetone, methanol, acetaldehyde, methacrolein, methyl vinyl ketone, 2-methyl-2-vinylloxirane, *cis*- and *trans*-3-methyl-1,3-pentadiene, a C5 prenyl alcohol (such as 3-methyl-3-buten-1-ol or 3-methyl-2-buten-1-ol), 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene, and 2,3-cycloheptenolpyridine at levels greater than or about 10 ppm, 1 ppm, 100 ppb, 10 ppb or 1 ppb.

*Carbon fingerprinting*

**[0669]** BioIsoFuels derived from bioisoprene can be distinguished from fuels derived from petrochemical carbon on the basis of dual carbon-isotopic fingerprinting. Additionally, the specific source of biosourced carbon (e.g. glucose vs. glycerol) can be determined by dual carbon-isotopic fingerprinting (see, US Patent Number 7,169,588, which is herein incorporated by reference).

**[0670]** This method usefully distinguishes chemically-identical materials, and apportions carbon in products by source (and possibly year) of growth of the biospheric (plant) component. The isotopes,  $^{14}\text{C}$  and  $^{13}\text{C}$ , bring complementary information to this problem. The radiocarbon dating isotope ( $^{14}\text{C}$ ), with its nuclear half life of 5730 years, clearly allows one to apportion specimen carbon between fossil ("dead") and biospheric ("alive") feedstocks [Currie, L. A. "Source Apportionment of Atmospheric Particles," Characterization of Environmental Particles, J. Buffle and H. P. van Leeuwen, Eds., 1 of Vol. I of the IUPAC Environmental Analytical Chemistry Series (Lewis Publishers, Inc) (1992) 3 74]. The basic assumption in radiocarbon dating is that the constancy of  $^{14}\text{C}$  concentration in the atmosphere leads to the constancy of  $^{14}\text{C}$  in living organisms. When dealing with an isolated sample, the age of a sample can be deduced approximately by the relationship  $t = (-5730/0.693)\ln(A/A_0)$  (Equation 14) where  $t = \text{age}$ , 5730 years is the half-life of radiocarbon, and  $A$  and  $A_0$  are the specific  $^{14}\text{C}$  activity of the sample and of the modern standard, respectively [Hsieh, Y., Soil Sci. Soc. Am J., 56, 460, (1992)]. However, because of atmospheric nuclear testing since 1950 and the burning of fossil fuel since 1850,  $^{14}\text{C}$  has acquired a second, geochemical time characteristic. Its concentration in atmospheric  $\text{CO}_2$  – and hence in the living biosphere – approximately doubled at the peak of nuclear testing, in the mid-1960s. It has since been gradually returning to the steady-state cosmogenic (atmospheric) baseline isotope rate ( $^{14}\text{C}/^{12}\text{C}$ ) of ca.  $1.2 \times 10^{-12}$ , with an approximate relaxation "half-life" of 7-10 years. (This latter half-life must not be taken literally; rather, one must use the detailed atmospheric nuclear input/decay function to trace the variation of atmospheric and biospheric  $^{14}\text{C}$  since the onset of the nuclear age.) It is this latter biospheric  $^{14}\text{C}$  time characteristic that holds out the promise of annual dating of recent biospheric carbon.  $^{14}\text{C}$  can be measured by accelerator mass spectrometry (AMS), with results given in units of "fraction of modern carbon" ( $f_M$ ).  $f_M$  is defined by National Institute of Standards and Technology (NIST) Standard Reference Materials (SRMs) 4990B and 4990C, known as oxalic acids standards HOxI and HOxII, respectively. The fundamental definition relates to 0.95 times

the  $^{14}\text{C}/^{12}\text{C}$  isotope ratio HOxI (referenced to AD 1950). This is roughly equivalent to decay-corrected pre-Industrial Revolution wood. For the current living biosphere (plant material),  $f_M \sim 1.1$ .

**[0671]** The stable carbon isotope ratio ( $^{13}\text{C}/^{12}\text{C}$ ) provides a complementary route to source discrimination and apportionment. The  $^{13}\text{C}/^{12}\text{C}$  ratio in a given biosourced material is a consequence of the  $^{13}\text{C}/^{12}\text{C}$  ratio in atmospheric carbon dioxide at the time the carbon dioxide is fixed and also reflects the precise metabolic pathway. Regional variations also occur. Petroleum,  $\text{C}_3$  plants (the broadleaf),  $\text{C}_4$  plants (the grasses), and marine carbonates all show significant differences in  $^{13}\text{C}/^{12}\text{C}$  and the corresponding  $\delta^{13}\text{C}$  values. Furthermore, lipid matter of  $\text{C}_3$  and  $\text{C}_4$  plants analyze differently than materials derived from the carbohydrate components of the same plants as a consequence of the metabolic pathway. Within the precision of measurement,  $^{13}\text{C}$  shows large variations due to isotopic fractionation effects, the most significant of which for the instant invention is the photosynthetic mechanism. The major cause of differences in the carbon isotope ratio in plants is closely associated with differences in the pathway of photosynthetic carbon metabolism in the plants, particularly the reaction occurring during the primary carboxylation, i. e., the initial fixation of atmospheric  $\text{CO}_2$ . Two large classes of vegetation are those that incorporate the " $\text{C}_3$ " (or Calvin-Benson) photosynthetic cycle and those that incorporate the " $\text{C}_4$ " (or Hatch-Slack) photosynthetic cycle.  $\text{C}_3$  plants, such as hardwoods and conifers, are dominant in the temperate climate zones. In  $\text{C}_3$  plants, the primary  $\text{CO}_2$  fixation or carboxylation reaction involves the enzyme ribulose-1,5-diphosphate carboxylase and the first stable product is a 3-carbon compound.  $\text{C}_4$  plants, on the other hand, include such plants as tropical grasses, corn and sugar cane. In  $\text{C}_4$  plants, an additional carboxylation reaction involving another enzyme, phosphoenol-pyruvate carboxylase, is the primary carboxylation reaction. The first stable carbon compound is a 4-carbon acid which is subsequently decarboxylated. The  $\text{CO}_2$  thus released is refixed by the  $\text{C}_3$  cycle.

**[0672]** Both  $\text{C}_4$  and  $\text{C}_3$  plants exhibit a range of  $^{13}\text{C}/^{12}\text{C}$  isotopic ratios, but typical values are ca. -10 to -14 per mil ( $\text{C}_4$ ) and -21 to -26 per mil ( $\text{C}_3$ ) [Weber et al., J. Agric. Food Chem., 45, 2942 (1997)]. Coal and petroleum fall generally in this latter range. The  $^{13}\text{C}$  measurement scale was originally defined by a zero set by pee dee belemnite (PDB) limestone, where values are given in parts per thousand deviations from this material. The " $\delta^{13}\text{C}$ ", values are in parts per thousand (per mil), abbreviated ‰, and are calculated as follows (Equation 15):

$$\delta^{13}\text{C} \equiv \frac{(^{13}\text{C}/^{12}\text{C})_{\text{sample}} - (^{13}\text{C}/^{12}\text{C})_{\text{standard}}}{(^{13}\text{C}/^{12}\text{C})_{\text{standard}}} \times 100\% \quad (\text{Equation 15})$$

Since the PDB reference material (RM) has been exhausted, a series of alternative RMs have been developed in cooperation with the IAEA, USGS, NIST, and other selected international isotope laboratories. Notations for the per mil deviations from PDB is  $\delta^{13}\text{C}$ . Measurements are made on  $\text{CO}_2$  by high precision stable ratio mass spectrometry (IRMS) on molecular ions of masses 44, 45 and 46.

**[0673]** For isoprene derived from extractive distillation of  $\text{C}_5$  streams from petroleum refineries,  $\delta^{13}\text{C}$  is about -22‰ to about -24‰. This range is typical for light, unsaturated hydrocarbons derived from petroleum, and products derived from petroleum-based isoprene typically contain isoprenic units with the same  $\delta^{13}\text{C}$ . Bioisoprene produced by fermentation of corn-derived glucose ( $\delta^{13}\text{C}$  -10.73‰) with minimal amounts of other carbon-containing nutrients (e.g., yeast extract) produces isoprene which can be polymerized into polyisoprene with  $\delta^{13}\text{C}$  -14.66‰ to -14.85‰. Products produced from such bioisoprene are expected to have  $\delta^{13}\text{C}$  values that are less negative than those derived from petroleum-based isoprene. For isoprene derived from the reaction of isobutylene with formaldehyde,  $\delta^{13}\text{C}$  values can be about -34.4‰ because formaldehyde is often derived from feedstocks with much more negative  $\delta^{13}\text{C}$  values.

**[0674]** The fuels and fuel constituents of this invention which are made with isoprene from the cell cultures that utilize bio-renewable carbon sources can be identified as such by virtue of their  $\delta^{13}\text{C}$  value and other fuel characteristics. In some embodiments, the fuel constituent derived from bioisoprene has  $\delta^{13}\text{C}$  values of greater (less negative) than -22‰. In some embodiments, the fuel constituent derived from bioisoprene has  $\delta^{13}\text{C}$  values of greater than -20, -18, -16, -14, -12, or -10 ‰. In some embodiments, the fuel constituent derived from bioisoprene has a  $\delta^{13}\text{C}$  value which is within the range of -22 to -10, -21 to -12, or -20 to -14 ‰. In some embodiments, the fuel constituent derived from bioisoprene has a  $\delta^{13}\text{C}$  value which is within the range of -34 to -24, -34 to -25, -33 to -25, -32 to -24, -32 to -25, -31 to -25, -30 to -29, -30.0 to -29.5, -29.5 to -28.5, or -29.0 to -28.5 ‰.

**[0675]** In some embodiments, the fuel constituent derived from bioisoprene comprises radioactive carbon-14. In some embodiments, the  $^{14}\text{C}/^{12}\text{C}$  ratio is greater than or about  $1.0 \times 10^{-12}$ ,  $1.05 \times 10^{-12}$ ,  $1.1 \times 10^{-12}$ ,  $1.15 \times 10^{-12}$ , or  $1.2 \times 10^{-12}$ . In some embodiments, the fuel constituent derived from bioisoprene has an  $f_M$  value of greater than or about 0.9, 0.95, 1.0, 1.05 or 1.1. In

some embodiments, the fuel constituent derived from bioisoprene has an  $f_M$  value of greater than or about 0.9, 0.95, 1.0, 1.05 or 1.1 and  $\delta^{13}C$  values of greater (less negative) than -22‰. In some embodiments, the fuel constituent derived from bioisoprene has an  $f_M$  value of greater than or about 0.9, 0.95, 1.0, 1.05 or 1.1 and a  $\delta^{13}C$  value which is within the range of -22 to -10, -21 to -12, or -20 to -14 ‰. In some embodiments, the fuel constituent derived from bioisoprene has an  $f_M$  value of greater than or about 0.9, 0.95, 1.0, 1.05 or 1.1 and a  $\delta^{13}C$  value which is within the range of -34 to -24, -34 to -25, -33 to -25, -32 to -24, -32 to -25, -31 to -25, -30 to -29, -30.0 to -29.5, -29.5 to -28.5, or -29.0 to -28.5 ‰.

**[0676]** The bioisoprene derivatives and the associated BioIsoFuels, intermediates, and mixtures may be completely distinguished from their petrochemical derived counterparts on the basis of  $^{14}C$  ( $f_M$ ) and dual carbon-isotopic fingerprinting, indicating new compositions of matter.

**[0677]** In some embodiments, the fuel constituent of the invention has an energy density higher than that of ethanol. In some embodiments, the fuel constituent boosts the cetane number of a fuel, e.g., a petroleum-based fuel. In some embodiments, the fuel constituent reduces emission of petroleum based fuels. In some embodiments, the fuel composition has an octane number in the range between about 80 to about 120. In some embodiments, the fuel composition has a cetane number in the range between about 30 to about 130.

**[0678]** In some embodiments, a fuel composition of the invention comprises one or more dimethylcyclooctane compounds. In some embodiments, a fuel composition of the invention comprises one or more C10 hydrocarbons such as substituted cyclohexanes. In some embodiments, a fuel composition of the invention comprises one or more isoprene derived oxygenates described herein. In some embodiments, any of the fuel compositions described herein further comprises a petroleum based fuel in the amount of from about 1% to about 95% by weight or volume, based on the total weight or volume of the total fuel composition.

**[0679]** The invention further provides methods for making a fuel composition comprising obtaining a petroleum distillate and adding a fuel constituent of the invention.

**[0680]** The invention can be further understood by reference to the following examples, which are provided by way of illustration and are not meant to be limiting.

## EXAMPLES

### Example 1: Production of isoprene in *E. coli* expressing recombinant kudzu isoprene synthase

I. Construction of vectors for expression of the kudzu isoprene synthase in *E. coli*

**[0681]** The protein sequence for the kudzu (*Pueraria montana*) isoprene synthase gene (IspS) was obtained from GenBank (AAQ84170). A kudzu isoprene synthase gene, optimized for *E. coli* codon usage, was purchased from DNA2.0 (SEQ ID NO:1). The isoprenic synthase gene was removed from the supplied plasmid by restriction endonuclease digestion with *Bsp*LU111/*Pst*I, gel-purified, and ligated into pTrcHis2B (Invitrogen) that had been digested with *Nco*I/*Pst*I. The construct was designed such that the stop codon in the isoprenic synthase gene 5' to the *Pst*I site. As a result, when the construct was expressed the His-Tag is not attached to the isoprenic synthase protein. The resulting plasmid, pTrcKudzu, was verified by sequencing (Figures 2 and 3; SEQ ID NO:2).

**[0682]** The isoprene synthase gene was also cloned into pET16b (Novagen). In this case, the isoprenic synthase gene was inserted into pET16b such that the recombinant isoprene synthase protein contained the N-terminal His tag. The isoprenic synthase gene was amplified from pTrcKudzu by PCR using the primer set pET-His-Kudzu-2F: 5'-CGTGAGATCATATGTGTGCGACCTCTTCTCAATTTAC (SEQ ID NO:49) and pET-His-Kudzu-R: 5'-CGGTCGACGGATCCCTGCAGTTAGACATACATCAGCTG (SEQ ID NO:50). These primers added an *Nde*I site at the 5'-end and a *Bam*H1 site at the 3' end of the gene respectively. The plasmid pTrcKudzu, described above, was used as template DNA, Hercules polymerase (Stratagene) was used according to manufacture's directions, and primers were added at a concentration of 10 pMols. The PCR was carried out in a total volume of 25  $\mu$ l. The PCR product was digested with *Nde*I/*Bam*H1 and cloned into pET16b digested with the same enzymes. The ligation mix was transformed into *E. coli* Top10 (Invitrogen) and the correct clone selected by sequencing. The resulting plasmid, in which the kudzu isoprene synthase gene was expressed from the T7 promoter, was designated pETNHisKudzu (Figures 4 and 5; SEQ ID NO:51).

**[0683]** The kudzu isoprene synthase gene was also cloned into the low copy number plasmid pCL1920. Primers were used to amplify the kudzu isoprene synthase gene from pTrcKudzu described above. The forward primer added a *Hind*III site and an *E. coli* consensus RBS to the 5' end. The *Pst*I cloning site was already present in pTrcKudzu just 3' of the stop codon so the reverse primer was constructed such that the final PCR product includes the *Pst*I site. The sequences of the primers were: *Hind*III-rbs-Kudzu F: 5'-CATATGAAAGCTTGTATCGATTAAATAAGGAGGAATAAACC (SEQ ID NO:51) and *Bam*H1-Kudzu R:

**[0684]** 5'-CGGTCGACGGATCCCTGCAGTTAGACATACATCAGCTG (SEQ ID NO:50). The PCR product was amplified using Herculase polymerase with primers at a concentration of 10 pmol and with 1 ng of template DNA (pTrcKudzu). The amplification protocol included 30 cycles of (95° C for 1 minute, 60° C for 1 minute, 72° C for 2 minutes). The product was digested with *HindIII* and *PstI* and ligated into pCL1920 which had also been digested with *HindIII* and *PstI*. The ligation mix was transformed into *E. coli* Top10. Several transformants were checked by sequencing. The resulting plasmid was designated pCL-lac-Kudzu (Figures 6 and 7; SEQ ID NO:4).

## II. Determination of isoprene production

**[0685]** For the shake flask cultures, one ml of a culture was transferred from shake flasks to 20 ml CTC headspace vials (Agilent vial cat# 5188 2753; cap cat# 5188 2759). The cap was screwed on tightly and the vials incubated at the equivalent temperature with shaking at 250 rpm. After 30 minutes the vials were removed from the incubator and analyzed as described below (*see* Table 1 for some experimental values from this assay).

**[0686]** In cases where isoprene production in fermentors was determined, samples were taken from the off-gas of the fermentor and analyzed directly as described below (*see* Table 2 for some experimental values from this assay).

**[0687]** The analysis was performed using an Agilent 6890 GC/MS system interfaced with a CTC Analytics (Switzerland) CombiPAL autosampler operating in headspace mode. An Agilent HP-5MS GC/MS column (30 m x 0.25 mm; 0.25 µm film thickness) was used for separation of analytes. The sampler was set up to inject 500 µL of headspace gas. The GC/MS method utilized helium as the carrier gas at a flow of 1 ml/min. The injection port was held at 250° C with a split ratio of 50:1. The oven temperature was held at 37° C for the 2 minute duration of the analysis. The Agilent 5793N mass selective detector was run in single ion monitoring (SIM) mode on m/z 67. The detector was switched off from 1.4 to 1.7 minutes to allow the elution of permanent gases. Under these conditions isoprene (2-methyl-1,3-butadiene) was observed to elute at 1.78 minutes. A calibration table was used to quantify the absolute amount of isoprene and was found to be linear from 1 µg/L to 70,000 µg/L. The limit of detection was estimated to be 50 to 100 ng/L using this method.

## III. Production of isoprene in shake flasks containing *E. coli* cells expressing recombinant isoprene synthase

**[0688]** The vectors described above were introduced to *E. coli* strain BL21 (Novagen) to produce strains BL21/ptrcKudzu, BL21/pCL-lac-Kudzu and BL21/pETHisKudzu. The strains were spread for isolation onto LA (Luria agar) + carbenicillin (50 µg/ml) and incubated overnight at 37° C. Single colonies were inoculated into 250 ml baffled shake flasks containing 20 ml Luria Bertani broth (LB) and carbenicillin (100 µg/ml). Cultures were grown overnight at 20° C with shaking at 200 rpm. The OD<sub>600</sub> of the overnight cultures were measured and the cultures were diluted into a 250 ml baffled shake flask containing 30 ml MagicMedia (Invitrogen) + carbenicillin (100 µg/ml) to an OD<sub>600</sub> ~ 0.05. The culture was incubated at 30° C with shaking at 200 rpm. When the OD<sub>600</sub> ~ 0.5 - 0.8, 400 µM IPTG was added and the cells were incubated for a further 6 hours at 30° C with shaking at 200 rpm. At 0, 2, 4 and 6 hours after induction with IPTG, 1 ml aliquots of the cultures were collected, the OD<sub>600</sub> was determined and the amount of isoprene produced was measured as described above. Results are shown in Figure 8.

#### IV. Production of Isoprene from BL21/ptrcKudzu in 14 liter fermentation

**[0689]** Large scale production of isoprene from *E. coli* containing the recombinant kudzu isoprene synthase gene was determined from a fed-batch culture. The recipe for the fermentation media (TM2) per liter of fermentation medium was as follows: K<sub>2</sub>HPO<sub>4</sub> 13.6 g, KH<sub>2</sub>PO<sub>4</sub> 13.6 g, MgSO<sub>4</sub> \* 7H<sub>2</sub>O 2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> 3.2 g, yeast extract 5 g, 1000X Modified Trace Metal Solution 1 ml. All of the components were added together and dissolved in diH<sub>2</sub>O. The pH was adjusted to 6.8 with potassium hydroxide (KOH) and q.s. to volume. The final product was filter sterilized with 0.22 µ filter (only, do not autoclave). The recipe for 1000X Modified Trace Metal Solution was as follows: Citric Acids \* H<sub>2</sub>O 40 g, MnSO<sub>4</sub> \* H<sub>2</sub>O 30 g, NaCl 10 g, FeSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CoCl<sub>2</sub> \* 6H<sub>2</sub>O 1 g, ZnSO \* 7H<sub>2</sub>O 1 g, CuSO<sub>4</sub> \* 5H<sub>2</sub>O 100 mg, H<sub>3</sub>BO<sub>3</sub> 100 mg, NaMoO<sub>4</sub> \* 2H<sub>2</sub>O 100 mg. Each component was dissolved one at a time in diH<sub>2</sub>O, pH to 3.0 with HCl/NaOH, then q.s. to volume and filter sterilized with a 0.22 µ filter.

**[0690]** This experiment was carried out in 14 L bioreactor to monitor isoprene formation from glucose at the desired fermentation, pH 6.7 and temperature 34° C. An inoculum of *E. coli* strain BL21/ptrcKudzu taken from a frozen vial was prepared in soytone-yeast extract-glucose medium. After the inoculum grew to OD<sub>550</sub> = 0.6, two 600 ml flasks were centrifuged and the contents resuspended in 70 ml supernatant to transfer the cell pellet (70 ml of OD 3.1 material)

to the bioreactor. At various times after inoculation, samples were removed and the amount of isoprene produced was determined as described above. Results are shown in Figure 9.

Example 2: Production of isoprene in *E. coli* expressing recombinant poplar isoprene synthase

**[0691]** The protein sequence for the poplar (*Populus alba* x *Populus tremula*) isoprene synthase (Schnitzler, J-P, *et al.* (2005) *Planta* 222:777-786) was obtained from GenBank (CAC35696). A gene, codon optimized for *E. coli*, was purchased from DNA2.0 (p9796-poplar, Figures 30 and 31; SEQ ID NO:14). The isoprene synthase gene was removed from the supplied plasmid by restriction endonuclease digestion with *Bsp*LU11I /*Pst*I, gel-purified, and ligated into pTrcHis2B that had been digested with *Nco*I/*Pst*I. The construct is cloned such that the stop codon in the insert is before the *Pst*I site, which results in a construct in which the His-Tag is not attached to the isoprene synthase protein. The resulting plasmid pTrcPoplar (Figures 32 and 33; SEQ ID NO:15), was verified by sequencing.

Example 2B: Demonstration of isoprene synthase activity from several *populus* isoprene synthases

**[0692]** The following isoprene synthases were examined; *Populus alba* (Accession number BAD98243; Figures 137A and B; SEQ ID NO:30), *Populus nigra* (Accession number CAL69918; Figures 137C and D; SEQ ID NO:31), *Populus tremuloides* (Accession number AAQ16588; Figure 137 E, F, and G; SEQ ID NOs:32-33), *Populus trichocarpa* (Accession number ACD70404; Figures 137H and I; SEQ ID NO:34), *Populus alba* x *Populus tremula* (Accession number CAJ29303; Figures 137J and K; SEQ ID NO:35), and MCM112-Kudzu.

**[0693]** pET24Kudzu (also referred to as MCM112) was constructed as follows: the kudzu isoprene synthase gene was subcloned into the pET24d vector (Novagen) from the pCR2.1 vector (Invitrogen). The kudzu IspS gene was amplified from pTrcKudzu template DNA using primers MCM50 5'-GATCATGCAT TCGCCCTTAG GAGGTAAAAAACATGTGTGCGACCTCTTC TCAATTTACT (SEQ ID NO:52); and MCM53 5'-CGGTTCGACGGATCCCTGCAG TTAGACATAC ATCAGCTG (SEQ ID NO:50). PCR reactions were carried out using Taq DNA Polymerase (Invitrogen), and the resulting PCR product was cloned into pCR2.1-TOPO TA cloning vector (Invitrogen), and transformed into *E. coli* Top10 chemically competent cells (Invitrogen). Transformants were plated on L-agar containing carbenicillin (50 µg/ml) and incubated overnight at 37°C. Five ml Luria Broth cultures containing carbenicillin 50 µg/ml were inoculated with single transformants and grown

overnight at 37°C. Five colonies were screened for the correct insert by sequencing of plasmid DNA isolated from 1 ml of liquid culture (Luria Broth) and purified using the QIAprep Spin Mini-prep Kit (Qiagen). The resulting plasmid, designated MCM93, contains the kudzu IspS coding sequence in a pCR2.1 backbone (Figure 137L). The sequence of MCM93 (SEQ ID NO:36) is shown in Figures 137M and N.

**[0694]** The kudzu coding sequence was removed by restriction endonuclease digestion with *PciI* and *BamHI* (Roche) and gel purified using the QIAquick Gel Extraction kit (Qiagen). The pET24d vector DNA was digested with *NcoI* and *BamHI* (Roche), treated with shrimp alkaline phosphatase (Roche), and purified using the QIAprep Spin Mini-prep Kit (Qiagen). The kudzu IspS fragment was ligated to the *NcoI/BamHI* digested pET24d using the Rapid DNA Ligation Kit (Roche) at a 5:1 fragment to vector ratio in a total volume of 20 µl. A portion of the ligation mixture (5 µl) was transformed into *E. coli* Top 10 chemically competent cells and plated on L agar containing kanamycin (50 µg/ml). The correct transformant was confirmed by sequencing and transformed into chemically competent BL21(λDE3)pLysS cells (Novagen). A single colony was selected after overnight growth at 37°C on L agar containing kanamycin (50 µg/ml). A map of the resulting plasmid designated as pET24D-Kudzu is shown in Figure 137O. The sequence of pET24D-Kudzu (SEQ ID NO:37) is shown in Figures 137P and Q.

**[0695]** *Escherichia coli* optimized isoprene synthase genes cloned into the pET24a expression vector (Novagen) were purchased from DNA2.0 (Menlo Park, CA) for *Populus tremuloides*, *Populus alba*, *Populus nigra* and *Populus trichocarpa*. Genes were synthesized with the chloroplast transit peptide sequence removed, resulting in expression of mature proteins.

**[0696]** The construct for the Kudzu isoprene synthase was used as control in this example. The plasmids were transformed into the *E. coli* expression host BL21(DE3)pLysS and transformants were grown in 0.6 ml TM3 medium. The recipe for TM3 medium is as follows: K<sub>2</sub>HPO<sub>4</sub> (13.6 g/l) KH<sub>2</sub>PO<sub>4</sub> (13.6 g/l), MgSO<sub>4</sub> \* 7H<sub>2</sub>O (2 g/L) Citric Acid Monohydrate (2 g/L) Ferric Ammonium Citrate (0.3 g/L) (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> (3.2 g/L) yeast extract (0.2 g/L) 1 ml of 1000x Trace Elements solution, pH adjusted to 6.8 with ammonium hydroxide qs to volume with sterile DI H<sub>2</sub>O and filter sterilized with a 0.22 micron filter. The recipe for 1000X Trace Elements solution is as follows: Citric Acids \* H<sub>2</sub>O (40 g/L), MnSO<sub>4</sub> \* H<sub>2</sub>O (30 g/L), NaCl (10 g/L), FeSO<sub>4</sub> \* 7 H<sub>2</sub>O (1 g/L), CoCl<sub>2</sub> \* 6 H<sub>2</sub>O (1 g/L), ZnSO<sub>4</sub> \* 7 H<sub>2</sub>O (1 g/L), CuSO<sub>4</sub> \* 5 H<sub>2</sub>O (100 mg/L), H<sub>3</sub>BO<sub>3</sub> (100 mg/L), NaMoO<sub>4</sub> \* 2 H<sub>2</sub>O (100 mg/L). Each component was dissolved one at a time in DI H<sub>2</sub>O, pH adjusted to 3.0 with HCl/NaOH, qs to volume and filter sterilized with a 0.22 micron filter.

**[0697]** The cultures were induced with 400  $\mu\text{M}$  IPTG and growth was continued to  $\text{OD}_{600}$  of about 5. Aliquots of culture were transferred to a deep well glass plate and wells were sealed with aluminum plate sealer. The plate was incubated at 25°C for 30 minutes with shaking at 450 rpm. The reactions were heat inactivated by raising the temperature to 70°C for 5 minutes. Whole cell head space was measured by the GCMS method as described in Example 1, Part II.

**[0698]**  $K_m$  values were obtained from cultures grown in similar manner but cells were harvested and lysed by a freeze/thaw lysozyme protocol. A volume of 400  $\mu\text{L}$  of culture was transferred into a new 96-well plate (Perkin Elmer, Catalog No. 6008290) and cells were harvested by centrifugation in a Beckman Coulter Allegra 6R centrifuge at 2500 x g. The pellet was resuspended in 200 mL of hypotonic buffer (5 mM  $\text{MgCl}_2$ , 5 mM Tris HCl, 5 mM DTT pH 8.0) and the plate was frozen at -80°C for a minimum time of 60 minutes. Cell lysate was prepared by thawing the plate and adding 32 mL of isoprene synthase DMAPP assay buffer (57 mM Tris HCl, 19 mM  $\text{MgCl}_2$ , 74 mg/mL DNase I (Sigma Catalog No. DN-25),  $2.63 \times 10^5$  U/mL of ReadyLyse lysozyme solution (Epicentre Catalog No. R1802M), and 5 mg/mL of molecular biology grade BSA. The plate was incubated with shaking at 25°C for 30 minutes and then placed on ice. DMAPP and lysate were added at desired concentration in a sealed deep well glass block for the whole cell head space assay described above. The reactions were allowed to proceed for 1 hour and then terminated by the heat step described above and head space activity was measured also as described.

**[0699]** In an alternate approach, the activity of the enzymes was measured from cells cultured in 25 mL volume and induced similarly as described above. Cells were harvested by centrifugation and the pellets were lysed by French pressing in buffer consisting of 50% glycerol mixed 1:1 with 20 mM Tris/HCl pH 7.4, 20 mM  $\text{MgCl}_2$ , 200 mM KCl, 1 mM DTT. A lysate volume of 25  $\mu\text{L}$  was assayed for isoprene synthase activity in 2 mL screw cap vials containing 75  $\mu\text{L}$  of assay buffer (66.6 mM Tris/HCl pH 8, 6.66 mM DMAPP, 43 mM,  $\text{MgCl}_2$ ). The reaction was incubated for 15 minutes at 30°C and was quenched by the addition of 100  $\mu\text{L}$  of 250 mM EDTA through the septum of the vial. Isoprene was measured by GC/MS as described in Example 1, Part II.

**[0700]** All methods for the determination of activity showed that the poplar enzyme derived from the pure bred poplars were several-fold higher than the *Populus [alba x tremula]*. Figures 138 and 139 showed these results for the whole cell head space assay and the DMAPP assay, respectively, and surprisingly indicate that enzymes from *P. nigra*, *P. tremuloides*, *P. trichocarpa*, and *P. alba* all had significantly higher activity than hybrid [*P. alba x P. tremula*].

[0701] The DMAPP assay was performed as follows: a volume of 400  $\mu$ L of culture was transferred into a new 96-well plate (Perkin Elmer, Catalog No. 6008290) and cells were harvested by centrifugation in a Beckman Coulter Allegra 6R centrifuge at 2500 x g. The pellet was resuspended in 200 mL of hypotonic buffer (5 mM MgCl<sub>2</sub>, 5 mM Tris HCl, 5 mM DTT pH 8.0) and the plate was frozen at -80°C for a minimum time of 60 minutes. Cell lysate was prepared by thawing the plate and adding 32 mL of isoprene synthase DMAPP assay buffer (57 mM Tris HCl, 19 mM MgCl<sub>2</sub>, 74 mg/mL DNase I (Sigma Catalog No. DN-25), 2.63x10<sup>5</sup> U/mL of ReadyLyse lysozyme solution (Epicentre Catalog No. R1802M), and 5 mg/mL of molecular biology grade BSA. The plate was incubated with shaking at 25°C for 30 minutes and then placed on ice. For isoprene production an 80 mL aliquot of lysate was transferred to a 96-deep well glass plate (Zinsser Catalog No. 3600600) and 20 mL of a 10 mM DMAPP solution in 100 mM KHPO<sub>4</sub>, pH 8.2 (Cayman Chemical Catalog No. 63180) was added. The plate was sealed with an aluminum plate seal (Beckman Coulter Catalog No. 538619) and incubated with shaking at 30°C for 60 minutes. The enzymatic reactions were terminated by heating the glass block (70°C for 5 minutes). The cell head space of each well was quantitatively analyzed as described in Example 1, Part II.

[0702] Notably, *P. alba*, *P. tremuloides*, *P. trichocarpa* had higher activity than the isoprene synthase from Kudzu. The enzyme from *P. alba* was expressed with the greatest activity of all enzymes tested. The higher activities observed with the cell lysate compared to the whole cell head space assay was likely due to limitations in DMAPP, the substrate for these enzymes, delivered by the endogenous deoxyxylulose 5-phosphate (DXP) pathway of the cell.

[0703] K<sub>m</sub> kinetic parameter was measured to be about 2 to 3 mM for all enzymes for which the value was determined.

#### Example 3: Production of isoprene in *Panteoa citrea* expressing recombinant kudzu isoprene synthase

[0704] The pTrcKudzu and pCL-lac Kudzu plasmids described in Example 1 were electroporated into *P. citrea* (U.S. Pat. No. 7,241,587). Transformants were selected on LA containing carbenicillin (200  $\mu$ g/ml) or spectinomycin (50  $\mu$ g/ml) respectively. Production of isoprene from shake flasks and determination of the amount of isoprene produced was performed as described in Example 1 for *E. coli* strains expressing recombinant kudzu isoprene synthase. Results are shown in Figure 10.

Example 4: Production of isoprene in *Bacillus subtilis* expressing recombinant kudzu isoprene synthase

I. Construction of a *B. subtilis* replicating plasmid for the expression of kudzu isoprene synthase

**[0705]** The kudzu isoprene synthase gene was expressed in *Bacillus subtilis aprEnprE P<sub>xyl</sub>-comK* strain (BG3594comK) using a replicating plasmid (pBS19 with a chloramphenicol resistance cassette) under control of the *aprE* promoter. The isoprene synthase gene, the *aprE* promoter and the transcription terminator were amplified separately and fused using PCR. The construct was then cloned into pBS19 and transformed into *B. subtilis*.

a) Amplification of the *aprE* promoter

**[0706]** The *aprE* promoter was amplified from chromosomal DNA from *Bacillus subtilis* using the following primers:

CF 797 (+) Start *aprE* promoter MfeI

5'- GACATCAATTGCTCCATTTTCTTCTGCTATC (SEQ ID NO:53)

CF 07-43 (-) Fuse *aprE* promoter to Kudzu ispS

5'- ATTGAGAAGAGGTCGCACACACTCTTACCCTCTCCTTTTA (SEQ ID NO:54)

b) Amplification of the isoprene synthase gene

**[0707]** The kudzu isoprene synthase gene was amplified from plasmid pTrcKudzu (SEQ ID NO:2). The gene had been codon optimized for *E. coli* and synthesized by DNA 2.0. The following primers were used:

CF 07-42 (+) Fuse the *aprE* promoter to kudzu isoprene synthase gene (GTG start codon)

5'- TAAAAGGAGAGGGTAAAGAGTGTGTGCGACCTCTTCTCAAT (SEQ ID NO:55)

CF 07-45 (-) Fuse the 3' end of kudzu isoprene synthase gene to the terminator

5'- CCAAGGCCGGTTTTTTTTTAGACATACATCAGCTGGTTAATC (SEQ ID NO:56)

c) Amplification of the transcription terminator

**[0708]** The terminator from the alkaline serine protease of *Bacillus amyliquefaciens* was amplified from a previously sequenced plasmid pJHPms382 using the following primers:

CF 07-44 (+) Fuse the 3' end of kudzu isoprene synthase to the terminator

5'- GATTAACCAGCTGATGTATGTCTAAAAAAAACCGGCCTTGG (SEQ ID NO:57)

CF 07-46 (-) End of *B. amyliquefaciens* terminator (BamHI)

5'- GACATGACGGATCCGATTACGAATGCCGTCTC (SEQ ID NO:58)

**[0709]** The kudzu fragment was fused to the terminator fragment using PCR with the following primers:

CF 07-42 (+) Fuse the *aprE* promoter to kudzu isoprene synthase gene (GTG start codon)

5'- TAAAAGGAGAGGGTAAAGAGTGTGTGCGACCTCTTCTCAAT (SEQ ID NO:55)

CF 07-46 (-) End of *B. amyliquefaciens* terminator (BamHI)

5'- GACATGACGGATCCGATTACGAATGCCGTCTC (SEQ ID NO:58)

**[0710]** The kudzu-terminator fragment was fused to the promoter fragment using PCR with the following primers:

CF 797 (+) Start *aprE* promoter MfeI

5'- GACATCAATTGCTCCATTTTCTTCTGCTATC (SEQ ID NO:53)

CF 07-46 (-) End of *B. amyliquefaciens* terminator (BamHI)

5'- GACATGACGGATCCGATTACGAATGCCGTCTC (SEQ ID NO:58)

**[0711]** The fusion PCR fragment was purified using a Qiagen kit and digested with the restriction enzymes *MfeI* and *BamHI*. This digested DNA fragment was gel purified using a Qiagen kit and ligated to a vector known as pBS19, which had been digested with *EcoRI* and *BamHI* and gel purified.

**[0712]** The ligation mix was transformed into *E. coli* Top 10 cells and colonies were selected on LA+50 carbenicillin plates. A total of six colonies were chosen and grown overnight in LB+50 carbenicillin and then plasmids were isolated using a Qiagen kit. The plasmids were digested with *EcoRI* and *BamHI* to check for inserts and three of the correct plasmids were sent in for sequencing with the following primers:

CF 149 (+) *EcoRI* start of *aprE* promoter

5'- GACATGAATTCCTCCATTTTCTTCTGC (SEQ ID NO:59)

CF 847 (+) Sequence in pXX 049 (end of *aprE* promoter)

5'- AGGAGAGGGTAAAGAGTGAG (SEQ ID NO:60)

CF 07-45 (-) Fuse the 3' end of kudzu isoprene synthase to the terminator

5'- CCAAGGCCGGTTTTTTTTAGACATACATCAGCTGGTTAATC (SEQ ID NO:56)

CF 07-48 (+) Sequencing primer for kudzu isoprene synthase

5'- CTTTCCATCACCCACCTGAAG (SEQ ID NO:61)

CF 07-49 (+) Sequencing in kudzu isoprene synthase

5'- GGCGAAATGGTCCAACAACAAAATTATC (SEQ ID NO:62)

**[0713]** The plasmid designated pBS Kudzu #2 (Figures 52 and 12; SEQ ID NO:5) was correct by sequencing and was transformed into BG 3594 comK, a *Bacillus subtilis* host strain.

Selection was done on LA + 5 chloramphenicol plates. A transformant was chosen and struck to single colonies on LA + 5 chloramphenicol, then grown in LB+5 chloramphenicol until it reached an OD<sub>600</sub> of 1.5. It was stored frozen in a vial at -80° C in the presence of glycerol. The resulting strain was designated CF 443.

## II. Production of isoprene in shake flasks containing *B. subtilis* cells expressing recombinant isoprene synthase

**[0714]** Overnight cultures were inoculated with a single colony of CF 443 from a LA + Chloramphenicol (Cm, 25 µg/ml). Cultures were grown in LB + Cm at 37° C with shaking at 200 rpm. These overnight cultures (1 ml) were used to inoculate 250 ml baffled shake flasks containing 25 ml Grants II media and chloramphenicol at a final concentration of 25 µg/ml. Grants II Media recipe was 10 g soytone, 3 ml 1M K<sub>2</sub>HPO<sub>4</sub>, 75 g glucose, 3.6 g urea, 100 ml 10X MOPS, q.s. to 1 L with H<sub>2</sub>O, pH 7.2; 10X MOPS recipe was 83.72 g MOPS, 7.17 g tricine, 12 g KOH pellets, 10 ml 0.276M K<sub>2</sub>SO<sub>4</sub> solution, 10 ml 0.528M MgCl<sub>2</sub> solution, 29.22 g NaCl, 100 ml 100X micronutrients, q.s. to 1 L with H<sub>2</sub>O; and 100X micronutrients recipe was 1.47 g CaCl<sub>2</sub>\*2H<sub>2</sub>O, 0.4 g FeSO<sub>4</sub>\*7H<sub>2</sub>O, 0.1 g MnSO<sub>4</sub>\*H<sub>2</sub>O, 0.1 g ZnSO<sub>4</sub>\*H<sub>2</sub>O, 0.05 g CuCl<sub>2</sub>\*2H<sub>2</sub>O, 0.1 g CoCl<sub>2</sub>\*6H<sub>2</sub>O, 0.1 g Na<sub>2</sub>MoO<sub>4</sub>\*2H<sub>2</sub>O, q.s. to 1 L with H<sub>2</sub>O. Shake flasks were incubated at 37° C and samples were taken at 18, 24, and 44 hours. At 18 hours the headspaces of CF443 and the control strain were sampled. This represented 18 hours of accumulation of isoprene. The

amount of isoprene was determined by gas chromatography as described in Example 1.

Production of isoprene was enhanced significantly by expressing recombinant isoprene synthase (Figure 11).

### III. Production of isoprene by CF443 in 14 L fermentation

**[0715]** Large scale production of isoprene from *B. subtilis* containing the recombinant kudzu isoprene synthase gene on a replication plasmid was determined from a fed-batch culture. Bacillus strain CF 443, expressing a kudzu isoprene synthase gene, or control stain which does not express a kudzu isoprene synthase gene were cultivated by conventional fed-batch fermentation in a nutrient medium containing soy meal (Cargill), sodium and potassium phosphate, magnesium sulfate and a solution of citric acid, ferric chloride and manganese chloride. Prior to fermentation the media is macerated for 90 minutes using a mixture of enzymes including cellulases, hemicellulases and pectinases (see, WO95/04134). 14-L batch fermentations are fed with 60% wt/wt glucose (Cargill DE99 dextrose, ADM Versadex greens or Danisco invert sugar) and 99% wt/wt oil (Western Family soy oil, where the 99% wt/wt is the concentration of oil before it was added to the cell culture medium). Feed was started when glucose in the batch was non-detectable. The feed rate was ramped over several hours and was adjusted to add oil on an equal carbon basis. The pH was controlled at 6.8 – 7.4 using 28% w/v ammonium hydroxide. In case of foaming, antifoam agent was added to the media. The fermentation temperature was controlled at 37°C and the fermentation culture was agitated at 750 rpm. Various other parameters such as pH, DO%, airflow, and pressure were monitored throughout the entire process. The DO% is maintained above 20. Samples were taken over the time course of 36 hours and analyzed for cell growth (OD<sub>550</sub>) and isoprene production. Results of these experiments are presented in Figures 53A and 53B.

### IV. Integration of the kudzu isoprene synthase (ispS) in *B. subtilis*.

**[0716]** The kudzu isoprene synthase gene was cloned in an integrating plasmid (pJH101-cmpR) under the control of the *aprE* promoter. Under the conditions tested, no isoprene was detected.

## Example 5: Production of isoprene in *Trichoderma*

### I. Construction of vectors for expression of the kudzu isoprene synthase in *Trichoderma reesei*

**[0717]** The *Yarrowia lipolytica* codon-optimized kudzu IS gene was synthesized by DNA 2.0 (SEQ ID NO:6) (Figure 13). This plasmid served as the template for the following PCR amplification reaction: 1  $\mu$ l plasmid template (20 ng/ $\mu$ l), 1  $\mu$ l Primer EL-945 (10  $\mu$ M) 5'-GCTTATGGATCCTCTAGACTATTACACGTACATCAATTGG (SEQ ID NO:63), 1  $\mu$ l Primer EL-965 (10  $\mu$ M) 5'-CACCATGTGTGCAACCTCCTCCCAGTTTAC (SEQ ID NO:64), 1  $\mu$ l dNTP (10mM), 5  $\mu$ l 10x PfuUltra II Fusion HS DNA Polymerase Buffer, 1  $\mu$ l PfuUltra II Fusion HS DNA Polymerase, 40  $\mu$ l water in a total reaction volume of 50  $\mu$ l. The forward primer contained an additional 4 nucleotides at the 5'-end that did not correspond to the *Y. lipolytica* codon-optimized kudzu isoprene synthase gene, but was required for cloning into the pENTR/D-TOPO vector. The reverse primer contained an additional 21 nucleotides at the 5'-end that did not correspond to the *Y. lipolytica* codon-optimized kudzu isoprene synthase gene, but were inserted for cloning into other vector backbones. Using the MJ Research PTC-200 Thermocycler, the PCR reaction was performed as follows: 95° C for 2 minutes (first cycle only), 95° C for 30 seconds, 55° C for 30 seconds, 72° C for 30 seconds (repeat for 27 cycles), 72° C for 1 minute after the last cycle. The PCR product was analyzed on a 1.2% E-gel to confirm successful amplification of the *Y. lipolytica* codon-optimized kudzu isoprene synthase gene.

**[0718]** The PCR product was then cloned using the TOPO pENTR/D-TOPO Cloning Kit following manufacturer's protocol: 1  $\mu$ l PCR reaction, 1  $\mu$ l Salt solution, 1  $\mu$ l TOPO pENTR/D-TOPO vector and 3  $\mu$ l water in a total reaction volume of 6  $\mu$ l. The reaction was incubated at room temperature for 5 minutes. One microliter of TOPO reaction was transformed into TOP10 chemically competent *E. coli* cells. The transformants were selected on LA + 50  $\mu$ g/ml kanamycin plates. Several colonies were picked and each was inoculated into a 5 ml tube containing LB + 50  $\mu$ g/ml kanamycin and the cultures grown overnight at 37° C with shaking at 200 rpm. Plasmids were isolated from the overnight culture tubes using QIAprep Spin Miniprep Kit, following manufacturer's protocol. Several plasmids were sequenced to verify that the DNA sequence was correct.

**[0719]** A single pENTR/D-TOPO plasmid, encoding a *Y. lipolytica* codon-optimized kudzu isoprene synthase gene, was used for Gateway Cloning into a custom-made pTrex3g vector. Construction of pTrex3g is described in WO 2005/001036 A2. The reaction was performed following manufacturer's protocol for the Gateway LR Clonase II Enzyme Mix Kit (Invitrogen): 1  $\mu$ l *Y. lipolytica* codon-optimized kudzu isoprene synthase gene pENTR/D-TOPO donor vector, 1  $\mu$ l pTrex3g destination vector, 6  $\mu$ l TE buffer, pH 8.0 in a total reaction volume of 8  $\mu$ l. The

reaction was incubated at room temperature for 1 hour and then 1  $\mu$ l proteinase K solution was added and the incubation continued at 37° C for 10 minutes. Then 1  $\mu$ l of reaction was transformed into TOP10 chemically competent *E. coli* cells. The transformants were selected on LA + 50  $\mu$ g/ml carbenicillin plates. Several colonies were picked and each was inoculated into a 5 ml tube containing LB + 50  $\mu$ g/ml carbenicillin and the cultures were grown overnight at 37° C with shaking at 200 rpm. Plasmids were isolated from the overnight culture tubes using QIAprep Spin Miniprep Kit (Qiagen, Inc.), following manufacturer's protocol. Several plasmids were sequenced to verify that the DNA sequence was correct.

**[0720]** Biolistic transformation of *Y. lipolytica* codon-optimized kudzu isoprene synthase pTrex3g plasmid (Figure 14) into a quad delete *Trichoderma reesei* strain was performed using the Biolistic PDS-1000/HE Particle Delivery System (see WO 2005/001036 A2). Isolation of stable transformants and shake flask evaluation was performed using protocol listed in Example 11 of patent publication WO 2005/001036 A2.

## II. Production of isoprene in recombinant strains of *T. reesei*

**[0721]** One ml of 15 and 36 hour old cultures of isoprene synthase transformants described above were transferred to head space vials. The vials were sealed and incubated for 5 hours at 30° C. Head space gas was measured and isoprene was identified by the method described in Example 1. Two of the transformants showed traces of isoprene. The amount of isoprene could be increased by a 14 hour incubation. The two positive samples showed isoprene at levels of about 0.5  $\mu$ g/L for the 14 hour incubation. The untransformed control showed no detectable levels of isoprene. This experiment shows that *T. reesei* is capable of producing isoprene from endogenous precursor when supplied with an exogenous isoprene synthase.

### Example 6: Production of isoprene in *Yarrowia*

#### I. Construction of vectors for expression of the kudzu isoprene synthase in *Yarrowia lipolytica*.

**[0722]** The starting point for the construction of vectors for the expression of the kudzu isoprene synthase gene in *Yarrowia lipolytica* was the vector pSPZ1(MAP29S<sub>pb</sub>). The complete sequence of this vector (SEQ ID NO:7) is shown in Figure 15.

**[0723]** The following fragments were amplified by PCR using chromosomal DNA of a *Y. lipolytica* strain GICC 120285 as the template: a promoterless form of the URA3 gene, a fragment of 18S ribosomal RNA gene, a transcription terminator of the *Y. lipolytica* XPR2 gene

and two DNA fragments containing the promoters of XPR2 and ICL1 genes. The following PCR primers were used:

ICL1 3

5'- GGTGAATTCAGTCTACTGGGGATTCCCAAATCTATATATACTGCAGGTGAC (SEQ ID NO:65)

ICL1 5

5'- GCAGGTGGGAAACTATGCACTCC (SEQ ID NO:66)

XPR 3

5'- CCTGAATTCTGTTGGATTGGAGGATTGGATAGTGGG (SEQ ID NO:67)

XPR 5

5'- GGTGTCGACGTACGGTCGAGCTTATTGACC (SEQ ID NO:68)

XPRT3

5'- GGTGGGCCCCGCATTTTGCCACCTACAAGCCAG (SEQ ID NO:69)

XPRT 5

5'- GGTGAATTCTAGAGGATCCCAACGCTGTTGCCTACAACGG (SEQ ID NO:70)

Y18S3

5'- GGTGCGGCCGCTGTCTGGACCTGGTGAGTTTCCCCG (SEQ ID NO:71)

Y18S 5

5'- GGTGGGCCCATTAATCAGTTATCGTTTATTTGATAG (SEQ ID NO:72)

YURA3

5'- GGTGACCAGCAAGTCCATGGGTGGTTTGATCATGG (SEQ ID NO:73)

YURA 50

5'- GGTGCGGCCGCCTTTGGAGTACGACTCCAACACTATG (SEQ ID NO:74)

YURA 51

5' - GCGGCCGCAGACTAAATTTATTTTCAGTCTCC (SEQ ID NO:75)

**[0724]** For PCR amplification the PfuUltraII polymerase (Stratagene), supplier-provided buffer and dNTPs, 2.5  $\mu$ M primers and the indicated template DNA were used as per the manufacturer's instructions. The amplification was done using the following cycle: 95° C for 1 min; 34x (95° C for 30 sec; 55° C for 30 sec; 72° C for 3 min) and 10 min at 72° C followed by a 4° C incubation.

**[0725]** Synthetic DNA molecules encoding the kudzu isoprene synthase gene, codon-optimized for expression in *Yarrowia*, was obtained from DNA 2.0 (Figure 16; SEQ ID NO:8). Full detail of the construction scheme of the plasmids pYLA(KZ1) and pYLI(KZ1) carrying the synthetic kudzu isoprene synthase gene under control of XPR2 and ICL1 promoters respectively is presented in Figure 18. Control plasmids in which a mating factor gene (MAP29) is inserted in place of an isoprene synthase gene were also constructed (Figure 18E and 18F).

**[0726]** A similar cloning procedure can be used to express a poplar (*Populus alba* x *Populus tremula*) isoprene synthase gene. The sequence of the poplar isoprene is described in Miller B. *et al.* (2001) *Planta* 213, 483-487 and shown in Figure 17 (SEQ ID NO:9). A construction scheme for the generation the plasmids pYLA(POP1) and pYLI(POP1) carrying synthetic poplar isoprene synthase gene under control of XPR2 and ICL1 promoters respectively is presented in Figure 18A and B.

## II. Production of isoprene by recombinant strains of *Y. lipolytica*.

**[0727]** Vectors pYLA(KZ1), pYLI(KZ1), pYLA(MAP29) and pYLI(MAP29) were digested with *Sac*II and used to transform the strain *Y. lipolytica* CLIB 122 by a standard lithium acetate/polyethylene glycol procedure to uridine prototrophy. Briefly, the yeast cells grown in YEPD (1% yeast extract, 2% peptone, 2% glucose) overnight, were collected by centrifugation (4000 rpm, 10 min), washed once with sterile water and suspended in 0.1 M lithium acetate, pH 6.0. Two hundred  $\mu$ l aliquots of the cell suspension were mixed with linearized plasmid DNA solution (10-20  $\mu$ g), incubated for 10 minutes at room temperature and mixed with 1 ml of 50% PEG 4000 in the same buffer. The suspensions were further incubated for 1 hour at room temperature followed by a 2 minutes heat shock at 42° C. Cells were then plated on SC his leu plates (0.67% yeast nitrogen base, 2% glucose, 100 mg/L each of leucine and histidine). Transformants appeared after 3-4 days of incubation at 30° C.

[0728] Three isolates from the pYLA(KZ1) transformation, three isolates from the pYLI(KZ1) transformation, two isolates from the pYLA(MAP29) transformation and two isolates from the pYLI(MAP29) transformation were grown for 24 hours in YEP7 medium (1% yeast extract, 2% peptone, pH 7.0) at 30° C with shaking. Cells from 10 ml of culture were collected by centrifugation, resuspended in 3 ml of fresh YEP7 and placed into 15 ml screw cap vials. The vials were incubated overnight at room temperature with gentle (60 rpm) shaking. Isoprene content in the headspace of these vials was analyzed by gas chromatography using mass-spectrometric detector as described in Example 1. All transformants obtained with pYLA(KZ1) and pYLI(KZ1) produced readily detectable amounts of isoprene (0.5 µg/L to 1 µg/L, Figure 20). No isoprene was detected in the headspace of the control strains carrying phytase gene instead of an isoprene synthase gene.

Example 7: Production of isoprene in *E. coli* expressing kudzu isoprene synthase and *idi*, or *dxs*, or *idi* and *dxs*

I. Construction of vectors encoding kudzu isoprene synthase and *idi*, or *dxs*, or *idi* and *dxs* for the production of isoprene in *E. coli*

i) Construction of pTrcKudzuKan

[0729] The *bla* gene of pTrcKudzu (described in Example 1) was replaced with the gene conferring kanamycin resistance. To remove the *bla* gene, pTrcKudzu was digested with *Bsp*HI, treated with Shrimp Alkaline Phosphatase (SAP), heat killed at 65° C, then end-filled with Klenow fragment and dNTPs. The 5 kbp large fragment was purified from an agarose gel and ligated to the kan<sup>r</sup> gene which had been PCR amplified from pCR-Blunt-II-TOPO using primers MCM22 5'- GATCAAGCTTAACCGGAATTGCCAGCTG (SEQ ID NO:76) and MCM23 5'- GATCCGATCGTCAGAAGAAGCTCGTCAAGAAGGC (SEQ ID NO:77), digested with *Hind*III and *Pvu*I, and end-filled. A transformant carrying a plasmid conferring kanamycin resistance (pTrcKudzuKan) was selected on LA containing kanamycin 50 µg/ml.

ii) Construction of pTrcKudzu yIDI Kan

[0730] pTrcKudzuKan was digested with *Pst*I, treated with SAP, heat killed and gel purified. It was ligated to a PCR product encoding *idi* from *S. cerevisiae* with a synthetic RBS. The primers for PCR were NsiI-YIDI 1 F 5'- CATCAATGCATCGCCCTTAGGAGGTAAAAAAAATGAC (SEQ ID NO:78) and *Pst*I-YIDI 1 R 5'- CCTTCTGCAGGACGCGTTGTTATAGC (SEQ ID NO:79); and the template

was *S. cerevisiae* genomic DNA. The PCR product was digested with *NsiI* and *PstI* and gel purified prior to ligation. The ligation mixture was transformed into chemically competent TOP10 cells and selected on LA containing 50 µg/ml kanamycin. Several transformants were isolated and sequenced and the resulting plasmid was called pTrcKudzu-yIDI(kan) (Figures 34 and 35; SEQ ID NO:16).

iii) Construction of pTrcKudzu DXS Kan

**[0731]** Plasmid pTrcKudzuKan was digested with *PstI*, treated with SAP, heat killed and gel purified. It was ligated to a PCR product encoding *dxs* from *E. coli* with a synthetic RBS. The primers for PCR were MCM13 5'-

GATCATGCATTCGCCCTTAGGAGGTAAAAAACATGAGTTTTGATATTGCCAAATAC  
CCG (SEQ ID NO:80) and MCM14 5' - CATGCTGCAGTTATGCCAGCCAGGCCTTGAT

(SEQ ID NO:81); and the template was *E. coli* genomic DNA. The PCR product was digested with *NsiI* and *PstI* and gel purified prior to ligation. The resulting transformation reaction was transformed into TOP10 cells and selected on LA with kanamycin 50 µg/ml. Several transformants were isolated and sequenced and the resulting plasmid was called pTrcKudzu-DXS(kan) (Figures 36 and 37; SEQ ID NO:17).

iv) Construction of pTrcKudzu-yIDI-dxs (kan)

**[0732]** pTrcKudzu-yIDI(kan) was digested with *PstI*, treated with SAP, heat killed and gel purified. It was ligated to a PCR product encoding *E. coli dxs* with a synthetic RBS (primers MCM13 5'-

GATCATGCATTCGCCCTTAGGAGGTAAAAAACATGAGTTTTGATATTGCCAAATAC  
CCG (SEQ ID NO:80) and MCM14 5' - CATGCTGCAGTTATGCCAGCCAGGCCTTGAT

(SEQ ID NO:81); template TOP10 cells) which had been digested with *NsiI* and *PstI* and gel purified. The final plasmid was called pTrcKudzu-yIDI-dxs (kan) (Figures 21 and 22; SEQ ID NO:10).

v) Construction of pCL PtrcKudzu

**[0733]** A fragment of DNA containing the promoter, structural gene and terminator from Example 1 above was digested from pTrcKudzu using *SspI* and gel purified. It was ligated to pCL1920 which had been digested with *PvuII*, treated with SAP and heat killed. The resulting ligation mixture was transformed into TOP10 cells and selected in LA containing spectinomycin 50 µg/ml. Several clones were isolated and sequenced and two were selected. pCL PtrcKudzu

and pCL PtrcKudzu (A3) have the insert in opposite orientations (Figures 38-41; SEQ ID NOs:18-19).

vi) Construction of pCL PtrcKudzu yIDI

**[0734]** The *NsiI-PstI* digested, gel purified, IDI PCR amplicon from (ii) above was ligated into pCL PtrcKudzu which had been digested with *PstI*, treated with SAP, and heat killed. The ligation mixture was transformed into TOP10 cells and selected in LA containing spectinomycin 50 µg/ml. Several clones were isolated and sequenced and the resulting plasmid is called pCL PtrcKudzu yIDI (Figures 42 and 43; SEQ ID NO:20).

vii) Construction of pCL PtrcKudzu DXS

**[0735]** The *NsiI-PstI* digested, gel purified, DXS PCR amplicon from (iii) above was ligated into pCL PtrcKudzu (A3) which had been digested with *PstI*, treated with SAP, and heat killed. The ligation mixture was transformed into TOP10 cells and selected in LA containing spectinomycin 50 µg/ml. Several clones were isolated and sequenced and the resulting plasmid is called pCL PtrcKudzu DXS (Figures 44 and 45; SEQ ID NO:21).

II. Measurement of isoprene in headspace from cultures expressing kudzu isoprene synthase, *idi*, and/or *dxs* at different copy numbers.

**[0736]** Cultures of *E. coli* BL21(λDE3) previously transformed with plasmids pTrcKudzu(kan) (A), pTrcKudzu-yIDI kan (B), pTrcKudzu-DXS kan (C), pTrcKudzu-yIDI-DXS kan (D) were grown in LB kanamycin 50 µg/mL. Cultures of pCL PtrcKudzu (E), pCL PtrcKudzu, pCL PtrcKudzu-yIDI (F) and pCL PtrcKudzu-DXS (G) were grown in LB spectinomycin 50 µg/mL. Cultures were induced with 400 µM IPTG at time 0 (OD<sub>600</sub> approximately 0.5) and samples taken for isoprene headspace measurement (see Example 1). Results are shown in Figure 23A-23G.

**[0737]** Plasmid pTrcKudzu-yIDI-dxs (kan) was introduced into *E. coli* strain BL21 by transformation. The resulting strain BL21/pTrc Kudzu IDI DXS was grown overnight in LB containing kanamycin (50 µg/ml) at 20° C and used to inoculate shake flasks of TM3 (13.6 g K<sub>2</sub>PO<sub>4</sub>, 13.6 g KH<sub>2</sub>PO<sub>4</sub>, 2.0 g MgSO<sub>4</sub>\*7H<sub>2</sub>O), 2.0 g citric acid monohydrate, 0.3 g ferric ammonium citrate, 3.2 g (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.2 g yeast extract, 1.0 ml 1000x Modified Trace Metal Solution, adjusted to pH 6.8 and q.s. to H<sub>2</sub>O, and filter sterilized) containing 1% glucose. Flasks were incubated at 30° C until an OD<sub>600</sub> of 0.8 was reached, and then induced with 400 µM IPTG.

Samples were taken at various times after induction and the amount of isoprene in the head space was measured as described in Example 1. Results are shown in Figure 23H.

### III. Production of isoprene from biomass in *E. coli*/pTrcKudzu yIDI DXS

**[0738]** The strain BL21 pTrcKudzuIDIDXS was tested for the ability to generate isoprene from three types of biomass; bagasse, corn stover and soft wood pulp with glucose as a control. Hydrolysates of the biomass were prepared by enzymatic hydrolysis (Brown, L and Torget, R., 1996, NREL standard assay method Lap-009 “Enzymatic Saccharification of Lignocellulosic Biomass”) and used at a dilution based upon glucose equivalents. In this example, glucose equivalents were equal to 1% glucose. A single colony from a plate freshly transformed cells of BL21 (DE3) pTrcKudzu yIDI DXS (kan) was used to inoculate 5 ml of LB plus kanamycin (50 µg/ml). The culture was incubated overnight at 25° C with shaking. The following day the overnight culture was diluted to an OD<sub>600</sub> of 0.05 in 25 ml of TM3 + 0.2% YE + 1% feedstock. The feedstock was corn stover, bagasse, or softwood pulp. Glucose was used as a positive control and no glucose was used as a negative control. Cultures were incubated at 30° C with shaking at 180 rpm. The culture was monitored for OD<sub>600</sub> and when it reached an OD<sub>600</sub> of ~0.8, cultures were analyzed at 1 and 3 hours for isoprene production as described in Example 1. Cultures are not induced. All cultures containing added feedstock produce isoprene equivalent to those of the glucose positive control. Experiments were done in duplicate and are shown in Figure 46.

### IV. Production of isoprene from invert sugar in *E. coli*/pTrcKudzuIDIDXS

**[0739]** A single colony from a plate freshly transformed cells of BL21 (λDE3)/pTrcKudzu yIDI DXS (kan) was used to inoculate 5 mL of LB + kanamycin (50 µg/ml). The culture was incubated overnight at 25° C with shaking. The following day the overnight culture was diluted to an OD<sub>600</sub> of 0.05 in 25 ml of TM3 + 0.2% YE + 1% feedstock. Feedstock was glucose, inverted glucose or corn stover. The invert sugar feedstock (Danisco Invert Sugar) was prepared by enzymatically treating sucrose syrup. AFEX corn stover was prepared as described below (Part V). The cells were grown at 30° C and the first sample was measured when the cultures reached an OD<sub>600</sub> ~0.8-1.0 (0 hour). The cultures were analyzed for growth as measured by OD<sub>600</sub> and for isoprene production as in Example 1 at 0, 1 and 3 hours. Results are shown in Figure 47.

### V. Preparation of hydrolysate from AFEX pretreated corn stover

**[0740]** AFEX pretreated corn stover was obtained from Michigan Biotechnology Institute. The pretreatment conditions were 60% moisture, 1:1 ammonia loading, and 90 °C for 30 minutes, then air dried. The moisture content in the AFEX pretreated corn stover was 21.27%. The contents of glucan and xylan in the AFEX pretreated corn stover were 31.7% and 19.1% (dry basis), respectively. The saccharification process was as follows; 20 g of AFEX pretreated corn stover was added into a 500 ml flask with 5 ml of 1 M sodium citrate buffer pH 4.8, 2.25 ml of Accellerase 1000, 0.1 ml of Grindamyl H121 (Danisco xylanase product from *Aspergillus niger* for bread-making industry), and 72.65 ml of DI water. The flask was put in an orbital shaker and incubated at 50° C for 96 hours. One sample was taken from the shaker and analyzed using HPLC. The hydrolysate contained 38.5 g/l of glucose, 21.8 g/l of xylose, and 10.3 g/l of oligomers of glucose and/or xylose.

VI. The effect of yeast extract on isoprene production in *E. coli* grown in fed-batch culture

**[0741]** Fermentation was performed at the 14-L scale as previously described with *E. coli* cells containing the pTrcKudzu yIDI DXS plasmid described above. Yeast extract (Bio Springer, Montreal, Quebec, Canada) was fed at an exponential rate. The total amount of yeast extract delivered to the fermentor was varied between 70-830 g during the 40 hour fermentation. Optical density of the fermentation broth was measured at a wavelength of 550 nm. The final optical density within the fermentors was proportional to the amount of yeast extract added (Figure 48A). The isoprene level in the off-gas from the fermentor was determined as previously described. The isoprene titer increased over the course of the fermentation (Figure 48B). The amount of isoprene produced was linearly proportional to the amount of fed yeast extract (Figure 48C).

VII. Production of isoprene in 500 L fermentation of pTrcKudzu DXS yIDI

**[0742]** A 500 liter fermentation of *E. coli* cells with a kudzu isoprene synthase, *S. cerevisiae* IDI, and *E. coli* DXS nucleic acids (*E. coli* BL21 (λDE3) pTrc Kudzu dxs yidi) was used to produce isoprene. The levels of isoprene varied from 50 to 300 µg/L over a time period of 15 hours. On the basis of the average isoprene concentrations, the average flow through the device and the extent of isoprene breakthrough, the amount of isoprene collected was calculated to be approximately 17 g.

VIII. Production of isoprene in 500 L fermentation of *E. coli* grown in fed-batch culture

Medium Recipe (per liter fermentation medium):

**[0743]** K<sub>2</sub>HPO<sub>4</sub> 7.5 g, MgSO<sub>4</sub> \* 7H<sub>2</sub>O 2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, 1000X Modified Trace Metal Solution 1 ml. All of the components were added together and dissolved in diH<sub>2</sub>O. This solution was autoclaved. The pH was adjusted to 7.0 with ammonium gas (NH<sub>3</sub>) and q.s. to volume. Glucose 10 g, thiamine \* HCl 0.1 g, and antibiotic were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

**[0744]** Citric Acids \* H<sub>2</sub>O 40 g, MnSO<sub>4</sub> \* H<sub>2</sub>O 30 g, NaCl 10 g, FeSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CoCl<sub>2</sub> \* 6H<sub>2</sub>O 1 g, ZnSO \* 7H<sub>2</sub>O 1 g, CuSO<sub>4</sub> \* 5H<sub>2</sub>O 100 mg, H<sub>3</sub>BO<sub>3</sub> 100 mg, NaMoO<sub>4</sub> \* 2H<sub>2</sub>O 100 mg. Each component is dissolved one at a time in DI H<sub>2</sub>O, pH to 3.0 with HCl/NaOH, then q.s. to volume and filter sterilized with 0.22 micron filter.

**[0745]** Fermentation was performed in a 500-L bioreactor with *E. coli* cells containing the pTrcKudzu yIDI DXS plasmid. This experiment was carried out to monitor isoprene formation from glucose and yeast extract at the desired fermentation pH 7.0 and temperature 30° C. An inoculum of *E. coli* strain taken from a frozen vial was prepared in soytone-yeast extract-glucose medium. After the inoculum grew to OD 0.15, measured at 550 nm, 20 ml was used to inoculate a bioreactor containing 2.5-L soytone-yeast extract-glucose medium. The 2.5-L bioreactor was grown at 30° C to OD 1.0 and 2.0-L was transferred to the 500-L bioreactor.

**[0746]** Yeast extract (Bio Springer, Montreal, Quebec, Canada) and glucose were fed at exponential rates. The total amount of glucose and yeast extract delivered to the bioreactor during the 50 hour fermentation was 181.2 kg and 17.6 kg, respectively. The optical density within the bioreactor over time is shown in Figure 49A. The isoprene level in the off-gas from the bioreactor was determined as previously described. The isoprene titer increased over the course of the fermentation (Figure 49B). The total amount of isoprene produced during the 50 hour fermentation was 55.1 g and the time course of production is shown in Figure 49C.

Example 8: Production of isoprene in *E. coli* expressing kudzu isoprene synthase and recombinant mevalonic acid pathway genes

I. Cloning the lower MVA pathway

**[0747]** The strategy for cloning the lower mevalonic pathway was as follows. Four genes of the mevalonic acid biosynthesis pathway; mevalonate kinase (MVK), phosphomevalonate kinase

(PMK), diphosphomevalonate decarboxylase (MVD) and isopentenyl diphosphate isomerase genes were amplified by PCR from *S. cerevisiae* chromosomal DNA and cloned individually into the pCR BluntII TOPO plasmid (Invitrogen). In some cases, the *idi* gene was amplified from *E. coli* chromosomal DNA. The primers were designed such that an *E. coli* consensus RBS (AGGAGGT (SEQ ID NO:82) or AAGGAGG (SEQ ID NO:83)) was inserted at the 5' end, 8 bp upstream of the start codon and a *Pst*I site was added at the 3' end. The genes were then cloned one by one into the pTrcHis2B vector until the entire pathway was assembled.

**[0748]** Chromosomal DNA from *S. cerevisiae* S288C was obtained from ATCC (ATCC 204508D). The MVK gene was amplified from the chromosome of *S. cerevisiae* using primers MVKF (5'-AGGAGGTAAAAAACATGTCATTACCGTTCTTAACTTCTGC, SEQ ID NO:84) and MVK-PstI-R (5'-ATGGCTGCAGGCCTATCGCAAATTAGCTTATGAAGTCCATGGTAAATTCGTG, SEQ ID NO:85) using PfuTurbo as per manufacturer's instructions. The correct sized PCR product (1370 bp) was identified by electrophoresis through a 1.2% E-gel (Invitrogen) and cloned into pZeroBLUNT TOPO. The resulting plasmid was designated pMVK1. The plasmid pMVK1 was digested with *Sac*I and *Taq*I restriction endonucleases and the fragment was gel purified and ligated into pTrcHis2B digested with *Sac*I and *Bst*BI. The resulting plasmid was named pTrcMVK1.

**[0749]** The second gene in the mevalonic acid biosynthesis pathway, PMK, was amplified by PCR using primers: *Pst*I-PMK1 R (5'-GAATTCGCCCTTCTGCAGCTACC, SEQ ID NO:86) and *Bsi*HKA I-PMK1 F (5'-CGACTGGTGCACCCTTAAGGAGGAAAAAACATGTCAG, SEQ ID NO:87). The PCR reaction was performed using Pfu Turbo polymerase (Stratagene) as per manufacturer's instructions. The correct sized product (1387 bp) was digested with *Pst*I and *Bsi*HKI and ligated into pTrcMVK1 digested with *Pst*I. The resulting plasmid was named pTrcKK. The MVD and the *idi* genes were cloned in the same manner. PCR was carried out using the primer pairs *Pst*I-MVD 1 R (5'-GTGCTGGAATTCGCCCTTCTGCAGC, SEQ ID NO:88) and *Nsi*I-MVD 1 F (5'-GTAGATGCATGCAGAATTCGCCCTTAAGGAGG, SEQ ID NO:89) to amplify the MVD gene and *Pst*I-YIDI 1 R (5'-CCTTCTGCAGGACGCGTTGTTATAGC, SEQ ID NO:79) and *Nsi*I-YIDI 1 F (5'-CATCAATGCATCGCCCTTAGGAGGTAAAAAAAATGAC, SEQ ID NO:78) to amplify the yIDI gene. In some cases the IPP isomerase gene, *idi* from *E. coli* was used. To amplify *idi* from *E. coli* chromosomal DNA, the following primer set was used: *Pst*I-CIDI 1 R (5'-GTGTGATGGATATCTGCAGAATTCG, SEQ ID NO:90) and *Nsi*I-CIDI 1 F (5'-

CATCAATGCATCGCCCTTAGGAGGTAAAAAACATG, SEQ ID NO:91). Template DNA was chromosomal DNA isolated by standard methods from *E. coli* FM5 (WO 96/35796 and WO 2004/033646, which are each hereby incorporated by reference in their entireties, particularly with respect to isolation of nucleic acids). The final plasmids were named pKKDIy for the construct encoding the yeast *idi* gene or pKKDIc for the construct encoding the *E. coli idi* gene. The plasmids were transformed into *E. coli* hosts BL21 for subsequent analysis. In some cases the isoprene synthase from kudzu was cloned into pKKDIy yielding plasmid pKKDIyIS.

**[0750]** The lower MVA pathway was also cloned into pTrc containing a kanamycin antibiotic resistance marker. The plasmid pTrcKKDIy was digested with restriction endonucleases *ApaI* and *PstI*, the 5930 bp fragment was separated on a 1.2% agarose E-gel and purified using the Qiagen Gel Purification kit according to the manufacturer's instructions. The plasmid pTrcKudzuKan, described in Example 7, was digested with restriction endonucleases *ApaI* and *PstI*, and the 3338 bp fragment containing the vector was purified from a 1.2% E-gel using the Qiagen Gel Purification kit. The 3338 bp vector fragment and the 5930 bp lower MVA pathway fragment were ligated using the Roche Quick Ligation kit. The ligation mix was transformed into *E. coli* TOP10 cells and transformants were grown at 37° C overnight with selection on LA containing kanamycin (50 µg/ml). The transformants were verified by restriction enzyme digestion and one was frozen as a stock. The plasmid was designated pTrcKanKKDIy.

## II. Cloning a kudzu isoprene synthase gene into pTrcKanKKDIy

**[0751]** The kudzu isoprene synthase gene was amplified by PCR from pTrcKudzu, described in Example 1, using primers MCM50 5'-

GATCATGCATTCGCCCTTAGGAGGTAAAAAACATGTGTGCGACCTCTTCTCAATTT  
ACT (SEQ ID NO:52) and MCM53 5'-

CGGTCGACGGATCCCTGCAGTTAGACATACATCAGCTG (SEQ ID NO:50). The resulting PCR fragment was cloned into pCR2.1 and transformed into *E. coli* TOP10. This fragment contains the coding sequence for kudzu isoprene synthase and an upstream region containing a RBS from *E. coli*. Transformants were incubated overnight at 37° C with selection on LA containing carbenicillin (50 µg/ml). The correct insertion of the fragment was verified by sequencing and this strain was designated MCM93.

**[0752]** The plasmid from strain MCM93 was digested with restriction endonucleases *NsiI* and *PstI* to liberate a 1724 bp insert containing the RBS and kudzu isoprene synthase. The 1724 bp fragment was separated on a 1.2% agarose E-gel and purified using the Qiagen Gel Purification

kit according to the manufacturer's instructions. Plasmid pTrcKanKKDIy was digested with the restriction endonuclease *Pst*I, treated with SAP for 30 minutes at 37° C and purified using the Qiagen PCR cleanup kit. The plasmid and kudzu isoprene synthase encoding DNA fragment were ligated using the Roche Quick Ligation kit. The ligation mix was transformed into *E. coli* TOP10 cells and transformants were grown overnight at 37° C with selection on LA containing Kanamycin at 50 µg/ml. The correct transformant was verified by restriction digestion and the plasmid was designated pTrcKKDyIkISKan (Figures 24 and 25; SEQ ID NO:11). This plasmid was transformed into BL21(λDE3) cells (Invitrogen).

III. Isoprene production from mevalonate in *E. coli* expressing the recombinant lower mevalonate pathway and isoprene synthase from kudzu.

**[0753]** Strain BL21/pTrcKKDyIkISKan was cultured in MOPS medium (Neidhardt *et al.*, (1974) *J. Bacteriology* 119:736-747) adjusted to pH 7.1 and supplemented with 0.5% glucose and 0.5% mevalonic acid. A control culture was also set up using identical conditions but without the addition of 0.5% mevalonic acid. The culture was started from an overnight seed culture with a 1% inoculum and induced with 500 µM IPTG when the culture had reached an OD<sub>600</sub> of 0.3 to 0.5. The cultures were grown at 30° C with shaking at 250 rpm. The production of isoprene was analyzed 3 hours after induction by using the head space assay described in Example 1. Maximum production of isoprene was  $6.67 \times 10^{-4}$  mol/L<sub>broth</sub>/OD<sub>600</sub>/hr where L<sub>broth</sub> is the volume of broth and includes both the volume of the cell medium and the volume of the cells. The control culture not supplemented with mevalonic acid did not produce measurable isoprene.

IV. Cloning the upper MVA pathway

**[0754]** The upper mevalonate biosynthetic pathway, comprising two genes encoding three enzymatic activities, was cloned from *Enterococcus faecalis*. The *mvaE* gene encodes a protein with the enzymatic activities of both acetyl-CoA acetyltransferase and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the first and third proteins in the pathway, and the *mvaS* gene encodes second enzyme in the pathway, HMG-CoA synthase. The *mvaE* gene was amplified from *E. faecalis* genomic DNA (ATCC 700802D-5) with an *E. coli* ribosome binding site and a spacer in front using the following primers:  
CF 07-60 (+) Start of *mvaE* w/ RBS + ATG start codon *Sac*I

5' - GAGACATGAGCTCAGGAGGTAAAAAACATGAAAACAGTAGTTATTATTG (SEQ ID NO:93)

CF 07-62 (-) Fuse *mvaE* to *mvaS* with RBS in between

5' - TTTATCAATCCCAATTGTCATGTTTTTTTACCTCCTTTATTGTTTTCTTAAATC (SEQ ID NO:94)

**[0755]** The *mvaS* gene was amplified from *E. faecalis* genomic DNA (ATCC 700802D-5) with a RBS and spacer from *E. coli* in front using the following primers:

CF 07-61 (+) Fuse *mvaE* to *mvaS* with RBS in between

5' -

GATTTAAGAAAACAATAAAGGAGGTAAAAAACATGACAATTGGGATTGATAAA (SEQ ID NO:95)

CF 07-102 (-) End of *mvaS* gene *Bg/II*

5' -GACATGACATAGATCTTTAGTTTCGATAAGAACGAACGGT (SEQ ID NO:96)

**[0756]** The PCR fragments were fused together with PCR using the following primers:

CF 07-60 (+) Start of *mvaE* w/ RBS + ATG start codon *SacI*

5' -GAGACATGAGCTCAGGAGGTAAAAAACATGAAAACAGTAGTTATTATTG (SEQ ID NO:93)

CF 07-102 (-) End of *mvaS* gene *Bg/II*

5'-GACATGACATAGATCTTTAGTTTCGATAAGAACGAACGGT (SEQ ID NO:96)

**[0757]** The fusion PCR fragment was purified using a Qiagen kit and digested with the restriction enzymes *SacI* and *Bg/II*. This digested DNA fragment was gel purified using a Qiagen kit and ligated into the commercially available vector pTrcHis2A, which had been digested with *SacI* and *Bg/II* and gel purified.

**[0758]** The ligation mix was transformed into *E. coli* Top 10 cells and colonies were selected on LA+50 µg/ml carbenicillin plates. A total of six colonies were chosen and grown overnight in LB+50 µg/ml carbenicillin and plasmids were isolated using a Qiagen kit. The plasmids were

digested with *SacI* and *BglIII* to check for inserts and one correct plasmid was sequenced with the following primers:

CF 07-58 (+) Start of *mvaE* gene

5' – ATGAAAACAGTAGTTATTATTGATGC (SEQ ID NO:97)

CF 07-59 (-) End of *mvaE* gene

5' – ATGTTATTGTTTTCTTAAATCATTTAAAATAGC (SEQ ID NO:98)

CF 07-82 (+) Start of *mvaS* gene

5' – ATGACAATTGGGATTGATAAAATTAG (SEQ ID NO:99)

CF 07-83 (-) End of *mvaS* gene

5' – TTAGTTTCGATAAGAACGAACGGT (SEQ ID NO:100)

CF 07-86 (+) Sequence in *mvaE*

5' – GAAATAGCCCCATTAGAAGTATC (SEQ ID NO:101)

CF 07-87 (+) Sequence in *mvaE*

5' – TTGCCAATCATATGATTGAAAATC (SEQ ID NO:102)

CF 07-88 (+) Sequence in *mvaE*

5' – GCTATGCTTCATTAGATCCTTATCG (SEQ ID NO:103)

CF 07-89 (+) Sequence *mvaS*

5' – GAAACCTACATCCAATCTTTTGCCC (SEQ ID NO:104)

**[0759]** The plasmid called pTrcHis2AUpperPathway#1 was correct by sequencing and was transformed into the commercially available *E. coli* strain BL21. Selection was done on LA+ 50 µg/ml carbenicillin. Two transformants were chosen and grown in LB+ 50 µg/ml carbenicillin until they reached an OD<sub>600</sub> of 1.5. Both strains were frozen in a vial at -80° C in the presence of glycerol. Strains were designated CF 449 for pTrcHis2AUpperPathway#1 in BL21, isolate #1 and CF 450 for pTrcHis2AUpperPathway#1 in BL21, isolate #2. Both clones were found to behave identically when analyzed.

#### V. Cloning of UpperMVA Pathway into pCL1920

**[0760]** The plasmid pTrcHis2AUpperPathway was digested with the restriction endonuclease *SspI* to release a fragment containing pTrc-*mvaE-mvaS*-(His tag)-terminator. In this fragment, the his-tag was not translated. This blunt ended 4.5 kbp fragment was purified from a 1.2% E-gel using the Qiagen Gel Purification kit. A dephosphorylated, blunt ended 4.2 kbp fragment from pCL1920 was prepared by digesting the vector with the restriction endonuclease *PvuII*, treating with SAP and gel purifying from a 1.2% E-gel using the Qiagen Gel Purification kit. The two fragments were ligated using the Roche Quick Ligation Kit and transformed into TOP10 chemically competent cells. Transformants were selected on LA containing spectinomycin (50 µg/ml). A correct colony was identified by screening for the presence of the insert by PCR. The plasmid was designated pCL PtrcUpperPathway (Figures 26 and 27A-27D; SEQ ID NO:12).

#### VI. Strains expressing the combined Upper and Lower Mevalonic Acid Pathways

**[0761]** To obtain a strain with a complete mevalonic acid pathway plus kudzu isoprene synthase, plasmids pTrcKKDyIkISkan and pCLpTrcUpperPathway were both transformed into BL21(λDE3) competent cells (Invitrogen) and transformants were selected on LA containing kanamycin (50 µg/ml) and Spectinomycin (50 µg/ml). The transformants were checked by plasmid prep to ensure that both plasmids were retained in the host. The strain was designated MCM127.

#### VII. Production of mevalonic acid from glucose in *E. coli*/pUpperpathway

**[0762]** Single colonies of the BL21/pTrcHis2A-*mvaE/mvaS* or FM5/pTrcHis2A-*mvaE/mvaS* are inoculated into LB + carbenicillin (100 µg/ml) and are grown overnight at 37° C with shaking at 200 rpm. These cultures were diluted into 50 ml medium in 250 ml baffled flasks to an OD<sub>600</sub> of 0.1. The medium was TM3 + 1 or 2% glucose + carbenicillin (100 µg/ml) or TM3 + 1% glucose + hydrolyzed soy oil + carbenicillin (100 µg/ml) or TM3 + biomass (prepared bagasse, corn stover or switchgrass). Cultures were grown at 30° C with shaking at 200 rpm for approximately 2-3 hours until an OD<sub>600</sub> of 0.4 was reached. At this point the expression from the *mvaE mvaS* construct was induced by the addition of IPTG (400 µM). Cultures were incubated for a further 20 or 40 hours with samples taken at 2 hour intervals to 6 hour post induction and then at 24, 36 and 48 hours as needed. Sampling was done by removing 1 ml of culture, measuring the OD<sub>600</sub>, pelleting the cells in a microfuge, removing the supernatant and analyzing it for mevalonic acid.

**[0763]** A 14 liter fermentation of *E. coli* cells with nucleic acids encoding *Enterococcus faecalis* AA-CoA thiolase, HMG-CoA synthase, and HMG-CoA reductase polypeptides produced 22 grams of mevalonic acid with TM3 medium and 2% glucose as the cell medium. A shake flask of these cells produced 2-4 grams of mevalonic acid per liter with LB medium and 1% glucose as the cell culture medium. The production of mevalonic acid in these strains indicated that the MVA pathway was functional in *E. coli*.

VIII. Production of isoprene from *E. coli* BL21 containing the upper and lower MVA pathway plus kudzu isoprene synthase.

**[0764]** The following strains were created by transforming in various combinations of plasmids containing the upper and lower MVA pathway and the kudzu isoprene synthase gene as described above and the plasmids containing the *idi*, *dxs*, and *dxr* and isoprene synthase genes described in Example 7. The host cells used were chemically competent BL21( $\lambda$ DE3) and the transformations were done by standard methods. Transformants were selected on L agar containing kanamycin (50  $\mu$ g/ml) or kanamycin plus spectinomycin (both at a concentration of 50  $\mu$ g/ml). Plates were grown at 37° C. The resulting strains were designated as follows:

Grown on Kanamycin plus Spectinomycin (50  $\mu$ g/ml each)

MCM127 - pCL Upper MVA + pTrcKKDyIkIS (kan) in BL21( $\lambda$ DE3)

MCM131 - pCL1920 + pTrcKKDyIkIS (kan) in BL21( $\lambda$ DE3)

MCM125 - pCL Upper MVA + pTrcHis2B (kan) in BL21( $\lambda$ DE3)

Grown on Kanamycin (50  $\mu$ g/ml)

MCM64 - pTrcKudzu yIDI DXS (kan) in BL21( $\lambda$ DE3)

MCM50 - pTrcKudzu (kan) in BL21( $\lambda$ DE3)

MCM123 - pTrcKudzu yIDI DXS DXR (kan) in BL21( $\lambda$ DE3)

**[0765]** The above strains were streaked from freezer stocks to LA + appropriate antibiotic and grown overnight at 37° C. A single colony from each plate was used to inoculate shake flasks (25 ml LB + the appropriate antibiotic). The flasks were incubated at 22° C overnight with shaking at 200 rpm. The next morning the flasks were transferred to a 37° C incubator and grown for a further 4.5 hours with shaking at 200 rpm. The 25 ml cultures were centrifuged to pellet the cells and the cells were resuspended in 5 ml LB + the appropriate antibiotic. The

cultures were then diluted into 25 ml LB+1% glucose + the appropriate antibiotic to an OD<sub>600</sub> of 0.1. Two flasks for each strain were set up, one set for induction with IPTG (800 μM) the second set was not induced. The cultures were incubated at 37° C with shaking at 250 rpm. One set of the cultures were induced after 1.50 hours (immediately following sampling time point 1). At each sampling time point, the OD<sub>600</sub> was measured and the amount of isoprene determined as described in Example 1. Results are presented in Table 3. The amount of isoprene made is presented as the amount at the peak production for the particular strain.

**Table 3. Production of isoprene in *E. coli* strains**

Strain	Isoprene (μg/liter/OD/hr)
MCM50	23.8
MCM64	289
MCM125	ND
MCM131	Trace
MCM127	874

ND: not detected

Trace: peak present but not integratable.

#### IX. Analysis of mevalonic acid

**[0766]** Mevalonolactone (1.0 g, 7.7 mmol) (CAS# 503-48-0) was supplied from Sigma-Aldrich (WI, USA) as a syrup that was dissolved in water (7.7 mL) and was treated with potassium hydroxide (7.7 mmol) in order to generate the potassium salt of mevalonic acid. The conversion to mevalonic acid was confirmed by <sup>1</sup>H NMR analysis. Samples for HPLC analysis were prepared by centrifugation at 14,000 rpm for 5 minutes to remove cells, followed by the addition of a 300 μl aliquot of supernatant to 900 μl of H<sub>2</sub>O. Perchloric acid (36 μl of a 70% solution) was then added followed by mixing and cooling on ice for 5 minutes. The samples were then centrifuged again (14,000 rpm for 5 min) and the supernatant transferred to HPLC. Mevalonic acid standards (20, 10, 5, 1 and 0.5 g/L) were prepared in the same fashion. Analysis of mevalonic acid (20 μL injection volume) was performed by HPLC using a BioRad Aminex 87-H+ column (300 mm by 7.0 mm) eluted with 5 mM sulfuric acid at 0.6 mL/min with refractive index (RI) detection. Under these conditions mevalonic acid eluted as the lactone form at 18.5 minutes.

#### X. Production of isoprene from *E. coli* BL21 containing the upper MVA pathway plus kudzu isoprene synthase

[0767] A 15-L scale fermentation of *E. coli* expressing mevalonic acid pathway polypeptides and Kudzu isoprene synthase was used to produce isoprene from cells in fed-batch culture. This experiment demonstrates that growing cells under glucose limiting conditions resulted in the production of 2.2 g/L of isoprene.

Medium Recipe (per liter fermentation medium):

[0768] The medium was generated using the following components per liter fermentation medium:  $K_2HPO_4$  7.5 g,  $MgSO_4 \cdot 7H_2O$  2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, and 1000X modified trace metal solution 1 ml. All of the components were added together and dissolved in  $diH_2O$ . This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glucose 10 g, thiamine  $\cdot$  HCl 0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

[0769] The 1000X modified trace metal solution was generated using the following components: citric acids  $\cdot$   $H_2O$  40 g,  $MnSO_4 \cdot H_2O$  30 g, NaCl 10 g,  $FeSO_4 \cdot 7H_2O$  1 g,  $CoCl_2 \cdot 6H_2O$  1 g,  $ZnSO \cdot 7H_2O$  1 g,  $CuSO_4 \cdot 5H_2O$  100 mg,  $H_3BO_3$  100 mg, and  $NaMoO_4 \cdot 2H_2O$  100 mg. Each component was dissolved one at a time in  $diH_2O$ , pH to 3.0 with HCl/NaOH, then q.s. to volume, and filter sterilized with a 0.22 micron filter.

[0770] Fermentation was performed in a 15-L bioreactor with BL21 (DE3) *E. coli* cells containing the pCL P<sub>trc</sub>UpperPathway (Figure 26) and p<sub>Trc</sub>KKDyIkIS plasmids. This experiment was carried out to monitor isoprene formation from glucose at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated into soytone-yeast extract-glucose medium. After the inoculum grew to OD 1.0 when measured at 550 nm, 500 mL was used to inoculate a 5-L bioreactor.

[0771] Glucose was fed at an exponential rate until cells reached the stationary phase. After this time the glucose feed was decreased to meet metabolic demands. The total amount of glucose delivered to the bioreactor during the 54 hour fermentation was 3.7 kg. Induction was achieved by adding isopropyl-beta-D-1-thiogalactopyranoside (IPTG). The IPTG concentration was brought to 25  $\mu$ M when the optical density at 550 nm ( $OD_{550}$ ) reached a value of 10. The IPTG concentration was raised to 50  $\mu$ M when  $OD_{550}$  reached 190. IPTG concentration was raised to 100  $\mu$ M at 38 hours of fermentation. The  $OD_{550}$  profile within the bioreactor over time is shown in Figure 54. The isoprene level in the off gas from the bioreactor was determined as

described herein. The isoprene titer increased over the course of the fermentation to a final value of 2.2 g/L (Figure 55). The total amount of isoprene produced during the 54 hour fermentation was 15.9 g, and the time course of production is shown in Figure 56.

XI. Isoprene fermentation from *E. coli* expressing genes from the mevalonic acid pathway and grown in fed-batch culture at the 15-L scale

**[0772]** A 15-L scale fermentation of *E. coli* expressing mevalonic acid pathway polypeptides and Kudzu isoprene synthase was used to produce isoprene from cells in fed-batch culture. This experiment demonstrates that growing cells under glucose limiting conditions resulted in the production of 3.0 g/L of isoprene.

Medium Recipe (per liter fermentation medium):

**[0773]** The medium was generated using the following components per liter fermentation medium: K<sub>2</sub>HPO<sub>4</sub> 7.5 g, MgSO<sub>4</sub> \* 7H<sub>2</sub>O 2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, and 1000X Modified Trace Metal Solution 1 ml. All of the components were added together and dissolved in diH<sub>2</sub>O. This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glucose 10 g, thiamine \* HCl 0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

**[0774]** The 1000X modified trace metal solution was generated using the following components: citric acids \* H<sub>2</sub>O 40 g, MnSO<sub>4</sub> \* H<sub>2</sub>O 30 g, NaCl 10 g, FeSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CoCl<sub>2</sub> \* 6H<sub>2</sub>O 1 g, ZnSO \* 7H<sub>2</sub>O 1 g, CuSO<sub>4</sub> \* 5H<sub>2</sub>O 100 mg, H<sub>3</sub>BO<sub>3</sub> 100 mg, and NaMoO<sub>4</sub> \* 2H<sub>2</sub>O 100 mg. Each component was dissolved one at a time in diH<sub>2</sub>O, pH to 3.0 with HCl/NaOH, then q.s. to volume, and filter sterilized with a 0.22 micron filter.

**[0775]** Fermentation was performed in a 15-L bioreactor with BL21 (DE3) *E. coli* cells containing the pCL PtrcUpperMVA and pTrc KKDyIkIS plasmids. This experiment was carried out to monitor isoprene formation from glucose at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated into tryptone-yeast extract medium. After the inoculum grew to OD 1.0, measured at 550 nm, 500 mL was used to inoculate a 5-L bioreactor.

**[0776]** Glucose was fed at an exponential rate until cells reached the stationary phase. After this time, the glucose feed was decreased to meet metabolic demands. The total amount of

glucose delivered to the bioreactor during the 59 hour fermentation was 2.2 kg. Induction was achieved by adding IPTG. The IPTG concentration was brought to 25  $\mu$ M when the optical density at 550 nm ( $OD_{550}$ ) reached a value of 10. The IPTG concentration was raised to 50  $\mu$ M when  $OD_{550}$  reached 190. The  $OD_{550}$  profile within the bioreactor over time is shown in Figure 93. The isoprene level in the off gas from the bioreactor was determined as described herein. The isoprene titer increased over the course of the fermentation to a final value of 3.0 g/L (Figure 94). The total amount of isoprene produced during the 59 hour fermentation was 22.8 g, and the time course of production is shown in Figure 95. The molar yield of utilized carbon that went into producing isoprene during fermentation was 2.2%. The weight percent yield of isoprene from glucose was 1.0%.

XII. Isoprene fermentation from *E. coli* expressing genes from the mevalonic acid pathway and grown in fed-batch culture at the 15-L scale

[0777] A 15-L scale fermentation of *E. coli* expressing mevalonic acid pathway polypeptides, *Pueraria lobata* isoprene synthase, and Kudzu isoprene synthase was used to produce isoprene from cells in fed-batch culture. This experiment demonstrates that growing cells under glucose limiting conditions resulted in the production of 3.3 g/L of isoprene.

i) Construction of pCLPtrcUpperPathwayHGS2

[0778] The gene encoding isoprene synthase from *Pueraria lobata* was PCR-amplified using primers NsiI-RBS-HGS F (CTTGATGCATCCTGCATTCGCCCTTAGGAGG, SEQ ID NO:105) and pTrcR (CCAGGCAAATTCTGTTTTATCAG, SEQ ID NO:106), and pTrcKKDyIkIS as a template. The PCR product thus obtained was restriction-digested with *NsiI* and *PstI* and gel-purified. The plasmid pCL PtrcUpperPathway was restriction-digested with *PstI* and dephosphorylated using rAPid alkaline phosphatase (Roche) according to manufacturer's instructions.

[0779] These DNA fragments were ligated together and the ligation reaction was transformed into *E. coli* Top10 chemically competent cells (Invitrogen), plated on L agar containing spectinomycin (50  $\mu$ g/ml) and incubated overnight at 37 °C. Plasmid DNA was prepared from 6 clones using the Qiaquick Spin Mini-prep kit. The plasmid DNA was digested with restriction enzymes *EcoRV* and *MluI* to identify a clone in which the insert had the right orientation (*i.e.*, the gene oriented in the same way as the pTrc promoter).

**[0780]** The resulting correct plasmid was designated pCLPtrcUpperPathwayHGS2. This plasmid was assayed using the headspace assay described herein and found to produce isoprene in *E. coli* Top10, thus validating the functionality of the gene. The plasmid was transformed into BL21(LDE3) containing pTrcKKDyIkIS to yield the strain BL21/pCLPtrcUpperPathwayHGS2-pTrcKKDyIkIS. This strain has an extra copy of the isoprene synthase compared to the BL21/pCL PtrcUpperMVA and pTrc KKDyIkIS strain (Example 8, part XI). This strain also had increased expression and activity of HMGS compared to the BL21/pCL PtrcUpperMVA and pTrc KKDyIkIS strain used in Example 8, part XI.

ii) Isoprene fermentation from *E. coli* expressing pCLPtrcUpperPathwayHGS2-pTrcKKDyIkIS and grown in fed-batch culture at the 15-L scale

Medium Recipe (per liter fermentation medium):

**[0781]** The medium was generated using the following components per liter fermentation medium:  $K_2HPO_4$  7.5 g,  $MgSO_4 \cdot 7H_2O$  2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, and 1000X modified trace metal solution 1 ml. All of the components were added together and dissolved in  $diH_2O$ . This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glucose 10 g, thiamine  $\cdot$  HCl 0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

**[0782]** The 1000X modified trace metal solution was generated using the following components: citric acids  $\cdot$   $H_2O$  40 g,  $MnSO_4 \cdot H_2O$  30 g, NaCl 10 g,  $FeSO_4 \cdot 7H_2O$  1 g,  $CoCl_2 \cdot 6H_2O$  1 g,  $ZnSO \cdot 7H_2O$  1 g,  $CuSO_4 \cdot 5H_2O$  100 mg,  $H_3BO_3$  100 mg, and  $NaMoO_4 \cdot 2H_2O$  100 mg. Each component is dissolved one at a time in  $Di H_2O$ , pH to 3.0 with HCl/NaOH, then q.s. to volume and filter sterilized with 0.22 micron filter.

**[0783]** Fermentation was performed in a 15-L bioreactor with BL21 (DE3) *E. coli* cells containing the pCLPtrcUpperPathwayHGS2 and pTrc KKDyIkIS plasmids. This experiment was carried out to monitor isoprene formation from glucose at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated into tryptone-yeast extract medium. After the inoculum grew to OD 1.0 measured at 550 nm, 500 mL was used to inoculate a 5-L bioreactor.

**[0784]** Glucose was fed at an exponential rate until cells reached the stationary phase. After this time the glucose feed was decreased to meet metabolic demands. The total amount of glucose delivered to the bioreactor during the 58 hour fermentation was 2.1 kg. Induction was achieved by adding IPTG. The IPTG concentration was brought to 25  $\mu$ M when the optical density at 550 nm (OD<sub>550</sub>) reached a value of 9. The IPTG concentration was raised to 50  $\mu$ M when OD<sub>550</sub> reached 170. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 104. The isoprene level in the off gas from the bioreactor was determined as described herein. The isoprene titer increased over the course of the fermentation to a final value of 3.3 g/L (Figure 105). The total amount of isoprene produced during the 58 hour fermentation was 24.5 g and the time course of production is shown in Figure 106. The molar yield of utilized carbon that went into producing isoprene during fermentation was 2.5%. The weight percent yield of isoprene from glucose was 1.2%. Analysis showed that the activity of the isoprene synthase was increased by approximately 3-4 times that compared to BL21 expressing CL PtrcUpperMVA and pTrc KKDyIkIS plasmids (data not shown).

### XIII. Chromosomal Integration of the Lower Mevalonate Pathway in *E. coli*.

**[0785]** A synthetic operon containing mevalonate kinase, mevalonate phosphate kinase, mevalonate pyrophosphate decarboxylase, and the IPP isomerase was integrated into the chromosome of *E. coli*. If desired, expression may be altered by integrating different promoters 5' of the operon.

**[0786]** Table 4 lists primers used for this experiment.

**Table 4. Primers**

MCM78	attTn7 up rev for integration construct	gcatgctcgagcggccgcTTTTAATCAAACATCCTGCCAACTC (SEQ ID NO:107)
MCM79	attTn7 down rev for integration construct	gatcgaagggcgatcgTGTCACAGTCTGGCGAAACCG (SEQ ID NO:108)
MCM88	attTn7 up forw for integration construct	ctgaattctgcagatcTGTTTTTCCACTCTTCGTTCACTT (SEQ ID NO:109)
MCM89	attTn7 down forw for integration construct	tctagagggccAAGAAAATGCCCGCTTACG (SEQ ID NO:110)
MCM104	GII.2 promoter – MVK	Gatcgcggccgcgcccttgacgatgccacatctgagcaataattcaaccac taattgtgagcggataacacaaggaggaacagctatgcatcattaccgttctaacttc (SEQ ID NO:111)
MCM105	aspA terminator – yIDI	Gatcgggccccaaagaaaaggcacgtcatctgacgtgcctttttattgtagacgctgttatagcattcta (SEQ ID NO:112)
MCM120	Forward of attTn7: attTn7 homology, GB	aaagtagccgaagatgacggtttgtcacatggagttggcaggatgtttgattaaa agcAATTAACCCTCACTAAAGGGCGG (SEQ ID

	marker homology	NO:113)
MCM127	Rev complement of 1.2 GI: GB marker homology(extra long), promoter, RBS, ATG	AGAGTGTTACCCAAAAATAATAACCTTTCCCGG TGCAGAagttaagaacggaatgacatagctgttcctccttggttatccgct cacaattagtggtgaattattgctcaggatgtggcatcgtcaagggcTAAT ACGACTCACTATAGGGCTCG (SEQ ID NO:114)

i) Target vector construction

**[0787]** The attTn7 site was selected for integration. Regions of homology upstream (attTn7 up) (primers MCM78 and MCM79) and downstream (attTn7 down) (primers MCM88 and MCM89) were amplified by PCR from MG1655 cells. A 50  $\mu$ L reaction with 1  $\mu$ L 10  $\mu$ M primers, 3  $\mu$ L ddH<sub>2</sub>O, 45  $\mu$ L Invitrogen Platinum PCR Supermix High Fidelity, and a scraped colony of MG1655 was denatured for 2:00 at 94 °C, cycled 25 times (2:00 at 94 °C, 0:30 at 50 °C, and 1:00 at 68 °C), extended for 7:00 at 72 °C, and cooled to 4 °C. This resulting DNA was cloned into pCR2.1 (Invitrogen) according to the manufacturer's instructions, resulting in plasmids MCM278 (attTn7 up) and MCM252 (attTn7 down). The 832bp *ApaI-PvuI* fragment digested and gel purified from MCM252 was cloned into *ApaI-PvuI* digested and gel purified plasmid pR6K, creating plasmid MCM276. The 825bp *PstI-NotI* fragment digested and gel purified from MCM278 was cloned into *PstI-NotI* digested and gel purified MCM276, creating plasmid MCM281.

ii) Cloning of lower pathway and promoter

**[0788]** MVK-PMK-MVD-IDI genes were amplified from pTrcKKDyIkIS with primers MCM104 and MCM105 using Roche Expand Long PCR System according to the manufacturer's instructions. This product was digested with *NotI* and *ApaI* and cloned into MCM281 which had been digested with *NotI* and *ApaI* and gel purified. Primers MCM120 and MCM127 were used to amplify CMR cassette from the GeneBridges FRT-gb2-Cm-FRT template DNA using Stratagene Pfu Ultra II. A PCR program of denaturing at 95 °C for 4:00, 5 cycles of 95 °C for 0:20, 55 °C for 0:20, 72 °C for 2:00, 25 cycles of 95 °C for 0:20, 58 °C for 0:20, 72 °C for 2:00, 72 °C for 10:00, and then cooling to 4 °C was used with four 50  $\mu$ L PCR reactions containing 1  $\mu$ L ~10ng/ $\mu$ L template, 1  $\mu$ L each primer, 1.25  $\mu$ L 10mM dNTPs, 5  $\mu$ L 10x buffer, 1  $\mu$ L enzyme, and 39.75  $\mu$ L ddH<sub>2</sub>O. Reactions were pooled, purified on a Qiagen PCR cleanup column, and used to electroporate water-washed Pir1 cells containing plasmid MCM296. Electroporation was carried out in 2mM cuvettes at 2.5V and 200 ohms.

Electroporation reactions were recovered in LB for 3hr at 30 °C. Transformant MCM330 was selected on LA with CMP5, Kan50 (Figures 107 and 108A-108C; SEQ ID NO:25).

iii) Integration into *E. coli* chromosome

**[0789]** Miniprep DNA (Qiaquick Spin kit) from MCM330 was digested with *Sna*BI and used to electroporate BL21(DE3) (Novagen) or MG1655 containing GeneBridges plasmid pRedET Carb. Cells were grown at 30 °C to ~OD1 then induced with 0.4% L-arabinose at 37 °C for 1.5 hours. These cells were washed three times in 4 °C ddH<sub>2</sub>O before electroporation with 2µL of DNA. Integrants were selected on L agar with containing chloramphenicol (5 µg/ml) and subsequently confirmed to not grow on L agar + Kanamycin (50 µg/ml). BL21 integrant MCM331 and MG1655 integrant MCM333 were frozen.

iv) Construction of pET24D-Kudzu encoding Kudzu isoprene synthase

**[0790]** The kudzu isoprene synthase gene was subcloned into the pET24d vector (Novagen) from the pCR2.1 vector (Invitrogen). In particular, the kudzu isoprene synthase gene was amplified from the pTrcKudzu template DNA using primers MCM50 5'-GATCATGCAT TCGCCCTTAG GAGGTAAAA AACATGTGTG CGACCTCTTC TCAATTTACT (SEQ ID NO:52) and MCM53 5'-CGGTCGACGG ATCCCTGCAG TTAGACATAC ATCAGCTG (SEQ ID NO:50). PCR reactions were carried out using Taq DNA Polymerase (Invitrogen), and the resulting PCR product was cloned into pCR2.1-TOPO TA cloning vector (Invitrogen), and transformed into *E. coli* Top10 chemically competent cells (Invitrogen). Transformants were plated on L agar containing carbenicillin (50 µg/ml) and incubated overnight at 37°C. Five ml Luria Broth cultures containing carbenicillin 50 µg/ml were inoculated with single transformants and grown overnight at 37°C. Five colonies were screened for the correct insert by sequencing of plasmid DNA isolated from 1 ml of liquid culture (Luria Broth) and purified using the QIAprep Spin Mini-prep Kit (Qiagen). The resulting plasmid, designated MCM93, contains the kudzu isoprene synthase coding sequence in a pCR2.1 backbone.

**[0791]** The kudzu coding sequence was removed by restriction endonuclease digestion with *Pci*I and *Bam*H1 (Roche) and gel purified using the QIAquick Gel Extraction kit (Qiagen). The pET24d vector DNA was digested with *Nco*I and *Bam*H1 (Roche), treated with shrimp alkaline phosphatase (Roche), and purified using the QIAprep Spin Mini-prep Kit (Qiagen). The kudzu isoprene synthase fragment was ligated to the *Nco*I/*Bam*H1 digested pET24d using the Rapid DNA Ligation Kit (Roche) at a 5:1 fragment to vector ratio in a total volume of 20 µl. A portion

of the ligation mixture (5  $\mu$ l) was transformed into *E. coli* Top 10 chemically competent cells and plated on L agar containing kanamycin (50  $\mu$ g/ml). The correct transformant was confirmed by sequencing and transformed into chemically competent BL21( $\lambda$ DE3)pLysS cells (Novagen). A single colony was selected after overnight growth at 37°C on L agar containing kanamycin (50  $\mu$ g/ml). A map of the resulting plasmid designated as pET24D-Kudzu is shown in Figure 109. The sequence of pET24D-Kudzu (SEQ ID NO:26) is shown in Figures 110A and 110B. Isoprene synthase activity was confirmed using a headspace assay.

v) Production strains

**[0792]** Strains MCM331 and MCM333 were cotransformed with plasmids pCLPtrcupperpathway and either pTrcKudzu or pETKudzu, resulting in the strains shown in Table 5.

**Table 5. Production Strains**

Background	Integrated Lower	Upper MVA plasmid	Isoprene synthase plasmid	Production Stain
BL21(DE3)	MCM331	pCLPtrcupper Pathway	pTrcKudzu	MCM343
BL21(DE3)	MCM331	pCLPtrcupper Pathway	pET24D-Kudzu	MCM335
MG1655	MCM333	pCLPtrcupper Pathway	pTrcKudzu	MCM345

vi) Isoprene fermentation from *E. coli* expressing genes from the mevalonic acid pathway and grown in fed-batch culture at the 15-L scale.

Medium Recipe (per liter fermentation medium):

**[0793]** The medium was generated using the following components per liter fermentation medium: K<sub>2</sub>HPO<sub>4</sub> 7.5 g, MgSO<sub>4</sub> \* 7H<sub>2</sub>O 2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, and 1000X modified trace metal solution 1 ml. All of the components were added together and dissolved in diH<sub>2</sub>O. This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glucose 10 g, thiamine \* HCl 0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

[0794] The 1000X modified trace metal solution was generated using the following components: citric acids \* H<sub>2</sub>O 40 g, MnSO<sub>4</sub> \* H<sub>2</sub>O 30 g, NaCl 10 g, FeSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CoCl<sub>2</sub> \* 6H<sub>2</sub>O 1 g, ZnSO \* 7H<sub>2</sub>O 1 g, CuSO<sub>4</sub> \* 5H<sub>2</sub>O 100 mg, H<sub>3</sub>BO<sub>3</sub> 100 mg, and NaMoO<sub>4</sub> \* 2H<sub>2</sub>O 100 mg. Each component is dissolved one at a time in Di H<sub>2</sub>O, pH to 3.0 with HCl/NaOH, then q.s. to volume and filter sterilized with a 0.22 micron filter.

[0795] Fermentation was performed in a 15-L bioreactor with BL21 (DE3) *E. coli* cells containing the *gil.2* integrated lower MVA pathway described above and the pCL PtrcUpperMVA and pTrcKudzu plasmids. This experiment was carried out to monitor isoprene formation from glucose at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated into tryptone-yeast extract medium. After the inoculum grew to OD 1.0, measured at 550 nm, 500 mL was used to inoculate a 5-L bioreactor.

[0796] Glucose was fed at an exponential rate until cells reached the stationary phase. After this time, the glucose feed was decreased to meet metabolic demands. The total amount of glucose delivered to the bioreactor during the 57 hour fermentation was 3.9 kg. Induction was achieved by adding IPTG. The IPTG concentration was brought to 100 µM when the carbon dioxide evolution rate reached 100 mmol/L/hr. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 111A. The isoprene level in the off gas from the bioreactor was determined as described herein. The isoprene titer increased over the course of the fermentation to a final value of 1.6 g/L (Figure 111B). The specific productivity of isoprene over the course of the fermentation is shown in Figure 111C and peaked at 1.2 mg/OD/hr. The total amount of isoprene produced during the 57 hour fermentation was 16.2 g. The molar yield of utilized carbon that went into producing isoprene during fermentation was 0.9%. The weight percent yield of isoprene from glucose was 0.4%.

XIV. Production of isoprene from *E. coli* BL21 containing the kudzu isoprene synthase using glycerol as a carbon source

[0797] A 15-L scale fermentation of *E. coli* expressing Kudzu isoprene synthase was used to produce isoprene from cells fed glycerol in fed-batch culture. This experiment demonstrates that

growing cells in the presence of glycerol (without glucose) resulted in the production of 2.2 mg/L of isoprene.

Medium Recipe (per liter fermentation medium):

**[0798]** The medium was generated using the following components per liter fermentation medium:  $K_2HPO_4$  7.5 g,  $MgSO_4 \cdot 7H_2O$  2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, and 1000X modified trace metal solution 1 ml. All of the components were added together and dissolved in  $diH_2O$ . This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glycerol 5.1 g, thiamine  $\cdot HCl$  0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

**[0799]** The medium was generated using the following components per liter fermentation medium: citric acids  $\cdot H_2O$  40 g,  $MnSO_4 \cdot H_2O$  30 g, NaCl 10 g,  $FeSO_4 \cdot 7H_2O$  1 g,  $CoCl_2 \cdot 6H_2O$  1 g,  $ZnSO \cdot 7H_2O$  1 g,  $CuSO_4 \cdot 5H_2O$  100 mg,  $H_3BO_3$  100 mg, and  $NaMoO_4 \cdot 2H_2O$  100 mg. Each component was dissolved one at a time in  $diH_2O$ , pH to 3.0 with HCl/NaOH, then q.s. to volume and filter sterilized with a 0.22 micron filter.

**[0800]** Fermentation was performed in a 15-L bioreactor with BL21 (DE3) *E. coli* cells containing the pTrcKudzu plasmid. This experiment was carried out to monitor isoprene formation from glycerol at the desired fermentation pH 7.0 and temperature 35°C. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LA broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated into soytone-yeast extract-glucose medium and grown at 35°C. After the inoculum grew to OD 1.0, measured at 550 nm, 600 mL was used to inoculate a 7.5-L bioreactor.

**[0801]** Glycerol was fed at an exponential rate until cells reached an optical density at 550 nm ( $OD_{550}$ ) of 153. The total amount of glycerol delivered to the bioreactor during the 36 hour fermentation was 1.7 kg. Other than the glucose in the inoculum, no glucose was added to the bioreactor. Induction was achieved by adding IPTG. The IPTG concentration was brought to 20  $\mu M$  when the  $OD_{550}$  reached a value of 50. The  $OD_{550}$  profile within the bioreactor over time is shown in Figure 57. The isoprene level in the off gas from the bioreactor was determined as described herein. The isoprene titer increased over the course of the fermentation to a final value

of 2.2 mg/L (Figure 58). The total amount of isoprene produced during the 54 hour fermentation was 20.9 mg, and the time course of production is shown in Figure 59.

XV. Isoprene fermentation from *E. coli* expressing genes from the mevalonic acid pathway and grown in fed-batch culture at the 15-L scale using invert sugar as a carbon source

**[0802]** A 15-L scale fermentation of *E. coli* expressing mevalonic acid pathway polypeptides and Kudzu isoprene synthase was used to produce isoprene from cells fed invert sugar in fed-batch culture. This experiment demonstrates that growing cells in the presence of invert sugar resulted in the production of 2.4 g/L of isoprene.

Medium Recipe (per liter fermentation medium):

**[0803]** The medium was generated using the following components per liter fermentation medium: K<sub>2</sub>HPO<sub>4</sub> 7.5 g, MgSO<sub>4</sub> \* 7H<sub>2</sub>O 2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, and 1000X Modified Trace Metal Solution 1 ml. All of the components were added together and dissolved in diH<sub>2</sub>O. This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Invert sugar 10 g, thiamine \* HCl 0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

**[0804]** The 1000X modified trace metal solution was generated using the following components: citric acids \* H<sub>2</sub>O 40 g, MnSO<sub>4</sub> \* H<sub>2</sub>O 30 g, NaCl 10 g, FeSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CoCl<sub>2</sub> \* 6H<sub>2</sub>O 1 g, ZnSO \* 7H<sub>2</sub>O 1 g, CuSO<sub>4</sub> \* 5H<sub>2</sub>O 100 mg, H<sub>3</sub>BO<sub>3</sub> 100 mg, and NaMoO<sub>4</sub> \* 2H<sub>2</sub>O 100 mg. Each component is dissolved one at a time in Di H<sub>2</sub>O, pH to 3.0 with HCl/NaOH, then q.s. to volume and filter sterilized with 0.22 micron filter.

**[0805]** Fermentation was performed in a 15-L bioreactor with BL21 (DE3) *E. coli* cells containing the pCL PtrcUpperMVA and pTrc KKDyIkIS plasmids. This experiment was carried out to monitor isoprene formation from invert sugar at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated into tryptone-yeast extract medium. After the inoculum grew to OD 1.0, measured at 550 nm, 500 mL was used to inoculate a 5-L bioreactor.

**[0806]** Invert sugar was fed at an exponential rate until cells reached the stationary phase. After this time the invert sugar feed was decreased to meet metabolic demands. The total amount of invert sugar delivered to the bioreactor during the 44 hour fermentation was 2.4 kg. Induction was achieved by adding IPTG. The IPTG concentration was brought to 25  $\mu\text{M}$  when the optical density at 550 nm ( $\text{OD}_{550}$ ) reached a value of 9. The IPTG concentration was raised to 50  $\mu\text{M}$  when  $\text{OD}_{550}$  reached 200. The  $\text{OD}_{550}$  profile within the bioreactor over time is shown in Figure 96. The isoprene level in the off gas from the bioreactor was determined as described herein. The isoprene titer increased over the course of the fermentation to a final value of 2.4 g/L (Figure 97). The total amount of isoprene produced during the 44 hour fermentation was 18.4 g and the time course of production is shown in Figure 98. The molar yield of utilized carbon that went into producing isoprene during fermentation was 1.7%. The weight percent yield of isoprene from glucose was 0.8%.

Example 9. Construction of the upper and lower MVA pathway for integration into *Bacillus subtilis*

I. Construction of the Upper MVA pathway in *Bacillus subtilis*

**[0807]** The upper pathway from *Enterococcus faecalis* is integrated into *B. subtilis* under control of the *aprE* promoter. The upper pathway consists of two genes; *mvaE*, which encodes for AACT and HMGR, and *mvaS*, which encodes for HMGS. The two genes are fused together with a stop codon in between, an RBS site in front of *mvaS*, and are under the control of the *aprE* promoter. A terminator is situated after the *mvaE* gene. The chloramphenicol resistance marker is cloned after the *mvaE* gene and the construct is integrated at the *aprE* locus by double cross over using flanking regions of homology.

**[0808]** Four DNA fragments are amplified by PCR such that they contain overhangs that will allowed them to be fused together by a PCR reaction. PCR amplifications are carried out using Herculase polymerase according to manufacturer's instructions.

1. PaprE

CF 07-134 (+) Start of *aprE* promoter PstI

5'- GACATCTGCAGCTCCATTTTCTTCTGC (SEQ ID NO:115)

CF 07-94 (-) Fuse PaprE to *mvaE*

5'- CAATAATAACTACTGTTTTCACTCTTACCCTCTCCTTTTAA (SEQ ID NO:116)

Template: *Bacillus subtilis* chromosomal DNA

2. *mvaE*

CF 07-93 (+) fuse *mvaE* to the *aprE* promoter (GTG start codon)

5'- TTAAAAGGAGAGGGTAAAGAGTGAAAACAGTAGTTATTATTG (SEQ ID NO:117)

CF 07-62 (-) Fuse *mvaE* to *mvaS* with RBS in between

5'- TTTATCAATCCCAATTGTCATGTTTTTTTACCTCCTTATTGTTTTCTTAAATC  
(SEQ ID NO:94)

Template: *Enterococcus faecalis* chromosomal DNA (from ATCC)

3. *mvaS*

CF 07-61 (+) Fuse *mvaE* to *mvaS* with RBS in between

5'-

GATTTAAGAAAACAATAAAGGAGGTAAAAAACATGACAATTGGGATTGATAAA  
(SEQ ID NO:95)

CF 07-124 (-) Fuse the end of *mvaS* to the terminator

5'- CGGGGCCAAGGCCGGTTTTTTTTAGTTTCGATAAGAACGAACGGT (SEQ ID  
NO:118)

Template: *Enterococcus faecalis* chromosomal DNA

4. *B. amyliquefaciens* alkaline serine protease terminator

CF 07-123 (+) Fuse the end of *mvaS* to the terminator

5'- ACCGTTTCGTTCTTATCGAAACTAAAAAAACCGGCCTTGGCCCCG (SEQ ID  
NO:119)

CF 07-46 (-) End of *B. amyliquefaciens* terminator BamHI

5'- GACATGACGGATCCGATTACGAATGCCGTCTC (SEQ ID NO:58)

Template: *Bacillus amyliquefaciens* chromosomal DNA

## PCR Fusion Reactions

5. Fuse *mvaE* to *mvaS*CF 07-93 (+) fuse *mvaE* to the *aprE* promoter (GTG start codon)

5'- TTAAAAGGAGAGGGTAAAGAGTGAAAACAGTAGTTATTATTG (SEQ ID NO:117)

CF 07-124 (-) Fuse the end of *mvaS* to the terminator

5'- CGGGGCCAAGGCCGGTTTTTTTTAGTTTCGATAAGAACGAACGGT (SEQ ID NO:118)

Template: #2 and 3 from above

6. Fuse *mvaE-mvaS* to *aprE* promoterCF 07-134 (+) Start of *aprE* promoter PstI

5'- GACATCTGCAGCTCCATTTTCTTCTGC (SEQ ID NO:115)

CF 07-124 (-) Fuse the end of *mvaS* to the terminator

5'- CGGGGCCAAGGCCGGTTTTTTTTAGTTTCGATAAGAACGAACGGT (SEQ ID NO:118)

Template #1 and #4 from above

7. Fuse *PapE-mvaE-mvaS* to terminatorCF 07-134 (+) Start of *aprE* promoter PstI

5'- GACATCTGCAGCTCCATTTTCTTCTGC (SEQ ID NO:115)

CF 07-46 (-) End of *B. amyliquefaciens* terminator BamHI

5'- GACATGACGGATCCGATTACGAATGCCGTCTC (SEQ ID NO:58)

Template: #4 and #6

**[0809]** The product is digested with restriction endonucleases *PstI/BamHI* and ligated to pJM102 (Perego, M. 1993. Integrational vectors for genetic manipulation in *Bacillus subtilis*, p. 615–624. In A. L. Sonenshein, J. A. Hoch, and R. Losick (ed.), *Bacillus subtilis* and other gram-positive bacteria: biochemistry, physiology, and molecular genetics. American Society for Microbiology, Washington, D.C.) which is digested with *PstI/BamHI*. The ligation is transformed into *E. coli* TOP 10 chemically competent cells and transformants are selected on LA containing carbenicillin (50 µg/ml). The correct plasmid is identified by sequencing and is designated pJMUpperpathway2 (Figures 50 and 51). Purified plasmid DNA is transformed into *Bacillus subtilis aprEnprE Pxyl-comK* and transformants are selected on L agar containing chloramphenicol (5 µg/ml). A correct colony is selected and is plated sequentially on L agar containing chloramphenicol 10, 15 and 25 µg/ml to amplify the number of copies of the cassette containing the upper pathway.

**[0810]** The resulting strain is tested for mevalonic acid production by growing in LB containing 1% glucose and 1%. Cultures are analyzed by GC for the production of mevalonic acid.

**[0811]** This strain is used subsequently as a host for the integration of the lower mevalonic acid pathway.

**[0812]** The following primers are used to sequence the various constructs above.

Sequencing primers:

CF 07-134 (+) Start of *aprE* promoter *PstI*

5'- GACATCTGCAGCTCCATTTTCTTCTGC (SEQ ID NO:115)

CF 07-58 (+) Start of *mvaE* gene

5'- ATGAAAACAGTAGTTATTATTGATGC (SEQ ID NO:97)

CF 07-59 (-) End of *mvaE* gene

5'- ATGTTATTGTTTTCTTAAATCATTAAAATAGC (SEQ ID NO:98)

CF 07-82 (+) Start of *mvaS* gene

5'- ATGACAATTGGGATTGATAAAATTAG (SEQ ID NO:99)

CF 07-83 (-) End of *mvaS* gene

5'- TTAGTTTCGATAAGAACGAACGGT (SEQ ID NO:100)

CF 07-86 (+) Sequence in *mvaE*

5'- GAAATAGCCCCATTAGAAGTATC (SEQ ID NO:101)

CF 07-87 (+) Sequence in *mvaE*

5'- TTGCCAATCATATGATTGAAAATC (SEQ ID NO:102)

CF 07-88 (+) Sequence in *mvaE*

5'- GCTATGCTTCATTAGATCCTTATCG (SEQ ID NO:103)

CF 07-89 (+) Sequence *mvaS*

5'- GAAACCTACATCCAATCTTTTGCCC (SEQ ID NO:104)

**[0813]** Transformants are selected on LA containing chloramphenicol at a concentration of 5 µg/ml. One colony is confirmed to have the correct integration by sequencing and is plated on LA containing increasing concentrations of chloramphenicol over several days, to a final level of 25 µg/ml. This results in amplification of the cassette containing the genes of interest. The resulting strain is designated CF 455: pJMupperpathway#1 X *Bacillus subtilis aprEnprE PxyI comK* (amplified to grow on LA containing chloramphenicol 25 µg/ml).

## II. Construction of the Lower MVA pathway in *Bacillus subtilis*

**[0814]** The lower MVA pathway, consisting of the genes *mvk1*, *pmk*, *mpd* and *idi* are combined in a cassette consisting of flanking DNA regions from the *nprE* region of the *B. subtilis* chromosome (site of integration), the *aprE* promoter, and the spectinomycin resistance marker (see Figures 28 and 29; SEQ ID NO:13). This cassette is synthesized by DNA2.0 and is integrated into the chromosome of *B. subtilis* containing the upper MVA pathway integrated at the *aprE* locus. The kudzu isoprene synthase gene is expressed from the replicating plasmid described in Example 4 and is transformed into the strain with both upper and lower pathways integrated.

### Example 10: Exemplary isoprene compositions and methods of making them

#### I. Compositional analysis of fermentation off-gas containing isoprene

**[0815]** A 14 L scale fermentation was performed with a recombinant *E. coli* BL21 (DE3) strain containing two plasmids (pCL upperMev; pTrcKKDyIkIS encoding the full mevalonate pathway for isoprenoid precursor biosynthesis, an isoprenyl pyrophosphate isomerase from yeast, and an isoprene synthase from Kudzu. Fermentation off-gas from the 14 L tank was collected into 20 mL headspace vials at around the time of peak isoprene productivity (27.9 hours elapsed fermentation time, “EFT”) and analyzed by headspace GC/MS for volatile components.

**[0816]** Headspace analysis was performed with an Agilent 6890 GC/MS system fitted with an Agilent HP-5MS GC/MS column (30 m x 250  $\mu$ m; 0.25  $\mu$ m film thickness). A combiPAL autoinjector was used for sampling 500  $\mu$ L aliquots from 20 mL headspace vials. The GC/MS method utilized helium as the carrier gas at a flow of 1 mL/min. The injection port was held at 250 °C with a split ratio of 50:1. The oven temperature was held at 37 °C for an initial 2 minute period, followed an increase to 237 °C at a rate of 25 °C/min for a total method time of 10 minutes. The Agilent 5793N mass selective detector scanned from m/z 29 to m/z 300. The limit of detection of this system is approximately 0.1  $\mu$ g/L<sub>gas</sub> or approximately 0.1 ppm. If desired, more sensitive equipment with a lower limit of detection may be used.

**[0817]** The off-gas consisted of 99.925 % (v/v) permanent gases (N<sub>2</sub>, CO<sub>2</sub> and O<sub>2</sub>), approximately 0.075% isoprene (2-methyl-1,3-butadiene) (~750 ppmv, 2100  $\mu$ g/L) and minor amounts (<50 ppmv) of ethanol, acetone, and two C5 prenyl alcohols. The amount of water vapor was not determined but was estimated to be equal to the equilibrium vapor pressure at 0 °C. The composition of the volatile organic fraction was determined by integration of the area under the peaks in the GC/MS chromatogram (Figs. 86A and 86B) and is listed in Table 6. Calibration curves for ethanol and acetone standards enabled the conversion of GC area to gas phase concentration in units of  $\mu$ g/L using standard methods.

**Table 6. Composition of volatile organic components in fermentation off-gas.** The off-gas was analyzed at the 27.9 hour time point of a fermentation using an *E. coli* BL21 (DE3) strain expressing a heterologous mevalonate pathway, an isoprenyl pyrophosphate isomerase from yeast, and an isoprene synthase from Kudzu.

Compound	RT (min)	GC area	Area %	Conc. ( $\mu\text{g/L}$ )
Ethanol	1.669	239005	0.84	62 +/- 6
Acetone	1.703	288352	1.02	42 +/- 4
Isoprene (2-methyl-1,3-butadiene)	1.829	27764544	97.81	2000 +/- 200
3-methyl-3-buten-1-ol	3.493	35060	0.12	<10
3-methyl-2-buten-1-ol	4.116	58153	0.20	<10

II. Measurement of trace volatile organic compounds (VOCs) co-produced with isoprene during fermentation of a recombinant *E. coli* strain

**[0818]** A 14 L scale fermentation was performed with a recombinant *E. coli* BL21 (DE3) strain containing two plasmids (pCL upperMev; pTrcKKDyIkIS) encoding the full mevalonate pathway for isoprenoid precursor biosynthesis, an isoprenyl pyrophosphate isomerase from yeast, and an isoprene synthase from Kudzu.

**[0819]** Fermentation off-gas was passed through cooled headspace vials in order to concentrate and identify trace volatile organic components. The off-gas from this fermentation was sampled at a rate of 1 L/min for 10 minutes through a 20 mL headspace vial packed with quartz wool (2g) and cooled to  $-78\text{ }^{\circ}\text{C}$  with dry ice. The vial was recapped with a fresh vial cap and analyzed by headspace GC/MS for trapped VOCs using the conditions described in Example 10, part I. The ratios of compounds observed in Figs. 87A-87D are a combination of overall level in the fermentation off-gas, the relative vapor pressure at  $-78\text{ }^{\circ}\text{C}$ , and the detector response of the mass spectrometer. For example, the low level of isoprene relative to oxygenated volatiles (*e.g.*, acetone and ethanol) is a function of the high volatility of this material such that it does not accumulate in the headspace vial at  $-78\text{ }^{\circ}\text{C}$ .

**[0820]** The presence of many of these compounds is unique to isoprene compositions derived from biological sources. The results are depicted in Figs. 87A-87D and summarized in Tables 7A and 7B.

**Table 7A: Trace volatiles present in off-gas produced by E. coli BL21 (DE3) (pCL upperMev; pTrcKKDyIkIS) following cryo-trapping at -78oC.**

Compound	RT (min)	GC Area <sup>1</sup>	Area% <sup>2</sup>	Ratio% <sup>3</sup>
Acetaldehyde	1.542	4019861	4.841	40.14
Ethanol	1.634	10553620	12.708	105.39
Acetone	1.727	7236323	8.714	72.26
2-methyl-1,3-butadiene	1.777	10013714	12.058	100.00
1-propanol	1.987	163574	0.197	1.63
Diacetyl	2.156	221078	0.266	2.21
2-methyl-3-buten-2-ol	2.316	902735	1.087	9.01
2-methyl-1-propanol	2.451	446387	0.538	4.46
3-methyl-1-butanal	2.7	165162	0.199	1.65
1-butanol	2.791	231738	0.279	2.31
3-methyl-3-buten-1-ol	3.514	14851860	17.884	148.32
3-methyl-1-butanol	3.557	8458483	10.185	84.47
3-methyl-2-buten-1-ol	4.042	18201341	21.917	181.76
3-methyl-2-butenal	4.153	1837273	2.212	18.35
3-methylbutyl acetate	5.197	196136	0.236	1.96
3-methyl-3-buten-1-yl acetate	5.284	652132	0.785	6.51
2-heptanone	5.348	67224	0.081	0.67
2,5-dimethylpyrazine	5.591	58029	0.070	0.58
3-methyl-2-buten-1-yl acetate	5.676	1686507	2.031	16.84
6-methyl-5-hepten-2-one	6.307	101797	0.123	1.02
2,4,5-trimethylpyridine	6.39	68477	0.082	0.68
2,3,5-trimethylpyrazine	6.485	30420	0.037	0.30
(E)-3,7-dimethyl-1,3,6-octatriene	6.766	848928	1.022	8.48
(Z)-3,7-dimethyl-1,3,6-octatriene	6.864	448810	0.540	4.48
3-methyl-2-buten-1-yl butyrate	7.294	105356	0.127	1.05
Citronellal	7.756	208092	0.251	2.08
2,3-cycloheptenolpyridine	8.98	1119947	1.349	11.18

<sup>1</sup> GC area is the uncorrected area under the peak corresponding to the listed compound.

<sup>2</sup> Area % is the peak area expressed as a % relative to the total peak area of all compounds.

<sup>3</sup> Ratio % is the peak area expressed as a % relative to the peak area of 2-methyl-1,3-butadiene.

**Table 7B. Trace volatiles present in off-gas produced by E. coli BL21 (DE3) (pCL upperMev; pTrcKKDyIkIS) following cryo-trapping at -196oC.**

Compound	RT (min)	GC Area <sup>1</sup>	Area% <sup>2</sup>	Ratio% <sup>3</sup>
----------	----------	----------------------	--------------------	---------------------

Compound	RT (min)	GC Area1	Area%2	Ratio%3
Acetaldehyde	1.54	1655710	0.276	0.33
Methanethiol	1.584	173620	0.029	0.03
Ethanol	1.631	10259680	1.707	2.03
Acetone	1.722	73089100	12.164	14.43
2-methyl-1,3-butadiene	1.771	506349429	84.269	100.00
methyl acetate	1.852	320112	0.053	0.06
1-propanol	1.983	156752	0.026	0.03
Diacetyl	2.148	67635	0.011	0.01
2-butanone	2.216	254364	0.042	0.05
2-methyl-3-buten-2-ol	2.312	684708	0.114	0.14
ethyl acetate	2.345	2226391	0.371	0.44
2-methyl-1-propanol	2.451	187719	0.031	0.04
3-methyl-1-butanal	2.696	115723	0.019	0.02
3-methyl-2-butanone	2.751	116861	0.019	0.02
1-butanol	2.792	54555	0.009	0.01
2-pentanone	3.034	66520	0.011	0.01
3-methyl-3-buten-1-ol	3.516	1123520	0.187	0.22
3-methyl-1-butanol	3.561	572836	0.095	0.11
ethyl isobutyrate	3.861	142056	0.024	0.03
3-methyl-2-buten-1-ol	4.048	302558	0.050	0.06
3-methyl-2-butenal	4.152	585690	0.097	0.12
butyl acetate	4.502	29665	0.005	0.01
3-methylbutyl acetate	5.194	271797	0.045	0.05
3-methyl-3-buten-1-yl acetate	5.281	705366	0.117	0.14
3-methyl-2-buten-1-yl acetate	5.675	815186	0.136	0.16
(E)-3,7-dimethyl-1,3,6-octatriene	6.766	207061	0.034	0.04
(Z)-3,7-dimethyl-1,3,6-octatriene	6.863	94294	0.016	0.02
2,3-cycloheptenolpyridine	8.983	135104	0.022	0.03

1 GC area is the uncorrected area under the peak corresponding to the listed compound.

2 Area % is the peak area expressed as a % relative to the total peak area of all compounds.

3 Ratio % is the peak area expressed as a % relative to the peak area of 2-methyl-1,3-butadiene.

III. Absence of C5 hydrocarbon isomers in isoprene derived from fermentation.

[0821] Cryo-trapping of isoprene present in fermentation off-gas was performed using a 2 mL headspace vial cooled in liquid nitrogen. The off-gas (1 L/min) was first passed through a 20 mL vial containing sodium hydroxide pellets in order to minimize the accumulation of ice and solid CO<sub>2</sub> in the 2 mL vial (-196 °C). Approximately 10L of off-gas was passed through the vial, after which it was allowed to warm to -78 °C with venting, followed by resealing with a fresh vial cap and analysis by GC/MS.

[0822] GC/MS headspace analysis was performed with an Agilent 6890 GC/MS system using a 100 $\mu$ L gas tight syringe in headspace mode. A Zebron ZB-624 GC/MS column (30 m x 250  $\mu$ m; 1.40  $\mu$ m film thickness) was used for separation of analytes. The GC autoinjector was fitted with a gas-tight 100  $\mu$ L syringe, and the needle height was adjusted to allow the injection of a 50  $\mu$ L headspace sample from a 2 mL GC vial. The GC/MS method utilized helium as the carrier gas at a flow of 1 mL/min. The injection port was held at 200 °C with a split ratio of 20:1. The oven temperature was held at 37 °C for the 5 minute duration of the analysis. The Agilent 5793N mass selective detector was run in single ion monitoring (SIM) mode on m/z 55, 66, 67 and 70. Under these conditions, isoprene was observed to elute at 2.966 minutes (Figure 88B). A standard of petroleum derived isoprene (Sigma-Aldrich) was also analyzed using this method and was found to contain additional C5 hydrocarbon isomers, which eluted shortly before or after the main peak and were quantified based on corrected GC area (Figure 88A).

**Table 8A: GC/MS analysis of petroleum-derived isoprene**

Compound	RT (min)	GC area	Area % of total C5 hydrocarbons
2-methyl-1-butene	2.689	18.2 x 10 <sup>3</sup>	0.017%
(Z)-2-pentene	2.835	10.6x 10 <sup>4</sup>	0.101%
Isoprene	2.966	10.4x 10 <sup>7</sup>	99.869%
1,3-cyclopentadiene (CPD)	3.297	12.8 x 10 <sup>3</sup>	0.012%

**Table 8B: GC/MS analysis of fermentation-derived isoprene (% total C5 hydrocarbons)**

Compound	RT (min)	Corrected GC Area	% of total C5 hydrocarbons
Isoprene	2.966	8.1 x 10 <sup>7</sup>	100%

[0823] In a separate experiment, a standard mixture of C5 hydrocarbons was analyzed to determine if the detector response was the same for each of the compounds. The compounds were 2-methyl-1-butene, 2-methyl-1,3-butadiene, (E)-2-pentene, (Z)-2-pentene and (E)-1,3-pentadiene. In this case, the analysis was performed on an Agilent DB-Petro column (100 m x 0.25 mm, 0.50  $\mu$ m film thickness) held at 50 °C for 15 minutes. The GC/MS method utilized helium as the carrier gas at a flow of 1 mL/min. The injection port was held at 200 °C with a split ratio of 50:1. The Agilent 5793N mass selective detector was run in full scan mode from

m/z 19 to m/z 250. Under these conditions, a 100 µg/L concentration of each standard produced the same detector response within experimental error.

#### IV. Compositions comprising isoprene adsorbed to a solid phase.

**[0824]** Biologically-produced isoprene was adsorbed to activated carbon resulting in a solid phase containing 50 to 99.9% carbon, 0.1% to 50% isoprene, 0.01% to 5% water, and minor amounts (<0.1%) of other volatile organic components.

**[0825]** Fermentation off-gas was run through a copper condensation coil held at 0 °C, followed by a granulated silica desiccant filter in order to remove water vapor. The dehumidified off-gas was then run through carbon containing filters (Koby Jr, Koby Filters, MA) to the point at which breakthrough of isoprene was detected in the filter exhaust by GC/MS. The amount of isoprene adsorbed to the cartridge can be determined indirectly by calculating the concentration in the off-gas, the overall flow rate and the percent breakthrough over the collection period. Alternately the adsorbed isoprene can be recovered from the filters by thermal, vacuum, or solvent-mediated desorption.

#### V. Collection and analysis of condensed isoprene.

**[0826]** Fermentation off-gas is dehumidified, and the CO<sub>2</sub> removed by filtration through a suitable adsorbent (*e.g.*, ascarite). The resulting off-gas stream is then run through a liquid nitrogen-cooled condenser in order to condense the VOCs in the stream. The collection vessel contains t-butyl catechol to inhibit the resulting isoprene condensate. The condensate is analyzed by GC/MS and NMR in order to determine purity using standard methods, such as those described herein.

#### VI. Production of prenyl alcohols by fermentation

**[0827]** Analysis of off-gas from an *E. coli* BL21 (DE3) strain expressing a Kudzu isoprene synthase revealed the presence of both isoprene and 3-methyl-3-buten-1-ol (isoprenol). The levels of the two compounds in the fermentation off-gas over the fermentation are shown in Figure 89 as determined by headspace GC/MS. Levels of isoprenol (3-methyl-3-buten-1-ol, 3-MBA) attained was nearly 10 µg/L<sub>offgas</sub> in this experiment. Additional experiments produced levels of approximately 20 µg/L<sub>offgas</sub> in the fermentation off-gas.

Example 11: The de-coupling of growth and production of isoprene in *E. coli* expressing genes from the mevalonic acid pathway and fermented in a fed-batch culture

**[0828]** Example 11 illustrates the de-coupling of cell growth from mevalonic acid and isoprene production.

#### I. Fermentation Conditions

Medium Recipe (per liter fermentation medium):

**[0829]** The medium was generated using the following components per liter fermentation medium:  $K_2HPO_4$  7.5 g,  $MgSO_4 \cdot 7H_2O$  2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, and 1000X modified trace metal solution 1 ml. All of the components were added together and dissolved in  $diH_2O$ . This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glucose 10 g, thiamine  $\cdot$  HCl 0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

**[0830]** The 1000X modified trace metal solution was generated using the following components: citric acids  $\cdot$   $H_2O$  40 g,  $MnSO_4 \cdot H_2O$  30 g, NaCl 10 g,  $FeSO_4 \cdot 7H_2O$  1 g,  $CoCl_2 \cdot 6H_2O$  1 g,  $ZnSO \cdot 7H_2O$  1 g,  $CuSO_4 \cdot 5H_2O$  100 mg,  $H_3BO_3$  100 mg, and  $NaMoO_4 \cdot 2H_2O$  100 mg. Each component was dissolved one at a time in  $Di H_2O$ , pH to 3.0 with HCl/NaOH, then q.s. to volume, and filter sterilized with a 0.22 micron filter.

**[0831]** Fermentation was performed with *E. coli* cells containing the pTrcHis2AUpperPathway (also called pTrcUpperMVA, Figures 91 and 92A-92C; SEQ ID NO:23) (50  $\mu$ g/ml carbenicillin) or the pCL PtrcUpperMVA (also called pCL PtrcUpperPathway (Figure 26)) (50  $\mu$ g/ml spectinomycin) plasmids. For experiments in which isoprene was produced, the *E. coli* cells also contained the pTrc KKDyIkIS (50  $\mu$ g/ml kanamycin) plasmid. These experiments were carried out to monitor mevalonic acid or isoprene formation from glucose at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of an *E. coli* strain taken from a frozen vial was streaked onto an LA broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated into tryptone-yeast extract medium. After the inoculum grew to optical density 1.0 when measured at 550 nm, it was used to inoculate the bioreactor.

**[0832]** Glucose was fed at an exponential rate until cells reached the stationary phase. After this time the glucose feed was decreased to meet metabolic demands. Induction was achieved by adding IPTG. The mevalonic acid concentration in fermentation broth was determined by

applying perchloric acid (Sigma-Aldrich # 244252) treated samples (0.3 M incubated at 4°C for 5 minutes) to an organic acids HPLC column (BioRad # 125-0140). The concentration was determined by comparing the broth mevalonic acid peak size to a calibration curve generated from mevalonolactone (Sigma-Aldrich # M4667) treated with perchloric acid to form D,L-mevalonate. The isoprene level in the off gas from the bioreactor was determined as described herein. The isoprene titer is defined as the amount of isoprene produced per liter of fermentation broth.

II. Mevalonic acid production from *E. coli* BL21 (DE3) cells expressing the pTrcUpperMVA plasmid at a 150-L scale

**[0833]** BL21 (DE3) cells that were grown on a plate as explained above in Example 11, part I were inoculated into a flask containing 45 mL of tryptone-yeast extract medium and incubated at 30°C with shaking at 170 rpm for 5 hours. This solution was transferred to a 5-L bioreactor of tryptone-yeast extract medium, and the cells were grown at 30 °C and 27.5 rpm until the culture reached an OD<sub>550</sub> of 1.0. The 5 L of inoculum was seeded into a 150-L bioreactor containing 45-kg of medium. The IPTG concentration was brought to 1.1 mM when the OD<sub>550</sub> reached a value of 10. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 60A. The mevalonic acid titer increased over the course of the fermentation to a final value of 61.3 g/L (Figure 60B). The specific productivity profile throughout the fermentation is shown in Figure 60C and a comparison to Figure 60A illustrates the de-coupling of growth and mevalonic acid production. The total amount of mevalonic acid produced during the 52.5 hour fermentation was 4.0 kg from 14.1 kg of utilized glucose. The molar yield of utilized carbon that went into producing mevalonic acid during fermentation was 34.2%.

III. Mevalonic acid production from *E. coli* BL21 (DE3) cells expressing the pTrcUpperMVA plasmid at a 15-L scale

**[0834]** BL21 (DE3) cells that were grown on a plate as explained above in Example 11, part I were inoculated into a flask containing 500 mL of tryptone-yeast extract medium and grown at 30 °C at 160 rpm to OD<sub>550</sub> 1.0. This material was seeded into a 15-L bioreactor containing 4.5-kg of medium. The IPTG concentration was brought to 1.0 mM when the OD<sub>550</sub> reached a value of 10. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 61A. The mevalonic acid titer increased over the course of the fermentation to a final value of 53.9 g/L (Figure 61B). The specific productivity profile throughout the fermentation is shown in Figure 61C and a

comparison to Figure 61A illustrates the de-coupling of growth and mevalonic acid production. The total amount of mevalonic acid produced during the 46.6 hour fermentation was 491 g from 2.1 kg of utilized glucose. The molar yield of utilized carbon that went into producing mevalonic acid during fermentation was 28.8%.

IV. Mevalonic acid production from *E. coli* FM5 cells expressing the pTrcUpperMVA plasmid at a 15-L scale

**[0835]** FM5 cells that were grown on a plate as explained above in Example 11, part I were inoculated into a flask containing 500 mL of tryptone-yeast extract medium and grown at 30 °C at 160 rpm to OD<sub>550</sub> 1.0. This material was seeded into a 15-L bioreactor containing 4.5-kg of medium. The IPTG concentration was brought to 1.0 mM when the OD<sub>550</sub> reached a value of 30. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 62A. The mevalonic acid titer increased over the course of the fermentation to a final value of 23.7 g/L (Figure 62B). The specific productivity profile throughout the fermentation is shown in Figure 62C and a comparison to Figure 62A illustrates the de-coupling of growth and mevalonic acid production. The total amount of mevalonic acid produced during the 51.2 hour fermentation was 140 g from 1.1 kg of utilized glucose. The molar yield of utilized carbon that went into producing mevalonic acid during fermentation was 15.2%.

V. Isoprene production from *E. coli* BL21 (DE3) cells expressing the pCL PtrcUpperMVA and pTrc KKDYIkIS plasmids at a 15-L scale

**[0836]** BL21 (DE3) cells expressing the pCL PtrcUpperMVA and pTrc KKDYIkIS plasmids that were grown on a plate as explained above in Example 11, part I were inoculated into a flask containing 500 mL of tryptone-yeast extract medium and grown at 30 °C at 160 rpm to OD<sub>550</sub> 1.0. This material was seeded into a 15-L bioreactor containing 4.5-kg of medium. The IPTG concentration was brought to 25 μM when the OD<sub>550</sub> reached a value of 10. The IPTG concentration was raised to 50 μM when OD<sub>550</sub> reached 190. The IPTG concentration was raised to 100 μM at 38 hours of fermentation. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 63A. The isoprene titer increased over the course of the fermentation to a final value of 2.2 g/L broth (Figure 63B). The specific productivity profile throughout the fermentation is shown in Figure 63C and a comparison to Figure 63A illustrates the de-coupling of growth and isoprene production. The total amount of isoprene produced during the 54.4 hour

fermentation was 15.9 g from 2.3 kg of utilized glucose. The molar yield of utilized carbon that went into producing isoprene during fermentation was 1.53%.

VI. Isoprene production from *E. coli* BL21 (DE3) tuner cells expressing the pCL PtrcUpperMVA and pTrc KKDyIkIS plasmids at a 15-L scale

**[0837]** BL21 (DE3) tuner cells expressing the pCL PtrcUpperMVA and pTrc KKDyIkIS plasmids that were grown on a plate as explained above in Example 11, part I were inoculated into a flask containing 500 mL of tryptone-yeast extract medium and grown at 30 °C at 160 rpm to OD<sub>550</sub> 1.0. This material was seeded into a 15-L bioreactor containing 4.5-kg of medium. The IPTG concentration was brought to 26 μM when the OD<sub>550</sub> reached a value of 10. The IPTG concentration was raised to 50 μM when OD<sub>550</sub> reached 175. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 64A. The isoprene titer increased over the course of the fermentation to a final value of 1.3 g/L broth (Figure 64B). The specific productivity profile throughout the fermentation is shown in Figure 64C and a comparison to Figure 64A illustrates the de-coupling of growth and isoprene production. The total amount of isoprene produced during the 48.6 hour fermentation was 9.9 g from 1.6 kg of utilized glucose. The molar yield of utilized carbon that went into producing isoprene during fermentation was 1.34%.

VII. Isoprene production from *E. coli* MG1655 cells expressing the pCL PtrcUpperMVA and pTrc KKDyIkIS plasmids at a 15-L scale

**[0838]** MG1655 cells expressing the pCL PtrcUpperMVA and pTrc KKDyIkIS plasmids that were grown on a plate as explained above in Example 11, part I were inoculated into a flask containing 500 mL of tryptone-yeast extract medium and grown at 30 °C at 160 rpm to OD<sub>550</sub> 1.0. This material was seeded into a 15-L bioreactor containing 4.5-kg of medium. The IPTG concentration was brought to 24 μM when the OD<sub>550</sub> reached a value of 45. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 65A. The isoprene titer increased over the course of the fermentation to a final value of 393 mg/L broth (Figure 65B). The specific productivity profile throughout the fermentation is shown in Figure 65C and a comparison to Figure 65A illustrates the de-coupling of growth and isoprene production. The total amount of isoprene produced during the 67.4 hour fermentation was 2.2 g from 520 g of utilized glucose. The molar yield of utilized carbon that went into producing isoprene during fermentation was 0.92%.

VIII. Isoprene production from *E. coli* MG1655ack-pta cells expressing the pCL PtrcUpperMVA and pTrc KKDyIkIS plasmids at a 15-L scale

**[0839]** MG1655ack-pta cells expressing the pCL PtrcUpperMVA and pTrc KKDyIkIS plasmids that were grown on a plate as explained above in Example 11, part I were inoculated into a flask containing 500 mL of tryptone-yeast extract medium and grown at 30 °C at 160 rpm to OD<sub>550</sub> 1.0. This material was seeded into a 15-L bioreactor containing 4.5-kg of medium. The IPTG concentration was brought to 30 μM when the OD<sub>550</sub> reached a value of 10. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 66A. The isoprene titer increased over the course of the fermentation to a final value of 368 mg/L broth (Figure 66B). The specific productivity profile throughout the fermentation is shown in Figure 66C and a comparison to Figure 66A illustrates the de-coupling of growth and isoprene production. The total amount of isoprene produced during the 56.7 hour fermentation was 1.8 g from 531 g of utilized glucose. The molar yield of utilized carbon that went into producing isoprene during fermentation was 0.73%.

IX. Isoprene production from *E. coli* FM5 cells expressing the pCL PtrcUpperMVA and pTrc KKDyIkIS plasmids at a 15-L scale

**[0840]** FM5 cells expressing the pCL PtrcUpperMVA and pTrc KKDyIkIS plasmids that were grown on a plate as explained above in Example 11, part I were inoculated into a flask containing 500 mL of tryptone-yeast extract medium and grown at 30 °C at 160 rpm to OD<sub>550</sub> 1.0. This material was seeded into a 15-L bioreactor containing 4.5-kg of medium. The IPTG concentration was brought to 27 μM when the OD<sub>550</sub> reached a value of 15. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 67A. The isoprene titer increased over the course of the fermentation to a final value of 235 mg/L broth (Figure 67B). The specific productivity profile throughout the fermentation is shown in Figure 67C and a comparison to Figure 67A illustrates the de-coupling of growth and isoprene production. The total amount of isoprene produced during the 52.3 hour fermentation was 1.4 g from 948 g of utilized glucose. The molar yield of utilized carbon that went into producing isoprene during fermentation was 0.32%.

Example 12: Production of isoprene during the exponential growth phase of *E. coli* expressing genes from the mevalonic acid pathway and fermented in a fed-batch culture

**[0841]** Example 12 illustrates the production of isoprene during the exponential growth phase of cells.

Medium Recipe (per liter fermentation medium):

**[0842]** The medium was generated using the following components per liter fermentation medium:  $K_2HPO_4$  7.5 g,  $MgSO_4 \cdot 7H_2O$  2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, and 1000X modified trace metal solution 1 ml. All of the components were added together and dissolved in  $diH_2O$ . This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glucose 10 g, thiamine  $\cdot HCl$  0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

**[0843]** The 1000X modified trace metal solution was generated using the following components: citric acids  $\cdot H_2O$  40 g,  $MnSO_4 \cdot H_2O$  30 g, NaCl 10 g,  $FeSO_4 \cdot 7H_2O$  1 g,  $CoCl_2 \cdot 6H_2O$  1 g,  $ZnSO \cdot 7H_2O$  1 g,  $CuSO_4 \cdot 5H_2O$  100 mg,  $H_3BO_3$  100 mg, and  $NaMoO_4 \cdot 2H_2O$  100 mg. Each component is dissolved one at a time in  $Di H_2O$ , pH to 3.0 with  $HCl/NaOH$ , then q.s. to volume and filter sterilized with 0.22 micron filter.

**[0844]** Fermentation was performed in a 15-L bioreactor with ATCC11303 *E. coli* cells containing the pCL PtrcUpperMVA and pTrc KKDyIkIS plasmids. This experiment was carried out to monitor isoprene formation from glucose at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated into tryptone-yeast extract medium. After the inoculum grew to OD 1.0, measured at 550 nm, 500 mL was used to inoculate a 5-L bioreactor.

**[0845]** Glucose was fed at an exponential rate until cells reached the stationary phase. After this time the glucose feed was decreased to meet metabolic demands. The total amount of glucose delivered to the bioreactor during the 50 hour fermentation was 2.0 kg. Induction was achieved by adding IPTG. The IPTG concentration was brought to 25  $\mu M$  when the optical density at 550 nm ( $OD_{550}$ ) reached a value of 10. The IPTG concentration was raised to 50  $\mu M$  when  $OD_{550}$  reached 190. The  $OD_{550}$  profile within the bioreactor over time is shown in Figure 99. The isoprene level in the off gas from the bioreactor was determined as described herein. The isoprene titer increased over the course of the fermentation to a final value of 1.4 g/L (Figure

100). The total amount of isoprene produced during the 50 hour fermentation was 10.0 g. The profile of the isoprene specific productivity over time within the bioreactor is shown in Figure 101. The molar yield of utilized carbon that contributed to producing isoprene during fermentation was 1.1%. The weight percent yield of isoprene from glucose was 0.5%.

Example 13: Flammability modeling and testing of isoprene

I. Summary of flammability modeling and testing of isoprene

[0846] Flammability modeling and experiments were performed for various hydrocarbon/oxygen/nitrogen/water/carbon dioxide mixtures. This modeling and experimental tested was aimed at defining isoprene and oxygen/nitrogen flammability curves under specified steam and carbon monoxide concentrations at a fixed pressure and temperature. A matrix of the model conditions is shown in Table 9, and a matrix of the experiments performed is shown in Table 5.

**Table 9. Summary of Modeled Isoprene Flammability**

Series	Temperature (°C)	Pressure (psig)	Steam Concentration (wt%)	Carbon Dioxide Concentration (wt. %)	Isoprene Concentration (vol. %)	Oxygen Concentration (vol. %)
A	40	0	0	0	Varying	Varying
B	40	0	4	0	Varying	Varying
C	40	0	0	5	Varying	Varying
D	40	0	0	10	Varying	Varying
E	40	0	0	15	Varying	Varying
F	40	0	0	20	Varying	Varying
G	40	0	0	30	Varying	Varying

**Table 10. Summary of Isoprene Flammability Tests**

Series Number	Temperature (°C)	Pressure (psig)	Steam Concentration (vol. %)	Isoprene Concentration (vol. %)	Oxygen Concentration (vol. %)
1	40	0	0	Varying	Varying
2	40	0	4	Varying	Varying

## II. Description of calculated adiabatic flame temperature (CAFT) model

**[0847]** Calculated adiabatic flame temperatures (CAFT) along with a selected limit flame temperature for combustion propagation were used to determine the flammability envelope for isoprene. The computer program used in this study to calculate the flame temperatures is the NASA Glenn Research Center CEA (Chemical Equilibrium with Applications) software.

**[0848]** There are five steps involved in determining the flammability envelope using an adiabatic flame temperature model for a homogeneous combustion mechanism (where both the fuel and oxidant are in the gaseous state): selection of the desired reactants, selection of the test condition, selection of the limit flame temperature, modification of the reactants, and construction of a flammability envelope from calculations.

**[0849]** In this first step, selection of desired reactants, a decision must be made as to the reactant species that will be present in the system and the quantities of each. In many cases the computer programs used for the calculations have a list of reactant and product species. If any of the data for the species to be studied are not found in the program, they may be obtained from other sources such as the JANAF tables or from the internet. In this current model data for water, nitrogen, oxygen and carbon dioxide were present in the program database. The program database did not have isoprene as a species; therefore the thermodynamic properties were incorporated manually.

**[0850]** The next step is to decide whether the initial pressure and temperature conditions that the combustion process is taking place in. In this model the pressure was 1 atmosphere (absolute) and the temperature was 40°C, the boiling point of isoprene.

**[0851]** The limit flame temperature for combustion can be either selected based on theoretical principles or determined experimentally. Each method has its own limitations.

**[0852]** Based on prior studies, the limit flame temperatures of hydrocarbons fall in the range of 1000 K to 1500 K. For this model, the value of 1500 K was selected. This is the temperature at which the reaction of carbon monoxide to carbon dioxide (a highly exothermic reaction and constitutes a significant proportion of the flame energy) becomes self sustaining.

**[0853]** Once the limit flame temperature has been decided upon, model calculations are performed on the given reactant mixture (species concentrations) and the adiabatic flame temperature is determined. Flame propagation is considered to have occurred only if the temperature is greater than the limit flame temperature. The reactant mixture composition is then modified to create data sets for propagation and non-propagation mixtures.

**[0854]** This type of model shows good agreement with the experimentally determined flammability limits. Regions outside the derived envelope are nonflammable and regions within it are flammable. The shape of the envelope forms a nose. The nose of the envelope is related to the limiting oxygen concentration (LOC) for gaseous fuels.

### III. Results from calculated adiabatic flame temperature (CAFT) model

**[0855]** Plotted in Figs. 68 through 74 are the CAFT model results for Series A to G, respectively. The figures plot the calculated adiabatic flame temperature (using the NASA CEA program) as a function of fuel concentration (by weight) for several oxygen/nitrogen ratios (by weight). The parts of the curve that are above 1500 K, the selected limit flame temperature, contain fuel levels sufficient for flame propagation. The results may be difficult to interpret in the form presented in Figs. 68 through 74. Additionally, the current form is not conducive to comparison with experimental data which is generally presented in terms of volume percent.

**[0856]** Using Series A as an example the data in Figure 68 can be plotted in the form of a traditional flammability envelope. Using Figure 68 and reading across the 1500 K temperature line on the ordinate one can determine the fuel concentration for this limit flame temperature by dropping a tangent to the abscissa for each curve (oxygen to nitrogen ratio) that it intersects. These values can then be tabulated as weight percent of fuel for a given weight percent of oxidizer (Figure 75A). Then knowing the composition of the fuel (100 wt.% isoprene) and the composition of the oxidizer (relative content of water, oxygen and nitrogen) molar quantities can be established.

**[0857]** From these molar quantities percentage volume concentrations can be calculated. The concentrations in terms of volume percent can then be plotted to generate a flammability envelope (Figure 75B). The area bounded by the envelope is the explosible range and the area excluded is the non-explosible range. The “nose” of the envelope is the limiting oxygen concentration. Figs. 76A and 76B contain the calculated volume concentrations for the flammability envelope for Series B generated from data presented in Figure 69. A similar approach can be used on data presented in Figs. 70-74.

### IV. Flammability testing experimental equipment and procedure

**[0858]** Flammability testing was conducted in a 4 liter high pressure vessel. The vessel was cylindrical in shape with an inner diameter of 6” and an internal height of 8.625”. The temperature of the vessel (and the gases inside) was maintained using external heaters that were

controlled by a PID controller. To prevent heat losses, ceramic wool and reflective insulation were wrapped around the pressure vessel. Type K thermocouples were used to measure the temperature of the gas space as well as the temperature of the vessel itself. Figure 77 illustrates the test vessel.

**[0859]** Before a test was run, the vessel was evacuated and purged with nitrogen to ensure that any gases from previous tests were removed. A vacuum was then pulled on the vessel. The pressure after this had been done was typically around 0.06 bar(a). Due to the nitrogen purging, the gas responsible for this initial pressure was assumed to be nitrogen. Using partial pressures, water, isoprene, nitrogen, and oxygen were then added in the appropriate amounts to achieve the test conditions in question. A magnetically driven mixing fan within the vessel ensured mixing of the gaseous contents. The gases were allowed to mix for about 2 minutes with the fan being turned off approximately 1 minute prior to ignition.

**[0860]** The igniter was comprised of a 1.5 ohm nicrome coil and an AC voltage source on a timer circuit. Using an oscilloscope, it was determined that 34.4 VAC were delivered to the igniter for 3.2 seconds. A maximum current of 3.8 amps occurred approximately halfway into the ignition cycle. Thus, the maximum power was 131 W and the total energy provided over the ignition cycle was approximately 210 J.

**[0861]** Deflagration data was acquired using a variable reluctance Validyne DP215 pressure transducer connected to a data acquisition system. A gas mixture was considered to have deflagrated if the pressure rise was greater than or equal to 5%.

## V. Results of flammability testing

**[0862]** The first experimental series (Series 1) was run at 40°C and 0 psig with no steam. Running tests at varying concentrations of isoprene and oxygen produced the flammability curve shown in Figure 78A. The data points shown in this curve are only those that border the curve. A detailed list of all the data points taken for this series is shown in Figs. 80A and 80B.

**[0863]** Figure 78B summarizes the explosibility data points shown in Figure 78A. Figure 78C is a comparison of the experimental data with the CAFT model predicted flammability envelope. The model agrees very well with the experimental data. Discrepancies may be due to the non-adiabatic nature of the test chamber and limitations of the model. The model looks at an infinite time horizon for the oxidation reaction and does not take into consideration any reaction kinetic limitation.

[0864] Additionally, the model is limited by the number of equilibrium chemical species that are in its database and thus may not properly predict pyrolytic species. Also, the flammability envelope developed by the model uses one value for a limit flame temperature (1500K). The limit flame temperature can be a range of values from 1,000K to 1,500K depending on the reacting chemical species. The complex nature of pyrolytic chemical species formed at fuel concentrations above the stoichiometric fuel/oxidizer level is one reason why the model may not accurately predict the upper flammable limit for this system.

[0865] The second experimental series (Series 2) was run at 40°C and 0 psig with a fixed steam concentration of 4%. Running tests at varying concentrations of isoprene and oxygen produced the flammability curve shown in Figure 79A. The data points shown in this curve are only those that border the curve. A detailed list of all the data points taken for this series is shown in Figure 81. Due to the similarity between the data in Series 1 only the key points of lower flammable limit, limiting oxygen concentration, and upper flammable limits were tested. The addition of 4% steam to the test mixture did not significantly change the key limits of the flammability envelope. It should be noted that higher concentrations of steam/water and or other inertants may influence the flammability envelope.

[0866] Figure 79B summarizes the explosibility data points shown in Figure 79A. Figure 79C is a comparison of the experimental data with the CAFT model predicted flammability envelope. The model agrees very well with the experimental data. Discrepancies may be due to the same factors described in Series 1

#### VI. Calculation of Flammability Limits of Isoprene in Air at 3 Atmospheres of Pressure

[0867] The methods described in Example 13, parts I to IV were also used to calculate the flammability limits of isoprene at an absolute system pressure of 3 atmospheres and 40°C. These results were compared to those of Example 13, parts I to IV at an absolute system pressure of 1 atmosphere and 40°C. This higher pressure was tested because the flammability envelope expands or grows larger as the initial system pressure is increased. The upper flammability limit is affected the most, followed by the limiting oxygen composition. The lower flammability limit is the least affected (*see*, for example, “Bulletin 627 – Flammability Characteristics of Combustible Gases and Vapors” written by Michael G. Zabetakis and published by the former US Bureau of Mines (1965), which is hereby incorporated by reference in its entirety, particular with respect to the calculation of flammability limits).

**[0868]** In Figure 82, the calculated adiabatic flame temperature is plotted as a function of isoprene (fuel) concentration, expressed in weight percent of the total fuel/nitrogen/oxygen, where the system pressure was initially 3 atmospheres. The calculated flame temperatures are very similar to those determined initially in the 1 atmosphere system (Figure 83). As a result, when flammability envelopes are generated using the calculated adiabatic flammability data, the curves are very similar (see Figs. 84 and 85). Therefore, based on these theoretical calculations, a system pressure increase from 1 atmosphere to 3 atmosphere does not result in a significant increase/broadening of the flammability envelope. If desired, these model results may be validated using experimental testing (such as the experimental testing described herein at a pressure of 1 atmosphere).

## VII. Summary of flammability studies

**[0869]** A calculated adiabatic temperature model was developed for the flammability envelope of the isoprene/oxygen/nitrogen/water/ carbon dioxide system at 40°C and 0 psig. The CAFT model that was developed agreed well with the experimental data generated by the tests conducted in this work. The experimental results from Series 1 and 2 validated the model results from Series A and B.

### Example 14: Expression Constructs and Strains

#### I. Construction of plasmids encoding mevalonate kinase.

**[0870]** A construct encoding the *Methanosarcina mazei* lower MVA pathway (Accession numbers NC\_003901.1, NC\_003901.1, NC\_003901.1, and NC\_003901.1, which are each hereby incorporated by reference in their entireties) was synthesized with codon optimization for expression in *E. coli*. This construct is named *M. mazei* archeal Lower Pathway operon (Figures 112A-112C; SEQ ID NO:27) and encodes *M. mazei* MVK, a putative decarboxylase, IPK, and IDI enzymes. The gene encoding MVK (Accession number NC\_003901.1) was PCR amplified using primers MCM165 and MCM177 (Table 11) using the Stratagene Herculase II Fusion kit according to the manufacturer's protocol using 30 cycles with an annealing temperature of 55 °C and extension time of 60 seconds. This amplicon was purified using a Qiagen PCR column and then digested at 37 °C in a 10 µL reaction with PmeI (in the presence of NEB buffer 4 and BSA). After one hour, NsiI and Roche buffer H were added for an additional hour at 37 °C. The digested DNA was purified over a Qiagen PCR column and ligated to a similarly digested and

purified plasmid MCM29 (MCM29 is *E. coli* TOP10 (Invitrogen) transformed with pTrcKudzu encoding Kudzu isoprene synthase) in an 11  $\mu$ L reaction 5 $\mu$ L Roche Quick Ligase buffer 1, 1  $\mu$ L buffer 2, 1  $\mu$ L plasmid, 3  $\mu$ L amplicon, and 1  $\mu$ L ligase (1 hour at room temperature). MCM 29 is pTrcKudzuKan. The ligation reaction was introduced into Invitrogen TOP10 cells and transformants selected on LA/kan50 plates incubated at 37 °C overnight. The MVK insert in the resulting plasmid MCM382 was sequenced (Figures 113A-113C; SEQ ID NO: 28).

**Table 11. Oligonucleotides.**

MCM161	<i>M.mazei</i> MVK for	CACCATGGTATCCTGTTCTGCG (SEQ ID NO:120)
MCM162	<i>M.mazei</i> MVK rev	TTAATCTACTTTCAGACCTTGC (SEQ ID NO:121)
MCM165	<i>M.mazei</i> MVK for w/ RBS	gggaacgATGCATAaaggaggtaaaaaacATGGTATCCTGTTCTG CGCCGGGTAAGATTTACCTG (SEQ ID NO:122)
MCM177	<i>M.mazei</i> MVK rev Pst	gggcccggttaaactttaactagactTTAATCTACTTTCAGACCTTGC (SEQ ID NO:123)

II. Creation of strains overexpressing mevalonate kinase and isoprene synthase.

**[0871]** Plasmid MCM382 was transformed into MCM331 cells (which contains chromosomal construct gi1.2KKDyI encoding *S. cerevisiae* mevalonate kinase, mevalonate phosphate kinase, mevalonate pyrophosphate decarboxylase, and IPP isomerase) that had been grown to midlog in LB medium and washed three times in iced, sterile water. One  $\mu$ L of DNA was added to 50  $\mu$ L of cell suspension, and this mixture was electroporated in a 2 mm cuvette at 2.5 volts, 25 uFd followed immediately by recovery in 500  $\mu$ L LB medium for one hour at 37 °C. Transformant was selected on LA/kan50 and named MCM391. Plasmid MCM82 was introduced into this strain by the same electroporation protocol followed by selection on LA/kan50/spec50. The resulting strain MCM401 contains a cmp-marked chromosomal construct gi1.2KKDyI, kan-marked plasmid MCM382, and spec-marked plasmid MCM82 (which is pCL PtrcUpperPathway encoding *E. faecalis* mvaE and mvaS). See Table 12.

**Table 12. Strains overexpressing mevalonate kinase and isoprene synthase.**

MCM382	<i>E. coli</i> BL21 (lambdaDE3) pTrcKudzuMVK(M. mazei)GI1.2KKDyI
MCM391	MCM331 pTrcKudzuMVK(M. mazei)
MCM401	MCM331pTrcKudzuMVK(M.mazei)pCLPtrcUpperpathway
MCM396	MCM333pTrcKudzuMVK(M. mazei)
MCM406	MCM333pTrcKudzuMVK(M.mazci)pCLPtrcUpperpathway

III. Construction of plasmid MCM376 - MVK from *M. mazei* archeal Lower in pET200D.

**[0872]** The MVK ORF from the *M. mazei* archeal Lower Pathway operon (Figures 112A-112C; SEQ ID NO:27) was PCR amplified using primers MCM161 and MCM162 (Table 11) using the Invitrogen Platinum HiFi PCR mix. 45  $\mu$ L of PCR mix was combined with 1  $\mu$ L template, 1  $\mu$ L of each primer at 10  $\mu$ M, and 2  $\mu$ L water. The reaction was cycled as follows: 94  $^{\circ}$ C for 2:00; 30 cycles of 94  $^{\circ}$ C for 0:30, 55  $^{\circ}$ C for 0:30, and 68  $^{\circ}$ C for 1:15; and then 72  $^{\circ}$ C for 7:00, and 4  $^{\circ}$ C until cool. 3  $\mu$ L of this PCR reaction was ligated to Invitrogen pET200D plasmid according to the manufacturer's protocol. 3  $\mu$ L of this ligation was introduced into Invitrogen TOP10 cells, and transformants were selected on LA/kan50. A plasmid from a transformant was isolated and the insert sequenced, resulting in MCM376 (Figures 114A-114C; SEQ ID NO:29).

IV. Creation of expression strain MCM378.

**[0873]** Plasmid MCM376 was transformed into Invitrogen BL21(DE3) pLysS cells according to the manufacturer's protocol. Transformant MCM378 was selected on LA/kan50.

Example 15: Production of isoprene by *E. coli* expressing the upper mevalonic acid (MVA) pathway, the integrated lower MVA pathway (gi1.2KKDyI), mevalonate kinase from *M. mazei*, and isoprene synthase from Kudzu and grown in fed-batch culture at the 20 mL batch scale

Medium Recipe (per liter fermentation medium):

**[0874]** Each liter of fermentation medium contained K<sub>2</sub>HPO<sub>4</sub> 13.6 g, KH<sub>2</sub>PO<sub>4</sub> 13.6 g, MgSO<sub>4</sub> \* 7H<sub>2</sub>O 2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> 3.2 g, yeast extract 1 g, and 1000X Trace Metal Solution 1 ml. All of the components were added together and dissolved in diH<sub>2</sub>O. The pH was adjusted to 6.8 with ammonium hydroxide (30%) and brought to volume. Media was filter sterilized with a 0.22 micron filter. Glucose (2.5 g) and antibiotics were added after sterilization and pH adjustment.

1000X Trace Metal Solution:

**[0875]** 1000X Trace Metal Solution contained citric Acids \* H<sub>2</sub>O 40 g, MnSO<sub>4</sub> \* H<sub>2</sub>O 30 g, NaCl 10 g, FeSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CoCl<sub>2</sub> \* 6H<sub>2</sub>O 1 g, ZnSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CuSO<sub>4</sub> \* 5H<sub>2</sub>O 100 mg, H<sub>3</sub>BO<sub>3</sub> 100 mg, and NaMoO<sub>4</sub> \* 2H<sub>2</sub>O 100 mg. Each component was dissolved one at a time in di

H<sub>2</sub>O, pH to 3.0 with HCl/NaOH, then brought to volume and filter sterilized with a 0.22 micron filter.

Strains:

**[0876]** MCM343 cells are BL21 (DE3) *E. coli* cells containing the upper mevalonic acid (MVA) pathway (pCL Upper), the integrated lower MVA pathway (gi1.2KKDyI), and isoprene synthase from Kudzu (pTrcKudzu).

**[0877]** MCM401 cells are BL21 (DE3) *E. coli* cells containing the upper mevalonic acid (MVA) pathway (pCL PtrcUpperPathway), the integrated lower MVA pathway (gi1.2KKDyI), and high expression of mevalonate kinase from *M. mazei* and isoprene synthase from Kudzu (pTrcKudzuMVK(M.mazei)).

**[0878]** Isoprene production was analyzed by growing the strains in 100 mL bioreactors with a 20 mL working volume at a temperature of 30°C. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 30°C. A single colony was inoculated into media and grown overnight. The bacteria were diluted into 20 mL of media to reach an optical density of 0.05 measured at 550 nm. The 100 mL bioreactors were sealed, and air was pumped through at a rate of 8 mL/min. Adequate agitation of the media was obtained by stirring at 600 rpm using magnetic stir bars. The off-gas from the bioreactors was analyzed using an on-line Hiden HPR-20 mass spectrometer. Masses corresponding to isoprene, CO<sub>2</sub>, and other gasses naturally occurring in air were monitored. Accumulated isoprene and CO<sub>2</sub> production were calculated by summing the concentration (in percent) of the respective gasses over time. Atmospheric CO<sub>2</sub> was subtracted from the total in order to estimate the CO<sub>2</sub> released due to metabolic activity.

**[0879]** Isoprene production from a strain expressing the full mevalonic acid pathway and Kudzu isoprene synthase (MCM343) was compared to a strain that in addition over-expressed MVK from *M. mazei* and Kudzu isoprene synthase (MCM401) in 100 mL bioreactors. The bacteria were grown under identical conditions in defined media with glucose as carbon source. Induction of isoprene production was achieved by adding isopropyl-beta-D-1-thiogalactopyranoside (IPTG) to a final concentration of either 100 µM or 200 µM. Off-gas measurements revealed that the strain over-expressing both MVK and isoprene synthase (MCM401) produced significantly more isoprene compared to the strain expressing only the mevalonic acid pathway and Kudzu isoprene synthase (MCM343) as shown in Figures 115A-115D. At 100 µM induction, the MCM401 strain produced 2-fold more isoprene compared to

the MCM343 strain. At 200  $\mu$ M IPTG induction, the MCM401 strain produced 3.4-fold more isoprene when compared to the MCM343 strain. Analysis of CO<sub>2</sub> in the off-gas from the bioreactors, which is a measure of metabolic activity, indicates that metabolic activity was independent from IPTG induction and isoprene production.

Example 16: Production of isoprene by *E. coli* expressing the upper mevalonic acid (MVA) pathway, the integrated lower MVA pathway (gi1.2KKDyI), mevalonate kinase from *M. mazei*, and isoprene synthase from Kudzu and grown in fed-batch culture at the 15-L scale

Medium Recipe (per liter fermentation medium):

**[0880]** Each liter of fermentation medium contained K<sub>2</sub>HPO<sub>4</sub> 7.5 g, MgSO<sub>4</sub> \* 7H<sub>2</sub>O 2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, and 1000X Modified Trace Metal Solution 1 ml. All of the components were added together and dissolved in DI H<sub>2</sub>O. This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glucose 10 g, thiamine \* HCl 0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

**[0881]** 1000X Modified Trace Metal Solution contained citric Acids \* H<sub>2</sub>O 40 g, MnSO<sub>4</sub> \* H<sub>2</sub>O 30 g, NaCl 10 g, FeSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CoCl<sub>2</sub> \* 6H<sub>2</sub>O 1 g, ZnSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CuSO<sub>4</sub> \* 5H<sub>2</sub>O 100 mg, H<sub>3</sub>BO<sub>3</sub> 100 mg, and NaMoO<sub>4</sub> \* 2H<sub>2</sub>O 100 mg. Each component was dissolved one at a time in DI H<sub>2</sub>O, pH to 3.0 with HCl/NaOH, then q.s. to volume and filter sterilized with a 0.22 micron filter.

**[0882]** Fermentation was performed in a 15-L bioreactor with BL21 (DE3) *E. coli* cells containing the upper mevalonic acid (MVA) pathway (pCL PtrcUpperPathway encoding *E. faecalis* mvaE and mvaS), the integrated lower MVA pathway (gi1.2KKDyI encoding *S. cerevisiae* mevalonate kinase, mevalonate phosphate kinase, mevalonate pyrophosphate decarboxylase, and IPP isomerase), and high expression of mevalonate kinase from *M. mazei* and isoprene synthase from Kudzu (pTrcKudzuMVK(M.mazei)). This experiment was carried out to monitor isoprene formation from glucose at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated

into tryptone-yeast extract medium. After the inoculum grew to OD 1.0, measured at 550 nm, 500 mL was used to inoculate 5-L of medium in a 15-L bioreactor.

**[0883]** Glucose was fed at an exponential rate until cells reached the stationary phase. After this time the glucose feed was decreased to meet metabolic demands. The total amount of glucose delivered to the bioreactor during the 68 hour fermentation was 3.8 kg. Induction was achieved by adding isopropyl-beta-D-1-thiogalactopyranoside (IPTG). The IPTG concentration was brought to 51  $\mu\text{M}$  when the optical density at 550 nm ( $\text{OD}_{550}$ ) reached a value of 9. The IPTG concentration was raised to 88  $\mu\text{M}$  when  $\text{OD}_{550}$  reached 149. Additional IPTG additions raised the concentration to 119  $\mu\text{M}$  at  $\text{OD}_{550} = 195$  and 152  $\mu\text{M}$  at  $\text{OD}_{550} = 210$ . The  $\text{OD}_{550}$  profile within the bioreactor over time is shown in Figure 116. The isoprene level in the off gas from the bioreactor was determined using a Hiden mass spectrometer. The isoprene titer increased over the course of the fermentation to a final value of 23.8 g/L (Figure 117). The total amount of isoprene produced during the 68 hour fermentation was 227.2 g and the time course of production is shown in Figure 118. The metabolic activity profile, as measured by TCER, is shown in Figure 119. The total viable count (total colony forming units) decreased by two orders of magnitude between 10 and 39 hours of fermentation (Figure 120). The molar yield of utilized carbon that went into producing isoprene during fermentation was 13.0%. The weight percent yield of isoprene from glucose was 6.3%.

Example 17: Production of isoprene by *E. coli* expressing the upper mevalonic acid (MVA) pathway, the integrated lower MVA pathway (*gl1.2KKDyI*), mevalonate kinase from *M. mazei*, and isoprene synthase from Kudzu and grown in fed-batch culture at the 15-L scale (2x 100 $\mu\text{M}$  IPTG induction)

Medium Recipe (per liter fermentation medium):

**[0884]** Each liter of fermentation medium contained  $\text{K}_2\text{HPO}_4$  7.5 g,  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, and 1000X Modified Trace Metal Solution 1 ml. All of the components were added together and dissolved in DI  $\text{H}_2\text{O}$ . This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glucose 10 g, thiamine  $\cdot$  HCl 0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

**[0885]** 1000X Modified Trace Metal Solution contained citric Acids \* H<sub>2</sub>O 40 g, MnSO<sub>4</sub> \* H<sub>2</sub>O 30 g, NaCl 10 g, FeSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CoCl<sub>2</sub> \* 6H<sub>2</sub>O 1 g, ZnSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CuSO<sub>4</sub> \* 5H<sub>2</sub>O 100 mg, H<sub>3</sub>BO<sub>3</sub> 100 mg, and NaMoO<sub>4</sub> \* 2H<sub>2</sub>O 100 mg. Each component was dissolved one at a time in DI H<sub>2</sub>O, pH to 3.0 with HCl/NaOH, then q.s. to volume and filter sterilized with a 0.22 micron filter.

**[0886]** Fermentation was performed in a 15-L bioreactor with BL21 (DE3) *E. coli* cells containing the upper mevalonic acid (MVA) pathway (pCL PtrcUpperPathway encoding *E. faecalis* mvaE and mvaS), the integrated lower MVA pathway (gi1.2KKDyI encoding *S. cerevisiae* mevalonate kinase, mevalonate phosphate kinase, mevalonate pyrophosphate decarboxylase, and IPP isomerase), and high expression of mevalonate kinase from *M. mazei* and isoprene synthase from Kudzu (pTrcKudzuMVK(*M.mazei*)). This experiment was carried out to monitor isoprene formation from glucose at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated into tryptone-yeast extract medium. After the inoculum grew to OD 1.0, measured at 550 nm, 500 mL was used to inoculate 5-L medium in a 15-L bioreactor.

**[0887]** Glucose was fed at an exponential rate until cells reached the stationary phase. After this time the glucose feed was decreased to meet metabolic demands. The total amount of glucose delivered to the bioreactor during the 55 hour fermentation was 1.9 kg. Induction was achieved by adding isopropyl-beta-D-1-thiogalactopyranoside (IPTG). The IPTG concentration was brought to 111 μM when the optical density at 550 nm (OD<sub>550</sub>) reached a value of 9. The IPTG concentration was raised to 193 μM when OD<sub>550</sub> reached 155. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 121. The isoprene level in the off gas from the bioreactor was determined using a Hiden mass spectrometer. The isoprene titer increased over the course of the fermentation to a final value of 19.5 g/L (Figure 122). The total amount of isoprene produced during the 55 hour fermentation was 133.8 g and the time course of production is shown in Figure 123. Instantaneous volumetric productivity levels reached values as high as 1.5 g isoprene/L broth/hr (Figure 124). Instantaneous yield levels reached as high as 17.7% w/w (Figure 125). The metabolic activity profile, as measured by TCER, is shown in Figure 126. The total viable count (total colony forming units) decreased by two orders of magnitude between 8 and 36 hours of fermentation (Figure 127). The molar yield of utilized carbon that went into producing isoprene during fermentation was 15.8%. The weight percent yield of isoprene from glucose over the entire fermentation was 7.4%.

**[0888]** In addition, as a control, fermentation was performed in a 15-L bioreactor with BL21 (DE3) *E. coli* cells containing the upper mevalonic acid (MVA) pathway (pCL PtrcUpperPathway encoding *E. faecalis* mvaE and mvaS), the integrated lower MVA pathway (gi1.2KKDyI encoding *S. cerevisiae* mevalonate kinase, mevalonate phosphate kinase, mevalonate pyrophosphate decarboxylase, and IPP isomerase), and high expression of mevalonate kinase from *M. mazei* and isoprene synthase from Kudzu (pTrcKudzuMVK(*M.mazei*)). This experiment was carried out to monitor uninduced cell metabolic activity as measured by CER from glucose at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of *E. coli* strain (MCM401 described above) taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated into tryptone-yeast extract medium. After the inoculum grew to OD 1.0, measured at 550 nm, 500 mL was used to inoculate 5-L medium in a 15-L bioreactor. Glucose was fed at an exponential rate until cells reached the stationary phase. After this time the glucose feed was decreased to meet metabolic demands.

**[0889]** Figure 148 compares the CER profiles for the uninduced cells described above and the cells induced by adding isopropyl-beta-D-1-thiogalactopyranoside (IPTG) in Examples 16 and 17.

Example 18: Production of isoprene by *E. coli* expressing the upper mevalonic acid (MVA) pathway, the integrated lower MVA pathway (gi1.2KKDyI), mevalonate kinase from *M. mazei*, and isoprene synthase from Kudzu and grown in fed-batch culture at the 15-L scale (1x 50µM IPTG + 150µM IPTG fed induction)

Medium Recipe (per liter fermentation medium):

**[0890]** Each liter of fermentation medium contained K<sub>2</sub>HPO<sub>4</sub> 7.5 g, MgSO<sub>4</sub> \* 7H<sub>2</sub>O 2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, and 1000X Modified Trace Metal Solution 1 ml. All of the components were added together and dissolved in diH<sub>2</sub>O. This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glucose 10 g, thiamine \* HCl 0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

**[0891]** 1000X Modified Trace Metal Solution contained citric Acids \* H<sub>2</sub>O 40 g, MnSO<sub>4</sub> \* H<sub>2</sub>O 30 g, NaCl 10 g, FeSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CoCl<sub>2</sub> \* 6H<sub>2</sub>O 1 g, ZnSO<sub>4</sub> \* 7H<sub>2</sub>O 1 g, CuSO<sub>4</sub> \* 5H<sub>2</sub>O 100 mg, H<sub>3</sub>BO<sub>3</sub> 100 mg, and NaMoO<sub>4</sub> \* 2H<sub>2</sub>O 100 mg. Each component was dissolved one at a time in DI H<sub>2</sub>O, pH to 3.0 with HCl/NaOH, then q.s. to volume and filter sterilized with a 0.22 micron filter.

**[0892]** Fermentation was performed in a 15-L bioreactor with BL21 (DE3) *E. coli* cells containing the upper mevalonic acid (MVA) pathway (pCL PtrcUpperPathway encoding *E. faecalis* mvaE and mvaS), the integrated lower MVA pathway (gi1.2KKDyI encoding *S. cerevisiae* mevalonate kinase, mevalonate phosphate kinase, mevalonate pyrophosphate decarboxylase, and IPP isomerase), and high expression of mevalonate kinase from *M. mazei* and isoprene synthase from Kudzu (pTrcKudzuMVK(M.mazei)). This experiment was carried out to monitor isoprene formation from glucose at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 37°C. A single colony was inoculated into tryptone-yeast extract medium. After the inoculum grew to OD 1.0, measured at 550 nm, 500 mL was used to inoculate 5-L medium in a 15-L bioreactor.

**[0893]** Glucose was fed at an exponential rate until cells reached the stationary phase. After this time the glucose feed was decreased to meet metabolic demands. The total amount of glucose delivered to the bioreactor during the 55 hour fermentation was 2.2 kg. Induction was achieved by adding isopropyl-beta-D-1-thiogalactopyranoside (IPTG). The IPTG concentration was brought to 51 μM when the optical density at 550 nm (OD<sub>550</sub>) reached a value of 10. In addition to the IPTG spike, at OD<sub>550</sub> = 10 a constant feed began and delivered 164 mg of IPTG over 18 hours. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 128. The isoprene level in the off gas from the bioreactor was determined using a Hiden mass spectrometer. The isoprene titer increased over the course of the fermentation to a final value of 22.0 g/L (Figure 129). The total amount of isoprene produced during the 55 hour fermentation was 170.5 g and the time course of production is shown in Figure 130. The metabolic activity profile, as measured by TCER, is shown in Figure 131. When the airflow to the bioreactor was decreased from 8 slpm to 4 slpm for a period of about 1.7 hours, the concentration of isoprene in the offgas increased from 0.51 to 0.92 w/w % (Figure 132). These elevated levels of isoprene did not appear to have any negative impact on cell metabolic activity as measured by the total carbon dioxide evolution rate (TCER), since TCER declined only 7% between 37.2 and 39.3 hours (Figure 132). The total viable count (total colony forming units) decreased by two orders

of magnitude between 7 and 36 hours of fermentation (Figure 133). The molar yield of utilized carbon that went into producing isoprene during fermentation was 16.6%. The weight percent yield of isoprene from glucose over the entire fermentation was 7.7%.

Example 19: The effect of externally applied isoprene on a wild-type *E. coli* grown in fed-batch culture at the 1-L scale

Medium Recipe (per liter fermentation medium):

**[0894]** Each liter of fermentation medium contained  $K_2HPO_4$  7.5 g,  $MgSO_4 \cdot 7H_2O$  2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, and 1000X Modified Trace Metal Solution 1 ml. All of the components were added together and dissolved in  $diH_2O$ . This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glucose 10 g, thiamine \* HCl 0.1 g, and antibiotics were added after sterilization and pH adjustment.

1000X Modified Trace Metal Solution:

**[0895]** 1000X Modified Trace Metal Solution contained citric Acids \*  $H_2O$  40 g,  $MnSO_4 \cdot H_2O$  30 g, NaCl 10 g,  $FeSO_4 \cdot 7H_2O$  1 g,  $CoCl_2 \cdot 6H_2O$  1 g,  $ZnSO_4 \cdot 7H_2O$  1 g,  $CuSO_4 \cdot 5H_2O$  100 mg,  $H_3BO_3$  100 mg, and  $NaMoO_4 \cdot 2H_2O$  100 mg. Each component was dissolved one at a time in DI  $H_2O$ , pH to 3.0 with HCl/NaOH, then q.s. to volume and filter sterilized with a 0.22 micron filter.

**[0896]** Fermentation was performed in a 1-L bioreactor with BL21 (DE3) *E. coli* cells. This experiment was carried out to monitor the effects of isoprene on cell viability and metabolic activity in a glucose fed-batch bioreactor at the desired fermentation pH 7.0 and temperature 30°C. An inoculum of *E. coli* strain from a frozen vial was inoculated into tryptone-yeast extract medium. After the inoculum grew to OD 1.0, measured at 550 nm, 50 mL was used to inoculate 0.5-L medium in a 1-L bioreactor.

**[0897]** Glucose was fed at an exponential rate until cells reached the stationary phase. After this time the glucose feed was fed to meet metabolic demands. Isoprene was fed into the bioreactor using nitrogen gas as a carrier. The rate of isoprene feeding was 1 g/L/hr during mid-growth phase ( $OD_{550} = 31-44$ ) and lasted for a total of 75 minutes (13.2 to 14.4 hours). The  $OD_{550}$  profile within the bioreactor over time is shown in Figure 134. The metabolic activity profile, as measured by TCER, is shown in Figure 135. The total viable count (total colony

forming units) increased by 14-fold during the period when isoprene was introduced into the bioreactor (Figure 136).

Example 20: Production of isoprene and expression of isoprene synthase by *Saccharomyces cerevisiae*

**[0898]** The Kudzu isoprene synthase enzyme was optimized for expression according to a hybrid *Saccharomyces cerevisiae/Pichia pastoris* codon usage table, synthesized, and cloned into pDONR221:19430 (by DNA 2.0, Figure 140 for map and Figure 141 for sequence (SEQ ID NO:38)). A Gateway® Cloning (Invitrogen) reaction was performed according to the manufacturer's protocol: Since pDONR221:19430 was an "entry" vector, the LR Clonase II enzyme (the LR Reaction) was used to introduce the codon-optimized isoprene synthase into the "destination" vector pYES-DEST52 (Invitrogen).

**[0899]** The LR Reaction was then transformed into Top10 chemically competent cells (Invitrogen) according to the manufacturer's protocol, and bacteria harboring pYES-DEST52 plasmids with the isoprene synthase ORF were selected for on LA plates containing 50 µg/ml carbenicillin. Individual positive transformants were tested by colony PCR (see below for primer concentrations and thermocycling parameters) using illustra PuReTaq Ready-To-Go™ PCR Beads (GE Healthcare) with the T7 forward primer and the Yeast isoprene synthase -Rev2 primer (See Table 13).

**Table 13. Primer sequences for amplifying isoprene synthase.**

Primer Name	Sequence (5' to 3')	Purpose
Yeast HGS - For2	CACCAAAGACTTCATAGACT (SEQ ID NO:124)	Forward primer for yeast optimized isoprene synthase
Yeast HGS - Rev2	AGAGATATCTTCCTGCTGCT (SEQ ID NO:125)	Reverse primer for yeast optimized isoprene synthase
T7 Forward	TAATACGACTCACTATAGGG (SEQ ID NO:126)	PCR and sequencing primer

**[0900]** Plasmids that yielded a PCR fragment of the correct size (1354 bp) were purified by miniprep (Qiagen) and sent for sequencing (Quintara Biosciences, Berkeley, CA) with the T7 Forward and Yeast isoprene synthase-For2 primers (See Table 13). Results from sequencing runs were compared to the known sequence of pDONR221:19430 (using Vector NTI software, Invitrogen), and a single plasmid, pDW14, was selected for further study (Figure 142A for map and Figures 142B and C for the complete sequence (SEQ ID NO:39)). The sequence of pDW14

diverged from that of pDONR221:19430 by a single nucleotide (marked in bold in Figure 142B). The single nucleotide change (G to A) did not result in a change in the ORF, since it was in the third position of a lysine-encoding codon.

**[0901]** Purified pDW14 was transformed into *Saccharomyces cerevisiae* strain INVSc-1 using the protocol described in the *S. c.* EasyComp Transformation kit (Invitrogen). INVSc-1 strains harboring pDW14 or pYES-DEST52 (which contains an intact URA3 gene) were selected for and maintained on SC Minimal Medium with 2% glucose without uracil, as described in the pYES-DEST52 Gateway Vector manual (Invitrogen). Two independent isolates of INVSc-1 containing pDW14 and a single control strain with pYES-DEST52 were chosen for further analysis.

**[0902]** To induce isoprene synthase expression, cultures were grown overnight in liquid SC Minimal Medium. The cultures were then diluted to an OD<sub>600</sub> of approximately 0.2 and grown for 2-3 hours. Cultures were spun by centrifugation, washed once, resuspended in an equal volume (10 ml) of SC minimal medium with 1% raffinose, 2% galactose without uracil, and grown overnight to induce the expression of isoprene synthase. The OD<sub>600</sub> of the strains was determined (Figure 144A), and strains were harvested by centrifugation and resuspended in 2 ml of lysis buffer (a 1:1 mix of 50% glycerol and PEB pH 7.4: Tris Base 2.423 g/L, MgCl<sub>2</sub> (Anhydrous) 1.904 g/L, KCl 14.910 g/L, DTT 0.154 g/L, Glycerol 50 mL/L).

**[0903]** The lysis mixtures were passed through a french press three times, and lysates were analyzed by SDS-PAGE. For Coomassie gel analysis (Figure 143A), samples were diluted 1:1 with 2X SDS loading buffer with reducing agent, loaded (20 µl total volume) onto a 4-12% bis-tris gel, run in MES buffer, and stained using SimplyBlue SafeStain according to the manufacturer's protocol (the Invitrogen Novex system).

**[0904]** The WesternBreeze kit (Invitrogen) was used for transfer and chromogenic detection of isoprene synthase on a nitrocellulose membrane. The primary antibody was 1799A 10 week diluted 1:1000 in Invitrogen antibody diluent. Primary antibody binding was followed by development with a secondary antibody labeled with Alexa Fluor 488 (Invitrogen Catalog No. A-11008) to permit quantitative signal determination. The western blot procedure was carried out as described by Invitrogen. The fluorescence signal was recorded with a Molecular Dynamics Storm instrument using the blue filter setting and quantitatively analyzed with the Molecular Dynamics ImageQuant image analysis software package. Specific activity of the library members was calculated from the ratio of the amount of isoprene produced divided by either the A600 of the induction cultures or the isoprene synthase protein concentration

determined by western blot. Figure 143B shows that isoprene synthase was present in the induced INVSc-1 strains harboring pDW14 (lanes 2 and 3) in comparison to the control harboring pYES-DEST52 (lane 1).

**[0905]** The DMAPP assay for isoprene synthase headspace was performed on 25  $\mu$ L of the lysate from each strain for which 5  $\mu$ L 1 M MgCl<sub>2</sub>, 5  $\mu$ L 100 mM DMAPP, and 65  $\mu$ L 50 mM Tris pH 8 were added. The reaction was performed at 30°C for 15 minutes in a gas tight 1.8 mL GC tube. Reactions were terminated by addition of 100  $\mu$ L 250 mM EDTA pH 8. Figure 144B showed the specific activity values (in  $\mu$ g HG/L/OD) of the induced strains harboring pDW14 in comparison to the control. Induced strains harboring pDW14 displayed approximately 20X higher activity than the control lacking isoprene synthase.

#### PCR Cycling Parameters

**[0906]** Illustra PuReTaq Ready-To-Go™ PCR Beads (GE Healthcare) were used with oligonucleotide primer pairs at a concentration of 0.4  $\mu$ M each in 25  $\mu$ l total volume/reaction. For analysis of plasmids resulting from the LR Clonase reaction (Invitrogen), a small amount of bacteria from individual colonies on a selective plate was added to each tube containing the PCR mix described above. The reaction cycle was as follows: 1) 95°C for 4 minutes; 2) 95°C for 20 seconds; 3) 52°C for 20 seconds; 4) 72°C for 30 seconds; 5 cycles of steps 2 through 4; 5) 95°C for 20 seconds; 6) 55°C for 20 seconds; 7) 72°C for 30 seconds; 25 cycles of steps 5 through 7, 72°C for 10 minutes, and 4°C until cool.

#### Example 21: Production of isoprene in *Pseudomonas* and other Gram negative bacteria Construction of pBBR5HGSOpt2\_2, conjugation in *Pseudomonas* and measurement of isoprene synthase activity

**[0907]** A gene encoding isoprene synthase from *Pueraria lobata* (Kudzu plant) was codon-optimized for different microbial species of interest (Table 14; fluo-opt2v2 was the sequence chosen) and was synthesized by DNA2.0, Menlo Park, CA. The map and sequence of fluo-opt2v2 can be found in Figures 145A and 145B (SEQ ID NO:40). HindIII and BamHI restriction sites were added to the synthesized sequence for easier cloning, and a RBS was added in front of the ATG to enhance transcription.

**[0908]** Number of rare codons, as a function of the microbial species, in different versions of codon-optimized isoprene synthase from *Pueraria lobata*. Several rounds of optimization led to a gene with no rare codons in the all the species of interest.

**Table 14. Number of rare codons.**

Organism	fluo-opt1 (quote)	fluo-opt2	fluo-opt3	E. coli opt	fluo-opt2v2
<i>Pseudomonas fluorescens</i> Pf-5	19	X	X	57	0
<i>Phodopsseudomonas palustris</i> CGA009	37	13	3	74	0
<i>Pseudomonas putida</i> F1	0	0	0	29	0
<i>Corynebacterium glutamicum</i> (ATCC)	4 (Ser)	0	0	0	0
<i>Pseudomonas fluorescens</i> PfO-1	1 (Val)	0	0	57	0

**[0909]** The gene was provided by DNA2.0 in a cloning vector. The vector was digested with HindIII/BamHI, the band corresponding to the insert of interest was gel-purified, and recombined with HindIII/BamHI-digested pBBR1MCS5 (Kovach et al, *Gene* 166:175-176, 1995, which is incorporated by reference in its entirety, particularly with respect to pBBR1MCS5), Figure 146A for map and Figures 146B and C for sequence (SEQ ID NO:41). This resulted in plasmid pBBR5HGSOpt2\_2 (Figure 147A for map and Figures 147B and C for sequence (SEQ ID NO:42)) in which isoprene synthase was expressed from the lac promoter presented in pBBR1MCS5.

**[0910]** The vector was transformed in *E. coli* S17-1 and mated with *Pseudomonas putida* F1 ATCC700007 and *Pseudomonas fluorescens* ATCC 13525. After conjugation on LB, selection for plasmid-harboring *Pseudomonas* strains was on M9 + 16 mM sodium citrate +Gentamicin 50 µg/ml. Presence of the plasmid in the strains thus generated was checked by plasmid preparation using the Qiagen kit (Valencia, CA).

**[0911]** Isoprene synthase activities of the recombinant strains *P. putida*, pBBR5HGSOpt2\_2 and *P. fluorescens*, pBBR5HGSOpt2\_2 were assayed by growing the strains in TM3 medium (as described in Example 1 Part II) + 10 g/L glucose, harvesting the biomass in mid-log phase, breaking the cells by French Press and proceeding with the DMAPP assay. Results of the assay were presented in Table 15. The presence of activity measured by the DMAPP assay confirmed that isoprene synthase was expressed in *Pseudomonas*.

**[0912]** Isoprene synthase activity was examined in *Pseudomonas putida* and *Pseudomonas fluorescens* expressing isoprene synthase from the lac promoter, using plasmid pBBR5HGSOpt2\_2

**Table 15. Isoprene synthase activity in *Pseudomonas putida* and *Pseudomonas fluorescens*.**

Strain	OD	Isoprene synthase activity mg isoprene/(L.h.OD)
<i>P. fluorescens</i> , pBBR5HGSOpt2_2	1.46	0.96
<i>P. putida</i> , pBBR5HGSOpt2_2	3.44	0.65
Control ( <i>P. putida</i> w/o plasmid)	8.32	To be determined

Example 22: Growth of *E. coli* and *Pseudomonas* strains on sugar cane compared to glucose, and expression of isoprene synthase using both substrates

#### I. Preparation of liquid sugar cane

**[0913]** Crystallized raw cane sugar was dissolved in water in the following way: 750 g H<sub>2</sub>O was added to 250 g sugar. The solution was stirred and gently heated until dissolution. Some material was not soluble. The weight of the solution was adjusted to 1 kg after dissolution to replenish the evaporated water. The volume of the solution was measured to be 940 mL. Hence the concentration of the solution was 265 g/L. The product label claimed 14 g of carbohydrate for 15 g of raw sugar cane. Hence the carbohydrate concentration of the solution was 248 g/L. Dry solids were measured to be 24.03 %, close enough of the expected 250 g/kg. pH of the solution was 5.49. Glucose concentration was measured using an enzymatic/spectrophotometric assay, with glucose oxidase. The glucose concentration was 17.4 g/L.

**[0914]** As a majority of microorganisms do not use sucrose, but can use glucose and fructose, the solution was split in two. One half was autoclaved once for 30 minutes (sugar cane as is). Some inversion resulted, as the glucose content increased to 29.75 g/L (See Figure 149). The other half of the solution was adjusted to pH 4.0 using phosphoric acid, then the solution was inverted by autoclaving (inverted sugar cane). Three cycles of 30 min were sufficient to obtain complete inversion, as shown on Figure 149. Both solutions were used for the growth curves described below.

#### II. Growth curves of different strains of *E. coli* and *Pseudomonas* on sugar cane compared to glucose

**[0915]** One colony of each of the strains presented in Table 16 was inoculated in 25 ml TM3 + 10 g/L glucose, and was grown overnight at 30°C and 200 rpm. TM3 is described in Example 7, Section II. The morning after, 1 ml of each culture was used to inoculate flasks containing 25

mL TM3 and 10 g/L glucose, 10 g/L sugar cane as is, or 10 g/L inverted sugar cane (sugar cane solutions described above). The flasks were incubated at 30°C and 200 rpm and samples were taken regularly to measure OD<sub>600</sub>. Figures 150 and 151 show that growth rate and biomass yield were comparable for glucose and inverted sugar cane, both for *Pseudomonas* and *E. coli* strains. *P. fluorescens* showed some signs of being able to use sugar cane which has not been inverted too.

**Table 16. Strains used in this study.**

	Strain
<i>Escherichia coli</i>	BL21
	MG1655
	ATCC11303
	B REL 606
<i>Pseudomonas</i>	<i>putida</i> F1 (ATCC700007)
	Fluorescens (ATCC13525)

III. Comparison of isoprene production from *E. coli* expressing isoprene synthase when grown on glucose or sugar cane

**[0916]** *E. coli* MCM401 (BL21(DE3)) containing the full MVA pathway, mevalonate kinase from *M. mazei* and isoprene synthase from *Pueraria lobata*, as described in Example 14, Section II was grown in TM3 + either 10 g/L glucose or 10 g/L inverted sugar cane (based on carbohydrate concentration of the syrup). Flasks were inoculated from an overnight culture on TM3 + 10 g/L glucose at an OD<sub>600</sub> = 0.2. Antibiotics were added where needed. After two hours, the *E. coli* cultures were induced with 400 µM IPTG. After 6 hours of growth, isoprene production and isoprene synthase activities, using the DMAPP assay as described in Example 2B, were measured. Results are presented in Table 17 and illustrate clearly that inverted sugar cane is equivalent to glucose in terms of isoprene and isoprene synthase production on a per cell basis.

**Table 17.**

Strain	Carbon Source	OD	Isoprene synthase activity mg isoprene/(L.h.OD)	Isoprene production mg isoprene/(L.h.OD)
MCM401	Glucose	2.20	21.06	8.98
MCM401	Sugar cane inverted	2.32	20.20	9.23

Example 23: Construction of *E. coli* strains expressing the *S. cerevisiae* gi1.2KKDyI operon, *P. alba* isoprene synthase, *M. mazei* mevalonate kinase, pCL Upper MVA (*E. faecalis* mvaE and mvaS) and ybhE (pgl)

**(i) Construction of strain EWL201 (BL21, Cm-GII.2-KKDyI)**

**[0917]** *E. coli* BL21 (Novagen brand, EMD Biosciences, Inc.) was a recipient strain, transduced with MCM331 P1 lysate (lysate prepared according to the method described in Ausubel, *et al.*, *Current Protocols in Molecular Biology*. John Wiley and Sons, Inc.). MCM331 cells contain chromosomal construct gi1.2KKDyI encoding *S. cerevisiae* mevalonate kinase, mevalonate phosphate kinase, mevalonate pyrophosphate decarboxylase, and IPP isomerase (*i.e.*, the gi1.2-KKDyI operon from *S. cerevisiae*). Transductants were selected for by spreading cells onto L Agar and 20 µg/µl chloramphenicol. The plates were incubated overnight at 30°C. Analysis of transductants showed no colonies on control plates (water + cells control plate for reversion and water and P1 lysate control plate for lysate contamination).

**[0918]** Four transductants were picked and used to inoculate 5 mL L Broth and 20 µg/µl chloramphenicol. The cultures were grown overnight at 30°C with shaking at 200 rpm. To make genomic DNA preps of each transductant for PCR analysis, 1.5mL of overnight cell culture were centrifuged. The cell pellet was resuspended with 400µl Resuspension Buffer (20mM Tris, 1mM EDTA, 50mM NaCl, pH 7.5) and 4µl RNase, DNase-free (Roche) was added. The tubes were incubated at 37°C for 30 minutes followed by the addition of 4µl 10% SDS and 4µl of 10mg/ml Proteinase K stock solution (Sigma-Aldrich). The tubes were incubated at 37°C for 1 hour. The cell lysate was transferred into 2 ml Phase Lock Light Gel tubes (Eppendorf) and 200µl each of saturated phenol pH7.9 (Ambion Inc.) and chloroform were added. The tubes were mixed well and microcentrifuged for 5 minutes. A second extraction was done with 400µl chloroform and the aqueous layer was transferred to a new eppendorf tube. The genomic DNA was precipitated by the addition of 1ml of 100% ethanol and centrifugation for 5 minutes. The genomic DNA pellet was washed with 1ml 70% ethanol. The ethanol was removed and the genomic DNA pellet was allowed to air dry briefly. The genomic DNA pellet was resuspended with 200µl TE.

**[0919]** Using Pfu Ultra II DNA polymerase (Stratagene) and 200ng/µl of genomic DNA as template, 2 different sets of PCR reaction tubes were prepared according to manufacturer's protocol. For set 1, primers MCM130 and GB Cm-Rev (Table 18) were used to ensure

transductants were successfully integrated into the attTn7 locus. PCR parameters for set 1 were 95°C for 2 minutes (first cycle only), 95°C for 25 seconds, 55°C for 25 seconds, 72°C for 25 seconds (repeat steps 2-4 for 28 cycles), 72°C for 1 minute. For set 2, primers MVD For and MVD Rev (Table 18) were used to ensure that the gi1.2-KKDyI operon integrated properly. PCR parameters for set 2 were 95°C for 2 minutes (first cycle only), 95°C for 25 seconds, 55°C for 25 seconds, 72°C for 10 seconds (repeat steps 2-4 for 28 cycles), 72°C for 1 minute. Analysis of PCR amplicons on a 1.2% E-gel (Invitrogen Corp.) showed that all 4 transductant clones were correct. One was picked and designated as strain EWL201.

(ii) Construction of Strain EWL204 (BL21, loopout-GI1.2-KKDyI)

**[0920]** The chloramphenicol marker was looped out of strain EWL201 using plasmid pCP20 as described by Datsenko and Wanner (2000) (Datsenko *et al.*, *Proc Natl. Acad. Sci USA* 97:6640-6645, 2000). One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. (Datsenko *et al.*, *PNAS*, 97: 6640-6645, 2000). EWL201 cells were grown in L Broth to midlog phase and then washed three times in ice-cold, sterile water. An aliquot of 50µl of cell suspension was mixed with 1µl of pCP20 and the cell suspension mixture was electroporated in a 2mm cuvette (Invitrogen Corp.) at 2.5 Volts and 25µF using a Gene Pulser Electroporator (Bio-Rad Inc.). 1ml of LB was immediately added to the cells, then transferred to a 14ml polypropylene tube (Sarstedt) with a metal cap. Cells were allowed to recover by growing for 1 hour at 30°C. Transformants were selected on L Agar and 20µg/µl chloramphenicol and 50µg/µl carbenicillin and incubated at 30°C overnight. The next day, a single clone was grown in 10ml L Broth and 50µg/µl carbenicillin at 30°C until early log phase. The temperature of the growing culture was then shifted to 42°C for 2 hours. Serial dilutions were made, the cells were then spread onto LA plates (no antibiotic selection), and incubated overnight at 30°C. The next day, 20 colonies were picked and patched onto L Agar (no antibiotics) and LA and 20µg/µl chloramphenicol plates. Plates were then incubated overnight at 30°C. Cells able to grow on LA plates, but not LA and 20µg/µl chloramphenicol plates, were deemed to have the chloramphenicol marker looped out (picked one and designated as strain EWL204).

(iii) Construction of plasmid pEWL230 (pTrc P. alba)

**[0921]** Generation of a synthetic gene encoding *Populus alba* isoprene synthase (*P. alba* HGS) was outsourced to DNA2.0 Inc. (Menlo Park, CA) based on their codon optimization method for *E. coli* expression. The synthetic gene was custom cloned into plasmid pET24a (Novagen brand, EMD Biosciences, Inc.) and delivered lyophilized (Figures 152, 153A-B; SEQ ID NO:43).

**[0922]** A PCR reaction was performed to amplify the *P. alba* isoprene synthase (*P. alba* HGS) gene using pET24 *P. alba* HGS as the template, primers MCM182 and MCM192, and Herculase II Fusion DNA polymerase (Stratagene) according to manufacturer's protocol. PCR conditions were as follows: 95°C for 2 minutes (first cycle only), 95°C for 25 seconds, 55°C for 20 seconds, 72°C for 1 minute, repeat for 25 cycles, with final extension at 72°C for 3 minutes. The *P. alba* isoprene synthase PCR product was purified using QIAquick PCR Purification Kit (Qiagen Inc.).

**[0923]** *P. alba* isoprene synthase PCR product was then digested in a 20µl reaction containing 1µl *Bsp*HI endonuclease (New England Biolabs) with 2µl 10X NEB Buffer 4. The reaction was incubated for 2 hours at 37°C. The digested PCR fragment was then purified using the QIAquick PCR Purification Kit. A secondary restriction digest was performed in a 20µl reaction containing 1µl *Pst*I endonuclease (Roche) with 2µl 10X Buffer H. The reaction was incubated for 2 hours at 37°C. The digested PCR fragment was then purified using the QIAquick PCR Purification Kit. Plasmid pTrcHis2B (Invitrogen Corp.) was digested in a 20µl reaction containing 1µl *Nco*I endonuclease (Roche), 1µl *Pst*I endonuclease, and 2µl 10X Buffer H. The reaction was incubated for 2 hours at 37°C. The digested pTrcHis2B vector was gel purified using a 1.2% E-gel (Invitrogen Corp.) and extracted using the QIAquick Gel Extraction Kit (Qiagen) (Figure 154). Using the compatible cohesive ends of *Bsp*HI and *Nco*I sites, a 20µl ligation reaction was prepared containing 5µl *P. alba* isoprene synthase insert, 2µl pTrc vector, 1µl T4 DNA ligase (New England Biolabs), 2µl 10X ligase buffer, and 10µl ddH<sub>2</sub>O. The ligation mixture was incubated at room temperature for 40 minutes. The ligation mixture was desalted by floating a 0.025µm nitrocellulose membrane filter (Millipore) in a petri dish of ddH<sub>2</sub>O and applying the ligation mixture gently on top of the nitrocellulose membrane filter for 30 minutes at room temperature. MCM446 cells (*see* Section II) were grown in LB to midlog phase and then washed three times in ice-cold, sterile water. An aliquot of 50µl of cell suspension was mixed with 5µl of desalted pTrc *P.alba* HGS ligation mix. The cell suspension mixture was electroporated in a 2mm cuvette at 2.5 Volts and 25µF using a Gene Pulser

Electroporator. 1ml of LB is immediately added to the cells, then transferred to a 14ml polypropylene tube (Sarstedt) with a metal cap. Cells were allowed to recover by growing for 2 hour at 30°C. Transformants were selected on L Agar and 50µg/µl carbenicillin and 10mM mevalonic acid and incubated at 30°C. The next day, 6 transformants were picked and grown in 5ml L Broth and 50µg/µl carbenicillin tubes overnight at 30°C. Plasmid preps were performed on the overnight cultures using QIAquick Spin Miniprep Kit (Qiagen). Due to the use of BL21 cells for propagating plasmids, a modification of washing the spin columns with PB Buffer 5X and PE Buffer 3X was incorporated to the standard manufacturer's protocol for achieving high quality plasmid DNA. Plasmids were digested with *Pst*I in a 20µl reaction to ensure the correct sized linear fragment. All 6 plasmids were the correct size and shipped to Quintara Biosciences (Berkeley, CA) for sequencing with primers MCM65, MCM66, EL1000 (Table 18). DNA sequencing results showed all 6 plasmids were correct. One plasmid was picked designated as plasmid EWL230 (Figures 155, 156A-B; SEQ ID NO:44).

iv) Construction of plasmid pEWL244 (pTrc *P. alba*-mMVK)

**[0924]** A PCR reaction was performed to amplify the *Methanosarcina mazei* (*M. mazei*) MVK gene using MCM376 as the template (see section (v) below), primers MCM165 and MCM177 (see Table 18), and Pfu Ultra II Fusion DNA polymerase (Stratagene) according to manufacturer's protocol. PCR conditions were as follows: 95°C for 2 minutes (first cycle only), 95°C for 25 seconds, 55°C for 25 seconds, 72°C for 18 seconds, repeat for 28 cycles, with final extension at 72°C for 1 minute. The *M. mazei* MVK PCR product was purified using QIAquick PCR Purification Kit (Qiagen Inc.).

**[0925]** The *M. mazei* MVK PCR product was then digested in a 40µl reaction containing 8µl PCR product, 2µl *Pme*I endonuclease (New England Biolabs), 4µl 10X NEB Buffer 4, 4µl 10X NEB BSA, and 22µl of ddH<sub>2</sub>O. The reaction was incubated for 3 hours at 37°C. The digested PCR fragment was then purified using the QIAquick PCR Purification Kit. A secondary restriction digest was performed in a 47µl reaction containing 2µl *Nsi*I endonuclease (Roche), 4.7µl 10X Buffer H, and 40µl of *Pme*I digested *M. mazei* MVK fragment. The reaction was incubated for 3 hours at 37°C. The digested PCR fragment was then gel purified using a 1.2% E-gel and extracted using the QIAquick Gel Extraction Kit. Plasmid EWL230 was digested in a 40µl reaction containing 10µl plasmid, 2µl *Pme*I endonuclease, 4µl 10X NEB Buffer 4, 4µl 10X NEB BSA, and 20µl of ddH<sub>2</sub>O. The reaction was incubated for 3 hours at 37°C. The

digested PCR fragment was then purified using the QIAquick PCR Purification Kit. A secondary restriction digest was performed in a 47 $\mu$ l reaction containing 2 $\mu$ l *Pst*I endonuclease, 4.7 $\mu$ l 10X Buffer H, and 40 $\mu$ l of *Pme*I digested EWL230 linear fragment. The reaction was incubated for 3 hours at 37°C. The digested PCR fragment was then gel purified using a 1.2% E-gel and extracted using the QIAquick Gel Extraction Kit (Figure 157). Using the compatible cohesive ends of *Nsi*I and *Pst*I sites, a 20 $\mu$ l ligation reaction was prepared containing 8 $\mu$ l *M. mazei* MVK insert, 3 $\mu$ l EWL230 plasmid, 1 $\mu$ l T4 DNA ligase, 2 $\mu$ l 10X ligase buffer, and 6 $\mu$ l ddH<sub>2</sub>O. The ligation mixture was incubated overnight at 16°C. The next day, the ligation mixture was desalted by floating a 0.025 $\mu$ m nitrocellulose membrane filter in a petri dish of ddH<sub>2</sub>O and applying the ligation mixture gently on top of the nitrocellulose membrane filter for 30 minutes at room temperature. MCM446 cells were grown in LB to midlog phase and then washed three times in ice-cold, sterile water. An aliquot of 50 $\mu$ l of cell suspension was mixed with 5 $\mu$ l of desalted pTrc *P.alba*-mMVK ligation mix. The cell suspension mixture was electroporated in a 2mm cuvette at 2.5 Volts and 25 $\mu$ Fd using a Gene Pulser Electroporator. 1ml of LB is immediately added to the cells, then the cells are transferred to a 14ml polypropylene tube with a metal cap. Cells were allowed to recover by growing for 2 hour at 30°C. Transformants were selected on LA and 50 $\mu$ g/ $\mu$ l carbenicillin and 5mM mevalonic acid plates and incubated at 30°C. The next day, 6 transformants were picked and grown in 5ml LB and 50 $\mu$ g/ $\mu$ l carbenicillin tubes overnight at 30°C. Plasmid preps were performed on the overnight cultures using QIAquick Spin Miniprep Kit. Due to the use of BL21 cells for propagating plasmids, a modification of washing the spin columns with PB Buffer 5X and PE Buffer 3X was incorporated to the standard manufacturer's protocol for achieving high quality plasmid DNA. Plasmids were digested with *Pst*I in a 20 $\mu$ l reaction to ensure the correct sized linear fragment. Three of the 6 plasmids were the correct size and shipped to Quintara Biosciences for sequencing with primers MCM65, MCM66, EL1000, EL1003, and EL1006 (Table 18). DNA sequencing results showed all 3 plasmids were correct. One was picked and designated as plasmid EWL244 (Figures 158 and 159A-B; SEQ ID NO:45).

v) Construction of plasmid MCM376 - MVK from *M. mazei* archaeal Lower in pET200D.

**[0926]** The MVK ORF from the *M. mazei* archaeal Lower Pathway operon (Figures 160A-C; SEQ ID NO:46) was PCR amplified using primers MCM161 and MCM162 (Table 18) using the Invitrogen Platinum HiFi PCR mix. 45  $\mu$ L of PCR mix was combined with 1  $\mu$ L template, 1  $\mu$ L

of each primer at 10  $\mu$ M, and 2  $\mu$ L water. The reaction was cycled as follows: 94 °C for 2:00 minutes; 30 cycles of 94 °C for 0:30 minutes, 55 °C for 0:30 minutes and 68 °C for 1:15 minutes; and then 72 °C for 7:00 minutes, and 4 °C until cool. 3  $\mu$ L of this PCR reaction was ligated to Invitrogen pET200D plasmid according to the manufacturer's protocol. 3  $\mu$ L of this ligation was introduced into Invitrogen TOP10 cells, and transformants were selected on LA/kan50. A plasmid from a transformant was isolated and the insert sequenced, resulting in MCM376 (Figures 161A-C).

vi) Construction of strain EWL251 (BL21(DE3), Cm-GI1.2-KKDyI, pTrc P.alba-mMVK)

**[0927]** MCM331 cells (which contain chromosomal construct gi1.2KKDyI encoding *S. cerevisiae* mevalonate kinase, mevalonate phosphate kinase, mevalonate pyrophosphate decarboxylase, and IPP isomerase) were grown in LB to midlog phase and then washed three times in ice-cold, sterile water. Mixed 50 $\mu$ l of cell suspension with 1 $\mu$ l of plasmid EWL244. The cell suspension mixture was electroporated in a 2mm cuvette at 2.5 Volts and 25 $\mu$ Fd using a Gene Pulser Electroporator. 1ml of LB is immediately added to the cells, and then the cells were transferred to a 14ml polypropylene tube with a metal cap. Cells were allowed to recover by growing for 2 hours at 30°C. Transformants were selected on LA and 50 $\mu$ g/ $\mu$ l carbenicillin and 5mM mevalonic acid plates and incubated at 37°C. One colony was selected and designated as strain EWL251.

vii) Construction of strain EWL256 (BL21(DE3), Cm-GI1.2-KKDyI, pTrc P.alba-mMVK, pCL Upper MVA)

**[0928]** EWL251 cells were grown in LB to midlog phase and then washed three times in ice-cold, sterile water. Mixed 50 $\mu$ l of cell suspension with 1 $\mu$ l of plasmid MCM82 (comprising pCL PtrcUpperPathway (also known as "pCL Upper MVA"), encoding *E. faecalis* mvaE and mvaS). Plasmid pCL Ptrc Upper Pathway was constructed as described in Example 8 above. The cell suspension mixture was electroporated in a 2mm cuvette at 2.5 Volts and 25  $\mu$ Fd using a Gene Pulser Electroporator. 1ml of LB was immediately added to the cells. Cells were then transferred to a 14ml polypropylene tube with a metal cap. Cells were allowed to recover by growing for 2 hours at 30°C. Transformants were selected on LA and 50 $\mu$ g/ $\mu$ l carbenicillin and 50 $\mu$ g/ $\mu$ l spectinomycin plates and incubated at 37°C. One colony was picked and designated as strain EWL256.

**Table 18: Primer Sequences**

Primer name	Primer sequence
MCM130	ACCAATTGCACCCGGCAGA (SEQ ID NO:127)
GB Cm Rev	GCTAAAGCGCATGCTCCAGAC (SEQ ID NO:128)
MVD For	GACTGGCCTCAGATGAAAGC (SEQ ID NO:129)
MVD Rev	CAAACATGTGGCATGGAAAG (SEQ ID NO:130)
MCM182	GGGCCCGTTTAAACTTTAACTAGACTCTGCAGTTAGCGTTCAAACGGCAGAA (SEQ ID NO:131)
MCM192	CGCATGCATGTCATGAGATGTAGCGTGTCCACCGAAAA (SEQ ID NO:132)
MCM65	ACAATTTACACAGGAAACAGC (SEQ ID NO:133)
MCM66	CCAGGCAAATTCTGTTTTATCAG (SEQ ID NO:106)
EL1000	GCACTGTCTTTCCGTCTGCTGC (SEQ ID NO:134)
MCM165	GCGAACGATGCATAAAGGAGGTAAAAAACATGGTATCCTGTTCTGCGCCGGGTAAGATTTACCTG (SEQ ID NO:122)
MCM177	GGGCCCGTTTAAACTTTAACTAGACTTTAATCTACTTTCAGACCTTGC (SEQ ID NO:123)
EL1003	GATAGTAACGGCTGCGCTGCTACC (SEQ ID NO:137)
EL1006	GACAGCTTATCATCGACTGCACG (SEQ ID NO:138)
MCM161	CACCATGGTATCCTGTTCTGCG (SEQ ID NO:120)
MCM162	TTAATCTACTTTCAGACCTTGC (SEQ ID NO:121)

viii) Construction of strain RM111608-2 (Cm-GI1.2-KKDyI, pTrc *P.alba*-mMVK, pCL Upper MVA, pBBRCMPGI1.5-pgl)

**[0929]** The BL21 strain of *E. coli* producing isoprene (EWL256) was constructed with constitutive expression of the *ybhE* gene (encoding *E. coli* 6-phosphogluconolactonase) on a replicating plasmid pBBR1MCS5(Gentamycin) (obtained from Dr. K. Peterson, Louisiana State University).

**[0930]** FRT-based recombination cassettes, and plasmids for Red/ET-mediated integration and antibiotic marker loopout were obtained from Gene Bridges GmbH (Germany). Procedures using these materials were carried out according to Gene Bridges protocols. Primers Pgl-F (SEQ ID NO:139) and PglGI1.5-R (SEQ ID NO:140) were used to amplify the resistance cassette

from the FRT-gb2-Cm-FRT template using Stratagene Herculase II Fusion kit according to the manufacturer's protocol. The PCR reaction (50  $\mu$ L final volume) contained: 5  $\mu$ L buffer, 1  $\mu$ L template DNA (FRT-gb2-Cm-F from Gene Bridges), 10 pmols of each primer, and 1.5  $\mu$ L 25mM dNTP mix, made to 50  $\mu$ L with dH<sub>2</sub>O. The reaction was cycled as follows: 1 x 2 minutes, 95°C then 30 cycles of (30 seconds at 95°C; 30 seconds at 63°C; 3 minutes at 72°C).

**[0931]** The resulting PCR product was purified using the QiaQuick PCR purification kit (Qiagen) and electroporated into electrocompetent MG1655 cells harboring the pRed-ET recombinase-containing plasmid as follows. Cells were prepared by growing in 5 mLs of L broth to and OD<sub>600</sub>~0.6 at 30°C. The cells were induced for recombinase expression by the addition of 4% arabinose and allowed to grow for 30 minutes at 30°C followed by 30 minutes of growth at 37°C. An aliquot of 1.5 mLs of the cells was washed 3-4 times in ice cold dH<sub>2</sub>O. The final cell pellet was resuspended in 40  $\mu$ L of ice cold dH<sub>2</sub>O and 2-5  $\mu$ L of the PCR product was added. The electroporation was carried out in 1-mm gap cuvettes, at 1.3 kV in a Gene Pulser Electroporator (Bio-Rad Inc.). Cells were recovered for 1-2 hours at 30°C and plated on L agar containing chloramphenicol (5  $\mu$ g/mL). Five transformants were analyzed by PCR and sequencing using primers flanking the integration site (2 primer sets: pgl and 49 rev and 3' EcoRV-pglstop; Bottom Pgb2 and Top GB's CMP (946)). A correct transformant was selected and this strain was designated MG1655 GI1.5-pgl::CMP.

**[0932]** The chromosomal DNA of MG1655 GI1.5-pgl::CMP was used as template to generate a PCR fragment containing the FRT-CMP-FRT-GI1.5 - ybhE construct. This construct was cloned into pBBR1MCS5(Gentamycin) as follows. The fragment, here on referred to as CMP-GI1.5-pgl, was amplified using the 5' primer Pglconfirm-F (SEQ ID NO:141) and 3' primer 3' EcoRV-pglstop (SEQ ID NO:142). The resulting fragment was cloned using the Invitrogen TOPO-Blunt cloning kit into the plasmid vector pCR-Blunt II-TOPO as suggested from the manufacturer. The *Nsi*I fragment harboring the CMP-GI1.5-pgl fragment was cloned into the *Pst*I site of pBBR1MCS5 (Gentamycin). A 20 $\mu$ l ligation reaction was prepared containing 5 $\mu$ l CMP-GI1.5-pgl insert, 2 $\mu$ l pBBR1MCS5 (Gentamycin) vector, 1 $\mu$ l T4 DNA ligase (New England Biolabs), 2 $\mu$ l 10X ligase buffer, and 10 $\mu$ l ddH<sub>2</sub>O. The ligation mixture was incubated at room temperature for 40 minutes then 2-4  $\mu$ L were electroporated into electrocompetent Top10 cells (Invitrogen) using the parameters disclosed above. Transformants were selected on L agar containing 10  $\mu$ g/ml chloramphenicol and 5  $\mu$ g/ml Gentamycin. The sequence of the selected clone was determined using a number of the primers described above as well as with the

in-house T3 and Reverse primers provided by Sequetech, CA. This plasmid was designated pBBRCMPGII.5-pgl (Figures 162, 163A-B and SEQ ID NO:48).

**[0933]** Plasmid pBBRCMPGII.5-pgl was electroporated into EWL256, as described herein and transformants were plated on L agar containing Chloramphenicol (10 µg/mL), Gentamycin (5 µg/mL), spectinomycin (50 µg/mL), and carbenicillin (50 µg/mL). One transformant was selected and designated strain RM111608-2.

Primers:

Pgl-F

5'-

ACCGCCAAAAGCGACTAATTTTAGCTGTTACAGTCAGTTGAATTAACCCTCACTAAA  
GGGCGGCCGC-3' (SEQ ID NO:139)

PglGII.5-R

5'-

GCTGGCGATATAAACTGTTTGCTTCATGAATGCTCCTTTGGGTTACCTCCGGGAAAC  
GCGGTTGATTTGTTTAGTGGTTGAATTATTTGCTCAGGATGTGGCATAGTCAAGGGC  
GTGACGGCTCGCTAATACGACTCACTATAGGGCTCGAG-3' (SEQ ID NO:140)

3' EcoRV-pglstop:

5'-CTT GAT ATC TTA GTG TGC GTT AAC CAC CAC (SEQ ID NO:142)

pgl +49 rev: CGTGAATTTGCTGGCTCTCAG (SEQ ID NO:136)

Bottom Pgb2: GGTTTAGTTCCTCACCTTGTC (SEQ ID NO:135)

Top GB's CMP (946): ACTGAAACGTTTTTCATCGCTC (SEQ ID NO:92)

Pglconfirm-F

5'-ACCGCCAAAAGCGACTAATTTTAGCT-3' (SEQ ID NO:141)

Example 24: Improvement of isoprene production by constitutive expression of *ybhE* (pgl) in *E. coli*.

**[0934]** This example shows production of isoprene in a strain constitutively expressing *E. coli ybhE* (pgl) compared to a control strain expressing *ybhE* at wild-type levels (*i.e.*, EWL256). The gene *ybhE* (pgl) encodes *E. coli* 6-phosphogluconolactonase that suppresses posttranslational gluconylation of heterologously expressed proteins and improves product solubility and yield

while also improving biomass yield and flux through the pentose phosphate pathway (Aon *et al.*, *Applied and Environmental Microbiology*, 74(4): 950-958, 2008).

i) Small scale analysis

**[0935]** Media Recipe (per liter fermentation media):  $K_2HPO_4$  13.6 g,  $KH_2PO_4$  13.6 g,  $MgSO_4 \cdot 7H_2O$  2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g,  $(NH_4)_2SO_4$  3.2 g, yeast extract 1 g, 1000X Trace Metals Solution 1 ml. All of the components were added together and dissolved in  $diH_2O$ . The pH was adjusted to 6.8 with ammonium hydroxide (30%) and brought to volume. Media was filter-sterilized with a 0.22 micron filter. Glucose 5.0 g and antibiotics were added after sterilization and pH adjustment.

**[0936]** 1000X Trace Metal Solution (per liter fermentation media): Citric Acid \*  $H_2O$  40g,  $MnSO_4 \cdot H_2O$  30g, NaCl 10g,  $FeSO_4 \cdot 7H_2O$  1g,  $CoCl_2 \cdot 6H_2O$  1g,  $ZnSO_4 \cdot 7H_2O$  1g,  $CuSO_4 \cdot 5H_2O$  100mg,  $H_3BO_3$  100mg,  $NaMoO_4 \cdot 2H_2O$  100mg. Each component is dissolved one at a time in  $diH_2O$ . The pH is adjusted to 3.0 with HCl/NaOH, and then the solution is brought to volume and filter-sterilized with a 0.22 micron filter.

(a) Experimental procedure

**[0937]** Isoprene production was analyzed by growing the strains in a Cellerator<sup>TM</sup> from MicroReactor Technologies, Inc. The working volume in each of the 24 wells was 4.5 mL. The temperature was maintained at 30°C, the pH setpoint was 7.0, the oxygen flow setpoint was 20 sccm and the agitation rate was 800 rpm. An inoculum of *E. coli* strain taken from a frozen vial was streaked onto an LB broth agar plate (with antibiotics) and incubated at 30°C. A single colony was inoculated into media with antibiotics and grown overnight. The bacteria were diluted into 4.5 mL of media with antibiotics to reach an optical density of 0.05 measured at 550 nm.

**[0938]** Off-gas analysis of isoprene was performed using a gas chromatograph-mass spectrometer (GC-MS) (Agilent) headspace assay. Sample preparation was as follows: 100  $\mu$ L of whole broth was placed in a sealed GC vial and incubated at 30°C for a fixed time of 30 minutes. Following a heat kill step, consisting of incubation at 70°C for 5 minutes, the sample was loaded on the GC.

**[0939]** Optical density (OD) at a wavelength of 550 nm was obtained using a microplate reader (Spectramax) during the course of the run. Specific productivity was obtained by dividing the isoprene concentration ( $\mu\text{g/L}$ ) by the OD reading and the time (hour).

**[0940]** The two strains EWL256 and RM11608-2 were assessed at 200 and 400  $\mu\text{M}$  IPTG induction levels. Samples were analyzed for isoprene production and cell growth (OD550) at 1, 2.5, 4.75, and 8 hours post-induction. Samples were done in duplicate.

#### (b) Results

**[0941]** The experiment demonstrated that at 2 different concentrations of IPTG the strain expressing the *ybhE* (*pgl*) had a dramatic 2-3 fold increase in specific productivity of isoprene compared to the control strain.

ii) Isoprene fermentation from *E. coli* expressing Cm-GI1.2-KKDyI, *M. mazei* mevalonate kinase, *P. alba* isoprene synthase, and *ybhE* (*pgl*) (RM11608-2) and grown in fed-batch culture at the 15-L scale

**[0942]** Medium Recipe (per liter fermentation medium):  $\text{K}_2\text{HPO}_4$  7.5 g,  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, yeast extract 0.5 g, 1000X Modified Trace Metal Solution 1 ml. All of the components were added together and dissolved in  $\text{dH}_2\text{O}$ . This solution was autoclaved. The pH was adjusted to 7.0 with ammonium hydroxide (30%) and q.s. to volume. Glucose 10 g, thiamine \* HCl 0.1 g, and antibiotics were added after sterilization and pH adjustment.

**[0943]** 1000X Modified trace Metal Solution: Citric Acids \*  $\text{H}_2\text{O}$  40 g,  $\text{MnSO}_4 \cdot \text{H}_2\text{O}$  30 g, NaCl 10 g,  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$  1 g,  $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$  1 g,  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$  1 g,  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$  100 mg,  $\text{H}_3\text{BO}_3$  100 mg,  $\text{NaMoO}_4 \cdot 2\text{H}_2\text{O}$  100 mg. Each component is dissolved one at a time in  $\text{D}_i$   $\text{H}_2\text{O}$ , pH to 3.0 with HCl/NaOH, then q.s. to volume and filter sterilized with a 0.22 micron filter

**[0944]** Fermentation was performed in a 15-L bioreactor with BL21 (DE3) *E. coli* cells containing the upper mevalonic acid (MVA) pathway (*pCL Upper*), the integrated lower MVA pathway (*gi1.2KKDyI*), high expression of mevalonate kinase from *M. mazei* and isoprene synthase from *P. alba* (*pTrcAlba-mMVK*), and high expression of *E. coli pgl* (*pBBR-pgl*). This experiment was carried out to monitor isoprene formation from glucose at the desired fermentation pH 7.0 and temperature 34°C. A frozen vial of the *E. coli* strain was thawed and

inoculated into tryptone-yeast extract medium. After the inoculum grew to OD 1.0, measured at 550 nm, 500 mL was used to inoculate a 15-L bioreactor bringing the initial volume to 5-L.

**[0945]** Glucose was fed at an exponential rate until cells reached the stationary phase. After this time the glucose feed was decreased to meet metabolic demands. The total amount of glucose delivered to the bioreactor during the 40 hour (59 hour) fermentation was 3.1 kg (4.2 kg at 59 hour). Induction was achieved by adding IPTG. The IPTG concentration was brought to 110  $\mu$ M when the optical density at 550 nm (OD<sub>550</sub>) reached a value of 4. The IPTG concentration was raised to 192  $\mu$ M when OD<sub>550</sub> reached 150. The OD<sub>550</sub> profile within the bioreactor over time is shown in Figure 164A. The isoprene level in the off gas from the bioreactor was determined using a Hiden mass spectrometer. The isoprene titer increased over the course of the fermentation to a maximum value of 33.2 g/L at 40 hours (48.6 g/L at 59 hours) (Figure 164B). The isoprene titer increased over the course of the fermentation to a maximum value of 40.0 g/L at 40 hours (60.5 g/L at 59 hours) (Figure 164C). The total amount of isoprene produced during the 40-hour (59-hour) fermentation was 281.3 g (451.0 g at 59 hours) and the time course of production is shown in Figure 164D. The time course of volumetric productivity is shown in Figure 164E and shows that an average rate of 1.0 g/L/hr was maintained between 0 and 40 hours (1.4 g/L/hour between 19 and 59 hour). The metabolic activity profile, as measured by CER, is shown in Figure 164F. The molar yield of utilized carbon that went into producing isoprene during fermentation was 19.6% at 40 hours (23.6% at 59 hours). The weight percent yield of isoprene from glucose was 8.9% at 40 hours (10.7% at 59 hours).

Example 25: Co-production of isoprene and hydrogen in *E. coli* strains expressing *M. mazei* mevalonate kinase, *P. alba* isoprene synthase, pCL Upper MVA (*E. faecalis* *mvaE* and *mvaS*) and *ybhE* (pgl)

#### **Collection and analysis of fermentation off-gas for hydrogen and isoprene levels**

**[0946]** Fermentations were performed using strains RM111608-2 (*E. coli* BL21 (DE3), pCL Upper MVA, cmR-gi1.2-yKKDyI, pTrcAlba-mMVK, pBBR cmR-gi1.5-pgl) and EWL 256 (*E. coli* BL21 (DE3), pCL Upper MVA, cmR-gi1.2-yKKDyI, pTrcAlba-mMVK). Construction of bacterial strains is described in Example 23 above.

**[0947]** Large scale production of isoprene from *E. coli* was determined from a fed-batch culture of *E. coli* strains EWL256 and RM111608-2 expressing *M. mazei* mevalonate kinase, *P. alba* isoprene synthase, pCL Upper MVA (*E. faecalis* *mvaE* and *mvaS*) and either constitutively expressing *ybhE* (pgl) (RM111608-2) or normally expressing *ybhE* (pgl) (EWL256). This

experiment demonstrates that growing cells in the presence of glucose resulted in the co-production of isoprene and hydrogen.

**[0948]** The recipe for the fermentation medium (TM2) per liter of TM2 fermentation medium was as follows:  $K_2HPO_4$  13.6 g,  $KH_2PO_4$  13.6 g,  $MgSO_4 \cdot 7H_2O$  2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g,  $(NH_4)_2SO_4$  3.2 g, yeast extract 5 g, 1000X Modified Trace Metal Solution 1 ml. 1000X Modified Trace Metal Solution: Citric Acids \*  $H_2O$  40 g,  $MnSO_4 \cdot H_2O$  30 g, NaCl 10 g,  $FeSO_4 \cdot 7H_2O$  1 g,  $CoCl_2 \cdot 6H_2O$  1 g,  $ZnSO_4 \cdot 7H_2O$  1 g,  $CuSO_4 \cdot 5H_2O$  100 mg,  $H_3BO_3$  100 mg,  $NaMoO_4 \cdot 2H_2O$  100 mg. For the 1000X Modified Trace Metal Solution, each component is dissolved one at a time in  $Di H_2O$ , pH to 3.0 with HCl/NaOH, then brought to final volume in distilled water and filter sterilized with a 0.22 micron ( $\mu m$ ) filter (this solution is not autoclaved). For the TM2 fermentation medium, all of the components were added together, dissolved in  $diH_2O$ , the pH was adjusted to 6.8 with potassium hydroxide (KOH), q.s. to volume, and the medium was filter sterilized with a 0.22 micron ( $\mu m$ ) filter. Glucose was sourced from Cargill as 99DE (dextrose equivalent), 71% DS (dry solids) syrup.

**[0949]** Fermentations were performed in 15-L bioreactors with *E. coli* strains EWL256 or RM111608-2, containing the upper mevalonic acid (MVA) pathway (pCL Upper MVA), the integrated lower MVA pathway (cmR-gil.2-yKKDyI), mevalonate kinase from *M. mazei* and isoprene synthase from *P. alba* (pTrcAlba-mMVK), and constitutively expressing *ybhE* (pgl) (RM111608-2) or normally expressing *ybhE* (pgl) (EWL256). This experiment was carried out to monitor isoprene formation from glucose at the desired fermentation conditions (pH 7.0 and temperature 34°C).

**[0950]** An inoculum of the appropriate *E. coli* strain taken from a frozen vial was prepared in peptone-yeast extract medium. After the inoculum grew to  $OD_{550} = 0.6$ , 600 mL was used to inoculate a 15-L bioreactor containing TM2 medium. Glucose was fed at an exponential rate until cells reached the stationary phase. After this time the glucose feed was decreased to meet metabolic demands. The total amount of glucose delivered to the bioreactor during the 67 hour fermentation was 3.9 kg. Induction was achieved by adding isopropyl-beta-D-1-thiogalactopyranoside (IPTG). The IPTG concentration was brought to 102  $\mu M$  when the optical density at 550 nm ( $OD_{550}$ ) reached a value of 9. The IPTG concentration was raised to 192  $\mu M$  when  $OD_{550}$  reached 140. At various times after inoculation, samples were removed and the amount of isoprene produced was determined as described below. Levels of hydrogen, nitrogen, oxygen, carbon dioxide, and isoprene in the off gas from the bioreactor were determined using a Hiden HPR-20 mass spectrometer as discussed below.

[0951] Samples of fermentation off-gas from 15-L bioreactors were collected into 20 mL glass headspace vials by sparging the vials at 1 L<sub>offgas</sub>/min for 10 seconds and sealed with metal screw caps fitted with teflon-coated septa (Agilent, CA). The vials were analyzed within 30 minutes of collection.

[0952] Analysis of the two samples was performed by infusion into a Hiden HPR-20 mass spectrometer (Hiden Analytics, U.K.) at a rate of 4 scc/min (4 mL/min) by placing the inlet tube of the mass spectrometer into the uncapped headspace vials for 1-2 minutes. The HPR-20 instrument was configured to scan masses corresponding to hydrogen ( $m/z$  2), nitrogen ( $m/z$  28), oxygen ( $m/z$  32), carbon dioxide ( $m/z$  44) and isoprene ( $m/z$  67). The Faraday detector was used for masses 28, 32, 44 and 67. The SEM detector was used for hydrogen ( $m/z$  2). Detector response was measured in arbitrary units of pressure (Torr). Absolute hydrogen levels were estimated by comparison to an authentic hydrogen gas standard. Results were recorded using MASsoft V 6.21.0.51 software (Hiden Analytics, United Kingdom).

## Results

[0953] Off-gas samples were taken from two fermentation runs and analyzed as described above:

[0954] A) Strain RM111608-2 (*E. coli* BL21 (DE3), pCL upper, cmR-gi1.2-yKKDyI, pTrcAlba-mMVK, pBBR cmR-gi1.5-pgl). Sample was taken at 64.8 hours into the run during which time the fermentation was being run anaerobically with a nitrogen sparge at 1 vvm.

[0955] B) Strain EWL256 (*E. coli* BL21 (DE3), pCL upper, cmR-gi1.2-yKKDyI, pTrcAlba-mMVK). Sample was taken at 34.5 hours into the run during which time the fermentation was being run aerobically with an air sparge at 1 vvm.

[0956] The results are depicted in Figures 165A-B. In both cases low levels of hydrogen were detected, in addition to isoprene, oxygen and carbon dioxide. The baseline reading for hydrogen was  $0.95 \times 10^{-8}$  Torr. Both Sample A and B gave reading of around  $1.3 \times 10^{-8}$  Torr. Based on a comparison to a hydrogen standard, the amount of hydrogen present in the off-gas for samples A and B was estimated to be less than 10 ppmv (parts per million volume) but above the baseline. As shown in Figures 165A-B, both samples A and B also contained significant amounts of isoprene and carbon dioxide.

Example 26: Co-production of isoprene and hydrogen in *E. coli* strains expressing *M. mazei* mevalonate kinase, *P. alba* isoprene synthase, pCL Upper MVA (*E. faecalis* mvaE and mvaS) and *ybhE* (pgl)

**Collection and analysis of fermentation off-gas for hydrogen and isoprene levels**

**[0957]** The objective of this experiment is co-produce hydrogen and isoprene in an engineered strain of *E. coli*. For this purpose, a portion of the *hyc* operon encoding *E. coli* hydrogenase-3 will be expressed in strain EWL256 [BL21 (DE3), pCL upper, cmR-gi1.2-yKKDyI, pTrcAlba-mMVK], prepared as described herein, although any of the bacterial strains described herein, such as RM111608-2, can be similarly modified. An expression construct comprising *hyc* operon genes *hycB* (gi|16130631), *hycC* (gi|16130630), *hycD* (gi|16130629), *hycE* (gi|16130628), *hycF* (gi|16130627), and *hycG* (gi|16130626) is prepared by standard cloning methods known in the art based upon publicly available gene sequences, and introduced into strain EWL256 to produce new strain EWL256+Hyd-3.

**[0958]** The impact of additional mutations on co-production of hydrogen and isoprene is assessed alone or in combination in EWL256+Hyd-3, by introducing genes involved in the maturation or regulation of hydrogenase-3 (e.g., *hycH* (gi|16130625) and *hycI* (gi|16130624)), by inactivating or deleting genes involved in hydrogen uptake or transport (e.g., *E. coli* hydrogenase-1 (*hya* operon) and hydrogenase-2 (*hyb* operon)) or related proteins (e.g., formate dehydrogenase (*fdhF* (gi|16130624)), repressor of formate lyase (*hycA* (gi|16130632)), formate dehydrogenase N, alpha subunit (*fdnG* (gi|16129433)), formate dehydrogenase O, large subunit (*fdoG* (gi|16131734)), nitrate reductase (*narG* (gi|16129187)), fumarate reductase regulator (*fnr* (gi|16129295)), and acetyl-coenzyme A synthetase (*acs* (gi|16131895))), by activating genes involved in upregulation of hydrogenases (e.g., activator of formate hydrogen lyase (*fhlA* (gi|16130638)), by inactivating or deleting genes involved in the production of fermentation side products (e.g., lactate dehydrogenase (*ldhA* (gi|16129341)), fumarate reductase membrane protein (*frdC* (gi|16131977)), alcohol dehydrogenase (*adhE* (gi|16129202)), pyruvate oxidase (*poxB* (gi|16128839)), pyruvate dehydrogenase E1 component *ackA/pta* (*aceE* (gi|16128107)), formate dehydrogenase regulatory protein (*hycA* (gi|16130632)), and formate transporters A and B (*FocA* (gi|16128871) and *FocB* (gi|16130417)), or by expression of heterologous genes involved in hydrogen metabolism (e.g., glyceraldehyde-3-phosphate dehydrogenase from *Clostridium acetobutylicum* (*gapC* (gi|15893997))).

**[0959]** Fermentations are performed using engineered variants of strain EWL 256+Hyd-3 (BL21 (DE3), pCL upper, cmR-gi1.2-yKKDyI, pTrcAlba-mMVK and *hycB-F*), modified to comprise one or more additional mutations as described herein, either alone or in combination, essentially as described in Example 25 above. Co-production of hydrogen and isoprene is

assessed by analysis of off-gas samples essentially as described above. Strains are selected for further analysis based upon the rate of isoprene and hydrogen co-production.

**[0960]** Unless defined otherwise, the meanings of all technical and scientific terms used herein are those commonly understood by one of skill in the art to which this invention belongs.

Singleton, *et al.*, Dictionary of Microbiology and Molecular Biology, 2nd ed., John Wiley and Sons, New York (1994), and Hale & Marham, The Harper Collins Dictionary of Biology, Harper Perennial, N.Y. (1991) provide one of skill with a general dictionary of many of the terms used in this invention. It is to be understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary. One of skill in the art will also appreciate that any methods and materials similar or equivalent to those described herein can also be used to practice or test the invention.

Example 27: Production of isoprene or mevalonate from fatty acid or palm oil in *E. coli fadR atoC* LS5218 containing the upper or upper and lower Mevalonic Acid pathway plus kudzu isoprene synthase.

**[0961]** *Escherichia coli fadR atoC* strain LS5218 (#6966) was obtained from the Coli Genetic Stock Center. FadR encodes a transcription repressor that negatively regulates expression of the genes encoding fatty acid degradation enzymes (Campbell *et al.*, *J. Bacteriol.* 183: 5982-5990, 2001). AtoC is a response regulator in a two-component regulatory system wherein AtoS regulates acetolactate metabolism. The *fadR atoC* strain allows constitutive expression of the fatty acid degradation genes and incorporates long chain fatty acids into long-chain-length polyhydroxyalkanoates. When palm oil is used as a carbon source for either mevalonate or isoprene production, the palm oil was converted to glycerol plus fatty acid. Methods for this are well known in the art, and it can be done either enzymatically by incubation with a lipase (for example Porcine pancreatic lipase, *Candida rugosa* lipase, or other similar lipases) or chemically by saponification with a base such as sodium hydroxide.

i) *E. coli fadR atoC* strain expressing the upper Mevalonic Acid pathway

**[0962]** Strain WW4 was created by electroporating pCLPtrcUpperPathway into LS5218 using standard methods (Sambrooke *et al.*, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., Cold Spring Harbor, 1989). Incorporation of the plasmid was demonstrated by the production of mevalonic acid (MVA) when cells were cultured in TM3 medium supplemented with either C12 fatty acid (FA) or palm oil as the carbon source. To demonstrate production of MVA by WW4

from fatty acid, cells from an overnight culture were diluted 1 to 100 into 5 mL of modified TM3 medium (TM3 without yeast extract) supplemented with 0.25% C12 FA (Sigma cat # L9755). The first sign of MVA production (24 mg/L) was apparent after overnight incubation at 30°C of the IPTG induced culture. Production increased over three days with the final level of 194 mg/L of MVA produced. To demonstrate production of MVA by WW4 from oil, cells from an overnight culture were diluted 1 to 100 into modified TM3 medium supplemented with 200 mg of digested palm oil per 5 mL of TM3 medium. The first sign of MVA production (50 mg/L) was apparent after overnight incubation of the IPTG induced culture at 30°C. Production increased over three days with a final level of 500 mg/L of MVA produced.

ii) *E. coli fadR atoC* strain expressing the upper and lower MVA pathway plus kudzu isoprene synthase

**[0963]** *Escherichia coli* strain WW4 (LS5218 *fadR atoC pCLPtrcUpperPathway*) was transformed with pMCM118 [pTrcKKDyIkIS] to yield WW10. The incorporation of the plasmid was demonstrated by evidence of production of isoprene when the strain was cultured in TM3 and glucose and induced with IPTG (100, 300, or 900  $\mu$ M). The strain was relatively sensitive to IPTG and showed a significant growth defect even at 100  $\mu$ M IPTG. These results are shown in Figure 70A.

**[0964]** To test isoprene production from dodecanoic acid, WW10 was cultured overnight in L broth containing spectinomycin (50  $\mu$ g/ml), and kanamycin (50  $\mu$ g/ml) at 37C with shaking at 200 rpm. The cells were washed with modified TM3 medium by centrifugation and resuspension in their original culture volume with this medium. The washed and resuspended cells from this starter culture were diluted 1 to 100 and 1 to 10 into 5 mL of modified TM3 medium containing 0.125% C12 Fatty Acid (Sigma cat # L9755).

**[0965]** To demonstrate production of mevalonate from palm oil, the oil was predigested with lipase at 37°C and 250 rpm for several days to release the fatty acids (evidence of hydrolysis was judged by the foam formed when tubes were shaken).

**[0966]** In addition, a culture was set up by diluting the washed cells at 1 to 10 into modified TM3 medium contained in test tubes with palm oil. A further tube was set up by the addition of 0.125% C12FA to the remainder (2.5 mL) of the washed cells without further dilution (bioconversion). After 3.75 hours of growth at 30°C with shaking at 250 rpm all of the cultures were induced by the addition of 50  $\mu$ M IPTG. Incubation was continued for 4 hours after which time 200  $\mu$ L of each of the cultures was assayed for isoprene accumulation with a modified head

space assay (1 hour accumulation at 30°C with shaking at 500 rpm). An additional isoprene assay was conducted by a 12 hour incubation of the assay glass block prior to GCMS analysis. Incubation of the induced cultures was continued overnight and 200 µL aliquots were again assayed for isoprene production (1 hour, 30 deg, 500 rpm Shel-Lab shaker) the following morning. Analysis of these cultures showed the production of significant levels of isoprene. The highest levels of isoprene were observed in the culture which was seeded at 1/10 dilution from the overnight starter culture after it had been incubated and induced overnight. This result suggests that this culture continued to grow and increase in cell density. These results are shown in Figure 70B. Cell density could not be measured directly because the fatty acid suspension had a turbid appearance. Cell density of this culture was therefore determined by plating an aliquot of the culture and showed  $8 \times 10^7$  colony forming units. This corresponds approximately to an OD<sub>600</sub> of 0.1. Nevertheless, this culture provided significant isoprene production; no isoprene is observed for similar strains without the pathway described in this example.

Example 28: Expression of isoprene-synthase from plant in *Streptomyces* sp.

**[0967]** The gene for isoprene synthase Kudzu was obtained from plasmid pJ201:19813. Plasmid pJ201:19813 encodes isoprene synthase from *Pueraria lobata* (Kudzu plant) and was codon-optimized for *Pseudomonas fluorescens*, *Pseudomonas putida*, *Rhodopseudomonas palustris* and *Corynebacterium* (Figures 79A-79C (SEQ ID NO:123)). Digestion of plasmid pJ201:19813 with restriction enzymes NdeI and BamHI liberated gene iso19813 that was ligated into the *Streptomyces-E.coli* shuttle vector pUWL201PW (Doumith *et al.*, *Mol. Gen. Genet.* 264: 477-485, 2000; Figure 71) to generate pUWL201\_iso. Successful cloning was verified by restriction analysis of pUWL201\_iso. Expression of isoprene synthase iso19813 was under control of the *erm*-promoter which allows for constitutive expression in *Streptomyces* species, but not for expression in *E. coli*.

**[0968]** pUWL201PW (no insert) and pUWL201\_iso were introduced in *Streptomyces albus* J1074 (Sanchez *et al.*, *Chem. Biol.* 9:519-531, 2002) by transformation of protoplasts as described by Hopwood *et al.*, *The John Innes Foundation, Norwich*, 1985.

**[0969]** A 200 µl aliquot of protoplast suspensions was transformed with 1.9 µg pUWL201PW or 2.9 µg pUWL201\_iso. After incubation overnight at 28°C on non-selective R5-agar plates, positive transformants were selected by further incubation for 4 days in R3-overlay agar containing thiostrepton (250 µg/ml). Thiostrepton resistant transformants were examined for presence of the pUWL-plasmids by plasmid preparation using Plasmid Mini Kit (Qiagen).

Prepared plasmid DNA was reintroduced in *E. coli* DH5 $\alpha$  to generate sufficient amounts of plasmid DNA to be analyzed by restriction analysis. Positive transformants were selected on ampicillin-containing L-agar plates and insert analysis was done by digestion of plasmid DNA with *Nde*I and *Bam*HI endonucleases. Isoprene synthase was identified as a 1.7 kb fragment in positive pUWL201 iso clones while in the control strains (pUWL201PW) no such fragment was observed.

**[0970]** Wild type strain and transformants of *S. albus* containing control plasmid pUWL201PW or isoprene synthase encoding pUWL201\_iso were analyzed for isoprene formation. Strains were cultivated in duplicate on solid media (tryptic soy broth agar, TSB; 2.5 ml) in presence or absence of thiostrepton (200  $\mu$ g/ml) and incubated for 4 days at 28°C in sealed head-space vials (total volume 20 ml). 500  $\mu$ l head-space samples (end point measurements) were analyzed by GC-MS in SIM-mode and isoprene was identified according to reference retention times and molecular masses (67 m/z). Isoprene present in head-space samples was quantified by previously generated calibration curves. While wild-type *S. albus* and control strains harboring pUWL201PW produced isoprene in concentrations slightly higher than the detection limit (0.04 – 0.07 ppm), *S. albus* harboring pUWL201\_iso produced isoprene in at least tenfold excess compared to controls (0.75 ppm; Figure 72). The results demonstrate successful expression of plant-derived isoprene synthase in a prokaryotic organism of the *Actinomycetes* group.

#### Example 29: Recovery of Bioisoprene™

**[0971]** Bioisoprene™ was recovered from a set of four 14-L scale fermentations in a two-step operation involving stripping of isoprene from the fermentation off-gas stream by adsorption to activated carbon, followed by off-line steam desorption and condensation to give liquid Bioisoprene™ (Figures 166A and 166B). The total amount of Bioisoprene™ produced by the four fermentors was 1150 g (16.9 mol), of which 953 g (14 mol, 83%) was adsorbed by the carbon filters. Following the steam desorption/condensation step, the amount of liquid Bioisoprene™ recovered was 810 g, corresponding to an overall recovery yield of 70%. The recovered Bioisoprene™ was analyzed for the presence of impurities.

#### Analysis and impurity profile of Bioisoprene™ liquid

[0972] Recovered Bioisoprene™ liquid was analyzed by GC/MS and gas chromatography/flame ionization detection (GC/FID) to determine the nature and levels of impurities. The product was determined to be >99.5% pure and contained several dominant impurities in addition to many minor components. The GC/FID chromatogram is depicted in Figure 167, and the typical levels of impurities are shown in Table 19. The impurity profile was similar to other Bioisoprene™ batches produced on this scale.

**Table 19.** Summary of the nature and levels of impurities seen in several batches of Bioisoprene™.

Compound	Retention Time (min)		Conc. Range
	GC/MS	GC/FID	
Ethanol	1.59	11.89	<50 ppm
Acetone	1.624	12.673	<100 ppm
Methacrolein	1.851	15.369	<200 ppm
Methyl vinyl ketone	1.923	16.333	<20 ppm
Ethyl acetate	2.037	17.145	100 to 800 ppm
3-Methyl-1,3-pentadiene	2.27	18.875	50 to 500 ppm
Methyl vinyl oxirane	2.548	19.931	<100 ppm
Isoprenol	2.962	21.583	<500 ppm
3-methyl-1-butanol	2.99	21.783	<50 ppm
3-hexen-1-ol	4.019	24.819	<100 ppm
Isopentenyl acetate	4.466	25.733	200 to 1000 ppm
3-hexen-1-yl acetate	5.339	27.223	<400 ppm
limonene	5.715	27.971	< 500 ppm
Other cyclics	5.50 – 6.50	27.5 – 28.0	<200 ppm

Purification of Bioisoprene™ by treatment with adsorbents

**[0973]** Adsorbents are widely used by industry for the removal of trace impurities from hydrocarbon feedstocks. Suitable adsorbents include zeolite, alumina and silica-based materials. Bioisoprene™ can be substantially purified by passage over silica gel, and to a lesser extent with alumina. Figure 168 shows the GC/FID chromatograms of a Bioisoprene™ sample before (A) and after treatment with alumina (B) or silica (C). The Scelxsorb™ adsorbent products from

BASF is one of the adsorbents of choice for the removal of polar impurities from Bioisoprene™. Specifically, the Selexsorb CD and CDX products are preferred given their proven utility for removal of polar impurities from isoprene and butadiene feedstocks.

Example 30: Chemical transformations of Bioisoprene™

**[0974]** Chemicals and solvents were used as received from Sigma Aldrich Corp (WI, USA). BioIsoprene™ was produced by fermentation of *E. coli* BL21 strains expressing Isoprene synthase and a heterologous mevalonic acid (MVA) isoprene precursor biosynthetic pathway. Bioisoprene was recovered from fermentation off-gas by adsorption to activated carbon, followed by steam desorption and condensation to obtain crude, liquid Bioisoprene. Bioisoprene was purified by fractional distillation immediately before use.

*<sup>1</sup>H NMR analysis*

**[0975]** Proton (<sup>1</sup>H) nuclear magnetic resonance (NMR) spectra were recorded on a Varian VNMRs 500 MHz NMR system. All NMR spectra are referenced to tetramethylsilane (TMS, 0 ppm) or chloroform (CHCl<sub>3</sub>, 7.26 ppm) and peak frequencies are recorded in ppm unless otherwise specified. Samples were run in either deuterated chloroform (CDCl<sub>3</sub>) or methanol (CD<sub>3</sub>OD).

*GC/MS analysis*

**[0976]** The analysis was performed using an Agilent 6890 GC/MS system interfaced with a CTC Analytics (Switzerland) CombiPAL autosampler operating in headspace mode. An Agilent HP-5MS GC/MS column (30 m x 0.25 mm; 0.25 μm film thickness) was used for separation of analytes. The autosampler was set up to inject 1 μL of a liquid sample from a 10 μL liquids syringe. The GC/MS method utilized helium as the carrier gas at a flow of 1 mL/minute. The injection port was held at 250° C with a split ratio of 100:1. The oven program began at 50° C for 2 minutes, increasing to 225° C at a rate of 25° C/min. followed by a 1 minute hold for a total run time of 10 minutes. The Agilent 5793N mass selective detector was run in scan mode from m/z 29 to 500. A solvent delay of 1.5 minutes was employed. Under these conditions isoprene (2-methyl-1,3-butadiene) was observed to elute at 0.675 minutes.

*GC/FID analysis*

[0977] The analysis was performed using an Agilent 6890 GC/FID system interfaced with a CTC Analytics (Switzerland) CombiPAL autosampler operating in liquids mode. An Agilent DB-Petro GC column (100 m x 0.25 mm; 0.50  $\mu$ m film thickness) was used for separation of analytes. The autosampler was set up to inject 1  $\mu$ L of a liquid sample from a 10  $\mu$ L liquids syringe. The GC/FID method utilized helium as the carrier gas at a flow of 1 mL/minute. The injection port was held at 200° C with a split ratio of 50:1. The oven program began at 50° C for 15 minutes, increasing to 250° C at a rate of 25° C/min. followed by a 10 minute hold for a total run time of 33 minutes. The FID detector was held at 280° C in Constant makeup mode with a hydrogen flow of 35 mL/min and air flow of 250 mL/min. Under these conditions isoprene (2-methyl-1,3-butadiene) was observed to elute at 13.54 minutes.

#### I. Preparation of cyclic dimers of isoprene through thermal Diels-Alder cycloaddition

[0978] Isoprene (1.02 g, 0.015 mole) was heated at 150° C for 24 hours in the presence of 2,6-di-tert-butyl-4-methylphenol (0.165 g, 0.05 mole) acting as an inhibitor of thermal polymerization. The reaction was carried out in a sealed thick-walled glass reaction vessel that was dried in the vacuum oven for 24 hours prior to the reaction. The reaction mixture was stirred with a magnetic stirrer. The progress of the reaction was monitored by gas chromatography with mass-spectrometer detector (GC-MS). After the reaction was finished, the resulting mixture of isomers was purified using silica gel chromatography with hexane as the eluent. Following concentration on a rotary vacuum evaporator the product was characterized by GC-MS and <sup>1</sup>H-NMR. GC-MS: product A: 5.17, 5.19 min; product B: 5.72, 5.74 min; product C: 6.11 min. <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 5.8 (m); 5.4 (m); 4.95 (m); 2.4-1.2 (m).

#### II. Preparation of isoprene oligomers through Pd-catalyzed oligomerization

[0979] Isoprene (2.03 g, 0.03 mole) was mixed with isopropanol (1.79 g, 0.03 mole) in a sealed thick-walled glass reaction vessel. Prior to the reaction the glass chamber was dried in a vacuum oven for 24 hours. Transfer of all reagents was done under inert nitrogen atmosphere. Palladium acetylacetonate (0.55 mg, 0.06 mmole) and triphenylphosphine (1.49 mg, 0.19 mmol) were added to the reaction mixture. The reaction chamber was then heated to 100° C for 24 hours with mixing provided via magnetic stirrer. The course of the reaction was analyzed by GC-MS. Once the reaction was finished the products were isolated by silica gel column chromatography using hexane as the eluent. The final products were characterized by GC-MS and <sup>1</sup>H-NMR spectroscopy. GC-MS: product A: 5.54 min; product B: 6.6 min; product C: 6.85 min.


### III. Hydrogenation of unsaturated compounds

**[0980]** The mixture of isomers obtained in Example 2 (1.36 g, 0.01 mole) is put in a glass chamber equipped with magnetic stirrer and containing a hydrogenation catalyst (Pd/C, 5 wt%) (0.21 g, 0.1 mmol). All glassware is vacuum dried prior to carrying out the experiments. Hydrogen gas is introduced into the system and the pressure is kept at 3 atm. After several hours the reaction mixture Pd/C is filtered from the reaction mixture and the products are separated using silica gel chromatography. Final analysis is done using GC-MS and NMR.

### IV. Preparation of ethoxylated derivatives of isoprene

**[0981]** Isoprene (0.982 g, 0.014 mole) was mixed with absolute ethanol (0.665 g, 0.014 mol) in a thick glass wall chamber equipped with magnetic stirrer. A catalytic amount of concentrated sulfuric acid was added to the reaction mixture, followed by stirring overnight at 85°C. The progress of the reaction was monitored by GC-MS. After 16 hours of heating the GC-MS trace revealed the presence of a mixture of isomers with following retention times: product A: 2.66 min  $m/z^+ = 99$ ; product B: 3.88  $m/z^+ = 99, 114$ ; product C: 5.41min,  $m/z^+ = 87, 99, 114$ .


### V. Conversion of isoprene to C10 cyclic dimers using a ruthenium catalyst



**[0982]** The conversion of isoprene into C10 cyclic dimers has been achieved in excellent yield using a ruthenium catalyst to a mixture of dimethyl-cyclooctadienes (Itoh, Kenji; Masuda, Katsuyuki; Fukahori, Takahiko; Nakano, Katsumasa; Aoki, Katsuyuki; Nagashima, Hideo, *Organometallics* (1994), 13(3), 1020-9.) Conversions higher than 95% are reported at very moderate temperatures (as low as 60°C). The catalyst, a pentamethylcyclopentadienyl-based ruthenium organometallic compound, can be prepared in two easy steps using ruthenium chloride ( $\text{RuCl}_3$ ) and pentamethylcyclopentadiene ( $\text{C}_5\text{Me}_5\text{H}$ ) as starting materials. For the

dimerization reaction the catalyst is activated with silver triflate (AgOTf) to produce the active species, but other activators could be used as well.

#### VI. Conversion of isoprene to C15 trimers using a chromium catalyst



**[0983]** Conversion of isoprene into the C15 trimers can be carried out using a chromium catalyst with a P-N-P ligand, *N,N*-bis(diarylphosphino)amine. The catalyst is prepared *in situ* and it is activated using MAO, as described in Bowen, L.; Charemsuk, M.; Wass, D.F. *Chem. Commun.* (2007) 2835-2837. The reported conversion of isoprene into the C15 trimers, consisting in a mixture (3:1) of linear and cyclic products, is as high as 95% at moderate temperatures (70°C). Tetramers are identified as the major other product in every case.

#### VII. Hydrogenation of isoprene

**[0984]** Isoprene (10 mL of a 10% solution in absolute ethanol (v/v)) was hydrogenated to 2-methylbutane (isopentane) in a continuous manner using an H-cube hydrogenation instrument (ThalesNano, Princeton, NJ, U.S.A.). The isoprene solution was pumped at 0.5 mL/min through a 10% Pd/C catalyst cartridge held at 70°C. Hydrogen gas was introduced using “full mode” at 1 atm pressure. The product was collected and analyzed by  $^1\text{H}$  NMR and GC/FID which confirmed the conversion of isoprene to 2-methylbutane in over 90% yield, in addition to minor amounts of partially hydrogenated mono-olefins.  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.8 (m, 9H,  $\text{CH}_3$ ); 1.12 (m, 2H,  $\text{CH}_2$ ); 1.37 (m, 1H,  $\text{CH}$ ). GC/FID: 2-methylbutane; retention time = 12.69 minutes.

#### VIII. Partial hydrogenation of isoprene

[0985] BioIsoprene™ product (50 mL, 0.5 mol) was mixed with toluene (200 mL) and partially hydrogenated over a 5% Pd/C catalyst on an Midi-Cube hydrogenation instrument (ThalesNano, Budapest, Hungary) at 40°C and 5 bar hydrogen pressure. Substrate flow rate was 10 mL/min and hydrogen was delivered at 125 mL/min (5 mmol/min). The product stream was recycled through the instrument for a period of 2 hours after which time an aliquot of the product was analyzed by GC/MS and GC/FID which showed that the majority of the starting material had been converted to a mixture of isoamylenes (2-methyl-1-butene, 2-methyl-2-butene and 3-methyl-1-butene), in addition to isopentane and some unreacted isoprene (Figure 170).

#### IX. Selective hydrogenation of BioIsoprene™ product

[0986] BioIsoprene™ product is selectively hydrogenated under the conditions cited in the above example using an eggshell Pd/d-Al<sub>2</sub>O<sub>3</sub> catalyst giving a mixture of isoamylenes where 2-methyl-2-butene is the dominant product accounting for >50% of the total isoamylenes and 3-methyl-1-butene is the minor product accounting for <25% of the total isoamylenes products as determined by GC/MS analysis. The amount of isopentane and residual isoprene account for <10% of the total product stream. A similar result is obtained when a sulfided palladium on carbon catalyst is used to perform the reaction.

#### X. Partial hydrogenation of BioIsoprene™ product in the gas phase

[0987] A dry gas stream containing BioIsoprene™ product is mixed with a slight excess of hydrogen gas (mol/mol) and the gaseous mixture passed over a heterogenous hydrogenation catalyst, such as a Group IB-promoted palladium catalyst with high pore volume as described in US Pat. Appl. 20090203520, to produce a mixture of isoamylenes and one or more impurities derived from the fermentation process from which the BioIsoprene™ product was originally derived. The conversion is carried out at pressures ranging from 0.5 to 200 bar, and temperatures from 0°C to 200°C.


#### XI. Dimerization of Isoamylenes with a solid acid catalyst

[0988] 2-Methyl-2-butene (1.5 mL) and toluene (4 mL) were stirred at room temperature with Amberlyst 15 acid resin (186 mg) for 12 h at room temperature. An aliquot (500 uL) was removed from the reaction mixture and transferred to a GC vial. Analysis of the mixture was

performed by GC/MS (Figure 171) and revealed the partial conversion to C10 dimers (diisoamylenes) suitable as BioIsofuel™ components.

[0989] The products of the dimerization reaction (diisoamylenes, C10 dimate) are optionally fully hydrogenated under conditions described in Example 30, part VII, or through conditions known in the art for the hydrogenation of olefins to isoparaffins [for example, see Marichonna (2001)].

## XII. Oligomerization of BioIsofuel™ product with a solid acid catalyst



[0990] A mixture of BioIsofuel™ monomer, 2-methyl-2-butene (1.5 mL) and toluene (4 mL) was stirred at room temperature with Amberlyst 15 acid resin (186 mg) for 12 h at room temperature. An aliquot (500 uL) was removed from the reaction mixture and transferred to a GC vial. Analysis of the mixture was performed by GC/MS (Figure 172) and revealed a complex mixture of products consisting of isoprene, linear, cyclic and aromatic C10, C15 and higher oligomers.

## XIII. Continuous oligomerization of BioIsofuel™ product with a solid acid catalyst

[0991] BioIsofuel™ monomer is continuously converted into C10 dimers and C15 trimers in a dimerization reactor containing Amberlyst 15 ion exchange resin or an equivalent catalyst. The BioIsofuel™ feed stream comprises BioIsofuel™ monomer and optionally C5 derivatives of BioIsofuel™ and a co-solvent. The process is conducted at temperatures ranging from 20 to 200°C and pressures from 0.5 to 200 bar. The products of the dimerization step are fractionated in a first fractionation column to separate unreacted isoprene from higher (>C5) oligomers. The C5 fraction is returned to the dimerization reactor and the heavy >C5 fraction is introduced into a second fractionation column in which the desired C10/C15 fraction is collected from the overhead stream. The bottom fraction consisting of >C15 oligomers is fed into a heavy recycle reactor containing a metathesis catalyst such as the Grubbs 2<sup>nd</sup> generation catalyst. The metathesis catalyst converts a portion of the higher oligomer fraction into lighter

components by olefin cross-metathesis reactions that are subsequently fed into fractionation column #1 as depicted in Figure 173.

**[0992]** Overall, the process results in conversion of BioIsoprene monomer into C10 dimer and C15 trimer BioIsofuel™ precursors which are then subjected to partial or complete hydrogenation under conditions described in example 30, section VII. The resulting partially or fully saturated compounds are suitable as BioIsofuel™ compositions and as BioIsofuel™ blendstocks.

Example 31  $^{13}\text{C}/^{12}\text{C}$  isotope analysis

**[0993]**  $^{13}\text{C}$  analysis can be done by loading 0.5 to 1.0 mg samples into tin cups for carbon isotopic analysis using a Costech ECS4010 Elemental Analyzer as an inlet for a ThermoFinnigan Delta Plus XP isotope ratio mass spectrometer. Samples are dropped into a cobaltous/cobaltic oxide combustion reactor at 1020°C with combustion gases being passed in a helium stream at 85mL/min through a copper reactor (650°C) to convert  $\text{NO}_x$  to  $\text{N}_2$ .  $\text{CO}_2$  and  $\text{N}_2$  are separated using a 3-m 5Å molecular sieve column. Then,  $^{13}\text{C}/^{12}\text{C}$  ratios are calibrated to the VPDB scale using two laboratory standards (Acetanilide B,  $-29.52 \pm 0.02\text{‰}$  and cornstarch A,  $-11.01 \pm 0.02\text{‰}$ ) which have been carefully calibrated to the VPDB scale by off-line combustion and dual-inlet analysis using the 2-standard approach of T. B. Coplen et al, New Guidelines for  $\text{d}^{13}\text{C}$  Measurements, Anal. Chem., 78, 2439-2441 (2006). The teachings of Coplen are incorporated herein by reference for the purpose of teaching the technique for determining  $\text{d}^{13}\text{C}$  values.

**[0994]** U.S. Provisional Patent Application No. 61/133,521 filed on June 30, 2008 and WO 2010/05525 A1 list  $\delta^{13}\text{C}$  values for feedstock and polymers of isoprene derived from various sources, including ones listed in Table 20.





**Table 20**

Sample	$\delta^{13}\text{C}$
Palm oil	-30.00
Yeast extract	-25.70
Commercial polyisoprene from extractive distillation	-23.83
Sugar from softwood pulp	-23.00
Polyisoprene from Isoprene Sample B (emulsion polymerization)	-19.67
Invert Sugar	-15.37
Polyisoprene from Isoprene Sample A (Neodymium catalyst)	-14.85
Glucose from bagasse	-13.00
Glucose from corn stover	-11.20
Cornstarch	-11.10
Glucose	-10.73

Example 32 – Exemplary Fuel Properties

[0995] Table 21 lists fuel properties of certain compounds that can be made from isoprene using methods described herein.

Table 21

	Formula	MW (g/mol)	Boiling point (°C)	Density (g/cm <sup>3</sup> )	Vapor pressure (Torr, 25°C)*	ΔHc (kcal/mol)	Lower Heating Value (kBTU/gal)	Higher Heating Value (kBTU/gal)	Octane (Cetane)
a-Limonene		136.23	177	0.8477	1.54	1474	130.6	137.9	88
1-Methyl-4-isopropylcyclohexane		140.27	170.2	0.8060	2.16	1561	126.5	134.9	75
2,7-dimethyl-(4E)-2,4,6-Octatriene		136.23	186.4*	0.782	0.915	1481	121.1	127.8	110
2,7-dimethyloctane		142.28	160	0.728	3.35	1620	116.5	124.7	97
3,7-dimethyl-1,5-cyclooctadiene		136.23	182.7*	0.860	1.09	1490	134.0	141.4	95
1,5-Dimethylcyclooctene (BIF-10)		138.25	178.5*	0.830	1.33	1545	131.6	139.4	90
1,5-Dimethylcyclooctane		140.27	158.5	0.800	1.39	1560	125.4	133.8	85
2,6,11-Trimethyldodecane		212.41	247.8*	0.766	0.0396	2400	121.7	130.1	(65)
Cyclododecane, 1,4,8-trimethyl		210.40	278.0*	0.850	7.38E-3	2380	135.7	144.6	(40)
BIF-15	3:1 mixture of linear and cyclic C15	211.9	255.4	0.787	0.0315	2395	125.2	133.7	(58.8)

[0996] The headings provided herein are not limitations of the various aspects or embodiments of the invention which can be had by reference to the specification as a whole.

[0997] All publications, patent applications, and patents cited in this specification are herein incorporated by reference as if each individual publication, patent application, or patent were specifically and individually indicated to be incorporated by reference. In particular, all publications cited herein are expressly incorporated herein by reference for the purpose of describing and disclosing compositions and methodologies which might be used in connection with the invention. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

[0998] Where the terms “comprise”, “comprises”, “comprised” or “comprising” are used in this specification, they are to be interpreted as specifying the presence of the stated features, integers, steps or components referred to, but not to preclude the presence or addition of one or more other feature, integer, step, component or group thereof.

[0999] Further, any prior art citation or statement provided in the specification is not to be taken as an admission that such art constitutes, or is to be understood as constituting, part of the common general knowledge in Australia.

## Appendix 1

### **Exemplary 1-deoxy-D-xylulose-5-phosphate synthase nucleic acids and polypeptides**

ATH: AT3G21500(DXPS1) AT4G15560(CLA1)  
 AT5G11380(DXPS3)  
 OSA: 4338768 4340090 4342614  
 CME: CMF089C  
 PFA: MAL13P1.186  
 TAN: TA20470  
 TPV: TP01\_0516  
 ECO: b0420(dxS)  
 ECJ: JW0410(dxS)  
 ECE: Z0523(dxS)  
 ECS: ECs0474  
 ECC: c0531(dxS)  
 ECI: UT189\_C0443(dxS)  
 ECP: ECP\_0479  
 ECV: APECO1\_1590(dxS)  
 ECW: EcE24377A\_0451(dxS)  
 ECX: EcHS\_A0491  
 STY: STY0461(dxS)  
 STT: t2441(dxS)  
 SPT: SPA2301(dxS)  
 SEC: SC0463(dxS)  
 STM: STM0422(dxS)  
 YPE: YPO3177(dxS)  
 YPK: y1008(dxS)  
 YPM: YP\_0754(dxS)  
 YPA: YPA\_2671  
 YPN: YPN\_0911  
 YPP: YPDSF\_2812  
 YPS: YPTB0939(dxS)  
 YPI: YpsIP31758\_3112(dxS)  
 SFL: SF0357(dxS)  
 SFX: S0365(dxS)  
 SFV: SFV\_0385(dxS)  
 SSN: SSON\_0397(dxS)  
 SBO: SBO\_0314(dxS)  
 SDY: SDY\_0310(dxS)  
 ECA: ECA1131(dxS)  
 PLU: plu3887(dxS)  
 BUC: BU464(dxS)  
 BAS: BUsg448(dxS)  
 WBR: WGLp144(dxS)  
 SGL: SG0656  
 KPN: KPN\_00372(dxS)  
 BFL: Bfl238(dxS)  
 BPN: BPEN\_244(dxS)  
 HIN: HI1439(dxS)  
 HIT: NTHI1691(dxS)  
 HIP: CGSHiEE\_04795  
 HIQ: CGSHiGG\_01080  
 HDU: HD0441(dxS)  
 HSO: HS\_0905(dxS)

PMU: PM0532(dxS)  
 MSU: MS1059(dxS)  
 APL: APL\_0207(dxS)  
 XFA: XF2249  
 XFT: PD1293(dxS)  
 XCC: XCC2434(dxS)  
 XCB: XC\_1678  
 XCV: XCV2764(dxS)  
 XAC: XAC2565(dxS)  
 XOO: XOO2017(dxS)  
 XOM: XOO\_1900(XOO1900)  
 VCH: VC0889  
 VVU: VV1\_0315  
 VVY: VV0868  
 VPA: VP0686  
 VFI: VF0711  
 PPR: PBPRA0805  
 PAE: PA4044(dxS)  
 PAU: PA14\_11550(dxS)  
 PAP: PSPA7\_1057(dxS)  
 PPU: PP\_0527(dxS)  
 PST: PSPTO\_0698(dxS)  
 PSB: Psyr\_0604  
 PSP: PSPPH\_0599(dxS)  
 PFL: PFL\_5510(dxS)  
 PFO: Pfl\_5007  
 PEN: PSEEN0600(dxS)  
 PMY: Pmen\_3844  
 PAR: Psyc\_0221(dxS)  
 PCR: Pcryo\_0245  
 ACI: ACIAD3247(dxS)  
 SON: SO\_1525(dxS)  
 SDN: Sden\_2571  
 SFR: Sfri\_2790  
 SAZ: Sama\_2436  
 SBL: Sbal\_1357  
 SLO: Shew\_2771  
 SHE: Shewmr4\_2731  
 SHM: Shewmr7\_2804  
 SHN: Shewana3\_2901  
 SHW: Sputw3181\_2831  
 ILO: IL2138(dxS)  
 CPS: CPS\_1088(dxS)  
 PHA: PSHAA2366(dxS)  
 PAT: Patl\_1319  
 SDE: Sde\_3381  
 PIN: Ping\_2240  
 MAQ: Maqu\_2438  
 MCA: MCA0817(dxS)  
 FTU: FTT1018c(dxS)  
 FTF: FTF1018c(dxS)

FTW: FTW\_0925(dxS)  
FTL: FTL\_1072  
FTH: FTH\_1047(dxS)  
FTA: FTA\_1131(dxS)  
FTN: FTN\_0896(dxS)  
NOC: Noc\_1743  
AEH: Mlg\_1381  
HCH: HCH\_05866(dxS)  
CSA: Csal\_0099  
ABO: ABO\_2166(dxS)  
AHA: AHA\_3321(dxS)  
BCI: BCI\_0275(dxS)  
RMA: Rmag\_0386  
VOK: COSY\_0360(dxS)  
NME: NMB1867  
NMA: NMA0589(dxS)  
NMC: NMC0352(dxS)  
NGO: NGO0036  
CVI: CV\_2692(dxS)  
RSO: RSc2221(dxS)  
REU: Reut\_A0882  
REH: H16\_A2732(dxS)  
RME: Rmet\_2615  
BMA: BMAA0330(dxS)  
BMV: BMASAVP1\_1512(dxS)  
BML: BMA10299\_1706(dxS)  
BMN: BMA10247\_A0364(dxS)  
BXE: Bxe\_B2827  
BUR: Bcep18194\_B2211  
BCN: Bcen\_4486  
BCH: Bcen2424\_3879  
BAM: Bamb\_3250  
BPS: BPSS1762(dxS)  
BPM: BURPS1710b\_A0842(dxS)  
BPL: BURPS1106A\_A2392(dxS)  
BPD: BURPS668\_A2534(dxS)  
BTE: BTH\_H0614(dxS)  
BPE: BP2798(dxS)  
BPA: BPP2464(dxS)  
BBR: BB1912(dxS)  
RFR: Rfer\_2875  
POL: Bpro\_1747  
PNA: Pnap\_1501  
AJS: Ajs\_1038  
MPT: Mpc\_A2631  
HAR: HEAR0279(dxS)  
MMS: mma\_0331  
NEU: NE1161(dxS)  
NET: Neut\_1501  
NMU: Nmul\_A0236  
EBA: cbA4439(dxS)

AZO: azo1198(dxS)  
DAR: Daro\_3061  
TBD: Tbd\_0879  
MFA: Mfla\_2133  
HPY: HP0354(dxS)  
HPJ: jhp0328(dxS)  
HPA: HPAG1\_0349  
HHE: HH0608(dxS)  
HAC: Hac\_0968(dxS)  
WSU: WS1996  
TDN: Tmden\_0475  
CJE: Cj0321(dxS)  
CJR: CJE0366(dxS)  
CJJ: CJJ81176\_0343(dxS)  
CJU: C8J\_0298(dxS)  
CJD: JJD26997\_1642(dxS)  
CFF: CFF8240\_0264(dxS)  
CCV: CCV52592\_1671(dxS) CCV52592\_1722  
CHA: CHAB381\_1297(dxS)  
CCO: CCC13826\_1594(dxS)  
ABU: Abu\_2139(dxS)  
NIS: NIS\_0391(dxS)  
SUN: SUN\_2055(dxS)  
GSU: GSU0686(dxS-1) GSU1764(dxS-2)  
GME: Gmet\_1934 Gmet\_2822  
PCA: Pcar\_1667  
PPD: Ppro\_1191 Ppro\_2403  
DVU: DVU1350(dxS)  
DVL: Dvul\_1718  
DDE: Dde\_2200  
LIP: LI0408(dxS)  
DPS: DP2700  
ADE: Adeh\_1097  
MXA: MXAN\_4643(dxS)  
SAT: SYN\_02456  
SFU: Sfum\_1418  
PUB: SAR11\_0611(dxS)  
MLO: mlr7474  
MES: Meso\_0735  
SME: SMc00972(dxS)  
ATU: Atu0745(dxS)  
ATC: AGR\_C\_1351  
RET: RHE\_CH00913(dxS)  
RLE: RL0973(dxS)  
BME: BMEI1498  
BMF: BAB1\_0462(dxS)  
BMS: BR0436(dxS)  
BMB: BruAb1\_0458(dxS)  
BOV: BOV\_0443(dxS)  
BJA: bl12651(dxS)  
BRA: BRADO2161(dxS)

BBT: BBta\_2479(dxS)  
 RPA: RPA0952(dxS)  
 RPB: RPB\_4460  
 RPC: RPC\_1149  
 RPD: RPD\_4305  
 RPE: RPE\_1067  
 NWI: Nwi\_0633  
 NHA: Nham\_0778  
 BHE: BH04350(dxS)  
 BQU: BQ03540(dxS)  
 BBK: BARBAKCS583\_0400(dxS)  
 CCR: CC\_2068  
 SIL: SPO0247(dxS)  
 SIT: TM1040\_2920  
 RSP: RSP\_0254(dxSA) RSP\_1134(dxS)  
 JAN: Jann\_0088 Jann\_0170  
 RDE: RD1\_0101(dxS) RD1\_0548(dxS)  
 MMR: Mmar10\_0849  
 HNE: HNE\_1838(dxS)  
 ZMO: ZMO1234(dxS) ZMO1598(dxS)  
 NAR: Saro\_0161  
 SAL: Sala\_2354  
 ELI: ELI\_12520  
 GOX: GOX0252  
 GBE: GbCGDNIH1\_0221 GbCGDNIH1\_2404  
 RRU: Rru\_A0054 Rru\_A2619  
 MAG: amb2904  
 MGM: Mmcl\_1048  
 SUS: Acid\_1783  
 BSU: BG11715(dxS)  
 BHA: BH2779  
 BAN: BA4400(dxS)  
 BAR: GBAA4400(dxS)  
 BAA: BA\_4853  
 BAT: BAS4081  
 BCE: BC4176(dxS)  
 BCA: BCE\_4249(dxS)  
 BCZ: BCZK3930(dxS)  
 BTK: BT9727\_3919(dxS)  
 BTL: BALH\_3785(dxS)  
 BLI: BL01523(dxS)  
 BLD: BLi02598(dxS)  
 BCL: ABC2462(dxS)  
 BAY: RBAM\_022600  
 BPU: BPUM\_2159  
 GKA: GK2392  
 GTN: GTNG\_2322  
 LMO: lmo1365(ktB)  
 LMF: LMOF2365\_1382(dxS)  
 LIN: lin1402(ktB)  
 LWE: lwe1380(ktB)  
 LLA: L108911(dxSA) L123365(dxSB)  
 LLC: LACR\_1572 LACR\_1843  
 LLM: llmg\_0749(dxSB)  
 SAK: SAK\_0263  
 LPL: lp\_2610(dxS)  
 LJO: LJ0406  
 LAC: LBA0356  
 LSL: LSL\_0209(dxS)  
 LGA: LGAS\_0350  
 STH: STH1842  
 CAC: CAC2077 CA\_P0106(dxS)  
 CPE: CPE1819  
 CPF: CPF\_2073(dxS)  
 CPR: CPR\_1787(dxS)  
 CTC: CTC01575  
 CNO: NT01CX\_1983  
 CTH: Cthe\_0828  
 CDF: CD1207(dxS)  
 CBO: CBO1881(dxS)  
 CBA: CLB\_1818(dxS)  
 CBH: CLC\_1825(dxS)  
 CBF: CLI\_1945(dxS)  
 CKL: CKL\_1231(dxS)  
 CHY: CHY\_1985(dxS)  
 DSY: DSY2348  
 DRM: Dred\_1078  
 PTH: PTH\_1196(dxS)  
 SWO: Swol\_0582  
 CSC: Csac\_1853  
 TTE: TTE1298(dxS)  
 MTA: Moth\_1511  
 MPE: MYPE730  
 MGA: MGA\_1268(dxS)  
 MTU: Rv2682c(dxS1) Rv3379c(dxS2)  
 MTC: MT2756(dxS)  
 MBO: Mb2701c(dxS1) Mb3413c(dxS2)  
 MLE: ML1038(dxS)  
 MPA: MAP2803c(dxS)  
 MAV: MAV\_3577(dxS)  
 MSM: MSMEG\_2776(dxS)  
 MMC: Mmcs\_2208  
 CGL: NCgl1827(cgl1902)  
 CGB: cg2083(dxS)  
 CEF: CE1796  
 CDI: DIP1397(dxS)  
 CJK: jk1078(dxS)  
 NFA: nfa37410(dxS)  
 RHA: RHA1\_ro06843  
 SCO: SCO6013(SC1C3.01) SCO6768(SC6A5.17)  
 SMA: SAV1646(dxS1) SAV2244(dxS2)  
 TWH: TWT484

TWS: TW280(Dxs)  
LXX: Lxx10450(dxs)  
CMI: CMM\_1660(dxsA)  
AAU: AAur\_1790(dxs)  
PAC: PPA1062  
TFU: Tfu\_1917  
FRA: Francci3\_1326  
FAL: FRAAL2088(dxs)  
ACE: Acel\_1393  
SEN: SACE\_1815(dxs) SACE\_4351  
BLO: BL1132(dxs)  
BAD: BAD\_0513(dxs)  
FNU: FN1208 FN1464  
RBA: RB2143(dxs)  
CTR: CT331(dxs)  
CTA: CTA\_0359(dxs)  
CMU: TC0608  
CPN: CPn1060(tktB\_2)  
CPA: CP0790  
CPJ: CPj1060(tktB\_2)  
CPT: CpB1102  
CCA: CCA00304(dxs)  
CAB: CAB301(dxs)  
CFE: CF0699(dxs)  
PCU: pc0619(dxs)  
TPA: TP0824  
TDE: TDE1910(dxs)  
LIL: LA3285(dxs)  
LIC: LIC10863(dxs)  
LBJ: LBJ\_0917(dxs)  
LBL: LBL\_0932(dxs)  
SYN: sll1945(dxs)  
SYW: SYNW1292(Dxs)  
SYC: syc1087\_c(dxs)  
SYF: Synpcc7942\_0430  
SYD: Syncc9605\_1430  
SYE: Syncc9902\_1069  
SYG: sync\_1410(dxs)  
SYR: SynRCC307\_1390(dxs)  
SYX: SynWH7803\_1223(dxs)  
CYA: CYA\_1701(dxs)  
CYB: CYB\_1983(dxs)  
TEL: tll0623  
GVI: gll0194  
ANA: alr0599  
AVA: Ava\_4532  
PMA: Pro0928(dxs)  
PMM: PMM0907(Dxs)  
PMT: PMT0685(dxs)  
PMN: PMN2A\_0300  
PMI: PMT9312\_0893  
PMB: A9601\_09541(dxs)  
PMC: P9515\_09901(dxs)  
PMF: P9303\_15371(dxs)  
PMG: P9301\_09521(dxs)  
PMH: P9215\_09851  
PMJ: P9211\_08521  
PME: NATL1\_09721(dxs)  
TER: Tery\_3042  
BTH: BT\_1403 BT\_4099  
BFR: BF0873 BF4306  
BFS: BF0796(dxs) BF4114  
PGI: PG2217(dxs)  
CHU: CHU\_3643(dxs)  
GFO: GFO\_3470(dxs)  
FPS: FP0279(dxs)  
CTE: CT0337(dxs)  
CPH: Cpha266\_0671  
PVI: Cvib\_0498  
PLT: Plut\_0450  
DET: DET0745(dxs)  
DEH: cdb\_A720(dxs)  
DRA: DR\_1475  
DGE: Dgeo\_0994  
TTH: TTC1614  
TTJ: TTHA0006  
AAE: aq\_881  
TMA: TM1770  
PMO: Pmob\_1001

**Exemplary acetyl-CoA-acetyltransferase nucleic acids and polypeptides**

HSA: 38(ACAT1) 39(ACAT2) STM: STM3019(yqeF)  
 PTR: 451528(ACAT1) SFL: SF2854(yqeF)  
 MCC: 707653(ACAT1) 708750(ACAT2) SFX: S3052(yqeF)  
 MMU: 110446(Acat1) 110460(Acat2) SFV: SFV\_2922(yqeF)  
 RNO: 25014(Acat1) SSN: SSON\_2283(atoB) SSON\_3004(yqeF)  
 CFA: 484063(ACAT2) 489421(ACAT1) SBO: SBO\_2736(yqeF)  
 GGA: 418968(ACAT1) 421587(RCJMB04\_34i5) ECA: ECA1282(atoB)  
 XLA: 379569(MGC69098) 414622(MGC81403) ENT: Ent638\_3299  
 414639(MGC81256) SPE: Spro\_0592  
 444457(MGC83664) HIT: NTHI0932(atoB)  
 XTR: 394562(acat2) XCC: XCC1297(atoB)  
 DRE: 30643(acat2) XCB: XC\_2943  
 SPU: 759502(LOC759502) XCV: XCV1401(th1A)  
 DME: Dmel\_CG10932 Dmel\_CG9149 XAC: XAC1348(atoB)  
 CEL: T02G5.4 T02G5.7 T02G5.8(kat-1) XOO: XOO1881(atoB)  
 ATH: AT5G48230(ACAT2/EMB1276) XOM: XOM\_1778(XOO1778)  
 OSA: 4326136 4346520 VCH: VCA0690  
 CME: CMA042C CME087C VCO: VC0395\_0630  
 SCE: YPL028W(ERG10) VVU: VV2\_0494 VV2\_0741  
 AGO: AGOS\_ADR165C VVY: VVA1043 VVA1210  
 PIC: PICST\_31707(ERG10) VPA: VPA0620 VPA1123 VPA1204  
 CAL: CaO19.1591(erg10) PPR: PBPRB1112 PBPRB1840  
 CGR: CAGL0L12364g PAE: PA2001(atoB) PA2553 PA3454 PA3589  
 SPO: SPBC215.09c PA3925  
 MGR: MGG\_01755 MGG\_13499 PAU: PA14\_38630(atoB)  
 ANI: ANI409.2 PPU: PP\_2051(atoB) PP\_2215(fadAx) PP\_3754  
 AFM: AFUA\_6G14200 AFUA\_8G04000 PP\_4636  
 AOR: AO090103000012 AO090103000406 PPF: Pput\_2009 Pput\_2403 Pput\_3523 Pput\_4498  
 CNE: CNC05280 PST: PSPTO\_0957(phbA-1) PSPTO\_3164(phbA-2)  
 UMA: UM03571.1 PSB: Psyr\_0824 Psyr\_3031  
 DDI: DDB\_0231621 PSP: PSPPH\_0850(phbA1) PSPPH\_2209(phbA2)  
 PFA: PF14\_0484 PFL: PFL\_1478(atoB-2) PFL\_2321 PFL\_3066  
 TET: TTHERM\_00091590 TTHERM\_00277470 PFL\_4330(atoB-2) PFL\_5283  
 TTHERM\_00926980 PFO: Pfl\_1269 Pfl\_1739 Pfl\_2074 Pfl\_2868  
 TCR: 511003.60 PEN: PSEEN3197 PSEEN3547(fadAx)  
 ECO: b2224(atoB) PSEEN4635(phbA)  
 ECJ: JW2218(atoB) JW5453(yqeF) PMY: Pmen\_1138 Pmen\_2036 Pmen\_3597  
 ECE: Z4164(yqeF) Pmen\_3662 Pmen\_3820  
 ECS: ECs3701 PAR: Psyc\_0252 Psyc\_1169  
 ECC: c2767(atoB) c3441(yqeF) PCR: Pcryo\_0278 Pcryo\_1236 Pcryo\_1260  
 ECI: UTI89\_C2506(atoB) UTI89\_C3247(yqeF) PRW: PsycPRwf\_2011  
 ECP: ECP\_2268 ECP\_2857 ACI: ACIAD0694 ACIAD1612 ACIAD2516(atoB)  
 ECV: APECO1\_3662(yqeF) APECO1\_4335(atoB) SON: SO\_1677(atoB)  
 APECO1\_43352(atoB) SDN: Sden\_1943  
 ECX: EcHS\_A2365 SFR: Sfri\_1338 Sfri\_2063  
 STY: STY3164(yqeF) SAZ: Sama\_1375  
 STT: t2929(yqeF) SBL: Sbal\_1495  
 SPT: SPA2886(yqeF) SBM: Shew185\_1489  
 SEC: SC2958(yqeF) SBN: Sbal195\_1525

SLO: Shew\_1667 Shew\_2858  
 SPC: Sputcn32\_1397  
 SSE: Ssed\_1473 Ssed\_3533  
 SPL: Spca\_2783  
 SHE: Shewmr4\_2597  
 SHM: Shewmr7\_2664  
 SHN: Shewana3\_2771  
 SHW: Sputw3181\_2704  
 ILO: IL0872  
 CPS: CPS\_1605 CPS\_2626  
 PHA: PSIAa0908 PSIAa1454(atoB)  
 PSHAA1586(atoB)  
 PAT: Patl\_2923  
 SDE: Sde\_3149  
 PIN: Ping\_0659 Ping\_2401  
 MAQ: Maqu\_2117 Maqu\_2489 Maqu\_2696  
 Maqu\_3162  
 CBU: CBU\_0974  
 LPN: lpg1825(atoB)  
 LPF: lpl1789  
 LPP: lpp1788  
 NOC: Noc\_1891  
 AEH: Mlg\_0688 Mlg\_2706  
 IHHA: Hhal\_1685  
 HCH: HCH\_05299  
 CSA: Csal\_0301 Csal\_3068  
 ABO: ABO\_0648(fadAx)  
 MMW: Mmwyll\_0073 Mmwyll\_3021 Mmwyll\_3053  
 Mmwyll\_3097 Mmwyll\_4182  
 AHA: AHA\_2143(atoB)  
 CVI: CV\_2088(atoB) CV\_2790(phaA)  
 RSO: RSc0276(atoB) RSc1632(phbA) RSc1637(bktB)  
 RSc1761(RS02948)  
 REU: Reut\_A0138 Reut\_A1348 Reut\_A1353  
 Reut\_B4561 Reut\_B4738  
 Reut\_B5587 Reut\_C5943 Reut\_C6062  
 REH: H16\_A0170 H16\_A0867 H16\_A0868  
 H16\_A0872 H16\_A1297  
 H16\_A1438(phaA) H16\_A1445(bktB) H16\_A1528  
 H16\_A1713 H16\_A1720  
 H16\_A1887 H16\_A2148 H16\_B0380 H16\_B0381  
 H16\_B0406 H16\_B0662  
 H16\_B0668 H16\_B0759 H16\_B1369 H16\_B1771  
 RME: Rmet\_0106 Rmet\_1357 Rmet\_1362 Rmet\_5156  
 BMA: BMA1316 BMA1321(phbA) BMA1436  
 BMV: BMASAVP1\_A1805(bktB)  
 BMASAVP1\_A1810(phbA)  
 BML: BMA10299\_A0086(phbA) BMA10299\_A0091  
 BMN: BMA10247\_1076(bktB)  
 BMA10247\_1081(phbA)

BXE: Bxe\_A2273 Bxe\_A2335 Bxe\_A2342  
 Bxe\_A4255 Bxe\_B0377 Bxe\_B0739  
 Bxe\_C0332 Bxe\_C0574 Bxe\_C0915  
 BVI: Bcep1808\_0519 Bcep1808\_1717  
 Bcep1808\_2877 Bcep1808\_3594  
 Bcep1808\_4015 Bcep1808\_5507 Bcep1808\_5644  
 BUR: Bcep18194\_A3629 Bcep18194\_A5080  
 Bcep18194\_A5091  
 Bcep18194\_A6102 Bcep18194\_B0263  
 Bcep18194\_B1439  
 Bcep18194\_C6652 Bcep18194\_C6802  
 Bcep18194\_C6874  
 Bcep18194\_C7118 Bcep18194\_C7151  
 Bcep18194\_C7332  
 BCN: Bcen\_1553 Bcen\_1599 Bcen\_2158 Bcen\_2563  
 Bcen\_2998 Bcen\_6289  
 BCH: Bcen2424\_0542 Bcen2424\_1790  
 Bcen2424\_2772 Bcen2424\_5368  
 Bcen2424\_6232 Bcen2424\_6276  
 BAM: Bamb\_0447 Bamb\_1728 Bamb\_2824  
 Bamb\_4717 Bamb\_5771 Bamb\_5969  
 BPS: BPSL1426 BPSL1535(phbA) BPSL1540  
 BPM: BURPS1710b\_2325(bktB)  
 BURPS1710b\_2330(phbA)  
 BURPS1710b\_2453(atoB-2)  
 BPL: BURPS1106A\_2197(bktB)  
 BURPS1106A\_2202(phbA)  
 BPD: BURPS668\_2160(bktB) BURPS668\_2165(phbA)  
 BTE: BTH\_I2144 BTH\_I2256 BTH\_I2261  
 PNU: Pnuc\_0927  
 BPE: BP0447 BP0668 BP2059  
 BPA: BPP0608 BPP1744 BPP3805 BPP4216  
 BPP4361  
 BBR: BB0614 BB3364 BB4250 BB4804 BB4947  
 RFR: Rfer\_0272 Rfer\_1000 Rfer\_1871 Rfer\_2273  
 Rfer\_2561 Rfer\_2594  
 Rfer\_3839  
 POL: Bpro\_1577 Bpro\_2140 Bpro\_3113 Bpro\_4187  
 PNA: Pnap\_0060 Pnap\_0458 Pnap\_0867 Pnap\_1159  
 Pnap\_2136 Pnap\_2804  
 AAV: Aave\_0031 Aave\_2478 Aave\_3944 Aave\_4368  
 AJS: Ajs\_0014 Ajs\_0124 Ajs\_1931 Ajs\_2073  
 Ajs\_2317 Ajs\_3548  
 Ajs\_3738 Ajs\_3776  
 VEI: Veis\_1331 Veis\_3818 Veis\_4193  
 DAC: Daci\_0025 Daci\_0192 Daci\_3601 Daci\_5988  
 MPT: Mpe\_A1536 Mpe\_A1776 Mpe\_A1869  
 Mpe\_A3367  
 HAR: HEAR0577(phbA)  
 MMS: mma\_0555  
 NEU: NE2262(bktB)

NET: Neut\_0610  
 EBA: ebA5202 p2A409(tioL)  
 AZO: azo0464(fadA1) azo0469(fadA2) azo2172(thlA)  
 DAR: Daro\_0098 Daro\_3022  
 HPA: HPAG1\_0675  
 HAC: Hac\_0958(atoB)  
 GME: Gmet\_1719 Gmet\_2074 Gmet\_2213  
 Gmet\_2268 Gmet\_3302  
 GUR: Gura\_3043  
 BBA: Bd0404(atoB) Bd2095  
 DOL: Dole\_0671 Dole\_1778 Dole\_2160 Dole\_2187  
 ADE: Adeh\_0062 Adeh\_2365  
 AFW: Anae109\_0064 Anae109\_1504  
 MXA: MXAN\_3791  
 SAT: SYN\_02642  
 SFU: Sfum\_2280 Sfum\_3582  
 RPR: RP737  
 RCO: RC1134 RC1135  
 RFE: RF\_0163(paaJ)  
 RBE: RBE\_0139(paaJ)  
 RAK: A1C\_05820  
 RBO: A1I\_07215  
 RCM: A1E\_04760  
 PUB: SAR11\_0428(thlA)  
 MLO: mlr3847  
 MES: Meso\_3374  
 PLA: Plav\_1573 Plav\_2783  
 SME: Sma1450 SMc03879(phbA)  
 SMD: Smed\_0499 Smed\_3117 Smed\_5094  
 Smed\_5096  
 ATU: Atu2769(atoB) Atu3475  
 ATC: AGR\_C\_5022(phbA) AGR\_L\_2713  
 RET: RHE\_CH04018(phbAch)  
 RHE\_PC00068(ypc00040) RHE\_PF00014(phbA1)  
 RLE: RL4621(phaA) pRL100301 pRL120369  
 BME: BMEI0274 BMEII0817  
 BMF: BAB1\_1783(phbA-1) BAB2\_0790(phbA-2)  
 BMS: BR1772(phbA-1) BRA0448(phbA-2)  
 BMB: BruAb1\_1756(phbA-1) BruAb2\_0774(phbA-2)  
 BOV: BOV\_1707(phbA-1)  
 OAN: Oant\_1130 Oant\_3107 Oant\_3718 Oant\_4020  
 BJA: bli0226(atoB) bli3949 bli7400 bli7819  
 bli3724(phbA)  
 BRA: BRADO0562(phbA) BRADO0983(pimB)  
 BRADO3110 BRADO3134(atoB)  
 BBT: BBta\_3558 BBta\_3575(atoB) BBta\_5147(pimB)  
 BBta\_7072(pimB)  
 BBta\_7614(phbA)  
 RPA: RPA0513(pcaF) RPA0531 RPA3715(pimB)  
 RPB: RPB\_0509 RPB\_0525 RPB\_1748  
 RPC: RPC\_0504 RPC\_0636 RPC\_0641 RPC\_0832  
 RPC\_1050 RPC\_2005  
 RPC\_2194 RPC\_2228  
 RPD: RPD\_0306 RPD\_0320 RPD\_3105 RPD\_3306  
 RPE: RPE\_0168 RPE\_0248 RPE\_3827  
 NWI: Nwi\_3060  
 XAU: Xaut\_3108 Xaut\_4665  
 CCR: CC\_0510 CC\_0894 CC\_3462  
 SIL: SPO0142(bktB) SPO0326(phbA) SPO0773  
 SPO3408  
 SIT: TM1040\_0067 TM1040\_2790 TM1040\_3026  
 TM1040\_3735  
 RSP: RSP\_0745 RSP\_1354 RSP\_3184  
 RSH: Rsph17029\_0022 Rsph17029\_2401  
 Rsph17029\_3179 Rsph17029\_3921  
 RSQ: Rsph17025\_0012 Rsph17025\_2466  
 Rsph17025\_2833  
 JAN: Jann\_0262 Jann\_0493 Jann\_4050  
 RDE: RD1\_0025 RD1\_0201(bktB) RD1\_3394(phbA)  
 PDE: Pden\_2026 Pden\_2663 Pden\_2870 Pden\_2907  
 Pden\_4811 Pden\_5022  
 DSH: Dshi\_0074 Dshi\_3066 Dshi\_3331  
 MMR: Mmar10\_0697  
 HNE: HNE\_2706 HNE\_3065 HNE\_3133  
 NAR: Saro\_0809 Saro\_1069 Saro\_1222 Saro\_2306  
 Saro\_2349  
 SAL: Sala\_0781 Sala\_1244 Sala\_2896 Sala\_3158  
 SWI: Swit\_0632 Swit\_0752 Swit\_2893 Swit\_3602  
 Swit\_4887 Swit\_5019  
 Swit\_5309  
 ELI: ELI\_01475 ELI\_06705 ELI\_12035  
 GBE: GbCGDNIH1\_0447  
 ACR: Acry\_1847 Acry\_2256  
 RRU: Rru\_A0274 Rru\_A1380 Rru\_A1469 Rru\_A1946  
 Rru\_A3387  
 MAG: amb0842  
 MGM: Mmc1\_1165  
 ABA: Acid345\_3239  
 BSU: BG11319(mmgA) BG13063(yhfS)  
 BHA: BH1997 BH2029 BH3801(mmgA)  
 BAN: BA3687 BA4240 BA5589  
 BAR: GBAA3687 GBAA4240 GBAA5589  
 BAA: BA\_0445 BA\_4172 BA\_4700  
 BAT: BAS3418 BAS3932 BAS5193  
 BCE: BC3627 BC4023 BC5344  
 BCA: BCE\_3646 BCE\_4076 BCE\_5475  
 BCZ: BCZK3329(mmgA) BCZK3780(thl)  
 BCZK5044(atoB)  
 BCY: Bcer98\_2722 Bcer98\_3865  
 BTK: BT9727\_3379(mmgA) BT9727\_3765(thl)  
 BT9727\_5028(atoB)

BTL: BALH\_3262(mmgA) BALH\_3642(fadA)  
 BALH\_4843(atoB)  
 BLI: BL03925(mmgA)  
 BLD: BLi03968(mmgA)  
 BCL: ABC0345 ABC2989 ABC3617  
 ABC3891(mmgA)  
 BAY: RBAM\_022450  
 BPU: BPUM\_2374(yhfS) BPUM\_2941 BPUM\_3373  
 OIH: OB0676 OB0689 OB2632 OB3013  
 GKA: GK1658 GK3397  
 SAU: SA0342 SA0534(vraB)  
 SAV: SAV0354 SAV0576(vraB)  
 SAM: MW0330 MW0531(vraB)  
 SAR: SAR0351(thl) SAR0581  
 SAS: SAS0330 SAS0534  
 SAC: SACOL0426 SACOL0622(atoB)  
 SAB: SAB0304(thl) SAB0526  
 SAA: SAUSA300\_0355 SAUSA300\_0560(vraB)  
 SAO: SAOUHSC\_00336 SAOUHSC\_00558  
 SAJ: SaurJH9\_0402  
 SAH: SaurJH1\_0412  
 SEP: SE0346 SE2384  
 SER: SERP0032 SERP0220  
 SHA: SH0510(mvaC) SH2417  
 SSP: SSP0325 SSP2145  
 LMO: lmo1414  
 LMF: LMOf2365\_1433  
 LIN: lin1453  
 LWE: lwe1431  
 LLA: L11745(thiL) L25946(fadA)  
 LLC: LACR\_1665 LACR\_1956  
 LLM: llmg\_0930(thiL)  
 SPY: SPy\_0140 SPy\_1637(atoB)  
 SPZ: M5005\_Spy\_0119 M5005\_Spy\_0432  
 M5005\_Spy\_1344(atoB)  
 SPM: spyM18\_0136 spyM18\_1645(atoB)  
 SPG: SpyM3\_0108 SpyM3\_1378(atoB)  
 SPS: SPs0110 SPs0484  
 SPH: MGAS10270\_Spy0121 MGAS10270\_Spy0433  
 MGAS10270\_Spy1461(atoB)  
 SPI: MGAS10750\_Spy0124 MGAS10750\_Spy0452  
 MGAS10750\_Spy1453(atoB)  
 SPJ: MGAS2096\_Spy0123 MGAS2096\_Spy0451  
 MGAS2096\_Spy1365(atoB)  
 SPK: MGAS9429\_Spy0121 MGAS9429\_Spy0431  
 MGAS9429\_Spy1339(atoB)  
 SPF: SpyM50447(atoB2)  
 SPA: M6\_Spy0166 M6\_Spy0466 M6\_Spy1390  
 SPB: M28\_Spy0117 M28\_Spy0420  
 M28\_Spy1385(atoB)  
 SAK: SAK\_0568  
 LJO: LJ1609  
 LAC: LBA0626(thiL)  
 LSA: LSA1486  
 LDB: Ldb0879  
 LBU: LBUL\_0804  
 LBR: LVIS\_2218  
 LCA: LSEI\_1787  
 LGA: LGAS\_1374  
 LRE: Lreu\_0052  
 EFA: EF1364  
 OOE: OEOE\_0529  
 STH: STH2913 STH725 STH804  
 CAC: CAC2873 CA\_P0078(thiL)  
 CPE: CPE2195(atoB)  
 CPF: CPF\_2460  
 CPR: CPR\_2170  
 CTC: CTC00312  
 CNO: NT01CX\_0538 NT01CX\_0603  
 CDF: CD1059(thlA1) CD2676(thlA2)  
 CBO: CBO3200(thl)  
 CBE: Cbei\_0411 Cbei\_3630  
 CKL: CKL\_3696(thlA1) CKL\_3697(thlA2)  
 CKL\_3698(thlA3)  
 AMT: Amet\_4630  
 AOE: Clos\_0084 Clos\_0258  
 CHY: CHY\_1288 CHY\_1355(atoB) CHY\_1604  
 CHY\_1738  
 DSY: DSY0632 DSY0639 DSY1567 DSY1710  
 DSY2402 DSY3302  
 DRM: Dred\_0400 Dred\_1491 Dred\_1784 Dred\_1892  
 SWO: Swol\_0308 Swol\_0675 Swol\_0789 Swol\_1486  
 Swol\_1934 Swol\_2051  
 TTE: TTE0549(paaJ)  
 MTA: Moth\_1260  
 MTU: Rv1135A Rv1323(fadA4) Rv3546(fadA5)  
 MTC: MT1365(phbA)  
 MBO: Mb1167 Mb1358(fadA4) Mb3576(fadA5)  
 Mb3586c(fadA6)  
 MBB: BCG\_1197 BCG\_1385(fadA4)  
 BCG\_3610(fadA5) BCG\_3620c(fadA6)  
 MLE: ML1158(fadA4)  
 MPA: MAP2407c(fadA3) MAP2436c(fadA4)  
 MAV: MAV\_1544 MAV\_1573 MAV\_1863  
 MAV\_5081  
 MSM: MSMEG\_2224 MSMEG\_4920  
 MUL: MUL\_0357  
 MVA: Mvan\_1976 Mvan\_1988 Mvan\_4305  
 Mvan\_4677 Mvan\_4891  
 MGI: Mflv\_1347 Mflv\_1484 Mflv\_2040 Mflv\_2340  
 Mflv\_4356 Mflv\_4368

MMC: Mmcs\_1758 Mmcs\_1769 Mmcs\_3796  
 Mmcs\_3864  
 MKM: Mkms\_0251 Mkms\_1540 Mkms\_1805  
 Mkms\_1816 Mkms\_2836 Mkms\_3159  
 Mkms\_3286 Mkms\_3869 Mkms\_3938 Mkms\_4227  
 Mkms\_4411 Mkms\_4580  
 Mkms\_4724 Mkms\_4764 Mkms\_4776  
 MJL: Mjls\_0231 Mjls\_1739 Mjls\_1750 Mjls\_2819  
 Mjls\_3119 Mjls\_3235  
 Mjls\_3800 Mjls\_3850 Mjls\_4110 Mjls\_4383  
 Mjls\_4705 Mjls\_4876  
 Mjls\_5018 Mjls\_5063 Mjls\_5075  
 CGL: NCgl2309(cgl2392)  
 CGB: cg2625(pcaF)  
 CEF: CE0731 CE2295  
 CJK: jk1543(fadA3)  
 NFA: nfa10750(fadA4)  
 RHA: RHA1\_ro01455 RHA1\_ro01623  
 RHA1\_ro01876 RHA1\_ro02517(catF)  
 RHA1\_ro03022 RHA1\_ro03024 RHA1\_ro03391  
 RHA1\_ro03892  
 RHA1\_ro04599 RHA1\_ro05257 RHA1\_ro08871  
 SCO: SCO5399(SC8F4.03)  
 SMA: SAV1384(fadA5) SAV2856(fadA1)  
 ART: Arth\_1160 Arth\_2986 Arth\_3268 Arth\_4073  
 NCA: Noca\_1371 Noca\_1797 Noca\_1828 Noca\_2764  
 Noca\_4142  
 TFU: Tfu\_1520 Tfu\_2394  
 FRA: Francci3\_3687  
 FRE: Franean1\_1044 Franean1\_2711 Franean1\_2726  
 Franean1\_3929  
 Franean1\_4037 Franean1\_4577  
 FAL: FRAAL2514 FRAAL2618 FRAAL5910(atoB)  
 ACE: Acel\_0626 Acel\_0672  
 SEN: SACE\_1192(mmgA) SACE\_2736(fadA6)  
 SACE\_4011(catF)  
 SACE\_6236(fadA4)  
 STP: Strop\_3610  
 SAQ: Sare\_1316 Sare\_3991  
 RXY: Rxyl\_1582 Rxyl\_1842 Rxyl\_2389 Rxyl\_2530  
 FNU: FN0495  
 BGA: BG0110(fadA)  
 BAF: BAPKO\_0110(fadA)  
 LIL: LA0457(thiL1) LA0828(thiL2) LA4139(fadA)  
 LIC: LIC10396(phbA)  
 LBJ: LBJ\_2862(paaJ-4)  
 LBL: LBL\_0209(paaJ-4)  
 SYN: slr1993(phaA)  
 SRU: SRU\_1211(atoB) SRU\_1547  
 CHU: CHU\_1910(atoB)  
 GFO: GFO\_1507(atoB)

FJO: Fjoh\_4612  
 FPS: FP0770 FP1586 FP1725  
 RRS: RoseRS\_3911 RoseRS\_4348  
 RCA: Rcas\_0702 Rcas\_3206  
 HAU: Haur\_0522  
 DRA: DR\_1072 DR\_1428 DR\_1960 DR\_2480  
 DR\_A0053  
 DGE: Dgeo\_0755 Dgeo\_1305 Dgeo\_1441 Dgeo\_1883  
 TTH: TTC0191 TTC0330  
 TTJ: TTHA0559  
 TME: Tmel\_1134  
 FNO: Fnod\_0314  
 PMO: Pmob\_0515  
 HMA: rrnAC0896(acaB3) rrnAC2815(aca2)  
 rrnAC3497(yqeF)  
 rrnB0240(aca1) rrnB0242(acaB2) rrnB0309(acaB1)  
 TAC: Ta0582  
 TVO: TVN0649  
 PTO: PTO1505  
 APE: APE\_2108  
 SSO: SSO2377(acaB-4)  
 STO: ST0514  
 SAI: Saci\_0963 Saci\_1361(acaB1)  
 MSE: Msed\_0656  
 PAI: PAE1220  
 PIS: Pisl\_0029 Pisl\_1301  
 PCL: Pcal\_0781  
 PAS: Pars\_0309 Pars\_1071  
 CMA: Cmaq\_1941



SSV: SSU98_1652	OOE: OEOE_0968
SGO: SGO_0244	LME: LEUM_1184
LPL: lp_2067(mvaS)	NFA: nfa22120
LJO: LJ1607	SEN: SACE_4570(pksG)
LAC: LBA0628(hmcS)	BBU: BB0683
LSA: LSA1484(mvaS)	BGA: BG0706
LSL: LSL_0526	BAF: BAPKO_0727
LDB: Ldb0881(mvaS)	FJO: Fjoh_0678
LBU: LBUL_0806	HAL: VNG1615G(mvaB)
LBR: LVIS_1363	HMA: rrnAC1740(mvaS)
LCA: LSEI_1785	HWA: HQ2868A(mvaB)
LGA: LGAS_1372	NPH: NP2608A(mvaB_1) NP4836A(mvaB_2)
LRE: Lreu_0676	
PPE: PEPE_0868	
EFA: EF1363	

### Exemplary hydroxymethylglutaryl-CoA reductase nucleic acids and polypeptides

HSA: 3156(HMGCR)	PAT: Patl_0427
PTR: 471516(HMGCR)	CBU: CBU_0030 CBU_0610
MCC: 705479(HMGCR)	CBD: COXBU7E912_0151
MMU: 15357(Hmgcr)	COXBU7E912_0622(hmgA)
RNO: 25675(Hmgcr)	TCX: Tcr_1717
CFA: 479182(HMGCR)	DNO: DNO_0797
BTA: 407159(HMGCR)	CVI: CV_1806
GGA: 395145(RCJMB04_14m24)	SUS: Acid_5728 Acid_6132
SPU: 373355(LOC373355)	SAU: SA2333(mvaA)
DME: Dmel_CG10367(Hmgcr)	SAV: SAV2545(mvaA)
CEL: F08F8.2	SAM: MW2466(mvaA)
OSA: 4347443	SAB: SAB2419c(mvaA)
SCE: YLR450W(HMG2) YML075C(HMG1)	SEP: SE2109
AGO: AGOS_AER152W	LWE: lwe0819(mvaA)
CGR: CAGL0L11506g	LLA: L10433(mvaA)
SPO: SPCC162.09c(hmg1)	LLC: LACR_1664
ANI: AN3817.2	LLM: limg_0931(mvaA)
AFM: AFUA_1G11230 AFUA_2G03700	SPY: SPy_0880(mvaS.1)
AOR: AO090103000311 AO090120000217	SPM: spyM18_0941(mvaS1)
CNE: CNF04830	SPG: SpyM3_0599(mvaS.1)
UMA: UM03014.1	SPS: SPs1254
ECU: ECU10_1720	SPI: MGAS10270_Spy0744
DDI: DDB_0191125(hmgA) DDB_0215357(hmgB)	SPI: MGAS10750_Spy0778
TBR: Tb927.6.4540	SPJ: MGAS2096_Spy0758
TCR: 506831.40 509167.20	SPK: MGAS9429_Spy0742
LMA: LmjF30.3190	SPA: M6_Spy0703
VCH: VCA0723	SPN: SP_1726
VCO: VC0395_0662	SAG: SAG1317
VVU: VV2_0117	SAN: gbs1387
VVY: VVA0625	STC: str0576(mvaA)
VPA: VPA0968	STL: stu0576(mvaA)
VFI: VFA0841	STE: STER_0620

SSA: SSA_0337(mvaA)	HAL: VNG1875G(mvaA)
LPL: lp_0447(mvaA)	HMA: rrnAC3412(mvaA)
LJO: LJ1608	HWA: HQ3215A(hmgR)
LSL: LSL_0224	NPH: NP0368A(mvaA_2) NP2422A(mvaA_1)
LBR: LVIS_0450	TAC: Ta0406m
LGA: LGAS_1373	TVO: TVN1168
EFA: EF1364	PTO: PTO1143
NFA: nfa22110	PAB: PAB2106(mvaA)
BGA: BG0708(mvaA)	PFU: PF1848
SRU: SRU_2422	TKO: TK0914
FPS: FP2341	RCI: RCIX1027(hmgA) RCIX376(hmgA)
MMP: MMP0087(hmgA)	APE: APE_1869
MMQ: MmarC5_1589	IHO: Igni_0476
MAC: MA3073(hmgA)	HBU: Hbut_1531
MBA: Mbar_A1972	SSO: SSO0531
MMA: MM_0335	STO: ST1352
MBU: Mbur_1098	SAI: Saci_1359
MHU: Mhun_3004	PAI: PAE2182
MEM: Memar_2365	PIS: Pisl_0814
MBN: Mboo_0137	PCL: Pcal_1085
MTH: MTH562	PAS: Pars_0796
MST: Msp_0584(hmgA)	
MSI: Msm_0227	
MKA: MK0355(HMG1)	
AFU: AF1736(mvaA)	

### Exemplary mevalonate kinase nucleic acids and polypeptides

HSA: 4598(MVK)	TET: TTHERM_00637680
MCC: 707645(MVK)	TBR: Tb927.4.4070
MMU: 17855(Mvk)	TCR: 436521.9 509237.10
RNO: 81727(Mvk)	LMA: LmjF31.0560
CFA: 486309(MVK)	CBU: CBU_0608 CBU_0609
BTA: 505792(MVK)	CBD: COXBU7E912_0620(mvk)
GGA: 768555(MVK)	LPN: lpg2039
DRE: 492477(zgc:103473)	LPF: lpl2017
SPU: 585785(LOC585785)	LPP: lpp2022
DME: Dmel_CG33671	BBA: Bd1027(lmbP) Bd1630(mvk)
OSA: 4348331	MXA: MXAN_5019(mvk)
SCE: YMR208W(ERG12)	OIH: OB0225
AGO: AGOS_AER335W	SAU: SA0547(mvaK1)
PIC: PICST_40742(ERG12)	SAV: SAV0590(mvaK1)
CGR: CAGL0F03861g	SAM: MW0545(mvaK1)
SPO: SPAC13G6.11c	SAR: SAR0596(mvaK1)
MGR: MGG_06946	SAS: SAS0549
ANI: AN3869.2	SAC: SACOL0636(mvk)
AFM: AFUA_4G07780	SAB: SAB0540(mvaK1)
AOR: AO090023000793	SAA: SAUSA300_0572(mvk)
CNE: CNK01740	SAO: SAOUHSC_00577
ECU: ECU09_1780	SEP: SE0361
DDI: DDBDRAFT_0168621	SER: SERP0238(mvk)

SHA: SH2402(mvaK1)	LCA: LSEI_1491
SSP: SSP2122	LGA: LGAS_1033
LMO: lmo0010	LRE: Lreu_0915
LMF: LMOF2365_0011	PPE: PEPE_0927
LIN: lin0010	EFA: EF0904(mvk)
LWE: lwe0011(mvk)	OOE: OEOE_1100
LLA: L7866(yeaG)	LME: LEUM_1385
LLC: LACR_0454	NFA: nfa22070
LLM: limg_0425(mvk)	BGA: BG0711
SPY: SPY_0876(mvaK1)	BAF: BAPKO_0732
SPZ: M5005_Spy_0682(mvaK1)	FPS: FP0313
SPM: spyM18_0937(mvaK1)	MMP: MMP1335
SPG: SpyM3_0595(mvaK1)	MAE: Maeo_0775
SPS: SPs1258	MAC: MA0602(mvk)
SPH: MGAS10270_Spy0740(mvaK1)	MBA: Mbar_A1421
SPI: MGAS10750_Spy0774(mvaK1)	MMA: MM_1762
SPJ: MGAS2096_Spy0753(mvaK1)	MBU: Mbur_2395
SPK: MGAS9429_Spy0737(mvaK1)	MHU: Mhun_2890
SPF: SpyM51126(mvaK1)	MEM: Memar_1812
SPA: M6_Spy0699	MBN: Mboo_2213
SPB: M28_Spy0662(mvaK1)	MST: Msp_0858(mvk)
SPN: SP_0381	MSI: Msm_1439
SPR: spr0338(mvk)	MKA: MK0993(ERG12)
SPD: SPD_0346(mvk)	HAL: VNG1145G(mvk)
SAG: SAG1326	HMA: rrnAC0077(mvk)
SAN: gbs1396	HWA: HQ2925A(mvk)
SAK: SAK_1357(mvk)	NPH: NP2850A(mvk)
SMU: SMU.181	PTO: PTO1352
STC: str0559(mvaK1)	PHO: PH1625
STL: stu0559(mvaK1)	PAB: PAB0372(mvk)
STE: STER_0598	PFU: PF1637(mvk)
SSA: SSA_0333(mvaK1)	TKO: TK1474
SSU: SSU05_0289	RCI: LRC399(mvk)
SSV: SSU98_0285	APE: APE_2439
SGO: SGO_0239(mvk)	HBU: Hbut_0877
LPL: lp_1735(mvaK1)	SSO: SSO0383
LJO: LJ1205	STO: ST2185
LAC: LBA1167(mvaK)	SAI: Saci_2365(mvk)
LSA: LSA0908(mvaK1)	MSE: Msed_1602
LSL: LSL_0685(eRG)	PAI: PAE3108
LDB: Ldb0999(mvk)	PIS: Pisl_0467
LBU: LBUL_0906	PCL: Pcal_1835
LBR: LVIS_0858	

### Exemplary phosphomevalonate kinase nucleic acids and polypeptides

HSA: 10654(PMVK)	CFA: 612251(PMVK)
PTR: 457350(PMVK)	BTA: 513533(PMVK)
MCC: 717014(PMVK)	DME: Dmel_CG10268
MMU: 68603(Pmvk)	ATH: AT1G31910

OSA: 4332275	SPS: SPS1256
SCE: YMR220W(ERG8)	SPH: MGAS10270_Spy0742(mvaK2)
AGO: AGOS_AER354W	SPI: MGAS10750_Spy0776(mvaK2)
PIC: PICST_52257(ERG8)	SPJ: MGAS2096_Spy0755(mvaK2)
CGR: CAGL0F03993g	SPK: MGAS9429_Spy0739(mvaK2)
SPO: SPAC343.01c	SPF: SpyM51124(mvaK2)
MGR: MGG_05812	SPA: M6_Spy0701
ANI: AN2311.2	SPB: M28_Spy0664(mvaK2)
AFM: AFUA_5G10680	SPN: SP_0383
AOR: AO090010000471	SPR: spr0340(mvaK2)
CNE: CNM00100	SPD: SPD_0348(mvaK2)
UMA: UM00760.1	SAG: SAG1324
DDI: DDBDRAFT_0184512	SAN: gbs1394
TBR: Tb09.160.3690	SAK: SAK_1355
TCR: 507913.20 508277.140	SMU: SMU.938
LMA: LmjF15.1460	STC: str0561(mvaK2)
MXA: MXAN_5017	STL: stu0561(mvaK2)
OIH: OB0227	STE: STER_0600
SAU: SA0549(mvaK2)	SSA: SSA_0335(mvaK2)
SAV: SAV0592(mvaK2)	SSU: SSU05_0291
SAM: MW0547(mvaK2)	SSV: SSU98_0287
SAR: SAR0598(mvaK2)	SGO: SGO_0241
SAS: SAS0551	LPL: lp_1733(mvaK2)
SAC: SACOL0638	LJO: LJ1207
SAB: SAB0542(mvaK2)	LAC: LBA1169
SAA: SAUSA300_0574	LSA: LSA0906(mvaK2)
SAO: SAOUHSC_00579	LSL: LSL_0683
SAJ: SaurJH9_0615	LDB: Ldb0997(mvaK)
SEP: SE0363	LBU: LBUL_0904
SER: SERP0240	LBR: LVIS_0860
SHA: SH2400(mvaK2)	LCA: LSEI_1092
SSP: SSP2120	LGA: LGAS_1035
LMO: lmo0012	LRE: Lreu_0913
LMF: LMOI2365_0013	PPE: PEPE_0925
LIN: lin0012	EFA: EF0902
LWE: lwe0013	NFA: nfa22090
LLA: L10014(yebA)	BGA: BG0710
LLC: LACR_0456	BAF: BAPKO_0731
LLM: llmg_0427	NPH: NP2852A
SPY: SPy_0878(mvaK2)	SSO: SSO2988
SPZ: M5005_Spy_0684(mvaK2)	STO: ST0978
SPM: spyM18_0939	SAI: Saci_1244
SPG: SpyM3_0597(mvaK2)	

### Exemplary diposphomevalonate decarboxylase nucleic acids and polypeptides

HSA: 4597(MVD)	CFA: 489663(MVD)
PTR: 468069(MVD)	GGA: 425359(MVD)
MCC: 696865(MVD)	DME: Dmel_CG8239
MMU: 192156(Mvd)	SCE: YNR043W(MVD1)
RNO: 81726(Mvd)	AGO: AGOS_AGL232C

PIC: PICST\_90752  
CGR: CAGLOC03630g  
SPO: SPAC24C9.03  
MGR: MGG\_09750  
ANI: AN4414.2  
AFM: AFUA\_4G07130  
AOR: AO090023000862  
CNE: CNL04950  
UMA: UM05179.1  
DDI: DDBDRAFT\_0218058  
TET: THERM\_00849200  
TBR: Tb10.05.0010 Tb10.61.2745  
TCR: 507993.330 511281.40  
LMA: LmjF18.0020  
CBU: CBU\_0607(mvaD)  
CBD: COXBU7E912\_0619(mvaD)  
LPN: lpg2040  
LPF: lpl2018  
LPP: lpp2023  
TCX: Tcr\_1734  
DNO: DNO\_0504(mvaD)  
BBA: Bd1629  
MXA: MXAN\_5018(mvaD)  
OIH: OB0226  
SAU: SA0548(mvaD)  
SAV: SAV0591(mvaD)  
SAM: MW0546(mvaD)  
SAR: SAR0597(mvaD)  
SAS: SAS0550  
SAC: SACOL0637(mvaD)  
SAB: SAB0541(mvaD)  
SAA: SAUSA300\_0573(mvaD)  
SAO: SAOUHSC\_00578  
SAJ: SaurJH9\_0614  
SAH: SaurJH1\_0629  
SEP: SE0362  
SER: SERP0239(mvaD)  
SHA: SH2401(mvaD)  
SSP: SSP2121  
LMO: lmo0011  
LMF: LMOF2365\_0012(mvaD)  
LIN: lin0011  
LWE: lwe0012(mvaD)  
LLA: L9089(ycaH)  
LLC: LACR\_0455  
LLM: llmg\_0426(mvaD)  
SPY: SPy\_0877(mvaD)  
SPZ: M5005\_Spy\_0683(mvaD)  
SPM: spyM18\_0938(mvd)  
SPG: SpyM3\_0596(mvaD)  
SPS: SPs1257  
SPH: MGAS10270\_Spy0741(mvaD)  
SPI: MGAS10750\_Spy0775(mvaD)  
SPJ: MGAS2096\_Spy0754(mvaD)  
SPK: MGAS9429\_Spy0738(mvaD)  
SPF: SpyM51125(mvaD)  
SPA: M6\_Spy0700  
SPB: M28\_Spy0663(mvaD)  
SPN: SP\_0382  
SPR: spr0339(mvd1)  
SPD: SPD\_0347(mvaD)  
SAG: SAG1325(mvaD)  
SAN: gbs1395  
SAK: SAK\_1356(mvaD)  
SMU: SMU.937  
STC: str0560(mvaD)  
STL: stu0560(mvaD)  
STE: STER\_0599  
SSA: SSA\_0334(mvaD)  
SSU: SSU05\_0290  
SSV: SSU98\_0286  
SGO: SGO\_0240(mvaD)  
LPL: lp\_1734(mvaD)  
LJO: LJ1206  
LAC: LBA1168(mvaD)  
LSA: LSA0907(mvaD)  
LSL: LSL\_0684  
LDB: Ldb0998(mvaD)  
LBU: LBUL\_0905  
LBR: LVIS\_0859  
LCA: LSEI\_1492  
LGA: LGAS\_1034  
LRE: Lrcu\_0914  
PPE: PEPE\_0926  
EFA: EF0903(mvaD)  
LME: LEUM\_1386  
NFA: nfa22080  
BBU: BB0686  
BGA: BG0709  
BAF: BAPKO\_0730  
GFO: GFO\_3632  
FPS: FP0310(mvaD)  
HAU: Haur\_1612  
HAL: VNG0593G(dmd)  
HMA: rrnAC1489(dmd)  
HWA: HQ1525A(mvaD)  
NPH: NP1580A(mvaD)  
PTO: PTO0478 PTO1356  
SSO: SSO2989  
STO: ST0977  
SAI: Saci\_1245(mvd)  
MSE: Mscd\_1576

**Exemplary isopentenyl phosphate kinases (IPK) nucleic acids and polypeptides**

*Methanobacterium thermoautotrophicum*  
gi|2621082  
*Methanococcus jannaschii* DSM 2661 gi|1590842 ;  
*Methanocaldococcus jannaschii* gi|1590842  
*Methanothermobacter thermautotrophicus*  
gi|2621082

*Picrophilus torridus* DSM9790 (IG-57) gi|48477569  
*Pyrococcus abyssi* gi|14520758  
*Pyrococcus horikoshii* OT3 gi|3258052  
*Archaeoglobus fulgidus* DSM4304 gi|2648231

**Exemplary isopentenyl-diphosphate Delta-isomerase (IDI) nucleic acids and polypeptides**

HSA: 3422(IDI1) 91734(IDI2)  
PTR: 450262(IDI2) 450263(IDI1)  
MCC: 710052(LOC710052) 721730(LOC721730)  
MMU: 319554(Idi1)  
RNO: 89784(Idi1)  
GGA: 420459(IDI1)  
XLA: 494671(LOC494671)  
XTR: 496783(idi2)  
SPU: 586184(LOC586184)  
CEL: K06H7.9(idi-1)  
ATH: AT3G02780(IPP2)  
OSA: 4338791 4343523  
CME: CMB062C  
SCE: YPL117C(IDI1)  
AGO: AGOS\_ADL268C  
PIC: PICST\_68990(IDI1)  
CGR: CAGL0J06952g  
SPO: SPBC106.15(idi1)  
ANI: AN0579.2  
AFM: AFUA\_6G11160  
AOR: AO090023000500  
CNE: CNA02550  
UMA: UM04838.1  
ECU: ECU02\_0230  
DDI: DDB\_0191342(ipi)  
TET: THERM\_00237280 THERM\_00438860  
TBR: Tb09.211.0700  
TCR: 408799.19 510431.10  
LMA: LmjF35.5330  
EHI: 46.100025  
ECO: b2889(idi)  
ECJ: JW2857(idi)  
ECE: Z4227  
ECS: ECs3761  
ECC: c3467  
ECI: UTI89\_C3274  
ECP: ECP\_2882  
ECV: APECO1\_3638  
ECW: EcE24377A\_3215(idi)  
ECX: EcHS\_A3048

STY: STY3195  
STT: t2957  
SPT: SPA2907(idi)  
SEC: SC2979(idi)  
STM: STM3039(idi)  
SFL: SF2875(idi)  
SFX: S3074  
SFV: SFV\_2937  
SSN: SSON\_3042 SSON\_3489(yhfK)  
SBO: SBO\_3103  
SDY: SDY\_3193  
ECA: ECA2789  
PLU: plu3987  
ENT: Ent638\_3307  
SPE: Spro\_2201  
VPA: VPA0278  
VFI: VF0403  
PPR: PBPRA0469(mvaD)  
PEN: PSEEN4850  
CBU: CBU\_0607(mvaD)  
CBD: COXBU7E912\_0619(mvaD)  
LPN: lpg2051  
LPF: lpl2029  
LPP: lpp2034  
TCX: Ter\_1718  
HHA: Hha1\_1623  
DNO: DNO\_0798  
EBA: ebA5678 p2A143  
DVU: DVU1679(idi)  
DDE: Dde\_1991  
LIP: LI1134  
BBA: Bd1626  
AFW: Anae109\_4082  
MXA: MXAN\_5021(fni)  
RPR: RP452  
RTY: RT0439(idi)  
RCO: RC0744  
RFE: RF\_0785(fni)  
RBE: RBE\_0731(fni)  
RAK: A1C\_04190

RBO: AII\_04755  
RCM: A1E\_02555  
RRI: AIG\_04195  
MLO: mlr6371  
RET: RHE\_PD00245(ypd00046)  
XAU: Xaut\_4134  
SIL: SPO0131  
SIT: TM1040\_3442  
RSP: RSP\_0276  
RSH: Rsph17029\_1919  
RSQ: Rsph17025\_1019  
JAN: Jann\_0168  
RDE: RD1\_0147(idi)  
DSH: Dshi\_3527  
BSU: BG11440(ypgA)  
BAN: BA1520  
BAR: GBAA1520  
BAA: BA\_2041  
BAT: BAS1409  
BCE: BC1499  
BCA: BCE\_1626  
BCZ: BCZK1380(fni)  
BCY: Bcer98\_1222  
BTK: BT9727\_1381(fni)  
BTL: BALH\_1354  
BLI: BL02217(fni)  
BLD: BLi02426  
BAY: RBAM\_021020(fni)  
BPU: BPUM\_2020(fni)  
OIH: OB0537  
SAU: SA2136(fni)  
SAV: SAV2346(fni)  
SAM: MW2267(fni)  
SAR: SAR2431(fni)  
SAS: SAS2237  
SAC: SACOL2341(fni)  
SAB: SAB2225c(fni)  
SAA: SAUSA300\_2292(fni)  
SAO: SAOUHSC\_02623  
SEP: SE1925  
SER: SERP1937(fni-2)  
SHA: SH0712(fni)  
SSP: SSP0556  
LMO: lmo1383  
LMF: LMOt2365\_1402(fni)  
LIN: lin1420  
LWE: lwe1399(fni)  
LLA: L11083(yebB)  
LLC: LACR\_0457  
LLM: llmg\_0428(fni)  
SPY: SPy\_0879  
SPZ: M5005\_Spy\_0685  
SPM: spyM18\_0940  
SPG: SpyM3\_0598  
SPS: SPs1255  
SPH: MGAS10270\_Spy0743  
SPI: MGAS10750\_Spy0777  
SPJ: MGAS2096\_Spy0756  
SPK: MGAS9429\_Spy0740  
SPF: SpyM51123(fni)  
SPA: M6\_Spy0702  
SPB: M28\_Spy0665  
SPN: SP\_0384  
SPR: spr0341(fni)  
SPD: SPD\_0349(fni)  
SAG: SAG1323  
SAN: gbs1393  
SAK: SAK\_1354(fni)  
SMU: SMU.939  
STC: str0562(idi)  
STL: stu0562(idi)  
STE: STER\_0601  
SSA: SSA\_0336  
SGO: SGO\_0242  
LPL: lp\_1732(idi1)  
LJO: LJ1208  
LAC: LBA1171  
LSA: LSA0905(idi)  
LSL: LSL\_0682  
LDB: Ldb0996(fni)  
LBU: LBUL\_0903  
LBR: LVIS\_0861  
LCA: LSEI\_1493  
LGA: LGAS\_1036  
LRE: Lreu\_0912  
EFA: EF0901  
OOE: OEOE\_1103  
STH: STH1674  
CBE: Cbci\_3081  
DRM: Dred\_0474  
SWO: Swol\_1341  
MTA: Moth\_1328  
MTU: Rv1745c(idi)  
MTC: MT1787(idi)  
MBO: Mb1774c(idi)  
MBB: BCG\_1784c(idi)  
MPA: MAP3079c  
MAV: MAV\_3894(fni)  
MSM: MSMEG\_1057(fni) MSMEG\_2337(fni)  
MUL: MUL\_0380(idi2)  
MVA: Mvan\_1582 Mvan\_2176  
MGI: Mflv\_1842 Mflv\_4187

MMC: Mmcs\_1954  
MKM: Mkms\_2000  
MJL: Mjls\_1934  
CGL: NCgl2223(cgl2305)  
CGB: cg2531(idi)  
CEF: CE2207  
CDI: DIP1730(idi)  
NFA: nfa19790 nfa22100  
RHA: RHA1\_ro00239  
SCO: SCO6750(SC5F2A.33c)  
SMA: SAV1663(idi)  
LXX: Lxx23810(idi)  
CMI: CMM\_2889(idiA)  
AAU: AAur\_0321(idi)  
PAC: PPA2115  
FRA: Francci3\_4188  
FRE: Franeanl\_5570  
FAL: FRAAL6504(idi)  
KRA: Krad\_3991  
SEN: SACE\_2627(idiB\_2) SACE\_5210(idi)  
STP: Strop\_4438  
SAQ: Sare\_4564 Sare\_4928  
RXY: Rxyl\_0400  
BBU: BB0684  
BGA: BG0707  
SYN: sl11556  
SYC: syc2161\_c  
SYF: Synpcc7942\_1933  
CYA: CYA\_2395(fni)  
CYB: CYB\_2691(fni)  
TEL: tll1403  
ANA: all4591  
AVA: Ava\_2461 Ava\_B0346  
TER: Tery\_1589  
SRU: SRU\_1900(idi)  
CHU: CHU\_0674(idi)  
GFO: GFO\_2363(idi)  
FJO: Fjoh\_0269  
FPS: FP1792(idi)  
CTE: CT0257  
CCH: Cag\_1445  
CPH: Cpha266\_0385  
PVI: Cvib\_1545  
PLT: Plut\_1764  
RRS: RoseRS\_2437  
RCA: Rcas\_2215  
HAU: Haur\_4687  
DRA: DR\_1087  
DGE: Dgeo\_1381  
TTH: TT\_P0067  
TTJ: TTHB110  
MJA: MJ0862  
MMP: MMP0043  
MMQ: MmarC5\_1637  
MMX: MmarC6\_0906  
MMZ: MmarC7\_1040  
MAE: Maeo\_1184  
MVN: Mevan\_1058  
MAC: MA0604(idi)  
MBA: Mbar\_A1419  
MMA: MM\_1764  
MBU: Mbur\_2397  
MTP: Mthe\_0474  
MHU: Mhun\_2888  
MLA: Mlab\_1665  
MEM: Memar\_1814  
MBN: Mboo\_2211  
MTH: MTH48  
MST: Msp\_0856(fni)  
MSI: Msm\_1441  
MKA: MK0776(1ldD)  
AFU: AF2287  
HAL: VNG1818G(idi) VNG6081G(cert\_1)  
VNG6445G(cert\_2) VNG7060 VNG7149  
HMA: rrnAC3484(idi)  
HWA: HQ2772A(idiA) HQ2847A(idiB)  
NPH: NP0360A(idiB\_1) NP4826A(idiA)  
NP5124A(idiB\_2)  
TAC: Ta0102  
TVO: TVN0179  
PTO: PTO0496  
PHO: PH1202  
PAB: PAB1662  
PFU: PF0856  
TKO: TK1470  
RCI: LRC397(fni)  
APE: APE\_1765.1  
SMR: Smar\_0822  
IHO: Igni\_0804  
HBU: Hbut\_0539  
SSO: SSO0063  
STO: ST2059  
SAI: Saci\_0091  
MSE: Msed\_2136  
PAI: PAE0801  
PIS: Pisl\_1093  
PCL: Pcal\_0017  
PAS: Pars\_0051  
TPE: Tpen\_0272

**Exemplary isoprene synthase nucleic acids and polypeptides**

Genbank Accession Nos.

AY341431

AY316691

AY279379

AJ457070

AY182241

The Claims defining the invention are as follows:

1. A method for producing a fuel constituent from a bioisoprene composition comprising chemically transforming a substantial portion of the isoprene in the bioisoprene composition to non-isoprene compounds by:
  - (a) subjecting the bioisoprene composition to heat or catalytic conditions suitable for isoprene dimerization to produce an isoprene dimer and then catalytically hydrogenating the isoprene dimer to form a saturated C10 fuel constituent; or
  - (b) (i) partially hydrogenating the bioisoprene composition to produce an isoamylene, (ii) dimerizing the isoamylene with a mono-olefin selected from the group consisting of isoamylene, propylene and isobutene to form a dimate and (iii) completely hydrogenating the dimate to produce a fuel constituent.
2. The method of claim 1, wherein at least about 95% of isoprene in the bioisoprene composition is converted to non-isoprene compounds.
3. The method of claim 1 or claim 2, wherein the bioisoprene composition is heated from about 150 °C to 250 °C to produce an unsaturated cyclic isoprene dimer and the unsaturated cyclic isoprene dimer is hydrogenated catalytically to produce a saturated cyclic isoprene dimer fuel constituent.
4. The method of any one of claims 1 to 3, wherein the method comprises: (i) contacting the bioisoprene composition with a catalyst for catalyzing cyclo-dimerization of isoprene to produce an unsaturated cyclic isoprene dimer and the unsaturated cyclic isoprene dimer is hydrogenated catalytically to produce a saturated cyclic isoprene dimer fuel constituent.
5. The method of claim 4, wherein the catalyst for catalyzing cyclo-dimerization of isoprene comprising a catalyst selected from the group consisting of a nickel catalyst, iron catalysts and chromium catalysts.
6. The method of any one of claims 1 to 5, wherein the step of partially hydrogenating the bioisoprene composition comprises contacting the bioisoprene composition with hydrogen gas and a catalyst for catalyzing partial hydrogenation of isoprene.

7. The method of claim 6, wherein the catalyst for catalyzing partial hydrogenation of isoprene comprises a palladium catalyst.
8. The method of any one of claims 1 to 7, wherein the step of dimerizing the isoamylene with a mono-olefin comprises contacting the isoamylene with the mono-olefin in the presence of a catalyst for catalyzing dimerization of mono-olefin.
9. The method of claim 8, wherein the catalyst for catalyzing dimerization of mono-olefin comprises an acid catalyst.
10. The method of any one of claims 1 to 9, further comprising purifying the isoprene from the bioisoprene composition prior to chemically transforming the bioisoprene composition to a fuel constituent.
11. A system for producing a fuel constituent from a bioisoprene composition, wherein a substantial portion of the isoprene in the bioisoprene composition is chemically converted to non-isoprene compounds, the system comprising a bioisoprene composition and :
  - (a) (i) one or more chemicals capable of dimerizing isoprene in the bioisoprene composition or a source of heat capable of dimerizing isoprene in the bioisoprene composition; and (ii) a catalyst capable of hydrogenating the isoprene dimer to form a saturated C10 fuel constituent; or
  - (b) (i) a chemical capable of partially hydrogenating isoprene in the bioisoprene composition to produce an isoamylene, (ii) a chemical capable of dimerizing the isoamylene with mono-olefins selected from the group consisting of isoamylene, propylene and isobutene to form a dimate and (iii) a chemical capable of completely hydrogenating the dimate to produce a fuel constituent.
12. The system of claim 11, wherein the bioisoprene composition comprising greater than about 2 mg of isoprene and comprising greater than or about 99.94% isoprene by weight compared to the total weight of all C5 hydrocarbons in the composition.
13. The system of claim 11 or claim 12, wherein the one or more chemicals capable of dimerizing isoprene comprises catalyst for catalyzing cyclo-dimerization of isoprene comprising a catalyst selected from the group consisting of ruthenium catalysts, nickel catalysts, iron catalysts and chromium catalysts.

14. The system of any one of claims 11 to 13, wherein the catalyst for hydrogenating the unsaturated isoprene dimers comprises a catalyst selected from the group consisting of palladium catalysts, nickel catalysts, ruthenium catalysts and rhodium catalysts.
15. The system of any one of claims 11 to 14, wherein the chemical capable of partially hydrogenating isoprene comprises a palladium catalyst.
16. The system of any one of claims 11 to 15, wherein the chemical capable of dimerizing the isoamylene with mono-olefins comprises an acid catalyst.
17. A fuel composition comprising a fuel constituent produced by the method of any one of claims 1 to 10.
18. The fuel composition of claim 17, wherein the fuel composition is substantially free of isoprene.
19. The fuel composition of claim 17 or claim 18, wherein the fuel composition has  $\delta^{13}\text{C}$  value which is greater than -22‰ or within the range of from -32‰ to -24‰.
20. The method of any one of claims 1 to 10, wherein at least about 80% of isoprene in the bioisoprene composition is converted to non-isoprene compounds.
21. The method of any one of claims 1 to 10 or claim 20, wherein the bioisoprene composition comprises one or more compounds selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms.
22. The method of any one of claims 1 to 10 or claims 20 or 21, wherein the bioisoprene composition comprises one or more compounds selected from the group consisting of ethanol, acetone, methanol, acetaldehyde, methacrolein, methyl vinyl ketone, 2-methyl-2-vinyloxirane, cis- and trans-3-methyl-1,3-pentadiene, and C5 prenyl alcohols.
23. The method of any one of claims 1 to 10 or claims 20 to 22, wherein the bioisoprene composition comprises one or more compounds selected from the group consisting of 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, acetaldehyde, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanal, 3-methyl-2-

butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene, and 2,3-cycloheptenolpyridine.

24. The method of any one of claims 1 to 10 or claims 20 to 23, wherein the isoprene in the bioisoprene composition is continuously chemically transformed to the non-isoprene compounds.

25. The system of any one of claims 11 to 16, wherein at least 80% of the isoprene in the bioisoprene composition is chemically converted to non-isoprene compounds.

26. The system of any one of claims 11 to 16 or claim 25, wherein the bioisoprene composition comprises one or more compounds selected from the group consisting of ethanol, acetone, C5 prenyl alcohols, and isoprenoid compounds with 10 or more carbon atoms.

27. The system of any one of claims 11 to 16 or claims 25 or 26, wherein the bioisoprene composition comprises one or more compounds selected from the group consisting of ethanol, acetone, methanol, acetaldehyde, methacrolein, methyl vinyl ketone, 2-methyl-2-vinyloxirane, cis- and trans-3-methyl-1,3-pentadiene, and C5 prenyl alcohols.

28. The system of any one of claims 11 to 16 or claims 25 to 27, wherein the bioisoprene composition comprises one or more compounds selected from the group consisting of 2-heptanone, 6-methyl-5-hepten-2-one, 2,4,5-trimethylpyridine, 2,3,5-trimethylpyrazine, citronellal, acetaldehyde, methanethiol, methyl acetate, 1-propanol, diacetyl, 2-butanone, 2-methyl-3-buten-2-ol, ethyl acetate, 2-methyl-1-propanol, 3-methyl-1-butanol, 3-methyl-2-butanone, 1-butanol, 2-pentanone, 3-methyl-1-butanol, ethyl isobutyrate, 3-methyl-2-butenal, butyl acetate, 3-methylbutyl acetate, 3-methyl-3-buten-1-yl acetate, 3-methyl-2-buten-1-yl acetate, 3-hexen-1-ol, 3-hexen-1-yl acetate, limonene, geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol), citronellol (3,7-dimethyl-6-octen-1-ol), (E)-3,7-dimethyl-1,3,6-octatriene, (Z)-3,7-dimethyl-1,3,6-octatriene, and 2,3-cycloheptenolpyridine.

Figure 1

1-

atgtgtgagacctcttctcaatttactcagattaccgagcataaattcccgctggttcgcgaaact  
atcagccaaacctgtggaatttogaattcctgcaatccctggagaacgacctgaaagtggaaaa  
gctggaggagaaagcgaccaaaactggaggaagaagttcgtgcatgatcaaccgtgtagacacc  
cagccgctgtccctgctggagctgatcagcagatgtgcagcgcctgggtctgaactacaaatttg  
aaaagacatcattaaagccctggaaaacatcgtactgctggacgaaaaacaaaaagaacaaatc  
tgaactgcacgcaaccgctctgtctttccgtctgctgcgtcagcaagggttcgaggtttctcag  
gatgtttttgagcgtttcaaggataaagaagggtggtttcagcggggaactgaaagggtgacgtcc  
aaggcctgctgagcctgtatgaagcgtcttaccctgggtttcgaggggtgagaacctgctggagga  
ggcgcgtaccttttccateacccacctgaagaacaaacctgaaagsaggcattaataccaagggtt  
gcagaacaagtggagccacgcccctggaactgccatataccacagcgtctgcaccgctctggaggcac  
gttggttcctggataaatacgaaccgaaagaacccgcataccacagctgctgctggagctggcga  
gctggattttaacatggtagacacccctgcaccagaaagagctgcaagatctgtcccgctgggtg  
accgagatgggctggctagcaaaactggattttgtacgcgaccgctgatggaagtttatcttct  
gggcaactgggtatggcgcagacccgcagtttgggtgaatgtcgcasaagctgttactaaaatgtt  
tggctctggtgacgatcatcgatgacgtgtatgacgtttatggcaactctggacgaaactgcaactg  
ttcaccgatgctgtagagcgtgggacgttaacgctattaacacccctgcccggactatatgaaac  
tgtgtttcctggcactgtacacacccgttaacgacaacgctcctattctattctgaaagagaagg  
tcataacaacctgtcctatctgacgaaaagctggcgtgaaactgtgcaaagcctttctgaaagag  
gcgaaatggtccaacaacaaaattatcccggtttctccaagtaacctggaaaacgcccagcgttt  
cctcctccggtgtagcgtctgctggcgcgtctctacttttccgtatgccagcagcaggaagacat  
ctccgaccacgcgctgctgttccctgaccgaactccatggtctggtgcttctagctgcttctc  
ttccgctgtgcaacgatctggccacctctgcccggagctggaaactggcagactaocaaatt  
ctatcattagctacatgcacgaaaacgatggtaccagcgaggaaacagcccgccaagaactgctg  
taaaactgatcgaacccgaatggaaaaagatgaatcgtgaaacgcttagcgaactccacctgctg  
cctaaagcgttcatggaatcgcagttaacatggcaccgtgtttcccactgcaactaccagtatg  
gggatggtctgggtgcgccagactacgcgactgaaaaaccgcatcaaaactgctgctgattgaccc  
ttcccgattaaaccagctgatgtatgtc  
taactgcag  
(SEQ ID NO:1)

Figure 2




Figure 3A

1-

gtttgacagcttatcatogactgcacgggtgcaccaatgcttctggcgtcagggcagccatcggaagctgtgggtatggctgtgcaggtcgtaaatcactgcataatcgtgtcgctcaaggcgcactcccgttctggataaatgttttttgcgcgcgacateataacgggtctctggcaaatattctgaaatgagctgttgacaattaatcatccggctcgtataatgtgtggaattgtgagcggataacaatttcacacaggaacagcgcgcgctgagaaaaagcgaagcggcactgctctttaacaatttatcagacaatctgtgtgggcactcogacoggaattatcgattaactttattttaaaaattaaagaggtatataatlaagtatcogattaaataaggaggaataaaaccATGtgtgogacotcttctcaatttactcagattaccgagcataattcccgtcgttccgcaaaactatcagccaaacctgtggaatttcogaattcctgcaatccctgggagaacgacctgaaagtggaaaagctggaggagaaaagcgaaccaaacctggagggaagaagttogetgcatgatcaaccgtgtagacacccagccgctgtccctgctggagctgatcgacgatgtgcagcgcctgggtctgacctacaaatttgaaaaagacatcattaaagccctggaaaacatcgtacgctggacgaaaaacaaaaagaacaaatctgacctgcaocgaaccgctctgtcttccgctctgctgctcagcaocggtttcogaggtttctcaggatgtttttgagcgtttcaaggataaagaaggtgggtttcagcgggtgaactgaaaggtgacgtccaaggcctgctgagcctgtatgaagcgtcttaccctgggtttcogaggtgagaacctgctggaggagggcgtaccttttccatcaccocctgaaagacaaectgaaagaaggcattaataccaaggttgacagaacaagtggccacgcctggaaactgocatatcaccagcgtctgcaccgtctggaggcaogtgggttccctggataaatacgaaccgaaagaaccgcatacaccagctgctgctggagctggcgaagctggattttaacatggtacagaacctgcaccagaaagagctgcaagatctgtcccgtggtggaccgagstgggctggctagcaaacctggattttgtagcgcaccgctgatggaagtttattctctggcactgggtatggcgccagaccgcagtttggtgaatgtcgcgaagctgttactaaaatgtttgggtctggtgacgatcatogatgacgtgtatgacgtttatggcactctggaogaaactgcaactgftcaccogatgctgtagagcgtgggacgttaacgctattaacacccctgcccgaactatgaaactgtttccctggcactgtacaacaccggttaacgacaogtccctattctattctgaaagagaaggtcataacaacctgtccctatctgacgaaaagctggcgtgaaactgtgcaaaagcctttctgcaagaggcgaatgggtccaacaacaaattatcccggctttctccaagtaoctggaaaaagccagcgtttccctccctccggtgtagcgtgctggcgccctcttacttttccgtatgocagcaggaagacatctccgacacogcctgogttccctgaccgacttccatggtctggtgogtctctagctgogttatcttccgctgtgcaacgatctggccacctctgogggcgagctggaacgtggcgagactaccaattctatcattagctacatgcacgaaaaagatggtaaccagcgaggaacaggcccgcgaagaactgogtaaacgatcagcgcgcaatggaaaaagatgaatcgtgaacgogttagcgaactccacctgctgocaaagcgttcattggaaatcgcagttaacatggcaogtgtttcccactgcacctaccagtatggcgaatgggtctgggtcgcgccagactacgcgactgaaaacogcatcaaaactgctgctgattgaccccttcccgattaccagctgatgtatgtcTAActgcaogtggtaacctatgggaattcgaagctttctagaacaaaaactcatctcagaagaggatctgaaatagcgcctgacaccatcatcatcatcatcattgagtttaaacgggtctccagcttggtctgttttgogggstygagagaagattttcagcctgatacagattaaatcagaacgcgagaagcgtctgataaaaacagaatttgccctggcggcagtagcgcgggtgggtcccacctgaccccaatgocgaactcagaagtgaaacgccttagcgcogagtggtagtggtggggctctcccctgagagagtagggaaactgcccaggcatcaaataaaacgaaaaggctcagtcgaaaagactgggcctttcgttttatctgtttgttggctggaacgctctcctgagtaggacaaatccgcggggagcggatttgaacggttgogaagcaacggcccccgg

Figure 3B

aggggtggggggcaggagcgcgcgcataaaaactgccaggcatcaaattaagcagaaggccatccctg  
acggatggcctttttggctttctacaaaactctttttggtttatttttctaaatcattcaaatat  
gtatccgctcatgagacaataaccotgataaatgcttcaataatattgaaaaaggaagagtatg  
agtattcaacatttccgtgtgccttattcccttttttggggcattttgccttccctgtttttg  
ctcaccocagaaaacgctgggtgaaagttaaagatgctgaagatcagttgggtgacagagtggtta  
catcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaaagaacgttttcca  
atgatgagcacttttaaagtctctgctatgtggcgcgggtattatccctgttgacgcggggcaag  
agcaactcggctcgcgcatacactattctcagaatgacttgggtgagtaactcaccagtccacaga  
aaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgat  
aacactgcccgaacttacttctgacaacgatcggaggaccgaaggagctaacgcttttttgc  
acaacatgggggatcatgtaactgccttgatcgttgggaaaccggagctgaatgaagccatacc  
aaacgacggagcgtgacaccacgatgocctgtagcaatggcaacaacgttggcacaactattaact  
ggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttg  
caggaccacttctgcctcggcccttccggctggctggtttatgtctgataaatctggagccgg  
tgagcgtgggtctcgcgggtatcattgcagcactggggccagatggtaagccctcccgatcgtta  
gttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcctgagatag  
gtgectcactgattaagcattggtaactgtcagaccgaagttaactcatatatacttttagattga  
tttaaaacttcaatttttaatttaaaggatctaggtgaagatcccttttgataatctcatgacc  
aaastcccttaacgtgagttttcgttccactgagcgtcagacccttagaaaagatcaaaggat  
cttcttgagatccctttttctgcgcgtaatctgctgcttgcacaacaaaaaacacccgtacc  
agcgggtgggtttggttgcggatcaagagetacccaactcttttccgaaggtaactggcttccagc  
agagcgcagataccaaaactgtctctctagtgtagccgtagttaggccaccacttcaagaact  
ctgtagcaccgcctacatacctcgtctctgctaatcctgttaccagtggtgctgcccagtgccga  
taagtcgtgtcttacogggttggactcaagacgatagttaccggataaggcgcagcgggtcgggc  
tgaacgggggggtctgtgocacacagcccagcttggagogaacgacctacaccgaactgagatacc  
tacagcgtgagctatgagaaaagcgcacgcttcccgaaaggagaaaggcgyacaggtatccgggt  
aagcggcagggctcggaaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctt  
tatagtcctgtcgggtttcggccacctctgacttgagcgtcagatttttgtgatgctcgtcagggg  
ggcggagcctatggaaaaacggcagcaacgcggcctttttacgggttccctggccttttctgctgccc  
ttttgctcacatgttctttcctgugttatccctgattctgtggataaccgtattaccgccttt  
gagtgagctgataccgctcgcgcgcagccgaacgacccgagcgcagcaggtcagtgagcaggaag  
cggaaagagcgcctgtagcgggtatttctccttaccgcatctgtgaggatatttccacaccgcatag  
gtgcactctcagttacaactctgctctgtagtcgcatagtttaagccagtatacaetccgctatcgc  
taogtgactgggtcatggctgcccgcgacacccgccaaacccgcctgacgcgcctgacggggc  
ttgtctgctcgcggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcag  
aggttttcccgctcatcaccgaaacgcgcgagggcagcagatcaattcgcgcgcgaaggcgaagc  
ggcatgcaattacgttgacccatcgaatgggtgcaaaaaccttccgsgtatggcatgatagcgc  
ccggaaagagagtcattcagggtgggtgaatgtgaaaccagtaacgttatacagatgtcgcagagt  
atgcccgtgtctcttatacagaccgtttccgcgctggtgaaaccaggccagccacgtttctgcgaa  
aacgcgggaaaaagtggaagcggcgatggcggagctgaattacattcccaacgcgctggcaciaa  
caactggcgggcaaacagtcgttgcctgattggcgttgcacctccagctctggcctgcaocgc  
cgtcgcaaaattgtcgcggcgattaaatctcgcgcagatcaactgggtgcccagcgtgggtgctc  
gatggtagaaogaagcggcgtcgaagcctgtaaagcggcgggtgcacaatctctcgcgcacgc  
gtcagtgggctgatcaattaactatccgctggatgaccaggatgccattgctgtggaagctgct

Figure 3C

Gcactaatgttcggggttatttcttgatgtctctgaccagacacccatcaacagtattatttt  
ctcccatgaagaaggtagcgcgactgggctggagcatctggctgcattgggtcaccagcaaatc  
ggctgttagcgggccattaaagtctgtctcggcggctctgctctggctggctggcataaat  
atctcactcgcaatcaaatcagccgatagcggaaacgggaaggcactggagtgccatgtcgg  
tttcaacaaaccatgcaaatgctgaatgagggcatcgttcccactgcgatgctggttgccaac  
gatcagatggcgtgggcaatgcgcgccattaccgagtcgggctgcgcgcttggtgcggata  
tctcggtagtgggatacgcgataaccgaagacagctcatgttatatcccgcgctcaaceccat  
caaacaggattttgcctgctggggcaaacagcgtggaccgcttgctgcaactctctcagggc  
caggcggatgaaggcaatcagctgttgccgctctcactggtgaaaagaaaaaccacctggcgc  
ccaatacgcaaacgcctctcccgcgcttgggcagattcattaatgcagctggcagcaggt  
tcccactggaaagcgggcagtgagcgcacccaattaatgtgagttagcgggaattgatctg  
(SEQ ID NO:2)

Figure 4




Figure 5A

1-  
 ttctcatgtttgacagcttatcatogataagctttaatgcygtagtttatcacagttaaattgc  
 taacgcagtcaggcaccgtgatatgaaatctaacaatgagctcatogtcatcctcggcaccgtca  
 ccttgatgctgtaggcataagccttggttatgcccgtactgcccggcctcttgccggatatecg  
 gatagttctcctccttcagcaaaaaaccctcaagaaccgtttagaggccccaaggggttatg  
 ctagtattgctcagcgggtggcagcagccaactcagcttcttccgggctttggttagcagccgg  
 atcctgacagttagacafacatcagctggtaaatcgggaaagggccaatcagcagcagtttgat  
 ggggtttcagtcgcgtagctctgggcgaccagaccatcgccatactggtaggtgcagtgaggaa  
 acacgtgccatgtaactgcgatttccatgaaocgttttaggcagcagggggagtcgctaacgc  
 gttcaogattcatcttttccattcggcgtogatacagtttacgcagttcttccggggcctgttc  
 ctogctggtaaccatcgttttccgtgcatgtagctaatgatagaattggtagtctcggcaagttcc  
 agctccgcgcagaggtggccagatcgtttgcacagggcgaagataaacgcagctagaacgcacca  
 gaecatggaagtgggtcagggaaagcagcgcgtgggtcggagatgtcttctgctgctggcatac  
 ggaanaagtaagacgggcgcagcagcgcctacaccggaggaggaaacgcctggcgttttccaggtac  
 ttgggaaagccgggataaatttggttggtggaccatttcgcctcttgcagaaaggtttgcaca  
 gttcacgcacagctttcgtcagataggacaggttggttatgaccttctcttccagaaatagaata  
 ggaogtgcgttaacgggttggtagcagtgccaggaaacacagtttcatatagtcggcagggtg  
 ttaantagcgttaacgtcccagcgcctacagcctcggtgaaocagttgcagttcgtccagagtg  
 cataaacgtcatcacagtcctcagatgatcgtcaaccgaccaaaccatttagtaacagctttgog  
 acattcaccaaaactgcccgtctggcgcctatacccagtgcccagaaataaacttccatcagggcg  
 tcgcttacasaatccagtttggtagccagggccatctcgggtccaccagcgggacagatcttgc  
 gctcttctgggtgcagggctctgtaccaatgtaaaatccagcttcggcagctccagcagcagctg  
 gtgatgcccgttcttccgggttggatatttatccaggaaccaacgtgcctccagacgggtgcaga  
 tgggtgatagggcagttccagggcgtggctcacttggttctgcaacctgggtatlaatgcctctt  
 tcaggttggttctcaggtgggtgatggaaaaggtacgcgcctcctccagcaggtctccaccctc  
 gaaaccaggttaagaagcttcatcacaggtcagcagggccttggacgtcaaccttcagttcaocg  
 ctgaaaccacctcttcttatecttgaaacgctcaasaacatcctgagaaacctcgaaaccgctgct  
 gaocgcagcagaaggaaagacagagcgggttgcgtgcaggtcagatattgttcttttggtttccg  
 cagcagtacgatgttttccagggctttaatgatgtcttttcaaatttgtaggtcagaccaggg  
 cgtgcacatcgtcagatcagctccagcagggacagcggctgggtgtctacacgggttgatcatgc  
 agcgaacttcttccctcagtttgggtcgttctctcctccagcttttccacttccaggtcgttctc  
 cagggattgcaggaattcgaatccacaggtttggctgatagtttgcggaacgacggggaatt  
 tgcctggtaattcagtaaatggagaagaggtgcacacatagcagaccttcgatatggccgc  
 tgcgtgatgatgatgatgatgatgatgatggccatgggtatctctctctttaaagtha  
 acaaaattatttctagaggggaattgttatccgctcacaacttcccctatagtgagtcgattaa  
 tttcgggggatcgagatctcagatctctacgcggacgcacgtggccggcctcaccgggcgcca  
 caggtgcgggttgcctggcgcctatctcgcagacatcaccgatggggaagatcgggctcggccactt  
 cgggctcatgagoccttggttcggcgtgggtatgggtggcagggcccggtggccgggggactgttg  
 gggccatctccttgcagcaaccattccttggcgggggggtgctcaacggcctcaacctactac  
 tggcctgcttctaatgcaggagtcgcataagggagagcgtcgagatccgggacaccatcgaat  
 gggcgaaaaccttccgggtatggcatgatagcggccggaaagagagtcattcaggggtggtgaa  
 tgtgaaaccagtaacgttatcagatgtgcagagtatgcgggtgtctcttatcagacogtttcc  
 cggctggtgaaaccagggccagccagcttctcgggaaacggggaaaaagtggaagcggcgatgg  
 cggagctgaattacattcccaaccgcgtggcacaacaactggcgggcaaacagtcggttgcgat  
 tggcgttgcacacctcagctctggccctgcacgcgcgctcgcgaattgtcggcggcattasatct

Figure 5B

cgcgccgatcaactgggtgccagcgtggtggtgtcgatggtagaacgaagcggcgctcgaagcct  
 gtaaacggcggtgcacaatctctcgcgcaacgcgtcagtggtgatcattaaactatccgct  
 ggatgaccaggatgccattgctgtggaagctgectgcaactaagtccggcgttatttcttgat  
 gtctctgaccagacacccatcaacagttatttctcccatgaagacggtagcgcactgggog  
 tggagcatctggctcgcaattgggtcaccagcaaatcgcgctgttagcgggcccattaagtctctg  
 ct.cggcgctctgctgctggctggctggcataaatafctcactcgcaatcaaatccagccgata  
 goggaacgggaaggcgactggagtgccatgtccggttttcaacaaacctgcaaatgctgaatg  
 agggcatcgttcccactgcgatgctggttgccaaacgatcagatggcgctgggcccgaatgcgcgc  
 cattaccgagtcgggctgcgctggtgoggatctctcggtagtgggatacgcagataccgaa  
 gacagctcatgttatatccgcgcttaaccaecatcaaacaggatttctcctgctggggcaaa  
 ccagcgtggaccgcttgctgcaactctctcagggccaggcgggtgaagggaatcagctgttgcc  
 cgtctcactggtgaaaagaaaaaccacccctggcgcccaatacgcacaaccgctctccccgcgc  
 ttggccgattcattaatgcagctggcacgacaggttccgactggaaagcgggcagtgagcgc  
 aacgcattaatgtaagttagctcactcattaggccacgggatctcgaccgatgaccttgagag  
 ccttcaaccagtcagctcctccgggtgggcggggggcatgactatcgtcgcgcacttatgac  
 tgtcttctttatcatgcaactcgtaggacaggtgccggcagcgctctgggtcatttccggcag  
 gaccgcttccgctggagcgcgacgatgatccgctctcgttccgggtattccggaatcttgcaacg  
 cctcctcgaagccttcgctcactggtcccgcacccaaacggttccggcagaaagcaggccattat  
 cgcggcatggcgccgaacgcgctgggctacgtcttgctggcgttcgcgacgogaggctggatg  
 gccttccccattatgattctctcgttccggcggcatcgggatgcccgcttgcaaggccatgc  
 tgtccaggcaggtagatgacgaccatcagggacagcttcaaggatcgtcgcggctcttaaccag  
 cctaaacttcgatcactggaccogctgatcgtcagggcagtttatgcccctcggcgagccatgg  
 aacgggttggeatggattgtaggcgcgcgcctataccttgtctgctccccgcgttgccgtcgcg  
 gtgcattggagccgggccaactcgacctgaatggaagccggcggcaccctcgcataaccgattcacc  
 actccaagaattggagccaatcaattcttgcgggagaactgtgaatgocgcaaaccaacccttggc  
 agaacatatccatcgcgctccgccatctccagcagccgcacgcggcgcatctcgggcagcgttgg  
 gtccctggccacgggtggcagatgatcgtgctcctgctgcttgaggaccggctaggctggcggggt  
 tgccttactggttagcagaatgaatcaccgatcgcgagcgaacgtgaaagcactgctgctgca  
 aaacgtctcgcgacctgagcaacaacatgaatggtcttcgggttccgctgcttctgtaaagtctgga  
 aacggggaagtcagcgcctgcaccattatggtccggatctgcatcgcaggatgctgctggcta  
 cctgtggaaacacctacatctgtattaaagaaagcgtggcattgacctgagtgattttctct  
 gctccgcgcgatccataccgcaggtggttaccctcaaacgctccagtaaccgggcatgttc  
 atcatcagtaaccglatcgtgagcaatcctctctcgttccatcggtatcattaccoccatgaa  
 agaastcccccttacacggagcagcagtgaccacaacaggaaaaaaacgccttaacatgccc  
 gctttatcagaagccagacattaaagctctctgggaaactcaacgagctggacgcggatgaaca  
 ggcagacatctgtgaatcgcctcaccgaccaogctgatgagctttaccgcagctgctcgcgcgt  
 ttccggtgatgacgggtgaaaacctctgacacatgcagctcccggagacgggtcacagcttgtctgt  
 aagcggatgcccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcggggtcgggg  
 cgcagccatgacccagtcacgtagcgatagcggagtgataactggcttaactatggggcatcag  
 agcagattgtactgagagtgaccatataatgoggtgtgaaataccgcacagatgctgaaggaga  
 aaataccgcatacaggcctcttccgcttccctcgcctcactgactcgcctgogctcggctcgttcggc  
 tgcggcagcggatcagctcactcaaggcggtaatacgggttatccacagaatcaggggataa  
 cgcaggaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttg  
 ctggcgtttttccataggtccgcocccctgacgsgcatcacaasaatcgacgctcaagtcaga

Figure 5C

ggtagcgaaaccgacaggactataaagataaccaggcgtttcccctggaagctccctcgtgog  
ctctcctgttcgacccctgcegttacoggatacctgtccgctttctcccttcgggaagcgtg  
gcgctttctcatagctcaecgtgtaggtaatcagttcgggtgtaggtcgttcgctccaagctgg  
gctgtgtgcacgaaaccccggttcagcccgaccgctgcgcttatccggtaactatcgtcttga  
gtccaaccggtaagacaagacttatcgccactggcagcagccactggtaacaggattagcaga  
gagaggtatgtaggcgggtgctacagagttcttgaagtggtggcctaaactacggctacactagaa  
ggacagtatttgggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctc  
ttgatccggcaaacaaaccaccgctggtagcgggtgttttttggtttgcagcagcagattacg  
cgcagaaaaaaaggatctcaagaagatcctttgatctttctacgggggtctgaagctcagtgga  
acgaaaaactcagcttaagggattttgggtcatgagattatcaaaaaggatcttcaactagatcct  
tttaaattaaaaatgaagttttasatcaatctaaagtatatatgagtaaacttggctcagcgt  
taccaatgottaatcagtgaggcacctatctcagcgatctgtctatctcgttcacatagttg  
cctgactcccgtcgtgtagataaactacgatacgggaggggttaccatctggcccagtgctgc  
aatgataccgcgagacccaagctcaccggctccagatttatcagcaataaacagccagccgga  
agggccgagcgcagaagtggtcctgcaactttatccgctccatccagctctattaattgttgc  
gggaagctagagtaagtagttccgcttaatagtttgcgcaacgttgttgcactgtcgcagg  
catcgtggtgtcacgctcgtcgtttgggtatggcttcattcagctccggttcccacgatcaagg  
cgagttacatgatccccatggttggcaaaaaagcgggttagctccttcggctcctccgatcgttg  
tcagaagtaagttggccgagtggtatcactcatggttatggcagcactgcataattctcttac  
tgtcatgccatccgtaagatgctttctgtgactggtgagtaactcaaccaagtcattctgagaa  
tagtgtatgoggogaccagttgctcttgcgggctcaaacgggataataccgcgccacata  
gcagaactttaaaagtgtcatcatggaaaaagcttcttcggggcgaaaactctcaaggatctt  
accgctgttgagatccagttogatgtaacccactcgtgcacccaactgatcttcagcatctttt  
actttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaaatgcccgcasaaaagggataa  
gggogacacggaaatgttgaatactcatactctcctttttcaatattattgaagcatttatca  
gggttattgtctcatgagcggatacataatttgaatgtatttagaaaaataaacaataggggtt  
ccgcgcacatttcccggaaaagtgccacctgacgtctaaagaaaccattattatcatgacattaa  
cctataaaaaatagggctatcaogagcccttctctcaagas

SEQ ID NO:3

Figure 6




Figure 7A

1-

cecgttactgttcgggaattccgcttgccgattcattaatgcagctggccacgacaggtttcc  
 cgactggaaagcgggcagtgagcgcgaacgcaattaatgtgagttagctcactcattagccccc  
 caggctttacactttatgcttccggctcgtatgttgtgtggaattgtgagcggataacaatttc  
 acacaggaaacagctatgaccatgattacgccaagcttgtatcgattasataaggaggaataaa  
 ccatgtgtgogacctcttctcaatttactcagattaccgagcataaattcccgctcgttccgcaa  
 ctatcagccaaacctgtggaatttcgaattccctgcaatccctggagaaacgacctgaaagtggaa  
 aagctggaggagaaagcgacccaaactggaggaagaagtccgctgcatgatcaaccgtgtagaca  
 cccagccgctgtccctgctggagctgatcgacgatgtgcagcgcctgggtctgaactcaaaatt  
 tgaanaagacatcattaaagccctggaaacacatcgtactgctggacgaaaacaaaaagaacaaa  
 tetgaactgcacgcaacccgctctgtcttccgctcgtcgtcagcaagggtttccgaggtttctc  
 aggatgtttttgagcgtttcaaggataaagaagggtggtttcagcgggtgaactgaaaggtgacgt  
 ccaagccctgctgagcctgtatgaagcgtcttaccctgggtttccgaggggtgagaacctgctggag  
 gagcgcgctacctttccatcaccacccctgaaacaaacctgaaagaaggcattaataccaagg  
 ttgcagaacaagtgagccacgcccctggaactgccatataccagcgtctgcaacctctggagcc  
 acgtttggttccctggataaatacgaaccgaaagaaccgcatcaccagctgctgctggagctggcg  
 aagctggatttttaacatggtacagacctgcaccagaaagagctgcaagatctgtcccgtcgt  
 ggaccgagatggccctgctagcaaaactggattttgtacgcgaccgctgatggaagtttat  
 ctgggcaactgggtatggcgcgaccccgagtttgggtgaatgtcgcaagctgttactaaaatg  
 tttggctcgtgtgacgatcatcgatgacgtgtatgacgtttatggcactctggacgaactgcaac  
 tgttcaaccgatgctgtagagcgtgggacgttaacgctattaaacacctgcccggactatatgaa  
 actgtgtttccctggcactgtacaacaccttaaccgacacgctcctattctattctgaaagagaaa  
 ggtcataacaacctgtcctatctgacgaaaagctggcgtgaaactgtgcaaaagcctttctgcaag  
 aggcgaaatgggtccaaacaaacaaattatcccggtttctccaagtaacctggaaaacgccagcgt  
 tccctccctccggtgtagcgtctgctggcgcgctcttactttccgctatgccagcagcaggaagac  
 atctccgaccacgocgtgcttccctgaccgacttccatggtctgggtgcttctagctgctta  
 tcttccgctgtgcaacgatctggccacctctgcccggagctggaaactggcgagactaccaaa  
 ttctatcattagctacatgcaacgaaacgatggtaaccagcaggaacaggcccgcaagaactg  
 cgtaaactgatcgacgcgcaatggaaaaagatgaaactgtaacgcgcttagcgaactccacctgc  
 tgcctaaagcgttccatggaaatcgcagttaaactggcagctgtttccactgcacctaccagta  
 tggcgtggtctgggtcggccagactacgcgactgaaaaaccgcatcaactgctgctgatgac  
 cctttccgattaaccagctgatgtatgtctaactgcaggtcgaactctagaggatccccgggt  
 ccgagctcgaattcactggccgtcgttttacaacgtcgtgactgggaaaaacctggcgttacc  
 aacttaatcgccttgcagcaatccccctttccgacgctggcgtaatagcgaagagggcccgac  
 cgatcgccttcccaacagttgcccagcctgaatggcgaatggcgcctgatgaggtatttctc  
 cttaacgcatctgtgcggtatttcacaccgcatatggtgcaactctcagtacaactctgctctgatg  
 ccgcatagttaaagccagccccgaccccccaacacccgctgaogagcttagtaaaagccctggc  
 tagattttaatgcccgatgttgcgattacttcgccaactattggcataacaagaaaagccagcc  
 tttcatgatataatccccaatgtgttagggcttattatgcaacttaaaaataaataaagcag  
 acttgacctgatagtttggctgtgagcaattatgtgcttagtgcactcaacgcttgagttangc  
 ccgcccgcgaagcggcgtcggcttgaacgaattgttagacattatttgcccgaactaccttggtga  
 tctcgcctttcactgtagtggaacaaattcttccaactgatctgcgcgcgagggccaagcagcttc  
 ttcttgcacaagataagcctgtctagcttcaagtatgaogggctgatactggcggcggcagggc  
 tccattgcccagtcggcagcagacatccttcggcgcgattttgcccgttactgocgtgacccaaa  
 tgggggacaacgtgaagcactacatttcgctcatcgcagcccagtcgggcggcgagttccatag

Figure 7B

cgTTaaggTttcatttagogcctcaaatagatcctgTtcaggaaocggatcaaaagagttcctcc  
 gccgctggacctaaccaaggcaacgctatgTttctctTgctttTgtcagcaagatagccagatcaa  
 TgtcgatcgtggctggctegaagatacctgcaagaatgTcattgogctgccattctccaaattg  
 cagTtcggcgttagctggataaacgcocaggaatgatgtogtctgTgcacaacaatggtgactct  
 acagcggggagaatctcgcctctctccaggggaagcogaagTttccaaaaggTcgtTgatcaaag  
 ctccggcgtTgtttcactcaagccttacggTcacccgtaaccagocaaatcaatatcactgtgtgg  
 ctTcaggccgccatccactgeggagccgtacaaatgTaccggccagcaacgTcggTtcgagatgg  
 cgctcgatgacgccaactacctctgatagTtgagTcgatacttcggcgatcacccgcttccctca  
 TgatgtTtaactTtgTtttagggcgactgccctgctgctgTaaacatcgTtTgctgctccataacat  
 caaacatcgaccacggcgTaaacggctTgctgctTggatgcccggagccatagactgtacccca  
 aaaaaacagTcataacaagccatgaaaaacggccactgcccgtTaccacogctgogTtcggTca  
 aggtTctggaccagTtTgctgagcgcatacgcTactTgcattacagctTaccgaacogaacagge  
 TtatgtccactgggtTcgtgcttccactccgTttccacggTgtgctgTcacccggcaacctTggc  
 agcagcgaagTcgaggcattTctgtcctggtTggcgaacgagcgcgaaggtTtcggTctccagc  
 atcgtcaggcattTggcggcctTgctgTctTctacggcaaggtTgctgTgcacggatctgcccTg  
 gctTcaggagatcggaaagacctcggccgtcgcggcgtTgcggTggtgctgaccccggatgaa  
 gtggTtcgcatacctcggTttctTggaaggcagcactcgtTtTgtTcggccagctTctgtatgaa  
 ogggcatgcccgatcagTgagggtTtgcaactgcccggTcaaggatctggattTcgatcacggcac  
 gatcatcgtgcccggaggccaaaggctccaaaggatcgggctTgatgtTaccgagagctTggca  
 cccagcctgcccgagcaggggaaattaatTcccacgggtTtTgctgcccgcasaacgggctgtTct  
 ggtgtTgctagTttgttatcagaatcgcagatccggctTcagccgTtTgcccggctgaaagcgc  
 TattTctccagaattTgcaatgattTttTcccacgggaggcgtcactggctcccgTgtTgtcg  
 gcagctTtgatTcgataagcagcatcgcctgTttcaggctgtctatgtTgTgactgtTgagctgt  
 aacaagTtTgtctcaggTgtTcaattTctagTctagTctgctTtTgtTttactggTttcaacctgt  
 ctattaggtgtTacatgctgtTcatctgtTacattTgTcgatctgtTcatggTgaacagctTtga  
 atgcaacaaaaactcgtaaaagctctgatgtatctatctTttTtaaccgTttTcatctgtTgca  
 TatggacagTttTcctTtgatagTaaacggTgaacagTtTgtTctactTttTgtTttTgtTagtct  
 gatgctTcactgatagatacaagagccataagaacctcagatcctTccgtatTtagccagTatg  
 TctctagTgtTgTtcgTtTgtTttTgctgagccatgagaacgaacctTgagatcataactTac  
 TttgcatgTcactcaaaaattTtgcctcaaaaactggTgagctgaattTttgcaagTtaaagcact  
 gtTgagTgtTttTcttagTccgtTatgtagTtaggaatctgatgtaatggTtTgtTggtatTttg  
 TcaaccattcattTttatctggTtTgtTctcaagTtcggTtacgagatccattTgtctatctagTt  
 caactTggaaaatcaacgtatcagTcgggcccctcgtTatecaaccaccaattTcatattgct  
 gTaaagTgtTaaatctTactTattggTttcanaaccocattTggTtaagcctTttaaactcattg  
 tagTtatTttcaagcattTaatatgaactTaaattTcatcaaggctaatctctatatTtgcctTgt  
 gagTttctTttTgtTgtTtagTttctTtaataaccactcataaatctctcatagagTattTgtTttc  
 aaagactTaacatgTtcagattatattTtatgaattTttTtaactggaaaagataaggcaat  
 atctctTcactaanaactaatTctaatTttTcgtTtgagaactTggcatagTttTgtccactTgga  
 aatctcaagcctTtaaccaaaggattcctgatTtTccacagTtctcgtcatcagctctctggt  
 TgctTtagctaatcaaccataagcattTtTcctactgatgtTcatcaTctgagcgtatTggtta  
 TaagTgaacgataaccgTccgTtctTtTcctTgtagggtTtTcaatcgtggggtTgagTagtTgca  
 cacagcataaaaattagctTggTtTcatgctccgTtaagTcatagcactaatcgttagTtcatT  
 TgctTtgaaaacaactaatTcagacatacatctcaattggTctaggtgattTtaactactatac  
 caattTgagatgggctagTcaatgataattTactagTcctTttTcctTtgagTtTgtgggtatctgta

Figure 7C

Aattctgctagaccctttgctggaaaacttgtaattctgctagaccctctgtaattccgctag  
acctttgtgtgtttttttttttatattcaagtgggtataatttatagaataaagaagaataa  
aaaaagataaaaagaatagatcccagccctgtgtataactcactactttagtcagttcogcagt  
attacaaaaggatgtcgcaaacgctgtttgctcctotacaaaacagacottaaaaccctaagg  
cttaagttagcaccctcgcaagctcgggcaaactcgtgaatattccttttgtctccgaccatcag  
gcacctgagtegtgtctttttcgtgacattcagttcgtcgcgtcaccggctctggcagtgat  
gggggtaaatggcactacagggccttttatggattcctgcaaggaaactaccataatacaag  
aaaagcccgtcagggcttctcagggcgttttatggcgggtctgctatgtgggtgatctgact  
ttttgctgttcagcagttcctgcccctctgattttccagctcgaaccctcggattatcccgtga  
caggtcattcagaactggctaattgcacccagtaaggcagcggatcatcaacaggctta

SEQ ID NO:4

Figure 8A




Figure 8B




Figure 8C




Figure 8D




Figure 9A

A.




Figure 9B




Figure 10A




Figure 10B




Figure 10C




Figure 11




Figure 12A

1-

gaattgctccattttcttctgctatcaaaaataacagactogtgattttccaaaacgagctttcaa  
 aaaagcctctgcccttggcaatcggatgacctgtctataaaattcccgatattgggtaaacagc  
 ggcgcaatggcggcgcgcatctgatgtctttgcttggcgaatggtcatcttatttcttccctcc  
 ctcaataattttttcattctatcccttttctgtaaagtttatttttcagaatacttttatcctc  
 atgctttgaaaaaatatccagataaatatccattggtctcaccggaagcaccgcaggtcatttga  
 acgaattttttogacaggaatttgccgggactcaggagcatttaacctaaaaagcatgacatt  
 tcagcataatgaacatttactcatgtctattttctgttcttttctgtatgaaaatagttatttctg  
 agtctctacggaaatagcggagagatgatataacctaaatagagataaaatcatctcaaaaaatg  
 ggtctactaaaaatattatccatctatfacaataaattcacagaaatagctcttttaagtaagtct  
 actctgaatttttttaaaggagagggtaaaagagtggtgtgacacctctctcaatttactcaga  
 ttaccggagcataattcccgctgttccgcaactatcagccaaacctgtggaatttogaattcct  
 gcaatccctggagaacgacctgaaagtggaaaagctggaggagaaagcgaaccaactggaggaa  
 gaagtccgctgcctgatcaacctgtgacacccagccgctgtccctgctggagctgatcagcag  
 atgtgcagcgcctgggtctgacctacaatttgaaaaagacatcattaaagcctggaaaaacat  
 cgtactgctggacgaaacaaaaagaacaaatctgacctgcaacgcaacctctgtcttccgct  
 ctgctgctgctcagcaaggtttccgaggttctcaggatggtttttgagcgtttcaaggataaagaag  
 gtgggtttcagcgggtgaactgaaaggtgscgtccaaggcctgctgagcctgtatgaaagctctta  
 cctgggtttcaggggtgagaacctgctggaggaggcggtaacctttccatccccacctgaag  
 acaaacctgaaagsaggcattataaccaaggttgcagaacaagtgagccacgccttggaaactgc  
 catatcaccagcgtctgcaacgctctggaggcagcttgggttccctggataaatacgaaccgaaaga  
 accgcatcaccagctgctgctggagctggcgaagctggattttaaactggtacagaccctgca  
 cagaagagctgcaagatctgtcccgctgggtggaccgagatgggctggctagcaaacctggatt  
 ttgtacggacccgctgatggaagtttatttctgggcaactgggtatggcgcagaccgcagtt  
 tggtyaatgtccgaaagctgttactaaaatgtttggctctggtgacgatcatcgatgacgtgat  
 gacgtttatggcactctggacgaactgcaactgttccaccgatgctgtagagcctgggacqttta  
 aogctattaacacctgcccgaactatgaaactgtgttccctggcactgtacaacacctta  
 cgacagctcctattctattctgaaagagaaaggtcataacaacctgtcctctctgacgaaagc  
 tggcgtgaactgtgcaagccttctgcaagaggcgaatgggtcccaacaacaaaattatccggg  
 cttctccaagtacctggaaaaacgcagcgttctctccctccgggtgtagcctgctgctggcgcg  
 ttactttccgctatgcccagcagcaggaagacatctccgaccgcgctgcttccctgaccgac  
 tccatggtctggtgcttctagctgcttattctccgctgtgcaacgatctggccacctctg  
 cggcggagctggaaactgcccagactaccaattctctcattagctacatgcaacgaaacgatgg  
 taccagcaggaacaggcccgcgaagaactgcgtaaacctgatcagcgcgcaatggaaaaagatg  
 aatcgtgaaacgcttagcgaactccacctgctgacctaaagcgttccatggaaatcgcagttaca  
 tggcacgtgttcccactgeacctaccagtatggcagatgggtctgggtcgcaccagactaccgac  
 tgaaaaccgcatcaaacctgctgctgattgacctttcccgattaaaccagctgatgtatgtctaa  
 aaaaaaccggccttggccccgcgggttttttattttttcttccctccgcatgttcaatccgct  
 ccaataatcgaacggatggctcctctgaaaatttttaacgsgaaaacggcgggttgaccggctcag  
 tcccgtaaaggccaagctcctgaaactctcaatcgcgccttccgggtttccggctcagctcaatg  
 ccgtaacggctcggcggcgttttccctgataccgggagacggcattcgtaatcggatcctctagag  
 tgcacctgcaggcatgcaagcttgcctccgcttccgggtgatgacggtgaaaaacctctgaca  
 catgcagctcccgagagacggctcacagcttctctgtaagcggatgccgggagcagacaagccgt  
 cagggcgcgctcagcgggtgttggcgggtgtcggggcgcagccatgacccagtcacgtagcagata

Figure 12B

g c g g a g t g t a t a c t g g c t t a a c t a t g c g g c a t c a g a g c a g a t t g t a c t g a g a g t g c a c c a t a t g  
c g g t g t g a a a t a c c g c a c a g a t g c g t a a g g a g a a a a t a c c g c a t c a g g c g e t e t t c c g t t c o c t  
c g e t c a c t g a c t e g e t g c g e t c g g t c g t t c g g c t g c g g c g a g e g g t a t c a g t c a c t c a a a g g c  
g g t a a t a c g g t t a t c c a c a g a a t c a g g g g a t a a c c g a g a a a g a a c a t g t g a g c a a a a g g c c a g  
c a a a a g g c c a g g a a c c g t a a a a a g g c c g g t t g c t g g c g t t t t t c c a t a g g c t c c g c c c c c t g  
a c g a g c a t c a c a a a a t c g a c g t c a a g t c a g a g g t g g c g a a a c c o g a c a g g a c t a t a a a g a t a  
c c a g g o g t t t c e c c e t g g a a g c t c c c t c g t g c g e t e t c c t g t t c c g a c c e t g e o g e t t a c e g g a  
t a c c t g t c o g c e t t t t c c c t t c g g g a a g c g t g g c g t t t c t c a a t g c t c a e g e t g t a g g t a t c  
t c a g t t o g g t g t a g g t c g t t c g e t c c a a g e t g g g c t g t g t g c a c g a a c c c c c g t t c a g c c o g a  
c o g t g e g c e t t a t c o g g t a a c t a t c g t c t t g a g t c c a a c c o g g t a a g a c a c g a c t t a t o g c c a  
e t g g c a g c a g c c a c t g g t a a c a g g a t t a g c a g a g c a g g t a t g t a g g c g g t g c t a c a g a g t t e t  
t g a a g t g g t g g c e t a a c t a c g g t a c a c t a g a a g g a c a g t a t t t g g t a t c t g c g e t e t g e t g a a  
g c c a g t t a c c t c o g g a a a a g a g t t g g t a g c t e t t g a t c c g g c a a a c a a c c a c c g e t t g g t a g c  
g g t g g t t t t t t g t t f g c a a g c a g c a g a t t a c g c g c a g a a a a a a g g a t c t c a a g a a g a t c e t t  
t g a t c t t t t c t a c g g g t c t g a c g t c a g t g g a a c g a a a a c t c a c g t t a a g g a t t t t g g t e a t  
g a g a t t a t c a a a a g g a t c g a a g t c g g t t c a g a a a a g a a g g a t a t g g a t e t g g a g c t g t a a t a  
t a a a a c o t t e t t c a a c t a a c g g g c a g g t t a g t g a c a t t a g a a a c c g a c t g t a a a a g t a c a  
g t e g g c a t t a t c t c a t a t t a t a a a a g c c a g t c a t t a g g c e t a t c t g a c a a t t e c t g a a t a g a g t  
t c a t a a c a a t c e t g c a t g a t a a c c a t c a c a a c a g a a t g a t g t a c c t g t a a a g a t a g c g g t a a  
a t a t a t t g a a t t a c e t t t a t t a a t g a a t t t t c e t g c t g t a a t a a t g g g t a g a a g g t a a t t a c t a  
t t a t t a t t g a t t a t t a a g t t a a a c c a g t a a a t g a a g t c c a t g g a a t a a t a g a a a g a g a a a a g  
c a t t t c a g g t a t a g g t g t t t t g g g a a c a a t t t a a a g a a c c a t t a t a t t t c t c t a c a t c a g a  
a a g g t a t a a a t c a t a a a a c t c t t g a a g t c a t t c t t t a c a g g a g t c c a a a t a c c a g a g a a t g t t  
t t a g a t a c a c c a t c a a a a a t t g t a t a a a g t g g c t c t a a c t t a t c c c a a t a a c c t a a c t c t c e g t  
c g c t a t t g t a a c c a g t c t a a a a g c t g t a t t t g a g t t t a t c a c c e t t g t c a c t a g a a a a t a a a  
t g c a g g g t a a a a t t a t a t c e t t c t t g t t t t a t g t t t o g g t a t a a a a c a c t a a t a t c a a t t t c t  
g t g g t a t a c t a a a a g t c g t t t g t t g g t t c a a a t a a t g a t t a a a t a t c t c t t t c t c t t c c a a t  
t g t c a a a t c a a t t t t a t t a a a g t t c a t t t g a t a t g c c t c e t a a a t t t t a t c t a a a g t g a a t t  
t a g g a g g e t t a c t t g t e t g e t t e t t c a t t a g a a t c a a t c e t t t t t a a a g t c a a t a t t a c t g t  
a a c a t a a a t a t a t a t t t a a a a a t a t c c c a c t t t a t c c a a t t t t c g t t t g t t g a a c t a a t g g g t  
g c t t t a g t t g a a g a t a a a g a c c a c a t t a a a a a a t g t g g t c t t t t g t g t t t t t t a a a g g a t t t  
g a g e g t a c g c g a a a a a t c e t t t t t c t t t t e t t a t c t t g a t a s t a a g g g t a a c t a t t g c c g g t  
t g t c c a t t e a t g g c t g a a c t e t g e t t e c t c t g t t g a c a t g a c a c a c a t c a t e t c a a t a t c o g a a  
t a g g g c c a t c a g t c t g a c g a c c a a g a g a g c c a t a a a c a c c a a t a g c e t t a a c a t o a t c o c c a t  
a t t t a t c c a a t a t t c g t t e c t t a a t t t c a t g a a c a a t e t t c a t t c t t t c t t c t o t a g t c a t t a t  
t a t t g g t c c a t t e a c t a t t c t c a t t c c c t t t c a g a t a a t t t t a g a t t t g e t t t t c t a a a t a a g  
a a t a t t t g g a g a g c a c c g t t e t t a t t c a g c t a t t a a t a a c t c g t o t t c c t a a g c a t c e t t c a a t  
c e t t t t a a t a a c a a t t a t a g c a t e t a a t c t t c a a c a a a c t g g c c c g t t t g t t g a a c t a c t e t t t  
a a t a a a a t a a t t t t c o g t t c c c a a t t c c a c a t t g c a a t a a t a g a a a a t c c a t o t t c a t e g g e t  
t t t t c g t c a t c a t e t g t a t g a a t c a a a t o g c e t t e t t t c t g t g t o a t c a a g g t t t a a t t t t t a t  
g t a t t t c t t t t a a c a a a c c a c c a t a g g a g a t t a a c c t t t a c g g t g t a a c c t t c e t c o a a a t c  
a g a c a a a c g t t t c a a a t t c t t t t c t c a t c a t c o g g t c a t a a a a t c o g t a t c e t t t a c a g g a t a t  
t t t g c a g t t t c g t c a a t t g c o g a t t g t a t a t c e g a t t t a t a t t t a t t t t t e g g t o g a a t c a t t t  
g a a c t t t t a c a t t t g g a t c a t a g t e t a a t t t c a a t t g c e t t t t t c c a a a a t t g a a t c a a t t g t t t

Figure 12C

ttgattcaogtagttttctgttattctaaaataagttggttccacacataccattacatgcatg  
tgctgattataagaattatcittattattttattgtcacatccgttgcaegcataaaaaccaacaa  
gatttttattaattttttttatattgcatcattoggogaatccttgagccataatctgtcaaact  
cttatttaattctctogccatcataaacatttttaactgttaatgtgagaaacaaccaacgaact  
gttggcttttgtttaataacttcagcaacaaccttttgtgactgaatgcoatgtttcattgctc  
tctccagttgcaattggacaaaagcctggatttgcaaaaccacactcgataccactttctttc  
gootgtttcaogattttgtttatactctaataatttcagcacaatcttttactctttcagocctt  
ttaaattcaagaaatagcagaagttcaagtaatcaacattagcgattttcttttctctccatg  
gtctcactttccactttttgtcttgtccactaaaacccttgatttttcatctgaataaatgct  
actattaggacacataatattaaaagaacccccatctatttagttattttgttttagtcaactat  
aactttaacagatggggtttttctgtgcaaccaattttaagggttttcaatactttaaaacaca  
tacataccaacacttcaacgcacctttcagcaactaaaataaaaatgaogttaatttctatatgt  
atcaagataaagaaagaacaagttcaaaaccatcaaaaaagacaccttttcagggtgctttttt  
atttataaactcattccctgatctcgaacttoggcttttttttaoctctcgggttatgagttagt  
tcaaatcogtcttttttaggttctaaatcgtgtttttcttggaaattgtgctgttttatccttta  
ccttgtctacaaaccccttaaaaacgttttttaaggcttttaagocgtctgtaogttccttaag

SEQ ID NO:5

Figure 13

ATGTGTGCAACCTCCTCCAGTTTACTCAGATTACCGAGCATAATTCCTCGACGATCTGCTAACT  
ACCAGCCGAACCTTTGGAACTTTGAGTTTCTCCAGTCTCTCGAAAATGACCTGAAGGTGGAAA  
GCTCGAGGAGAAGGCGACCAAACCTCGAGGAGGAGGTGCCATGTATGATCAACAGAGTTGACACC  
CAACCCCTGTCTTTGCTGGAGCTGATCGACGATGTGCAGCGGTTGGGTTTGACTTATAAATTCG  
AGAAGGACATTTATCAAGGCACTGGAGAACATTGTGCTCCTCGACGAGAACAAAGAAGAACAGTCT  
TGATCTTCACGCTACCGCTCTCTCTTTCCGACTTCTTCGACAACACGGCTTCGAGGTGTGCGAG  
GACGTCTTCGAGAGATTTAAGGACAAGGAGGGAGGATTTAGCGCGGAGCTGAAGGGAGACGTTT  
AGGGTCTTCTCTCCTTGTACGAGGGGCTTCTACCTGGGATTCGAGGGAGAGAACCTCCTGGAGGA  
AGCTCGTACATTTTCCATCACTCACCTTAAGAATAACCTTAAGGAGGGAAATTAACACCAAGGTG  
GCCGAGCAGGTTTCTCAGCGCCCTGGAGCTCCCTACCACCAACGGCTCCATAGACTGGAGGCTC  
GTTGGTTCCTGGACAAATATGAGCCAAAGGAGCCTCATCATCAGTTCGCTGTTGGAGTTGGCCAA  
GCTGGACTTCAATATGGTTTCAGACGCTGCACCAAAAGGAGTTCAGGACCTGTCTCGATGGTGG  
ACCGAGATGGGATTTGGCCTCGAAGCTGGATTTTGTCCGTTGACCGACTTATGGAGGTCTATTTTT  
GGSCCCTTGGAAATGGCGCTGACCCCCAGTTCCGGASAGTGGCCSAAGGCGGTGACGAAGATGTT  
CGGTCTTGTGACTATCATCGACGACGTCTACGATGTCTACGGCACACTCGACGAGTTGCAGCTG  
TTCCTGACGCGCTCGAGCGATGGGATGTGAACGUCATTAACTCTCCCTGACTATATGAAGC  
TGTGCTTCCCTGGCTCTGTACAACACTGTCAACGATACCTCGTACTCTATCCTCAAGGAGAAGGG  
ACACAACAATCTCTCTACTTGGACCAAATCCTGGCGAGAACTGTGCAAGGCTTTTCTGCAGGAG  
GCTAAATGGTCCAATAACAAGATCATTCCTGCTTTTCTTAATAACCTGGAAAATGCCTCGGTGT  
CGAGCTCTGGGCTCGCCCTTCCTGGCCCTTCCTACTTCTCCGCTCGCCAGCAGCAGGAGGATAT  
TTCGGATCATGCTCTTATGATCGCTGACCGATTTTCACGGCCTCGTGGGATCTTCTCGCTGATT  
TTTCGGTTGTGTAATGACCTTSCGACTCTGCTGCTGAGCTGGAAACGAGGCGGAGACTACAAAT  
CCATTAATTTCTTACATGCACGAAAACGATGGAACATCTGAAGABCAGGCTAGAGAGGAACTGCG  
AAAGTTGATCGACCGCGAGTGGAGAGATGCAACAGAGAGCGGGTGTCCGACTCTACCCTGCTT  
CCCAAGSCCTTCATGGAGATCGCCGTGAACATGGCTCGAGTTTCCATTGTACTTACCAGTACG  
GPGACGGCCTGGGTCTCCGACTACGCTACAGAGAACCGAATCAAGCTGCTGCTCATCGACCC  
CTTCCCTATCAACCAATGATGTACGTGTAA

SEQ ID NO:6

Figure 14




Figure 15A

1 TCGACCGGFG AGAAGAACAG CATCGGGBCA AGGGAAGGAA GABCAAAGAC AAAGAAAACA  
61 AAAGAAAGCA ATTGAARACA AAACAAAACA ATTTTCATTC CTTCCTTAT CATTCCTTYY  
121 CPTTCTPTT CPTCCTATCA AGSCACTCCA TCRATCCCF ATTCCTCTPA TTTTCTCTCF  
181 TCTCTTAT CCATTTCTT CTCTCTAGGT GTGCTCTC TCCTCTTCA ATTTCTCTAC  
241 TCCGCAFTCC AACSCATCTT TCCCCCAACC TCCCATTTCC TCCCTACGGC CCGATAGCGA  
301 TCBUTTTTCC CTGCGTATCA CTGSETACGS SCCCCTCCFC TGCACCGTAA CCCTCTAGGT  
361 ATTTACCATA TCATAAAGTY TTTCCGNGG CTTATCGGTG ACCCCCTGTC GCCCTCCTAT  
421 TGGCTTCCGG ATATCTCTCF TCTCCATTAAG GTGATCCATG CTTCCTFGAAG ATCCCCGAAA  
481 TSTTCCACY TTGGCGGGGA ATCATTCCNF CCACTTCTTY CTCTCTCGCT TTCTCTCATTC  
541 GGCGTCCCC TTCCCGGCTF CATTCGCTT CCGCTCCGPT TTTGCTTTGG CGATGTTACT  
601 TGGGGAGAGG TCGGATPATC CTTTGGCAAA AACTTGGTTF GAGGCTCCOC ATGGTATPAA  
661 TAGTGGGTGG TGGACAGGTG CTTTGGCTTY TCTTAAAGCA AGAGAAFOOC ATTTCTCTGA  
721 CTATCAGGAA TTCACATACA TTATGAAGAT CACCGGTGTC ATTGCCCTTF TATTTCTACT  
781 TCGTCTGCCC TCCCTATTC CAGTTGCCGA TCCCTGGTGS STTTCAGTTA GCAGTCAFA  
841 TCGTCAFTTC CPTCGTPTT ACCAAAATG GMACTCTTF GCAATCTCTG ATAGACCCBA  
901 CCTTAAAGAG ABAATGATA CACTTGCAG TGGTATCAA GTTGAABAAG TOSTAATTTT  
961 GCTCCTCTAC GCTGTTAGGG CCCCACAAA AATGACTCAA ACCATGGCTG ATGCTCCTCC  
1021 TATCAGTGG CAGAAATGGC CCGTAAAT AGGATATAT ACACCAAGAG GTGAACCTT-  
1081 GATATCTCT ATGGCGGCTT TTTACCTCA AAAATTCAG CAACAAGGAA TUCPTTCTA  
1141 GGCTCTCTT CCACTCCTA ACTCCATTA TCTCTGGCTT GACCTGATC ASCCTACTTY  
1201 AAAAAGCTG GAGCAATTC TTGCTGCTT GGCACACAA TGGGCTTGA CAATTCATCA  
1261 CCAACAAAAT CTTGAGAAAG CPTGATCTCT TTTTCTCTCC GTTAAAGCTG GAACCTCTCC  
1321 TATEGATAA ACTGAAGTC AACRAGCTG TGGAGAGAG GCACAAGTC CTATBGTAA  
1381 TTTCAATCAA CATTACATCC CCTTTTACG TTAAAGTAT ACACATPAA ATTTAGTAC  
1441 TCTGCTGG TGGCAAAAAC ACTCTCTGA TAAATCTCT GACCTAGGT TATCTAGCC  
1501 TTYAATTT TCCATAAAAG ATATAGTAA CAAGGTGCGA TTGATGGAG CTATTGGCTY  
1561 ATCTCTACT TTGGCGAGA TTTTCTCTT TGAATPAGCT CANGCATG TCACAGCTGC  
1621 TTGGGTRAG ATCCACTCG ASGRAGGTG GCTTCTTG CTRAGTTGC ATATGTTC  
1681 ATTCGATTTG ATGGCCGAA CACTTATAT TGTCTGACT AACGCTACTC CTTTATTGCA  
1741 AGCTATATCA AATGCCCTA ATCCCAAGC CACTGAATCA AATETCCAG ATATPTCAG  
1801 TGATACAAA ATATTTCTA TTGCAGTCA TGACCAAA ATTTCTAATA TAGCCGCTY  
1861 GTTAAATATG CSTTGGACAT TACCAGGTC ACCGATART ACTCCCTCAG GTGGTCCCT  
1921 AGTATPAAA CPTCTGCTG ATAAAAGTGG ABAACATAT GTTCTCTAT CTATGGTTA  
1981 TCAACACTA GAACACTTC GATCAGAGC TCCCCTCTT CTAAATCAGC CTGCGGATC  
2041 TGTCTACTT AATATTCAG GTTGAATTA TCAACAGCC GGGGTTACT STCTCTTTC  
2101 CACTTTTACA AGAGTCTTCT CCAATCTGT TGAACCTGSA TGCACACTC AATATGAGG  
2161 ATCCAGTAA GCGAATGGA ATGATCTCA CPTTAAATC CTAAATGATA CATGCTATA  
2221 GTTCTTTCTT TTTTCTCTT ATGCTGTTT TGGTGGTAC GSCCTTCTC AATCTCAAT  
2281 TGTGCTCTG GTTCCAGCTT GPTTCAAA CTGTTCTAT CATGAATCTT FTACCATTTC  
2341 ACCACAGCTT TATACCTTC TCTCATAGA TCTTATPAA ACCATCTCGG GCTTAGGCTG  
2401 GAAGAAAGT CTTGPTCTT TATTTCTCTT TTTCCATCT CAAGGCTTCT CTTTCTTCC  
2461 TCTCCCTCT TCACTTGGG GTTTGACCTG TCTTTTAGA ATTTTGGCTY GTTGCAGCAT  
2521 CTTATTTTCT GTTTTGGGAA AACGAAGGCT TTTACTCTCT TCACTAGTTC GACGATTTA  
2581 CCTTTGAAA CCAACTACTT TTGCATGTT TGTATAGAAA TCAATGATAT TAGAATCCA  
2641 TCCTTTAAAT TCTTTCAAAG TAGTTGAGCT ATAGTTAAGT GTAAGGGCCC TACTGCSAA  
2701 GCATTTGCCA AGATTTTCT CATTATCAA GAACGAAGT TAGGGATCG AAGACATCA  
2761 GATACCTGCG TAGTCTTAC GATARACTT GCGGATAGG GATGSGCAA TSTTTCTTT  
2821 ATCGACTTGC TCGCAACTY ACGAGAATC AAAGTCTTTS GCTTCCGSGG CGAGTATGGT  
2881 CGCAAGGCTG AABCTTAAG GAATTAAGG AAGGCAACA CAATGGAGTG GAGCTCTGGG  
2941 CTTAATTTGA CTCAACAGG GGAATCTAC CAGGCTGSA CATAGTAGG ATTTGACAGY  
3001 TTAGAGCTCT TCTTTGATC TATGGGTGTF GGTTCATGGC CPTTCTTAGT TGGTGGAGT  
3061 ATTTGCTCTG TTAATTTGCA TAACGAAGG GACTTAACT TCCFAAATAG CTGCACTAGC  
3121 CATTTGCTG GATLATTAG TCTTAGAGG GACTATTGEC ATAAASCCAA TGGAGTTTG  
3181 AGGCAATAC ASEPCTGTA TCCCTTAGA TGTCTGSGC GGCACGCTG CTACCTGAC  
3241 GGAACCAAG AGTTAARAA ATCTTTTGA TTTTATTC TTGGCCGAA GGTCTGGTA  
3301 ATCTGTTAA ACTCCGCTG CTTGGGATA GAGCATTECA ATTTATGCG CCGCTCTCA  
3361 ATTCGATGTT GCGATTTTA CAAGTTTYA AATGCAATT CATYATYACT TTTTATATG  
3421 CTAAFAAAA AGCCATAGT TATCTATAG ATACTTTTT TTCCAGTCA CTACCGAGC

Figure 15B

3481 TTACATTCOC ATACANAAC TGGTAGTAA ACCTAAGSAA AACTAATAT CATGTTAATF  
3541 AAATACCCDA TTFACATFA GACATTAAC TCATTTTAT CGTTCATAT GAATAACCA  
3601 TTTCCAGCGA TTTTAAACAR ACATCGTTCA CCTCGTTAA GGATATCTTG TGTATGGGGT  
3661 GTTCACTTGC TTYATCGAAT AATFACCGTA COTGATATG GCTTGTGGA TAAAGCCGTA  
3721 GCTCAATATC TAGCAAAAAT CTTTTGGGTG AAAAGGCTTG CAATTCACG ACACCGAAT  
3781 AATGTCATF TTYAATAAG GAATTTTCC AATAATTCCT GTAATTCCTG GTTGCATFAA  
3841 TTGAAAAGG YAGTTTTGCA TCAGATGAG GAGGCTTTT GTAGABAAA ATAGCAACG  
3901 AACGAAAATC AGCGTTGCCA TCGCTTTCGA CAAAGCTCC TACCTGAAG AGTCCGATTT  
3961 TATTCATGAA CTTATAACTY CCAAGCATGC AACCAABAG GGAGACBAE TAATCCAGT  
4021 AGACACCGCA ATTGATTCCT TCGATCAGAT GTATCATECA CTGGCTAABC ATGCAGGCTE  
4081 GAGCTACGA CTTTACTCAA GAGGTGATTT AATCATCGAT GATCTCACA CTGCAGAGGA  
4141 TACTGCTATT GCACCTGGTA TTGCATTCBA GCAGGCTATG GGTAACTTTG CCGCGGTTAA  
4201 ABGATTTGSA CATGCTTATY GTCCACTTGA CGAGCTCTT TCTAGABGCE TACTTGCATY  
4261 GTCCGGACCG CCTATGCTE TTAGCGATTT GGGATTAAG CTTGAAAAGG TTGGGGATY  
4321 GTCCGTGAAA ATGATCCCTC ACTTACTATA TTCTTTTTCG GTAGCAGCTE GAATTAATTT  
4381 GCATGTTACC TGCTTATATG GATGATGTA CCTCATCGT CCGTGAAGCG CTTTAAATC  
4441 TCTGGCTGTT GCGATGCGCG CGCTACTAE TCTTACTGGA AGTTCTGAG TCCCAAGCAC  
4501 GAGCGGAGTG TTGTAAAGAT GAATTTGAT ATGTCAAGAA AAGAACGACA ATTTTGCATC  
4561 CAATTTGCTY AAATTTTAGA GTTCTTGA AACAATAGAA CTTTACTTGC TTTATAATTA  
4621 CGTAAATAG AAGCTTATC TCGTGAAGGA ATATAGTACG TAGCCGTATA AATTTGAATG  
4681 RATGTCAGC TTATAGATA GAGACACTT GCTGTCAAT GGTCTGTCB TTACCATACT  
4741 CACTTATTA TACGACTTTA AGTATAAAT CCGCGTTTAT GGTAAATTA ATGATGCACA  
4801 AACGTCGGAT TCCATATGG TACACTACAA TTAATATCTT TTAGCTGAT CCCCCACCA  
4861 CCATAGCTE AAATATTTTC TACCTCTTYT TACTCTTTC AGATTTTCTC GGACCCCGG  
4921 CATGCGCTA CCACTTCAA AACACAAAGC AGACATACT AATTTTCCC TCTTCTCTC  
4981 TCTAGGSET CTTAATTTAC CCGTACTAAA GGTTTGAAA AAAAAAAGA GACCGCTCG  
5041 TTTCTTTTTC TCTGCGAAR BAGGCATTA AAATTTTAT CACTTTCTT TTTCTGAAA  
5101 TTTTFTTTT TGTTTTTTT CTCFTTCACT GACCTCCTT GATTTTTAG TTAATTAAC  
5161 GTCCTCAAT TCTCAAGTTT CACTTCAAT TTTCTGTTC TATTAGACT TTTTACTT  
5221 CTTCTTCAAT AGAAGAAAG CATAGCAATC TAATCTAAG GCGTGTGTA CAATTAATC  
5281 TGGGCTAGY ATATCGCAT ATATTAATAC GACAAGTGA GAACTAABC CATGSCAAG  
5341 TTAGCCAGT CCGTTCGGT SCTCAGCCG CGCGAGCTG CCGGAGCGT CGAGTCTGG  
5401 ACCACCGCG TCGGTTCTC CCGGACTTC GTGGAGAGC ACTTCCCGG TGTGTCCG  
5461 GACGCGTGA CCGTCTTAT CAGGCGCTC CAGGACAGG TGTGTCGGA CAACACCTG  
5521 GCTGCGGTG GCGTCCCGG CTFGAGCAG CTGTACCGG AGTGTCTGA GTCCTGTCC  
5581 ACGACTTTC GCGACGCTC CCGCCCGCC ATGACCGGA TCGGCGGCA CCGTGGGG  
5641 CCGGCTTTC CCGTCCGCA CCGGCGCGC AACCTGCTG ACTTCTGCG CAGGAGCAG  
5701 GACTGACAG TCCGACCGG CCGCAGCGY CCGAGCCTC GGAGATCCG CCCCCTTTC  
5761 CTTTGTGAT ATCATGTAAT TAGTATGTC ACCCTTACT TACGCGCTC CCCCCAATC  
5821 CGCTTAAGC GAAAGGAG GATTAAGCA ACTTAAGT TGGTCCCTA TTTATTTTT  
5881 TATAGTTATG TTAGTATTA GAACTTAT TATATTTCA ATTTTTCTT TTTTCTGT  
5941 CAGACCGAG CTTCCAGTA ATGTCGAT CTCTAGCA GAAACCGTT CCCCCATAG  
6001 GTCTCTCTT TGGCTCTTT TTAGGTTGG CTTGTTCTY CTTGAGCTC TCTAGGGG  
6061 CTTCACTCAT AGGCAATTA CTTTCCCCAC CCGCTGCTT CTTAAGCGCA CAAGGACTG  
6121 TCCCAAGAT CTTAGCGGG ATTTTCCGA TTTCCGCTA AAGAAACCG AACACGTAG  
6181 AAGCCAGTCC GCAGAACCG TCGTACCCC GATTAAGT CAGCTACTG GCTATCTGA  
6241 CAGCGGAAA CCGAGCGCA AAGAGAAAG AGTATGCTC CATGCGCTT ACATGCGAT  
6301 AACTGACTG GCGGTTTTA TGCACAGCA GCGAACGGA ATTGCAGCT GCGCGCCCT  
6361 CTGTAAGST TGGGAGCCC TCCAAGTAA ACTGATGTC TTTCTTCCG CCAAGGATCT  
6421 CATGCCGAG GGGATCAAA TCTGATCAAS AGACAGATG AGGATGCTT CCAATGATG  
6481 AACAGATG ATTCACGCA GCTTCTCCG CCGCTTGGT GGGAGGCTA TTTGGTATG  
6541 ACTGGGCACA ACAGCAATC GCTGCTCTG ATGCGCGCT GTTCCGCTE TCGCCAGG  
6601 GCGCCCGCT TCTTTTCTC AAGACGAGC TGTCCGCTC CCGTAATGA CTCCAGGAG  
6661 AGGACCGCG GATTCGCGT CTGGCCGCA CCGGCTTTC TTGGGAGCT GTCTCGAGC  
6721 TTTCACTGA AGCGGGAAG GACTGCTCT TATTGGGGA AGTGCAGCG CAGATCTCC  
6781 TTTCACTG CTTTCTCTT CCGGCAAG TATCCATAT GCTGATGCA ATGCGCGGC  
6841 TGCATACCT TGTCCGCT ACCTCCCAAT TCGACAGCA AGCGAAAT CCGATCGAGC  
6901 GACCACTAC TCGGATGAA GCTGCTCTG TCGATCAGGA TGAATCTGAC GAAGAGCATC  
6961 AGGCGCTCC GCCAGCGAA CTGTTCCGA GCTCAAGCC GCGATGCGC GACGGGAGG

Figure 15C

```

7021 ATCTCTCTCT GATCCATGGC GATGCTGCT TCCGAAATAT CATGGTGGAA AATGGCCGCT
7081 TTTCTGGATT CAACGACTGT GCGCGGCTGG GTGTGGCGGA CCGCTATCAG CACATAGCGT
7141 TGGATACCCG TGATATTCCT GAAGAGCTTG GCGGCGAATG GCGTGAACCG TTCTCTGCTC
7201 TTTACGGTAT CCGCGCTCCC GATTGCGAGC GCATCGCCTT CTATCGCCTT CTTGAGGAGT
7261 TCTTCTGAAT TGAABAAGGT ACCAAGTTTA CTCATATATA CTTTAGATTG ATTTAAAATC
7321 TCATTTTAA TTTAAAAGGA TCTAGGTGAA GATCCTTTT GATATTCFCA TGACCAAAAT
7381 CCCTTAACGT GAGTTTTCGT TCCACTGACC CTCAGACCCC GTAGAAAGA TCAAAGGATC
7441 TCTTCGAGT CTTTTTTTC TCCGCTAAT CTGCTGCTG CAACCAAAA ANCCACCGCT
7501 ACCAGCGGTG GFTTGTTC GGGATCARGA SCTACCAACT CTTTTTCGA AGGTAACTGG
7561 CTTACAGGA GCGCAGTAC CAATACATGT CCTTCTAGTG TAGCCATAGT TAGGCCACCA
7621 CTTCAAGAAC TCTGTASCAC CCGCTACATR CCYCGCTCG CTATTCCTGT TACCAGTGGC
7681 TGCTGCCAT GCGATATAGT CGTSTCTTAC CCGGTTGGAC TCRAGCGAT ASTTACCGA
7741 TAAGGCGCAG CCGTCGGGCT GAACGGGGG TTCTGTGCA CAGCCAGCT TGGAGCGAC
7801 GACCTACAC GACTGAGAT ACCTACAGCG TGAGCAATGA GAAAGCGCA CCCTTCCCG
7861 AGGAGAGAG GCGGACAGGT ATCCGGTAA GCGCGGCTC GGAACAGGAG AGCGCACGAG
7921 GGAGCTTCCA GGGGAAAGC CTTGGTATCT TTATACCTCT GTGGGTTTC GGCACCTCTG
7981 ACTTGAGCGT CGATTTTGT GATGCTCTG AGGGGGCGG AGCCTATGCA AAAACGCCAG
8041 CAACGCGGCC TTTTACGGT TCTGCGCCT TTGCTGGCTT TTTGCTGACA TGTTCCTTCC
8101 TCGCTTATCC CCTGATTCGT TGGATAACCG TATTACGGC TTTGAGGAG CTGATACCC
8161 TCGCCGAGC CGRACGACG AGCCAGCGG G
    
```

SEQ ID NO:7

Figure 16

```

1 GAATTCANAA CAAATGTST GCAACTTCTT CCCAGTTTAC TCAGATTACC GAGCATTAAT
61 CTCGACGHTC TGCTAARTAC CAGCCGAAAC TTGGAACTT TGAGTTTCTC CAGTCTCTCG
121 ABAATGACCT GRAGGTGGAA AAGCTCGAGG AGBAGGCGAC CABACTCGAG GAGGAGGTGC
181 GATGATATGAT CAACAGAGTT GACACCCAAAC CCCGTGCTTT GCTGGAGCTG ATCGAGGATG
241 TGCAGCGEFT GSETPTGACT TATAAATTCG AGAAGGACAT TATCABGGCA CTGGGAAACA
301 TTGTGCTCCT CGACGAGAAC AAGAGGACA AENCTGATCT TCAGGCTACC GCTCTCTCTT
361 TCCGACTTCT TCGACACAC GGCYTCGAGG TGTCCGAGGA CGCTCTCGAG AGATTTAAGG
421 ACAAGGAGGG AGRATTTAGC GCGGAGCTGA AGCGAGAGCT TCAGGCTCTT CTCTCTCTCT
481 ACBAGGCGTC CTACTTGGGA TTCGAGGGAG AGAAGCTCCT GGAGGAGCTT GGTACTTTT
541 CCATCACTCA CCTTARGAAT AACCTTAGG AGGGANTTAA CAACAAGGTC GCGGAGCGG
601 TTYCTCAGGC CCGGAGCTC CCGTACGACC AACGGCTCCA TAGACTGGAG GCTCTCTGGT
661 TCCTEGACAA ATATGAGCCA AAGGAGCTC ATCATCACTT GCTGTTGGAG TTGCCCAGC
721 TGGACTTCAA TATGOTTCAG ACGCTGCACC AAAGGAGTT GCAGGACCTG TCTCGATGGT
781 GGACCGAGAT GSGATTEGDC TCGAGCTGG ATTTTSTCCG TGACCGACTT ATGGAGTCT
841 ATTTTGGGC CTTTGGATG GCGCTGACC CCGAGTGGG AGAGTGGCGG AAGCGGTGA
901 CGAAGATGTT CGGTCTTGTG ACTATCATCG ACEAGCTCTA CGATGCTAC GGCACACTCG
961 ACGAGTTCGA GCTGTTCACT GACGGCTCG ASCGATGGGA TGTGAGCGCC ATTAATATC
1021 TCCCTGACTA TATGAGCTG TCGTTCCTGG CTCTGTACA CACTGTCAAC GATACCTCT
1081 ACTCTATCTT CAGGAGAAAG GGACACACA ATCTCTCTTA CTGACCAA TCTTGGGCG
1141 AACGTGCAA GCGTFTCTG CAGGAGCTA AATGRTCAA TAACAGATC ATTCCTCTT
1201 TTTTAAATA CTTGGAATY GCTTGGTGT CEAGCTCTG GCTGGCTCTT CTGCCCCTT
1261 GCTACTTCTC CGTCTGGCAG CAGGAGGAG ATATTTCDGA TCATGCTCTT AGATGCTGA
1321 CGATTTTCA CCGCTCTGTG CGATCTCTT GCGTGAATTT TCGGTCTCTT AATGACCTTG
1381 CCACTCTGTC TGCTGAGCTG GAACGAGCG AGACTACAAA TTCCATATT TCTTACTTC
1441 ACCAARACGA TGGACATCTT GAAGACAGG CTAGGAGGA ACTGCGAAG TTGATCSAGC
1501 CCGAGTGGAA GAGATGAGC AGAGAGCGG TGTCCGACTC TACCTCTCTT CCCAGGCTT
1561 TATGAGAGAT CCGCGTGAAC ATGCTCGAG TTTCCCATG TACTTACCAG TACGCTGAGC
1621 GCTTGGGTCG TCCGACTAC GCTACAGGA ACCGANTTAA GCTGCTGCTC ATCGACCCY
1681 TCCCTATCAA CCAATGATG TACGTGTAAT AGTCTAGAGG ATCC

```


SEQ ID NO:8

Figure 17


```

1 GAATTCAACA AAAATGTGCT CTGTTTCCAC TGAGAACGTG TCCTTTACTG AGACTGAGAC
61 TGAAGCACGT AGAAGCGCCA ACTACGAACC CAACTCCTGG GATTATGACT TTCTGCTGTC
121 TTCTGACACC GACGAGTCGA TCGAGGTTTA TAAGGATAAG GCCAAGAAAC TTGAGGCCGA
181 GGTCCAGACGA GAGATTAACA ACGAGAAGGC CGAGTTCTCTG ACCCTTCTTG AGCTGATCGA
241 CAACGTTCAA CGACTTGGTC TTGGTTACCG TTTCGAATCC GATATCCGAC GTGCATTGGA
301 TCGATTTGTC TCGTCCGGAG GTTTCGATGG TGTGACTAAG ACGTCGCTGC ACGCCACAGC
361 TCTTTCCTTC AGACTGTTGC GGCAGCATGG ATTTGAGGTT TCCCAGGAAG CCTTTTCTGG
421 TTTCAAGGAT CAGAACGGAA ACTTTTTGGA GAATCTCAAG GAGGACACCA AGGCCATCCT
481 GTCGTGTGAT GAGGCCTCGT TCCTGGCTCT TGAGGGCGAG AATATTCTGG ATGAGGCTCG
541 GGTTCGCTCT ATTTCCGACC TGAAGGAGTT GTCGGAGGAA AAGATCCGAA AGGAACTGGC
601 CGAGCAGGTC AACCATGCAC TTGAACTTCC CCTGCATCGA CGTACCCAGC GACTGGAGGC
661 CGTGTGGAGC ATCGAGGCGT ACAGAAAAAA GGAGGATGCT AATCAGGTTT TGCTCGAACT
721 CGCTATCCTC GACTATAACA TGATTACAGG CGTGTACCAG CGTGAATTGC GAGAGACAAG
781 CCGGTGGTGG CGACGGGTGG GACTGGCCAC GAAGCTCCAC TTGCTAAAG ATCGATTGAT
841 TGAGTCGTTT TACTGGGCAG TGGGTGTGGC CTTTGAGCCT CAGTACTCCG ACTGCCGAAA
901 CTCCGTTGCA AAGATGTTTT CTTTTGTCAC TATCATCGAC GACATCTACG ATGTTTACGG
961 CACTCTCGAT GAACTCGAAC TCTTCACGGA CGCTGTCGAG CGATGGGATG TGAATGCCAT
1021 TAATGATCTG CCAGATTATA TGAAGTTGTG TTTCTTGGCG CTCTACAACA CAATTAATGA
1081 AATTGCCTAC GACAACCTCA AGGACAAGGG AGAGAACATT CTGCCCTACC TTAATAAAGC
1141 CTGGGCCGAC CTGTGTAACG CCTTTTTGCA GGAAGCCAAG TGGCTCTATA ACAAATCTAC
1201 TCCTACATTT GATGACTACT TCGGCAACGC TTGGAAGTCT TCCAGCGGCC CTCTCCAGTT
1261 GATCTTCGCT TACTTTGCAG TGGTCCAGAA CATCAAGAAA GAGGAGATTG AGAACCTCCA
1321 GAAGTATCAC GACATCATCT CCCGACCTTC GCACATCTTT CGACTGTGCA ATGACCTTGC
1381 CTCCGCATCC GCTGAGATTG CCCGAGGAGA AACAGCCAAT TCTGTGTCTG GTTACATGCG
1441 TACAAAGGGC ATCTCCGAGG AGCTGGCTAC CGAGTCTGTG ATGAACCTGA TCGATGAAAC
1501 CTGTAAGAAG ATGAACAAAG AGAAACTGGG CGGTTCTCTG TTCGCCAAAC CATTTGTTGA
1561 AACCCGATC AATCTGGCTC GTCAGTCTCA TTGTACTTAC CATAACGGTG ACGCGCACAC
1621 TTCGCCGGAC GAATTGACCC GTAAGCGTGT GCTTTCGGTG ATTACCGAGC CGATCCTGCC
1681 GTTCGAAAGA TAATAGGATC C
    
```

**Figure 18A1**



**Figure 18A2**






Figure 18B






Figure 18C

**Figure 18D**








Figure 18F

Figure 19A




Figure 19B




Figure 20A

***Y. lipolytica* CLIB122:: pYLA(MAP29)**




Figure 20B




Figure 21






Figure 22B

gagtc aattc aggggtggtgaatgtgaaaccagtaacggtatacogatgtcgcagagtatgccggt  
 gtctcttatcagacogt tteccggtggtgaaccaggccagccacggt tctgcgaaaaacgggg  
 aaaaagtggaaagggcgatggggagctgaattacattcccaacogcgtggcacaacaactgpc  
 gggcaaacagfngttgctgattggggttgcacacctcagtetggccctgcacgycogctcgcaa  
 attgtcgcggcgattha aatctcgcgcgatcaactgggtgccagcgtgggtggtgctgagtggtag  
 aacgaagcggcgtcgaagcctgtaaaagcggcgtgcacaatcttctcgcgcaacogcgtcagtg  
 gctgatcattaactatccgctggatgaccaggatgccattgctgkggaaagctgcctgcaactaa  
 gtccggcgttatttcttgatgtctctgaccagacacccalcaacagtatatttttctcccattg  
 aagacggtacgcgactgggctggagcatctggtcgcattgggtcaccagcaaatcgcgctgtt  
 agcgggcccattaaagtctctgctcgcggcgtctgctgctggctggctggcataaatatctcact  
 cgpcaatcaaatcagcogataagcggaaacgggaaggcactggagtgccatgtccggttttcaac  
 aaaccatgcaaatgctgaatgagggcatcgttcccactgcgatgctgggtgccaacgatcagat  
 ggcgctggggcgaatgcgcgccattaccyagtccgggctgcgcgttgggtgoggatactcggta  
 gtgggatacgcagataccgaagacagctcatggtatatacccgccgtcaaccaccatcaaacagg  
 attttgcctgctggggcaaacagcgtggaccgcttgcctgcaactctctcagggccaggcgt  
 gaagggcaatcagctgttgcgcctctcactggtgaaaagaaaaaacccctggcgcaccaatcgc  
 caaacgcctctccccgcgcttggccgattcattaatgcagctggcagcaggttccccgac  
 tggaaagcgggcagtgagcgcacaacgcaattaatgtgagttagcgcgaattgatctggtttgaca  
 gcttatcatcgactgcacggtgcaccaatgcttctggcgtcaggcagccatcggaaagctgtggt  
 atggctgtcaggtcgtaaatcactgcataattcgtgtcctcaaggcgcactcccgttctgga  
 taatgttttttgcgcgcacatcafaacggttctggcaaatatctgaaa tgagctgttgacaa  
 taatcatccgctcgtataatgtgtggaattgtgagcggataacaatttcaacacaggaaacagc  
 gcgcctgagaaaaagcgaagcggcactgctctttaaacaatttatcagacaactctgtgtgggcac  
 tcgaccggaattatogattaactttattatfaaaaaattaaagaggtataatattaatgtalogat  
 taataaaggaggaataaaaccatgtgtgogacctctctcaatttactcagattaccgagcataa  
 tccccgtcgttccgcaaaactatcagccaaaacctgtggaaatttogaattcctgcaatccctggag  
 aacgacctgaaagtggaaaagctggaggagaaagcagccaaaactggagggaagaagtccgctgca  
 tgatcaacogtgtagacacccagccctgtccctgctggagctgatcgaagatgtgcagcgcct  
 gggctgacctacaaaatttgaaaaagacatcattaaagccctggaaaacatcgtactgctggac  
 gaaaacaaaaagaacaatctgacctgcacgcaacogctctgtcttccgctcgtctgctgctcagc  
 acggtttcagggttctcaggatgittttgagcgtttcaaggataaagaagggtggtttcagcgg  
 tgaactgaaaggtgacgtccaagcctgctgagcctgatagaagcgtcttacctgggtttogag  
 ggtgagaacctgctggaggagggcgtacctttccatcaccacactgaaagaacaacctgaaag  
 aaggcattaataccsaaggttgcagaacaagtgcagccacgcctggaaactgccatataccagc  
 tctgcaacgtctggaggcaogtgggttccctggataaatacgaacccgaaagaacccgcatcacaq  
 ctgctgctggagctggcgaagctggattttaaactggtaacagccctgcaccagaagagctgc  
 aagatctgtcccgctggtggaccgagatgggcccggctagcaaacctggattttgtacgcgaccg  
 cctgatggaagtttatttctgggcactgggtatggcgcagacccgcagtttgggtgastgtgc  
 aaagctgttactaaaatgtttggtctggtgacgatcatogatgaogtgtatgacgtttatggca  
 ctctggaagaaactgcaactgttaccgatgctgtagagcgtggaagcttaacgctattaacac  
 cctgccggactatataaactgtgtttcctggcactgtacaacacccgttaacgacagctcctat  
 tctattctgaaagagaaaggtcataacaacctgtcctatctgacgaaaagctggcgtgaaactgt  
 gcaaaccttctgcaagaggcgaatgggtccacaacaaaaattatccggctttctccaagta  
 cctggaaaacgcagcgtttcctcctccggtgtagcgtgctggcgcogctcttactttccgta

Figure 22C

tgcacagcagcaggaagacatctccgaccacgcgctgcggttcctgacccgacttccatgggtctgg  
 tgcggttctagctgcggttatcttccgctgtgcaacgatctggccaectctgcggcgggagctgga  
 acgtggcgagactaccaattctatcattagctacatgcacgaaaaacgatggtagccagcggaggaa  
 caggcccgcgaagaactgcgtaaacctgatcgacgcgaatggaaaaagatgaatcgtgaacgcg  
 tttagcgactccaccctgctgcctaaagcgttcatggaaatcgcagttaacatggcacgtgttcc  
 ccactgcaectaccagtatggcgatggtctgggtcgcccagactacgcgactgaaaaccgcctc  
 aaactgctgctgattgacccttcccgattaacccagctgatgtatgtctaactgcatcgccctt  
 aggaggtaaaaaaaatgactgcccacaacaatagtatgccccatggtgcagtatctagttacg  
 ccaaatagtgcaaaaaccaaacacctgaagacatttgggaagagtttccctgaaattatccatt  
 acaacaaagacctaataccgatctagtgcagcgtcaaatgacgaagcgggagaacatgtttt  
 tctggtcatgatgaggagcaaatfaagttaatgaaatgaaaaattgtattgttttggattgggacg  
 ataatgctattggtgcccgtaccaagaaagtttgcatttaattggaaaaatattgaaaagggttt  
 actacatcgtgcatctccgctctttattttcaatgaacaaggtgaattacttttacaacaaaga  
 gccactgaaaaaataacttccctgatctttggactaacacatgctgctctcatccactatgta  
 ttgatgacgaattaggtttgaagggtaagctagacgataagattgaagggcgtattactgcggc  
 ggtgagaaaactagatcatgaaattaggtattccagaagatgaaactaagacaaggggtaagttt  
 cactttttaaacagaatccattacatggcaccagcaatgaaacctgggggtaacatgaaattg  
 attacatcctattttataagatcaacgctaaagaaaaacttgactgtcaacccaaacgtcaatga  
 agttagagacttcaaatgggtttcaccaaatgatttgaaaactatggttgcctgacccaagtta  
 aagtttacgcttgggttaagattatttgcgagaattacttattcaactggtgggagcaattag  
 atgaccttctgaagtggaaaatgacaggcaaatccatagaatgctataacaacgcgctcctgca  
 ttccgcttaggaggtaaaaaacatgagttttgatattgcaaataccgcaccctggcactgg  
 tcgactccaccaggagttacgactgttgcgaaagagagtttaccgaaactctgcgacgaact  
 gcycgctatttactcgacagcgtgagccgttccagcgggcaacttcgctccgggctgggcaacg  
 gtcgaactgacgctggcgctgcaactatgtctacaaaccccgtttgaccaattgatttgggatg  
 tggggcatcaggrttatccgcataaaaattttgaccggaagcgcgagcaaaaatcggcaaccatccg  
 tcagaaagggcgtctgcacccgttcccgtygcgcggcgaaagcgaatatgacgtatfaagcgtc  
 gggcattcatcaacctccatcagtgccggaattgggtattgongttgctgcccgaaaaagaggca  
 aaaaatgcgcgcaacgctctgtgtcattggcgatggcgagattaccgcaggcatggcgtttgaagc  
 gatgaatcagcggggcgaatctcgtcctgatattgctgggtgattctcaacgacaatgaaatgctc  
 atttccgaaaatgtoggcgcgctcaacaaccatctggcacagctgcttccggtaagcttact  
 cttcactgcgcgaaggcgggaaaaaagttttctctggcgtgccgcaattaaagagctgctcaa  
 acgcacgagaacatattaaaggcatggtagtgctggcacgcttggttgaagagctgggcttt  
 aactacatcggcccggtggaacggtcacgatgtgctgggcttatcccaacgctaaagaaacatgc  
 ggcacctgaaaggeccgcagttcctgcataatcatgaccaaaaaaggctcgtggttatgaaaccgc  
 agaaaaagaccgatcactttccacgcgctgcctaaaatttgatccctccagcgggtgtttgccc  
 aaaagttagcggcgggtttgcccagctatcaaaaaatcttggcgactggttgtgcgaaaacggcag  
 cgaagacaacaagctgatggcgattactccggcgatgcgtgaaggttccggcatggtcaggtt  
 ttccagtaaatcccggtatcctacttcgaagtggaattgcccagcaacaacgcggtgacctt  
 gctgcgggtctggcgattgggtgggtacaaaaccatgtgcgcatctactccacttccctgcaac  
 gcgctatgatcaggtgctgcatgacgtggcgattcaaaagctccggctcctgttcgcaatcga  
 ccgcgcgggcatgtttgggtgctgacgggtcaaaaccatcaggggtgctttgatctctcttacctg  
 cgtgcataaccggaattgggtcattatgaccccagcgatgaaaacgaatgtcgcagatgctct  
 ataccggctatcactataacgatggcccgctcagcgggtgcgctaacccgcgtggcaacgcggtcgg

Figure 22D

cgtggaactgaacgcccgtggaaaaactaccaattggcaaggcattgtgaagcgtcgtggcgag  
aaactggcgatccttaactttggtacgctgatgccagaagcggcgaaagtcgccgaatcgtga  
acgccacgctggctogatatgcgttttgtgaaacggcttgatgaagcgttaattctggaaatggc  
cgccagccatgaagcgtggtcaccgtagaagaaaaacgccattatggcgggcgaggcagcggc  
gtgaacgaagtgcctgatggccatcgtaaaccagtaccgctgctgaacattggcctgcccact  
tctttattccgcaaggaactcaggaagaaatgcgcgcgaaactcggcctcgatgccgctggtat  
ggaagccaaaatcaaggcctggctggcataactgca

SEQ ID NO: 10

Figure 23A




Figure 23B




Figure 23C




Figure 23D




Figure 23E




Figure 23F




Figure 23G




Figure 23H




Figure 24




Figure 25A

5' -

gtttgacagcttatcatcgactgcacgggtgcaccaatgcttctggcgtcaggcagccatcggaa  
 gctgtggtatggctgtgcaggctcgtaaatcactgcataatcgtgtcgcctcaagggcgcactccc  
 gttctggataatgtttttgcccgcacatcataacgggttctggcaaatattctgnaatgagctg  
 ttgacaattaatcatccggctcgtataatgtgtggaattgtgagcggataacaatttcacacag  
 gaaacagcgcgcgtgagaaaaagcgaagcggcactgctcttfaacaatttatacagacaactctgt  
 gtgggcactcgcaccggaattatcgatlaactttatttataaaaaattaaagaggtatataat  
 gtatcgattaaataaggagggaataaaacctggatcccgagctcggatccactagtaacggccgoc  
 agtgtgctggaaatcgcccttaggaggtaaaaaaacatgctcattaccgttcttaacttctgcac  
 cgggaaagggttattatttttggtagaacactctgctgtgtacaacaagcctgcgcgtcgtgctag  
 tgtgtctgcgttgagaacctacctgctaataagcagagtcactctgcaccagatactattgaaatg  
 gacttcccggacattagctttaaatacataagtggtccatcctatgatttcaatgccatcaccgagg  
 atcaagtaaaactccccaaaatttggccaaggctcaacaagccaccgatggcttgtctcaggaact  
 cgttagctcttttggatccgttggtagctcaactatccgaatccttccactaccatgcagcgttt  
 tgtttcctgtatagtgttggtttgcctatgccccatgccaagaatattaagtttctttaaggt  
 ctactttaccocatcgggtgctgggttgggctcaagcgcctctatttctgtatcactggccttagc  
 tatggcctacttgggggggttaataggatctaatgacttggaaaagctgtcagaaaacgataag  
 catatagtgaaatcaatgggccttcataggtgaaaagtgatccacggtaaccctcaggaatag  
 ataacgctgtggccacttatggtaatgcctgctatftgaaaaagactcacataatggaa caat  
 aaacacaaa caatttttaagttcttagatgatttcccagccatcccaatgatcctaacctatact  
 agaattccaaggctctacaaaagatcttggttgctcgcgttcgtgtgttggtcaccgagaaatftc  
 ctgaagttatgaagccaattctagatgccatgggtgaatgtgccctacaaggcttagagatcat  
 gactaagttaaagtaaatgtaaaggcccgatgacgagggctgtagaaactaataatgaactgtat  
 gaacaactattggaattgataagaataaatcatggactgcttgtctcaatcgggtgttctctc  
 ctggattagaacttattaaaaaatctgagcogatgatttgagaattggctccacaaaacttaccgg  
 tctgctggggcggcgggtgctcttggactttgttacgaagagacattactcaagagcgaatgac  
 agcttcaaaaagaaattgcaagatgatttagttacgagacatttgaaacagacttgggtggga  
 ctggctgctgtttggttaagcgcacaaaaatttgaataaagatcttaaaaatcaaatccctagtatt  
 ccaattatttgaaaaataaaactaccacaaaagcaacaatttgcgatctattattgccaggaaac  
 acgaatttaccatggacttcataagctaatftgogtaggcttgcacccttaaggaggaaaaaaa  
 acatgtcagagttgagagccttcagtgcaccagggaaagcgttactagctgggtggatatttagt  
 tttgatacaaaaatagaagcattttagttagcggatctatcggcaagaatgcatgctgttagccat  
 ccttaaggcttcaattgcaagggtctgataagtttgaagtgcgtgtgaaaagttaacaatttaag  
 atggggagtygctgtaccatataagtcctaaaaagtggettcattcctgtttcogataggcggatc  
 taagaaccttccattgaaaaagttatcgctaacgtatttagctactttaaacctaacatggac  
 gactactgcaatagaaacttgttctgtattgataatttctctgatgatgctaccatctcagg  
 aggatagcgttaccgaaacatcgtggcaacagaagattgagtttcatcgcacagaattgaaga  
 agtcccaaaaacagggctgggctcctcggcaggttttagtcacagttttaactacagctttggcc  
 tccctttttgtatcggacctggaaaataatgtagacaaatatagagaagttattcataatttag  
 cacaagttgctcattgtcaagctcagggttaaaattggaagcgggtttgatgtagcggcggcagc  
 atatggatctatcagatataagaagttcccaccggcattaatctctaatftgcccagatattgga  
 agtgcacttaccgycagttaaactggcgcatttggttgatgaagaagactggaatattacgatta  
 aaagtaaccatttaccctcgggatttaactttatggatggggcatattaagaatggttcagaaac  
 agtaaaactggctccagaaggtaaaaaattggtatgattcgcataatgccagaaagcttgaaaata

Figure 25B

tatacagaactcgatcatgcaaatctctagatttatggatggactatctaaactagatcgcttac  
 acgagactcatgacgattacagcgatcagatatttgagtctcttgagaggaatgactgtaoctg  
 tcaaaagtatcctgaaatcacagaagtttagagatgcagttgccacaattagacgttcctttaga  
 aaaaactaaagaatctgggtgccgatatcgaaacctcccgtaaaaaactagcttattggatgatt  
 gccagaccttaaaaggagttcttacttggcttaataacctgggtgctgggtggttatgacgccattgc  
 agtgattactaagcaagatggttgatcttagggctcaaaacgctaatgacaaaagaattttctaaag  
 gttcaatggctggatgtaactcaggtgactgggggttaggaaagaaaaagatccggaaactt  
 atcttgataaaataacttaaggtagctgcattgocagaattcgcccttaaggaggaaaaaaaatga  
 ccgtttacacagcatccgttacogcaaccgctcaacatcgcaaccttaagatattgggggaaaag  
 ggacaogaagttgaatctgcccccaattcgtccatcagtgactttatcgcaagatgacctc  
 agaacgttgacctctggctactgcaacctgagttgaaocggacactttgtggttaaatggag  
 aaccacacagcatcgacaatgaaagaactcaaaattgtctgcgcgacctacgccaattaagaaa  
 ggaaatggaaatcgaaggacgectcatggccacattatctcaatggaaactccacattgtctcc  
 gaaaaaasctttcctacagcagctgggtttagcttccctccgctgctggctttgctgacttggct  
 ctgcaattgctaagttataccaattaccaagctcaacttcagaaatactctagaatagcaagaa  
 ggggtctggctcagcttctagatcgttggcttggcgatcgtggcctgggaaatgggaaaagct  
 gaagatggctcatgattccatggcagtaaaaaatcgcaagcagctctgactggcctcagatgaag  
 ctgtgtctcctagttgtcagcgatattaasaaggatgtgagttccactcagggatgcaattgac  
 cgtggcaacctccgaactat. ttaagaaagaattgaacatgctctgtaaccaagagatttgaagtc  
 atgcttaaaagccattgttgaaaaagatttcggccacctttgcaaaaggaaacaatgatggattcca  
 actctttccatgccacatggttggactcttccctcccaatattctacatgaatgacacttccaa  
 gcgtatcatcagttgggtgccacaccattaatcagttttaocggagaascaatcgttgcatacacg  
 tttgatgcaggtccaaaatgctgtgttggactacttagctgaaaatgagtcgaaactctttgat  
 ttatctataaattggttggctctgttccctggatgggacaagaaatttactactgagcagcttga  
 ggctttccaccatcaatttgaatcctctaaacttactgcacgtgaattggatcttgagttgcaa  
 aaggatgttgccagagtgattttaaactcaagtcgggtcaggcccaagaagaascaaacgaatctt  
 tgattgacgcaaaagactggcttaccaaaggaataagatcaattcgtgcatcgcccttaggagg  
 taaaaaaaaatgactgcccacaacaatagttatgcccctgggtgcagtatctagttacgccaat  
 tagtgcaaaaaccaaacctgaagacatttttggaaagatttccctgaaattatccattacaaca  
 aagacctaataccogctctagtgagacgtcaaatgacgaaagcggagaaacatgttttctgggt  
 catgatgaggagcaaatgaagttaatgaatgaaaattgtattgttttggattggyacgataatg  
 ctattgggtgccgtaccaagaaagtttgcatttaattgaaaaatattgaaaagggtttactaca  
 tggctgacttctccgtctttatcttcaatgaacaagggtgaattacttttacaacaaagagccact  
 gaaaaataaactttccctgatctttggactaacacatgctgctctcctccactatgtattgatg  
 acgaattaggtttgaagggttaagctagacgataagatlaagggcctatttactgcccgggtgag  
 aaaactagatcatgaattaggtattccagaagatgaaactaagacaaggggtaagtttcaactt  
 ttaaacagaatccattacatggcaccacgaatgaacctgggggtgaacatgaaattgattaca  
 tccatatttataagatcaacgctaaagaaaaacttgactgtcaacccaaacgctcaatgaagttag  
 agacttcaaatgggtttcaccaaatgatttgaaaactatggttgotgaccccaagttacaagttt  
 aocgcttgggttaagattatttgcgagaattacttattcaactgggtgggagcaattagatgacc  
 tttctgaagtggaatgacaggcaattcatagaatgctataacaacgctcctgcaattcggc  
 cttaggaggttaaaaaacatgtgtgocacctctctcaatttactcagattaccogacataatt  
 ccogtcttcggcaaaactacagcccaacctgtggaatttcgaattcctgcaatccctggagaa  
 cgacctgaaagtggaaggtggaggagaagcgaacaaaactggaggaaagaagttcgtgcatg

Figure 25C

atcaaccggtgtagacaccagccgctgtccctgctggagctgatcgacgatgtgcagcgcctgg  
 gctctgacctacaaatTTGAAAAAGACATCATTAAGCCCTGGAAAACATCGTACTGCTGGACGA  
 AAACAAAAAGAACAAATCTGACCTGCACGCAACCCTCTGTCTTTCCGTCTGCTGGCTCAGCAC  
 GGTTCGAGGTTTCTCAGGATGTTTTTGAGCGTTTTCAAGGATAAAGAAGGTGTTTTCAGCGGTG  
 AACTGAAAGGTGACGTCACAGGCTGCTGAGCCTGTATGAAGCGCTTACCTGGGTTCGAGGG  
 TGAGAACCCTGCTGGAGGAGGCGCTACCTTTTCCATCACCCACCTGAAGAACAACCTGAAAGAA  
 GGCATTAATACCAAGGTTGCAGAACAGTGAGGCCACGCCCTGGAACGCCATATCACCCAGCGTC  
 TGCACCGTCTGGAGGCACGTTGTTTCCCTGGATAAATACGAAACCGAAAGAACCGCATCACCCAGCT  
 GCTGCTGGAGCTGGCGAAGCTGGATTTTAAACATGGTACAGACCCTGCACCAGAAAAGAGCTGCAA  
 GATCTGTCCCGCTGGTGGACCGAGATGGGCCCTGGCTAGCAAACCTGGATTTGTACGGAGCCGEC  
 TGATGGAAGTTTATTTCTGGGCACTGGGTATGGCGCCAGACCCCGAGTTTGGTGAATGTGCGAA  
 AGCTGTTACTAAAAATGTTTGGTCTGGTGAACGATCATCGATGAAGTGTATGAAGTTTATGGCACT  
 CTGGACGAACCTGCAACTGTTTACCAGTCTGTAGAGCGCTGGGACGTTAACGCTATTAACACC  
 TGCAGGACTATATGAAACTGTTTCTGGCACTGTACAACACCGTTAACGACAGTCTCTATTC  
 TATTCTGAAAGAGAAAGGTCAATAACAACCTGTCTATCTGACGAAAAGCTGGCGTGAACGTGTGC  
 AAAGCCTTCTGCAAGAGGCGAAATGGTCCAACAACAAAATTATCCCGGCTTCTCCAAGTACC  
 TGGAAAAACCGTAGCGTTTCTCCTCCCGTGTAGCGCTGCTGGCGCCGCTCTTACTTTCCGATG  
 CCAGCAGCAGGAAGACATCTCCGACCACGCGCTGCGTTCCTGACCAGACTCCATGGTCTGGTG  
 CGTTCTAGCTGGTTATCTCCGCTGTGCAACGATCTGGCCACCTCTGGGCGGGAGCTGGAAC  
 GTGGCGAGACTACCAATCTATCATTAGCTACATGCACGSAACGATGGTACCAGCGAGGAACA  
 GGCOCGCGAAGAACTGCGTAAACTGATCGACCGCGAATGGAAAAAGATGAATCGTGAACCGGTT  
 AGCGACTCCACCCTGCTGCTAAAGCGTTCATGGAAATCGCAGTTAACATGGCACGTGTTTCCC  
 ACTGCACCTACCAGTATGGCGATGGTCTGGTCCGCCAGACTACGCGACTGAAAACCGCATCAA  
 AACTGCTGCTGATTGACCCCTTCCCGATTAAACCAGCTGATGTATGTCTAACTGCAGCTGGTACCA  
 TATGGGAATTCGAAGCTTCTTAGAACAAAAACTCATCTCAGAAGAGGATCTGSAATAGCGCGCTC  
 GACCATCATCATCATCATCATTGAGTTTAAACGGTCTCCAGCTTGGCTGTTTGGCGGATGAGA  
 GAAGATTTTCAAGCTGATACAGATTAATCAGAACGCAAGAAGCGGTCTGATAAAACAGAATTTG  
 CCTGGCGGCGAGTAGCGCGGTGGTCCCACTGACCCATGCCGAACCTCAGAAGTGAACCGCGTA  
 GCGCGATGGTAGTGTGGGTCTCCCATGCGAGAGTAGGGAACCTGCCAGGCATCAATAAAAAC  
 GAAAGGCTCAGTCGAAAGACTGGGCCCTTCGTTTTATCTGTTTGTTCGGTGAACGCTCTCCT  
 GAGTAGGACAAATCCGCGGAGGGATTGAAACGTTGCGAAGCAACGGCCCGGAGGGTGGCGG  
 GCAGGACGCCCGCATAAACTGCCAGGCATCAATAAGCAGAAGGCCATCCTGACGGATGGCC  
 TTTTGGGTTTTCTACAAACTCTTTTGTATTATTTCTAAATACATTCAAAATATGTATCCGCTT  
 AACCGYAATTGCCAGCTGGGGCGCCTCTGGTAAGGTTGGGAAGCCCTGCAAAGTAAACTGGAT  
 GGCTTCTCGCGCCAAGGATCTGATGGCGCAGGGATCAAGCTCTGATCAAGAGACAGYATGA  
 GGATCGTTTCGCTGATTGAACAAGATGGATTGCAACGAGGTTCTCCGGCCGCTTGGGTGGAGA  
 GGCTATTCGGCTATGACTGGGCACAACAGACAACTGGCTGCTCTGATGCCGCGCTGTTCCGGCT  
 GTCAGCGCAGGGGCGCCGGTTCTTTTGTCAAGACCGACCTGTCCGGTGCCTGAATGAACGTG  
 CAAGACGAGGACGCGGGCTATCGTGGCTGGCCACGACGGCGTTCCTTGGCGAGCTGTGCTCG  
 ACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCTGGGCGAGGATCTCCT  
 GTCATCTCACCTTCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGGCGGCTGCAT  
 ACGETTGATCCGGCTACCTGCCATTCGACCAACAAAGCGAAACATCGCATCGAGCGAGCACGTA  
 CTGGATGGAAGCCGGTCTTGTGATCAGGATGATCTGGAAGAAGGCATCAGGGGCTCGCGCC  
 AGCCGAACGTCTCGCCAGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCCTGCTGACCCAT

Figure 25D

ggcgatgacctgcttgcogaataatcatgggtggaaaatggccgctttttctggattcatcgactgtg  
gcogctgggtgtggggaccgctatcaggacatagcgttggctaccogtgatattgctgaaga  
gcttggcggaatgggtgaccgcttccctcgtgctttacgggtatcgccgctccogattcgcag  
cogatogccttctatcgccttcttgacgagttctctgacgcctgacccaaatcccttaacgtg  
agttttctgctccactgagcgtcagaccocgtagaaaagatcaaaggatcttcttgagatccttt  
tttctgcgctaatctgctgcttgcacaacaaaaaacaccgctaccagcgggtggtttgtttg  
ccggatcaagagctaccaactcttttccgaaggtaactggcttcagcagagcgcagataccaa  
atactgtccttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctac  
atacctcgtctctgetaatcctgttaccagtggtgctgcccagtgggcgataagtctgtcttacc  
gggttggactcaagacgatagttaccggataaaggcgcagcgggtcgggtgaaacggggggttctg  
gcacacagcccagcttggagcgaacgcctacaaccgaactgagatacctacagcgtgagctatg  
agaaagcggccacgcttccgaaggggagaaaggcggacaggtatccggtaagcggcagggctcgg  
acaggagagcgcacaggggagctccagggggaacgcctggatctttatagtcctgtcgggt  
ttcgcaccctctgacttgagcgtcagatttttctgatgetcgtcagggggcggagcctatgaa  
aaacgcacgaacagcggccttttaccggttccctggccttttctgctggccttttctcaccatgttc  
tttctgcttctccctgattctgtggataacogtattaccgctttgagtgagctgataccg  
ctcgcgcagccgaacgcacogagcgcagcagctcagtgagcggaggcagcgaagagcgcctgat  
goggtattttctccttaccgatctgtgoggtatttcaaccgcctatgggtgcaetctcagtaaa  
atctgctctgatgcccgatagtttaagccagtaaacactccgctatcgttacgtgactgggtcct  
ggctgcccggcgaacccgccaaacaccocgtgacgcgcctgacgggcttctctgctcccggca  
tccgcttacagacaagctgtgaccgctctccgggagctgcatgtgtcagagggttttccocgctat  
caccgaaacgcggcggaggcagcagatcaattcgcgcgcgaaggcgaagcggcatgcaattacgtt  
gacaccatcgaatgggtgcaaaccttccgcggtatggcatgatagcgcggcgaagagagtcatt  
tcagggtgggtgaaatgtgaaaccagtaacgttatacagatgtcgcagagatgcccgggtctctta  
tcagaccgcttccgcgctgggtgaaaccaggccagccacgcttctgcgaaaacgcgggaaaaagt  
gaagcggcgatggcggagctgaattacattcccacccgctggcacaacaactggcgggcaaac  
agtcttctgatggcgttgcacacctccagctctggccctgacgcgcgctcgcgaattgtcgc  
ggcattaaatctcgcgcgatcaactgggtgcccagcgtgggtgggtctgatgggtgaaacgaagc  
ggcgtcgaagcctgtaaaagcggcgggtgcacaacttctcgcgcacgcgctcagtgggctgatca  
ttaactatccgctggatgaccaggatgcccattgctgtggaagctgctgcactaatgttccggc  
gttattctctgatgtctcgaaccagacaccatcaacagtattattttctcccatgaaagcgt  
accgactggcgtggagcatctggtcgcattgggtcaccagcaaatcgcgctgttagcgggcc  
calttaagttctgtctcggcgcgtctgctgctggtggctggcataaatactcaactcgcattca  
aattcagccgatagcggaaacgggaaggcgaactggagtccatgtccggttttcacaacaaccatg  
caaatgctgaatgagggcatcgttcccactgcgatgctggttgcacaagatcagatggcgtgg  
goccaatgocgocattaccgagtcgggctgcccgttgggtgaggatctcggtagtgggata  
cgacgatccgaagacagctcatgttatatcccgcgctcaaccaccatcaaacaggattttcgc  
ctgctggggcaaacagcgtggaccgcttgcctgcaactctctcagggccaggcgggtgaaqggca  
atcagctgttgcocgtctcactggtgaaaagaaaaaccaccctggcgcaccaatacgcacaaccgc  
ctctcccgcgcgttggcogattcaatgagctggcagcagaggtttcccgactggaaagc  
ggcagtgagcgcacacgaattaatgtgagtttagcgcgaattgatctg

SEQ ID NO:11

Figure 26




Figure 27A

5' -

ccggtctactgtcgggaattcgcggttgccgattcattaatgcagattctgaaatgagctgtt  
gacaattaatcatccggetcgtataatgtgtggaattgtgagcggataacaatttcacacagga  
aacagcgcgctgagaaaaagcgaagcggcactgctctttaacaatttatcagacaatctgtgt  
gggcactcgaccggaattatcgattaactttatttataaaaattaaagaggatataattaatgt  
atcgattaaataaggaggaataaaccatggatccgagctcaggaggtaaaaaacatgaaaaca  
gtagttattattgatgcattacgaacccaattggaaaatataaaggcagcttaagtcaagtaa  
gtgccgtagacttaggaacacatgttacaacacaacttttaaaaagacattccactatcttga  
agaaattgatcaagtaactctttggaatgttttacaagctggaatggcctaaatcccgcacga  
caaatagcaataaacagcggtttgcctcatgaaattcccgaatgacggtaatgaggtctgcg  
gatcaggaatgaaggccgttattttggcgaacaattgattcaattaggagaagcggagttt  
aattgctggcgggattgagaatagtcccaagcacctaaattacaacgttttuattacgaaaca  
gaaagctacgatgocctttttctagtatgatgtatgatggattaacggatgoccttagtggtc  
aggcaatgggcttaactgctgaaaatgtggccgaaaagtatcatgtaactagagaagagcaaga  
tcaatttctgtacattcacaattaaaagcagctcaagcaacagcagaagggatattcgctgac  
gaaatagcccattagaagtatcaggaaacgcttgtggagaagatgaagggattogccctaatt  
cgagcgttgagaagctaggaacgcttaaaacagtttttaagaagacggtaactgtaacagcagg  
caatgcataaccattaatgatgggcttctgctttgattatgcttcacaagaatattgocgaa  
gcacacgggtcttcttatttagctattatcgagacagtggtggaagtcgggtattgatccagcct  
atatgggaatcttgcgattaaagccattcaaaaactgttagcgcgcaatcaactactacgga  
agaaattgatctgtatgaaatcaacgaagcatttgcagcaactcaatcgtggtccaagagaa  
ctggctttaccagaggaaaaggtaacatttatgggtggcggatttccattaggtcatgagattg  
gtgccacaggtgctcgtttattaacgagtttaagtatcaattaaatcaaaaagaaaagaaata  
tggagtggtctctttatgatatcggcgytggttaggaactcgctatgctactagagagaocacag  
caaaaaaaaaaacagccgattttatcaaatgagtcctgaggaacgcctggcttctcttcaatg  
aaggccagatttctgctgatacaaaaaaagaatttgaaaatacggctttatcttcgagattgc  
caatcatatgattgaaaatcaaatcagtgaaacagaagtgccgatggcgggttggettacattta  
acagtgagcaaaactgattatttgggtaccaatggcgacagaagagccctcagttattgocgctt  
tgagtaatggtgcaaaaatagcacaaggatttaaaacagtgaaatcaacaacgcttaatgocgtgg  
acaaatcgtttttacgatggtgcagatcccagctcattgattgataaaactacaagtaagagaa  
gcggaagttttbaacaagcagagttlaagttatccatctatcgttaaacggggcggcggcttaa  
gagatttgaatatcgtacttttgatgaatcatttgatctgtcgactttttagtagatgttaa  
ggatgcaatgggggcaaatatcgttaacgctatgttgggaaggtgtggccgagttgttccgtgaa  
tggtttgcggagcaaaaagattttatcagatatttaagtaattatgccacggagtcggttgta  
cgatgaaaaacggctattccagtttcaagtttaagtaaggggagcaatggccgggaaatttgcga  
aaaaattgtttttagcttcacgctatgcttcatttagatccttatcgggcagtcacgcataacaaa  
ggaatcatgaaatggcattgaagctgtagtttttagctacaggaaatgatcacgcgctgttagcg  
cttcttgcctatgctttttgcggtgaaggaaggtcgcataccaaggcttgactagttggacgctgga  
tggcgaacaactaattggtgaaatttcagttccgcttgccttttagccacggttggcgggtgcaca  
aaagtcttacctaataatctcaagcagctcgtgatttgttagcagtgacggatgcaaaaagaactaa  
gtcagtagtagcggctgttggtttggcacaacaaatttagcggcgttacgggccttagtctctga  
aggaattcaaaaaggacacatggctctacaagcagcttctttagcagtgacggctggagctact  
ggtaaagaagttgagcagtcgctcaacaattaaaacgtcaaaaaacgatgaaccaagaccgag  
ccatggctattttaatgatttaagaaaacaataaaggaggtaaaaaacatgacaattgggat

Figure 27B

tgataaaaattagtttttttgggcccccttattatattgatatgacggcactggctggaagccaga  
aatgttagaccctggaaaatttcataattgggtattgggcaagaccaaatggcgggtgaacccaatca  
gccaagatattgtgacattttgcagccaatgcccgcagaagcgatcttgaccaaaagagataaaga  
ggcoattgatatgggtgatttggggactgagtcocagtatcgatgagtcaaaagcggccgcagtt  
gtcttacatcgttttaattggggatccaacctttcgctcgctctttcgaaatcaagggaagcttgtt  
acggagcaacagcaggcttacagtttagctaaagaatcacgtagccttacatccagataaaaaagt  
cttggctgtagcggcagatattgcaaaaataggcttaaaattctggcgggtgagcctacacaagga  
gctgggggggttgcgaatgttagttgctagtgaaacogcgcaitttggccttaaaaaggagataatg  
tgatgctgacgcaagatatactatgacttttggcgtccaacagggccaccggtatcctatggctga  
tggctctttgtcaaacgaaacctacatccaatctttgcccgaagtctgggatgaacataaaaaa  
cgaaccggctcttgattttgcagattatgatgctttagcgttccatattccttacacaaaaatgg  
gcaaaaaagccttattagcaaaaatctccgaccaaaactgaagcagaacagggaacttttagc  
ccgttatgaaagaaagtatcgtctatagtcgctcgcgtaggaaacttgtatacgggttcaactttat  
ctgggactcaatttcccttttagaaaatgcaacgactttaaccgcaggcaatcaaatgggtttat  
tcagttatggttctgggtgctgctgcaattttcaactgggtgaattagtagctggttatcaaaa  
tcatttacaaaaagaaactcatttagcactgctggataatcggacagaactttctatcgtgaa  
tatgaagccatgtttgcagaaactttagacacagacattgatcaaacgcttagaagatgaattaa  
aataatagttttctgctattaataataacoggttctgttcttatcgaaactaagagatctgcagctg  
gtaccatagggnaattcgaagcttgggcccgaacnaaaaactcattctcagaagaggatctgaata  
gcyccgtcgaccatcatcatcatcattgagtttaacgggtctccagcttggctgttttggc  
ggatgagagaagattttcagcctgatacagattaaatcagaacgcagaagcggctctgataaaac  
agaaatttgcctggcggcagtagcggcgggtggctcccactgaccccatgcccgaactcagaagtga  
acgccttagcggcggatggtagtctggggctctcccactgcgagagtagggaaactgcccagccatca  
aataaaacgaaaggctcagtcgaasagactgggccccttctgttttatctgtttgtttgtcgggtgaa  
gctctcctgagtaggacaaaatcccgcgggagcggatttgaacgcttgcgaagcaacggcccggag  
ggtggcgggcaggacgcccggccataaaactgcccaggeatcaaatgaagcagaaggccatcctgac  
ggatggcctttttggctttctcaaaaactctttttgttttatttttctaaatacatltaaaatagt  
atccgctcatgagacaataaacctgataaatgcttcaataatctggcgttaataagcgaagaggcc  
cgaaccgatcgccttcccacagtttgcgcagcctgaaatggcgaatggcgcctgactgctgctgatt  
ttctcttaccgcatctgtgoggtatttcacaccgcataatgggtgcaactctcagtaacaatctgtct  
tgatgcccgatagtttaagccagccccgcaccccgcacaaccccgcctgacgagcttagtaaaagcc  
ctcgtatagatttttaagggatggttgcgattaacttcgccaactattgcgataacaagaaaaagc  
cagcctttcatgatataatctcccattttgtgtagggttatttatgacgcttaaaaaataataaa  
agcagacttgacctgatagtttggctgtgagcaattatgtgcttagtgcatctaacgcttgagt  
taagccgcgcgcgogaagcggcgtcggcttgaacgaattggttagacattatitgcccactacctt  
ggtagctcgcctttcacgtagtggaacaaattcttccaactgatctgcgcgcgagggccaagcga  
tcttcttcttctgccaagataagcctgtctagcttcaagtatgacgggctgataactgggcggcga  
ggcgtccatitgcccagtcggcagcagacatccttcggcgcgattttgcccgttactgcccgtgta  
ccaaatgggggacaacgtaagcactacatttcgctcatcgcagcccagtcggggcggcagttc  
catagcgttaagggttccatttagcgcctcaaatagatcctgttcaggaaaccggatcaasaggtt  
cctccgcgcctggacctaccaaggcaacgctatggttctcttctgttttgcagcaagatagccag  
atcaatgtcgatcgtggctggctcgaagatacctgcaagaatgtoattggcctgcccattctcca  
aatggcagttcgcgcttagctggataacggccacggaaatgatgtcgtcgtgcacaacaatgggtga  
cttctacagcggcggagaa tctcgtctctccaggggaagccgaagtttccaaaaggtcgttga

Figure 27C

caaagetecgecgggttgtttcatcaagecctacgggtcaccgtaaccagcaaatacaatataactg  
 tgtggcttcagggcccatccactgaggagccgtacaaatgtaaggccagcaaeagtgggttcga  
 gatggcgctcgatgacgccaactacctctgatagttgagtcgatacttcggcgatcacccgttc  
 cctcatgatgtttaactttgttttagggcgactgcccctgctgctgtaacatcgtttgctgctccat  
 aacatcaaacatcgacccacggcgtaacggccttgctgcttggatgcccgaggcatagactgta  
 ccccaaaaaaacagtcataacaagccatgaaaacggccactgcccgttaccaccgctggttc  
 ggtcaagggttcctggaccagttgctgtagcgcatccgctacttgattacagcttacgaaaccgaa  
 caggcttatgtccaactgggttcgtgcttcatccgtttccagggtgtgctcaccocggcaacct  
 tgggcagcagcgaagtccggccattctgtctggctggcgaacgagccgcaagggttcgggtctc  
 caccgatcgtcaggcattggcggccttgcctgtctctctacggcaagggtgctgtcaccgcatctg  
 cctgcttcaggagatccggaagacctcggccctgcccggccttgcgggtggtgctgacccgg  
 atgaaatgggttcgcatcctcgggtttctggaagccgagcagcatcgtttgttcgcccagctctgta  
 tggaaacggccatgggatcagtgagggtttgcaactgcccgggtcaaggatctggatctcgatcc  
 ggcacgatcctcgtgcccggaggcgaagggttccaaggatccggcccttgatggttaccocgagagct  
 tggcaccacagcctgcccggagcaggggaatttaattcccaagggttttgcctgcccgaacacgggct  
 gttctgggtgttgcctagtttgttatcagaatccgagatccggcttcagccgggtttgcccggctgaa  
 agccttattctccagaattgccatgattttttcccacgggagggcctcactggctcccggtg  
 tgtccgagcctttgattcgataagcagcctccgctgtttcaggctgtctatgtgtgactgttga  
 gctgtaaccaagttgtctcagggtgttcaatttcatgttctagttgctttgttttactggttcac  
 ctgttctattagggtgttacatgctgttcatctgttaccattgttcgatctgttccatgggtgacagc  
 ttgaaatgcaccaaaaactcgtaaaagctctgatgtatctatcttttttacaccgttttccatct  
 gtgcataatggacagttttccctttgatatgtaaccgggtgacagttggttctacttttgtttgta  
 gtcttgatgcttcactgatagatacaagagccataagaacctcagatccctccogtatttagcca  
 gtatgttctctagttgtggttcggtttgttttgcctgagccatgagaacgaaaccttgagatcata  
 cttactttgcatgtcactcaaaaattttgcctcaaaaactgggtgagctgaatttttgcagttaaa  
 gcactcgtgtagttgttttcttagtcoggttatgtaggtaggaatctgatgtaatgggtgttggta  
 ttttgtcaccattcatttttatctgggtgttctcaagttcgggttacgagatccatttgtctatc  
 tagttcaacttggaaaaatcaacgtatcagtcggggcggcctccgcttatcaaccaaccaattcata  
 ttgctgtaagttgtttaaattcttactttatgggttcaaaaaccttgggttaagccttttaact  
 catggtagttattttcaagcattaacatgaacttaasttcatcaaggctaatctctatatttgc  
 cttgtgagttttcttttgtgttagttcttttaataaccactcataaattctcctatagagtattg  
 ttttcaaaagacttaacatgttccagattatattttatgaatttttttaactggaaaagataag  
 gcaatatacttcaactaaaaactaattctaatttttcgccttgagaacttggcatagtttgtcca  
 ctgaaaaatctcaagcctttaaccaaaaggattcctgatttccacagttctcgtcctcagctct  
 ctgggttgccttagctaatcacccataagcattttccctactgatgttccatcctcggcgtatt  
 ggttataagtgaaacgataccgtccggtctttccttctgtagggtttcaactcgtggggttagtag  
 tgcacacagcataaaaattagcttgggttccatgctccgttaagtcataagcactaatcgttagt  
 tcaatttgctttgaaaaaactaattcagacatacctctcaattgggtctaggtgattttaatcac  
 tataccaattgagatgggttagtcaatgataattactagtccttttccctttaggttgtgggtat  
 ctgtaaatctctgctagacctttgctggaacttgt.aaattctgctagacctctgtaaattcc  
 gctagacctttgtgtgtttttttgtttatattcaagtggttataatttatagaataaagaag  
 aataaaaaaagataaaaagaatagatcccagccctgtgtataactcactactttagtcagttcc  
 gcagtatcaaaaaggatgtcgaaaacgctgttgcctctcaaaaacagaccttaaaacct  
 aaaggcttaagtagcaccctcgcaagctcgggcaaatcgtgaaattctctttgtctccgacc

**Figure 27D**

Atcaggcacctgagtcgctgtctttttcgtgacattcagttcgtgcgctcacggctctggcag  
tgaatgggggtaaatggcactacaggcgcttttatggattcatgcaaggaaactaccataat  
acaagaaaagcccgtaacgggttctcagggcgtttatggcgggtctgctatgtgggtctatc  
tgactttttgctgttcagcagttcctgcctctgattttccagtctgaccacttcggattatcc  
cgtgacaggtcattcagactggctaattgcaaccagtaaggcagcggtatcatcaacaggetta

(SED ID NO:12)

Figure 28




Figure 29A

5' -

tgtaacottttgctttcaaatgagtagaataatgcacatccatggtttgtatogtgcaataaag  
 tgtttcctcogtaggaaaaaatgacttttagtatctgttccogttttttctgatgaaatgtgctcc  
 ccgacaaaattgaatgaatcatggacatttgcctggctttgatacagcgaagcagccgttctta  
 tgttatatatcggatttaacagcaggacaaaaaacaccatgacagccatogtcacccacttatt  
 cacacgcacataaacctttcctgacttttggaaacagatgatagctcatcaaaaaatcccgcatt  
 gccaaataaatcgtatatggcattactgcaccataatcttttgagatttgattgggatatggcg  
 caagcagcaagacaagcagtcogataatcagcgtataaaaaataagcctagttagatcttatccgt  
 tetccaatcagcttgaaaaaacactacattcaacgcaatgggaagagtgatgatgaaaaacaga  
 aacacgaatgcaatcggctccatcccacccgggtattccttccaatacgaaaaagaactsaana  
 tcatttctgacgatcggcaaaactgacaacagcaaggtogaacgtataaaaacttaacctttccgpc  
 atgatcaocggcatcagcatatagtgaanaagccgtcagcagcacatatccgtatacaaaaaaa  
 tgcagcagcggcagcagcttctttccgtcctctcttaagtaagcgtggtgaagtttgttgatt  
 gcaactggtgaataagttcaacagacactcccgcagcagcacaatccgcaatatacaaccccgc  
 caagaacattgtgctgctgcccgtttatfttgygatgatgacccaaaagataaagcccgcgaga  
 scaacaattgaccattgaatcagcagggctgtttgtctgcttaataaaaaataacgctcgaat  
 gcaatacataaatgactgaataaactccaacacgaacaacaactccattttctctgctatcaaaa  
 taacagactcgtgatttccaaacgagcttcaaaaaagcctctgccccttgcaaatcggatgc  
 ctgtctataaaattcccgatattggttaaacagcggggcaatggcggccgcacctgatgtcttt  
 gcttggcgaatgtrcatcttatttcttccctccctctcaataatttttctattctatccctttc  
 tghtaaagtttatitttcagaatactttatcctcatgctttgaaaaaatatcagcataatcc  
 atgttctcagcgaagcacacgcaggtcatttgaacgaatttttccagcaggaatttgcgggga  
 ctcaggagcatthaacctaaaaagcatgacatttccagcabaatgaacatttactcatgtctat  
 tttcgttctttctgtatgaaaatagttatttccagctctctacggaaatagcggagagatgat  
 acctaatagagatasaatcatctcaaaaaatgggtctactaaatattatccatctattsc  
 aataaattccagaaatagcttttaagtaagteractctgaatttttttaaaaggagagggtaa  
 agagtgctattacogtctcttaacttctgeaccgggaaagggtattatttttgggtgaacactctg  
 ctggtatacaaacagcotgcogtgcctgctagtgltgtctgcttgagaacctacctgetaataag  
 cgagtcactctgcaccagatactattgaattggacttcccggacattagctttaatcataagtg  
 tccatcaatgatttcaatgcatcaccgaggatcaagtaaaactcccaaaaattggccaaggctc  
 aacaagccaccgatggcttctcaggaaactcgttctgtcttttggatccgttcttagctcaact  
 atccgaatccttccaactaccatgcagcgttttggcttctctgtatattgtttgtttgcccata  
 catgccaagaatatttaagttttcttttaagctctactttaccatcgggtgtgggttgggtcaa  
 gcgctctatttctgtatcactggccttagctatggcctacttgggggggttaataaggatctaa  
 tgacttggaaaagctgtcagaaaacgataagcatatagtgaatcaatggccttcataggtgaa  
 aagtgatttccggtacccctcaggaatagataaacgctgtggccacttatggtaatgcctgc  
 tatttgaaaaagactcacataatggcaacaataaacacaaaacaatttttaagttcttagatgattt  
 cccagccattccaatgatcccaactataactagaattccaaggctctacaaaagatcttgttgc  
 cgcgttcgtgtgttgggtcaccgagaaatttccctgaagttatgaagccaattcttagatgccatgg  
 gtgaatgtgcccatacaaggcttagagatcatgactaagtttaagtaaaatgtaaaaggcaccgatga  
 cgaggctgtagaaaactaataatgaactgtatgaacaactatttggaaatgataagaataaatcat  
 ggactgcttctcctcaatccggtgtttctcctcctggattagaacttattaaaaatctgagcagatg  
 atttgagaattggctccacaaaacttaccgggtgctgggtggcgggggttgcctctttagctttgtt  
 acgaagagacattactcaagagcaaatggacagcttcaaaaagaaattgcaagatgatttttagt

Figure 29B

tacgagacatttgaaacagacttgggtgggactggctgctgfttgtaagcgcanaaaatttga  
ataaagatcttaaaatcaaatccctagatttccaattatttgaaaataaaaactaccacaagca  
acaaattgacgatctattattgccaggaaacacgaatttaccatggacttcataaaaggagagg  
gtgtcagagttgagagccttcagtgccccagggasagcgttactagetggtggatatttagttt  
tagatacaaaaatagaagcattttagtgcgattatcggaagaatgcatgctgtagccatcc  
ttacggttcattgcaagggtctgataagtttgaagtgcgtgtgaaaagtaacaatttaagat  
ggggagtggctgtaccatataagtcctaaaagtggcttcattcctgtttogataggcggateta  
agaaccctttcattgaaaaagttatcgctaacttatttagctactttaaacctaaccatggacga  
ctactgcaatagaaaacttgttcggtattgatattttctctgatgatgcctaccattctcaggag  
gatagcgttacccaacatcgtggcaacagaagattgagtttcattcgcacagaattgagaag  
ttcccaaaacagggctgggctcctcggcagggttagtcacagttttaactacagctttggcctc  
ctttttgtatcggacctggaaaataatgtagacaatatagagaagttattcataatttagca  
caagttgctcattgtcaagctcagggtaaaattggaagcgggtttgatgtagcggcggcagcat  
atggatctatcagatataagaagattcccaccgcattaatctctaatttgccagatattggaag  
tgctacttaoggcagtaaaactggcgcatttgggtgatgagaagcagctggaatattcagattaa  
agtaaccatttaccctcgggattaactttatggatggcggatattaagaatggttcagaaacag  
taaaactggctccagaaggtaaaaaattggtatgattcgcatatgccagaaagcttgaaaatata  
tacagaactcgatcatgcaaatctagatttatggatggaatctctaaaactagatcgcttacac  
gagactcatgacgattacagcagatcagatatttgagctcttgagaggaatgactgtacctgtc  
aaaagtatcctgaaatcacagaagttagagatgcagttgccacaattagacgttcccttagaaa  
aataactaaagaatctggtgcogatacgaacctcccgtaacasactagcttattggatgattgc  
cagaccttaaaaggagttcttacttgcttaatacctgggtgctgggtggttatgacgccattgacg  
tgattactaagcaagatggtgatcttagggctcaaacccgctaatgacaaaagattttctaaggt  
tcaatggctggatgtaactcaggtgactgggggtggttaggaaagaaaaagatccggaaaacttat  
cttgataaataaaaggagagggtgaccgtttacacagcatccggttaccgcaaccogtcaacatcg  
caacccttaagfattgggggsaaaagggacacgaagttgaaatctgcccccattcgtccatctc  
agtgactttatcgcaagatgacctcagaacggtgacctctgcggtactgcaacctgagttgaa  
cggacactttgtggttaaatggagaaccacacagcatcgacaatgaaagaactcaaaattgtc  
tgcgggaectacgccaattagaagaaggaaatggaaatogaaggacgctcattgcccacattatc  
tcaatggaaaactccacattgtctccgaaaataactttcctacagcagctgggttagcttccctc  
gctgctggcttgcctgcatgggtctctgcaattgctaagttataccaattaccacagtcaactt  
cagaaatctagaaatagcaagaaggggctcgtggttcagcttgtagatcgttggttggcggata  
cgtggcctgggaatgggaagaagctgaagatggtcatgattccatggcagtaaaaatcgcagac  
agctctgactggcctcagatgaaagcttggtgcttagttgctcagcagatataaaaaggatgtga  
gttccactcagggatgcaattgacctggcaacctccgaactatttaaggaaagattgaaaca  
tgtcgtaccaaagagatttgaagtcstgctgaaagccattggtgaaaaagatttcgccaacttt  
gcaaggaaacaatgatggattccaactcttccatgccacatggttggactcttccctccaa  
tattotacatgaatgacacttccaagcgtatcatcagttgggtgccacaccatlaactcagtttta  
cgggaaacaatcgttgcatcacggtttgatgcaggcccaaatgctgtgttactacttagct  
gaaaatgagtogaaactcttgcatttatctataaattggttggctctgttccctggatgggaca  
agaaatttactactgagcagcttgaggcttcaaccatcaatttgaatcatctaacttactgc  
acgtgaattggatcttgagttgcaaaaggatggtgccagagtgattttaactcaagtcgggtca  
ggcccacaagaacaacgaatctttgattgacgcaaaagactggtctaccaaaaggaataaaagg  
agaggggtgactgccgacaacaatagtatgcccactggtgaggtatctagttacgccaattagct

Figure 29C

gcaaaacccaacacactgaagacattttggaagagtttctgaaattattccattacaacaaaga  
 cctastaccogactagtgagacgtcaaatgaogaaagcgagaaacatggttttctggtcag  
 atgaggagcaaatagttaatgaatgaaaattgtattggtttggattgggacgataatgctat  
 tgggtgocggtaccaagaaagtttgtcatttaattggaataattgaaaagggttactacatcgt  
 gcatctocgctctttatcttcaatgaacaaggtgaattacttttaacaaagagccactgaaa  
 aataaactttccctgatctttggactaacacatgctgctctcatccactatgtattgatgacga  
 attaggtttgaagggttaagetagaogataagattaaggggcgtattactgocggcggtgagaaaa  
 ctagalcatgaattaggtattccagaagatgaaaactaagacaaggggtaagtttcaacttttaa  
 acagaatccattcaatggcaccagcaatgaaccaagggtgaaacatgaaattgattacatcct  
 attttataagatcaacgctaaagaaaaacttgactgtcaaccccaaacgtcaatgaagtttagagac  
 ttcaaatgggtttcaccaaatgatttgaaaactatggttctgacccaagttacaagtttaogc  
 cttggtttaagattatgtgogagaattacttattcaactgggtgggagcaattagatgaccttcc  
 tgaagtggaaaaatgacaggcaaatccatagaatgctataaaaaaaaccggccttggccccggc  
 gttttttatttattttctctcctcogcatggtcaatccogctccataatcgacggatggctccctc  
 tgaaaatttttaacgagaaaacggcgggttgaccoggtcagtcocgttaacggccaagttctgaaa  
 cgtctcaatcogcogcttcccgggttccoggtcagctcaatgocgtaacggctggcggcgtttcc  
 tgataccgggagacggcattogtaatttgaatacatacgaacaaattataaagtgaaaaaaat  
 acttoggaaacatttaaaaaataaccttattggtaacttacatggttggatcaggsgttgagagt  
 ggactaaaaccaaafagtgatcttgactttttagtcgtctgtatctgacccattgacagatcaaa  
 gtaagaaaacttatacaaaaaattagacctatctcaaaaaaaataggagataaaagcaactc  
 acgatataattgaattaacaattattttcagcaagaaatggtaacogtggaatcatcctcccaaa  
 caagaatttatttatgggagatgggttacaagagctttatgacaagatacattcctcagaagg  
 aattaaattcogatttaaccaaatgctttaccaagcaaacgaaaaaataaaagaatatcgg  
 aaattatgacttagaggaattactacctgatattccattttctgatgtgagaagagccattatg  
 gatcogtcagaggaattaatagataattatcaggatgatgaaaccaactctatatcttattat  
 gccgtatgattttaactatggacacgggttaaatccataccaaaagatattgcccggaaatgcagt  
 ggtgaaatctctccattagaacatagggagagaattttgttagcagttcgtagttatcttggg  
 gagaatattgaatggactaatgaaaatgtaatttaactataaactatftaaataacagattaa  
 aaaaattataatgtaacctttgctttcaaatgagtagaaatantgcacatccatggttgtatcg  
 tgcaataaaagtgtttcatcogtaggaaaaaatgactttagtatctggtccogctttttctgatg  
 aatgtgctcccagcaaaaattgaatgaatcatggacatttgctggctttgatcagcgaagc  
 agcgttccctatgttatatcggatttaacagcaggcaaaaaaacccatgacagccatcgtc  
 acccacttattcaacgcacataaacctttcctgacttttggacagatgatagctcatcaaaa  
 atcccgccattgccaaataaatcgtatatggcattactgcaccataatcttttgagatttgatt  
 gggatagggcgaagcagcaagacaagcagtcogataatcagcgtataaaaaaagcctagtaag  
 atcttatcogttctccaatacagcttgaaaaacactacattcaacgcaatgggaagagtgatga  
 tgaaaaaacagaacacgaatgcaatcggctccatcccatccgggtattccttccaatacgaaaa  
 gaaactaaaaatcatttgtacgatcggcaaacctgacaaacagcaaggtcgaaogtataaaactta  
 cctttccgcatgatcacgcggtcagcataatagtgaaaagccgtcagcagcacatctcogt  
 ataacaaaaaatgcagcagcggcagcagttctttccogtctctcttaagtaagegctggtgaa  
 gtttggttgattgcacctgggtgaataagttcaacagaaactcccgccagcagcaaatccgcaat  
 ataacacccgccaagaacattgtgocgtgccgggttattttgggatgatgcaaaaaagatata  
 agccccgcagacaacaattgaccattgaaatcagcaggggtgctttgtctgcttaatataaaaata  
 acgttcgaaatgcaatcacaatgactgaataactccaaacagcaacaacaaaagtgccgcaattt

Figure 29D

Ataaaagctaataatgattcagtcacacataattgatagacgaattctgctacaggtcacgtggctat  
gtgaaggatcgcyggtccagttaagagcassaaacattgacaaaaaaatttatttatgctaaaat  
ttactattaatatatttgtatgtataataagattctcctggccaggggaatcttattttttgtg  
gaggatcatttcatgaggaaaaatgagtcacagcttaacgtctctaaattcagcttttgcccggtg  
catatcacagccgatatgacacacctcttatttttgatgattttatcgcaaaagatctcattaa  
cgaaaaagagtttatcgacatcagtaaaaaatagattcaagaaatatcgtttttcaacaaagag  
atcgccgaacgtcttcaaaatgatcctgaaaaaatattaaaatgggttgacaaaatccagctgt  
ctcoaaccgcccctagcacgtgcttcttattgtgaaaaagtccttcacacacgaattaatcctggg  
ggcaaacagtatgtcattcttggagcgggactggatactttctgctttcggcatccagaatta  
gaaaacagcttacaggttttcgaggttgatcctccggccacacagcaattgaaaaaaataagc  
tgaaggatgcaaatctgacaattccgggtcatcttcattttgttctatggatttcacccaaaac  
gttttctgtatgatcctctcttagatgaaggattttaaasacacaaaacattcttcagccttctc  
ggagtgtcttattatgtaacacgggaagaaatgcaagcttyatcagcaattttattttctcatg  
tcccgcctggaagctctattgtttttgattatgaggacgaaacactttttacagcaaaagggac  
gtcgaatcgagttgaacatatggtgaagatggctgcccgaagcggggaaccgatgaaatcatgt  
ttcacttatcaagagattgaacatctg

SEQ ID NO: 13

Figure 30




Figure 31A

5' -

tagaaaaactcatcgagcatcaaatgaaactgcaatttattcatatcaggattatcaataccat  
atthttgaaaaagccgtttctgtaatgaaggagaaaaactcaccgaggcagttccataggatggc  
aagatcctgggtatcgggtctgcgattccgactcgtccaacatcaatacaacctattaatttcccc  
tcgtcaaaaaataaggttatcaagtgagaaatcaccatgagtgaagactgaatccggtgagaatg  
gcaaaagtttatgcatctcttccagacttgytcaacaggccagccattacgctcgtcatcaaa  
atcaactcgcatacaaccaaacogttattcattcgtgattgcccctgagcggaggcaaataccgga  
tcgctggttaaaaggacaattacaaccagggaatcgagtgcaacogggcgcagggaacactgccagcg  
catcaacaatattttcaccogaatcaggatattcttctaataacctggaacogctgtttttccggg  
gatcgcagtggtgagtaaccatgcatcatcaggagtaaggatanaatgcttgatggtcgggaagt  
ggcataaattccgtcagccagtttagtctgaccatctcatctgtaacatcatggcaacogctac  
ctttgcaatggttcagaaacaactctggcgcacatcgggcttccatacaagcagatagattgtcgc  
acctgattgcccagacattatcgcgagccatttatacccatataaantcagcatccatggtggaa  
tttaatcgcggcctcgaagtttccogttgaatatggctcatattcttcccttttcaatattatt  
gaaacatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataa  
acaaataggggtcagtggtacaaccaatttaaccaattctgaacattatcgcgagccatttata  
cctgaatatggctcataaacaccccttgtttgcccggcagtagcggcgggtggfcccacctgac  
cccagcgcgaactcagaagtgaacgcggtagcggcagatggtagtgtggggaactcccagcoga  
gagtagggaaactgccaggcatcaaataaaacgaaaggctcagtcgaaagactgggccccttccgc  
cgggctaattagggggtgtcccccctttagtcgctgaacatgtgctctgtttctaccgagaacgt  
ttccttcaactgagacggaaaccgagggcacgtcgttagcgcgaactacgagccogaatagctgggac  
taagatttccctgctgtcttccgatactgaogaatctattgaggtgtacaaagacaaagcaaaaga  
aactggaggctgaagtgcgcgcgcaaatcaacaacgagaaagctgaattccctgactctgctgga  
gctgatcgataacgtacagcgcctgggtctgggttacogcttcogaatctgatctcgttcgogca  
ctggatcgtttcgttaagcagcgggggtttcgatggcgtgacccaaaacgagccctgcaagctaccg  
cgtctccttccgtctgctgcgtcagcaecggcttcogaagtttctcaggaagcatctccgggttt  
caaagatcaaaacggtaacttccctggaaaaacctgaaagaagacactaaggcagatccctgagcctg  
tataggcaagctttctggccctggagggtgagaacatccctggatgaggcgcgcgtattcgcga  
ctcccatctgaaagagctgtctgaaagaaaaatcggtaaggaactggcagagcaggttaataca  
cgcactggaactgcccctgcctogtctgtaaccagcgtctggaggcgggtttggtccatcgaagcg  
taccgcaaaaaggaggtatgctaaccaggttctgctggaactggccatccctggactacaacatga  
tccagtcogtttaccagogtgatctgcgtgaaaacctccctgtggtggcgcogctgtggccctggc  
gaccaaaactgcacttcgtaaggaccgctgaitgagctcttttactgggcagtcygcgttggg  
ttcgaacctcagttattctgactgcgttaacagcgttgcgaaastgttcagcttcgttactatta  
tcgacgacatctacgacgtttacggtaactctggacgagctggaactgtttaccgacgctgtoga  
acgtttgggatgttaacggccatcaacgatctgcctgactacatgaaactgtgcttccctggcactg  
tataacacgatcaacgaaattgcatacgacaacctgaaagacaaaggtgaaanaatccctgcctg  
acctgactaaaagcgtgggcccgatctgtgtgtaacgctttctgcaagaagcgaatcgctgtataa  
caaatccactccgacctttgacgattatttcggcaatgcctggaaatccagctctggcccogctg  
caactgatcttccgttattttgcggttgcctcaaacatcaaaaaggaggaaattgaaaacctgc  
aaaaataccacgatatacattagccgtccctctcatatctttccgctgtgcaacgacctggcaag  
cggctccgcagagatcgcacgtggcgaaccgcttaactctgtttccctgctacatgcccaccaag  
ggcatttccgaagagctggcaaccgagagcgtaatgaaatctgatcgaacgaacctgtaagaaaa  
tgaaacaaagaaaaactgggtggctccctgttcgctaaaccttcgttagagactgctattaacct

Figure 31B

ggcaegt cagagccactgcacctaccacaatgggtgacgcacatactagcccggatgaactgact  
cgtaaacgtgtactgtctgttatcccgaaocgattctgocgttogaacgttaactgcagcgtc  
aatcgaaagggcgacacaaaatttattctaataatgcataataaatactgataacatcttatagtt  
tgtattatattttgtattatcgttgacatglataaattttgatatacaaaaactgatttcccttt  
attattttcgagatttattttcttaattctctttaacaaaactagaaaatattgtatatacaaaaa  
atcataaataatagatgaafagtttaattataggtgttcatcaatcgaaaaagcaacgtatctt  
atftaaagtgcggttgcctttttctcatttataaggttaaataattctcatalatcaagcaagt  
gacaggcgcocctaaatattctgacaaatgctctttccctaaactccccccataaaaaaacccg  
ccgaagcgggtttttacgttatttgccgattaacgattactcgttatcagaaccgcocaggggg  
cccagacttaagactggccgtcgtttttacaacacagaaagagttttgtagaaacgcasaaaggcc  
atccgtcaggggoccttctgcttagtttgatgcctggcagttccctactctcgccttccgcttcc  
tcgctcactgactcgtgcctcgttgcgttcggctgcggcgaagcggatcagctcactcaaagg  
cggtaaacgggttatccacagaatcaggggataaacgcaggaagaacatgtgagcaaaaggcca  
gcaaaaggccaggaaccgtaaaaaagccgcgttgctggcgtttttccatagggtccgcctccct  
gaogagcatcacaaaaatcgacgctcaagtccagaggtggcgaaccgcgacaggactataaagat  
accaggcgtttccccctggaagctccctcgtgcgctctcctgttcogaccctgcccgttacogg  
atacctgtccgcctttctcccttcgggaagcgtggcgcctttctcatalagctcacgctgtaggtat  
ctcagttcgggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccg  
accgctgcgccttatccgtaactatcgtcttgagttcaaccocggttaagacacgacttatcggc  
actggcagcagccactggtaacaggattagcagagcgaggtatgtaggcgggtgctacagagttc  
ttgaagtggtaggctaactacggctacactagaagaacagttatttggtatctgcgctctgctga  
agccagttaccttcggasaaagagttggtagctcttgatccggcaaacaaaccacgcgtggtag  
cgggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcct  
ttgatctttctacggggtctgacgctcagtggaacgacgcgcggttaactcacgttaagggat  
tttggtcatgagcttgocgcgtcccgtaagtcagcgttaatgctctgcttt

SEQ ID NO:14

Figure 32




Figure 33A

5' -

gtttgacagcttatcatcgactgcaoggtgcaaccaatgcttctggcgtcaggcagccatcggaa  
gctgtgggtatggctgtgcaggtogtaaatcaactgcataatfcgtgtcgcctcaaggcgcactccc  
gttctggataatgttttttgcgcgcgacatcataacggttctggcaaatattctgaaatgagctg  
ttgacaattaatcatccggctcgtataatgtgtggaattgtgagcggataaacaatttcacacag  
gaaacagcgcgcctgagaaaaagcgaagcggcactgctctttaacaatttatcagacaattctgt  
gtgggcactcgaocgggaattatogattaacotttattatataaaaattaaagaggtatataat  
gtatcgtataaataaggaggaataaaccatgtgctctggtttctaccgagaacgttctctcact  
gagacggaaaccgaggcagctogtagcgcgaactacgagccgaatagctgggactacgatttcc  
tgctgtcttccgatactgacgaatctattgagggtgtacaaagacaaaagcaaaactggagggc  
tgaagtgcgcgcgaaattaacaacgagaaaagctgaaatctctgactctgctggagctgatogaf  
aacgtacagcgcctgggtctgggttacogcttcgaatctgatatacogtgcgcactggatcgtt  
tcgtaagcagcggcgggttcogattggcgtgaccaaaaogagcctgcacgctaccgcgcctgctct  
ccgtctgctgc  
aacggttaacttctcggaaaaactgaaagaagacaactaaggcgcctcctgagcctgtatgagggca  
gctttctggccctggaggggtgagaacatcctggatgaggcgcgcgcgcgcgcgcgcgcgcgcgcgc  
gaaagagctgtctgaagagaaaaactcggtaaggaactggcagagcaggttaactcagcgcactggaa  
ctgcgcgcctcctcgtcgtacccagcgtctggaggcgggttgggtccatcgaagcgtaccgcaaaa  
aggaggatgctaaccaggttctgctggaactggccatcctggactacaacatgatccagtcgct  
ttaaccagcgtgatctgcgtgaaaactcccgttgggtggcgcgcgcgcgcgcgcgcgcgcgcgcgc  
cacttcgctaaaggaacgcctgatgagctcttttactgggcagtcggcgttgcgttcgaaactc  
agtaattctgactgcgcgtaacagcgtgcaaaaatgctcagcttcgcttactattatogacgacat  
ctaagcgtttacggtactctggacgagctggaactgttaccgacgcctgtcgaacgttgggat  
gttaacgccatcaacgatctgcctgactacatgaaactgtgcttctggcactgtataacacga  
tcaacgaaatgcataccgacaacctgaaagcaaaaggtgaaacatcctgcgcgtacctgactaa  
agcgtgggcgggatctgtgtaacgctttctgcaagaagcgaatggctgtatacaaatccact  
ccgaccttgaagattatttcggcaatgectggaaatccagctctggcccgctgcaactgatct  
tcgcttattttgcggtgtccaasacatcaaaaaggaggaaatgaaaacctgaaaaatacca  
cgatatacattagccgtcttctcatatcttgcctgtgcaacgacctggcaagcgcgcgcgcgcgc  
gagatcgcacgtggcgaaacgcctaacctctgttctcctgctacatgcgcaccasgggcatttccg  
aaagcctggcaacccgagagcgtaatgaaatctgatcgaacgaaacctgtaagaaaatgaacaaqa  
aaaactgggtggctcctggttcgctaaacggcttcgtagagactgctattaacctggcagctcag  
agccactgcacctaccacaatgggtgacgcacatactagcccgatgaactgactcgttaaactg  
tactgtctgttatcaccgaaccgattctgcgcgttcgaacgttaactgcagctggtaccataatgg  
gaattcgaagctttctagaacaaaaactcatctcagaagaggatctgaatagcgcgcctcgaacca  
tcatcatcatcattgagtttaaacggctctccagcttggctgttttggcggatgagagaaga  
tttcagcctgatacagattaaatcagaacgcgagagcgtctgataaaaacagaatttgcctgg  
cggcagtagcgcgggtggteccacctgaccccatgcccgaactcagaagtgaaacgcgcctagcgc  
gatggtagtggtgggtctcccctgogagagtagggaaactgccaggcatcaaataaaaagaaag  
gctcagtcgaaagactgggccttctgttttatctgtgtttgtcgggtgaaacgctctcctgagta  
ggacaaatccgcgggagcggatttgaacgttgcgaagcaacggcccgagggggtggcgggcagg  
acgcgcgcataaaactgccaggcatcaaatgaagcagaaggccatcctgacggatggccttttt  
gcgcttctacaaaactctttttgtttatttttctaaatacattcaaatatgtatccgctcatgag  
acaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagttatcaacatttc

Figure 33B

ogtgtogcccttatccctttttgcgccattttgocctccctgtttttgtcccccagaaacgc  
 tgggtgaaagtasaagatgctgaagatcagttgggtgcacgagtggttacatogaactggatct  
 caacagcggtaagatcccttgagagttttgccccgaagaacgtttccaatgatgagcacttt  
 aaagtctgctatgtggcgcggtattatcccggtgttgacgccccggaagagcaactcgggtccc  
 gcatacactattctcagaatgacttgggttgagtactcaccagtcacagaaaagcatcttacgga  
 tggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataaacactgcccgaac  
 ttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgccacaacatgggggatc  
 atglaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtga  
 caccacgatgcctgtagcaatggcaacaacgttgcgcaaacctattaactggcgaactacttact  
 ctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgc  
 gcteggeccctccggtggctggtttattgctgataaatctggagccggtgagcgtgggtctcg  
 cggatcattgacgactggggccagatggtaagccctcccgatcgttagttatctacacgacg  
 gggagtccggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgatta  
 agcattggtaactgtcagaccaagttaactcatatatactttagattgattttaaacttcattt  
 ttaattttaaaggatctaggtgaagatcccttttgataatctcatgacaaaaatcccttaacgt  
 gagtttctgttccactgagcgtcagaccocgtagaaaagatcaaaggatcttcttgagatcctt  
 tttttctgcgcgtaactcgtgcttgcacaacaaaaaacacccgctaccagcgggtggtttgttt  
 gccggatcaagagctaccaactcttttccgaaggtaactggcttcagcagagccagatacca  
 aatactgtccttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaocgcta  
 cataacctcgtctgtaaatcctgttaccagtggtgctgctgacagtgccgataagtcgtgtcttac  
 cgggttggactcaagaogatagtttaccggataaggcgcagcggctcgggtgaaacggggggttcg  
 tgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctac  
 gagaaagcgcacgcttccogaagggaagaaggcggacaggtatccggtaaagcggcagggtcgg  
 aacagggagagcgcacggagggttccagggggaaacgctcgtatctttatagtcctgtcggg  
 tttcgcacacctctgacttgagcgtcgatttttgtgatgctcgtcagggggcggagcctatgga  
 aaaaagccagcaacggcggcctttttaccggttctggccttttgcctggccttttgcctacatgtt  
 ctttccctgcttatccctgatctctgtggataaccgtattaccgctttgagtgagctgatacc  
 gotcgcgcagcgcgaacgacccgagcgcagcagtcagtgagcgaaggaaagcggagcgcctga  
 tgggttattttctcttacgcactctgtcgggtatttcaaccgcataatggtgcactctcagtae  
 aatctgctctgatgcccgatagtttaagccagtatacactccgctatcgctacgtgactgggtca  
 tggctgcccocgacaacccgccaacacccgctgacgcgcctgacgggcttgtctgctcccggc  
 atccgcttacagacaagctgtgaccgtctccgggagctgcatgigtcagagggttttccogtca  
 tcaccgaaacgcgcgagggcagcagatcaattcgcgcgcgaaggcgaagcggcatgcatttacgt  
 tgacaccatcgaatggtgcaaaacctttcgcgggtatggcatgatagcgcgggaagagagatcaa  
 ttcagggtgggtgaatgtgaaaccagtaacgltatacagatgtcgcagagtatgcccgtgtctctt  
 atcagaccgtttcccgctggtgaaaccagggccagccagctttctgcgaaaacgcgggaaaaagt  
 ggaagcggcgtatggcggagctgaattacattcccacccgctggcacaacaactggcgggcaaa  
 cagtcgttgcctgattggcgttgccacctccagctctggcctgcaagcgcctcgcgaattgtcg  
 cggcgtataaatctcgcgcgcatcaactgggtgccagcgtgggtggtcgtatggtagaacgaag  
 cggcgtcgaagcctgtaagcggcgggtgcacaactctctcgcgcgaacgcgctcagtgggctgatc  
 attaaactatccgctggatgaccaggatgccattgctgtggaagctgocctgcactaatgttccgg  
 cgttatttcttgatgtctctgaccagacacccatcaacagttatttttctcccataagaacgg  
 taagcagctggcgtggagcatctggtcgcattgggtcaccagcaaatcgcgctgttagcgggc  
 ccattaagtctctctcggcgcgtctgctctggctggctggcataaatactcactcgcactc

Figure 33C

aaattcagccgatagcggaacgggaaggcgaactggagtgccatgtccggttttcaacaaaccat  
gcaaatgctgaatgagggcatcgttcccactgcgalgctggttgccaacgatcagatggcgctg  
ggcgcaatgogcgccattaccgagtcgggctgcgcggttggtgcggatactcggtagtgggat  
acgacgataccgaagacagctcatgttatatccgcogtcaaccaccatcaascaggattttcg  
cctgctggggcaaacccagcgtggaccgcttgcctgcaactctctcagggccaggcggtgaagggc  
aatcagctgttgcccgctcactggtgaaaagaaaaaccacctggcgccaatacgcaaacog  
cctctccccggcggttggccgattcattaatgcagctggcagacagggttcccgactggaag  
cgggcagtgagcgcaacgcaattaatgtgagttagcgcgaattgatctg

SEQ ID NO:15

Figure 34




Figure 35A

5' -

ttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcag  
aggttttcacogtcatcaccgaaacgcgcgaggcagcagatcaattcgcgcgogaaggcgaagc  
ggcatgcatttacgttgacaccatcgaatgggtgcaaaacctttcgcggtatggcatgatagcgc  
ccggaagagagtcaattcaggggtggtgaatgtgaaccagtaacgttatacgatgtcgcagagt  
atgcoggtgtctcttatacagaccgtttcccgcggtggtgaaccaggccagccaogttctcgcgaa  
aacgcgggaasaagtggaagcggogattggcggagctgaattacattcccaaccgcgtggcaca  
caactggcgggcaaacagtcgttgcctgatggcggtggccacctocagctctggccctgcaacgc  
cgtcgcgaaatgtcgcggcgattaaatctcgcgcgatcaactgggtgccagcgtggtggtgtc  
gatggtagaacgaagcggcgtcgaagcctgtaaacgcggcgggtgcacaatctctcgcgcaacc  
gtcagtgggctgatcattaactatccgctggatgaccaggtgccattgctgtggaagctgctc  
cactaatgttccggcgttatttcttgatgtctctgaccagacccccatcaacagttatttt  
ctcccatgaagacgggtacgcgactggcggtgagcctctggctcgcattgggtcaccagcaatc  
gcgctgttagcgggcccattaagttctgtctcggcgcgtctgcgctctggctggctggcataaat  
atctcactgcgaatcaaatcagccgatagcggaaocgggaaggcactggagtgccatgtccgg  
ttttcaacaaaccatgcaaatgctgaatgagggcatcgttcccaactgcgatgctggttgccaac  
gatcagatggcgtggggcgcaatgcgcgccattaccagctccgggctgcgcgttggctgggata  
tctcggtagtgggatacgcagcgaataccgaagacagctcatgttataatcccgccgtcaaccaccat  
caaacaggattttccgctgctggggcaaacaccagcgtggaaccgcttgcctgcaactctctcagggc  
cagggcgtgaagggcaatcagctgttgcccgtctcactggtgaaaagaaaaaccaccctggcgc  
ccaatacgcgaaaccgcctctcccgcgcggttggccgatcattaatgcagctggcagcagcaggt  
ttcccgactggaaagcgggcagtgagcgcgaaccgaatlaatgtgagttagcgcgaattgatctg  
gtttgacagcttatcatcagactgcacgggtgcacpaatgcttctggcgtcaggcagccatcggaa  
gctgtggtatggtgtgtcaggtcgtaaatcactgcataaattcgtgtcgcctcaaggcgcactccc  
gttctggataatgtttttgcgcgcgacatcataaccggttctggcaaatattctgaaatgagctg  
ttgacaattaatcatccggctcgtataatgtgtggaattgtgagcggataacaatttcacacag  
gaaacagcgcgcctgagaaaaagcgaagcggcactgctcttaacaatttatcagcaatctgt  
gtgggeactcgcaccggaattatcgattaactttaktattasaaatlaagaggtatataattaat  
gtatcgatlaaataaggaggaataaaccaatgtgtgcgacctctctcaatttactcagattacc  
gagcataattcccgctcgttccgcgcaactatcagccaaacctgtggaatttcgaattcctgcaat  
cctctggagaacgcacctgaaagtggaaaagctggaggagaaagcgaaccgcaactggagggaagaagt  
tcgctgcctgatcaaccgctgtagacaaccagccgctgtccctgctggagctgatcgcagatgtg  
cagcgcctgggtctgacctacaaatttgaaaaagacatcattaagccctggaasaacatcgtac  
tgctggaagaaaaacaaaaagaacaaatctgacctgcacgcaacgcgtctgtctttccgtctgct  
ggctcagcagcgtttcagaggtttctcaggatgtttttgagcgtttcaaggataaagaagggtggt  
ttcagcgggtgaactgaaaggtgacgtccaaggcctgctgagcctgtatgaagcgtcttaccctgg  
gtttcagaggtgagaacctgctggaggaggcgcgtacctttccatcaccaccctgaagaacaa  
cctgaaagaaggttaataccaaggttgcaagaacaagtgagccacgcacctggaactgcoatat  
caccagcgtctgcaccgtctggaggcacgttggttccctggataaatacgaaccgaaagaaccgc  
atcaccagctgctgctggagctggcgaagctggattttaacatggtacagaccctgcaccagaa  
agagctgcaagatctgtcccgctggtggaccgagatgggcctggctagcaaacctggatthtga  
cgcgaccgcctgatggaagtttatttctgggcactgggtatggcgcagaccgcagtttgggtg  
aatgtcgcgaaagctgttactaaaatgtttggtctggtgacgatcatcgatgacgtgtatgacgt

Figure 35B

ttatggcaactctggacgaactgcaactgttcaccggatgctgtagagcgtgggacgttaacgct  
attaacaacctgcccgaactatatgaaactgtgttccctggcactgtacaacaaccttaacgaca  
cgtcctattctattctgaaagagaaaggctataacaacctgtcctatctgacgaaaagctggcg  
tgaactgtgcaaagcctttctgcaagaggcgaatggtccaaacaacaasattatcccggctttc  
tccaagtacctggaacacgcagcgtttccctcctccgggtgtagcgtgctggcgccgtcttact  
ttccogtatgccagcagcaggaagacatctccgaccagcgcctgctgcttccctgaccgactcca  
tggctgggtgcttctagctgcttattctccgctgtgcaacgatctggccacctctggcg  
gagctggaactggcgagactaccaattctatcattagctacatgcacgaaaacgatggtaacca  
gaggaacaggcccggaagaactgctaaactgatcgacgccaatggaaaaagatgaatcg  
tgaacggttagcgaactccacctgctgctaaagcgttcatggaaatcgagttaacatggca  
cgtgttcccaactgcaactaccagtatggcgatgggtctgggtcgcccagactacgcgactgaaa  
acggcatcaaaactgctgctgattgacctttcccgattaaaccagctgatgta'tgtctaactgca  
tcgcccttagggaggtaaaaaaaatgactgcccacaacaatagtatgccccatgggtgagtatc  
tagttacgccaaatttagtgcaaaacccaaacacctgaagacattttggaagagtttccotgaaatt  
attccattacaacaagaacctaataccogcatctagtgagacgtcaaatgacgaaagcgggagaaa  
catgttttctggctcatgatgaggagcaaatfaagttaatgaatgaaaattgtattgttttggaa  
ttgggacgataaatgctattgggtgcccgttccaagaagaagtttgtcatttaattggaaaatattgaa  
aagggttactacatcgtgcaattctccgtctttattttcaatgaacaagggtgaattacttttac  
aacaagagccactgaaaaaatfaactttccctgatctttggactaacacatgctgctctcctcc  
actatgtattgatgacgaattagggtttgaagggttaagctagacgataagatfaagggcgtctatt  
actgcccgggtgagaaaactagatcstgaattagggtattccagaagatgaaactaagacaaggg  
gtaagtttccactttttaaacagaatccattacatggcaaccaagcaatgaaccatggggtgaaaca  
tgaattgattacatcctattttataagatccacgctaaagaaaacttgactgtcaaccopaac  
gtcaatgaagttagagacttcaaatgggtttcaccaaatgatttgaaaactatgtttgcctgacc  
caagttacaagtttaogccttgggttaagattatttgcgagaattacttatccaactggtggga  
gcaattagatgacctttctgaagtggaanaatgacaggcaaatcatagaatgctatbaacaacgc  
gtcctgacgctgggtaccatattgggaattcogaagctttctagaacaaaaactcactcagaagag  
gatctgaatagcgcctgacaccatcatcatcatcattgagtttaaacggctctccagcttgg  
ctgttttggcggatgagagaaagattttcagcctgatacagattaaatcagaacgcagaagcgt  
ctgataaaaacagaatttgcctggcggcagtagcgggtgggtcccacctgacccctgcccgaact  
cagaagtgaacgcctgagcgcgatggtagtgtgggtctcccctgogagagtagggaaactg  
ccaggcatcaaataaaacgaaaggctcagtcgaaagactggyccttctgttttatctgttgttt  
gtcgggtgaacgctctcctgagtaggacaaaacccgcccggagcggatttgaacggttgcgaagcaa  
cggccccgaggggtggcgggcaggaccccgcataaactgccaggcatcaaatfaagcagaagg  
ccatcctgaocgatggcctttttgctttctacaaactctttttgtttattttctaaatadat  
tcaaatatgtaaccgcttaaccygaattgcccagctgggggcccctctggtaaggttgggaagcc  
ctgcaaaagtaaaactggatggctttctcgcgccaaaggatctgatggcgcaggggatcaagctct  
gatcaagagacaggatgaggatcgtttcgcattgattgaacaagatggattgcacgcaggttctc  
cggccgcttgggtggagagcctattcggctatgactgggcacaaacagacaatcggctgctctga  
tgcgcctgttccggctgtcagcgcagggcgcgccgggtcttttttgcagaacccgacctgtcc  
gggtgccctgaatgaaactgcaagacgaggcagcgcggctatcgtggctggccacgaagggcgttc  
cttgcgcagctgtcctcagcgttctcactgaagcgggaagggactggctgctattggycgaagt  
gcccgggcaggatctcctgtcatctcacttgcctcctgcccagaaagtatccatcatggctgat

Figure 35C

geaatgcggcggctgcatacgccttgatccggctacctgcccatcgcacccaagcgaacatc  
gcatacgcagcgcagcactcggatggaagccggctcttgctgatacaggatgatctggacgaaga  
gcatacaggggctcgcgccagccgaactgttcgccaggctcaaggccgagcatgcccgacggcgg  
gatctcgtcgtgacccatggcgcgatgcctgcttgccgaatatcatgggtggaaaatggcgccttt  
ctggattcatcgaactgtggccggctgggtgtggcggaccgctatcaggacatagcgttggtac  
ccgtgatattgctgaagagcttggcggcgaatgggctgaccgcttcctcgtgctttaccgtatc  
gcgcctcccgatcgcagcgcacatgccttctatgccttcttgacgagttctctcagcatgacc  
aaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggat  
cttcttgagatcctttttctgcgcgtaatctgctgcttgcaaacacaaaaaccaccgctacc  
agcggtygtttgtttgcocggatcaagagctaccaactccttttcggaagtaactggcttcagc  
agagcgcagatacccaatactgtccttctagtgtagccgtagttaggcccacttcaagaact  
ctgtagcaccgcctacatacctcgcctctgctaatcctggtaccagtggtgctgctgcccagtgggc  
taagtgcgtgcttaccgggttggactcaagaagatagttaccggataaggcgcagcggctgggc  
tgaacgggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacc  
tacagcgtgagctatgagaaagcgcacgcttccgaagggaagaaggcggacaggtatccggt  
aagcggcagggctggaaacaggagagcgcagggagcttccagggggaaacgcctggtatctt  
tatagtcctgctggggttcgcacaacctctgacttgagcgtcagatctttgtgatgctcgtcagggg  
ggcggagcctatggaaaaacgccagcaacgcggccttttaaggctcctggccttttgcctggc  
ttttgctcaatgcttcttctcgttatccctgattctgtggataaccgattaccgccttt  
gagtgagctgataccgctcgcgcagcgcgaacgaccgagcgcagcagtcagtgagcggaggaag  
cggaaagagcgcctgatgcggatattctccttaagcactcgtgaggatattcacaccgcatatg  
gtgcaactcagtaacaatctgctctgatgcgcacatagtttaagccagtatacactccgctatgc  
tacgtgactggctcatggctgcgccccgacacccgcacaacccgctgacgcgcctgacgggc

SEQ ID NO:16

Figure 36




Figure 37A

5'-  
 ttgtctgctcccgycatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcag  
 aggttttcacogtcatcaccgaaacgcgcgaggcagcagatcaattcgcgcgcgaaggcgaagc  
 ggcattgcatttacggtgacaccatogaatggtgcaaaacctttcgcggtatggcatgatagcgc  
 ccggaagagagtcaattcagggtggtgaaatgtgaaaccagtaacggtatacagatgtcgcagagt  
 atgcccgtgtctcttatcagacogtttcccgctggtgaaaccaggccagccaagttctgcgaa  
 aaocggggaaaaaagtggaaagcggcgatggcggagctgaattacattcccaaccgcgtggcaca  
 caactggcgggcaaacagtcggtgctgatggcgttgcacactccagctcggccctgcacgcgc  
 cgtcgcgaattgtcgcggcgattaaatctcgcgcgcatcaactgggtgcccagcgtgggtggtc  
 gatggtagaacgaagcggcgtcgaagcctgtaaaagcggcgggtgcacaatctctcgcgcacgc  
 gtcagtgggctgatcattaaactatccgctggatgaccaggatgccattgctgtggaagctgct  
 gcaactaatgttcggcgttatttcttgatgtctctgaccagacaacctcaacagatattattt  
 ctcccatgaagacggtacgcgactggcgtggagcatctggtcgcattgggtcaccagcaaatc  
 gcgctgttagcgggcccattaaagtctgtctcggcgcgtctgcgtctggctggctggcataaat  
 atctcaactgcgaatcaaatcagccgaatagcggaaocgggaaggcgaactggagtgccatgtccg  
 tttcaacaaaacctgcaaatgctgaaatgagggcatcgttcccactgcgatgctggttgcaca  
 gatcagatggcgtcggcgcgaatgcgcgccattaccgagctccgggctgcgcgttggctcgggata  
 tctcggtagtgggatacgcagcataccgaagacagctcatgttatatcccgcctcaccaccat  
 caaacaggattttgcctgctggggcaaacaccagcgtggaccgcttgcgcaactctctcagggc  
 caggcgggtgaagggcaatcagctgttgcggctctcactggtgaaaagaaaaaccacctggcgc  
 ccaatacgcgaaccgctctcccgccgcttggcgcattcattaatgcagctggcagcagcaggt  
 ttcccgactggaaagcgggcagtgagcgcacgcgaatlaatgtgagttagcgcgaattgatctg  
 gtttgacagcttatcatcagactgcacggtgcaccaatgcttctggcgtcaggcagccatccgaa  
 gctgtggtatggctgtgcaggtcgtaaatcactgcataattcgtgtctcgaaggcgcactccc  
 gttctggataatgtttttgcgcgcgacatcataacgggtctcggcaaatattctgaaatgagctg  
 ttgacaattaatcatccggctcgttataatgtgtggaattgtgagcgggataacaatttcacacag  
 gaaaacagcgcgcgctgagaaaaagcgaagcggcactgctcttaacaatttatcagacaatctgt  
 gtgggcactcgcacgggaattatcgattaaactttattattaaaaattaaagaggtatataat  
 gtatcgattaaataaggagggaataaaccaatgctgtgcgacctctctcaatttactcagattacc  
 gagcataattcccgctggttccgcapaactatcagccaaacctgtggaatttogaatctcgcgaat  
 ccttgagagaacgcacctgaaagtggaaaagctggaggagaaagcgaaccaactggaggaagaagt  
 tccgctgcattgatcaaccgctgtagacaccccagccgctgtccctgctggagctgatcagcagatgtg  
 cagcgcctgggtctgacctacaaatttgaaaaagacatcattaaagccctggaaaacatcgtac  
 tgcctggacgaaaaaacaagaacaaatctgacctgcaacgcacccgctctgtctttccgtctgct  
 gcgtcagcaecggtttcagggtttctcaggatgttttgagcgtttcaaggataaagaagggtggt  
 ttcagcggtgaaactgaaagggtgacgtccaaggcctgctgagcctgtatgaaagctcttacctgg  
 gtttcgaggggtgagaacctgctggaggaggcgcgtacctttccatcacccacctgaagaacaa  
 cctgaaagaaggcattaataccaagggttcagaaacaagtgcagccacgcacctggaaactgcata  
 caccagcgtctgcacogtctggaggcaogttggttccctggataaatacgaaccgaaagaaccgc  
 atcaccagctgctgctggagctggcgaagctggattttaacatgggtacagacccctgcaccagaa  
 agagctgcaagatctgtcccgtgggtggaccgagatgggcctggctagcaaacctggattttcta  
 ccggaaccgctgatggaagtttatttctgggcactgggtatggcgcagaccgcagctttggtg  
 aatgtcgcgaagctgttactaaaatgtttggctcgtgacgatcatcgatgacgtgtatgacgt  
 ttatggcactctggacgaactgcaactgttcaccgatgctgtagagcgtgggacgttaaccgt

Figure 37B

attaacacccctgcccgaactatatgaaactgtggttccctggcaactgtacaacacccgttaacgaca  
cgtoctattctctattctgaaagagaaagggtcataacaacctgtcctatctgaagaaaagctggcg  
tgaactgtgcaaaagcctttctgcaagaggcgaaatgggtccaacacaaaaattatcccggcittc  
tccaagtaacctggaaaaacgccagcggttccctccctccgggtgtagcgctgctggcgccgtcttaact  
tttccgtatgccagcagcaggaagacstctccgaaccaagcgctgcggttccctgaccgaactcca  
tgggtctgggtgcggttctagotgcttatctccgcctgtgcaacgatctggccacctctgcccgg  
gagctggaacgtggcgagactaccaattctatcatttagctacatgcacgaaaaagatggtaacca  
ggaggaaacagggcccgogaagaactgcgtaaaactgatogacgccgaatggaaaaagatgaatcg  
tgaacgcttagcgactccacctgctgacctaaagcgttcatggaaatcgcaqtaacatggca  
cgtgttcccaactgcaacctaccagtatggcgatggctgggtcgcccagactacggcactgaaa  
accgcatcaaaactgctgctgattgacctttcccgattaaaccagctgatgtatgtctaaactgca  
ttccgcttaggaggtaaaaaacatgagttttgatattgcaaaataccgcaacctggcactgg  
tcgactccaaccaggagttacgactgttgcgaaagagaggttaccgaaactctgcgacgaact  
ggcccgctattttaetcgacagcgtagcgcttccagcggoacttcgctccgggtgggcaag  
gtogaactgacogtggcgctgcaactatgtctcaaacacccogtttgaccaattgatttgggatg  
tggggcatcaggcttatccgcataaaaattttgaccggaacggcgcaaaaatcggcaccatccg  
tcagaaaaggcggtctgcaaccgttcccggtggcgggcgaaagogaatatgacgtattaagcgtc  
gggcattoatcaacctccatcagtgcgggaattgggtattggcggttgcctgccgaaaaagaaggca  
aaaatccgcgcaccgtctgtgtcattggcgatggcgcgattaccgcaggaatggcgtttgaaagc  
gatgaatcaacggggcgatataccgtccctgatatgctggtgattctcaacgacaatgaaatgtcg  
atthccgaaaaatgtcggcgcgctcaacaacctctggcacagctgcttcccggtaaagctttact  
cttcaactgcgcgaaggcgggaaaaaagttttctctggcggtgccgccaattaaagagctgctcaa  
accgacccgaagaacatattaaaggcatggtagtgctggcaagcttggttgaaagagctggcgttt  
aactacatccggccoggtggagggtaacgatgtgctggggcttatcaccacgctaaagaacstgc  
ggacctgaaagggcccgacgttccctgcataatcatgaccaaaaaagggtcgtggttatgaaccggc  
agaaaaagaccgatcacttccacggcgtgactaaatttgatccctccagcggttgtttgcccg  
aaaagtgcggcggtttgcccagctattcaaaaactttggcgactggttggcgcaaacggcag  
cgaagacaacaagctgatggcgattactccggcgatgcgtgaaggttccggcactggctcgagtt  
ttcaogtaaatcccggaatcgctacttccagctggcaattgccgagcaacaacgggtgaccttt  
gtgcgggtctgggatgggtgggtacaaaaccttgcgcgatttactccactttccctgcaac  
ggcctatgatcagggtgctgcatgacgtggcgattcaaaaagcttccggctctgttcccatcga  
ccggcggggcatgttgggtgctgacgggtcaaacccatcagggtgcttttgatctctcttaactg  
cgctgcataccggaaatgggtcattatgaccccgagcgatgaaaaagaaatgtcgcagatgctct  
ataccggctatacactataacgatggcccgctcagcggtgcgctaccgcggtggcaacggcggtcgg  
cgtggaactgacgcgctggaaaaactaccaattggcaaggcattgtgaagcgtcgtggcgag  
aaactggcgatccttaactttggtagctgatgccagaagcggcgaaagtcccgcaatcgctga  
acgccacgctggtcgatatgctttttgtgaaaccgcttgatgaaagcgttaattctggaatggc  
cgccagccatgaagcgtggtcacctgaaagaaaaacgcatttatggggggcgccagccagcggc  
gtgaaacgaagtgctgatggcccatcgtasaccagtaaccogtgcgaacattggcctgcccggact  
tctttattccgcaaggaaactcaggaagaatgocgcgccgaactccggcctcgatgccgctggtat  
ggaagccaaaatcaaggcctggctggcataactgcagctggtaaccatattgggaattcgaagctt  
tctagaacaaaaactcatctcagaagaggatctgaatagcggcgtcgaccatcatcatcat  
cattgagtttaaacggtctccagcttggctgttttggcggtgagagaaagattttcagcctgat  
acagattaaatcagaacgcgagaagcggctctgataaaaacagaatttgcctggcgccagctagcgcg

Figure 37C

gtggtcccacctgaccccatgccgaactcagaagtgaaacgccgtagcgcgatggtagtgtgg  
 ggtctcccacatgcgagagttagggaactgccaggcatcaaataaaacgaaaggetcagtcgaaag  
 actgggectttcgttttatctgtttgttgcggtgaacgctctcctgagttaggacaaatccgcc  
 gggagcggatttgaacgttgcaagcaacggcccgagggtggcgggaggaagcccgccataa  
 actgccaggcatcaaatgaagcagaaggccatcctgacggatggcctttttcgtttctacaaa  
 ctctttttgtttatttttctaaatacattcaaatatgtatccgcttaaccggaattgccagctg  
 gggcgccctctggttaagggttgggaagccctgcaagtaaacctggatggctttctccgcgcaag  
 gatctgatggcgaggggatcaagctctgatcaagagacaggatgaggatcgtttcgtatgatt  
 gaacaagatggattgcacgcaggttctccggccgcttgggtggagaggctattccgctatgact  
 gggcacaacagacaatcggctgctctgatgccgccttgggtccgctgtcagcgcagggggcggcc  
 ggtctcttttggtaagaccgacctgtccggtgcccgaatgaactgcaagacgagggcagcggg  
 ctatcgtggctggccacgacgggcttcccttgcgcagctgtctcgaagttgtcaactgaagcgg  
 gaagggactggctgctattgggcgaagtgcggggcaggatctcctgtcatctcaccttgcctcc  
 tgcggagaaggtatccatcatggctgatgcaatgcggggctgcataccttgcctccgctacc  
 tgcctatccgaccaccaagcgaacatcgcctcagcgcagcagctactcggatggaagccggtc  
 ttgtcagatcaggatgatctggacgaagagcatcaggggtccggccagccgaactgttcgcag  
 gctcaagcggagcatgcccgacgggagggatctcgtcgtgaccatggcagatggctgcttgcg  
 aatatcaggtggaaaatggccgctttctggattcctcagctgtggccggctgggtgtggcgg  
 accgctatccaggacatagcgttggctaccctgatattgctgaagagcttggcggcgaatgggc  
 tgaccgcttccctcgtgctttacggtatccgcctcccgattcgcagcgcategccttctatcgc  
 ctctctgacagagttctctgacgcctgacccaaaatcccttaacgtgagtttctgtccactgag  
 cgtcagaccccgtagaaaaagatcaaaggatctctctgagatccttttttctgcgcgtaatctg  
 ctgcttgcaaacaaaaaaaccaaccgctaccagcgggtggtttggtttgcggatcaagagctaca  
 actctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgt  
 agccgtagttaggccaccacttcaagaactctgtagcaccgctacatacctcgtctctgctaat  
 cctgttaccagtggtgctgctgccagtgccgataagtcygtcttaccgggttggactcaagaaga  
 tagttaccggataaaggcgcagcggctgggctgaaacggggggttcgtgcaacacagcccagcttgg  
 agcgaacagacctacaccgaactgagatacctacagcgtgagctatgagaagcgcaccagcttcc  
 cgaaggggagaaaggcggacaggtatccggtaagcggcagggctcggaacaggagagcgcagagg  
 gagcttccagggggaacgcctggtactttatagtcctgtcgggtttccgccacctctgacttg  
 agcgtcagatttttgtgatgctcgtcagggggcggagcctatggaanaacgccagcaacgcgyc  
 etttttacggttccctggccttttgcctggccttttgcctcacatgttcttccctgcttatccct  
 gattctgtggataaccgtattaccgctttgagtgagctgataccgctcgcgcagccgaacga  
 ccgagcgcagcagagtcagtgagcaggaagcgggaagagcgcctgatgggtattttctccttac  
 gcatctgtgcggtatctcacaccgcataatggtgcactctcagtaacaatctgctctgatgcgca  
 tagttaagccagtatcactccgctatcgtcactgactgggtcatggctgcgcccagacccc  
 gccaaacaccgctgacgcgcccctgacgggc

SEQ ID NO:17

Figure 38




Figure 39A

5' --  
 ctggcgtaaatagcgaagaggooocgoaccgatogcccttcccaacagttgcccagcctgaatggc  
 gaatggcgccctgatggggtatctctccttaogcatctgtgoggatattcaacaccgatatggg  
 gcactctcagtaacaatctgctctgatgcoccatagttaaagccagcccccgaaccccccacaacc  
 cggctgaecgagcttagttaaagccctcggtagatcttaagcgggatggtggcattacttcgccaac  
 tattggcgaataacaagaaaaagccagcccttcatgatataatctcccaatttggtagggcttatt  
 atgcacgccttaaaaaataataaaagcagacttgaacctgatagtttggctgtgagcaattatgtgc  
 ttagtgcatctaacgcttgagttaaagccgcgcgogaagccggcgtcggcttgaacgaatgttta  
 gacattatttggcgcactaccttgggtgatctcggccttcaacgtagtggaacaaattcttccaaactg  
 atctggcgcgogaggccaaagcgatctctctctgttccaagataagccctgtctagcttcaagtatg  
 acgggctgatactgggcccgcagggcctccattgcccagtcggcagcgcacatccttcggcgcya  
 ttttggccggttactgcgctgtaccaaatgggggacaacgtaagcaactacatttcgctcatcgcc  
 agcccagtcgggcccgcaggttccatagcgttaagggttccatttagcgcctcaaatagatcctgt  
 tcaggaaaccggatcaaaagagttcctccgcgcctggacctaccaaggaacgcctatgttctcttg  
 cttttgtcagcaagatagccagatcaatgtcgatcgtggctggctcgaagatacctgpaagaat  
 gtcattggcctgcccattctccaaattgcagttcgcgcttagctggataacggccacgggaatgatg  
 tctgctgacacaacaatggtgactctctacagcgcgggagaatctcgcctctctccaggggaagccg  
 aagtttccaaaaggctcgttgatcaaaagctcgcgcgcttggttccatcaagccttaccggtcaccg  
 aaccagcaaatcaatatcactgtgtggctcagggccgcctccactggggagccgtacaaatgt  
 acggccagcaacgtcggctogagatggcctcogatgaogccaaactacctctgatagttgagtcg  
 atacttcggcgatcaccgcttccctcatgatgtttaaactttgttttagggcgactgccttctg  
 cgtaacatcgttgcctcctataacatcaaacatcgacccaagggcgtaacgcgcttgetgcttg  
 gatgccogaggtcatagactgtacccccaaaaaacagtcataacaagccatgaaaaccgccaactg  
 cgcgcttaccaccgctgcgctcgggtcaaggctctctggaccagttcgcgtgagcgcatacgcctactt  
 gcattasagcttacgaaccgaacaggcttatgtccactgggttcgctgccttcatccgcttccac  
 ggtgtgcgtcaccgggcaacccttgggcagcagcgaagtccaggcatttctgtcctggctggcga  
 acgagccgaagggtttcggctccacgcctcgtcaggcatttggcggccttgcctgttctctacgg  
 caaggctgctgtgcaaggatctgccttggctcaggagatcggaagacctcggccgctcggggcgc  
 ttgcoggtggtgctgaccccggtgaagtggttcgcctcctcggcttctcgggaaggcagacatc  
 gtttgttcgccagcttctgtatggaacgggcctcgggatcagtgagggtttgcaactgcgggt  
 caaggatctggatctcgatcaccggcagatcctcgtgcgggagggcaagggtcccaaggatcgg  
 gccttgatggttaccggagagcttggcaccagcctcgcgcagcaggggaattaatcccaagggt  
 ttttgcctgcggcaaaagggtgttctgggtgttgcctagtttgttctcagaatcgcagatccggc  
 ttcagccggtttgcggctgaaagcctatcttccagaattgccatgatttttccccaagg  
 gagggctcactggctcccggtgttctcggcagctttgattcagataagcagcatcgcctgttccag  
 gctgtctatgtgtgactgtttagctgttaacaagttgtctcagggtgttcaatttcatggttctagt  
 tgctttgttttactgggttcaacctgttctattagggtgttccatgctgttccatctgttacattgt  
 cgtctgttccatggtgaacagcttgaatgcaccaaaaaactcgtaaaagctctgatgtatctat  
 cttttttacaccgcttctcatctgtgcataatggacagttttccctttgatakytaacgggtgaaca  
 gtttgttctacttttgtttgttagtcttgatgcttcaactgatagatacaagagccatangaacct  
 cagatccttccgtatcttagccagtatggtctctagtggttgcgttgttttggcgtgagccatg  
 agaacgaaccattgagatcacttacttfgcatgtcaactcaaaaattttgcctcaaaaactggt  
 gagctgaakttttgcagttaaagcactcgtgtagtggttttcttagtccgttatgtaggtaggaa  
 tctgatgtaaatggttgttggatatttggcaccattccatttttatctggttgttctcaagttcgg

Figure 39B

ttacgagatccatttggctctatctagttcaacttggaaaaatcaacgtatcagtcggggggcctcg  
cttatcaaccaccaatttcataattgctgtaagtggttaaatctttacttattgggtttcaaaaac  
cattgggttaagccttttaaacctcatggtagttattttcaagcattaacatgaacttaaattcac  
caaggctaatctctatattttgcocttgtgagttttcttttgggttagttcttttaataaccactc  
ataaatccctcatagagattttgttttcaaaagacttaacatgltccagattatattttatgaaat  
tttttaactggaaaagataaggcaatatctcttcaactaaaaactaatctctaatttttcgcttg  
agaacttggcatagtttgtccactggaaaaatctcaaaagcctttaaccaaaaggattcctgatctc  
cacagttctcgtcatcagctctctgggttgcctttagctaaatacaccataaggcattttccctactg  
atggtcatcatctgagcgtattgggttataagtgaaagataccgtccgttctctccttctgtaggg  
tttcaatcgtggggttgagtagtgccacacagcataaaattagcttgggttctcatgctccgttaa  
gtoatagcgaactaatcgctagttcatttgcctttgaaaacaactaatcagacatacatctcaat  
tgggtctaggtgattttaatcactataccaattgagatgggctagtcattgataaattactagctc  
ttttcctttgagttgtgggtatctgtaaaatctctgctagaacctttgctggaaaaactgaaatc  
tgdtagaacctctgaaattccgctagacchttgtgtgtttttttgtttatattcaagtgggtt  
ataaatttatagaataaagaaagaataaaaaagataaaaaagaatagatcccagccctgtgtata  
actcactacttttagtcagttccgcagttaccaaaaggatgtcgcaaacgctgtttgctcctct  
acaaaacagaccttaaa#ccctaaaggcttaagtagcaccctcgcaagctcgggcaaatcgctg  
aatattccttttggctccgaccatcaggcaacctgagtcgctgtctttttcgtgacattcagttc  
gctgcgctcaocggctctggcagtgaaatgggggttaaatggcactacaggcgccttttatggattc  
atgcaagyaactaccataatacaagaaaagccgctcaocggctctcagggcggttttatggc  
gggtctgctatgtgggtgctatctgactttttgctgttcagcagttcctgccctctgattttca  
gtctgaccacttcggattatcccgtagcaggtcattcagactggctaatgcacccagtaaggca  
gcygkatcatcaacaggcttaccogtcttactgtcgggaattccgcttggccogattcatlaatg  
cagattctgaaatgagctgttgacaattaatcatccggctcgtataatgtgtggaattgtgagc  
gyataacaattteacacaggaacagcgcgctgagaaaaagogaagcggcactgctctttaac  
aatttatcagacaatctgtgtgggcaactcgaccgggaattatcgattaaactttattatlaaaaaat  
taaagagggtatataattaatgtatcgattaaataaggagggaataaaacctgtgtggaacotcttc  
tcaatttactcagattacogagcataattcccgctcgttccgcaaaactatcagccaaacctgtgg  
aatttogaattcctgcaatccctggagaacgacctgaaagtggaaaagctggaggagaaagcga  
ccaaaactggaggaagaagttcgtctgatgatcaacogtgtagacacccagcggctgtccctgct  
gggctgatcgacgaltgtgcagcgcctgggtctgacctcaaaatttgaaaaagacatcatttaa  
gccctggaaaacatcgtactgctggacgaaaacaaaaagaacaaatctgacctgcacgcaaccg  
ctctgtctttccgtctgctgcgtcagcaccggtttcgagggtttctcaggatgtttttgagcgttt  
caaggataaagaagggtgggtttcagcgytgaactgaaagggtgacgtccaaggcctgctgagcctg  
tatgaagcgtcttacctgggtttcgagggtgagaacctgctggaggaggcgcgtaccttttcca  
tcaccacactgaagaaocaaactgaaagaaggcattaataccaaggttgacagaacaagtgagcca  
cgccctggaactgccatatacaccagcgtctgcaocgtctggaggeacgttgggtcctggataaa  
tacgaacccgaaagaacccgcatcaccagctgctgctggagctggggaagctggatttttaacatgg  
tacagaccctgcaccagaaagagctgcaagatctgtcccgctgggtggaccgagatgggcctggc  
tagcaaacctggattttgtacgcgacccgctgatggaagtttatttctgggcaactgggtatggcg  
ccagaccggcagtttgggtgaatgtogcaagctgttactaaaatgtttcgtctggtagcagatca  
tcgatgacgtgtatgacgttttatggcaactctggacgaactgcaactgttcaccogatgctgtaga  
gctctgggacgttaacgctatlaacaacctgocggactatataaaactgtgtttcctggcactg  
tacaacaccgttaacgacacgtcctatctctatctgaaaagagaaaggtcataacaacctgctcct

Figure 39C

atctgacgaaaagctggcgtgaactgtgcaaagcctttctgcaagagggcgaatgggtccaa  
caaaattatcccggctttctccaagtaacctggaaaacgcccagcgtttctctcctccgggtgtagcg  
ctgctggcgcogctcttacttttccgtatgccagcagcaggaagacatctccgaccaocgcgctgc  
gttccctgacogacttccatggtctgggtgcttctagctgogttatcttccgcctgtgcaaoga  
tctggccacctctgcggcggagctggaacgtggcgagactaccaattctatcattagctacatg  
cacgaaaacgatggtaaccagcaggaacaggcccgcgaagaactgogtaaacctgatogacgccc  
aatggaaaaagatgaatcgtgaacgcgttagcgcactccaccctgctgocctaaagcgttcatgga  
aatcgcagttaacatggcacggtgtttcccactgcaoctaaccagtatggogatgggtctgggtcgc  
ccagactacgcgactgaaaaaccgatcaaaactgctgctgattgaccctttcccgattaaccagc  
tgatgtatgtctaaactgcagctggtaccatattgggaattcgaagctttctagaacaaaaactca  
tctcagaagaggatctgaatagcgcogctogacatcatcatcatcatcattgagtttaaacggt  
ctccagcttggctgttttggcggatgagagaagatttccagcctgatacagattaaatcagaac  
gcagaagcggctctgataaaaacagaatttgcctggcggcagtagcoggggtggtcccacctgaccc  
catgccgaactcagaagtgaaacgcgcgtagcgcgatggtagtgtgggtctccccatgogaga  
gtagggaactgccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgtttt  
atctgtttgttgcggtgaacgctctcctgagtaggacaaatccgcccgggagcggatttgaacg  
ttgcgaagcaacggcccggagggtggcgggcaggacgcccgcataaaactgccaggcatcaaat  
taagcagaaggccatcctgacggatggcctttttgctttctacaaaactctttttgtttatttt  
tctaaatacattcaaatatgtaaccgctcatgagacaataaccctgataaatgcttcaataat

SEQ ID NO:18

Figure 40




Figure 41A

5' -  
 cccgtcttactgtcgggaattcgcggttgccgattcattaatgcagattattgaagcatttato  
 agggttattgtctcatgagcggatacatalattgaatgtatttagaaaataaacaasaaagagtt  
 tgtagaaacgcaaaaaggccatccgtcaggatggccttctgcttaatttgatgcctggcagttt  
 atggcgggctcctgcccgccacctccgggcccgttgccttcgcaacgttcaaatccgctcccgg  
 cggatttgtccctactcaggagagcgttcaccgacaascaacagataaaaacgaaaggcccagctc  
 ttcgactgagccttctgttttatttgatgcctggcagttccctactctcgcagtggggagacccc  
 acaactaccatcggcgctacggcgtttccactctcaggttcggcatggggtcagggtgggaccaccg  
 cgcactgcccgccaggcaaatctgttttatcagaccgcttctgcgtctcgtatttaactcigtat  
 caggtgaaaatctctctcatccgcaaaaacagccaagctggagaccgcttaaaactcaatgat  
 gatgatgatgatggctcgaecggcctattcagatcctctctcagatgagttttgttctagaaa  
 gcttcaaatcccatatggtaaccagctgcagcttagacatacatcagctggtttaactcgggaagg  
 gctcaatcagcagcagtttgatgcgggttccagtcgctagctcgggcgaccaccatcccca  
 tactggtaggtgcagtgggaaacacgtgccatgttaactgcgatttccatgaacgcttaggca  
 gcagggtggagtcgctaacgcgttcacgattcatttttccattcggcgtcgcagtcagtttacg  
 cagttcttcggggcctgttccctcgcgttgtaaccatcgttttcgtgcagtagctaatgatagaa  
 ttggtagctcgcacagttccagctccgcgcagaggtggccagatcgttgcacaggcgggaaga  
 taacgcagctagaacgcaccagaccatggaagtcggtcagggaaocgcagcgcgtggctcgggat  
 gtcttccctgctgctggcatalcggaaaagttaagacggcgcaccagcgcctacaccggaggaggaa  
 acgctggcgttttccaggtacttggagaaaagccgggataaattttgttgttggaccatttccgct  
 ctgcagaaaaggctttgcacagttccagcagcttttgcgtagataggacaggttcttatgacc  
 tttctctttcagaatagaataggacgtgtcgttaacgggtgttgtacagtgccaggaaacs cagt  
 ttcatatagtcggcagggtgttaatagcgttaacgtccacagcctctacagcatcgggtgaaca  
 gttgcagttcgtccagagtgccataaacgtcatalacagctcctcagatgatcgtccaccagccaaa  
 cattttagtasacagctttggacattcaccasaaactgggggtctggggccatacccagtgcccag  
 aataaaacttccatcaggcggctcgcgtacaaaatccagtttgcctagccaggcccctctcgggtcc  
 accagcgggacagatcttgcagctctttctgggtgcagggtctgtaaccatgttaaaatccagctt  
 cgcacagctccagcagcagctgggtgatgcgggtctttcgggtcgtatttatccaggaaccaacgt  
 gctccagaaagggtgcagacgctgggtgatggcagttccagggcgtggctcaactgtctcga  
 ccttqgtatataatgccttctttcaggttgttcttccaggtgggtgatggaaaaggtaccgcctc  
 ctccagcaggttctcaccctcgaaaaccaggttaagacgcttcatacaggtccagcagggccttgg  
 acgtccactttcagttccaccgctgaaaccaacttctttatccttgaaaocgtcaaaaacatcct  
 gagaaaacctcgaaaaccgtgctgacgcagcagacggaaaagacagagcgggttgcgtgcaggtcaga  
 tttgttctttttgttttctcagcagtaocgatgttttccagggctttaatgatgtctttttca  
 aattgttaggtcagaccaggcgtgcacatcgtcagatcagctccagcagggaacagcggctggg  
 tgtctacacgggttgatcatgcagcgaacttcttccctcagtttggctcgtttctcctccagctt  
 tccactttcaggtcgttctccagggtatgcagggaattcgaaattccacaggtttggctgatag  
 tttgcggaaocgacgggaattatgctcggtaactctgagtaaatggagaagaggtccacacatgg  
 tttatctctcttatttaategatcattaataataacctctttaaatttttaataataaagttta  
 atcgataaattccggctcagagtgcccacacagattgtctgataaattgttaagagcagtgccgct  
 tcgctttttctcagcggcgtgtttcctgtgtgaaattgttatccgctcacaattccacacatt  
 atacagaccggatgattaattgtcaacagctcatttcagaatctggcgttaatagcgaagaggcc  
 cgcaccgatcgccttcccaacagttgcgcagcctgaatggcgaatggcgcctgatgcggatt  
 ttctccttaocgatctgtgcggtaattccacaccgcatatggtgcactctcagtaaatctgctc

Figure 41B

tgatgcccgcatagttaagccagccccgcaccccgcacaacaccccgctgacgagccttagtaaaagcc  
 ctccgtagatttttaatgcccgatggttgcgattacttcyccaactattgcgataacaagaaaaagc  
 cagcctttcatgatatactcccantttgtgtagggttattatgcaagccttaaaaaataataga  
 agcagacttgacctgatagtttggctgtgagcaattatgtgcttagtgcatetaacgcttgagt  
 taagccgcgcgcgaagcggcgtcggcttgaacgaattggttagacattatlttgcgactacctt  
 ggtgatctccgctttcagctagtggaacaaatcttccaaactgatctgcgcgcgagggccaagcga  
 tcttctcttctgtccaaagataagcctgtctagcttcaagtatgacgggctgatactgggcccga  
 ggogctccattgcccagtcggcagcgacatccttcgggcgcgattttgcccggcttactgogctgta  
 ccaaatgcccgggacaagctaagcactacatttcgctcatogccagcccagtcgggcccgcgagttc  
 catagcgttaaggtttccatttagcgcctcaaatagatccctgttcaggaaccggatcaaagagtt  
 cctccgcgcgtggacctaccaaggecaacgctatgttctcttggcttttgcagcaagatagccag  
 atcaatgtcgcgctgtggctggctcgaagatacctgcaagaatgtcattgogctgocattctcca  
 aattgacagttcgcgcttagctggataaacgccacggaaatgatgtcgtcgtgcacaacaatgggtga  
 cttctacagegcgggagaatctcgcctctccaggggaagccgaagtttccaaaaggctcgttgat  
 caaagctcgcgcgcttgtttctcaagccttacgggtcacccgtaaccagcaaatcaatataactg  
 tgtggcttcaggccgccatccaactgcccagccgtacaaatgtaaggccagcaacgctcggctcga  
 gatggcgctcgcgtagcagccaaactacctctgatagttgagtcgataacttcggcgatcacgcttc  
 cctcatgatgttttaactttgttttagggcgaactgcccgtgctgctggaataacatogttgctgctccat  
 aacatcaaacactgaccccaagcgaagcgcgttgcctgcttggatgcccagggcatagactgta  
 cccccaaaaaaacagtcataaacaagccatgaaaaaccccactgcccgcgttaccacccgctgcgttc  
 ggtcaagggttetggaccagttgctgtgagcgcatacgcctacttgcattacagcttacgaaccgaa  
 caggettatgtccactgggttcgctgcccctcatccggtttccacgggtgctgcctcacccggcaact  
 tgggcagcagcgaagtgcaggcatttctgtcctggctggcgaaacgagcgcgaagggttcggctcc  
 caegcatogtcaggcaattggcggccttgcctgttctctacggcaagggtgctgtgacggatctg  
 cctggcttcaggagatcggaaagacctcggccctcgcggcgttgcgggtgggtgctgacccgg  
 atgaagtggcttcgcctcctcggttttctggaaggcgcagcatogttgttcgcccagcttctgta  
 tggaaacgggcgatgcccgatcagtgagggtttgcaactgcccgtcaaggatctggatttcgatcac  
 ggcaogatcatcgtcgcgggagggcaagggtcacaaggatcgggccttgatgttaccgagagct  
 tggcaccacagcctgcccagcagggggaatttaattcccacgggttttgcctgcccgaacgggct  
 gttctgggtgttgetagtttgttatcagaatcgcagatccggcttcagccggtttgcggctgaa  
 agcgctatttcttccagaattgoccatgattttttcccacgggagggcgtcactggctcccggtgt  
 tgtcggcagctttgatccgaataagcagcatcgcctgtttcaggctgtctatggtgactgttga  
 gctgtaacaagttgtctcagggtgttcaatttcatgttctagttgctttgttttactggtttccac  
 ctggtctatattaggtgttacatgctgttcatctgtttacattgtcgcgctctgttcatgggtgaacagc  
 tttgaatgcaaaaaaacctcgttaaaagctctgatgtatctatcttttttacaccgttttcatct  
 gtgcataatggaacagttttccctttgatatgtaacgggtgaacagttgttctacttttgtttgtta  
 gcttgcagcttcaactgatagatacaagagccataagaaacctcagatccttcgctattttagcca  
 gtatgttctctagtggttgcgttggtttttgcgtgagccatgagaacgaaccattgagatcata  
 cttaactttgcagctcactcaaaaaattttgcctcaaaactggtgagctgaatttttgcagttaaa  
 gcatcgtgtaggtttttctttagtcgcttatgttaggttaggaatctgatglaatggttggttgta  
 ttttgcaccattcatttttatctggttggttctcaagttcgggttacgagatccattttgtctatc  
 tagttcaacttggaaaaatcaacgtatcagtcgggcccctcgccttatcaaccaccaatttcata  
 ttgctgtaagtggttaaatctttacttattggtttcaaaaaccatgggttaagccttttaaacct  
 catggtagttatlttcaagcattaacatgaactaaatccatcaaggctaatctctatattttgc

Figure 41C

cttgtgagttttcttttgggttagttcttttaataaccaactcataaattcctcatagagttattg  
ttttcaaaagacttaacatggtccagattatattttatgaatttttttaactggaaaagataag  
gcaatatactcttcoactaaaaactaattotaatttttctgcttgagaacttggcatagtttgoca  
ctggaaaatctcaaaagcctttaaccaaggattcctgatttccacagttctctgcatcagctct  
ctggttgcttttagctaatacaccataagcattttccctactgatggttcacatctgagcgtatt  
ggttataagtgaacgataccgtccgttctttccttgtagggttttcaatcgtggggttgagbag  
tgccacacagcataaaaattagcttggtttcatgctccgttaagtcataagcagactaatcgtcagt  
tcatttgctttgaaaacaactaattcagacatacatctcaattgggtctagggtgattttaatoac  
tataccaatttgagatgggctagtcaatgataaattactagtccttttccctttgagttgtgggtat  
ctgtaaattctgctagacctttgctggaaaacttgtaaattctgctagacctctgtaaattcc  
gctagacctttgtgtgttttttttggtttatattcaagtggttataattatagaataaaagaaag  
aataaaaaaagataaaaaagaatagatcccagccctgtgtataactcactacttttagtcagttcc  
gcagttatcaaaaaggatgtcgcaaacgctgtttgctcctctacaaaacagaccttaaaacct  
aaaggcttaagtgcacctcgcaagctcgggcaaatcgtgaaatctcttttctctccgacc  
atcaggcaectgagtcgctgtctttttctgtgacattcagttcctctcgcctcacggctctggcag  
tgaatgggggttaaatggcaactacagggccttttatggattcattgcaaggaaactaccataat  
acaagaaaagccctcacgggtctctcagggcgttttatggcgggtctgctatgctgggtgctatc  
tgactttttgctgttcagcagttcctgcccctctgattttccagctctgaccactcggattatcc  
cgtgacaggtcattcagactggctaattgcaaccagtaaggcagcgggtatcatcaacaggctta

SEQ ID NO:19

Figure 42




Figure 43A

5' -

ctggcgtaaatagogaagaggcccgcaaccgatcgcccttcccaacagittgocgagocctgaatggc  
 gaatggcgocctgatgocgtatTTTTctocttaogcatctgtgocgtatTTTcacaccgcatatggt  
 gcaactctcagtaacaatctgctctgatgccgcatagtttaagccagccccgacacccgccaacaoc  
 cgttgacgagccttagtaaaagcctcgttagatTTTTaatgocgatggtgocgattacttcgccaac  
 tattgcgataaacaagaaaaagccagccttcatgatatactcccaatttgtgtagggttatt  
 atgcacgcttaaaaaataataaaagcagacttgacctgatagtttggtctgtgagcaattatgtgc  
 ttagtgcactaacgcttgagtttaagocgocgocgaagocggcgtocggcttgaacgaattgtta  
 gacattatttgcogactaccttggtgatctocgcttcaocgtagtggacaaattcttcccaactg  
 atctgcgcgcgagggccaagcgatcttcttcttcttcttcttcttcttcttcttcttcttcttctt  
 acgggctgataactgggocggcagggcgtocattgcccagtcggcagcgacatccttcggcgocga  
 ttttgcocggttactgocgtgtaccaaattgocgggacaocgtaagcactacatttgcctcatcgcc  
 agcccagtcgggocggcaggttccatagocggttaaggtttcatTTtagcgcctcaaatagatcctgt  
 tcaggaaaccggatcaaaaggttccctccgocgctggacctaccaaggcaacgctatggtctcttg  
 cttttgtcagcaagatagccagatcaatgtcogacgtggctggctogaagatacctgcaagaat  
 gtcattgocgtgccattctccaaattgcagttocgoccttagctggataacgccacgggaatgatg  
 tctgctgcacacaatggtgacttctacagocgocgagaatctocgctctctccaggggaagocg  
 aagtttccaaaaggctggttgatcaaaagctocgocgcttggttctcaagccttaaggctcaocgt  
 aaccgcaaatcaatatcactgtgtggttccagggccccatccactgocggagcogtacaasatgt  
 aagggcagaacgtocggttogaagatggcogctogacogccaactacctctgatagttgagtcg  
 atacttcggcgatcaaccgctccctcatgatgtttaaactttggttttagggcagactgocctgctg  
 cgtaacalcggttgcctgctccataacatcaaacatcgsccccagggcgtaacgoccttgcctgctg  
 gatgcccagggcatagactgtacccccaaaaaacagtcataacaagccatgaaaaccogccactg  
 ocgocgttaccacogctgocgttccgttcaagggttctggaccagttgocgtgagocgcafacocctactt  
 gcattacagoccttaogaaccgaacaggttatgtccactgggttgccttcatcogtttccac  
 ggtgtgocgtcaocccggcaaccttgggcagcagogaagtgcagggcatttctgtcctggctggcga  
 acgagocgaagggttccggtctccacogcatcgtcagggcattggcggccttgcctgttctctacgg  
 caaggctgctgtgcaocggatctgocctggcctcaaggagatoggaagacctcggocgctcggcggc  
 ttgcgggtggtgctgacccocggatgaagtggttcogcatcctcgggtttctggaaggocgagcctc  
 gtttgttgcocccagcttctgtatggaaocggcctgocggatcagtgaggggttgcaactgcgggt  
 caaggatctggatttcogatacggcaccgatcactgocgggagggcgaaggcctccaaggatcgg  
 gccttgcattgtaaccogagagcttggcaccocagcctgcgcgagcaggggaattaatccacggg  
 ttttgcctgcccgaacacgggctgttctgggtgttgcctagtttgttatcagaatocgagatccggc  
 ttcagocgggttgcocggctgaaagocctatttcttccagaattgccatgatttttcccccaggy  
 gagggctcactggctcccgctgttgcogcagccttgcattcgataagcagcactocctggtttcag  
 gctgtctatgtgtgactgttgagctgttaacaagttgtctcagggtgttcaatttcatggtctagt  
 tgccttgttttactgggttccacctgttctattagggtgtacatgctgttcaatctgtttacattgt  
 cगतctgttcoatgggtgaacagccttgaatgcacccaaaaactcgtaaaagcctctgatgtatctat  
 cttttttacaccggttttcactctgtgcatatggacagcttttcccttggatagtaacgggtgaaca  
 gttgttctacttttgtttgttagtcttgcctgactgatagatacaagagccataagaacct  
 cagatccttcogfatttagccagtatgttctctagtggttgccttgccttgcctcaaaaatttgcctcaaaaactggt  
 gagetgaatttttgcagttaaagcactcgtgtagtggttttcttagtcogttatgtaggtaggaa  
 tctgatgtaatggttgggttatttgcaccatccatttttatctggttgttctcaagttcgg

Figure 43B

ttacgagatccatttggctatctagttcaacttggaaaatcaacgtatcagtcgggcggectcg  
 cttatcaaccaccaatttcataattgctgtaagtggtttaaactcttacttattggttcaaaacc  
 cattgggttaagccttttaaactcatggtagttattttcaagcattaacatgaacttaaatcat  
 caaggetaattctctatatttgcccttgtagttttcttttgggttagttcttttaataaccactc  
 ataaatcctcatagaggtatttggtttcaaaaagacttaacatggtccagattatattttatgaat  
 ttttttaactggaaaagataaggcaatatctcttcaactaaaaactaattctaatttttgcgttg  
 agaaacttggcatagtttggccactggaaaatctcaaaagcctttaaccaaggattcctgatttc  
 cacagttctcgtcatoagctctctgggtgctttagctaatacaccataagcattttccctactg  
 atgttcatcatctgagcgtatgggtataagtgaaagataccgtccgttctttcctttaggggt  
 tttcaatcgtgggggttagtagtgccacacagcataaaaattagcttgggttcatgctccgttaa  
 gtcataagcactaatcgttagttcatttggcttggaaaacaactaattcagacatacatctcaat  
 tgggtctaggtgattttaatcactataccaattgagatgggctagtcattgataaatactagctc  
 ttttccctttaggttgggtatctgtaaattctgctagaccttggctggaaaacttggtaaatc  
 tggtagaacctctgtaaatcctgctagaccttgggtggttttttttggtttatattcaagtggtt  
 ataatttatagaataaagaaagaataaaaaagataaaaagaatagatcccagccctgtgtata  
 actcactactttagtcagttccgcagtttcaaaaaggatgtcgcacaacgctgtttgctcctct  
 acaaaaacagaccttaaaaccctaaaggcttaagtagcaacctcgcagctcgggcaaatcgtg  
 aatattccttttggctccgaacctcaggccacctgagtcgctgtcttttctgtagacttcagttc  
 gctgocctcacggctctggcagtgaaatgggggtaaatggcactacaggcgccttttatggattc  
 atgcaaggaaactaccataatacaagaaaagccctcagggcttctcagggcggttttatggc  
 ggtctgctatgtgggtgctatctgactttttgctgttcagcagttcctgocctctgattttcca  
 gctcagacccttcygattatcccgtgacaggtcattcagactggcctaatagcaaccagtaaggca  
 gcggatcatcaacaggettaccgctcttactgtcgggaattcgcgttggcogattcattaatg  
 cagattctgaaatgagctgttgacaattaatcctcggctcgtataatgtgtggaattgtgagc  
 ggaatacaatttcacacaggaaacagcgcgcctgagaaaagcgaagcggcctgctctttaac  
 aatttatcagacaattctgtgtgggcactcgaaccggaattatcagattaactttattttaaaaat  
 faagaggtatataattaatgtatcagattaaataaggaggaataaaccatgtgtgogacotcttc  
 tcaatttactcagattaccgagcataaattccogtcttccgcaaaactatcagccaaaacctgtgg  
 aatttcgaattcctgcaatccctggagaaagacotgaaagtggaaaagctggaggagaaaagcga  
 ccaactggaggaagaagttcgtctgatgatcaaccgtgtagacaccagccgctgtccctgct  
 ggagctgatcgaogatgtgcagcgcctgggtctgaectacaaaattgaaaaagacatcattaaa  
 gccctggaaaacatcgtactgctggacgaaaacaaaaagaacaaatctgacctgcacgcaaccg  
 ctctgtcttccgtctgctgctcagcaccggtttcagaggtttctcaggatgtttttgagcgttt  
 caaggataaagaaggtggtttcagcgggtgaactgaaaaggtgacgtccaaggcctgctgagcctg  
 tatgaaagcgtcttaccctgggtttcagaggtgagaacctgctggaggaggcogtaoctttcca  
 taccacacctgaagacaacctgaaagaaggcattaataccaaggttgcagaacaagttagcca  
 cgccttggaaactgcaatatacaccagcgtctgcaccgtctggaggccagcttggttcctggataaa  
 tacgaaccgaaagnaccgcatcaccagctgctgctggagctggcgaagctggattttaacatgg  
 tacagaccctgcaccagaasgagctgcaagatctgtcccgtgggtggaccgagatgggocctggc  
 tagcaaacctggattttttagcgcgacccctgatggaagtttattttctggycactgggtatggcg  
 ccagaccocgagtttgggtgaatgtcgcacaagctgttactaaaatgtttggctggtgacgatac  
 tcatgacgtgtatgacgtttatggcaactctggacgaactgcaactgttcaaccgatgctgtaga  
 gcgtcgggacgttaacgctattaacacacctgcoggaactatagaaactgtgtttcctggcactg  
 tacaacacctttaacgacagctoctattctattctgaaagagaaaggtcataaacaacctgtct

Figure 43C

atctgacgaaaagctggcgtgaactgtgcaaagcctttctgcaagagggcgaatgggtccaacaa  
caaaaattatcccggettctccaagtaectggaaaacgccagcgtttctctcccggtgtagcg  
ctgctggcgccttacttttccgtatgccagcagcaggaagacatctccgaccacgcgctgc  
gttccctgaccgacttccatggcttgggtgcttctagctgcgttatcttccgcctgtgcaacga  
tctggccacctctgcccggagctggaacgtggcgagactaccaattctatcattagctacatg  
cacgaaaacgatggtagcagcaggaacagggcccgcgaagaactgcgtaaactgatcgacgccc  
aatggaaaaagatgaatcgtgaacgcgttagcgaactccaccctgctgcctaaagcgttccatgga  
aatcgcagttaacatggcaecgtgttcccactgcaactaccagtatggcogatgggtcgggtcgc  
ccagactacgcgactgaaaaccgcatcaaacctgctgctgattgaccctttcccgattaaccagc  
tgatgtatgtcctaactgcatgcccttaggaggtaaaaaaaatgactgccgacaacaatagta  
tgccccatggtgcagtatctagttacgccaaattagtgcaaaaaccaaacacctgaagacatttt  
ggaagagtttccctgaaattattccattacaacaaagacctaataccogactctagtgagacgtca  
aatgacgaaagcggsgaaaacatgttttctgggtcatgatgaggagcaaataaagttaatgaatg  
aaaattgtattgttttggattgggacgataatgctattgggtgccggtaccaagaaagtgtgtca  
tttaattgaaaaatattgaaaagggtttactacatcgtgcattctccgtctttattttcaatgaa  
caaggtgaattacttttacaacaaagagccactgaaaaaataactttccctgatctttggacta  
acacatgctgctctccactatgtattgatgacgaattagggtttgaaggytaagctagaoga  
taagattaagggcctattactgcccgggtgagaaaaactagatcatgaattaggtattccagaa  
gatgaaactaagcacaaggggtaagtttccactttttaaacagaatccattacatggcaccagca  
atgaaccatgggggtgaacatgaaattgattacatcctattttataagatcaacgctaaagaaaa  
cttgactgtcaaccocaaacgtcaatgaagttagagacttcaaatgggtttcaaccaatgatttg  
aaaactatgtttgctgaccocaaagttacaagtttaagccttgggttaagattatttgcgagaatt  
acttattcaactgggtgggagcaattagatgacctttctgaagtggaaaatgacaggcaaatca  
tagaatgctataacgacgcgtcctgcagctggtaccatattgggaattcgaagctttctagaacg  
aaaactcatctcagaagaggatctgaatagcgcgctgaccatcatcatcatcatcatgaggtt  
taaaccggtctccagcttggctgttttggcgyatgagagaagattttcagcctgatcacagattaa  
atcagaacgcagaagcggctctgataaaacagaatttgctggcggcagtagcgcggtgggtccca  
cctgacccccatgccgaactcagaagtgaacgcgctagcgcgcatggtagtggtgggtctcccc  
atgcgagagtagggaactgccaggcatcaataaaaacgaaggctcagtcgaaagactgggctt  
ttcgttttatctgttgtttgtcggtagaagcctctccctgagtaggacaaatccgcggggagcggg  
tttgaacgttgggaagcaacggcccggaggggtggcgggcaggatcccgcataaaactgccagg  
catcaaatgaagcagaaggccatcctgacggatggcctttttgcgtttctacaaactcttttg  
tttatttttctaataacattcaaatatgtatccgctcatgagacaataaccctgataaatgctt  
caataat

SEQ ID NO:20

Figure 44




Figure 45A

5' -

ceogtcttactgtogggaaatcgcggttggccgattcoattaatgcagattattgaagcatttatac  
 agggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaasaagagtt  
 tgtagaaaocgcaaaaaggccatccgtcaggatggccttotgcttaatttgatgcoctggcagttt  
 atggcggggcgtcctgcccgccacccctcggggcggttgcttcgcaacggtcaaatccgcctccgg  
 cggatttgtcctactcaggagagcgttcaccgacaaacaacagatanaacgaaaggccagctot  
 ttgcactgagcctttcgttttatttgatgcoctggcagttcctactctcgcattggggagacccc  
 acactaccatcggcgcctacggcgtttcacttctgagttcggcatggggtcaggtgggaccaccg  
 cgctactgccgocaggcaaaattctgttttatcagaccgcttctgcggttctgatttaactctgat  
 cagggtgaaaaatctctctcatccgcaaaaacagccaaagctggagacggtttaaactcaatgat  
 gatgatgatgatggctcgacgcgcctattcagatcctctctgagatgagtttttgttctagaaa  
 gcttcgaattcccatatggtaaccagctgcagttatgccagccaggccttgattttggcttccat  
 accagcggcatcagggccgagttcggcgcgcatttcttctgagttccttggcgaataaagaag  
 tcggcaggcccaatgltcagcaecgggtactggtttacgatgggcccacagcacttcggtcacgc  
 cgtgcoctgcgcgcgccataaaggcgtttctctcagggtgaccagcgttcoatggctggcggc  
 catttccagaattaaacgcttcatcaagcgggttccacaaaacgcataatcgaccagcgtggcgttc  
 agcattcggcgaacttccgcgcttctggcctcagcgtaccaaaagtttaaggatccgcagttctct  
 cggccagacgcttcacaatgcctttgccaaattggtagtttttccagcggcgtcagttccacgce  
 gaccggttggccacggggtagcgcaccgctgacgggcccacgcttatagtgatagccgggtatag  
 agcatctggcgacattogtttctcatcgcctcggggtcataatgaccatttccgggtatgcagcga  
 ggtaaagagagatcaaaagcaccctgatgggtttgacogtccagcaccacaatgccgcgcgggtc  
 gatggcgaacaggacgggaagcttttgaatcggcagctcatgcagcaccctgatcatagggcggct  
 tgcaggaaagtgaggtaaatcggcgaatgggtttgtaaccaccaatcggccagaccgcagcaaa  
 aggtcaccgcgctgttgcctcggcaattgcccacgtcgaagtagcgtatccgggaatttacgtgaaaa  
 ctgcaccatgccggaaccttcacgcctcggcggagtaatcggccatcagcttggttgtcttccgct  
 gccgtttcgcacaaaccagtcgccaaagatttttgaatagctcggcacaaccgcgcctacttttcg  
 gcaaacaaaccgctggagggatcaaattaggcacggcgtggaaagtgatcgggtcttttctgc  
 cgttccataaaccagcacttttttgggtcatgatagcaggaactcggggccttccaggtcggc  
 atgttcttttagcgtgggtgataagcccccagcaccatcgtgaccgctccaccgggcccagtgatgaa  
 agcccagctcttcaaacaaacgtgcccaggeactaccatgcctttaataatgttcttgggtgogttt  
 gagcagctctttaaattggcggcaccgcagagaaaaactttttccgccttcggcagtgaaagag  
 taaagcttaccggnaagcagctgtgccagatgggtgttgagcgcgcgcagcattttcggaaatcg  
 acatttcaattgtcgttgagaatcaccagcattatcaggacggatatacggcgcgctgatccatgc  
 ttcaaacggccatgcctgcggtaatcggcgcctcggcaatgacacagacgggtcgggcgatttttg  
 ccttctttttcggcagcaaccgcaataccaattccggcactgatggaggttgatgaatgccoga  
 cgcttaatacgtcatattcgtttcggcgcgcaccgggaacgggtgcagaccgcctttctgacg  
 gatgggtgcgattttgtcggcggcgtcgggtcaaaaattttatgaggataagcctgatgccccaca  
 tcccaaatcaattgggtcaaacgggggtgtttagacatagtgacgcgcaccggtcagttogacog  
 tgcaccagccggaggogaagtgcccgtggaaacggctcaacgctgcagtaaatagcggcgcag  
 ttctgtcgcagagtttccggtaaactctcttccggcaacagctcgttaactcctgggtggagtcgacc  
 agtgcaccgggtcgggtatttggcaatatcaaaactcatgttttttaacctcctaagggcgaatg  
 cagttagaatatacatcagctgggttaategggaaagggtcaatcagcagcagtttgatgcgggtt  
 teagtcgcgtagctggggcagcccagaccatcggcatactggtaggtgcagtgggaaacacggtg  
 ceatgtaactgcgatttccatgaacgctttaggcagcagggtggagtcgctaacgcggttcacg

Figure 45B

attcattcttttccattcggcgtcgatcagtttacgcagttcttcggggcctgttcctcgcctg  
gtaccatcgttttctgtgcattgtagctaatgatagaattggtagtctcggccagttccagctccg  
ccgcagaggtggccagatcgttgcacaggcggaaagataacgcagctagaacgcaccagaccatg  
gaagtccgtcagggaaacgcagcgcgtggctcggagatgtcttctcgtcgtggcatacggaaaag  
taagacggcgcaccagcagcctacacccggaggaggaaaacgctggcgttttccaggtacttggaga  
aagccgggataattttgttggttggaaccatttgcctcttgcagaaaggcttgcacagttcag  
ccagcttttctcagataggacaggttgttatgacctttctcttccagaatagaataggacgtg  
tcgttaacgggtgttgcacagtgccaggaaacacagtttcataatagtcggcaggggtgttaatag  
cgttaacgtcccagcgtctacagcatcgggtgaaacagttgcagttcgtccagagtgccataaac  
gtcatalaacgctcatcagatgatcgtcaccagaccaaacatttttagtaacagctttgcgacattca  
ccaaactcggggctctggcgcacatcccagtgccacagaataaaacttccatcaggcggctccgta  
caaaaatccagtttgcctagccaggcccatctcgggtccaccagcgggacagatcttgcagctctt  
ctgggtgcagggtctgtaccatgttaaaatccagcttcgccagctccagcagcagctgggtgatgc  
ggttcttccggttcgtatttatccaggaaaccaagctgctccagacgggtgcagacgctgggtgat  
atggcagttccaggcgggtggtcacttgttctgcaaccttgggtattaatgccttcttccaggtt  
gttcttccaggtgggtgatggaaaaggtagcgcctctccagcaggttctcaccctcgaaaacc  
aggtaaagacgctcatalacaggtcagcaggtctggacgtcactttcagttccaccgctgaaac  
cacttctttatccttgaaacgctcaaaaacatcctgagaaacctcgaaacctgtctgacgcag  
cagaaggaaagacagagcgggtgcgtgcaggtcagatttgtcttcttcttcttctcgtccagcag  
acgatgttttccaggcctttaatgatgtcttttcaaatttgttaggtcagaccaccagcgtgca  
catcgtcagatcagctccagcagggacagcggctgggtgtctacacggttgatcatgcagcgaac  
ttctctccagtttggctcgttctctccagcttttccacttccaggtcgttctccagggtat  
tgcaggaaatcgaattccacaggtttggctgatagtttgcygaacgacgggaattatgctogg  
taatctgagtaaattgagaagaggtgcacacatggtttattcctccttatttaacgatatac  
taataataacctcttaatttttaataataaagttaatcgataattccggctcagagtcaccacac  
agattgtctgataaattgttaaagagcagtgccgcttctccttttctcagcggcgtctgttctct  
gltgaaatgttatccgctcacaattccacacattatacagagccggatgattaattgtcaaca  
gctcatttcagaatctggcgtatagcgaagagggccgcacogategcocttcccacagttgc  
gcagcctgaatggcgaatggcgcctgatgggtatcttctccttaogcatctgtgcggatattc  
accaccgatattggtgcaactctcagtaacaactctgctctgatgcggcatagtttaagccagcccca  
caccgcacaacaccgctgacgagcttagtaaaagccctcgtctagattttaatggcgatgttggc  
attacttcgccaactattgcgatacaagaaaaagccagccttccatgatatactcccattt  
gtgtaggccttattatgcaogcttaaaaataataaaaagcagacttgcctgatagtttggctgt  
gagcaattatgtgcttagtgcatctaacgcttgagtttaagccgcgcgcggaagcggcgtcggct  
tgaacgaattgttagacattatttgcogaactccttgggtgatctcgcctttcacgtagtggaca  
aattcttccaactgatctgcgcgcgagggcaagcagatcttctcttgtccaagataagcctgct  
tagcttcaagtatgacgggctgatactgggcggcagggcctccattgcccagtcggcagcggac  
atccttcggcgcgattttgcccgttactgcgctgtaccaaatgcgggacaacgtaagcactaca  
tttgcctcatcgcagcccagtcgggcggcaggtccatagcgttaaggtttcatttagcgcct  
caaatagatcctgttcaggaaaccggatcaaaagagttcctccgcctggacctaccaaggcaac  
getatgttctcttgcctttgtcagcaagatagccagatcaatgtcagtcgtggctggctcgaag  
atacctgcaagaatgctattgcgctgcccattctccaaattgcagttcgcgcttagctggataac  
gccaccggaatgatgtcgtcgtgcaacaatgggtgacttctacagcgcgggagaatctcgtctct  
tecaggggaaagccgaagtttccaaaggctcgttgatcaaaagctcgcgcgcttgtttcatcaagc

Figure 45C

cttacgggtcacoglaaccagcaaatcaatatacaactgtytggettccaggccgccatccactgccc  
agccgtacaaatgtacggccagcaacgtcgggttcgagatggcgctcgaatgacgccaaactacctc  
tgatagttgagtcgatacttcggcgatcaccgcttccctcatgatgtttaactttgttttaggg  
cgactgccctgctgogtaaacatcgtttgcctgctccataacatcaaacatcgacccaaggcgtaac  
gcgcttgctgcttggatgcccggaggcatagactgtacccccaaaaaacagtcataacaagccat  
gaaaaaccgccaactgcccgttaccaccgctgcccgttcgggtcaagggtctcggaccagttgctgag  
cgcatacgctacttgcatlacagcttaogaaccgaacaggcttatgtccactgggttcgctgoc  
tcatccgtttccaccggtgctgctcaccggcaacccctgggacagcagcgaagtccgaggcatctct  
gtccctggctggcgaaacgagcgcaagggttcgggtctccaccgcatcgtcaggcaattggcgccctg  
ctgttctctacggcaagggtgctgtgcaaggatctgccctggcttcaggagatcgyaaagacctc  
ggccgtcggcgccgttgcgggtggtgctgaccccggatgaagtggttcgcacccctcgggtttct  
ggaaggcgagcatcgtttgttcgcccagcttctgtatggaacgggcatgcccagtcagtgagggt  
ttgcaactgcccgtcaaggatctggatttcgatcaeggcaagatcactcgtgcccggaggccaagg  
gctccaaggatcgggccccttgatgttaccggagagcttggcacccagccctgcccagcaggggaa  
ttaattcccacgggttttgcctgcccgaacgggctgtctgggtgttgcctagtttgttatcaga  
ategcagatcccgccttcagccggtttgcccggctgaaagocctattctctcagaattgccatga  
ttttttcccacgggagggcgtcactggctcccgtgttctgcccagccttgattcagataagcagc  
ategcctgtttccaggctgtctatgtgtgactgttgagctgtaacaagtgtctcagggtgtcaa  
ttctatgtctcagttgctttgttttactggtttcaocctgtctctattagggtgttacatgctgttc  
atctgttacattgtcagatctgttcatggtgaaacagcttgaatgcaccaaaaactcgtaaagc  
totgabtgtatctatctttttacacogttttcatctgtgcataatggacagttttccctttgata  
tgtaacgggtgaaacagttgttctacttttgtttggttagctctgatgctcactgatagatacaag  
agccataagaacctcagatccttccgtatcttagccagatgttctctagtggtggttcgttgttt  
ttgcctgagccatgagaacgaaccattgagatcatacttacttctcactcactcaaaaatttt  
goccccaaaactgggtgagctgaaatttttgcagttaaagcactcgtgtagtggtttttcttagtccgt  
tatgtaggtaggaatctgatgtaatggttgttggtattttgtcaaccattcatttttatctggtt  
gttctcaagttcgggttaogagatccatttgtctatctagttcaacttggaaaatcaacgtatca  
gtcggggccctcgttatcaaccaccaatttcatattgctgttaagtgtttaaatcttactta  
ttggtttcaaaaaccattgggttaagcccttttaactcagtggtagttatlttcaagcattaacat  
gaacttaaatcactcaaggctaatctctatatttgccttgtgagtttctcttttgtgttagttct  
tttaataaccactcataaatccctcatagagtatltgttttcaaaagacttaacatgttccagat  
tatatttstatgaatttttttaactggaaaagataaggcaatatctctcactaaaaactaatc  
taatttttgccttgagaacttggcaatagtttgcactggaaaatctcaagccctttaaaccaaa  
ggattcctgatctccacagttctcgtcatcagctctctgggttgcctttagctaatcacaccataag  
cattttccctactgatgttcatcatctgagcgtattgggtataagtgaacgataccgtccgttc  
ttccttgtagggttttcaatcgtggggttgagtagtgccacacagcatalaaaattagcttgggt  
tcagctccgttaagtcataagcactaatcgttagttcatttgccttggaaaacaactaattcag  
acatacatctozattggctcaggtgattttaaactactataccaattgagatgggctagtonatg  
ataattactagtccttttccctttaggttgtgggtatctgtaaattctgctagacctttgctgga  
aaacttgaattctgctagacccctctgtasattccgctagacctttgtgtgttttttttggttt  
atattcaagtggttataatttatagaataaagaagaaataaaaaaagataaaaaagaatagatcc  
cagccctgtgtataactcactacttttagtcagttccgcagttatacaaaaggatgtcgaacag  
ctggttgcctctcaaaaacagaccttaaaaccctaaaggcttaagtagaacctcgcgaagct  
cgggcaaatcgcgtgaatattccttttgtctccgaccatcaggccacctgagtcgctgtctttttc

Figure 45D

Gtgacattcagttcgctgcggtcacggctotggcagtgsatgggggtaaatggcactacagggc  
ccttttatggattcatgcaaggaaactaccataatacaagasaagcccgtcacggggttctca  
ggcggttttatggcggtotgctatgtgggctatctgaacttttgotgttcagcagttcctgc  
cctctgattttccagtttgaccacttcggattatccctgacaggtcattcagactggctaattg  
caccagtaaggcagcgtatcatcaacaggetta

SEQ ID NO:21

Figure 46A




Figure 46B




Figure 46C




Figure 46D




Figure 46E




Figure 47A




Figure 47B




Figure 47C




Figure 47D




Figure 48A




Figure 48B




Figure 48C




Figure 49A




Figure 49B




Figure 49C




Figure 50




Figure 51A

5' -  
 teqctgcgctcggtcgtteggotgcccgcgagcggtatcagctcaactcaaaggcggtatacgggt  
 tatccacagaatcaggggataaacgcaggaaagaacatgtgagcraaaaggccagcaaaaggccag  
 gasccgtaaaaaaggcccgcttgctggcgcttttccataggctccgccccctgacgagcatcac  
 aaaaatcgacgctcaagtcagagggtggcgaaaccgcagaggactataaagataaccaggcgcttc  
 cccctggaagctccctcgtgctctctctgtccgaccctgcccgttacccggatacctgtccgc  
 ctttctcccttcgggaagcgtggcgctttctcatagctcaagctgttaggtatctcagttcggtg  
 taggtcgttcgctccaagctgggctgtgtgcaacgaaccccccggtccagcccagccgctgcccct  
 talccggtaactatcgtcttgagtcacaacccggtaagacacgacttatcgccactggcagcagc  
 cactggtaacaggattagcagagcgaggatgttaggocggtgctacagagttcttgaagtggtgg  
 cctaactacggctacaactagaagaacagtatcttggtatctgctgctgaagccagttacct  
 tcggaaaaagagttggtagctcttgatccggcaaacaaaccacccgctggtagcgggtgggttttt  
 tggttgcaagcagcagattacggcgagaaaaaaggatctcaagaagatcctttgatctttct  
 acggggtctgacgctcagtggaacgaaaaactccagttlaagggatcttggtcatgagattatcaa  
 aaaggatctcaactagatccttttaattaaaaatgaagttttaaatacaatctaaaglatata  
 tgagtaaacctggctctgacagttaccatgcttaacagtgaggccacctatctcagcagctctgt  
 ctatttcttccatccatagttgctgactccccctcgtgtagataaactacgatacgggagggct  
 taccatctggccccagtgctgcaatgatccgcgagaccacgctcaccggctccagatttate  
 agcaataaaccagccagccggaagggccgagcgcagaagtggtccctgcaactttatccgctcc  
 atccagctctattaattggtgcccgggaagctagagtaagtagttccgacgttaaatagtttgcgca  
 acgctgttgccattgctacagggcatcgtgggtgcccgcctcgttgggtatggcttcattcag  
 ctccggttcccaacgatcaaggcgagttacatgatccccatggtgtgcaaaaaagcgggttagc  
 tcttccggtcctccgatcgttggcagaagtaagttggccgcagtggttatcactcatggttatgg  
 cagcactgcataaattctctactgtcatgccatccgtaagatgcttttctgtgactggtagta  
 ctcaaccaagtcattctgagaatagtgatgcccgcgaccgagttgctcttgcgccggcgtcaata  
 cyggataaafccgcgcccacatagcagaactttaaaagtgctcatcatggaaaacgctctctcgg  
 ggcgaaaaactctcaaggatcttaccgctggtgagatccagttcgaatgtaacccaactcgtgcaac  
 caactgatcttcagcatcttttactttaccagcgtttctgggtgagcaaaaaacaggaaggcaaa  
 aatgcccgaaaaaagggcaataagggcgacacgggaatggtgaaatactcataactcttctctttc  
 aatattattgaagcatttatcagggttattgtctcatgagcggatacatatcttgaatgtattta  
 gaaaaataaacaatataggggttccgcgcacatttccccgaaaagtgccacctgacgtctaagaa  
 accattattatcatgacattaacctataaaaaataggcgtatcagcaggecctttcgtctcgcgc  
 gtttccggtgatgacgggtgaaaacctctgacacatgcagctcccggagacgggtcacagcttgctc  
 gtaagcggatgcccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcgggtgtcgg  
 ggctggcttaactatgcccgatcagagcagattgtactgagagtycaccatagatctggagctg  
 taatataaaaaacctcttcaactaacgggacaggttagtgacattagaaaaaccgactgtaaaaa  
 gtacagtcggcattatctcatattataaaagccagtcattaggccctatctgacaattcctgaat  
 agagttcataaaacatctctgcatgataaccatcacaacacagaatgatgtacctgtaaaagtagc  
 ggtaaatataattgaattaccttttattaaatgaattttccctgctgtaataatgggtagaaggtaat  
 tactattattattgatatttaagttaaacccagtaaatgaagtcacatggaataatagaagaga  
 aaaagcattttcaggtataggtgttttgggaaacaatttccccgaaccattatatttctctaca  
 tcagaaaaggtataaatcataaaaactctttgaagtcattctttacaggagtcacaataccagaga  
 atgtttttgatatacccatcaaaaattgtataaaagtggctetaacttatcccaataacctaacctc  
 tccgctcgtatttgtaaccagttctaaaagctgtatttgagtttatccacctgtcactaagaaa  
 ataaatgcagggttaaaatttatatccttctigttttatgtttc

Figure 51B

ggtataaaacactaatatcaatttctgtggttatactaaaagtcggttgggttcaaaataatg  
 atkkaatatctctttctcttccaattgtctaaatcaattttattaaagttcatttgatatgcc  
 tctaaatttttatctaaagtgaatttaggaggcttacttgtctgotttcttcattagaatcaa  
 tctttttttaaagtcfaatattactgtaacataaataatataatttttaaataatocccactttatc  
 caatttctggttggtaactaatgggtgcttttagtfgaagaataaaagacctatgcccgtgtgaa  
 ataccgcacagatgcgtaaggagaaaaataccgcacagggccattccgccattcaggctgcgca  
 actgttgggaagggogategggtgcccgcctctctogctattacgccagctggcgaaaggggatg  
 tgcgcaaggcgattaaagttgggtaacgcacaggggtttccagtcacgcagttgtaaaacgacg  
 gccagtgccaagcttgcatgocctgcaactccattttctctgctatcaaaaataacagactcgtga  
 ttttccaaaacgagctttcaaaaaagcctctgccccttgcaaatcggatgocctgtctataaaatt  
 cccgatattgggttaaacagcggcgcaatggcgggccgcactctgatgtctttgcttggcgaaatgtt  
 catcttatttctctctccctctcaataattttttcattctatcccttttctgtaaaagtttattt  
 ttcagaatacttttatcatcatgctttgaaaaaatatccagataatccattggtctcacgga  
 agcacaacgcaggtcatttgaacgaatttttlogaacaggaaatttgcgggactcaggagcattta  
 aactaaazaagcatgacatttccagcataatgaacatttactcatgtctattttcgttctttct  
 gtatgaaaatagttatttccaggtctctacggaaatagcagagagatgatatacctaataatagagat  
 aaaaatcatctcaaaaaaatgggtctactcaaaaatattattccatctattacaataaattcacaga  
 atagttcttttaagtaagttactctgaattttttttaaaggagagggtaaaagagtgaaaacagt  
 agttattattgatgcattacgaacaccaattggaaaataaaaggcagcttaagtcasgttaagt  
 gccgtagacttaggaacacatggttacacaacacaactttttaaagagacattccactatttctgaag  
 aatttgatcaagtaatctttgaaaatgttttacaagctggaaatggccaaaatcccgcaacgaca  
 aatagcaataaacaagcgggttctctcatgaaatcccgcaatgacgggttaatgaggtctgcgga  
 tcaggaaatgaaggccgttattttggcgaaacaattgattcaattaggagaagcgggaagttttaa  
 ttgctggcggggattgagaatatgtcccaagcaactaaattacaacggttttaattangaacaga  
 aagctacgatgcgcccctttcttagtatgatgtagatgattgattaaacggatgocctttagtggtcag  
 gcaatgggcttaactgctgaaaaatgtggccgaaaagtatcatgtaactagagaagagcaagatc  
 aattttctgtacattcaacaattaaaagcagctcaagcacaagcagaagggatattcgcctgacga  
 aatagccccattagaagtatcaggaacgcttctgaggagaagatgaagggattcgcocctaatcog  
 agcgttgagaagctaggaacgcttaaacagtttttaagaagaagcgtactgtaacagcagggga  
 atgcatcaaccattaatgtaggggctctctgcttggattattgcttcacaagaatatgcccgaagc  
 acacggctcttcttatttagctattattcagagacagtggtggaagtcggattgatccagcctat  
 atgggaatttccgcgatbaaagccattcaaaaactgtagcggcgaatcaacttactacggaag  
 aaattgatctgtatgaaatcaacgaagcatttgcagcaacttcaatcgtggtccaagagaact  
 ggcttaccagaggaaaaggtcaacattttatgggtggcggtatttcaattaggtcatgogattggt  
 gccacaggtgctcgttttattaacgagtttaagttatcaattaaatcaaaaagaaaagaastatg  
 gagtggcttctttatgtatcggcggtggccttaggactcgcctatgctactagagagacctcagca  
 aaaaaaaaacagcogattttatcaaatgagtcctgaggaaacgctggcttctcttcttaatgaa  
 ggccagatttctgctgatcaaaaaagaatttgaaaatacggctttatcttccgagattgccca  
 atcatatgattgaaaaatcaaatcagtgaaacagaagtgccgatgggcttggcttacatttaac  
 agtggacgaaactgattatttgggtaccaatggcgacagaagagocctcagttattgcccgtttg  
 agtaatggtgcaaaaatagcacaaggattttaaacagtgaaatcaacaacgcttaatgcccggac  
 aatcgttttttacgatggtgcagatcccgagtcattgattgataaaactacaagtaagagaagc  
 ggaagttttcaacaagcagagtttaagttatccatctatcgtttaaacggggggcgggcottaaga  
 gatttgcataatcgtactttttagatgaatccatttgtatctgtcgaactttttagtagatggttaagg  
 atgcaatgggggcaaatatcgttaacgctatggttggaggggtgtg

Figure 51C

gcccagttgttccgtgaaatgggttgcggagcaaaagattttattcagttatttaagtaattatg  
 ccacggagtcgggtgttacgatgaaaaacggctattccagtttcacgtttaagtaaggggagcaa  
 tggcggggaattgctgaaaaaatgttttagcttcacgctatgcttcattagatccttatcgg  
 gcagtcacgcataacaaaggaatcatgaatggcattgaagctgtagtttttagctacaggaaatg  
 atacacgcgctgttagcgtctcttgcctatgcttttgcgggtgaaggaaggctcgtaccaaggctt  
 gactagttggacgctggatggcgaacaactaattgggtgaaatttcagttccgcttgccttagcc  
 acgggttggcgggtgccacaaaagctcttacctaaatctcaagcagctgctgatttgttagcagtga  
 cggatgcaaaaagaactaagtcggtagtagcggctgttgggttggcacaataattagcggcgtt  
 acgggcttagtctctgaaggaattcaaaaaggacacatggctctacaagcaagttcttttagcg  
 atgacggctcggagctactggtaaaagaagttgaggcagtcgctcaacaattaaaacgtcaaaaa  
 cgatgaaccaagaccgagccatggctattttaaatgatttaagaaaaacaataaaaggagaggyt  
 gacaattgggattgatasaattagttttttgtgcccccttattatattgatatgaocggcactg  
 gctgaagccagaaatgtagaccctggaaaaatttcatattgggtattgggcaagaccatggcgg  
 tgaacccaatcagccaagatattgtgacatttgcagccaatgcgcagaaagcgatcttgacca  
 agaagataaagaggccattgatatgggtgattgtogggactgagtcacagtatcgatgagtcanaa  
 gggccgcagttgtcttscatcgtttaatggggattcaacctttcgcctcgtctcttcgaaatca  
 aggaagcttgttacggagcaacagcaggettacagttagctaaagaaatcagtagccttacatcc  
 agtaaaaaaagctcttggctcgtagcggcagatattgcanaataatggcttaaatctctggcggtag  
 octacacaaggagcttggggcgggttgcnaatgttagttgctagtgaacccgcgcaatttggcttbaa  
 aagaggataatgtgatgctgacgcaagatctctatgacttttggcgtccaacagccaccgta  
 tctatggctcgatggctcttcttgcnaaacgaaacctacatccaatcttttgcnaacgtctgggat  
 gaacatasaaaaacgaaacggctcttggattttgcagattatgatgcttttagcgttccatattcctt  
 acacaaaaatgggcaaaaaagccttattagcaaaaatctccgaccaaaactgaagcagaacagga  
 accaatttttagccggttatgaagaaagtatcgtctatagtcgtcgcgttaggaaacttgtstacg  
 ggttcactttatctgggactcatttcccttttagaaaaatgcaacgacttaaccggcaggcaatc  
 aatttgggttatctcagttatgggtctggtgctgtcgtgaaatcttccactggtgaaattagtagc  
 tggttatcaaaaatcatttcaaaaaagaaactcatttagcactgctggatnaatcggacagaactt  
 totatcgcctgaatatgaagccatgtttgcagaaactttagacacagacattgatcaaacgttag  
 aagatgaattaaaatatagtatctctgctattataataaccgttcgttcttatcgaaactaaaa  
 aaaaacggccttggccccggcgggtttttattattttcttccctccgcagttcaatccgctcc  
 ataatcgaacggatggctccctctgaaaatttaacgagaaaacggcgggttgaacccggctcagtc  
 ccgtaacggccaagtccctgaaacgtctcaatcgcgcgttcccggtttccggctcagctcaatgoc  
 gtaacggctcggcggcgttttctgataccggggagacggcattcgtaatcgggatccccgggtac  
 cggctcgaattcgtaatcatgtcatagctgttccctgtgtgaaattgttatccgctcacaatt  
 ccacacaaacatcagagccggaagcataaagtgtaaagcctgggggtgcctaatgagtgagctaac  
 tcaabtaattgcttgcgctcactgcctcgtttccagtcgggaaacctgtcgtgcccagctgca  
 ttaatgaatcggccaacgcgggggagagcggtttgctgatttggcgcctctccgcttccctcg  
 etcactgac

SEQ ID NO:22

Figure 52




Figure 53A




Figure 53B




Figure 54




Figure 55




Figure 56




Figure 57




Figure 58




Figure 59




Figure 60A




Figure 60B




Figure 60C




Figure 61A




Figure 61B




Figure 61C




Figure 62A




Figure 62B




Figure 62C




Figure 63A




Figure 63B




Figure 63C




Figure 64A




Figure 64B




Figure 64C




Figure 65A




Figure 65B




Figure 65C




Figure 66A




Figure 66B




Figure 66C




Figure 67A




Figure 67B




Figure 67C




Figure 68




Figure 69




Figure 70




Figure 71




Figure 72






Figure 74




Figure 75A

Concentration at Deflagration																			
Fuel Makeup					Oxidizer Makeup					Molar Concentration based on 100g of sample					Volumetric Concentrations based on total gas law				
Fuel Conc. (wt. %)	Oxidizer Conc. (wt. %)	Isoprene (wt. %)	H <sub>2</sub> O (wt. %)	O <sub>2</sub> (wt. %)	N <sub>2</sub> (wt. %)	Isoprene (mole)	H <sub>2</sub> O (mole)	O <sub>2</sub> (mole)	N <sub>2</sub> (mole)	Total (mole)	Isoprene (vol. %)	O <sub>2</sub> (vol. %)	N <sub>2</sub> (vol. %)	H <sub>2</sub> O (vol. %)					
3.10	95.90	100	0	12	88	4.56	0.00	36.34	304.54	345.44	1.32	10.52	88.16	0.00					
3.10	96.90	100	0	13	87	4.56	0.00	39.57	301.08	345.01	1.32	11.41	87.27	0.00					
3.10	96.90	100	0	14	86	4.56	0.00	42.39	297.92	344.57	1.32	12.30	86.37	0.00					
3.10	96.90	100	0	15	85	4.56	0.00	45.42	294.16	344.14	1.32	13.20	85.48	0.00					
3.10	96.90	100	0	16	84	4.56	0.00	48.45	290.70	343.71	1.33	14.10	84.58	0.00					
3.10	96.90	100	0	17	83	4.56	0.00	51.48	287.24	343.28	1.33	15.00	83.68	0.00					
3.10	96.90	100	0	21	79	4.56	0.00	63.59	273.40	341.55	1.33	18.62	80.05	0.00					
3.50	96.50	100	0	11.1	88.9	5.15	0.00	33.47	306.39	345.01	1.49	9.70	88.81	0.00					
4.40	95.60	100	0	12	88	6.47	0.00	35.85	300.46	342.78	1.89	10.46	87.65	0.00					
5.50	94.50	100	0	13	87	8.09	0.00	38.39	293.63	340.10	2.38	11.29	86.33	0.00					
6.60	93.40	100	0	14	86	9.71	0.00	40.86	286.87	337.44	2.88	12.11	85.01	0.00					
7.80	92.40	100	0	15	85	11.18	0.00	43.31	280.50	334.99	3.34	12.93	83.73	0.00					
8.50	91.50	100	0	16	84	12.50	0.00	45.75	274.50	332.75	3.75	13.75	82.49	0.00					
9.60	90.40	100	0	17	83	14.12	0.00	48.03	267.97	330.11	4.26	14.55	81.18	0.00					
13.50	86.50	100	0	21	79	19.85	0.00	56.77	244.05	320.67	6.19	17.70	76.11	0.00					

Figure 75B




Figure 76A

Concentration at Deflagration																	
		Fuel Makeup				Oxidizer Makeup				Molar Concentration based on 100g of sample				Volumetric Concentrations based on ideal gas law			
Fuel Conc. (wt.%)	Oxidizer Conc. (wt.%)	Isoprene (wt.%)	Isoprene (wt.%)	H <sub>2</sub> O (wt.%)	O <sub>2</sub> (wt.%)	N <sub>2</sub> (wt.%)	Isoprene (mmole)	H <sub>2</sub> O (mmole)	O <sub>2</sub> (mmole)	N <sub>2</sub> (mmole)	Total (mmole)	Isoprene (vol.%)	O <sub>2</sub> (vol.%)	N <sub>2</sub> (vol.%)	H <sub>2</sub> O (vol.%)		
3.252	96.748	100	4	12	84	4.78	21.50	36.28	290.24	352.81	1.36	10.28	82.27	6.09			
3.274	96.726	100	4	13	83	4.81	21.49	39.29	286.72	352.33	1.37	11.15	81.38	6.10			
3.290	96.710	100	4	14	82	4.84	21.49	42.31	283.22	351.86	1.38	12.02	80.49	6.11			
3.288	96.712	100	4	15	81	4.84	21.49	45.33	279.77	351.43	1.38	12.90	79.61	6.12			
3.286	96.714	100	4	16	80	4.83	21.49	48.36	276.33	351.01	1.38	13.78	78.72	6.12			
3.284	96.716	100	4	17	79	4.83	21.49	51.38	272.88	350.58	1.38	14.66	77.84	6.13			
3.276	96.724	100	4	21	75	4.82	21.49	63.48	259.08	348.87	1.38	18.19	74.26	6.16			
3.500	96.500	100	4	11.5	84.5	5.15	21.44	34.68	281.22	352.49	1.46	9.84	82.82	6.08			
4.200	95.800	100	4	12	84	6.18	21.29	35.93	267.40	350.79	1.76	10.24	81.93	6.07			
5.900	94.700	100	4	13	83	7.79	21.04	36.47	280.72	348.03	2.24	11.05	80.66	6.05			
6.400	93.600	100	4	14	82	9.41	20.80	40.95	274.11	345.28	2.73	11.86	79.39	6.02			
7.400	92.600	100	4	15	81	10.88	20.58	43.41	267.88	342.74	3.18	12.66	78.16	6.00			
8.500	91.500	100	4	16	80	12.50	20.33	45.75	261.43	340.01	3.66	13.46	76.89	5.98			
9.400	90.600	100	4	17	79	13.82	20.13	48.13	255.62	337.71	4.09	14.25	75.69	5.96			
13.300	86.700	100	4	21	75	19.56	19.27	56.90	232.23	327.95	5.96	17.35	70.81	5.87			

Figure 76B




Figure 77




Figure 78A




Figure 78B

<b>Explosions</b>		<b>Non-explosions</b>	
<b>O2</b>	<b>C5H8</b>	<b>O2</b>	<b>C5H8</b>
<b>Concentration</b>	<b>Concentration</b>	<b>Concentration</b>	<b>Concentration</b>
<b>(vol. %)</b>	<b>(vol. %)</b>	<b>(vol. %)</b>	<b>(vol. %)</b>
21.0	1.5	21.0	1.4
13.0	1.5	13.0	1.4
11.0	1.6	11.0	1.5
10.4	1.8	10.4	1.7
10.0	1.9	10.0	1.8
9.8	2	9.7	2
10.0	2.2	10.0	2.3
10.4	2.5	10.4	2.6
11.0	2.9	11.0	3.0
13.0	4.0	13.0	4.1
17.7	8.0	17.6	8.0
21.0	11.8	21.0	11.9

Figure 78C




Figure 79A




Figure 79B

<b>Explosions</b>		<b>Non-explosions</b>	
<b>O2</b>	<b>C5H8</b>	<b>O2</b>	<b>C5H8</b>
<b>Concentration</b>	<b>Concentration</b>	<b>Concentration</b>	<b>Concentration</b>
<b>(vol. %)</b>	<b>(vol. %)</b>	<b>(vol. %)</b>	<b>(vol. %)</b>
21.0	11.7	21.0	11.9
21.0	11.8	21.0	11.9
21.0	11.8	21.0	11.9
21.0	1.5	21.0	1.4
21.0	1.5	21.0	1.4
10.2	2.0	21.0	1.4
10.1	2.0	9.8	2.0
10.0	2.0	9.8	2.0
9.9	2.0	9.8	2.0

Figure 79C




Figure 80A

TEST SERIES 1

Test	Data File Name	Temp °C	Initial Pressure bara	Partial Pressures			Concentrations			Result	Pex bara
				C <sub>2</sub> H <sub>6</sub> mbar	N <sub>2</sub> mbar	O <sub>2</sub> mbar	C <sub>2</sub> H <sub>6</sub> vol. %	N <sub>2</sub> vol. %	O <sub>2</sub> vol. %		
1	T11120700	40	1.012	12	787	213	1.2	77.8	21.0	Non-Explosion	1.05
2	T11120701	40	1.016	16	787	213	1.6	77.5	21.0	Explosion	5.5
3	T11120702	40	1.015	14	788	213	1.4	77.6	21.0	Non-Explosion	<1.02
4	T11120703	40	1.014	15	786	213	1.5	77.5	21.0	Non-Explosion	<1.02
5	T11120704	40	1.014	15	786	213	1.5	77.5	21.0	Explosion	4.31
6	T11120705	40	1.017	18	785	214	1.8	77.2	21.0	Explosion	5.47
7	T11120706	40	1.014	15	786	213	1.5	77.5	21.0	Explosion	4.51
8	T11120707	40	1.014	14	787	213	1.4	77.6	21.0	Non-Explosion	<1.02
9	T11120708	40	1.014	14	787	213	1.4	77.6	21.0	Non-Explosion	1.05
10	T11120709	40	1.015	102	790	213	10.0	58.0	21.0	Explosion	1.45
11	T11120710	40	1.014	102	699	213	10.1	58.9	21.0	Explosion	1.39
12	T11120711	40	1.014	106	695	213	10.5	68.5	21.0	Explosion	1.34
13	T11120712	40	1.014	113	688	213	11.1	67.9	21.0	Explosion	1.29
14	T11120713	40	1.014	122	679	213	12.0	67.0	21.0	Non-Explosion	<1.02
15	T11120714	40	1.014	117	684	213	11.5	67.5	21.0	Explosion	1.32
16	T11120715	40	1.014	120	681	213	11.6	67.2	21.0	Non-Explosion	1.06
17	T11130700	40	1.014	120	681	213	11.8	67.2	21.0	Explosion	1.09
18	T11130701	40	1.014	121	680	213	11.9	67.1	21.0	Non-Explosion	1.07
19	T11130702	40	1.015	121	681	213	11.9	67.1	21.0	Non-Explosion	1.06
20	T11130703	40	1.015	121	681	213	11.9	67.1	21.0	Non-Explosion	1.07
21	T11130704	40	1.015	30	853	132	3.0	84.0	13.0	Explosion	1.61
22	T11130705	40	1.014	36	846	132	3.6	83.4	13.0	Explosion	1.26
23	T11130706	40	1.014	39	843	132	3.8	83.1	13.0	Explosion	1.12
24	T11130707	40	1.015	41	842	132	4.0	83.0	13.0	Explosion	1.09
25	T11130708	40	1.014	42	840	132	4.1	82.8	13.0	Non-Explosion	1.06
26	T11130709	40	1.015	42	841	132	4.1	82.9	13.0	Non-Explosion	1.06
27	T11130710	40	1.014	42	840	132	4.1	82.8	13.0	Non-Explosion	1.05
28	T11130711	40	1.014	15	867	132	1.5	85.5	13.0	Non-Explosion	1.03
29	T11130712	40	1.014	16	866	132	1.6	85.4	13.0	Explosion	4.81
30	T11130713	40	1.014	15	867	132	1.5	85.5	13.0	Explosion	4
31	T11130714	40	1.014	14	868	132	1.4	85.6	13.0	Non-Explosion	1.03
32	T11130715	40	1.014	14	868	132	1.4	85.6	13.0	Non-Explosion	<1.02
33	T11130716	40	1.014	14	868	132	1.4	85.6	13.0	Non-Explosion	1.03
34	T11130717	40	1.015	20	883	112	2.0	87.0	11.0	Explosion	1.7
35	T11130718	40	1.014	26	874	112	2.8	86.2	11.0	Non-Explosion	1.08
36	T11130719	40	1.014	26	874	112	2.8	86.2	11.0	Non-Explosion	1.08
37	T11130720	40	1.014	26	874	112	2.8	86.2	11.0	Explosion	1.13
38	T11130721	40	1.015	29	874	112	2.9	86.1	11.0	Non-Explosion	1.08
39	T11130722	40	1.014	29	873	112	2.9	86.1	11.0	Explosion	1.1

Figure 80B

Test	Data File Name	Temp °C	Initial Pressure bara	Partial Pressures			Concentrations			Result	P <sub>ex</sub> bara
				C <sub>2</sub> H <sub>6</sub> mbar	N <sub>2</sub> mbar	O <sub>2</sub> mbar	C <sub>2</sub> H <sub>6</sub> vol. %	N <sub>2</sub> vol. %	O <sub>2</sub> vol. %		
40	T11130723	40	1.014	30	872	112	3.0	86.0	11.0	Non-Explosion	1.08
41	T11130724	40	1.014	30	872	112	3.0	86.0	11.0	Non-Explosion	1.05
42	T11130725	40	1.014	30	872	112	3.0	86.0	11.0	Non-Explosion	1.05
43	T11130726	40	1.014	15	887	112	1.5	87.5	11.0	Non-Explosion	<1.02
44	T11130727	40	1.014	15	887	112	1.5	87.5	11.0	Non-Explosion	<1.02
45	T11140730	40	1.014	15	886	112	1.6	87.4	11.0	Non-Explosion	<1.02
46	T11140701	40	1.014	17	885	112	1.7	87.3	11.0	Explosion	1.81
47	T11140702	40	1.014	16	886	112	1.6	87.4	11.0	Explosion	1.54
48	T11140703	40	1.014	15	887	112	1.5	87.5	11.0	Non-Explosion	<1.02
49	T11140704	40	1.015	20	899	96	2.0	88.6	9.5	Non-Explosion	1.05
50	T11140705	40	1.014	20	898	98	2.0	88.6	9.5	Non-Explosion	1.05
51	T11140706	40	1.014	23	890	101	2.3	87.8	10.0	Non-Explosion	1.05
52	T11140707	40	1.015	23	886	106	2.3	87.3	10.4	Explosion	1.19
53	T11140708	40	1.014	25	884	105	2.5	87.2	10.4	Explosion	1.09
54	T11140709	40	1.014	26	883	105	2.6	87.1	10.4	Non-Explosion	1.05
55	T11140710	40	1.014	26	883	105	2.6	87.1	10.4	Non-Explosion	1.06
56	T11140711	40	1.014	26	882	105	2.6	87.1	10.4	Non-Explosion	1.07
57	T11140712	40	1.014	20	889	105	2.0	87.7	10.4	Explosion	1.21
58	T11140713	40	1.014	17	892	105	1.7	88.0	10.4	Non-Explosion	1.04
59	T11140714	40	1.014	18	891	105	1.8	87.9	10.4	Explosion	1.21
60	T11140715	40	1.014	17	892	105	1.7	88.0	10.4	Non-Explosion	1.03
61	T11140716	40	1.014	17	892	105	1.7	88.0	10.4	Non-Explosion	1.03
62	T11140717	40	1.014	21	890	103	2.1	87.8	10.2	Explosion	1.1
63	T11140718	40	1.014	21	891	102	2.1	87.9	10.1	Explosion	1.09
64	T11140719	40	1.014	21	892	101	2.1	88.0	10.0	Explosion	1.08
65	T11140720	40	1.014	22	891	101	2.2	87.9	10.0	Explosion	1.1
66	T11140721	40	1.014	23	890	101	2.3	87.9	10.0	Non-Explosion	1.06
67	T11140722	40	1.014	23	890	101	2.3	87.8	10.0	Non-Explosion	1.08
68	T11140723	40	1.014	19	894	101	1.9	88.2	10.0	Explosion	1.12
69	T11140724	40	1.014	18	895	101	1.8	88.3	10.0	Non-Explosion	1.06
70	T11140725	40	1.014	18	895	101	1.8	88.3	10.0	Non-Explosion	1.03
71	T11140726	40	1.014	18	895	101	1.8	88.3	10.0	Non-Explosion	1.04
72	T11140727	40	1.014	20	895	99	2.0	88.3	9.8	Non-Explosion	1.08
73	T11140728	40	1.014	20	895	99	2.0	88.3	9.8	Explosion	1.1
74	T11140729	40	1.014	20	896	98	2.0	88.4	9.7	Non-Explosion	1.06
75	T11140730	40	1.014	20	896	98	2.0	88.4	9.7	Non-Explosion	1.08
76	T11140731	40	1.014	20	896	98	2.0	88.4	9.7	Non-Explosion	1.07
77	T11140732	40	1.014	81	761	172	8.0	75.0	17.0	Non-Explosion	1.04
78	T11140733	40	1.014	81	750	183	8.0	74.0	18.0	Explosion	1.3
79	T11140734	40	1.014	81	754	179	8.0	74.4	17.7	Explosion	1.24
80	T11140735	40	1.014	81	757	176	8.0	74.7	17.4	Non-Explosion	1.03
81	T11140736	40	1.014	81	755	178	8.0	74.5	17.6	Non-Explosion	1.05
82	T11140737	40	1.014	81	755	178	8.0	74.5	17.6	Non-Explosion	1.03
83	T11140738	40	1.014	81	755	178	8.0	74.5	17.6	Non-Explosion	1.03

Figure 81

**TEST SERIES 2**

Test	Data File Name	Temp °C	Initial Pressure bara	Partial Pressures				Concentrations				Result	Pex bara
				H <sub>2</sub> O mbar	C <sub>2</sub> H <sub>6</sub> mbar	N <sub>2</sub> mbar	O <sub>2</sub> mbar	H <sub>2</sub> O vol. %	C <sub>2</sub> H <sub>6</sub> vol. %	N <sub>2</sub> vol. %	O <sub>2</sub> vol. %		
1	T11150700	40	1.014	41	119	641	213	4.0	11.7	63.2	21.0	Explosion	1.32
2	T11150701	40	1.014	40	121	640	213	3.9	11.9	63.1	21.0	Non-explosion	1.07
3	T11150702	40	1.014	41	120	640	213	4.0	11.8	63.1	21.0	Explosion	1.09
4	T11150703	40	1.014	40	121	640	213	3.9	11.9	63.1	21.0	Non-explosion	1.06
5	T11150704	40	1.014	40	120	641	213	3.9	11.8	63.2	21.0	Explosion	1.09
6	T11150705	40	1.014	40	121	640	213	3.9	11.9	63.1	21.0	Non-explosion	1.08
7	T11150706	40	1.014	40	15	746	213	3.9	1.5	73.6	21.0	Explosion	4.68
8	T11150707	40	1.014	41	15	745	213	4.0	1.5	73.5	21.0	Explosion	5.27
9	T11150708	40	1.014	41	14	746	213	4.0	1.4	73.6	21.0	Non-explosion	1.03
10	T11150709	40	1.014	42	14	745	213	4.1	1.4	73.5	21.0	Non-explosion	1.03
11	T11160700	40	1.014	41	14	746	213	4.0	1.4	73.6	21.0	Non-explosion	1.03
12	T11160701	40	1.014	41	20	850	103	4.0	2.0	63.6	10.2	Explosion	1.11
13	T11160702	40	1.014	41	20	851	102	4.0	2.0	63.9	10.1	Explosion	1.11
14	T11160703	40	1.014	41	20	852	101	4.0	2.0	64.0	10.0	Explosion	1.09
15	T11160704	40	1.014	41	20	853	100	4.0	2.0	64.1	9.9	Explosion	1.09
16	T11160705	40	1.014	41	20	854	99	4.0	2.0	64.2	9.8	Non-explosion	1.07
17	T11160706	40	1.014	40	20	855	99	3.9	2.0	64.3	9.8	Non-explosion	1.06
18	T11160707	40	1.014	41	20	854	99	4.0	2.0	64.2	9.8	Non-explosion	1.08



Figure 83




Figure 84




Figure 85




Figure 86A




Figure 86B




Figure 87A




Figure 87B




Figure 87C




Figure 87D





Figure 88A

Abundance



Time-->

Figure 88B




Figure 89






Figure 90




cyclopentadiene




"isopryne" = 3-Me-1-butyne




trans-piperylene




cis-piperylene




1-pentyne



pent-4-ene-1-yne



trans-pent-3-ene-1-yne



cis-pent-3-ene-1-yne

Figure 91




Figure 92A

1-

ggttgacagcctatcagcactgcacgggtgacccaatgcttcggcgtcaggcagccatcgggaagcgtgtgtatggctgtgcagg  
 tcgtaaatcaotgcataatcgtgtcgcctcaaggcgcactcccgttctggataatgtttttgcgccgacatcataacggctcggca  
 safattctgaatgagcgtgtgacaatfaalcctccggctcgtafaatgtgtgggaattgtgagcggataacaattccacacaggaaac  
 agcgcggctgagaaaaagcgaagcggcactgctcttaacaattatcagacaatctgtgtgggcactcgcaccggaattatcga  
 taacttatttfaaaaaaataagaggatataatgatacgttaataaaggaggaataaacatggatccggcctcaggaggta  
 aaaaaacatgaaaacagtagtattattgatgcattacgaacaccattggaaaatataaaggcagcthaagicaagtaagtcgg  
 tagacttaggaacacatgllacaacacaactttaaasagacattccactattctgaagaaatgatacagtaaatcttggaaatggt  
 facaagcgtgaaatggccaaaatccgcacgacaataagcaataaacagcgggttgcctcaigaaattcccgcaatgacggftaa  
 tgaggctcgcggatcaggaaatgaaggccgftatttggcgaacaattgarteaataggagaagcgggaaglltaattgctggcg  
 ggallgagaatgctccaagcacctaaatfacaacgttttaattacgaacagaaagctacgatcgccttttctaagtatgat  
 gatggataaacggatgcttttagtggcaggcaatgggcttaactgctgaaaatgtggccgaaaagtatcagtaactagagaag  
 agcaagatcaatitctgacatcacaatfaaaagcagctcaagcacaagcagaaggafatcgcctgacgaanaagccccatfa  
 gaagtacaggaaacgcttgggagaagaatgnaaggatcccaatcagcagcgttggagaagctaggaacgcttaaacagttt  
 itaaagaagacggctactgtaacagcagggaatgcatcaaccatfaatgaggggcttgccttgaattatgcttcacaagaatg  
 ccgaagcacacggcttcttattagctattatcgagacagtggtgaaglcgglatiagaccagcctatagggaattcgcggat  
 lasagccatcaaaaacigttagcgcgaatcaactactacgggaagaaatgatctgtatgaatcaacgaagcattgacgca  
 ctcaatcgtgttccaaagagaactggttaccagaggaaaaggctaacattatgggtggcgglattcattaggctatcggaltg  
 gtgccacaggtgctcgttallaacgagtttaagtatcaatfaaatcaaaaagaaaagaatagaggtggcttcttattgatacggc  
 ggtggcttaggactcgtatgctactagagagaactcagcaaaaaaaacagccgalltatacaatgagctcctgagggaacgc  
 ctggcttctcttfaatgaaggccagatfctcgtgatacaaaaaagaatllgaaaatacggcittatctcgcagattgccaatcat  
 atgattgaaaatcaaatcagtgaaacagaaagtgccgatggcgggtggctlacatttaacagtggaacgaaactgatatttggtaacca  
 atggcgacagaagagcccagttaltcggcttggatgagttggcgaataatagcacaaggatttaaacagtgantcaacaac  
 gcttaattcgggtggacaaaatgfttttacgatgttgcagatcccagcactgattgataaactacaagtaagagaagcgggaagttt  
 tcaacaagcagagtttaagttatcctatcaltcgttaaacggggcggcggctaaagagatttgcataatcgtacttggatgaatcattg  
 tatctcgcacttttagtagatgtaaggatgcaatgggggcaataatgtaaacgctatgttggaaaggtgtggccgagttgtccg  
 tgaatggttggcggagcaaaagatttattcagttatfaangtaattatgccacggagctcggttgtacgatganaacggctattccag  
 ttacagtttaagtaaggggagcaatggccgggaaatgctgaaaaaattgttttagcttcacgctatgcttcatfagatccttaccg  
 gcagtcacgcataacaanggaatcatgaatggcattgaaagctgtagtttagctacaggaaatgatacacgcgctgttagcggctc  
 ttgtatgcttttggcgtgaagggaaggtcgtaccaaaggcttactagttggacgctggatggcgaacaaactaattggtaaatc  
 agttccgcttcttagccacgggttggcgggtcccaaaaagcttaccataatcacaagcagcctgattttagcagtgacggga  
 tgcanaagaaactaagtcgagtagtagcggctgttggttggcacaanaatagcggcgttacggcccttagctcgaaggaaatc  
 aaaaagpacacatggctctacaagcacgttcttagcgtatgacggctggagctactggtaagaagttgaggcagtcgctcaac  
 aattaaaacgcaaaaaacgatgaaccaagaccgagccatggctattitaatgatfaagaaaacaafaaaggaggtaaaaaa  
 catgacaattgggattgataaaatagtttttggccccccttattatattgataagcggcactggctgaagccagaatgtagacc  
 ctggaaaattcatttggatttggcgaagaccanaatggcgggtgaaccantcagccaagalattgacatttgcagccaatgccc  
 gcagaaagcagcttaccanaagataaaggaggccattgatattggtgalttgcggactgagtcagtaicgatgagtcanaaa  
 gggcggcagttgtctacalcgttaatggggaacaccttctcgtcctcttcaaaatcaaggaaagcttggtaacggagcaaca  
 gcaggcttacagttagctaaagacagtagccttaccatcagataaaaaagcttggctgtagcggcagatattgcaaaatag  
 cttaaattcggcgggtgagcctacacaaaggagctggggcgggttgcattgattgctagtgaaccgcgcaatttggcttaaaag  
 aggataatgtatgctgacgcagatatactatgactttggcgtccaaacaggccaccgctatcctatggtcagatgcttctgca  
 aogaaacctacatcaatctttgcccagcttgggatgaacataaaaaacgaacggcttgaatttgcagattatgatgctttagc  
 gttccataatcttaccanaaaatgggcaaaaagccttattagcaaaaatctccgaccaaacaggaagcagaacaggaacgaatt  
 tagcccggtatgaagaagfatcgtctatagctcgtcggtaggaactgtatacgggttcaatttctgggactcatttcccttag  
 aaaaatgcaacgccttaaccgaggcaatcaatitggttattcagttatggttctgtgtcgtcgaattttcacatggigaattag

Figure 92B

tagctgggtatcaaaatcattfacaaaaagaaacicatttagcactgctgggataatoggacagaactttctatcgtggaatgaagc  
eatgtttgcagaaactttaacacagacattgatcaaacgfttagaagaagaataaaatatagtatitctgctsttaafantaaccgticg  
ttctatcgaaacaaagagatctgcagctggtaaccatafagggaaticgaagcttgggcccgaacaaaaactcctcagaaagg  
atctgaatagcccgctgacacatcattcattcattgagttfaaacggctcaccgctggctgtttggcgggatgagagaagatt  
ttcagcctgatacagaftaastcagaacgcagaagcggctgataaaaacagaattgcccggcggcagtagcggcgggtggccca  
ccctgaccccatgcccgaactcaagaaggaaacgcccgtagccggatggttagtgggggtctcccattgagagatggggaact  
ggcagccatcaaaiaaaacgaaaggctcagtcgaaaagactgggccccttctgtttatctgtttgttcggggaacgctcctgagt  
aggacaaatccggccgggagcgggallgaaactgtgcgaagcaacggcccggggggggggggcggcagggacggcccacataaac  
tgccaggcatcaaaftaagcagaaggccatcctgacggatggccttttgcgtttctacaaactcttttgtttatitctaaatacatt  
caaaatagtatccgtcatgagacaataacccctgataaafgctcaataatattgaaaaaggagagatgagatfcaacattccg  
tctgccccttaticcttttttggcgaattggccttctgttttctcaccagaaacgctgggtgaaaagaaagatgctgagatca  
gttgggtgcacagatgggttaccatgaactggatcacaacagcggtaagatccttgagagtttcccccgaagascgtttccaa  
tgatgagcactttfaagttctgctatgtggcgggtattatcccgtgtgacggcgggcaagagcaactcggctgccgcatcac  
tattctcagaafgactgtgtgagtactaccagctcacagaaaagcaicttacggatggcatgacagtaagagaattatgagtgct  
ggcataaccatgagtataaacactggcccacitactctgacaaagatcgggggaaccgaaggagctaacgccttttgcaca  
acatgggggatcatgtaactcgccttgatcgttgggaaccggagcctgaatgaagccataccsaacgacgagcgtgacaccacg  
atgctgtgagcaatggcaacaacgttggcgaactatgactgggcaactactctagcttcccggcaacaattafagactg  
gatggaggcggataaaagttgcaggaaccacttctgcctcggccccttccggctgctgggttattgctgataaatctggagccgg  
gagcgtgggtctcggcggatcattgcaagcactggggccagatggttaagccctcccgtatcgtatctatcacgacggggagt  
caggcaactatggatgaacgaatagacagatcctgagataggctcactgattaaageattggtaactgtcagaccaagttt  
actcataatactttagattgattfaaaacttcaattfaaanaaggatcagggtaagatccttttgataatctcagaccaaaatcc  
ctlaacgtaggtttctgctcactgagcgtcagaccggtaaaaagatcaaaaggatcttcttgagatcctttttctgcgcgtaatc  
gtctgttcaaaaacaaaaaacaccgctaccagcgggtgtttgtttgcccggatcaagagctaccactcttttccgaaggtaact  
ggcttcagcagagcagataccaaatactgtccttctagtgtagccgtatgtagccaccactcaagaactctgtagcaccgc  
ctacataactcgcctctgaactctgttaccagtgctgctgcccagtggaagtcgtctitaccgggtggactcaagacgat  
agttaccgggataaaggcagcggctgggctgaacgggggggttcgacacagcccagcttgggagcgaacgacctacaccg  
aactgagataccctacagcgtgagctatgagaaaagcggccacggctccgaaagggaagggagacaggtatccggtaagcg  
gcagggctcggaaacagggagcgcacgagggagcttccaggggaaacggcctggtatcttatagtccctgtcgggtttccac  
ctctgactgagcgtcgtattttgtatgctcctcagggggggcggagcctatgaaaaacgcagcaacggcggccttttaacgggt  
cctggccttttgcctggccttttgcacatgttcttctcgtttatcccctgattctgtggataaccgtattaccgctttagagtgact  
gataccgctcggcagccgaacgaccgagcgcagcagtcagtgagcgggaaagcggaaagagcgcctgacgggtatttt  
ctccttacgcatctgtcgggtatttcacaccgcatatggctcactctcagtaaatctgctctgntccgcatagtfaagccagata  
cactccgctatcgtactgtagctgggtcatggtcggcccggacaccggcaaacaccgctgacggcccctgacggggctgtc  
tgcctccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagagggtttcaaccgtcaccgaaacg  
cgcgaggcagcagatcaaitcgcgcgcgaagggcgaagcggcaatgacattgacaccatcgaatggtcaaaaactttcgg  
cggatgagcagatagcggccggagagagctcaaticagggtgggtgaaatgtaaacagtaacgttaacgatgtcgcagagta  
tgccgggtgtcttatacagaccgtttccggogtggtgaacaggccagccacgtttctgcgaaaacggcgggaaaaggtggaagc  
ggcagatggcggagctgaattatcccaaacgctgggcacacaacatggcgggcaaacagctgtgctgattggoggtgcca  
ctccagctggcccctgacgcggctgcaaitgtcggcggatfaaacctcgcgcgataacatgggtgcccagcgtggtgg  
tgcagtggtgagaacgaagcggcgtcgaagcctgnaagcggcgggtgcacaatctctcggcgaacgcgtcagtgggctgac  
atlaactaccgctggatgaccaggatgccattgctgtggaagctgctgcactaatgttcggcgttattcttgatgtcttgacc  
agacaccctaacagatattttctccatgaagacggctacggactgggcgtggagcatctggtcgcattggctaccagca  
aatcgcgctgtfagggggccatfaagttctgtcggcggctgtcgtctggtgctggcfaaaatctcactcgaatcaaat  
tcagccgatagcggaaacgggaaaggcactggagtgccatgtccgggtttcaacaacacatgcaaatgctgaatgagggcatc

Figure 92C

ttccacatgcatgctgggtggccaacgatacagatggcgtgggcgcaatgcgcgccattaccgagtcagggtgacgggtggg  
cggataatcctggtagtgggatacagacgataccgaagacagctcatgtaatafcccgcogtaaccaccatcaaacaggatttcg  
cctgcigggggcaaacaggcgtggaccgcttggctcaactctctcaggggccaggcggggaaggccastcagctgtgcccgtct  
cactggtgaaaagaaaaaccaccctggcgcccaatacgcasaccgctctcccgcggtlggccgattcattaatgcagctg  
gcacgacaggtttccgactggaagcgggcagtgagcgcaacgcaattaatgtgagttagcgcgaattgatctg

SEQ ID NO:23

Figure 93




Figure 94




Figure 95




Figure 96




Figure 97




Figure 98




Figure 99




Figure 100




Figure 101




Figure 102






Figure 103B

gaagatgaatfaaaatagatatttctgctaffaataataaccgttcgttctatcgaacfaaagatctgcatictgcattcggcccttag  
ggggtaaaaaaacatgtgtgcgacctcttcaatftacfcagattaccgagcataatfocgfgtccggcaaacatcagccaa  
cctgtggaatttcgaattcctgcaatecctggagascgacctgaaagtggaaaagctggaggagaaaagcggaccsaactggagg  
aagaagttcctgcatgafcaaccgtgtagacacccagccgctgtccctgctggagctgatcncgatgtgcagcgcctgggtc  
tgacctacaaattfgaaaagacatcattaangccctggaaaacatcgtactgtgacgaaacaaaaagaacaatctgacct  
gcacgcaaacgcctgtcttccgtctgctgctgicagcaagggttcgagggttcagagatgttttggagcgttcaaggataaagaa  
gggtgttcagcgggaaactgaaagggtgacctgcaaggcctgctgagrcctgtaagaagcgtcttaccgggttcgagggtgaga  
acctgctggaggaggcgcgtacctttccalcacccaccfgaagaacaacctgaagaagggcattaafaccagggtgcaagaac  
aagtggagccacgacctggaaactgcatatcaccagcgtctgaccgctggaggcacgttggttccigpataaafacgaaccga  
aagascgcctaccagctgctgctgagctggcgaagctggatttaacatgglacagaccctgcaccagaaagagctgca  
gatctgcccgtgtggaccgagatgggctggctagcaaacctggatllgtagcggaccgctgatggaagttattctgggc  
actgggtatggcgcagaccgagttggtaagtctgcaaacctgttactaaatgtttggctggtgacgatcaltgatgacg  
tgtatgacgllatggcactctggagaaactgcaactgttaccgatgctgtagagcgtgggagcttaacgctattaacacctg  
ccggactatagaaactgtgttccctggcactgtacascaccgttaacgacacgtcctattctattctgaagaagaaggtcataac  
aacctgtctatcagcaaaaagctggcgtgaaactgtcaaacgcttctgcaagaggcgaatggtecaacaacaaaattatcc  
eggcttctccaagfacctggaaaacgcccagcgttctctccgggtgtagcgtgctgctggcggcgtcttactttccglatgcccage  
agcaggaaagacatctccgaccagcgtgctgctccctgaccgacttccatggtctgggtcgttctagctgctgcttctccgctg  
tcaacgatctgcccaccctgctggcggagcgggagcggagactccaattctatcattagctacatgcaacgaaaacgat  
ggtaaccagcggaggaacagcggccggaagaactgctgaactgtatcagccgaatggaaaagatgaatcgtgaacggcfta  
gcpactccacctgctgctaaagcgtcatggaatcgcagtaacatggcacgttccactgcaacctaccagatggcgat  
ggctgggtgctgcccagactacgactgaaaaccgcatcaaacctgtctgattgaoccttcccgattaacagcgtgatgtatgt  
ctaactgcaactggtaacatagggaaactgaaagctgggcccgaacsaanaacatcacaagaagagatctgaatagcggcgt  
cgaccateateateateatfaggtfaaacgggtctccagctggctgttttggcggatgagagaagatttcagccctgatacaga  
tfaaatcagAACgcgaagcggctgataaaacagaattggcctggcggcagtagccgggtggtccacctgaccacctgccc  
aactcagaagtgaaacggctgagcggatggtagtggggctcccccagcgaagtagggaaactgcccaggcatcaaatfa  
aacgaaaggctcagctgaaagacggccttctgtttatctgttggctgggagcgtctccctgagtagacaatccgcccgg  
gagcgggttgaagctgcaagcaacggcccggagggtggcggcaggagcccgcataaacctgcccaggcatcaaatfa  
agcagaaggccactgcaaggatggccttctgttcaaacctcttggttatttttcaataacatcaaatatgtatccgctea  
tgagacaataacctgataaactgctcaataatctggcgaatagcgaagaggcccgcaccgategcccttccaacagctggc  
agcctgaatggcaatggcgcctgafgggtattttctctacgcacatctgtcggatttccaccggcatalggctcactcagta  
caatctgctctgatgcccagatagtaagccagcccgcacaccggccaacaccggctgacggagcttagtaagccctcctgat  
tttaatgggatgtgcatcttccaaactatctgcatascaagaasaagccagccttcatgatatactcccaattigttagg  
gcttatatgcaagcttaaaaataaaaagcagactgacctgatagttggctgtgagcaatfatgtgcttagtgcacttasegcti  
gagftaaggcccggcggaaaggcggctggctggaocgaatggttagacattatggcgaactacchtggtgatctgccccttcc  
gtagtggcaaatcttccaaactgatctgctgcccggaggccaaagcgaftctctctgtccaagataagcctgcttagcttcaagtai  
gacggcctgatactggcggcaggcgcctccattgcccagctggcagcagatctctggcgcgattttggcgggttactgctgct  
gtaccaaatgcccggacaacgtaagcactacattcgtctatcgcagcccagctggggcggcggagtccatagcgttaagggttca  
tttagcgcctcaaatagatcctgttcaggaaccggatcaaaagagttcctccggcgtggactaccaggcaacgctatgttctcti  
gcttttgcageaagatagccagatcaatgtcgtatctgctggcctgaaatgatacctgcaagaatgtcattgctgctgcaatctcca  
aatgcaatctgctgcttagctgataacgcccaggaatgatgtcgtgctgcaacaacatgggtacttctacagcgggagaatct  
cgtctctccaggggaaagccgaatttccaaaaggtcgttgatcaaaagctcggcggctgttctacaaagccttaccggcaccgta  
accagcaaatcaatcactgtgtggctcaggcccccactcgtggagccgtacaaatgtacggccagcaacgtcgggtc  
agatggcgtcgtgatgacgcaactacctctgatagttagctgatacttggcgtaccggcttccctcctgatgttaactttgttt  
aggggcactgcccctgctgtaacatcgttctgctcetaaacatcaaacatcgaaccacggcgttaacggcctgctgcttggat

Figure 103C

gcccagggcctagactgtaccccaaaaaacagtcataaacaagccatgaaaacgccactgcgccgtaccacogctggctt  
ggtaagggtctggaccagttgcgtgagcgcatacgcacttgcattacagcttacgaaccgaacaggcttatgiccactgggttc  
gtgccctcatccggttccacgggtgtgcgtcacccggcaacctggggcagcagcgaagtcgagggcatttctgctggctggcga  
cgagcgcgaagggttccggtctccacgcacogtcaggcattggcggccttgcctgttcttctacggcaagggtgctgtgcacggatctg  
ccctggcttcaggagatcggagaccctcggccgtcggggccttgcgggtgggtgctgaccocggatgaagtggtcgcacfcct  
cgggttctgggaaggcgagcagctgttctgcccagctctglatggaacgggcatgggatcagtgagggtttgcaactcggg  
gtcaaggatctggtatfcgatacaggccacgatcctgctggggagggcaagggtcccaaggatcggccttgaigtaccoga  
gagcttggcaccocagctgcgcgagcaggggaatfaatccacgggtttgctgccocgaacgggctgtctgggtgtgctag  
ttgtatcagaatcgcagatccggcttcagocgggttgcggcgtgaaagcgcctatttctccagaatggccatgatititccccacg  
ggaggcgtcactggctcccgtgtgtcggcagcttgattcgataagcagcagcctgttccaggctgtctatgtgtgactgttga  
gctgtacaagttgctcagggttcaattcctgcttagttgcttcttacttgggttccacctgtctatlaggtgttacatgtctgttcat  
ctgttaccatgtcagatctgtctatgttgaacagcttgaatgcaacaaacaclogfaaaagctctgatgtatctatcttttaccaccgtt  
ttcatctgtgcatatgacagtttcccttctgatgtgaacgggtgaacaggttctctacttttggttgtagctttagcttccactgatagat  
acaagagccataagaacctcagatccctccgtatttagccagatgttctctagtggtgtcgtgttttggctgagccatgagaac  
gaaccattgagatcacttactttgcatgtcactcaaaaatttgcctcaaaactgggtgagctgaattttgcagttaaagcagctgtgt  
agtggttttcttagtccgtatgtaggtaggaatctgatgtaatgggtgtgtgtattttgtccaccatcatttatactgggtgttcaangtc  
ggtttacgagatccatttctctatctagttcaacttggaaaatcaacgtatcagctcggggccctcgccttacaaccaccaatttcatat  
tgctgtaaggtttzaacttcttacttattgtttcaaaacccattggtaagcctttaaactcaggtgttattttcaagcatfaacatga  
acttaaatcactcaaggcctaactctatatttgccttggagtttcttttgggttagttctttaaataaccactcaaaactctcagat  
ttgtttcaaaaagacttaacatgttccagattatattatgaatttttaactgganaagataaggcaatatactctcactaaaactaat  
tctaattttccttggagaaacttggcagatgtttgcccactggaaaatctcaagcccttaaccaaggattcctgatttccacagttctc  
gtcatcagctctctgtgttgccttagcfaatacaccataagcatttccctactgatgttcatcctgagcgtattgggtataagfgaac  
gataccgtccgttcttcttctgtaggggtttcaatcgtggggttgagtagtccacacagcataaaattagcttgggttcatgtccgtt  
aagtcataagcgaactaactcgtatgttcttgggttgaanaaactaattcagacatacatctcaantggcttaggtgatttatacactat  
accantggagtggtcctagtcattgataaactactsgtcttcttcttgggttgggtatctgtaaattctgctagacccttctgtgaa  
aacttgtatattctgctagaccctctglaaattccgctagucccttctgtgttttttggttatattcaagtggtataattatagaataa  
gaaagataaaaaaagataaaaaaagataagatccagcccttggataactcactactttagtcagttccgcagattacaaaagga  
tctcgcanaacgctgttctctctacnaaacagaccttaaaacccnaaggcttaagtagcaccctcgaagctcgggcaaatc  
gctgaatattccttttctccgaccatcaggcaactgagctcgtcttcttctgacattcagttcgtcgtcgcctcagggctctggca  
gtgaatgggggtaaatggcactacagggcgcctttatggattcagcaaggaaactaccataatacaagaaaagcccgtcacg  
ggcttctcaggggtttatggcgggtctgtatgtgtgctatctgacttttctgttctcagcagttcctgccctctgatitccagct  
gaccactcggatataccctgacagggtcattcagactggctaatgcacctagtaaggcagcgggtatcacaacaggctta

SEQ ID NO:24

Figure 104




Figure 105




Figure 106





Figure 107



MCM330 - FRT-cm-FRT-gi1.2-KDYI at attTn7

10356 bp

Figure 108A

1-

caagaaaaatgcccccgttacgcaggccatccatttactcaaccglaaccgattitgccagggtacgcggctggtaaacgtcg  
gtgcccttggatcagcgcgcacatggtaagccagcagctgcagcggaaacgggtgtagagatcgggtgcaatcacctctccacatgc  
ggcactctgatgatgtgatgtatctgctacttacaaaaccgcacctctgatcggcgaaagacatacaactgaccgccagcgcgc  
gaactctcaatgttgattcagttttccagcaattcgtgttcgggcaacaacaalaaccggcatalcggcaicaattagcgc  
agcgggaccgtgttccagttccagcagcgttaggctcagcgtgaatgtaagagatcttccaaactcaatgcgcctccagcgc  
gattgggtacigatcggccagcggccaggaacagcgcgtgatgtttgtcaggaatctctgccagcgcctcaatgcttggct  
gagacagcatctgctcaatcagcgcggcagcgcctgcagaccatgcacgatgtcatgttcaafggaggccatccagacccttca  
ggcagagacagctcggccaccagcacaacagcacagttaactgagtggtgaatgctttagtggatgccagcgccttctgtacc  
cgcgttggctatlagcggcagatcggatcggcaccagagaagaaccggaaacgttacagattgccagtgaaaccaaggtaac  
ccagctcttgcagacagcagcggccagcgggtatcggcgggttccagactgtgacacagatgcccttcccaaccagtggc  
cagcctatacgtacggcagttlaagggttacacctataaaagagagagcggcttactgtctgtttggatgtacagagtgatatt  
gacacggcggggcagcggatgtggtatccctggccagtgcaagctcgtctgtagataaaagtctccggtaacttaccgggtg  
gtgcatatcggggatgaaagctggcgcctgatgaccaccgatatggccagtggtccggctccggtatcggggaaagaggtggct  
gatctcagccaccggcaaaatgacatcaaaaaccattaacctgatgtctgggaaatataatgtcagggcatgagattatcaaa  
aaggatctcactagatcctttcagctagaaagccagctccgcaaaacggctgctgaccccggatgaaatgcaactactggcct  
atctggacaagggaaaacgcagcgcgaagagaagcaggtgactgtcagtgggcttaccatggcgaatgcaactggcgc  
gtttatgacagcaaggcaaccggaattgcccagcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
ggcttctcggcggcaaggatctgatggcagggatcaagctctgacaaagacaggtatgaggaatcgttccatgatga  
acaagatggatgcaagcaggctctccggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
gctcctgatccggc  
actgcaagacggggcagcggc  
cggggaaggactggc  
tcatgctgatgcaatggc  
gagcagctactcggatggaaagccggcttctgcaatcaggtatgctggcgaagagcagcagggcggcggcggcggcggcggc  
gttccggc  
ggaaaaatggc  
gatattgcaagagctggc  
cctctatcggc  
cacaccgcaacagggtggc  
tcatgagacaataaccctgataaatgctcaataatagcacgtgaggaggccaccatggccaagtggaccagtgccggctccgg  
gctcaccggc  
gctggaaatcagycagttcancctgttgatagctactaagctctcagtttccagctactaagcctcctatgttaccgtaact  
ctcctgttaccgaactaaaccctcctgctaacgtaactaagctctcctgctaacgtaactaagcctcctcctatgttaccgtaact  
tcaigtitgaacaataaataaataaataaataaataaataaataaataaataaataaataaataaataaataaataaataaataaataa  
ctttaaagcttttaaggttttaacgggtgtggacaacaagccagggtatgtaacgcactgagaagcccttagagccctcctcaagcaa  
tttccagtgacacaggaacacttaacggctgacagcctgaatctcagatctgttttccactctctcactctcactctcactctcact  
ctgtgaaagacgaaggaagtcocggagccatctgcccggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
agtttggc  
actcagccctggaaatgtaaccggcaacacacggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
gtcagacagcggc  
gtgattaaactttataccggcttcttctgtaaggtgacggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
agccttctctcgaazcacaaggaagcactcactgataaggtcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
ataatgtctcctgggaggtatcaaaagcattgtttgttggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
gaaatgacagtttatgacagagagatnaaagcttcaagctgatttaataaagcgttgatattcagtcacttaacaacattataacg



Figure 108C

gggattaactttatggatgggcgataaasgaatgggtcagaacagtaaaactagtccagaaggtaaaaaattggatgattcge  
 atatgccaganaacttggaaaatataacagaactcgcacatgcaanattcagattatggatggactatcfaacttagatcgcitaca  
 cgagactcatgacgattscagocagatattttagctcttggagggaaatgactgtacctgtcaaaagtatccgaaatcacag  
 aagttagagatgcagttgccacaantagacgttcccttagaaaaaanaactaaagaatctgggtccgatacgaacctcccgtaca  
 actagcttattggatgattgccagaccitaaaaggagttctacttgccttaaacctgggtctgggtggttatgacgccattgcagtgat  
 tactaaagcaagatgtgatcttagggctcaaacccgcaatgacaaaaattttctaaaggttcaatggctggatgtaacacaggtga  
 ctgggggtgttaggaaagaaaagatccggaaacttatttgataaataactaaaggtagctgcatgcagaatcggccctaaaggag  
 gaaaaaaaatgacogttacacagcatccgttaccgcaaccgtcaacatcgaacccttaagtattgggggaaaaaggacacg  
 aagttgaatctgcccaccaatcgtccatcagtgactttatcgaagatgacctcagaacgttgacctctgctggctactgcaacct  
 gagttgaacggcaactttgtggttaaatgggagaaccacacagcatcgacaatgaaagaaacaaaaattgtctgctgacacac  
 gccaatlaagaaaggaaatggaaatcgaaggacgctcattgccacattatcicaatggaaactccacattgtctcggaaaata  
 cttctacagcagcttgggttagcttctcctcctgctgctggcttgcattggtctctgcaattgctaaattataccaattaccacagtc  
 aacttcagaataatcagaaatgcaagaaaggggtctggttcagctttagatcgttcttggcggatacctggcctgggaaatgg  
 gaaaagctgaaatggtcattcattggcaglacaaatcgcagacagctctgactggccatcagatgaaagcttggctctagtt  
 gtcagocgatataaaaaggatgtgagttccacacagggatgcaattgacctggcaaccctcgaactattasaagaaagaaatga  
 acatgtcgtaccaaagagattgaaatcagctgaaagcattgtgaaaagatttgcacaccttgcaaaaggaaacastgatgg  
 attccaactcttccatgccaatggttggactcttccctcactatcagaaatgacacttccaagcgtatcactcagttggtgco  
 acaccattaatcagtttaccggagaaacaaactgttgcatacaggtttagatgaggtccaaatgctgtgttactacttagctgaaaat  
 gactcgaanactcttgcatttatataaattgtttgctcgttctggatgggacaagaaatttactactgagcagctgaggcttcc  
 aaccatcaatttgaatcactaactttactgcacgtgaattggatcttggatggcaaaaggatgttgcagagtgatttaactcaugl  
 cgggtcaggcccaagaacaaaacgaatctttagatgacgcaaaagactgggtctaccaaaaggaaatagatcaattcctgcatc  
 ccttaggagggtaaaaaaaatgactgccgacaacaatagatgccccatgggtcagatctagttaccgcaaattagtgcaaaa  
 caaacaccctgagacatttggaaagatttctgaaatattccattacaacaagacctaataccgactagtgagacgtcaaa  
 tgacgaaagcgggaaacatgttttctggtcatgataggagcaaatgaatgaatgaaatgtattgtttgattgggac  
 gataatgctattgggtccgggtaccagaagattgtcatttaattgaaaaatgaaaagggttactacatcgtgcactctcctctt  
 atttcaatgaacaagggtgaattactttacaacaagagccactgzaaaasataacttccctgatcttggactaacscatgctgctc  
 tcatccactatgattgatgacgaatfaggttgaagggttaagctagacgataagattaaggcgcctattactgctggcgggtgana  
 aactagatcatgaattagggtatccugaagatgaactaaagacaagggttaagttcactttttaaacagaatccattacatggcac  
 caagcaatgaaccatgggggtgaacatgaaattgattacatcctattttataagatcaaacgctsaagaaaacttgactgcaacccaa  
 acgtcaatgaangtagagacttcaaatgggttcccaaatgatttgaactatgtttgctgacctcaagttacaagtttacgctt  
 gtttaagatatttgcgagaatfacttattcaacttgggggagcaattgattgaccttctgaagtggaaaatgacaggcaaatcata  
 gaatgctataacaacgcgtctacaataaaaaaggcagcagatgacgtgctttttcttggggcc

SEQ ID NO:25

Figure 109




Figure 110A

I-

gtgcggccgcaagcttgcgacggagcctcgaattcggatccctgcagttagacatacaicagctggtaatcgggaaagggtca  
 atcagecagcagttgatgcgggttccagtcgctagctctggggcaccagaccatcgcatactggtaggtgacagtggaaca  
 cgtgccatgffaactgcgaattccatgaacgcittaggcagcagggtggagtcgtaacgcgttcacgattcatctttccattcgg  
 cglcgatcagtttacgagttcttcggggcctgttcctcgetggtaccatcgtttcgtgcatgtagctaatgatagaattgtagtc  
 tggccacgttcagctcgcgcgagaggtggccagatcgttcacaggcgggaagafaacgcagctagaacgcaccagaccat  
 ggaagtcggcagggaacgcagcgcgtggcggagatgtcttccctgctgctggcatacggaaagtaagacggcggccagcag  
 cgtlacaccggaggaggaaacgctggcgtttccagggtactggagaaagccgggafaaftttgttggaccattcgcctctt  
 gcagaaggtcttgcacagttcscgccagctttcgtcagafaggacagggtgtatgaecttctcttcagaaatagaataggacgt  
 gctgtaacgggtgtgtagcagtgccaggaaacacagttcatatagctccggcagggtgttaatagcgtlaacgtcccagcgtcta  
 cagcatcggtaacagttgcaattcgtccagagtgccataaacgtcacaacgctcagatgacgctaccagaccaaacattta  
 gtaacagcttgcgacatcaccaactcgggtctggcgcataccagtgccagaataaacctccatcagcgggtcgcgt  
 acaaaatccagtttctagccaggccactcgggtccaccagcgggacagatctgcaactcttctggtcagggtctgtaccat  
 gttaaaatccagctcgcagctccagcagcagctggtagtgcgggttctttcgggtcgtatttatccaggaaaccaacgtccctccag  
 accggtcagacgcgtgtgatagtgccagttccagggcgtggctcactgttctgcaacctgggtatlaatgctcttccagggtgttct  
 fcaggtgggtgatggaaaaggtaacgcgcctcctccagcaggttctcaccctogaaacccaggtaaagacgcttcatacaggctca  
 gcaggccttggacgtcacccttcagttcaccgctgaaccacccttcttatccttgaacgcctcaaaaacatctgagaaacctcga  
 aaecgtgtgacgcagcagcggaaagacagagcgggtgctgctcaggtcagattgtctttttgtttcgtccagcagtaacgatg  
 ttccagggtttaaataatgctcttttcaaatgttaggtcagaccaggcgtgcacatcgtcagctccagcagggacagc  
 ggtcgggtgtctacacgggtgatcagcagcgaactctctccagtttggctgctgctcaccctcagcaggttctcctccagcttccac  
 ttcagggttgcaggaatcgaatccacagggttggctgtagaggttgggaacgacgggaattatgctcgttaatctgagtaaa  
 ttgagaagaggtgcacacatggtatatactctctttaaagtaaaacaaaatatttctagagggggaattgtatccctcacaattcc  
 cctatagtgagctgtataatlcgggggagcagatcctgacccagcagcagcagcagcagcagcagcagcagcagcagcagcagc  
 aggttgcgttgcctggcctataicgccagacatcaccgaggggagagcagcagcagcagcagcagcagcagcagcagcagcagc  
 gggttgggtatggtggcaggccccgtggcgggggactgttgggcccctatctcttgcagcaccatctcttggcggcgggt  
 gctaacggcctcaactactactggtgtctctaatgacaggagtgccataaggagagcgtcagatccggacacacatc  
 gaatggcgcacaaccttccgggtatggcatgtagcgcocgggaagagagcaatcagggttggtaatgtgaaaccagtaac  
 gttatacagatgctcagagatagccgggttctctatcagaccgttcccgctgggtgaaccagggccagccacggttctgcgaaaa  
 cgggggaaaagtggaagcggcgatggcggagctgaatfacatcccaaccgctgggcacaacaactgggggcaaacagct  
 cgttctgattgggttgcacctccagctcggcctgcagcggcggcgaatgtcggcggcgaatgaaatctcggccgatca  
 actgggtgccagcgtgggtgctgagatggtagaacgaagcggcgtcgaagccigtgaagcggcgggtgcacaatctctcggc  
 aacggctcagtgggctgatcaactatcctcgtggtgacagggatgccattgctgtggaagctgccctgcaataatgtccggc  
 gttattcttgatgctctgaccagacacccatcaacagatatttctccatgaagacgggtacggcagctggggcgtggagcatctg  
 gtcgcaattgggtaccagcaatcggcgtgttagcgggccattagttctgctcggcgtctcggctgggtggctggcagata  
 aatctcactcgaatcaatcagccgatagcggaacgggaaggcagctggagtgccatgctcgggtttcaacaaccatgc  
 aatgctgaatgaggccatcgttccactcgtatgctgttggcaacagatagatggcgtggcggcgaatgctcggcgcattaccg  
 agtccgggctgcgcttggctgggafatctcggtagtgggafacgacgataccgaagacagctcatgtatataccggcgttaac  
 caccatcaaacaggattttcgcctgctggggcaaacaccagcgtggaccgcttctgcaactctctcagggccaggcgggtgagg  
 gcaatcagctgttcccgtctcactggtgaaaagaaaaccacctggcggcccaatagcaaacggcctctcccggcgggtt  
 gccgaticatlaatgcagctggcaagcaggttcccgactggaaagcgggcagtgagcgaacgcaatlaatgtaagttagct  
 cactcattaggcaccgggactcgaaccgatgcccctgagagccttcaaccagctcctctccgggtggcggcggatgac  
 fatcgtcgcgcaatgactgtcttctatcatgcaactcgtaggacaggtgccggcagcgtctcgggtcattttcggcaggga  
 ccgcttccgtggagcgcgacgatgatggcctgctgctgggtatcgaactctgcaacccctcgcgaagccttctcactg  
 gtcccgcacacaacgtttcggcgagaagcaggccattatgccggcatggcggcccccgggtgctcgtatgctgctcctg



Figure 111A




Figure 111B




Figure 111C




Figure 112A







Figure 112C

ctgcacaactctccagtagtggaactggttggacccgcgaalacctggagcagcgggitttaacgttaaggacctctccctg  
ccgggcaacgcctctgtaagctcaacgcgtetacaataaaaaaggcagtcagatgacgtgcttittctgtctaga

SEQ ID NO:27

Figure 113A



MCMB82 - pTrcKudzuMMK(mazei)  
6848bp

Figure 113B


glttgacagcctatcactgactgcacgggtgcaccaatgcttctggcgtcagggcagccatcggaaagctgtggatggctgtgacgg  
tcgtaaatcactgcataatctgtctgctcaaggcgcacccccgtctggataatgtttttgcccgcacacataaacggctctggca  
aatattctgaaatgagctgtgacaatfaalcafcceggctcgtataatgtgtggaattgtgagcggataacaattcaccacaggaaac  
agcggccgctgagaaaaagcgaagcggcactgctcttaacaattatcagacaatctgtgtgggcactcggaccggaattatcgat  
taactttatfataaaaaaifaagagggtatataatgtatcgaffaaataaggaggaataaaccaigtgtgacgacctctcaatta  
ctcagafaacggagcataatcccgctcgtccgcaaaactatcagccaacctgtggaatttgaattcctgcaatccctggagaac  
gacctgaaagtggaasgctggaggagaagcggaccaaaactggaggagaaggtcgcctgcatgatcaaccgtgtagaacccc  
agccgctgtccctgctggagctgacggacatgtgcagcggcctgggtctgacctacaattgaaaaagacatcattaagccct  
ggaaaacatcgtactgclggacgaaaaaagaaacaaactgscctgacgcacaccgctctgtcttccgctcgtcgtcgtcag  
cacgggttcagggttctcagatgtttttagcggcttcaaggataaangaagggtgttccagcgggtgaactgaaagggtgacgtccaa  
ggccctgctgagcctgtatgaagcgtttaccctgggttccagggtgagaacctgtggaggaggcgcgtacctttccatcacc  
acctgaagaaacccigaaagaaggcaftaataccaagggttcagaaacaaagtgcacggccctggaaactgccataicaccag  
cgtctgcaccgctctggaggcactgtgttccctggafaaatacgaaccgaaagaaccgcatcaccagctgctgtctggagctggc  
gaaagctggatttaacatfgtaccagaccctgcaccagaaagagctgcaagatctgtcccgctgtgtggaccgagatggccctgg  
ctagcaaatggtattgtacggcagccctgatggaaagttaattctggcactgggtatggccagaccggcagtttgggtgaa  
tgtcgcgaagcgttactaaatgtttgctgtgtgacgatcagatgacgtgatgacgttattggcactctggaccgaaactgcaa  
ctgttccagatgctgtagagcggctgggacgttaacgctatfaacaccctgcgggactalalgaactgtgttctggcactgtac  
aacaccgttaacgacacgctctatctatcttggaaagagaaaggtcatalaacacctgtctatctgacgaaagcgtggcgtgaact  
gtgcaaaagccttctgcgaagggcgaatgttccaaacaacaaatataccgcttctccaagtactgtgaaacgccagcgtt  
tctcctccggctgtagcgtgctggcggcctctacttctctgtagcagcagggaaagacatctccgaccacggcgtgctg  
cctgaccgactccaaggctgtgtggtcgttctagctgctglatcttccgctgtgaaacgatctggccacctctgcccgggagctgg  
aacgtggcggagactaccaattctatcattagctacatgcacgaaaaacgatggtaaccagcggaggaaacggcccggaaagactg  
cgtaaactgtagcagccgaatggaaaaagatgaatcgtgaacggctgtagcactccacctgctgcttaaaagcgttcatggaa  
atcgcagttaacatggcagccgaatggaaaaagatgaatcgtgaacggctgtagcactccacctgctgcttaaaagcgttcatggaa  
catalcaaacctgtgctgattgaccttcccgattaacccagctgatgtatgctaacgtcataaaggagglaaaaaaacatggtatc  
ctgttctgcccgggtaagattacctgttccggtaacacggcctgattatggcgaacactgcaattgctgtgctggctggaactgc  
gtaccctgttccgcccgaactcaatgactctatcactatcagagccagatcggccaccggctgtgattcgaanaagcacc  
ttatgtgtctgcccgttaattgagaaaatggcgaatctatctctatfaaacgggttttcttggaccgtcgtatccggacatcccgggt  
cccgtctgggtgtagcagccgagccgttactatcggctctatgttggctgctgaaacgagctgttccgcttggcctcagcctgcaaga  
aatcgtctaaactggccacgaaatcgaatfaaaataggggtggccgctcccaaccgatacgtatgtttctaccttggcggc  
gtgtgtaaccatcccggaaactgcaaacctgaaaactccggactcggcattgtgaltggcgaataccggcgtttctctccacca  
naaggttagtagctaacgtlacgicagctgcccgaagctaccggatgtgacgaaccgctgatgacctctattggcaaaatctct  
cgtatcggcgaacascgttctgtctggcgaactacacatccatcggccgctgatgaacgtcaaccagggtctctggacgcc  
ctgggcgttaacatcttagaacgtgagccagctgactatccgctctgtgcccagggtgctgttggcgtataaatcagggcggctg  
gcggcgggtggctgtatgttgcctgacgctccgaaaaatgcaaccaagtgggcagaagcggtagcagggcctggcggta  
naagtagctatcactaaaccgaccgagcaaggctgaagtagatfaangcttagttaaagttaaacggctctcagcctggcgtgttt  
ggcggatgagagaagatttccagccgtatcagatfaaatcagaaccgcaagcggctgtataaaacagaaatttgcctggcggc  
agtagcggcgggtggctcccactgaccocatgccgauctcagaagtgaaacgccgtagcggcgtatggtagtggggctcctccc  
tgcgnagtagggaaactgccaggcaataaataaacgaaaggctcagtcgaaagaciggccttctgtttatctgtgtgtgctg  
gtgaacgctctcctgagtaggacaaatccggcgggagcggatgaaactgtcgaagcaaccggcccggagggtggcgggca  
ggaccggccgcaataactgcccagcctcaataaagcagaaggccatcctgacggatggcttttgcgttctacaacctttt  
gtttattttctaaatfacatcaantatgtatccgttaaccggaaattgccaagcggggcggccctctgttaagggttggaaagccctgc  
aaagtaaacctggatggcttctcggcccaaggatctgatggcgcaggggatcaagcctgatcaagagacaggatgagatc  
gttctgcatgatgaaacagatggattgcacgaggttctccggcggccttgggtggaggaggctatctggctatgactgggcacaa

Figure 113C

cagacaatcggctgctctgatgccgctggtccggctgctcagcgcaggggcgcccggttcttttgtcaagaccgacctgctccg  
 gtgccctgaatgaaactgcaagacgagggcagcgcggctalcgtggctggccacgacggggcgttccctgcgcagctgtctcgac  
 gttgtcactgaagcgggaaggactggctgctattggcggaagtccggggcaggatctctgtcctcaccctgtctctgcc  
 gagaaagtatccatcatggctgatgcaatcggcggtgctcatacgcitgatccggclacctgcccattcgaccaccaagcgaaa  
 catcgcacagcggagcacgctactcggatggaagccggctctgtcgtacaggatgatctggacgaagagcatcaggggctcgc  
 gccagccgaactgllccaggtcaaggcggagcatgccgacggcgaggatctcgtcgtgacccatggcgatgctctgtg  
 ccgaatatcatgggggaaaatggccgcttttctggattcctcactgactggcggcggctgggtgtggcgaccgctacaggacatag  
 cgttggctaccggtgatattgctgaagagcctggcgggcgaatggcgaccgctccicgtgcttaccggatcgcgcctccgat  
 tcgcagcgcacgccttctatcgcctctgtgacgagttctctgacgcgatgacaaaaatccctaacgtgagtttctgctcactgagc  
 gtcagaccgccgtagaaaaagatcaaggatctctgtgagatccttttttctggcgtaaatctgtctgtgcaaaaaaaaccacc  
 gctacagcgggtggttgggttggccggatcaagagctaccaactctttccggauggtactggcttcagcagagcgcagatacca  
 atactgtctctctagtgtagccgtgtagggccaccaactcaagaactctgtagcaccgootacatactcgtctctgtaactctgtt  
 accagtgggctgctgccagtgccgataagctgcttaccgggttggactcaagacgatagttaccggataaggcgcagcggte  
 gggctgaaagggggggttcgtgcaacagcccagctggagcgaacgacctacaccgaactgagatacctacagcgtgacta  
 tgagaaagcggccacgctccggaaaggagaaaggcggacaggtatccggtaagcggcaggggtggaaacaggagagcgc  
 cgaggggagcttcaggggggaaacgcctggtatcttatagctctgctgggttccgccacctgtgactgagcgtgatitttgtgat  
 gctcgtcaggggggggggagcctatggaaaaacgcccagcaacgccccttttaccgggtctgctggccttttctggcctttgtctca  
 atgttcttctcctcgcttalcctcctgattctgtggaataaccgtaftaccgctttttagtgagctgataccgctcggcgcagccgaacga  
 ccgagcgcagcagctagtgagcggaggaaagcggagagccgctgatgctggtatttctccttaccgcatctgtgctgggtatttcc  
 accgcataatgggtgcaactctcagtaacaatctgctctgatgccgcalagflaagccagttatacactccgctatcgtctacgtgactgggt  
 catggctgcccggacaccggcaaacaccgctgacggcccctgacgggcttctgctcctccggcatccgcttacagacaaa  
 gctgtgaccgctctcgggagctgcatgtgicagagggtttaccgctacaccgaaacgcgcgagggcagcagatcaatctgcgc  
 gcgaaggcgaagcggcatgcaftttacgltgacaccategaaatgggtgcaaaaaccttccgggtatggcatgatagcgcgggaa  
 gagagtaaatcagggtgggtgaatgtgaaaccagtaacgttatacgaatgctgcagagatgcccgggtctctatcagaccgtttcc  
 cggctggtgtaaccaggccagccacgtttctgcaaaaacgcccgggaaaaagtggaagcggcggatggcggagctgaatfacattc  
 ccaaccgctggtgcacaacaactggcgggcaaacagctgctgctgaitggcgttgcaccctcagcttggccctgcaacgcggc  
 tgcgcaattgtcggcgatfaaatctcgcgcgcgatacaactgggtgccagcgtgggtggtgctgatggtgagaaagcggcgtc  
 gaagcctgtaaaagcggcgggtgcacaatctctcgcgcaaacgcgtcagtggtggctgatcattaactatccgctggatgaccaggat  
 gccallgctgtggaagctgctgcaactatggtccggcgttatitctgatgctctgaccagacaccatcaacagtallattitctcc  
 catgaaagacggtacggcactggggcgtggagcatctggtcgaatgggtcaccagcaaatcgcgctgttagcggggccattaag  
 ttctgtctcggcgcgctgctgctggctggctggcataaatatctcactcgcatacaatcagccgatagcggaaacgggaaggc  
 gactggagtgccatgtccgggttcaacaaccatgcaaatgctgaatgaggggcactcgttccactgctgatgctgggttgcgaacg  
 atcagatggcgtggggcgaatgcgcgccatlacegagtcgggctgcggcttgggtgcggatactcgggtatgggatacgcac  
 gataccgaagacagctcatgtatataccgccgcaaaccaacatcaaacaggatttccctgctggggcaaacagcgtggac  
 cgttctgcaactctcagggccagcgggtgaaggggcaatcagctgttgcctcactggtgaaaagaaaaaccaccctg  
 gcgcccaaiscgcaaacgcctctcccccgcgctggccgattcattaatgacagctggcacgacagggttcccgactggaagc  
 gggcngtgagcgaacgcaatgagtagcgcgaattgatctg

SEQ ID NO:28

Figure 114A



MCM376 - MKK from *M. mazei* archeal Lowerin pET200D  
6647bp

Figure 114B

aaggggcagctcaacgatccggctgctaacaagccgaaaggaaagctgagttggctgctgcccaccgctgagcaataaciag  
cataaccoccttggggcctetanaacgggctcftgagggagtttttgcgaaaggagggaactafatccggatatacccgcaagaggccc  
ggcagtaaccggcalaaccagccatgcccacagcatccagggtgacgggtgcccggagatgacgulgagcgcattgftagattc  
atacacgggtgectgactgcttagcaatttaacigtgataaactaccgcalfaaagcttatcgatgataagctgtcaaacatgagaa  
ttaattctgaaagacgaaaaggccctcglalacgccatititaaaggttaatgcatgataanaatggttcttagacgtcagggtgca  
cttttggggaaatgtgcccgggaacccctatttgitatftttctaataacatcaaatatgtatccgctcatgagacaataaccctgat  
aaatgcttcaataataitgaaaagggaagagatgattgaaacagatggattgcacgcaggcttcccggccgcttgggtgggagag  
gctattcggctatgactgggcacaaactgacaatggctgctgatgcccggctgctcaggccaggggggcccgggt  
ctttttgcaagaccgacctgctcgggtgcccgaatgaactgcaaggacgggcaagcggcctatcgtggctggccacgacgg  
ggcttcttgcgcagctgctcgaactgctcactgaaagcgggaaaggactgctgctatggggcgaagtgcggggcaggat  
ctcctgtcactcaccctgctcctgcccagaaagatccatcatgagcctgatcaatggcggcctgcatagccttgaaccgctac  
ctgccattcggaccaccaagcgaaacatcgcacggcgggacgactcggatggaaagcccggcttctgcatcaggatgatct  
ggacgaaagagcaicaggggctcggccagccgaactgtccagggctcaagggcggcgalcccggacggcaggatctcgt  
cgtgacacalggcgatgctgctgcccgaatfatcaggtggaanaatggccgctttctggatcaccgacttggggcggctgggtg  
tggcggaccgctatcaggacatagcgttggctaccggatattgclgaagagccttggcggcgaatgggctgaccgcttccctgt  
gctttaccggtatcggccgctcccgaatcgcagcggcctacccttctatcgccttctgacgagttcttctgagcgggacictggggctc  
gaaatgaccggaccagcggacgctaactgtcagaccgaagttactcatatactttagattgattaaaaactcattitlaattanaaa  
ggatctagggtgaagatcccttttgataatctcatgaccaaaaacccttaacgtgagtttctgttccactgagcgtcagabcccgtaga  
aaagatcaaaaggatctcttgatgactctttttctcggctaatctgctgcttggcaacaaaaaacaccgctaccagcgggtggtt  
lgtttgcccggatcaagagctaccacacttcttccgaaggtaactggcttccagcagagcgcagatacccaatacltctcttagtgt  
agccgtagttaggcccaccacttcaagaactctgtlgaaccgectacataccctgctctgclaaactctgtaccagttggctgctgccc  
agtggcggataagctgtgcttaccgggttgactcaagacgtagtaccggataagggcggcagcggctgggctgaacgggggg  
gttctgtcavacagcccagcttggagcgaacgacctacccgaactgagatacctacagcgtgagctatgagaaaagcggccac  
gcttcccgaaggaggaaaggcgggacaggtatccggtaagcggcagggtcggaaacagagagcggcagggaggagcttca  
gggggaaacgectggatctttagtctctgctgggttccaccctctgactgagcctgatitttgtgatctcgtcagggggg  
cggagcctatggaanaacggcagcaacggcggctttttacgggttcccttggccttttctgctggccttttctcatalgttcttctgctg  
atcccctgacttctggataaccgtatnacgecttggagtgagctgataccgctcggcagcccgaacggaccgagcggcagcga  
gtcagttagcggaggaagcggaaagagcggctgattggctattttctcctacgcactgtgctgggtatttcaaccggcaatgtlga  
ctctcagtaacatctgctctgatgcccatagttaagccagtatcacctccgctatcgtacgtgactgggtcalggctgccc  
gacacccggcaacacccggctgacggccctgacgggcttgtctgctcccggcaccgcttacagacaagctgtgaccgctcc  
gggagctgcatgtgctcagagggttttaccgctcaccgctcagctcgttggatctccagaagcgttaatgtctggctctgataaagcgg  
gccaatgtaaggggcggcttttctctgttggctcactgactcctcgtgtaagggggatttctgttcaaggggglaatgataccgatga  
aacgagagaggatgctcacgatacgggttactgatgatgaacalggccggttactggaacgltgtgagggttaacaactggcg  
glatggatgcccggggggaacagagaaaaatcactcaggggtcaatgccagcggcttctgtaatacagatgtaggtgttccacagggt  
agccagcagcactctgctgatgagatccggaaacataatgggtgagggcggctgacttccggcttccagactttacgaaacacgg  
naaccgaagaccatctatgttgttctcaggtcgcagacggtttgcaagcagcagctgcttcaactgctcggctatcgggtgattca  
ttctgtaaccagtaaggcaaccccggcagcctagcccgggtcctcaacgacaggagcagcagatcatgcccaccgggtggccagg  
acccaacgctgcccggatgcccggctgctgggtgctgagatggcggacggcagatgagatgttctgccaagggttgggttgc  
gcaatcacagttctcggaaagaatgattggctcacttcttggagttggttaatccggttagcggagggtgcccggccttccattcagg  
tcagggttggcccggctcctatgacccggcagcgaacggcggggagggcagacaaggatagggcggggccctacaatccatgcc  
aaccggctccatgctcggcggaggcggcataaateggcctgacgatcagcggctccaatgacgaaagttagcctgtaagagc  
cggcagcagatccttgaagctgctcctgatgctgctatctacclgcttggacagcagctgcccgaacggggcctcccgaatgcc  
ggcggaaagcggaaagaaatcataatggggaaaggccatccagcctcggctcggnaacggcaagcaagcgtagcccagcggct

Figure 114C

cggccgccatgccggcgafaatggccgtctctcggcgaacgiltggggggaccagtgacgaaggcftgagcgagggc  
 gtgcaagaltccgaataaccgaagcgacaggccgatacctcgcgcagcgaagcggctccgcgaaaaagaccag  
 agecgtgcccggcacctgtctctacaggtlgaatgafaaagaagacagtcataagtgccggcgacgatagtcaccccgccccca  
 ccggaaggagctgactgggtgaaaggctcgaaggcatoggicgagatcccggtgcctaagtagtgagctaacctacattaft  
 gcggtgctcactgcccgcctccagtcgggaacctgtcgtgccagcgcattaatgaatggccaacgcgcggggagagg  
 cgggtgctgataggggcgccaggggtgggtttctctaccagtgagacggggcaacagctgattgcccctcaccgcccggccctga  
 gagagttgcagcaagcgggtccacgctgggttgcgccagcaggcgaaaatcctgttgatggtgggtaacggcggggatataacat  
 gagctgtctteggatctgtctgataccactaccgagataaccgcaccaacgcgcagcccggacccggaatggcgccgcaftggc  
 cccagcggccatctgagctgtggcaaccagcaicgcagtgggaaacgatgcctcattcagcattgcatggtttgtganaaccgg  
 acatggcaicccagtcgcccctccggttccgctatcggctgaattgattgcgagtgagatattatgccagccagccagcgcaga  
 cggccggagacagaacttaattggggcccgtaacagcgcgattgctggtagcccaatgcgaccagatgctccacggcccagctg  
 cgtaccgctctcatgggagaaaataactgttgatgggtgtctggtagagacatcaagaataaacggcggaaacattagtgcag  
 gcagcttccacagcaatggcalcctggctatccagcgggatagttatgacagccactgacgcgttgcgcgagaagattgtg  
 accgcccgtttacaggtctcgaagcgccttctctaccatcgacaccaccagcctggcaccagttgatcggcgcgagatttaa  
 tcgccgcgacaatttgcgacggcgcgtagggccagactggaggtggcaacgccaatcagcaacgactgtttgccggccag  
 ttgttggccacggcgttgggaatgtaatcagctccgccatcgcgcctccacttttcccgcttccgagaaaagtggtctg  
 ctggttaccacggcgggaaacggctctgataagagacaccggcatalactctgcgacatcgtataacgtaactggtttcacattacca  
 cccigaattgactctctccggcgctatcatgccataccgcgaaagggtttgcgccaitcagatgggtgctccgggatctcagcgtct  
 cccitattgcgactcctgcaatggaagcagcccagtagtaggttggagccggttagcaccggccggcaaggaatggtgcatg  
 caaggagatggcgcccacagctcccggccacggggcctggccaccatacccacggccgaacaagcgcctatgagccgga  
 agtggcgagcccgatctcccatcgggtgatgtcggcgatagggcgcagcaaccgcacctgtgcccgggtgatgccggc  
 caegatgctcggcgtagaggatcgagatctcgatcccgcgaaattaatacgaactactatagggggaattgtgagcggataac  
 aattcccctctagaaaataattgtttaacttaagaaggagatatacatatgctgggggtctcatcatcatcatcatcatggtatggcta  
 gcatgactgggtggacagcaaatgggtcgggatctgtacgacgatgacgataaggatcaccctcaccatggatcctgtctgc  
 gccgggtaagattaccgtgctgggaacacgccgtagtattatggcgaactgcaattgctgtgctgggtggaactggctaccggt  
 gttcggcgggaactcaatgactctatcactattcagagccagatcggccgcaccggctggtgatctgaaaagcacccttatgtct  
 tgggtaattgagaaaatgcgcaaatctatctcattaaacgggtgtttcttgaccgtcgatccgacatcccgggggctccggctg  
 ggtagcagcgcagccgttactatcgcgtctattgggtgcctgaacgagctgttcggcttggcctcagcctgcaagaaatcgccta  
 aactgggcccacgaaatgaaatlaaglacagggtgcccgcctcccaaccgatacgtatgttctaccttcggcggcgtggttac  
 cateccggaaacgctgcgcaactgaaaactccggactgcccattgtgattggcgafaccggcgtttctcctccaccaaaggatta  
 gttagctaacgtacgtcagctgcgcgaaagctacccggattgatcgaaccgctgatgacctctattggcaaaaatctctgtafcgg  
 cgaacaactggttctctggcgactacgcaaccatcggccgctgatgaacgcaaccagggctctcctggacgcccctggggcgt  
 taacatcttagaactgagccagctgatctattccgctcgtcggcgagggtgcttggcgclaaaatcacggggcgcctggcgggcgt  
 ggctgtatggttgcgctgaccgctccggaaaaatgcaaccaagtgccagaagcggtagcagggcgtggcggtaaaagtgactat  
 cactaaaccgaccgagcaaggctcgaagtagaataa

SEQ ID NO:29

Figure 115A-B





Figure 115C-D





Figure 116




Figure 117




Figure 118




Figure 119




Figure 120




Figure 121




Figure 122




Figure 123




Figure 124




Figure 125




Figure 126




Figure 127




Figure 128




Figure 129




Figure 130




Figure 131




Figure 132




Figure 133




Figure 134




Figure 135




Figure 136






Figure 137B

gtcgtatcccactaccgagatalccgcaccaacggcagcccggactcggiaatggcggcattggcccagcgcacatcgtat  
cgttggcaaccagcagcagtgagggaacgatgccctcattcagcatttgcattggtttgtgaaaaccggacatggcaccagtc  
gccttcccgtccgctatcggcgaatttgatggcagtgagatattatgccagccagccagaccagaccgcccagaccga  
actaatggggcccgaacagcggcatttgcctgggacccaatggcaccagatgctccacgccagtcggctaccgctcattg  
gagaaaaataaactggtgaggggtgctgggtcagagacatcaagaataaacgccggaacattagtgcaggcagcttccacagca  
atggcaccctggctcaccagcggafagttaatgatcagcccactgacggctggcgggagaagattgtgcaccgccgcttaccagg  
cttcgacgccctcgttctaccatcgacaccaccacgcctggcaccagttgatcggggcggagatttaategcgcggacaatttg  
cgaccggcggctgcaggggccagacaggagggtggcaacgccaatcagcaacgactggttgcgccagctggttggccacggcgg  
ttgggaatgtaaitcagctccgccatcggcgttccacttltcccgcgttttcgcagaaacgtggctggcctggcttaccacggcgg  
gaaacggctcgtataagagacaccggcactcggcagatcgtataacggtactgggttcacatccaccacctgaattgactctctt  
ccggggcgtatcgtccataccgcgaaagggtttggccactcgtatggctccgggactccgacgctcctctatgcgactcctg  
cattaggaagcagcccagtaggttgaggccggtgagcaccgccccgcaaggaaatggctgcatgcaaggagatggcggcc  
caacagtcccccggccacggggcctgccaccatcccacgccgaacaagcgcctcagcccgaagtggcgagcccgatc  
ttcccacgtggctgctggcgatataggcgccagcaaccgcacctgtggcgccgggtgatccggccacgatgcgtccggcgt  
agaggatcgagatcctgctcccgcaaatiaatacgaactcactataggggaaattgtagcgggataacaaitcccctctagaata  
atittgitaacttaagaaggagatatacatatgcgtttgagcgtgtccaccgaaatgtgtctttaccgaaactgaaacega  
agctcgtcgttctcgaactaegaaactaaeagctgggactatgattacctgctctcctcgcacacggagcagctccatcg  
aagtatacaaaagcaaaagcgaanaagctgggaagcgaagtctcgtcggagataataacgaaanaagcagaaittetg  
acctgtctggaaactgattgacaacgtccacgcctggcctgggttaccgtttcagctctgataaccggtggctggctggat  
cgttctgttctcctcggcggcttcgatgggtaaceaaagacttccctgcacggtaacggcactgtctttccgtctcgtcgtc  
aacacgggtttgagggttctcagggaagcgttcaagcggctcaanaagaccanaaagcgaacttctcggagaacctgaagga  
agatataaagctatcctgagcctgfacgaggccagcttctcgtctcgggaaggcgaanaacatcctggacgaggcga  
ggtttgcgaactctcctatcgaagaactgtctgaaagaaagatcggtaaaagagctggcagaaacaggtgaacctgca  
ctggaaactgcaactgcatcggctcactcagcgtctgggaagcagtaggtctatcagggcctacgtaaaaaggagggaag  
cgaatcagggtctcgtggagctggcaattcggattacaacatgatccagctctgtataccagcgtgatctcggtaaacgt  
cccggtgggtggcgtcgtgtgggtctggcgacaaactgcaacttctcgtgacggcctgattgagagcttctactggggcgg  
tgggtgtagcattcgaaccgcaactcctcagcctgtaactcctcgtcgaanaaatgtttcttctgtaaacattatcgcga  
tatctacgatgtatacggcaacctggacgaactggagctgttactgtagcagttgagcgttgggaagtaaacgctcata  
aegacctgcgggattactgaaactgtgcttctggctctgtataaacctatfaacgaaatgcctacgacaaactgaaag  
ataaagggtgagaacatcctcggctatcagcaaaagcctgggctgacctgtgaaacgcttctcgaagaagecaagtg  
gctgtaeaaacaactactcggaccttggcgaactctggcaacgcattggaaatcctcttctggcccgtcgaactgggt  
gttgccttacttctcgtctgctgagaaacttaaaaagggaagagatcgaaaacctgcaaaaataacatgacaccatctctc  
gtcttcccatacttctcgtctgtgcaatgacctggctagcggctctcgggaaattgcgctggtggtaaaccegaanaatgagc  
ttcttgttcatcgcgaactaaagggtatctcgaagaactggctaccgaaagcgtgatgaaatctgactgatgaaacctgg  
naaaagatgaaacaaggnaaaactgggtgggtngcctgttctcggaaacgcttctgggaaaceggaatcaacctggcaact  
caatctactgcaactatcaaacggcgaecggcactcctcggatgagctgaccgcnaacgcgttctgtctgtaate  
actgaaecgattctcggcttgaacgctaaaggatcgaatcggactcctcgcacaagcttggcggcgaactcagaccac  
caccaccaccactgagatccggctgtaacaagcccgaagggaagctgagttggctcctgccaccgctgagcaataactagc  
ataacccttggggcctctaaacgggtcttgggggttttctgtaaggagggaactatataccggat

SEQ ID NO:30



Figure 137D

gtcgtatcccactaccgagataatccgacccaacgcgcagcccgactcggtaatggcggcattggcccagcggccatctgat  
 cgttggcaaccagcctcgcagttgggaacgatccctcattcagcatttgcattggtttggtaasaccggacatggcactccagtc  
 gccctccogttccgctatcggctgaatttgattgcgagtgagataatfatccagccagccagaccgagacgcgcgagacaga  
 acttaatggggcccgcfaacagcgcgatfctggtgacccaatggaccagatgctccacgcccagtcgctgaccgtctcattgg  
 gagaaaataaactggtgatgggtgctctggctcagagacatcaagaataacgcccgaacattagtcaggcagctccacagca  
 atggcctcctggctatccagcggatagttaatgatcagcccactgacgcgttgcgcgagaagattgtcaccggcctttacagg  
 ctccagcggcctcctgctaccatcgacaccaccagcctggcaccacgtgatcggcgcgagattfaatcggcgcgacaattg  
 cgacggcgcgctgcaggccagactggaggggggcaacgcccaatcagcaacgactgtttgcccccagttgttggccacggg  
 ttgggaatgtaatcagctccgcaatcgcgcttccacttttcccgcttttcgcagaaacgtggctggccggcttccaccagcgg  
 gaaacggctctgataagagacaccggcactctgcgacatcgtataacgttactggtttccattcaccaccctgaattgactctt  
 ccgggctctatcagccataaccgcaagggttttgcgccattcagatggttccgggactcgaecgtctcccttatgagactcctg  
 cattaggaaagcagcccagtagtaggttagggccgttggagcaccggcgcgcgaagggaatgggtgcatgcaaggagatggcgc  
 caacagtccccggccacggggccttgcaccatacccagcgcgaacaaggcgtcctatgagcccgaagtgggcagcccgatc  
 tccccategggtgagtcggcgatalagggcgcagcaaccgcacctgtggcggcgggtgatgcccggccacgatgctcggcgt  
 agaggatcgagatcctgatcccgcaaatlaatacagactcaatlaggggaattgtgagcggataacaaltccctctagaafa  
 atttgtttaactttaagaaggagatalacata tggcttggtagcgtgtccaccgaaaaatgtgtcttccaeegaactgaanccga  
 aaegcgtgcttctggaactacgaacctaacagctgggactatgattactgctgtcctccgacacggacaggtccatcg  
 aagtaacaaga caaaagcgaanaaagctgggaagcgaagtctcgtcggagattaataacgaaaaagcagaatttctg  
 accttgcggaaactgattgacaacgtccagcgcctgggctgggttaccgtttcagctctgataicctcgttgcctggat  
 cgttcttctcctcggggcttctgagtgaggtaaceaaagacttccctgcacggcgaaggcaetgtcttctcgtctgctgctc  
 aacacggtttggaggttctcaggaagcgttgcggcttcaaaagcgaacttctgaaaaaacttgaanaggga  
 agatatacaaaagctctgagcctgtaagggccagcttccctggctctggaaaggcga aacatcttggacgagggca  
 ggttttcgcaatctctcatctgaanagaactgtctgaanagaagatcgggtaanagatctggcagaacagggtgaacctgca  
 ctggnaactgccactgcatcgcctactcagcgtctggaaagcagatgggtctatcagggcctaccgtaaaaaggaggagc  
 eggatcaggtctctgctggagctggcaattctggatta caacatgatcagctctgtataaccagcgtgatctcgtgaaactg  
 cccgttgggtggcgtctgtgggtctggcgacaaaactgcaacttctgctgtaacgcctgatfgagagcttctactgggccc  
 tgggtgtagcattcgaaaccgaatactcagactgcgctgaactcctctgcaaaaaatggttcttctgtaaccattatcgacga  
 tatctcagatgtatacggcaacctggagaactggagctgttactgacgcagttgagcgttgggacgtaaacgccatcg  
 acgatctgcgggattacatgaaactgtgcttctgctctgtataaactatfaacgaactcgcctacgacaacctgaaag  
 ataaagggtgagaacatctgctgctatcgaaccaaaagcctgggctgacctgtgcaacgcttctctgcaagaagccaagtg  
 gctgtaacaaactctactcgcacttctgacgaatactcggcaacgcctggaaatctcttctggcccctgcaactgggt  
 gttccttaactcctgctgctgagaaacattaaaaagggaagagatcgataaactgcaaaaafaceatgacatcaatctc  
 gcttcccaatactcctgctgctgcaatgacctggctagcggctctgggaaattgcgctgggtaaaaccgcaaatagc  
 tttctgttcaatgctgcaataaggatctcgaagaactggctaccgaaagcgtgataatctgatacgatgaaacctgg  
 aaaaagatgaaacaggaanaactgggtgtgagcctgttcgcaaacgcttctgggaaaccggatcaacctggcagct  
 caatctcactgcaactataaacggcgacggcactcctccggatgagctgaccgcgaacggcgttctgtctgtaatc  
 actgaaaccgattctgctggttgaacgctaaaggatcgaactcggctccgtctgacaaagcttgcggccgcaactcagaccac  
 caccaccactgagatccggctgtaacaaagcccgaagggaagctgagttggctgctgcccaccgctgagcaataactagc  
 ataaccttggggcccttaaacgggtctgagggggttttctgtaaaaggagggaactatctcggat

SEQ ID NO:31

Figure 137E

iggcgaaatgggacgcgccclgtagcggcgccattaagcgccggcgggtgtgggllacgpcagcgtgaccgctacactfgec  
agcgcocctagcggccgctccttgccttctccctcctttctcgcacagctcggccgcttccccgcaagctctaaatcgggggg  
tccctttaggggtccgalltagtcttacggcaectcgaccccaaaaacttgataggggtgatgggtcacgtagtgggcatcgc  
cctgatagacgggttttgcctttgacggtggagtcacgcttllaatagtgagactctgttccaaactggacaacacitcaacct  
atcfcgggtctattctttagttataagggtttgcgafllcggcctatttggflaaaaaatgagctgatttaacaaaaalltaacgcga  
atttlaacaaaafattaacgtitacaallfcagggtggcacitllcggggaatgtgcgcggaacccctatttgittatttttaatacat  
tcaaatatgtlatccgctcatgaaataatcttagaaaaactcaicgagcatcaaatgaaactgcaantitattcatatcaggalltcaat  
accatattttgaaaaagccggttctgtaatgaaggagaaaaactcaaccgaggcagttccataggatggcaagatcctggatcgggt  
ctgagcttccgactcgtccaacatcaatacaacctatfaalltcccctcgtcaaaaaatagggtatcaagtgagaaatcaccatgagt  
gacgactgaatccgggtgagaatggcaaaagtattgcatcttctccagactgttcaaacaggccagccattacgctcgtcatcaaa  
atcactcgcacacaaaccgtafctccttctgattgcgctcggagcagcaaaatacggcagctgctgtaaaaggacaaitac  
aaacaggaaatcgaatgcaaacggcgccaggaacactgccagcgcacacaanaatlltccactgaaatcaggtatctcttaatac  
ctggaaatgctgtttccgggggagcgcagtggtgaglaacatgcatcaccaggaagtcggataaaatgcttggatggtcggaaaga  
ggcataaattccgctcagccagtttagtctgaccatctcatctgtaaacatllggcaacgctaaccttggcatgttccgaaacaactc  
lggcgcatcgggcttccatcaaalcgatagattgfcgcaactgattgcccagactatfcgagcccatitatacccataaate  
agcatecatgttggaafttaategcggcctagagcaagacgtttcccggttgaatatggctcataaacacccttgtattactgtttagt  
aagcagacagtttattgttcatgacaaaaatcccitaacgtgagtttctgctccactgagcctcagaccocgtagaaaaatcaaaa  
ggatctcttgagatcctttttctgcgcglaaatcgtctcttgcacaacaaaaaacaccgctaccagcgggtgtgtgttggccgga  
teaagagctacccaactcttttccgnaaggtaactggcttcagcagcagcagafaccaatctgctccttagttagcggtagt  
aggccaccactcaagaactctgtagcaccgctacatacctcgtctctgctaactcctgtaccagtggtgctgcccagtgccgata  
agctcgtcttaccgggttggactcaagacgatagttaccggnaaggcggcagcggctggctgaaacgggggggctgcacaca  
cagcccagcttggagccgaacgactacaccgaaactgagatacctacagcgtgagctatgagaagccaccgctccggaag  
gggagaagggcggacaggtatccggtaagcggcagggctggaaacaggagagcgcagcaggagcctccagggggaacg  
cctggatctttatagctctgtcgggtttcggcaacctctgactgagcgtcgtatgttggatgctcgtcaggggggcggaagcctatg  
gaaaaacgccagaaacggcccttttaccggttccctggcctttgtgtgcccctttgctcacatgttcttctgcttaccctgattc  
tgtgataaccgtaaacgctttagttagctgataccgctcgcgcagccgaacgaccgagcgcagcggagtcagtgagcgg  
aggaaagggaagagcgcctgagcggatlltctctacgcatctggtgggtatttccaccgcaatattggtgcactctcagtac  
aatctgctctgagcgcatagttaagccagtataactcgtctatcgtacgtgactgggtcatgctgcgcccggacaccgc  
caacaccgctgacgcgcccgtacgggcttctctcctccggcactcgttacagacaagctgtgaccgtctccgggagctgc  
atgtgtcagagggtttaccgctacaccgaaacgcgcgaggcagctgctgtaaaagctcaccagcgtggctgtgaaagcattca  
cagatgtctgctgctcaccgctcagctcgttgagttctccagaagcgttaatgtctggcttctgataaagcgggcatgttaa  
gggcccgttttctctgtttggtaactgagctccctgtaaggggatttctgtcaagggggtaatgataccgatgaaacgagaga  
ggatgtctcacgatacgggttactgatgatgaacatgcccggttactggaaactgtgtgagggtaaacactggcggtatggatgc  
ggcgggaccagagaaaaatcactcagggtcaatgccagcgtctcgttaatacagatgtaggtgttccacagggtagccagcag  
catctgagatgcagatccggaaacataatggtgcaaggcgcctgactccgcttccagacttacgaaacacggaaaccgaaag  
accatcagttgttctcaggtcgcagacggtttgcagcagcagctcctcaccgtcctcgcgtatccgggtgattctctctaac  
caglaaggcaaccccggcagcctagccgggtcctcaacgacaggagcagatcatgcccaccggtggggccgctatccg  
gcaataatggcctgctctcgcgaaacggttgggtggcgggaccagtgacgaaaggcttggagcaggggcgtgcaagallccgaa  
taccgcaagcagcagggccgcatctctcgcgctcagcgaagcggctcctcggcaaaatgacccagagcgcctgcccggcact  
ctgtctacgagttgcalgataaagaagacagtcataatgtcggcgaacgatagtcacgcccggcccaccggaaaggagctga  
ctgggttgaaggctctcaaggcctcggctgagatccgggtgctaatgagtgagctaacctacatfaattgctgctcactg  
cccgttccagctgggaaacctgtctgcccagctgcattatgaaactggccaacgcgggggagaggcgggttgcgattggg  
cgccagggtgtgtttcttaccagtgagacgggcaacagctgattgcccctcaccgcccctggccctgagagagttgcaagcag  
cggtcaccgctgggttccccagcagcgcgaaatcctgtttaggtgtgtaaacggcgggataaataatgagctgtctcctglatc

Figure 137F

gftgataccactaccgagatatccgcaccaacggcagcccggactcggtaatggcgcgcattgcccagcggccatctgat  
 cgttggcaaccagcagcagtgagggaacgatgcccctcaltcagcattgcatggittgtgaaaaccggacatggcactccagtc  
 gccctcccgttccgatcggctgaatttgattgagtgagatattatgccagccagccagacgcagacggccggagacaga  
 actaatggcccgcataacagcgcgattgctggigacccaatggcagccagatgctccacgcccagtcgctaccgcttcatgg  
 gagaaaataatactggtgatgggtgctggcagagacatcaagaaataacggccggaacattagtgcaggcagcttccacagca  
 atggcctcctggctatccagcggalatagtaatgatcagcccactgacgcgttgcgcgagaaagattgtgaccggccgttacagg  
 ctccagcggcccttccctaccatcgacaccaccacgctggcaccagttgatcggcgcgagatttaateggccgcgacaattg  
 cgcagggcgcgtgcaggggccagactggagggtggcaacggcaatcagcaacgactgttggcccggcagttgttggccacggg  
 ttgggaatgtaaitcagctccggcaatcggccttccacttttcccggctttcgcagaaacgtggctggccctggcttcaaccggg  
 gaaacggctgataagagacaccggcatalactcgcgacatcgtataacgttactgggttccacattcaccaccctgaatgactctt  
 ccggggcctatcatgccataccgcgaaagggttggccactcagttgttccgggatctcgacgctctccctatfctgcactcctg  
 cattaggaagcagcccagtagttaggttggggccgttggacacggccggccgcaaggaaatgggtgcatgcaaggagatggcggcc  
 caacagtcccccggccacggggcctggccaccatacccacggccgaaacaaggcgtcatgagcccgaagtgggagcccggatc  
 itccccatcgggtgatgctggcgatagggccagcaaccggcaccctgtggcggccgggtgatccggccacgatgctcggcgt  
 agaggatcggagatcggatccggcgaallatcagactcactataggggaattgtgagcgggataacaattcccctctagaata  
 atttggtaactttaagaaggagatalacalatcgttggtagcgtgtccaccgaaaatgtgcttctcigaaactgaaaccgaaacg  
 cgtcgttctcgaactacgaacctaacagctgggactatgattacctgctgctcccgacacggacggaggtccatcgaagtacaca  
 aagacaagcgaanaagctggaagccgaagttcgcgcgagattaataacgaaanaagcagaatttctgaccctgctggaactg  
 attgacaacgtccagcggcctggggctgggttaaccgttccagctctgatatccgtcgtgctgctgagatcgttccctccgggg  
 ctctgatggggttaaccagacttccctgcacggtaaggcactgcttctccgtctgctgcaaacgggttggaggttctcagga  
 agcgttcagcggcttcaagaccanaaacggcaacttctgggagaacctgaaggaaalatcaaaagctatctgagcctgtacga  
 ggccagcttccctggctctggaaggcgaanaacatcctggacgagggcgaagggttcccaatctctcatctgaaagaactgtctgaa  
 gaaaagatcggtaaaagagctggcagaaacagggtgcccaltgcaactggaaactgccactgcatcggctacacagccttggaaagc  
 agtatggtctatcagggccctaccgtaaaaaggaggacggcgaaccagggttctgctgagctgccaattctgattacaacatgate  
 cagctgtatataccagcgtgatctgcgtgaaacgtcccggttgggtggcgtcgtgtgggtctggcgaccanaactgcactttgctcgtga  
 ccggcctgattgagagccttactggccgtgggtgtgacatcgaaccgcaatactccgactgccgtaactccgtcgaanaatg  
 tttcttctgtaaccattatcagcagatctacgatgatacggcaccctgggacgaactggagcigtftactgatgcagttgagcgtt  
 ggacgtaaacgccatcaacgacctcgggattacatgaaactgtgcttctggcctctgataacactatfaacgaaategcctacg  
 acaacctgaaagataaagggtgagaacatcctgccgtatctgaccaaaagcctgggctgacctgtgcaacgcttctcctgcaagaag  
 ccaagtggtgtgatacaacaatctactccgaccttggactacttggcgaacgcaltggaatcctctcttggcccgtgcaactg  
 atcttccctacttccgtctgctgcaagaacataaaaagggaagagatcgaanaacctgcaaaaataccatgacatcatctctgctct  
 tcccatacttccgtctgtgcaatgacctggctagcgcgtctgcccgaantggcgtggtgaaaccgcaaatagcgttctgttac  
 atggcactaaagggtatctccgaaagactggctaccgaaagcgtgatgaatctgatcgaatgaaacctggaaaagatgaaacaag  
 gaaaaactgggtgtagccgttccgcaaacggcttgggaaaccggcgaatcaacctggcagctcaatctcactgcaacttata  
 accggcagcggcatacctctccggaatgagctgaccggcaaacggcttctgtctctaaicactgaaacogattctccgttgaacg  
 ctaaggatccgaattcagctccgtcgaacagcttggccggcactcagaccaccaccaccaccactgagatccggctgct  
 aacaaagcccgaaaggaaagctgagttggctgctgcccaccctgagcaataactagcataaaccttggggcctctaaacgggt  
 ctggagggtttttgctgaaaggagggaactataccggat

SEQ ID NO:32

Figure 137G

MRCVSTENVSFSETETETRRSANYEPNSWDYDYLLSSDTDESIEVHKDKAKKLE  
AEVRREINNEKAEFLTLELIDNVQRLGLGYRFESDIRRALDRFVSSGGFDGVTKT  
SLHGTALSFRLLRQHGFVVSQEAFFSGFKDQNGNFLENLKEDIKAILSLYEASFLAL  
EGENILDEAKVFAISHLKELSEEKIGKELAEQVSHALELPLHRRRTQRLEAVWSIEA  
YRKKEDANQVLELAILDYNMIQSVYQRDLRETSRWWRRVGLATKLHFARDRL  
IESFYWAVGVAFEPQYSDCRNSVAKMFSFVTHIDDIYDVYGTLDLELELFTDAVER  
WDVNAINDLDPDYMKLCFLALYNTINEIAYDNLKDKGENILPYLTKAWADLCNAF  
LQEAKWLYNKSTPTFDDYFGNAWKSSSGPLQLIFAYFAVVQNIKKEEIEENLQKY  
HDHSRPSHFRLCNDLASASAEIARGETANSVSCYMRTKGISEELATESVMNLIDE  
TWKKNKEKLGGSLEAKPFVETAINLARQSHCTYHNGDAHTSPDELTRKRVL  
VITEPILPFER

SEQ ID NO:33

Figure 137H

tggcgaatgggacgcgccctgtagcggcgcatlaagcgcggcggggtggtggtgflacgcgcagcggacccgtacactggcc  
agcgcocctagcgcgccctcccttgccttcttcccttctcgcacacggfctgcggccttcccccgaugctctaaatcggggggc  
tcctttagggfctccgatttagtgcctttagcgcacctcgcaccccaaaaaactgatalaggggatgggtcacgtagtgggcccacgc  
ccctgatagacgggtttcgcctttagcggftaggagtcacgcttctaaatagtaggactcttgcacaaactggaaacaaactcaacct  
atctcggcttattctttagatitataaggatitggcgaattcggcctattgggtaaaaaatgagctgatttaacaaaaatfaacgcga  
atttaacaaaaatataacgtitacaattcaggggcgcactttcggggaaaigtgcgggaacccctattggttattttctianataca  
tcaaatatgtaiccgctcatgaaatfaattcttagaaaaactcgcagcacaatgaaactgcaattattcaatcaggattatcaat  
accatattttgaaaaagccgttctgtaatgaggagaaaaactcaccggagcagttccataggatggcaagatcctgggatcgggt  
ctgcgatccgactcgcacaacatcaafacaacctatfaattccctcgcicaaaaaaagggttatcaaglgagaaatcaccatgag  
gacgactgcaatccgggtgagaaatggcaaaagtatttgcattcttccagactgttcaacaggccagccattaccgctcgcatacaaa  
atcactcgcatacaaccaaacggtattcattctgtagtgcgctgagcggagacgaaatacgcgacgcgtgtaaaaaggacaatlac  
aaacaggaaatcgaatgcaaccggcgaggaacactgccagcgcatacaaatatttccacctgaatcaggatattcttcaaac  
ctggaaatgctgtttccgggggacgcagtggtgagtaaccatgcatacaaggagfacggataaaatgctgtatggctcggaaaga  
ggcataaatccgctcagccagtttagctgaccatcctctgtaacatcattggcaacgctaccttggccatgttccagaacaactc  
tggcgcacccgggttccatatacgaatcagatgctgcacctgattgcccgacattatcgcggagcccaattataccatataaaac  
agcactccatgttggaaatfaacgcggcctagaggcaagacgttcccggtgaaatggctcataaacaccctgtatfactgtttagt  
aagcagacagtttattgttcatgaccanaatcccttaacgtgagtttccgctcactgagcgcagaccccgtagaaaaagcnaaa  
ggatctcttggagatcccttttctgcgcgtaactgctgcttgcnaacaaaaaacaccgcctaccagcgggtgttcttggcggga  
teaaggactaccaactctttccgaagggttaactggcttcagcagagcgcagatacnaatactgtccttctagtgtagcctgtagt  
aggccaccacttcaagaactctgtagcaccgctacatacctcgcctctgtaatccctgtaccagtggtctgctccagtgccgata  
agctgtgcttaccgggttggactcaagacgatagtaaccgggataaggcgcagcggctcgggctgaacggggggctcgtgcaca  
cagccagcctggagcgaacgactacaccgaaactgagataccctacagcgtgagctatgagaaaagcggccacgctcccgaag  
ggagaaaaggcggacagctcggtaagcggcagggctggaaacaggagagcgcacagggagcttccaggggggaacag  
cctggtatctttagactgtcgggttccaccctctgactgagcgtcgaattttagtgatcctcagggggggcggagcctatg  
gaaaaacgcagcaacgcggccttttaccgggttccctgctgcttggcttgcacatgcttcttctgcttaccctgactc  
tgggataaccgtattaccgctttagtgagctgataccgctcggcagccgaacgacagcagcagcagctcagctgagcgg  
aggaaagcggagagcggcctgtagcgggtatttcttaccatctgtgctggtatttcaaccgcctatatagtgctcactctcagta  
aatctgctctgagccgatagtlaagccagatatacactccgctatcgtctacgtgactgggtcatggtctgccccgacaccgc  
caaacaccgctgacggccctgacggcctgtctcctccggcctaccagacaagctgtgaccgctcgggagctgc  
atgtgtagagggtttaccgctcaccgaaacgcggcagggcagctcgglaaagctcaccagctggtgctggaagcattca  
cagatgctgctgttcatccgctccagctcgtgaggttctccagaagcgttaatgcttggctctgataaagcgggcccattgaa  
ggcgggttttctggttggctcactgagctccctcgtgtaagggggatttctgctcagggglaatgataccgatgaaacgagagga  
ggatgctcagataggggttactgagatgaacatgcccgggttactggaaacgttggagggtaaacactggcgggtatggatgc  
ggcgggaccagaganaaaactcaggggtcaatgcccagcgccttggtaaacagatgtaggtgtccacaggggtagccagcag  
catctcggatgcagatccggaaacataatgggtgcagggcgtgacttccgcttccagacttaagaaacavggnaaccgaaag  
accatcagttgtgctcagctcagacgtttgacagcagcagctcctcacttccgctcagctcagctcagctcagctcagctc  
cagtaaggcaaccgccagccagccagccgggctcctcaacgacagggagcagatcagccaccgctggggccgocattccg  
ggataatggcctgctctcgcgaaacgtttgggtggcgggaccagtgacgaaggctgagcggaggcctgcaagatccgaa  
taccgnaagcagagccgatacctgctcgcctccagcgaagcggctcctcgcgaaaatgacccagagcgcctcggcggc  
ctgctcactcaggttgcataaagaagacagctcatalaggcggcgcagatagctatgccccgcccaccgggaaggagctga  
ctgggtgaggctctcaaggcctcagctcagatcccgtgctcaatgagtgagctaaccttaacatgctgctcactg  
cccgttccagctcggaaacctgctgctcagctcctaaatgaaatggcacaacgcgcggggagagggcgggttctgattggg  
cggcaggggtggtttcttaccagtgagacgggcaacagcctgattgcccctcaccgcttggccctgagagaggttgcagcag  
cggctcaccgctggttgcgccagcaggcgaaaactctgtttagtgggtggttaacggcgggataaacatgagctgctcctgctatc

Figure 137I

gtcgtatcccactaccgagatataccaccaacggcagcccggactcggtaantggcggcattggccccagcccatctgat  
cgttggcaaccagcatcgcagtgagggaacgatccctcattcagcatttgcattgggttggtaaaaceggacatggcactccagtc  
gcttcccggtccgctatcggctgaattgattggcagtgagatattatccagccagccagacgcagacgcgcccagacaga  
actaatggggcccgaacagcgcgatttgcctggtagcccaatgcgaccagatgctccacgcccagtcgctaccgcttcatgg  
gagaaaataatactgttgcattgggtgtctggctcagagacatcaagaaataacggcgaacattagtcagggcagctccacagca  
atggcattcctggctccagcggatagtaatgatacagcccactgacgcgttgcgagagaagattgtcaccgcccgtttacagg  
cttcgacgcgcgttcgttaccatcgacaccaccacgctggcaccagttgatcggcggcagagattaatcgcgcgacaattg  
cgacggcgcgttcagggccagactggagggtggcaacgccaatcagcaacgactgttgcgcgcagttgttggccacggg  
ttgggaatgtaattcagctccgccatcggcctccacttttcccgcttttcgcagaaacgtggctggcctggcttaccacgcgg  
gaaacggctcgtataagagacaccggcactctgcgacatcgtataacgtactggttcacattcaaccacccgtgaattgactctt  
ccggcgcctatcatgccataaccgcgaaagggtttgcgccattcagtggtgtccgggacccgcagcctctcccttatgcgactcctg  
cattagggaagcagcccagtagtaggttagggccgttggagcaaccggccgcgcaagggaatgggtcagcaaggagatggcgc  
caacagtcccccggccacggggccttccaccatacccacggcgaacaaggcctcatgagccgaagtggcggagcccgatc  
tccccatcgggtgattcggcgatagggccagcaaccgcacctgtggcggcgggtgatccggccacgatcgttccggcgt  
agaggatcagatcgcgacccgcgaaatcactcagactcaataggggaattgtgagcggataaacaattccctctagaata  
atthtttaacttaagaaggagatatacatatgcatactgctttagcgtgtccaccgaaatgtgtctttaccgaaactgaa  
accgaaacggctcgttctcgaactacgaaacctaacagctgggactatgattacctgtctctccgacacggacagagtc  
cattcgaagtatacaagacaagaagcaaaagcttgaagccgaagtctcgcgcagattataaagcaaaaagcagaat  
ttctgaaccctgggaactgattgacaaagtcaggcctgggctgggttaeegtttcgagttgatatacctcgtctgctg  
ggatctcttcttctccggcgtctctgagggtaaccaagaattccctgcaacggcagcttcttccgtctgctg  
cgtcaacaacgggtttgagggttctcaggaagcgttcagcggcttcaaaagacaaaaaggcaactctctggagaacciga  
aggaagatatacaagctatcctgagccctgtaagggccagctctctggctctgggaaggcgaaaaaactctggacgagg  
cgaagggttttcgcaactctctcattcgtgaaagaactctctgaaagaaaagatcggtaangactctggcagaacaggtgaaaca  
tgaactggaactgcaactgcatcgcctactcagcgtctggaageagtaetgtctatcagggcctacggtaaaaaggag  
gacgggatacaggttctctgagctggcaattctggattacaacatgattcagctctgataccagcgtgatctcgtgaa  
acgtcccggttggcgtcgttgggtctgggacaaaactgcaacttgcctgtaacggctgattgagagcttctactgg  
gcccgtgggtgtagcattcgaaacgcaatactcggactcggtaactcggctgcnaaaatgttttcttctgtaaccattatg  
acgatatacagatgatacggcaacctggacgaactggagctgtttactaacgcagttgagcgttgggacgtaaacggc  
atcgacgatctcgggattacatgaaaactgtcttctggctctgataaacactataacgaaaactcctcagcaaacctg  
aaagaaaaagggtgagaacatcctgcttctgaccnaagcctgggctgacctgtgcaacgttctctgcaagaagcca  
agtggctgtacaacaactctactcgaaccttgcgaatactcggcaacgcattggaaactctctctggcccgtgcaac  
tgggttctgcttaetctcgtctcgtcagaaacttaaaaagggaagagatcgaanaactgcaaaaaatacctgcaatc  
ctcgtctcttccatactctcgtctctgcaatgactcggctagcggctctgggaaattggcgggtgaaaacggcaata  
ggcttctgttatacgcactaaaggatctcgaagaactggctaccgaaacgctgatgaatctgatcgtatgaaacct  
ggaaaaagatgaacaaggnaaaactgggtggtagcctgttcgcaaacgcttctggtgaaaacggcagatcaacctggca  
cgtcaatctcactgcaactatcataacggcgacggcatacctctcggatgagctgacccgcaaacggctctgtctgta  
ataactgaaecgattctcggcttgaacgctaaaggatccgaattcagactcggctcagcaagcttggggccgactcagcac  
caccaccaccaccactgagatccggctgtaacaaagcccgaagggaagctgagttggctctgcccaccctgagcaataact  
agcataacccttggggcctctaaacgggctttaggggtttttgtcgaaggagggaactalacggat



Figure 137K

gtcgtatcccactaccgagatafcggcaccacggcgagcccggacloggtaatggcggcattggcccaggcgccatctgat  
 cgttgcaaccagcagcagfggggaacgatccctcaticagcatttgcaggttggfagaaccggacatggcactccagtc  
 gccctcccgctccgctatcggctgaattgatggcagtgagatattatgcccagccagccagacggcagcggcgagacaga  
 actfaatggggcccgaacagcggcatttgcctggtagcccaatgcgaccagatgctccacgcccagtcggctaccgtcttcattgg  
 gagaaaaaataactgttgatgggtgtctggtcagagacatcaagaaataacggccgaacatfagtgagcagcagctccacagca  
 atggcctcctggctaccagcggatagitaatgacagccactgacggctggcgaagagatgtgcaccggcgtttacagg  
 ctccagcggcggcttctacccatcgacaccaccacggctggcaccagttgafcgggcgagatttaotggccggacaattg  
 cgacggcgcgigcggggccagactggagggtggcaacgcccaatcagcagcagctgttggcccagattgttggccacggc  
 ttgggaaatgtaattcagctccggcctcggccttccacttttcccggctttccgagaaacgtggctggcctggctcaccacggc  
 gaaacggctctgataagagacaccggcatalactcggcagacatgataacgttactggtttcacattcaccacccctgaattgactctctt  
 ccggggcgctatcatgccataaccgggaaagggtttggccatcagatgggtgctccgggatctcgacgctctcccttatggcactcctg  
 cattaaggaaagcagcccagtagtaggttagggccgttgagcaccggccggcaagggaatgggtgcatgcaaggagatggcgcc  
 caacagtcccccggccacggggcctggccaccatacccagccgaaacaaggcctcatgagcccgaagtggcgagcccagatc  
 tccccatcgggtgatgctggcgatagggccagcaaccggcaccctgtggcgccgggtgatgcccggccacgatggctccggcgt  
 agaggatcggagatcctgatcccggcaaaftaalacgacacactataggggaattgtgagcggataacaaltccctctagaana  
 atttgttaacttaagaaggagatatacatatgtgctcgtttctaccgagaacgtttccttcactgagacgggaaaccggagggc  
 acgtctgagcggcaactacgagccgaatagctgggactacgatttctgctgcttccgatactgagcaatctattgaggt  
 gtaacaagacaaagcaaaactgggagctgaaggctggcggcaaaftaacaacgagaaagetgaattcctgactc  
 tgcctggagctgatcagatacgtacagcggcctgggtctgggttaccgcttcgaatctgatatecgtcggcactggatcgttt  
 cgtaaagcagcggcggttctgatggcgtgacaaaaagagcctgcaecgctaccggcgtgctctccgtctgctgctgctgagc  
 accgcttcgaagttctcaggaagcattctccggttcaaaagatcaaaaacggtaacttctggaaaaactgaanaagac  
 actaaggcgatctgagcctgtatgaggcaagcttctggccctggagggtgagaaacatcctggatgaggcggcggctatf  
 ctcaactcccatctgaaagagctgctgaaagagaaaactggtaagggaactggcagagcagggttaatacggcactggaa  
 ctggcctgcatcctgctaccagcctctggaggcgggtttggctcaatgaaagcgtaccgcaaaaaggaggatgetaacc  
 aggttctgctggaaactggcctctggactcaaacatgatacagtcctgttaccagcgtgatctgctgaaacctcctgtt  
 gggtggcggctgtgggctggcgcaaaaactgcaactctgctaaaggacggcctgatgagcttttttactgggcagctggc  
 gttgctgtaaccicagtatctgactccgtaacagcgttggcaaaaatgttcagctctgtaclatfalegacgacatct  
 acgacgtttscggtaactctggacgagctggaaactgttaecgacgctgtaacgttgggatgttaacgccatcaacgat  
 ctgctgactcaatgaaactgttcttctggcactgtataacacgatacaacgaaatgcafaegacaacctgaangacaa  
 aggtgaaaaacatctgctgactgactaagaacgggggggactctgtgtaacgctttctgcaagaagcgaatggctgt  
 ataacaatecactcggactttgacgattatctggcaatgctggaaaaceagctctggcctggcgaactgactctg  
 ctattttgggttggccaanaacataaaaaggaggaaattgaaaaactgcaaaaataaccacgatcatatagcctct  
 tctcaatcttctgctgtgcaacgactggcaagcggctccgcagagatgcaactggcgaaacccgtaactctgtttcc  
 tgcatactgcgcaaccaagggcattccgaagagctggcaaccggagagcglaatgaaatctgategaagaaactgtaag  
 aaaaatgaaasaagaaaaactgggtggctccctgttcgtaaacggctcgtagagactgctattaaactggcaactcaga  
 gccactgcaactcacaacatgggtgacgacatactagccggatgaaactgactgtaaacgtgtaactgctctgtataacc  
 ganccgattctgctgtaacgttaactgcagctggtaggactcgaattcagctccctcgacaagcttggcgccgcaactc  
 agcaccaccaccaccactgagatccggctgtaacaagcccgaagggaagctgagttggctgctgcccaccgctgagca  
 ataactagcataacccccggggcctcfaaacgggtctggagggtttttgtcgaaggaggaaactatctcggat

SEQ ID NO:35

Figure 137L




Figure 137M

plasmid MCM93 = pCR2.1-Kudzu

aaagggggaatttctgcagatataccatcacactggcggccgctcagagcatgcatctagaggggcccaatttcgcccctatag  
 tggagtctgatttacaatccactggccgctcgttttacaacgctcgtcgaatcggggaaaaacccctggcgttaaccacttaatk  
 gcccctggcagccacatcccctttcggccagctggcgttaaatggcgaaggaggcccccacccgatacggcccctcccaaacggttg  
 ccgagccctgaaatggcgaattggaaegccctctgagcggccgcatcaaggccggccgggtgctgggttaccggccagcgttg  
 accgctcaacacttggccagccgcccctagcggcccccctctcttggccttctctccctccctctctccggccacgcttcggccggtt  
 tcccggctcaagcctcaaatccgggggctccccttaggggttccggatattagtgcttcaacggcaacctcggaccccasaasaaac  
 ctgactagggtgagtggttccagctagtgggccatccgcccctgataagacgggttttctggcccctttgacgcttggagttccacg  
 tctcttcaatagtgagactctctgtcccaactgggaacaacactcaaccccctatctcgggtctattccttttgatttataagg  
 gatcttggccgatttccggccctattgggttaaaaaatggagctgatttcaaaaaaatttaacggcgaattttaaacaatctc  
 agggccgcaagggtctgctcaagggaagcgggaacaogtagaagagccagctccggccagaaacggctgctgaccccggatggaatg  
 tcaagctcactgggtctatctgggacaagggaaaaacggcaagccgcaaaaggaagcaggtagcttggcagttgggtctacatgg  
 cgaatagctagactggggcgggtttatgggacagcaaggcaacccggaaattggccagctcggggccgcccctctgggttaaggctgg  
 gaagccctcggcaaaagtaaacctgggctggcttctctggccgcccagggtctgagtgggccaggggagatcaaatctgatacaag  
 agcagggatgaggtatcgttctggcctgattgaaacaaagatgggtatgaaacagcaggtctctccggccggcttgggtgggaggg  
 ctatccggctatgactgggacaaacagcaaacctgggctgctctggatggccggctggcttccggctgcttccggccagggggcc  
 cccggctctctttctgcaagaccgacccctgctccggctggccctgaaatgaaactggcagggacgggcaagccgcccctatcgtggc  
 tggcccaagcagggggcttccctggccagcctgctgctcagcttctgctcactgaaagccgggaaggagactggcctgctattggggc  
 gaagctggccggggcagggtatcctcctgctcactcccactctgctcctcctggccagaaagttatccatcagctgctgataagcc  
 gcccgtctgacatacgccttgatccggctcactggcccattcgaaccccaaggcgaacatcggcactcggagccagccagcactc  
 ggtatggaaagccggctctctgctcagctcaggatgactctgggacagagagctcagggggctcggccagccagcccaactgctcggcc  
 aggtctcaaggccggccatgcccagcggccagggatctcagctcgtgacccatgggccagctgcccctgcttggccgaaatatacaggt  
 ggaacatggccgcttctctgggttcaatcagactgctggccggctgggtgctggccgggaacccctatcagggacatagccttgg  
 ctaccggctgatactgctgcaagagcttggccggccagctgggctgacccggctccctccctggcttcaagggcttcaagccgctcc  
 gactcggccagccatccgcccctctctggagcttctctggagcttctctggagcttctctggagcttctctggagcttctctggagct  
 caatctccggcttctctggagcttctctggagcttctctggagcttctctggagcttctctggagcttctctggagcttctctggagct  
 atggagcccccggcaagagcaactcggctcggccatcacttctctcaggaatgacttctctggagcttctctggagcttctctggagct  
 agaaaagcactctctcggatggccatgacagtaagagaaatctctcagctgctcggccataaacatggagctgataaacctcggcc  
 ccaactcactctctgacaaacgctcgggagggacccgagggagctcaaccgctctctctggcacaacatgggggggatacgttcaac  
 cggcccttgatcgttggggaacccggagctgaaatgaaagccatatacccaaacgagccagggctgaaacccacagctgcccctgtagcaat  
 gggcaacaaacgcttggcccaactatcaaacggccgcaactcactcagcttcccccggcaacaaatcaaacggcctggatgg  
 aggggggataaaagcttggcaggaacactctcggccctcggccctcggccctggctggcttctctggagcttctctggagcttctctggagcc  
 ggtgagcctgggtctcggccgctatccttggcagcactggggccagatggtaagcccccctccgctacgttagttatctacac  
 gacggggagctcagggcaacatctggatgaaagaaatgagacagatcggctggagatagggtgcccctcactgataagcattgggt  
 aaactgctaggaacaggttctcactcaatatacactttagatggattttaaaacctcactttttaaatttaaaaggatctcaggtg  
 aagatcccttctggataactctcagcaacaaaccccctcaacggctgagtttctcgttccactgagcctcagaccccggtaga  
 aagatcacaaggatctctctggagatctcttctctggccgctgaaatctgctgcttggcaaaaacaaacaaaccccctcagc  
 cagcggctgggttctgcttggccggatcacaagagctaacaaactctctctccgaaaggttaactggcttccagcagagccgagata  
 ccaaatcactgctctctcagctgtagccgtagcttagggccaccactcacaagaaactctctgtagcaccggccctcactaacctcgg  
 ctctgctcaaacctgcttccacagctggctgctcggccagctggccgataagctgctgcttcccccgggttggactcaagacgatagt  
 taaccggttaagggccagccggctcgggcttggaaaggggggttctggcccaacagcccccagcttggagccgaaagcactcaaccc  
 gaactgagatacctacagcctggagctatgggaaagccggccagcctcccccgaaggggagaaaggccgggacaggtatccgggt  
 aagccggccagggctcgggaacagggagagccgacagggggagcttccaggggggaaacggccctgggtatctctttagtccctgctc  
 ggttctcccccctctggacttggagccctcggatctcttgggtgctcctcagggggggcgggagccctatgggaaaaacggccagc  
 aagccggccctctctcaaggttcccccggcccttctgctggcccttctgctcacaatgctctctctccggcttactccctgactc  
 tggggatcaacccgcttcaacggcttctgggtgagctgataacccctcggccagccggaaacggccagccagccagccagctcag  
 tggccggaggaagccgggaagagccggcccaatagccaaacccgctcctcccggcggcttggccgctctcaatgagctgg  
 caagcaaggttctcccccagctgggaaagccggccagctgagccgcaacgcaattaatgagggttagctcactcacttagggcacc  
 ccagggcttcaacacttctatgctccggccctcgtatgcttgggtggaaattgctggagccggataaacaatttccacacaggaaca  
 gctatggacatgataccggccagcttgggtacccagctcggatcccttagtaaacggccggccagctgctgctggaattctcgg  
 cctgatacagcactccggcccttgggaggttaaaaacacatctgctggagccctctctcaatttactcagatcagccagc  
 ataaattccggctcctccggcaaacctctcagccaaacccctggtggaattctcgaattccctggcaatccctgggagaaacgactg

Figure 137N

aaagtggaaaagctggaggagaaagcgaacaaaactggaggaaagaagttcgcctgcatgatcaaccgtgttagacaccca  
gcccgtgctccctgctggagctgabcgacgatgtgcagcgccttgggtcttgacctacaaaatttgaaaaagacatcattta  
aagccctgggaaaaacatcctactgctggacgaaaaaagaacaaaactctgacctgcaacgcaacccgctctgtctttc  
cgtctgctggctcagcaccggtttcggaggtttctcaggatgtttctgagcgtttcaaggataaaagaaggctgggtttcag  
cggtgaaactgaaaagggtgacgtccaaaggcctgctgagcctgtatgaagcgtcttaacctgggtttcggagggtgagaaac  
tgctggaggaggcggctaccttttccatcaaccaacctgaaagaaacacctgaaagaaaggcathtaataccaagggttgc  
gaaacaagtggagccacgcccgggaactgcaatatacaccagcggctgcaaccgtctcggagggaacgttgggttctctggataa  
atacgaacccgaaagaaacccgcatcaaccagctgctgctggagctggggaaaggctggatcttbaacatgggtacagacccctgc  
accagaagagctgcaagatctgtcccgctgggtggacccgagatgggctcctggctagcaaacctggattttgtaacgac  
cgcctgatggaaagtttattcttgggcaactgggtatggcgcacagaccgcagcttgggtgaaatgtcgaagctgttac  
taaaaagtgtggctgggtgagatcctcagatgacgtgtatgacgtttatggcactctggagaaactgcaactggttca  
ccgatgctgttagagcctgggacgttaacgctataaacacccctgcccggactatatagaaactggttttctctggcactg  
taccacacccgttaacgacacgctcctattctattctgaaagagaaaggctcataacaacctgtcctatctgacgaaaaag  
ctggcgtgaaactgtgcaaaagcctttctgcaagaggcgaatgggtccaaacaacaaaatttatcccggctttctccaagt  
acctggaaaaacgcagcgtttcctcctccgggtgtagcgtctgctggcgccttcttacttttccgtaagccagcagcag  
gaagacatctccgaccacgcgctgcttccctgaaacgacttccatgggtctgggtgcttctagctggcttatctccg  
cctgtgcaaacgahctggcaccctctgcccggagctggaaacgtggcagagactaacaaattctabcatthagctacatgc  
acgaaaaagatgggtaccagcggaggaacaggcccgagaaactgctgtaaaactgatcgaacgcaaatgggaaaaagatg  
aatcgtgaaacgcttagcgaactcaacccctgctgctaaaggcttcatgggaaatcgcaggttaacatggcaacggtttc  
ccactgcacctacagatgggtctgggtcgcacagactacgagactgaaaaacggcatcaaacctgctgctga  
ttgaccttcccgatataacagctgatgtatgctaaactgacgggatccgtcgaacg

SEQ ID NO:36

Figure 1370






Figure 137Q

aaatcccccttacaaggaggcatcagtgacvaaaacaggaaaaaacccccccttaacatggccccccttatcageagcc  
agacatbbaocgcttctggagaaaactnaacagagctggagccggatgaaacaggcagacatctgtggaatcggcttccagac  
cacgctgatgagctttacccgagctgcccctccgccccttccggctgatgacgggtgaaaaactctggacacatgacagctccc  
ggagacgggtcacagcttctctgttaagcggatgcccggggagcagacaagcccccctcagggccgctcagccgggggttctggccg  
ggctgtccgggggocagccatgacccagtcacgttagcgtatagccggagctgtataactggcttaactatgcccacacagagc  
agattgtactgagaggtgacacatatactggcggctgtaaaatcccgccacagatggctaaaggagaaaaatccgcatcaggcc  
gctcttccgcttccctccgcccacccagctccgctggcctccggctcgttccggctggccggcagccgctatcagctcaactcaag  
gcccgttaacaggttatccacagaaatcagggggataaacccaggaagaaacatgctgagccaaaaggccacagcaaaaggccacg  
gaaacgttaaaaaggcccgcttggctggcgtttttccataggcctccgccccttgaacagccatcaacaaaaatccagcct  
caagtcagaggtgggggaaaaaccgacaggaactataaagataccaggccgtttcccccctgggaagctcccctcgtgcccct  
ccccttccggaccccctccgcccctacccggatccctgtccccccttctcccctccgggaagccctggccgctttctccatagctc  
acgctgtaggtatctcagcttccggctgtaggtccgttcccccacagccggccctgtgtgcaacgaaaccccctccagccc  
accgctgccccttatccggtaactatctgctctggagtcacaccccggtaagacacgacttatccgcccctggcagcagcc  
actggtaacagagattagccagagccaggtatgtagggctgctacagagcttcttgaagtggtggcctaacctacggctac  
cactagaaaggacagttatctggctctccgctccgctgaaagccagctacccctccggaaaaagagctgggtagcctcttggat  
ccggcacaacaaaccccggctggtagccggctggctttttctgttctgcaagccagcagatcaagccagcaaaaaaaggatct  
caagaaagatcccttggatcccttctacggggctctgaagctcagtggaacgaaaaactcaagcttaagggaacttctggctcat  
gaaacaataaaactgctctgctacataaaacagtaatacaagggggctgttatgagccatattcaacggggaacccgctctgc  
ctcagggcccgatbaaattccaacatggatgctgatttatatagggtataaatgggctccgcatatctcgggcaatc  
aggtgcgacaatctatcagattgtatgggaagcccagatggccacagagttgttctgaaacatggcaaaaggtagcctg  
ccaatgatgtcacagatgagatggctagacbaaactggctgaaggaatttatgcccctcccgacacbaagcctttt  
atccgtaactccgctgatgacatggcttactcaccactggatccccgggaaaaacggcattccaggtattagaagaaata  
tccctgatccaggtgaaaaatattgtctgattgctggcagctgttccctggcccccggcttgcattccgattccctgttctgaaat  
gtccctttaaaccagcgatcccgctattccgctccgctcagggcccaatccagaaatgaaataacggcttgggtgatgagagct  
gattttgatgacgagccgtaabggcttggccctgttgaacaagctctggaaagaaatgcataaaacttttggccatctccacc  
ggatccagctcgcactccatggctgattctcacttggataaccccttatcttggacgaggggaaatbaataggtctgtatctg  
atgttggacgagctggaaatccgacagacccgatccaggatcttgcacatccctatggaaactgcccctgggtgagtttctccct  
ccattacagaaaaaggcctttttcaaaaaatctggctattgataaactccgcatctgaaataaaactggcagcttccatctgactgct  
cgtatgagttttctcaagaaatbaatctcagggccggtatcacatatttgaaatgtattttgaaaaaatcaaaacaaataggggctt  
ccggcccaatctccccgaaaaagtgccacccctgaaacttggtaaacgctbaaactcttctgtcaaaatccggctcaaaatctctg  
ctaaactcagctcatctttctaaacaaataggccggaaatccggcaaaatccccttataaatcaaaagaaatagacccgagatag  
ggctgagctgtcttccagtttggaaacaagagctccactatbaaagaacgctggactccaaagctcaaaaggccgaaaaaac  
gtctatcagggccagatggcccaactaagtgaaacacaccccaatcaagcttttttggggctcagggctgcccgttaagccact  
aaatccggaaaccccaaaaggggagcccccgatttagagctttagccggggaaagccggccgaaacgctggcgagaaagggaaggga  
agaaagccgaaaggagccggccgctaggccgctggcaagctgtagccgtcacgctggccgctaaacacacaccccggccgg  
cttaatccgcccctcagggccgctcccatccgcaatccggatatagttccctccctccagcaaaaaaaccccctcaag  
accgcttagagggcccccaggggctatgctagttattgtctcagccggtggcagccagcccaactcagcttccctccggg  
cttctcagccagccggatctcagctggctggctggctggctcga

Figure 138




Figure 139




Figure 140



Figure 141

gaaitcaaaatgltgcaacttcacccaatcactcaaatcacagagcataatctagacgttcagctaaactccaaccaaactctgt  
ggaatttgaatttctcaatcccttgaaaatgattgaaagiggaaaagttggaggaaaaangccaaaaactagaggaaagaagtt  
agatgtatgataaacagagtagatacacaacctctgicactactagaaitgattgacgatgtccagaggctgggttaacatataag  
ttogaaaaggatataatcaangccttagaaaacatagtcctctagatgaaaacaagaagaataagctgacttgcacgcaaccg  
ctctgagtttagattgctgagacaacatggffttgaagtaagtcaagatgtgttfgaaagggtcaaaagacaagaggaggattct  
caggagaatfaaaggagatgtgcagggtctgttgcattgtacgaggccagttatttgggggttfgaaggggaaaatctactaga  
ggaggccagaacctctctafaacccatctgaagaataactgaaagaaggccatcaatacaaaagtggctgaacaagtctccat  
gcatgggaattgccctaccaccaagactctatagacttgaagccagatggttttggacaagfatgaaccaaggagcctcacc  
atcaactttattggaattagcaaaactggatttaacatggttcagacattacaccagaaagaattgcaggacctatcaagatggtg  
gacggagatgggttagccagcaagilagalltcgttagagatagatgatggaagtttactttgggacctgggaatggcaccag  
atcctcaatttggatgaatgtagaagcagttacaagatgtttggctagttaacaatcattgatgatgtttatgatgtgtacggaaactt  
tggatgaattacaactatccaccgacgcagttgaacgttgggatgtaaacgcaataaacacgttgcctgattatataagctgtgttt  
tctggcaattgtacaacacagtcfaatgacacttctactccatttaaggagaaaaggccataucaatctatctatttgacaaaatcat  
ggaggggagttatgcaaaagcattccitcaagaagctlaagtggctlaacaataagataalcccagcattctccaagtatcttgaaaac  
gcttccgtatcctcctcgggtgtggccctactagcaccatcatattttccgtctgcccagcagcaggaagafatctctgatcatgctt  
gagatccttaacaagatttcatggtctagtcagatcctcttgcgtgatttccagattgtgcaatgatitggctacttccagccagagtt  
agagaggggtgaaaccacgaactcaattatfatgtatatagcacgagaalgatggaacatccgaagaacaagcccgtgaagzaat  
aagaaaactgalcgnatgctgaatggaagaagatgaatagagaaaagattccgacagcactttgctgcctlaaggcattcatgga  
gatagctgtaacatggctagggttcacactgacataccaatacggggacgggtcttggaaaggcccgaactacgcaactgaaaat  
agaaitaaactgctactgatgatcctttcccaltaacagflaatgtacgtgtaatagggatccgaattc

SEQ ID NO:38

Figure 142A




Figure 142B

acggatfagaagccggagcggggacagccctcgaaggagacitcctcctcgtcgtcctcgtctcaccggcgctcc  
tgaaacgcgagatgctcctcgcggcctcgtcctcgaacaataaagattcacaatactagctttatggfataagaggasaaatt  
ggcagtaacctggccccacaacctcaaatgaacgaatcaaatcaaacatagggatgataatgagattagtttttagccttatt  
ctggggtaattaatcagcgaagcgatgattttgafclattaacagatataaataatgcaaaaactgcataaccacfttaactaactt  
caacatftteggfiftgattactcttattcaastgtaataaagtatcaaaaaaaatgftaafatacctctatactttaacgtcaagga  
gaaaaaaccccgactcggactactagcagctgtaatcagactcactatagggaaatllaagclatacaacaagttgtacaaaaa  
agcaggtcgaatfcaaaatggtgcaacttcctcctcaatcactcaaatcagagcatalaattctagacgttcagctaaactcaaac  
caactctggaatttgaatttctcaatcccttgaaaatgatttgaagtggaaaagtggaggaagaagccacaacttagagg  
aagaagttagatgtaatacaacagagtagatcacacaacclctgctactctagaattgattgacgatgccagagggcgggltta  
catataagttcgaaaagatataatcaaaccttagaaaacatagtcctctagatgaaaacaagaagaalaagctcacttgcac  
gcaaccgctctgagtttagattgctgagacaacatggttttaglaagtcgaagatgltttgaaaggttcaaaagcaaaagggg  
aggattctcagagaatlaaaggagatctcagggctctctctctcattctagcagccagttatggggttgaaggggaaaatc  
tactagaggaggccagaacctctctataacctctgaagaataacttgaagaaggccatcaatacaaaagttggcgaacagt  
ttcatalcattggaattgcccctaccaccaaaagacttcataacttgaagccagatglttttggacaagtatgaaccaaaagagc  
ctcaccatcaacttttattggaattagcaaacctggatttcaacatggttcagacattaccaccagaagaattgcaggacctatacag  
atgctgacgggagatgggttttagccagcaagtttagatttcttagagatagattgatggaagttactttgggcactgggaatggc  
accagatcccaatfttggtaattgagaagggcagtiacaagaatggttggctagtaacaatcattgatgattttatgatgtttagc  
gaaacttggatgaatfacaacttaccgacgcatggaactgggagatgaacgcaataaacacgttgcctgattatagaaagc  
tatttttctggatgtaaacacagtcactgacacttctcctcaatttaaaaggagaaggccataaacatctacttattgacaa  
aatcatggagggagttatgcaaaagcacttctcaagaagcctaaagcttaacaataagataatccagcattctccaaatctatc  
aaaaagcttccgtactcctcctcgggttggccctactagaccatcaatftttccgtctgcccagcagcaggaagatctctgatca  
tcttttagagaccttaacagatttcatggctagctagaccttctggctgatttccagatttgcattgatttgcctactcagccgca  
gattagagagggggtaaacaccgaaccicaattatgattatagcagcagagaatggaacatccgaagaacsagcccgtgaa  
gaatttaagaaactgactcagctgtaattgaaagaagatgaatagagaagagtttccgacagcactttgctgcccfaaa gcatca  
tggagatagctgtaacalggctagggtttcaactgtacataaccaataggggacggcttggaaaggcccactaccgccctga  
aaatagaaftaaactgactgattgacttctcccaataaccagtttaattgactgttaataggatccgaatcaccagcttcttg  
tacaagttgctgactcagggggccctcgaaggtaagcctatcccaaccctctcctcgtcgtcgtcgtcgtcgtcgtcgtcgtc  
catcaccatcaccatgagtttaaacccgtgatctagagggccgcatcatgtaattagttatgtacggctacattcacgcccctc  
cccacatccgcctaacgaaaagggaaggatitagaacacctgaagttaggtccctattttttatagttatgttagtattaa  
gaacttatttatattcaaaftttctttttctgtacagacgggtgacgatgtaacattatactgaaaaccttgcctgagaaggttt  
gggacgctcgaaggctttaaatttcaagctcggccctcattaatgaatcggccaacggcggggagagggggttgcgtatt  
ggggcctctc  
gtaatacggttatccacagaatcaggggataacggcaggaagaacatgttagcaaaaaggccagcaaaaagcccaggaaaccgta  
aaaaggcccggttgctggcgttttccataggctcggcccctcagcagcattcaaaaaatcagcgtcaaatcagaggttggc  
gaaacccgacaggactataaagaaccagggcttcccccggaaagctccctcgtgctcctcctcctcctcctcctcctcctcctc  
cggatacctgccccttctc  
cgtcctcaaggctgggtgtgtgacagcaaccocccgttccagcccagcctcctcctcctcctcctcctcctcctcctcctcctc  
cggtaagacacgacttatcggcactggcagcagccactggtaacagagtagcagagcgggtatgtaggggggtctacaga  
gttcttgaagttggtgctaaactacggctaacactagaaagacagtattggtatctgctcctcctcctcctcctcctcctcctc  
aaagggttggtagctctgacccggcaaaaaccaccgctggttagcgggtttttttgtttgcaagcagcagattacggcgagaa  
aaaaaggatctcaagagatcctttgatctttctacggggctcagcctcagtggaacgnaaacctacgftaagggtttgttca  
tgaatatacaaaaaggatcttcaactagatccttttaaatlaaaaalgaagtttaaatcaatcaaatgataatagataaacttggct  
tgacagttaccatgcttaactcagtgagccactatctcagcgtcgtctatttctgttcatccatagttgcctgactcccctcgtgt  
agataactacgatacggggagcgttaccatctggcccaggtctgcaatgataccggagaccacgctcaccggctcagatt

Figure 142C

taticgcaataaaccagccagccggaaggccgagccgcagaagtggctcgaactttatccgctccatccagcttattaattg  
 ttgccgggaagctagagtaagtagttccagttaanagtttgcgcaacgttggtggcattgclacaggcatcgtgggtcactctc  
 gtcgttgggtatggctcattcagctccgggtcccaacgatcaaggccgagttacatgatccccatgttggcaaaaaagcgggtag  
 ctcttcggctcccgatcgttgcagaaagtaagttggccgagtgtafcaactatggttatggcaagcactgcataatctctactg  
 tcatgccatccgtaagatgctttctgtgactggtgagtlactcaaccaagtcattctgagaatagtgatgcccggcagccgagttgctc  
 ttgccccggcgtcaatacgggataatagtgatcacatagcagaactttaaaagtgtcctatcattggaaaaagcttccggggcga  
 aactctcaaggatctacgcgttgtagatccagttcgaatgaacceactcgtgcacccaactgatctcagcatctttactttacc  
 agcgtttctgggtgagcaaaaaacagggaaggcaaaafgcccgaaaaagggaafaggggcagacaggaaatgttgaafactca  
 tactctccttttcaatgggtaataactgataaantaaatgaugctctuaatttgggtttatagatatacatgcatcttataaatacagtt  
 ttttagtttgcgtggccgcatctcuaatagctccagccctgctttctgtaacgttccaccttaecttagcatcctctccctttgca  
 aatagctctctcccaacaaataaagtcagatcctgtagagaccacatccacaggtttctatactgttgaaccaatgctctccctt  
 gtcactcaacecacaccgggtgctataaicaaccaatcgaacccatctctctccaccatgctctctttgagcaataaageogata  
 acaaaatcttltgctctccgcaatgtcaacagttacccttagtatattctccagtagatagggagcccttgcagcaaatctctgtaa  
 catcaaaaggccctcaggttcccttcttactctctctgcccgcctgctcaaacctggtgcccaccacaccctgctgct  
 atctgtaatgctctgcccattctgctatctctgatacaccggcagagttacgtcaatfagctgtattaccaatgtcagcaaatctctgctt  
 cgaagagtaaaaaattgtacttggcggalaatgcttttagcggcttaactgtgcccctccatggaaaaatcagtcagaatctccacal  
 gtgttttagtaacaatfittgggacctaatgcttcaactaactccagtaatctcttgggtacgaacatccaatgaagcacacaa  
 gtttgttctctctgctcagatataaataagcttggcagcaacaggactaggatgagtagcagcagctctctctctctctctctct  
 acatgatttactctcctctctcaggttttct  
 atcaaaaaaagaataaaaaaaatgataaattgaaatgaaaagctagcttctctctctctctctctctctctctctctctctctct  
 caaggactatagactatagactatct  
 ttltgtactctatgatccagctcagcaaaaggcagttgtgactcaagatctctctctctctctctctctctctctctctctctctct  
 gagactagaaatgcaaaaggcacttctcaaatggctgcccataatct  
 acccttggaggagatacagcctaatatccgacaaactgtttacagatttaccgactgactgttaccatctgaatttgaacatcc  
 gaacctgggagtttccctgaaacagatagatalttgaacctgtataaiaatataagctctagccttaccggaagaeastgtatgta  
 ttccggctctggagaaactattgcatctattgcalaggtaacttctgacagctccatcccggtcatttctctgcttccatcttgcactt  
 caatagcatacttctgtaacgaagcactctgtct  
 aictgagctctcttctacagaaacagaaatgcaacgcaaaagcctatttaccacgaagaatctgctctctctctctctctctctct  
 aatgcaacgctgagagagcctaatfctcaaacaaagaatctgagct  
 ctatfaccacaacaagaatctatact  
 tttttct  
 tatttctctctcaaaaaagccctgactccactctcccgcttactgacttagctgagctgagctgagctgagctgagctgagctgag  
 gctctcccgattatct  
 aattatgaaagggttct  
 tactcaaatfcttct  
 aggggatgggtaggtatfataggatatagcacagagatatagcacaagagafactttgagcaatgttggggaagcgggtatc  
 gcaatgggaagctccaccccggttgataatcagaaaagcccccaaaacaggnagatgataagcaaatatttaaatgtaaacg  
 ttaataatttgaatfctcgttaaatfctgtaaatcagctctatttfaacgaatagcccgaatcggcaaatccctfataaactca  
 aaagaatagaccgagatagggttgggttgggttccagtttccaacaagagctcactattaaagaacgtggactcacaactcaaacg  
 ggcgaaaaagggtctacagggcgaagccactacgtgascacaccccaatcaagtttttggggctgaggtgcccgtaaag  
 cagtaaatcggaaagggtaacgggatccccatttagagcttgcaggggaaagccggcgaacgttggcagaaagggaaggga  
 agaaaggcaaggagcgggggctagggcgggtgggaaggttaggggctacgctggggctaacaccacacccgcgcgctt  
 aatggggcctacagggcgcgtgggaatcactagtt

SEQ ID NO:59

Figure 143




Figure 144A




Figure 144 B





Figure 145A



HGS opt Pseudo fluo2-2 with Rest sites

1746 bp

Figure 145B

caictlaagcttgfttaactttaagaaggagatatacstatgigcgcaccaccagcagccagttcaccagatcaccgagcataatag  
 ccgctcgggtccgcgaactaccagcccaacctgtggaacttcgagttcctgcagagccctggaaaacgacctgaaaggaggagaag  
 ctggaagagaaggccaccaggctggaggaggagggtgcggttcgatgataaccgggtggacaccagcccctgagcctgctg  
 gagctcattcgacgacgigcagcgccctgggctgacctacaagtgtgagaagatatacaaggcggctggagaacatcgtcctg  
 ctggacggagaataagaagaacaaaagcgactgcacgcgaccgcccagcctcggcctgctgcccagcagatggcttggagg  
 gagccaggacgtgttcgagcgttcaaggacaaaaggggggcttctccggggaactgaagggtgacgfgcaggggccigt  
 gagectgtacaggccagctatctcgggttfgaaggcgaaaatctgctggaggaggcccgtaccttcagcatcaccatctgaa  
 gaacaacctcaaggagggggatcaaacgaagggtggccgagcagggtgtccacgcgctggagctgccgtatcataacgcc  
 gcaccgctggaggcgggtgggttctaggacaagctacgaacccaaggagccgcatcaccagctgctgctggaactggccaaa  
 ctcgattcaacatggctccagacctgcacaaaaagagctgacaggacctgagccgggtgggtggaccgagatggccctcggca  
 gcaagctggatttcgctggggaccgctgatggaaagtgtacttctggggcctggggcatggcggccggaccgagctggcgaa  
 tgcgcaaggccgtcaccaagatgtcggctgtggtcaccattatcgaigacgtctatgacgtgtacggtaacctggacgaactgc  
 agcttccaccgacgcgggtggaacgctgggacgtgaacgccatcaaacgctgcccactatataagctgtgcttctggccc  
 tgiacnacaccgtgaacgacacgctcctactcctcctgaaggagaagggccacaataacctgagctatctgacaaaagctggc  
 gcaactgtgcaaggccttctgcaagaagccaagtggagcaataacaagatcaccctcccttcagcaangtacctggagAAC  
 gccagcgtgtcctcagcggggtcgcgctgctggcgcggagctacttctggctgtccagcagcagggaagatactcggacca  
 cggcctccgctccctgaccgacttccagggcctggctggctcgtcctgctgctgctgctgctgctgctgctgctgctgctgctg  
 gcggcggaactegaacggcggaaccaccaacagcaccatcagctacatgcaagagaacgacggcagcagcagcagcagcagc  
 ggcccggaaagagctgcaagctgatcgacggcggagtggaagaaaatgaaccggcagcggcgtgtctggacagcaccctgc  
 tgcggaaggcgttatggagatgccctgaacatggcccgcgtgagccactgcacctaccaataggggacgggctggggccg  
 cccggattaccgcaccgagaaccgatcaagctgctgctcctcagcccgttcccacatcaaccagcigtatgtagctgtgaggatc  
 ccgtaac

SEQ ID NO:40

Figure 146A




Figure 146B

ctcggggcgtctcttgggcttgafoaggccitcttgcgeatctacgcgctcctgcggggcctttagggcaggctcacaacctg  
ccgaaaccgcttttgcagccggctggccacggcttccggcgtctcaagcgcctttaggattccagcttttggccaatccctgcg  
gtgcatagggcggctggctcggaccgcttgcgggcttggatggtgacgttggccacagggtggccctccaggggcctcgtagaacgc  
ctgaaatggcggctgtgacgtgcttgccttgcctcgtatgccccttgcagccctagatcggccacagcggccgcaaacgtggctg  
gtcgcgggctcatctgcgcttgttgcggatgaaactccttggccgacagccttgcctcctgcctcagcggccaccacgaaacgggt  
catgtcgggctgttctcagcgggtgatgctggcgtcacgatggatccgcccgtacttgcctcagccacccttgttgcgct  
ttctcgaagaaacggcgcctgtcttcttggctggccgacttccaccatccgggctgctcctcagctacgtactcggaccgccaaca  
cagcggcttcttgcggccttcttggcagcaactcggcagctcggccatcggcttccatgggtgcttgcctggcccccagtgctgtt  
ctctggcgtcctgtctggcgtcagcgttggggctctcgcctcggctaggcgtgcttggagactggccgcaacttggcccaatttc  
ggcagcttcttgcctcagctatgccttggatggccatggcttgccttccccttgggtgctcaaacggcctcagcggggcagcgc  
aaggcgggtgccctcggcggggccacccaatgcttggatctactcactagacttgccttgcgaagctgctgaccgctcagggcgt  
ggggggccctacgggcttgcctcggggttgccttgcggcgtccttgcggctccttggcagcccgtggatattggacgatg  
ggcggcagggggccaccggcttggctcgtctcggccttggacaaccccttgggacaagctgatggacagccttgcgct  
ggccacgagcttggaccacagggattgcccacggctacccagccttgcacacataccaccggctccaactgcgcggccttgc  
cggccttgcgccatcaatttttaatttctctggggaaaaagcctccggccttgcggccttgcgccttgccttgcgggttggacacc  
aagtggaaggcgggctcaaggctcgcgcagcggaccgctcagcggccttggccttgcgcgcccggaaacggcccaagcctatgc  
gagtgggggcagctcgaaggcgaagcccgcgccttgcgcccccggagcctcagcggcggcggcggggttcccaagggggg  
cagcggccacccttgggcaaggcggcaaggcggcggcagctcagatcaacaagcccggagggggccacttttggccggagggggag  
ccggcggcaaggcgtggggggaaccccggcaggggttgccttcttgggcaaccaaaagaactagatataggggcaaatgcgaaan  
gacttaaaaatacaacttaaaaagggggggtacgcaacagctcatttgcggcacccccggcaatagctcatttgcgtagggttaa  
agaaaatctgtaattgactggcaactttacgcaacgataaattgttgcggccttgcggcaaaaagttgcaagcttgcctcagctg  
gcaaccgttgcggcaccctacccgatggatagaagcattggccacgcagctcagagaatcggcaattcaagcgaagaacaagc  
ccggtcacttgggtgcaaacggaaagcgaagcctatgagggcttggggcggccttatttgcgaggaaccacggcggcaatg  
tgcctcaccctcgttggcggcagatggggccaccagaacggccttgggttggcagccaggaacacttccaaagctcattggcagct  
cttgcggacggctcaatcagcagctcaagggacttgggtggcggagccttggatctcctgctgtaagctcaacggcccccggcacc  
gttgcggcctcagctcaatgaaccgcttggcgttggggcggcagcccggaccagcttgccttgccttgccttgccttgccttgcctt  
gggtggttgcctcagcagcagcgaatcgttggggccttggcggcagccttgcggcctcagcagccttgccttgccttgccttgcctt  
cagcaactaccgagcggcccccggcggagggcggcccccagcccggcattccgggcatggaaccagaccctgcagcctt  
gaccgaaacgggaggaatgggacggcggcggcagcggccttgcggatcccggatgagcctgttcttgcggacgatggcga  
ggccttggagccggcagaccgggtaeacttgcggcggcggtagcacttgggttgcggcagcaaccgtaagtgctgttccca  
gactatcggcttgcggcctcggccttacccttgcctcctcggcttgccttgccttgccttgccttgccttgccttgccttgccttgc  
gacctgaatgggaagccggcggcaccctcgtaacggattcaccgcttttaccagccttggggaggcagaataaattgatcaatctgi  
caattattaccctccagggggagagccttgcgcaacttggcctcagggcattgagaagcacacggctcacacttccgggtatgta  
ataaaccggtaaacagcaatagacataagcggcttattaacgaccttgccttgaaccgagaccgggtcgaatttgccttgcgaa  
ttctgccttaccctccttattatcacttaccagcggtagcaccagggctttaaaggccaccastaaactgccttaaaaaattaccg  
ccgcccctgcctcactcagcagctggcccttattgggttaaaaaatgagcttattaaacaaaaatfaaacgcaattttaaacaataat  
cggctaacatttccatcggccttaccagcctgcgaacttggggaaaggcagccttgcggggccttcttgccttaccgcaagctgg  
cgaaggggggatgtctcgaagcggatfaagttgggtaacgcccaggggttccagctcagcggcttgaaacgagcggccagct  
gagcggcggtaatacagctcactataggcggaaattggagctcaccgggttggcggcggcctctagaaactagttggatccccg  
ggctcagggaaatcgaatcagcttaccgacctcagcggggggggcccggtaaccagcttggcttccctttagtgagg  
gttaatttgcggccttggcgttaateatggtcctagcttctcgttggatgaaattgttaccgctcaaatccacacacatacagacc  
ggaaagcctaaagtgtaagcctgggggtcctaaatgagtgagctaacctaacatlaatttgccttgcctcacttgccttgccttgc  
gggaacacctgtcgtcagccttgcctaaatgaatcggccaacggcggggagagggcgggttgccttatttggcggcctcagataaaa  
acttggtaattcaatagcattctcggacatggaagcctatcaaacggccttgccttgccttgccttgccttgccttgccttgccttgc

Figure 146C

cttgtgeetttgcgtataataatffgeccatggacggcacaccgtggaaacggatgaaggcacgaaccagttgacataagcctgtt  
cggttcgtaaactgtfaalgaagtagcgtatgcgctcaogcaaciggcaccagaacctgaccgaacgcagcgggtgtaacggc  
gcagtgggcgggttcatggcittgtatgactgtttttgtfacagictatgcccggcatccaagcagcaagcgcgttacgccgtgg  
gtcgtatgttgaatgatggagcagcaacgatgttacgcagcagcaacgatgttacgcagcagggcagtcgccctaaaacaag  
ftagtggtcacaagtatgggcatcattgcacatgttaggctcggccctgaccaagtcaaatccatgpcggctgtcttgaatcttc  
ggcgtgagttcggagacgttagccacctactccaacatcagccggactccgattacctcgggaacttgcctcgtagnaagacat  
tcateggcgttgcctcgcaccagaagcgggtgttggcgcctcgcggcttacgttctgccagggttgagcagccgcgtagt  
gagatctatactatgactcgcagctcgcggcagcaccggaggcaggggcattgccaccgcgcctcacaatctcccaagcatg  
aggccaacgcgcttgggtgcttatgtgatctacgtgcaagcagattacggtgacgatccgcagtggtctctafacaagttggg  
catacgggaagaagtgatgcacttgatacagaccaagttaccgcacctaacaattcgtfcaagccgagatcggcctcccgcc  
gcggagttgttcggtaaatgtcacaacgccgccagggtggcacttttcggggaatgtgcgcgcccgcttccctgctggcgcig  
ggcctgttctggcgtggacttcccgcttccgtcagcagcttttcccacggccttgatgatcggcggccttggcctgca  
talcccgaatcaacggccccaggcgtccagaacgggcttcaggcgttcccgaaggf

SEQ ID NO:41

Figure 147A




Figure 147B

ctcgggcccgtctctgggttgatggcccttcttgcgcaictcacggcgtccctggcggcggcctgtaggccagggcicaiaccctg  
ccgaaccgctttgtcagccgggtcggccacggcttccgggtcacaacggctttgagatccagcttttggccaatccctgg  
gtgcatagggcggcgtggctcagacccttggggctgtaggtgacgtagcccaactgggtggccctccaggggcctcgtagsaacgc  
ctgaatggcgtgtgacgttgccttgcctcctgatgcccggttgcagccctagatggccacagcggccgcaaacgttgggtctg  
gtcgggggtcacttgccttcttggccgatgaactccttggccgacagcctggcctctgctcagcggcaccacagaacgggt  
catgtcggggctgggttctcaccgttggatctggccgtcagcagatccgcccctactgtccggccagccacttggcggcc  
ttctcgaagaacgcggccttcttcttggctggccgacttccaccattccgggctggccctcagcagcactcgaacgccaaca  
cagcgtccttgcggcccttcttctggcagcaactcggcagctggcccatcgttccatcgggtgctgtggcccccaggtcctgt  
ctctggcgtcctgtgggtcagcgttggggctctcggcctcggcggtagggcgtgcttggagactggccggccaggttggccattc  
ggcagctcttgcacccatgatggctatggccgatgcttggccctcccttgggtgccaaccggcctcaggggggagcggc  
aaggccgggtgctccggcggggccactcaalgcttggatatactactagacttggcttgcacaagctgtagccctacggcggct  
ggcggcggccctacggcgttctcggggcttggccctcggcggctcggcctccttggcagccctggatalgtggacgatg  
ggccgagcggccaccggcgttggctcgttggcggccggtagaacacctgctggacaagctgatggacagggctggcct  
ggccacggagcttgaaccagggatggccaccggctaccagccttggaccacataaccaccggcctccaaactggcggcctg  
cggccttggcccacaatttttaattttctctgggaaaaagccctggccttggcggccttggccttggccttggccttggccttgg  
aagtggaggcggggcaaggctcggcagcggccggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
gagtggggcagtcgaaggcgaagcccggccctggcccccggagcctcagggcggcggcggcggcggcggcggcggcggcggc  
cagcggccaccttgggcaaggccgaaggccggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
ccggcggcgaaggcgttgggggaaaccggcaggggggtcccttcttgggcaacaaagaactagatataggggcgaatggcga  
gacttaaaaatcaaacacttaaaaaaggggggggtagcaacagctcatttggcggcacccccgaalagctcattggcgttaggta  
agaaaatctgaatgactggcacttttaccgcaacgataatgttggcggcggcggcggcggcggcggcggcggcggcggcggc  
gcaaccgttggcggcaccctaccgcatggagataagcagggccagcagcagcagcagcagcagcagcagcagcagcagcagc  
ccggctcacttgggtgaacggaaacgcaagcggcagggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
tgcctgcatcaccctgtggcggcagatggggcaccagaaacggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
cttggc  
gttggc  
cagcaactaccggaccggcccccggcggaggagccggccagccagccggcggcggcggcggcggcggcggcggcggcggcggc  
gaccgaaaccggagggaatggggaacggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
gactatcggcgttggc  
gacctgaatggaggc  
caattattaccctccacggggaggagcctgagcuaactggcctcaggcatttgaagcacacggcaccactgctccggtagtca  
ataaacggglaaacagcaatagacataagcggcctatttaacgaccctggccgaaccggagaccgggctggaatttggcttggaa  
ttctgcccattcaccgcttattatcacttattcaggcgttagcaccaggcgttgaaggcaccataactgcttataaaaaatcggc  
ccggccttgcaccctcaccgagcggc  
cgcttcaatitocaitcggcattcaggc  
cgaaaggggggtgtgtcgaaggcggaltaggttgggtaacggcagggttttccagctcagcagcgttgaaacgacggccagt  
gagcggcgggtaaacgactactataggcggcgaatggagctccaccggcggcggcggcggcggcggcggcggcggcggcggc  
cgtacatcagcgggttgggttgggggaacgggtcagtagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc  
ccgtcaccatattggtaggtgaggtggcctcagcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
tccgacacggcgtcgggttcttctcactcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc  
tggcttctggc  
ccgaaagatcagcaggaagcggc

Figure 147C

ctgctggcagaccgagaagtagctcggcggcagcagcggcagcccccgtgaggacacgcctggcgttctcaggtaactgctg  
 aaggcggggatgatctgttattgctccacttggcttcttcagggaaggccttgcacagttcggccagccttggtcagatagctc  
 aggttaltgtggcccttctccctcaggatggagtaggacggtgctgacgggtgtgtacagggccaggaagcacagcttcalata  
 gtcggggcagcgtgttgatggcgttcacgtcccagcgttccaccgctcgggtgaaagagctgcagttcgtccagggtaccgtacac  
 gtcataagacgtcatcgataatggtagaccagaccgaacatcttggtagcggccttggcggcattcggcgaactgggggtccggcgc  
 eatgcccagcggccagaagtacacttccatcaggcgggtcccgcacgaatccagcttgcctggcggagggccatctcgggtccacc  
 accggctcaggtctcagcgtcttgggtgtaggggtctggaccatgttgaatcagagttggccagttccagcagcagctgggtga  
 tgcggctccttgggttctgacttgcagaaaccaccggcctccaggggtgcaggcgttgatgatacggcagctccagcggc  
 tgggacacctgctcggccaccttctggtgacccctccttggaggttggcttcagatgggtgagctgaagggtacgggctcctcc  
 agcagatttctcctcgaaacgagatagctggcctcgtacaggctcagcaggccctgcacgtcaccctcagttcccggag  
 aagcccccttcttggcttgaagcgtcgaacacgtctcggctcaccctcaaggccatgctgccgcagcaggcgggaagctcagg  
 gctggctggctgcagatcgcttcttcttcttcttctcctccagcaggacagatgttctccagcggccttggatgatacttctcaactt  
 taggtcaggcccaggcgtcgcacgctgctgatggctccagcaggctcaggggctgggtgtccaccgggtgacatgcaacg  
 caetctctcctccagcgttgggtggccttctctcagcttctccacctcaggctcgttccaggctctgcaggaaactgaagttccac  
 aggttgggtggtagttcggcggaccgacggctatfatgctcgtgtagctgggtgaaactggctcgtggctggcgcacalatgtatac  
 tcttctttaaagtaaacagcttctgataccgtcgaacctgaggggggggccggtaaccagcttcttcttcttcttcttcttcttctt  
 attggcgccttggcgtatcatggctatagctgttctctgttgaattgttatccgctcacaattccacacaacafacgagccggaa  
 gcataaagtgtaaaagccctgggggtgctaatgagtgagctaacacacattaatgcttgcctcactgcccgttccagctgggga  
 aacctgtctgctccagctgcattaatgaatcggccaacggcgggggagaggcgggttgcgtatggggcgcagtcataaaaactgt  
 tgaattcattaaagcattctgcccagatggaaagccatcacaaaaggcatgatgaacctgaatgccagcggcctcagcaccctgt  
 cgccttgcgtataatattgcccagtggaacgcaaccgttggaaacggatgaaggcaagcaaccagttgacataagcctgttgggt  
 cgtaaacigtatgcaagtagcgtatgcctcagcgaactggtccagaacctgaccgaacgcagcgggtggtaagggcggcaggt  
 gggtgggttctcaggttggatgactgtttttgtacagctatgcccggggcatccaagcagcaagcggcttaccggctgggtcga  
 tgtttgatgttatggagcagcaacgatgttacgcagcagcaacgatgttacgcagcagggcagctcggcctaaaacaaagttagggt  
 ggctcaaglatgggcatctcgcacatgtaggtctggccttgaaccaagtcanaatccatgctgggtgctcttcttcttcttcttctt  
 gagttcgggagcgtagccacctctcccaacatcagccgggactccgattacctgggaacttgcctcgtatgaaagacattcctg  
 cgttggctgctcctcagcaagaagcgggttggcgtctctcgggcttaccgttctggcccagggttggagcagccggfagtgagat  
 ctatactatgatctcagctctcggcagcaccgggagggcaggggcattgcccaccgctcatcaatctctcagcagatgaggc  
 caacgcgttgggtgattatgtgatctacgtgcaagcagattaccgtgacgatcccagtggtctctatacaaaagttgggcatac  
 gggaagaagtgaigcacttggatctgacccaagfaccgccacctaacaattcgttcaagccgagatcggcttcccggcggcggg  
 agttgttgggtaaatgtcacaaccggcggcaggtggcacttctggggaaatgtcggcggccggcttctctgctggcgtgggtcct  
 gttctggcgtggacttcccgttctcgtcagcagcttctcggccacggccttggatctcggggcggccttggccttgcataccc  
 gattcaacggccccaggggctccagaacgggcttccaggtctcccgaagggt

SEQ ID NO:42

Figure 148




Figure 149




Figure 150




Figure 151




Figure 152






Figure 153B

ccagccagacgcagacgcgcgagacagaacttaatgggcccgtaacagcgcgattgctggtagcccaatgcaccagatgctccac  
gcccagtcgcgtaccgcttcacatgggagaaaataactgttgatgggtgtctggicagagacatcaagaataacgccggaacattagtc  
aggcagcttccacagcaatggcctcctggcctacccagcgatagtaatgatcagcccactgacgcgtggcgcgagaagattgacccgc  
cgtttacaggcttggacccgcttcctaccatcgacaccaccacgcctggcaccocagttgacggcgcgagatttaacgccggacaa  
tttggcagggcgcgtgcaggggccagactggaggtggcaacgccaatcagcaacgactgtttgcccccaggttggccacgcggttgg  
gaatgtaattcagctccgcctcgccttccacttttccgcgttttcgcagaaacgtggctggccctgggtaccacgcggaaacggctc  
gataagagacaccggcatactctgcacatcgtataacgtactggtttcacattcaccaccctgaattgactctctccgggcccctacatgc  
cataccgcgaagggtttggcgcattcgtatggtgctgggatctgcacgctccttatgctgactcctgcatlaggaagcagccagtagta  
ggttgaggccgttagcaccgccgcgaaggatggtgcatgcaaggagatggcggccaacagtcgccggccacggggcctgcca  
ccatacccacgccgaacaagcctcatgagccgaagtggcgagcccgatcttcccacatcgggtgatgctggcgatagggccagca  
accgcacctgtggcgccgggtgatccggccacgatgctgcccggcgtagagatcgcgatcccgcgaataataegactcacta  
taggggaattggtagcgggtaacaatccctctagaataaattgttttaacttaagaaggagatatacatatgggtgtagcgtgtccaccg  
aaaatgtgtcttccagaaactgaaaccgaagctcgtcgttcgcgaactacgaacctaacagctgggactatgattacctgctgtcccca  
cacggacgagctccatcgaagtatacaagacaagcgaaaaagctggaagccgnaagttcgtcgcgagatataaacganaaagcagaat  
ttctgacctgtcggaaactgattgacaacgtccagcgcctgggctgggttaccggttcgagctgatafccgtggtagcgtggatcgtcgt  
ttcctccggcgtcctcgtatcgggtaaccaagacttccctgcacggctacggcaactgtcttccgctcgtcgtcaaacacgggtttgaggttctc  
agggaagcgttcagcggctcacaagaccaaaacggcaacttccgtgagaaacctgaagggaagatcaaaagctatcctgagccgtgacgagg  
ccagcttccgtgctcgaaggcgaaaaactcctggacgagggcgaaggttttcgcaatctctcatctgaaagaactgtctgaaagaaagatc  
gglaaagagctggcgaacaggtgaaccatgcaactggaaactgccactgcatcggcgtactcagcgtctggaaagcagataggctatcggg  
gcttaccgtaaaaaggaggacgcgaatcagggtctcgtggagctggcaattcggattacaacatgatccagctctgataaccagcgtgatc  
gctgaaacgtcccgttgggtggcgtcgtgtgggtcgtggcgaacaaactgcacttgcctcgtaccgcccgtattgagagcttctactggccc  
tgggtgtgacattcgaaccgaatactcgcactgcccgtacccgtcgaaaaaigtcttctgtaaccattatcgcagatactacgatgat  
acggcaccctggacgaactggagctgttactgatcagttgagcgttgggaagtaaacgccatcaacgacctggccgattacatgaaact  
gtgctttctggctctgtataaactattaaacgaatcgcctacgacaacctgaaagataaaggtagaacaatcctgcccgtatcgtaccaaac  
ctgggctgacctgtgcaacgcttctcgaagaagccaagtggtctgacaacaatctactcggaccttgacgactacttggcaacgcatg  
gaaatcctctctgcccgtgcaactgggtgtcgttacttctgctgctgctgcaaacattaaaaagggaagagatcgaaaaacctgcaaaaata  
ccatgacaccatctctgctctcccatacttccgtctgtgcaatgacctggctagcgcgtctgggaaattgcgctgggtgaaaccgcaaat  
agcgtttctgttacatgcgcactaaaggatctccgaagaactggctaccgaaagcgtgatgaatcgtgatgaaacctggaaaaagatg  
aacaaaggaaaaactgggtggtagcctgttcgcaaaccttctgtgaaaccgcgatcaacctgcaacgtcaatctactgcaacttataa  
cggcgacggcctacctctccggatgagctgaccgcaaacgcttctgtctgtaatactgaaccgattcgcggttgaacgctaaaggat  
ccgaattcagctccgtcgacaagcttggcggcgcactcagcaccaccaccaccactgagatccggctglaacaaagcccgaaa  
ggaaagctgagttgctgctgccaccgctgagcaataactagcataaccccttggggcctctaaacgggtcttgagggggttttggctgaaag  
gsggaactatataccggat (SEQ ID NO: 43)

Figure 154




Figure 155




Figure 156A

1-

glttgaacagctatcactgacggtgacccaatgcttctggcgctcaggcagccatcgggaagctgtggtatggctgtgcoaggtcgtzaat  
cactgcatatsttcgtgctcaaggcgcactcccgctcggalaatgctttttggccgacatcataacggctcggcaaatattctgaaatgag  
ctgttgacaatfatcaccggctcgtataafgtgiggaaatgtgagcggalaacaafttcacacaggaascagcgcccgctgagaaaaagcg  
aagcggcaotgctcittaacaattatcagacaatctgtgtgggcacccgaccggaattatcgaffaaciffattafaaaaatfaaaggaggtat  
attaatglatcgaffaataaggaggastaaccatgagatgtagcgtgtccaccgaaaatgtgtcttcaccgaaactgaaaccgaaagctc  
ctgtctcggaaactacgaacctaacagctgggactatgaffacctgctgtccctccgacacggacggagtcctcgaagtatacaaaagacaag  
cgaaaaagctggagaccgaaagttcgtcggcagattaataacgaaaaagcgaatftctgaccctgctggaactgattgacaancgtccagcg  
cctgggctcgggtaccgcttcaggtctgataccgtgggtcggctgctcctcgtttccctccggcggctcgtatcgggtaaccaagacttcc  
ctgcacgggtacggcaactgtcttccgtctgctcgcgcaaacacggtttgagggtttctcagggaagcgticagcggctcnaaaagaccanaacggc  
aacttccctggagaaactgaaaggagatacaaaagctatcctgagcctgtacgaggccagcttccctgctcggaaaggcgaaaaacacttgg  
acgaggcgaaaggcttcccaatctcactgaaagaaactgtctgaagaaaagatcggtaaaaggactggcagaacagggtaaacatgcaact  
ggaaactgcaactgcatcgccgtactcagcgtctggaaagcagatggtctatcgaggccctacccgtaaaaaggaggacgccaatcaggctc  
ctggagctggcaactctggaftaacacatgatccagctctgtataaccagcgtgactcgtcgtgaaacgtccctgggtggcgtctggtgggtc  
gccaacaaactgcaactttgctcgtgacccgctgattgagagcttctactggggccgtgggtgtagcattcgaaccgcaactcggactgccc  
taactcgtcgcnaaaatgcttctcgttaaccattatcgacgatactcaogatgataccggcaccctggcgaactgagctgtgttactgatgc  
agttgagcgttgggacgtaaacgccatcaacgacctgccggatfacafgaaactgtgctttctggetctgtataaacactatfaacgaaatgcc  
taegacaactgnaagataaaagggtgagaaacacctgccglatctgaccaaagccctgggctgacctgtgcaacgcttctcgaagaaacca  
agtggctgtacaacaactctactcagacctttgacgactactcggcaacgcaaggaaatctctcttggcccgctgcaactgggtgttctgotta  
cttccgtctgtgcagaacatfaaaaagggaagatcgaanaacctcgaanaataccatgacacatctctcctccatctctccatctctcgtctg  
tgcactgacctggctagcgcgtctcggaaatgctgctgggtgaaaccgcaaatagcgtttctgttaactcgcactaaaggatctccgaa  
gaaactggctaccgaaagcgtgatgaatctgatcgafgaaacctggaanaagatgaacaaggaaanaactgggtggtagccgttctcggaaa  
ccgttctggaanaaccgcatcaacctggcaccgiccaactcactgcaactatataaccggcggcagcggcacaacctctccggatgagctgacc  
gcaaacgctgtctgtctgtaatacactgaaaccgacttctgcccgttgaacgtaactcagcctggtaccatagtggaaactgaaactctagaac  
naaaactcactcagaagagatctgaatagcgcctcgaacctatcactatcactatgagtttaaacgggtctccagcttggctgttttggcg  
gatgagagaaagatttccagcctgatacagattfaaacagaaaccgagaagcgggtctgataaaacagaaatgtccctggcggcagtagcgggt  
ggctccacctgaccccatcgcaacacagaaagtgaaacggcgtagcggcagatggtatgtgtgggtctcccatcgagagtagggaaact  
gccaggcactaataaaacgaaaggctcagtcgaaagactgggccccttctgtttatctgttggttgtcgggaaacgctctccctgagtaggacaa  
atccgcccgggagcggattgancgtgcaagcaacggcccgagggggtggcgggagggacggccgccaataaactgcccaggcatcaaat  
taagcagaaggccatctgacggatggccttttgcggttctacaactcttttggttatfttctaaatacatcaaaafatglatcctcatgaga  
caataacctgataaaactcaataaattgaaaaaggaaagatgtagatcaacatctccgtgctgccccttattcccttttggcgaatttgg  
ecttctgttttggcaccocagaaacgctgggtgaaagfaaaagatgctgaagatcagttgggtgacgagtggggtacatcgaactggatctc  
aacagcggtaagatcctgagagtttcccccgaagaacgcttccaatgatgagcacttfaaagttctgctatgtggcgggtattatccg  
tgttgaccggggcaagagcaactcggctcggcctafacacttctcagaatgacttgggtgagtagctaccagtcacagaaaagcacttacc  
ggatggcagtagcagtaagagaattatgagtgctgcccataaccatgagtgataaacactgcccgaacttacttctgacaacgatcggaggga  
ccgaaggagctaacggcttttgcnaaacatgggggatcatgtaactcggctgactgtggaaaccggagctgaaatgnaagccataccana  
cgacgagcgtgacaccacgatgctgtagcaatggcaaacgcttgcgcaactatctggcgaactacttacttacttctccggcaac  
aattaatagactggatggagcggataaagttgcaggaccactctcggctcggccctccggctggctgtttatttctgataaactcggag  
ccgggtgagcgtgggtctcgggtatctgagcactggggccagatggtaaggccctccgctatcgtatgatactcagcagcggggagta  
ggcaactatggatgaaagaaatagacagatcctgagataggctcactgattagcattggtaacgtcagaccagtttactatatafa  
cttagaitgattfaaaactcaatttfaaagatctaggtgaaagatccttttataaactcagaccnaaatccctaacgtgagtttctgt  
ccactgagcgtcagaccggtagaaaagatcaaggatctcttggagatccttttctcggctgtaactcgtcctcgtcnaaacnaaaaactc  
ccgctaccagcgggtgtgttggcggatcaagagctaacactcttttccgaaggtaactggctcagcagagcggcagatcaaaact  
gtctctaggttagcgggtgttagggccaccactcaagaactctgtgcaaccgctacafaccctcgtctaaactctgtaccagttggctc

Figure 156B

tgccagtggcgataaagtcgtgcttacccgggtggactcaagacgatagttaccgggataaggcgcagcggcgcgggctgaaccggggggtc  
gtgcacacagcccagctggagcgaacgacctacaccgaaactgagatacctacagcgtgagctatgagaaagcggccacgcttccgaag  
ggagaaaggcggacaggtatccggtaagcggcagggtcgggaacaggagagcgcacaggggagcttccagggggaaacgctgggtat  
ctttatagtcctgctgggttccaccctctgactgagcgtcgattttgtgatgctcgtcaggggggcgggacctatgaaaaacgccagca  
acgcggccttttacggctcctggccttttgcggccttttgcacatgcttccctggttatccctgattctgtgataaccgtataccgct  
ttgagtgagctgataccgctcggcagccgaacgaccgagcgcagcagtcagtgaggaggguagcggangcgcctgatcgggt  
atttctecttacgcatctgtcgggtatitacaccgcataatggcactcctcagtaaatctgctctgatccgcatagtaagccagtatacaact  
ccgctatcgtctacgtagctgggtcatggctgcgcccggacaccgcgaacaccgctgacgcgcccggacgggcttctgctccggca  
tccgcttacagcaagctgtgaccgtcctccggagctgcatgtgtagagggtttaccgctcaccgaaacgcggcaggcagcagatca  
attcgcgcggaaggcgaagcggcatgcatitacgttacaccatogaatgggtgcaaaaccttccgggtatggcatgatagcggcggaa  
gagagtaaitcagggtgggaatggaaccagtaaccgttatacagatgctgcagagatgctcgggtgctcttatcagaccgttccggcgtg  
gigaaccaggccagccacgttctgcgaaaaacgcgggaaaaagtggaagcggcgatggcggagctgaattacattcccacccgcgtggc  
acaacaactggcgggcaaacagtcgttgcgattggcgttccacctccagcttggccctgcacgcgcccgcgcaaatgtcggcgatt  
aaatctcgcgccgatcaactgggtgcccagcgtgggtgctgatggtagaacgaagcggcgtcgaagcctgtaaagcggcgggtgcacaa  
tcttctcgcgcaacgcgtcagtgggctgatcattaaactatccgctggatgaccaggatgccatigtctgtggaagctgctgcaactaatgttccg  
gcgfiatttctgatgtctctgaccagacaccataaacagtattatttttcccatgaagacgggtacgcgactggcgtggagcactctggtcgc  
attgggtaccagcaaatcgcgctgttagcgggcccattaagtctctcggcgcgtctgcttggctggcgtgataaataatctcactcgc  
caatcnaaitcagccgatagcggaaacgggaaggcgcactggagtgcaatgctcgggtttcaaaaaccatgcaaatgctgaatgaggcctc  
gttccactgctgatgctggttgcacacgatcagatggcgtcggcgcgaatgcgcgccattaccgagtcgggctgcgcttgggtggat  
atctggtagtgggatalcagcagataccgaagacagctcattatatacccgctcaaccaccalcaaacaggatttgcctgctggggca  
aacagcgtggaccgcttgcgaactctctcaggggcaggcgggtgaaggcaatcagctgttggcctctcactgggtgaaaagaaaaac  
caccctggcggccaatacgaacccgctctcccgcgcttggccgattcattaatgcagctggcagacaggttcccgactgaaaagc  
gggcatgtagcgaacgaatfatgagtttagcgcgaattgatctg (SEQ ID NO : 44)

Figure 157




Figure 158




Figure 159A


1.

gfttgacagcttatacagactgcacgggtgoaccaatgctctggcgctcauggcagccatcgggaagctgiggatgctgctgcaggctgtaaat  
cactgcaataatcctgctgctcaaggcgcaactcccgctctgggataatgcttttggcgccgacatcataacggctctggcaaatatctgaaatgag  
ctgttgacaatantcaccctggctctgataatgctgggaattgtgagcggalaacaatttcacacagggaacagcggccgctgagaaaaagc  
aaggcgacatgctctiaacaalitalcagacaatctgtgtgggaactcaccgggaattatcgattaaactttattataaaaattaaagaggtat  
atataatgatacgtataaaggaggantaaaacatgagatgagcgtgctccaccgaaatgctctttaccgaaactgaaaccgaaagctc  
icgtctgcaactacgaacctaacagctgggaactatgattactgctgctccaccgaaacggagcagctcaccgaaagtatacaaaagacaag  
cgaaaaaagctggaagccgaagctcgtcgcgagataaataacgaaaaagcagaatttctgacctgctggaaactgattgacaacgtccagc  
cctgggocctgggttaccgcttccgagctgataaccgtggtgctggtgagcctgctgctccaccggcggcctgagctggtaaccaagactcc  
ctgcaacggtaacggcaactgcttctcgtctgctgctcaaacggcttttggaggcttctcaggaaagcgtcagcggctcaagaccaaaacggc  
aactcctggagaacctgaaaggaaatcacaagctatctgagcctgacgagggccagcttctgctcctggcggcctgagctggtaaccaagactcc  
acggaggcgaaggcttctgcaactctctctctgaaagaactgctgaaagaaagatcggtaaaagagctggcagaacaggctgaacctgcaact  
ggaaactgccactgcaatcgcctgactcagcctgctgggaagcagatgctgctatcagggcctaccgtaaaaaggaggacgcgaatcaggctctg  
ctggagctggcaattctggattacaacatgactcagctgctgataccagcctgactcctgctgaaacgtcccgctggctgctgctggctgctg  
gcgaccaaaactgcaactg  
taactcctgcaaaaatgcttctctgtaaccattatcagcagatactcagatgatacggcaccctggacgactggagctgctgctgctgctg  
agctgagcctgggagcgtaaaacggcctcaacgacctgcccggattacatgaaactgctgcttctgctgctgctgctgctgctgctgctgctg  
tacgacaacctgaaagataaaagggtgagaaactcctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctg  
agtggctgtaacaacaactctactcggactctgactctgctgcaaacgcaaggaaatcctctctgctgctgctgctgctgctgctgctgctg  
cttctg  
tgcattgactg  
gaaactggctaccgaaagcctg  
ccgttctg  
gcaaacgctg  
ccgggtaagattaccctg  
gaaactcaatgactctatcaactattcagagccagatcggccgcaccggctgctgctgctgctgctgctgctgctgctgctgctgctgctg  
atgctgcaaatctattctatcaacggctg  
cggctctattgctg  
agggtgctg  
cggcattgctg  
cgaaccgctg  
cgtcaaccaggctg  
ctaaaatcaggctg  
gctggcggtaaaagctg  
gcttggcggatgagagaagatttctg  
agcggcgggtgctg  
agggaactg  
taggacaatcaggcgggagcggatttgaacgctg  
gcafaaataaagcagaaggccatcctgacggatgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctg  
ctcatgagacaataaccctgataaatgctcaataatattgaaaaaggaaagatgagatgagatgagatgagatgagatgagatgagatgag  
cggcatttggcttctg  
actggatctcaacagcggtaagactctgagagcttctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctg  
gtattatccgtgctg  
aageatcttaccggatggcagtaagagaatattgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctg

Figure 159B

atcggaggaccgaaggagctaaccgctttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaag  
ccafaccnaaacgacgagcgtgacaccacgatgcttagcaatggcaacaacgttgcgcaaacatlaactggcgaactacttactctagct  
tcccggcaacaatfaalagactggatggaggcgatnaaggttcaggaccactctcgcctcggccctccggctggctgtttatgctgat  
aaatctggagccggtagcgtgggtctcgggtatcattgcagcactggggccagatggtaagccctccgtatcgtatctacacgac  
ggggagtcaggcaactatggaatgaacgaaatagacagatcgtgagatgggtccctcactgattaagcattggtaactgacagccaagttf  
actcatatatacttta gattgattfaaaactcattttaaiftaaaaggatctaggtaagatccttttgataatcfcatacnaaatccctaacgt  
gagtttctgctcactgagcgtcagaccocgtagaaaagatcaaaaggatctctgagatcctttttctgagcgtatcgtcgttgcnaaca  
aaaaaaccaccgctaccagcgggtgtttgttccggatcaagagctaccaactcttttccgaaaggtaactgcttcagcagagcgcagat  
acaaalactgctctctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgctacatacctcgtctgtaactctgttac  
cagtggtcgtcctcagtggtgataagtcgtcttaccgggttgactcaagacgatagttaccggataaggcgcagcgtcgggtgaa  
cgggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaagcgcac  
gcttccgaaggagaaaggcgcgacaggtatcggtaagcggcagggtcggaaacaggagcgcacagggaggttccagggggaa  
acgctcgtgatactttatagtcctgtcgggttccaccctctgacttggcgtcatttttggatgctcgtcagggggggcggagcctatggaa  
aacgcagcaacgcggcctttttacgggtctctggccttttctgctcactatgttctctcgtgctatccctgaticgttgataacc  
gtattaccgctttgagtgagctgataccgctcgcogcagccgaacgaccgagcgcagcaggtcagtgagcgaaggaaaggagagc  
cctgatgcggatfittctcttaccgctctgtcgggtatttcaaccgcatatggtgcacltcaatcaatctgctctgatccgcatagtaag  
ccagtalacaciccgtatcgtctacgtgactgggtcatggctgcgccccgacaccgccaaaccccgtgacgcgacctgacgggtgt  
ctgctcccggcatccgtitacgacaagctgtgaccgtctccgggagctgcaftgtgicagaggtttaccgctacaccgaaacgcgcga  
ggcagcagatcaatcggcgcgaaggcgaagcggcatgcatcttaccgttgcacaccatcgaatgggtcnaaaccttccggtatggcatga  
tagcggccggagagatcaatcagggtgggtgaatgtgnaaacagtaacgttatacagatgctcagagatgcccgggtctcttaccagac  
cgttcccgctgtgtaaccaggccagccacttctcgaanaacgggggnaaaagtggaaagcgggagatggcggagctgaattacattcc  
caaccgcgtggcacaacaactggcgggcaaacagctgctgattggcgttgcaccctccagctcggcctgacgcgctcgcnaaatt  
gtcggcggatfaaatctcgcgccatcaactgggtgccagcgtggtggtgtaggtagaacgaaaggcggctgaaagcctgnaagc  
gagggtgcacaatctctcgcgaacgcgtcagtggtgcatctaacctctccgctggatgaccaggaigccatgctgtggaagctgectg  
caclaatgttccggcttatttctgagctcctgaccagacaccatcaacagatatttttctccatgaaagacgggtacgcgactggcggtg  
agcatctggtcgtatgggtcaccagcaaatcgcgctttagcgggcccattaaagttctgtctcggcggctctgctctggctggctggcata  
aatactcactcgeastcaatcagccgatagcggaaacgggaaggcgaactggagtgccatgctccggtttcaacaaacctgcaaatgctg  
aatgagggcatcgtccactgctgagctgtgttccaacgatcagatggcgtggcgcgaatgcgcgcccattaccgagtcgggctgcgc  
gttgggtcggatctcggtagtgggatacgaacgataccgaaacagctcctgttatatcccgctcaaccaccatcaaacaggatcttgc  
ctgctggggcaaacaggcgtgaccgctgtcgaactctctcaggggccagcggggaaggcaatcagctgttcccgtctcactggtg  
aaaagaaaaaccacctggcggccaatacgaacccgctctcccgcggttggccgaticatfaatgcagctggcagcagaggttccc  
gactggaaagcgggagtgagcgaacgcnaatgtagttagcggcaatgatctg (SEQ ID NO : 45)

Figure 160A






**Figure 160C**

ectgcacaactcaccagtagtggttaactgggtggacccggaatacctggagcagcgcggtttaacgtaaggacctccctg  
ccgggcaacgcctgtaagcttcaacgcgtctacaataaaaaaggcagtcagatgacgfgcctttttcttctctaga  
(SEQ ID NO: 46)

Figure 161A



MCM376 - MKK from *M. mazei* archeal Lowerin pET200D  
6647 bp

Figure 161B


naggggcagctcaacgataccggctgctaacaagcccgaagggaagctgagttggcctgctgccaccgctgagcaataactag  
cataaacccttggggcctctaaacgggcttggagggttttctgaaagggaaggaaactalatooggatutoccgcaaggggccc  
ggcagttaccggcataaccaagccatgcciacagcatccagggtgacggggccgaggatgacgatgagcgcattgttagattc  
atacacgggtgacctgactgcttagcaatttaacigtgataaactaccgcatlaaagcttaicgatgataaagctgcaaacatgagaa  
ttaatcttgaagacgnaaggggcctcgtgatacgcctatititataggftaaigtcatgataaataatggtttcttagacgctcagggtggca  
cttttggggaaatgtgcgggaacccctattigtitatttttaataacatcaaalatgtatccgctcagagacaataaccctgai  
aaatgctcaataatgtaaaaagggaagagtatgaaacagatggatgacgcaaggttccggccgcttgggtgggagag  
gctattoeggctatgactgggcaacaactgacaatcggctgctcagccggctgtccggctgacagcaggggggccggccgggt  
tcttttctcaagaccgacctgctgggtgccctgaaatgaaactgcaagagcagggcagcggcctatcgtggcggccacgacgg  
gcttctctgacagcctgtctcagcgttgcactgaaagcgggaagggaactggctgctatggggcgaaggtgcccggggcagggat  
ctcctgctatctcaccctgctcctgctgagaaagtatccatcatggctgtagcaatggcggcggctgcatacgcctgacccggctac  
ctgcccattcgaccaccaagcgaacatcgcacgagcggggcagctactcggatggaaagccggctctgtgctgacaggtatct  
ggacgaagagcatcaggggctcgcgctagccgaacigtctgccaggctcaaggccgcatgcccagcggcgaggtatctcgt  
cgtgacacatggcgatgcttgcctgcccgaatcatggtggaaaatggccgctttctggattcactgactgtggccggctgggtg  
tggcggaccgctatcaggacatagcgttggctaccggctgataattgctgaagagcttggcggcgaatgggctgaccgctcctcgt  
gctttaccggatcggcgtcccgatccagcggcactcctctatcgcctcttgaagagttctctgagcgggactctggggctc  
gaaaigaccgaccaagcggacgcttaactgacagcaaacgttactcatatatactttagattgatttaaacctcatttttaastfaaaa  
ggatctagggtgaagatccttttgaataatctcatgaccaaactccctaacgtgagtttctgctccactgagcctcagaccctgaga  
aaagatcaaaaggatctcttggatcctttttctgcccgtatctgctgcttgcacaacaaaaaacaccaccgctaccagcgggtggt  
igtlttggcggatcaagagctfaceaacctttttccgaaggtaactggcttcagcagagcgcagataccanatactgctcctctagtgt  
agccgtagttaggccaccactcaagaactctgtagcaccgctcaataccctcctgctgtaatectgttaccagttggctgctgctg  
agttggcgataagctgtgcttaccgggttggactcaagacgatagttaccgggataaggccagcggctcggggctgaacggggg  
gttctgtcacacagccagctgggagcgaacgacclacacggaactgagataectacagcgtgagctatgagaaaagcggccac  
gctcccgaagggaaggaaggcggacaggtatccgglaagcggcagggctcggaaacagggagagcgcacgaggggagcttcca  
gggggaaacgctggtatcttatagtcctgtcgggttgcocaccctgactgagcgtcgaatttttgpagctcgtcagggggg  
cggagcciatggaaaacgocagcaacgcgcccttttaccggttccctggccttttctgctgaccttttgcacatgittttctgctg  
atccctgattctgtggataaccglatfaccgctttgagtgagctgataccgctcggcgcagccgaacgaccgagcggagcga  
gtcagttgagcaggaagcgggaagagcggcctgatcgggtattttctccttaccgcatctgtcgggtatttcaaccggcaatggtgca  
ctctcagtaaatctgctctgatccgcatgtaagccagttatacctcctctatgctacgtgactgggtcatgtgctgccc  
gacaccggccaacaccgctgacggccctgacgggcttgcctcctccggcctccgcttaccagacangctgtgaccgtctcc  
ggggagctgcatgtgctcagagggtttaccggctcaaccggaacggcggagggagctcgggtaagctcaccagcgtggtctg  
aagcggattcacagatgtctgctgttcatccggctcagcctcgttgggtttctcagaagcgttaatgtctggctctgataaagcgg  
gcatgttaaggcgggttttcttggctcactgatgctcctcgtgtaagggggatttctgttcatgggggtaatgatacagatga  
aacgagagaggatgctcagatacgggttaactgatgatgaacatgcccggttactggaacgttctgagggglaaacactggcg  
gtatggatgctggcgggaccagagaaaatcactcagggtcaatgacagcgtctctgtaalacagatgtaggtgttccacagggt  
agccagcagcctcctgcatgcatcctggaaacataatggtgcaaggcggctgacttccgcttccagactttaccgaaacacgg  
aaaccgaagaccattcagttgttctcaggtcgcagacggtttgagcagcagctcgttccagcttccgctcggctatcgggtattca  
ttctgctaaccagtaaggcaaccccggcagcctagccgggtctcaacgacagggacatgatcatgcccaccctgtggccagg  
accnaacgctgcccgagatgcccggctgctggagatggcggacggatggatattcttccaaagggttgggttgc  
gctttcacagttctccgcaagaattgattggctccaattctggagttgtaatccgltagcagggttccgcccggcttccattcagg  
tcgaggtggcccgctccatgcaaccggcgaacggcggggaggcagacnaaggtataggggcggcggctfacaatcattcc  
aaccctgtccatgtctcggcagggcggcataaactcggctgacgatacgggtccaatgataaggttaggctggtaagc  
cggcagcgtatccttgaagctgtccctgaggtctgacatcactgctggacagcattggcctgcaaccggggacatcccgatgc  
gcccgaagcggagaaatcaaatggggaaaggccaccagcctcggctcggcaacggcagcaagacgttaccagcggct

Figure 161C

cggccgccaatgccggcgataatggcctgcttctcggcaaacggttggggggaccagtgacgaaggcctgagcgagggc  
 gtgcaagatccgaafaccgcaagcgacaggccgcatctcgcgcctccagcgaagcggtccctcggcaaatgaccag  
 agcgcgtccggcaccctgctctacgagtgcatgataaagaagacagtcataagtgccggcgacgatagtcacccccgccc  
 ccgggaaggagctgactgggtgaaggctctcaaggccatcggcgagatccgggtgctaatgagtgagcctaactacattaat  
 gctgtgctcactgccccttccagtcgggaacctgctgcccagctgcatlaatgaatggccaacgcgaggggagagg  
 cgggttgcgtatfggggccagggtggttttcttccaccagtgagacggcgaacagctgattgcccttaccgctggccctga  
 gagagtgacgaagcggtccacgctggttggcccagcaggcgaanaatcctgttgatggtggttaacggcgggatataacal  
 gagctgtcttggfategctgatcccactaccgagatccgcaaccaacgcgcagcccggactcggtaatggcgcgcaatggc  
 cccagcggccatctgacgtggcaaccagcaatcgagtggggaacgatgccctcattcagcattgcatggttgtgaaaaccgg  
 acatggcactccagtcgcttcccgtccgctatcggcgaatttgatgagtgagatatttggccagccagccagaccgaga  
 cgcgcccagacagaacttaattggcccgtcaacagcgcgalttgggtgacccaatgcgaccagatgctccacgccagctc  
 cgtaccgcttcatgggagaaaataactgttgatgggtgctggcagagacatcaagaaataacgccgggaacattagtgeag  
 gcagcttccacagcaatggcaacctggtcatccagcggafatgtaatgatcccaactgacgcgttgcgagaaagattgtgc  
 accgcccgtttacagcctcagcggcttcttaccatcgacaccacacagctggcaccagtgatcggcgcgagatitaa  
 tcgccgcgacnaattggcagcggcggctgacagggccagactggaggtggcaacgccaatcagcaacgactgttggcccag  
 ttgttggccacgcgggtggaaatgtaaticagctccgccatcgcgcttccacttttcccggcttccagaaaaccgtggtggc  
 ctggttaccacgcggggaacggctcgtataagagacaccggcactctgacatcgtatacgttactgtttcattaccacca  
 ccttgaattgactcttcccggcgctatccalaccggaagggttttgcgcaatcgtatgggtgicgggagatctcagcctc  
 ccttatgagactcctgacttaggaagcagcccagtagtaggtgaggccgttggcaccgccgcccgaaggatgggtgatg  
 caaggagatggcggcccaacagtcccccggccacggggcctgcccaccataccagccggaacaagcgtcatgagcccga  
 agtggcgagcccgatcttcccacatcgggtgatgctggcgatagggccagcaaccgcaactgtggcggcgggtgatggc  
 caagatgctccggcgttagagatcgagatctcgtacccgcaaatatagcactcactatagggaattgtgagcggataac  
 natccccctctagaanaattttgttaacttfaagaaggagatatacatatgggggtctcactatcatcatcatcatggtatgcta  
 gcatgactggtggacagcaaatgggtgggatctgtacgacgatgacgataaggatcatccctaccatgggtatcctgttctg  
 gccgggtaagatttaccgttccgtggaacacgcgtagtttatggcgaaactgcaattgctgtgctgggtggaactcgtaccct  
 gtlcgcgggaactcaatgactctatcactatcagagccagatcggccgcaaccggctggtttcggaaaagcaccctatgtg  
 tgggttaattgagaaaatcgcaaatctattctatfaacgggtgttcttaccgctgatccgacatcccgggtggcctcgggtg  
 ggtagcagcgcagccgttactatcgcgtctattggtgctgtaacgagctgttcggcttggcctcagcctgaaataatcgt  
 aactggccacgaaatcgaatfaaagiacagggtgcccgcctcccaaccgatacgtatgttctactctcggcggcgtggttac  
 catccgggaacgtcgaactgaaaactccggactggcattggtgagcagataccggcgttttctcctccaccaagaggtta  
 gtactaacgtacgtcagctgcgcgaagctaccggattgacgaaccgtgatgacctatggcaaatctctctgtatcgg  
 cgaacaactggtctgtcggcactacgcacatcggccgctgatgaacgtcaaccagggtctctggacgccctggcggct  
 taacatcttagaactgagccagctgatctatccgctcgtggcaggtgctgtggcgtanaatcaccggcgtcggcggcgt  
 ggtgtatggttgcctgaccgctccggaaaatgcaaccaagtggcagaagcggtagcagggcgtggcggtaaatgactat  
 cactaaaccgaccgagcaaggctgtaagtagatitaa

(SEQ ID NO : 47)

Figure 162



CDS 2: Gentamycin resistance gene; CDS: 1 *E. coli* replication protein



Figure 163B

ccggtagatattggcgggaatggcaaccgtccagccctcaccacatcgacgacgcccactggcagggccatctccagacgcgttacgc  
tcacgttaccggcattgtaagAACCTACAAGACAACtGCCCTGGTgaicgggTGGAAATATgCGTCGGACTACCCGGCAGCGCAGACTC  
tgcggcaaaagtcagtgccatcgtccggggcgatagacgatacggcaggacgcgaaactcagggcgaaacaccaacatagagataaagt  
ttgtcggggctgaccaccatcggctgcacctgccccggcacatcgacaacctgtgtcagcgtcagtgcccttcatgattcagattcagac  
gtgaatttgcctcctcagggtcggcgaataaactgtttgcttcatgaatgctccttgggttacctccgggaaacgcggttgattgttagtg  
gttgaattattgtcagcatgtggcatagtcaaggcggtgacggctcgttaatacaactactatagggtcgcaggaaagttcotatacttteta  
gagaataggaaactccgcgcgcacacacacacacacagatcagaaataaagctctttaitgggtaccgaattcggcaggggagct  
ctcagaactcgttggctgtctttatcgaaccccagagctccgcttaccgcccccttgcactcagcagactgtgttaattcattaaagc  
attcgtccgacatggaaagccatcacaacggcatgatgaacctgaatcgccagcggcatcagcaccttgcgecttgcgtataatattgcc  
atggtgaaacggggggcgaagaagtgtccatattggccacgtttaaactcaaaactgggaaactcaccagggaattggctgagacgaaaa  
acatattcctaataaaccttttagggaataggccagggtttcaccgtaacagccacatcttgcgaaatattgttagaaactgccggaaatc  
gtcgtgttattcactccagagcgaatgaanaacgtttcagtttctcatggaanaacgggtgaacaagggtgaacactatccataaccagctc  
accgtcttcatggcatacggaaatccggatgagcattcctcagcggcgcaagaatgtgaataaaggccggataaaactgtgctattttct  
tlacggcttttaaaaaggccgtaaatccagctgaacggctctgttataggtacattgagcaactgactgaaatgcctcaaaatgttcttaccg  
gccaattgggataatacaacgggtgtatatacagtgattttttcccatggttagtticctcacccttgcgtatatactatgcccgatalactatgccg  
atgattaattgtcaacacgtgctgctgcaggtcgaanaaggccccggagatgaggaaaggagaaacagcggcggcagacgtgcgctttgaaag  
cgtgcagaatgccggcctccggaggacettcggggccccgcccctgagcccgccccctgagccccccccggacccaccctt  
cccagccctcagcccagaaagcgaaggagcaaacgtctatggccgctgccccaaaggccctaccgcttcattgtcagcgggtgctg  
tccatctgcacgagactagtgagacgtgctacttccattgtcacgicctgcacgacgcggagctcggggggggggaacttctgacta  
ggggagggagtggaagggtggcgcgaaggggccacaaagAACGGAGCCGGTtggcgcctaccgggtggatgtgagcaggc  
cagagggcacttgtgtagcgaaggtcccagcggggctgctaaagcgcagctccagactcccttgggaaagcgcctcccoctaccg  
gtagaatgaagttcctatactttctagagaataggaaactcgcggccccctttagtgagggttaattcaactgactgtaacagctaaatagt  
cgctttggcgtgaaggcgaatccagcacaactggcggcgttactagtgatccggactcgggtaccaagcttgaatcaggaatcgaat  
caagctatcagataccgtcaccctcagggggggccccgtaccagcttttgccttttagtgagggttaattgcgcgcttggcgaatcag  
gtcatagcigtttctgtgtgaaatgttatccgctcacaattccacacacatcagagccggaagcataaagtgtaaagccttgggggtcctaa  
tgagttagctaaactcaattaatgtgttgcgctcaactgcccgcttccagtcgggaaacctgctgocagctgcatfaaataaagcggccaac  
gcgggggagaggcgggttgcgtattggcgcgatgataaaactggttgaattcattaaagcattctgcccagatggaagccatcacaacg  
gcgatgaacctgaatcgcagcggcagcacccttgcgcttgcgtataatattgccatggacgcacaccgtggaaacggatgaa  
ggcacgaaccagttgacataagcctgttcggttcgtaaactgtaagcaagtagcgtatgctcagcgaactggtccagaaccttgaccg  
aacgcagcgggtgtaacggcgcagtgccgggtttcatggcttgtatgactgtttttgtacagctatgctcctgggcatccaagcagcaagc  
gcgttacccgtgggtcgaatgttgaatgagcagcaacgatgttacgacagcaacgatgtacgcagcaggggcagctcgccttaa  
aacaaagttaggtggctcaagtatggcatcattcgcacatgtaggctcggccctgaccaagtcaantccatgcgggctgctcttgcatttc  
ggtcgtgagttcggagacgtagccactcaccacatcagccggactccgattaccicgggaaactgctcggtagtaagacattcctcge  
gcttgcgecttcgaccaagaagcgggtgttggcgtctcgcggcttaccgttctgcccagggtttagcagcccgtagtgagatctatctat  
gatctgcagctcggcggagcaccggaggcagggcattgccaccgctcatcaatctcctcaagcatgaggccaacgcgcttgggtct  
tatgtatctacgtcgaagcagattaccggtgacatcccgagtggtctctatacaaaagtgggcatacgggaaagtgatgcacttgaat  
atcgaaccaagtaccggcaccctaaacattcgtcaagccgagatcggcttccggcgcggaggtgttgggtaaatgtcacaacggccgc  
agggtggcactttcggggaatgtcgcgcccgcgttccgtcggcgttggcctgtttctggcgtcggacttcccgttccgtcagcag  
ctttcggccacggccttgaatgacgcggcggccttggcctgcatatcccgaattcaacggcccagggcgtccagaacgggctcagggc  
tcccgaaggf (SEQ ID NO : 48) .

Figure 164A




Figure 164B




Figure 164C


**Titer 78C**

Figure 164D




Figure 164E




Figure 164F




Figure 165A-B




Figure 166A




Figure 166B




Figure 167




Figure 168A-C




Figure 169




Figure 170




Figure 171




Figure 172




Figure 173

